{"PMC4835795": [["Epitopes of Mab 5D-8.1 and MAb 9D5 ::: ResultsSecondary goat anti-mouse IgG Ab did not show background interactions with antigen-derived peptides.", [["MAb 9D5", "SIMPLE_CHEMICAL", 27, 34], ["antigen-derived peptides", "GENE_OR_GENE_PRODUCT", 121, 145], ["Mab 5D", "PROTEIN", 12, 18], ["MAb 9D5", "PROTEIN", 27, 34], ["ResultsSecondary goat anti-mouse IgG Ab", "PROTEIN", 39, 78], ["goat", "SPECIES", 56, 60], ["anti-mouse", "SPECIES", 61, 71], ["goat", "SPECIES", 56, 60], ["Epitopes of Mab 5D", "TREATMENT", 0, 18], ["goat anti-mouse IgG Ab", "TEST", 56, 78], ["background interactions", "PROBLEM", 92, 115]]], ["As shown in Fig. 1a,c, MAb 5D-8.1 gave defined spots for the VP1 sequence of CV-B1, CV-B4, E-30, and reduced reactivity with CV-A1.", [["CV-B1", "GENE_OR_GENE_PRODUCT", 77, 82], ["CV-B4", "CELL", 84, 89], ["E-30", "GENE_OR_GENE_PRODUCT", 91, 95], ["CV-A1", "GENE_OR_GENE_PRODUCT", 125, 130], ["VP1 sequence", "DNA", 61, 73], ["A1", "PROTEIN", 128, 130], ["the VP1 sequence", "TEST", 57, 73], ["CV", "TEST", 77, 79], ["CV", "TEST", 84, 86], ["E", "TEST", 91, 92], ["reduced reactivity", "PROBLEM", 101, 119], ["A1", "ANATOMY", 128, 130]]], ["The peptide scan indicated IPALTAVETGHT as the consensus sequence containing the epitope of MAb 5D-8.1.", [["IPALTAVETGHT", "PROTEIN", 27, 39], ["consensus sequence", "DNA", 47, 65], ["MAb 5D-8.1", "PROTEIN", 92, 102], ["The peptide scan", "TEST", 0, 16], ["IPALTAVETGHT", "TREATMENT", 27, 39], ["the consensus sequence", "TEST", 43, 65], ["the epitope of MAb 5D", "TEST", 77, 98]]], ["Comparable signals were produced by MAb 9D5 (Fig. 1b,d) and attributed to the consensus motif SIGNAYSMFYDG.", [["MAb 9D5", "PROTEIN", 36, 43], ["consensus motif", "DNA", 78, 93]]], ["Thus, relative to the VP1 sequence of CV-B4 (GI: 61031)29, the sequence containing the epitope of 5D-8.1 was close to the N-terminus at AA residues 28\u201339, whereas that of 5D9 was located towards the C-terminus at residues 187\u2013198.", [["N", "CHEMICAL", 122, 123], ["C", "CHEMICAL", 199, 200], ["CV-B4", "ORGANISM", 38, 43], ["\u2013198", "AMINO_ACID", 225, 229], ["VP1 sequence", "DNA", 22, 34], ["5D", "PROTEIN", 98, 100], ["N-terminus", "PROTEIN", 122, 132], ["5D9", "PROTEIN", 171, 174], ["C-terminus", "PROTEIN", 199, 209], ["residues 187\u2013198", "PROTEIN", 213, 229], ["CV-B4 (GI: 61031)29", "SPECIES", 38, 57], ["the VP1 sequence", "TEST", 18, 34], ["CV", "TEST", 38, 40], ["the sequence", "TEST", 59, 71], ["the epitope", "TEST", 83, 94]]], ["Substitution scan of peptide IPALTAVETGHT against MAb 5D-8.1 allowed to delimit the antibody binding site to a conserved core motif 4-IPALTAAET-12.", [["MAb 5D-8.1", "CHEMICAL", 50, 60], ["MAb 5D", "PROTEIN", 50, 56], ["antibody binding site", "DNA", 84, 105], ["conserved core motif 4-IPALTAAET-12", "DNA", 111, 146], ["Substitution scan of peptide IPALTAVETGHT", "TEST", 0, 41], ["MAb 5D", "TEST", 50, 56], ["the antibody binding site", "PROBLEM", 80, 105], ["IPALTAAET", "TEST", 134, 143]]], ["AA positions 4I, 7L and 8T showed the highest degree of sequence conservation with a nearly complete loss in binding of MAb 5D-8.1 upon exchange by other amino acids.", [["MAb 5D-8.1", "CHEMICAL", 120, 130], ["amino acids", "CHEMICAL", 154, 165], ["amino acids", "CHEMICAL", 154, 165], ["amino acids", "AMINO_ACID", 154, 165], ["AA positions 4I, 7L and 8T", "DNA", 0, 26], ["MAb 5D", "PROTEIN", 120, 126], ["AA positions", "TEST", 0, 12], ["a nearly complete loss in binding of MAb 5D", "PROBLEM", 83, 126], ["other amino acids", "TREATMENT", 148, 165], ["loss", "OBSERVATION", 101, 105]]], ["AA positions 5P and 11E were well-conserved, exchange by Q and by H, respectively, caused a 60\u201380% loss in antibody binding.", [["11E", "DNA", 20, 23], ["AA positions 5P", "TEST", 0, 15], ["a 60\u201380% loss in antibody binding", "PROBLEM", 90, 123], ["antibody binding", "OBSERVATION", 107, 123]]], ["Compared to this, AA positions 6A and 10A exhibited a slightly higher susceptibility for substitution by selected amino acids with a maximal decrease of 50% of spot intensities.", [["AA", "CHEMICAL", 18, 20], ["amino acids", "CHEMICAL", 114, 125], ["amino acids", "CHEMICAL", 114, 125], ["amino acids", "AMINO_ACID", 114, 125], ["AA positions 6A", "TEST", 18, 33], ["a slightly higher susceptibility for substitution", "PROBLEM", 52, 101], ["selected amino acids", "TEST", 105, 125], ["spot intensities", "TEST", 160, 176], ["slightly", "OBSERVATION_MODIFIER", 54, 62], ["higher susceptibility", "OBSERVATION_MODIFIER", 63, 84], ["maximal", "OBSERVATION_MODIFIER", 133, 140], ["decrease", "OBSERVATION_MODIFIER", 141, 149]]], ["9A and 12T showed the highest tolerance for exchange by other amino acids.", [["amino acids", "CHEMICAL", 62, 73], ["amino acids", "CHEMICAL", 62, 73], ["amino acids", "AMINO_ACID", 62, 73], ["12T", "PROTEIN", 7, 10], ["other amino acids", "TREATMENT", 56, 73]]], ["Replacement by F (9A) and A (12T) was accepted without loss in antibody binding.Three dimensional analysis of the VP1 protein and the two MAb epitopes ::: ResultsFor each viral capsid organization level, the Solvent-Accessible Surface Area (SASA) was calculated in order to estimate the degree-of-burial of antibody epitopes within the protein.", [["F (9A)", "SIMPLE_CHEMICAL", 15, 21], ["VP1", "GENE_OR_GENE_PRODUCT", 114, 117], ["VP1 protein", "PROTEIN", 114, 125], ["MAb epitopes", "PROTEIN", 138, 150], ["antibody epitopes", "PROTEIN", 307, 324], ["Replacement", "TREATMENT", 0, 11], ["loss in antibody binding", "PROBLEM", 55, 79], ["Three dimensional analysis", "TEST", 80, 106], ["the VP1 protein", "TEST", 110, 125], ["each viral capsid organization level", "TEST", 166, 202], ["the Solvent", "TREATMENT", 204, 215], ["antibody epitopes", "PROBLEM", 307, 324], ["without", "UNCERTAINTY", 47, 54], ["antibody binding", "OBSERVATION", 63, 79], ["Surface", "OBSERVATION_MODIFIER", 227, 234], ["antibody epitopes", "OBSERVATION", 307, 324]]], ["The resolved structures of six reference enterovirus strains were obtained from the RCSB database and a 1.4 \u00c5 sphere probe was used to represent a water molecule.", [["enterovirus", "ORGANISM", 41, 52], ["six reference enterovirus strains", "PROBLEM", 27, 60], ["the RCSB database", "TEST", 80, 97], ["a 1.4 \u00c5 sphere probe", "TREATMENT", 102, 122], ["a water molecule", "PROBLEM", 145, 161], ["water molecule", "OBSERVATION", 147, 161]]], ["The exposed surface area was first calculated, and then normalized with the maximum allowed solvent-accessible area30.", [["surface area", "ANATOMY", 12, 24], ["area30", "PROTEIN", 111, 117], ["exposed", "OBSERVATION_MODIFIER", 4, 11], ["surface", "OBSERVATION_MODIFIER", 12, 19], ["area", "OBSERVATION_MODIFIER", 20, 24]]], ["Normalized SASA values take the form of Relative Solvent Accessibility (RSA), a quantity which varies between 0 (for completely buried residues) and 100 (for maximally exposed residues).", [["SASA", "PROTEIN", 11, 15]]], ["The alignment of the VP1 regions recognized by the two MAbs is shown in Fig. 3a.", [["VP1", "GENE_OR_GENE_PRODUCT", 21, 24], ["VP1 regions", "DNA", 21, 32], ["MAbs", "PROTEIN", 55, 59], ["alignment", "OBSERVATION_MODIFIER", 4, 13], ["VP1", "ANATOMY_MODIFIER", 21, 24], ["regions", "ANATOMY_MODIFIER", 25, 32]]], ["The target residues are mainly accessible in the monomeric form for the two epitopes (N-terminal 5D-8.1, yellow; C- terminal 9D5, green).", [["C", "CHEMICAL", 113, 114], ["monomeric form", "PROTEIN", 49, 63], ["epitopes", "PROTEIN", 76, 84], ["N-terminal 5D-8.1, yellow; C- terminal 9D5, green", "PROTEIN", 86, 135], ["The target residues", "PROBLEM", 0, 19], ["the two epitopes", "PROBLEM", 68, 84], ["N-terminal 5D", "TREATMENT", 86, 99], ["yellow", "TEST", 105, 111], ["target residues", "OBSERVATION", 4, 19]]], ["The exposed residues are highly conserved among different EV types, evidencing their importance in the capsid assembly process.", [["The exposed residues", "PROBLEM", 0, 20], ["exposed residues", "OBSERVATION", 4, 20], ["EV types", "OBSERVATION_MODIFIER", 58, 66]]], ["Localization of the VP1 protein within the capsomere (Fig. 3b) shows that the 5D-8.1 epitope is located in a domain where exposed residues are stabilized by a beta sheet structure.", [["VP1", "GENE_OR_GENE_PRODUCT", 20, 23], ["VP1 protein", "PROTEIN", 20, 31], ["capsomere", "PROTEIN", 43, 52], ["5D-8.1 epitope", "PROTEIN", 78, 92], ["beta sheet structure", "PROTEIN", 159, 179], ["the VP1 protein", "TEST", 16, 31], ["the 5D-8.1 epitope", "TREATMENT", 74, 92], ["VP1 protein", "OBSERVATION", 20, 31]]], ["Figure 3c shows the two epitopes in the VP1 protein assembled into the capsid.Detection of MAb epitope sequences among human and viral proteins ::: ResultsThe predicted reactivity of antibodies 5D-8.1 and 9D5 with human proteins and viral agents was explored using BLASTp queries vs. the human proteome and viruses.", [["VP1", "GENE_OR_GENE_PRODUCT", 40, 43], ["capsid", "CELLULAR_COMPONENT", 71, 77], ["MAb", "GENE_OR_GENE_PRODUCT", 91, 94], ["human", "ORGANISM", 119, 124], ["antibodies 5D-8.1", "GENE_OR_GENE_PRODUCT", 183, 200], ["9D5", "SIMPLE_CHEMICAL", 205, 208], ["human", "ORGANISM", 214, 219], ["human", "ORGANISM", 288, 293], ["epitopes", "PROTEIN", 24, 32], ["VP1 protein", "PROTEIN", 40, 51], ["MAb epitope sequences", "PROTEIN", 91, 112], ["human and viral proteins", "PROTEIN", 119, 143], ["antibodies 5D-8.1 and 9D5", "PROTEIN", 183, 208], ["human proteins", "PROTEIN", 214, 228], ["human", "SPECIES", 119, 124], ["human", "SPECIES", 214, 219], ["human", "SPECIES", 288, 293], ["human", "SPECIES", 119, 124], ["human", "SPECIES", 214, 219], ["human", "SPECIES", 288, 293], ["Figure 3c", "TEST", 0, 9], ["the two epitopes", "PROBLEM", 16, 32], ["the VP1 protein", "TREATMENT", 36, 51], ["Detection of MAb epitope sequences", "TEST", 78, 112], ["antibodies", "TEST", 183, 193], ["human proteins", "TREATMENT", 214, 228], ["viral agents", "TREATMENT", 233, 245], ["BLASTp queries", "TREATMENT", 265, 279], ["VP1 protein", "OBSERVATION", 40, 51], ["capsid", "ANATOMY_MODIFIER", 71, 77]]], ["It is deduced that the two MAbs may recognize linear targets producing significant alignments with sufficiently low E values.", [["MAbs", "PROTEIN", 27, 31], ["sufficiently low E values", "PROBLEM", 99, 124]]], ["Interestingly, MAb 5D-8.1 produced significant alignments for creatine kinase U-type and a mitochondrial ATP synthase, among other proteins.", [["mitochondrial", "ANATOMY", 91, 104], ["MAb 5D-8.1", "CHEMICAL", 15, 25], ["creatine", "CHEMICAL", 62, 70], ["ATP", "CHEMICAL", 105, 108], ["creatine", "CHEMICAL", 62, 70], ["ATP", "CHEMICAL", 105, 108], ["creatine kinase U", "GENE_OR_GENE_PRODUCT", 62, 79], ["mitochondrial", "CELLULAR_COMPONENT", 91, 104], ["ATP synthase", "GENE_OR_GENE_PRODUCT", 105, 117], ["MAb 5D", "PROTEIN", 15, 21], ["creatine kinase U", "PROTEIN", 62, 79], ["mitochondrial ATP synthase", "PROTEIN", 91, 117], ["MAb", "TEST", 15, 18], ["creatine kinase U", "TEST", 62, 79], ["a mitochondrial ATP synthase", "TEST", 89, 117]]], ["These targets may represent the antigens indicated as cross-reactive by Korsgren and collaborators in 201327.", [["may represent", "UNCERTAINTY", 14, 27]]], ["Similarly, MAb 9D5 may be expected to bind to a variety of human proteins, including the leucine-rich repeat-containing protein 66.", [["leucine", "CHEMICAL", 89, 96], ["leucine", "CHEMICAL", 89, 96], ["MAb 9D5", "GENE_OR_GENE_PRODUCT", 11, 18], ["human", "ORGANISM", 59, 64], ["leucine-rich repeat-containing protein 66", "GENE_OR_GENE_PRODUCT", 89, 130], ["MAb 9D5", "PROTEIN", 11, 18], ["human proteins", "PROTEIN", 59, 73], ["leucine-rich repeat-containing protein 66", "PROTEIN", 89, 130], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 59, 64], ["MAb", "TREATMENT", 11, 14], ["human proteins", "TEST", 59, 73], ["the leucine", "TEST", 85, 96], ["protein", "TEST", 120, 127]]], ["However, much better alignments (i.e., much lower E values) have been obtained for enteroviruses, rhinoviruses, and agents of the Rabovirus and Sapelovirus genera that represent the most recent members of the Picornaviridae family3132.Detection of MAb epitope sequences among human and viral proteins ::: ResultsThe expected reactivity of MAbs 5D-8.1 and 9D5 with different EV types of the A, B, C, D species is shown in Table 2.", [["enteroviruses", "DISEASE", 83, 96], ["rhinoviruses", "DISEASE", 98, 110], ["rhinoviruses", "ORGANISM", 98, 110], ["MAb", "GENE_OR_GENE_PRODUCT", 248, 251], ["human", "ORGANISM", 276, 281], ["B, C", "SIMPLE_CHEMICAL", 393, 397], ["D species", "SIMPLE_CHEMICAL", 399, 408], ["Picornaviridae family3132", "PROTEIN", 209, 234], ["MAb epitope sequences", "PROTEIN", 248, 269], ["human and viral proteins", "PROTEIN", 276, 300], ["MAbs 5D", "PROTEIN", 339, 346], ["9D5", "PROTEIN", 355, 358], ["B", "PROTEIN", 393, 394], ["human", "SPECIES", 276, 281], ["human", "SPECIES", 276, 281], ["enteroviruses", "PROBLEM", 83, 96], ["rhinoviruses", "PROBLEM", 98, 110], ["agents", "TREATMENT", 116, 122], ["the Rabovirus and Sapelovirus genera", "PROBLEM", 126, 162], ["Detection of MAb epitope sequences", "TEST", 235, 269], ["MAbs", "TEST", 339, 343], ["the A, B, C, D species", "PROBLEM", 386, 408], ["reactivity", "OBSERVATION_MODIFIER", 325, 335]]], ["Whereas reactivity of the two MAbs is largely equivalent, 5D-8.1 has a wider coverage of the A species as compared to MAb 9D5.", [["MAb 9D5", "GENE_OR_GENE_PRODUCT", 118, 125], ["MAbs", "PROTEIN", 30, 34], ["MAb 9D5", "PROTEIN", 118, 125], ["the A species", "PROBLEM", 89, 102], ["two", "OBSERVATION_MODIFIER", 26, 29], ["MAbs", "OBSERVATION", 30, 34], ["largely", "OBSERVATION_MODIFIER", 38, 45], ["equivalent", "OBSERVATION_MODIFIER", 46, 56]]], ["Scattered cases of complimentary specificity also occur, indicating that the combined use of both antibodies could widen the detection range in diagnostic/immunohistochemical procedures.Immunostaining of enterovirus-infected cell cultures ::: ResultsIn uninfected cells (AV3 and LLC-MK2 lines) MAb 9D5 did not produce fluorescence even at the concentration of 5 \u03bcg/ml (Fig. 4a), while 5D-8.1 yielded fine perinuclear and cytoplasmic fluorescence when used at the concentration of 1 \u03bcg/ml (Fig. 4b), but not at concentrations \u22641 \u03bcg/ml (Fig. 4c).", [["cell cultures", "ANATOMY", 225, 238], ["cells", "ANATOMY", 264, 269], ["AV3", "ANATOMY", 271, 274], ["LLC-MK2 lines", "ANATOMY", 279, 292], ["perinuclear", "ANATOMY", 405, 416], ["cytoplasmic", "ANATOMY", 421, 432], ["enterovirus-infected", "DISEASE", 204, 224], ["enterovirus", "ORGANISM", 204, 215], ["cell cultures", "CELL", 225, 238], ["cells", "CELL", 264, 269], ["AV3", "CELL", 271, 274], ["LLC-MK2 lines", "CELL", 279, 292], ["perinuclear", "ORGANISM_SUBSTANCE", 405, 416], ["cytoplasmic", "ORGANISM_SUBSTANCE", 421, 432], ["antibodies", "PROTEIN", 98, 108], ["enterovirus-infected cell cultures", "CELL_LINE", 204, 238], ["ResultsIn uninfected cells", "CELL_LINE", 243, 269], ["AV3 and LLC-MK2 lines", "CELL_LINE", 271, 292], ["MAb 9D5", "CELL_LINE", 294, 301], ["diagnostic/immunohistochemical procedures", "TREATMENT", 144, 185], ["enterovirus", "PROBLEM", 204, 215], ["infected cell cultures", "TEST", 216, 238], ["AV3", "TEST", 271, 274], ["LLC-MK2 lines", "TREATMENT", 279, 292], ["MAb", "TREATMENT", 294, 297], ["fine perinuclear and cytoplasmic fluorescence", "PROBLEM", 400, 445], ["enterovirus", "OBSERVATION", 204, 215], ["infected cell", "OBSERVATION", 216, 229], ["uninfected cells", "OBSERVATION", 253, 269], ["LLC", "ANATOMY", 279, 282], ["MK2 lines", "OBSERVATION", 283, 292], ["cytoplasmic fluorescence", "OBSERVATION", 421, 445]]], ["The two investigated MAbs produced dotted cytoplasmic fluorescence in human and monkey cells acutely infected with CV-B4 (Fig. 4d\u2013f).", [["cytoplasmic", "ANATOMY", 42, 53], ["cells", "ANATOMY", 87, 92], ["cytoplasmic", "ORGANISM_SUBSTANCE", 42, 53], ["human", "ORGANISM", 70, 75], ["monkey", "ORGANISM", 80, 86], ["cells", "CELL", 87, 92], ["CV-B4", "CELL", 115, 120], ["MAbs", "PROTEIN", 21, 25], ["human and monkey cells", "CELL_TYPE", 70, 92], ["human", "SPECIES", 70, 75], ["human", "SPECIES", 70, 75], ["CV-B4", "SPECIES", 115, 120], ["The two investigated MAbs", "TREATMENT", 0, 25], ["dotted cytoplasmic fluorescence", "PROBLEM", 35, 66], ["CV", "TEST", 115, 117], ["cytoplasmic fluorescence", "OBSERVATION", 42, 66]]], ["Fine dotted fluorescence was also seen in AV3 cells undergoing persistent infection by the CV-B1pc strain isolated from a case of pancreatic carcinoma (Fig. 4g\u2013i).", [["AV3 cells", "ANATOMY", 42, 51], ["pancreatic carcinoma", "ANATOMY", 130, 150], ["infection", "DISEASE", 74, 83], ["pancreatic carcinoma", "DISEASE", 130, 150], ["AV3 cells", "CELL", 42, 51], ["CV-B1pc strain", "ORGANISM", 91, 105], ["pancreatic carcinoma", "CANCER", 130, 150], ["AV3 cells", "CELL_LINE", 42, 51], ["CV-B1pc strain", "SPECIES", 91, 105], ["Fine dotted fluorescence", "PROBLEM", 0, 24], ["AV3 cells", "PROBLEM", 42, 51], ["persistent infection", "PROBLEM", 63, 83], ["the CV", "TEST", 87, 93], ["B1pc strain", "PROBLEM", 94, 105], ["pancreatic carcinoma", "PROBLEM", 130, 150], ["persistent", "OBSERVATION_MODIFIER", 63, 73], ["infection", "OBSERVATION", 74, 83], ["pancreatic", "ANATOMY", 130, 140], ["carcinoma", "OBSERVATION", 141, 150]]], ["In persistent infection, VP1 was expressed frequently in cells showing mitotic bars or dividing (Fig. 4h,i).", [["cells", "ANATOMY", 57, 62], ["infection", "DISEASE", 14, 23], ["VP1", "GENE_OR_GENE_PRODUCT", 25, 28], ["cells", "CELL", 57, 62], ["VP1", "PROTEIN", 25, 28], ["persistent infection", "PROBLEM", 3, 23], ["VP1", "PROBLEM", 25, 28], ["persistent", "OBSERVATION_MODIFIER", 3, 13], ["infection", "OBSERVATION", 14, 23], ["mitotic bars", "OBSERVATION", 71, 83]]], ["The slow infectious process was not accompanied by manifest CPE.Immunostaining of enterovirus-infected cell cultures ::: ResultsIIF was also used for investigating the inhibitory effects of peptides containing the epitopes of MAbs 5D-8.1 and 9D5 in the acute model of CV-B4 infection.", [["cell cultures", "ANATOMY", 103, 116], ["CPE", "DISEASE", 60, 63], ["enterovirus-infected", "DISEASE", 82, 102], ["CV-B4 infection", "DISEASE", 268, 283], ["enterovirus", "ORGANISM", 82, 93], ["cell cultures", "CELL", 103, 116], ["9D5", "GENE_OR_GENE_PRODUCT", 242, 245], ["CV-B4", "CELL", 268, 273], ["enterovirus-infected cell cultures", "CELL_LINE", 82, 116], ["epitopes", "PROTEIN", 214, 222], ["MAbs 5D", "PROTEIN", 226, 233], ["CV-B4", "SPECIES", 268, 273], ["The slow infectious process", "PROBLEM", 0, 27], ["CPE", "PROBLEM", 60, 63], ["enterovirus", "PROBLEM", 82, 93], ["infected cell cultures", "TEST", 94, 116], ["the inhibitory effects of peptides", "TREATMENT", 164, 198], ["the epitopes of MAbs", "TREATMENT", 210, 230], ["B4 infection", "PROBLEM", 271, 283], ["slow", "OBSERVATION_MODIFIER", 4, 8], ["infectious", "OBSERVATION", 9, 19], ["CPE", "OBSERVATION", 60, 63], ["enterovirus", "OBSERVATION", 82, 93], ["infected cell", "OBSERVATION", 94, 107], ["acute", "OBSERVATION_MODIFIER", 253, 258], ["B4 infection", "OBSERVATION", 271, 283]]], ["Fluorescent staining by 5D-8.1 was totally inhibited by pre-incubation with the peptide SESIPALTAAETGHT (8 \u03bcg/ml), but not with peptide SIGNAYSNFYDG.", [["Fluorescent staining", "TEST", 0, 20], ["the peptide SESIPALTAAETGHT", "TREATMENT", 76, 103]]], ["The reverse was true for MAb 9D5: pre-incubation with SIGNAYSNFYDG (8 \u03bcg/ml), but not with SESIPALTAAETGHT, inhibited cytoplasmic fluorescence (data not shown).", [["cytoplasmic", "ANATOMY", 118, 129], ["SIGNAYSNFYDG", "CHEMICAL", 54, 66], ["MAb 9D5", "SIMPLE_CHEMICAL", 25, 32], ["cytoplasmic", "ORGANISM_SUBSTANCE", 118, 129], ["MAb 9D5", "PROTEIN", 25, 32], ["SIGNAYSNFYDG", "TREATMENT", 54, 66], ["cytoplasmic fluorescence", "TEST", 118, 142]]], ["Thus, IIF confirmed that the two AA sequences encompass the relevant epitopes.Enterovirus neutralization assays with MAbs 5D-8.1 and 9D5 ::: ResultsThe neutralizing activity of 5D-8.1 and 9D5 was explored against CV-B1 and CV-B4.", [["IIF", "GENE_OR_GENE_PRODUCT", 6, 9], ["Enterovirus", "ORGANISM", 78, 89], ["5D-8.1", "SIMPLE_CHEMICAL", 177, 183], ["9D5", "SIMPLE_CHEMICAL", 188, 191], ["CV-B1", "CELL", 213, 218], ["CV-B4", "CELL", 223, 228], ["IIF", "PROTEIN", 6, 9], ["epitopes", "PROTEIN", 69, 77], ["CV-B4", "SPECIES", 223, 228], ["IIF", "TEST", 6, 9], ["the two AA sequences", "TEST", 25, 45], ["Enterovirus neutralization assays", "TEST", 78, 111], ["MAbs", "TEST", 117, 121], ["The neutralizing activity", "TEST", 148, 173], ["CV", "TEST", 213, 215], ["B4", "ANATOMY", 226, 228]]], ["As controls, horse antiserum against CV-B1 and the CV-B4-neutralizing MAb 356 were used.", [["MAb 356", "CHEMICAL", 70, 77], ["horse", "ORGANISM", 13, 18], ["antiserum", "ORGANISM_SUBSTANCE", 19, 28], ["CV-B1", "ORGANISM", 37, 42], ["CV-B4", "GENE_OR_GENE_PRODUCT", 51, 56], ["B1", "PROTEIN", 40, 42], ["horse", "SPECIES", 13, 18], ["horse", "SPECIES", 13, 18], ["horse antiserum", "TEST", 13, 28], ["CV", "TEST", 37, 39], ["the CV", "TEST", 47, 53], ["neutralizing MAb", "TREATMENT", 57, 73], ["CV", "ANATOMY", 51, 53], ["B4", "ANATOMY", 54, 56]]], ["As shown in Table 3, the two pan-EV antibodies did not neutralize CV-B1 and CV-B4 (titer <1:8).", [["CV-B4", "CELL", 76, 81], ["pan-EV antibodies", "PROTEIN", 29, 46], ["the two pan-EV antibodies", "TEST", 21, 46], ["CV", "TEST", 76, 78], ["B4", "ANATOMY", 79, 81]]], ["As expected, control antibodies had high homotypic, but not heterotypic, neutralizing titers (anti CV-B1: 1:4096 vs. CV-B1; <1:8 vs. CV-B4 - anti CV-B4: 1:512 vs. CV-B4; <1:8 vs. CV-B1).", [["CV-B1", "ORGANISM", 117, 122], ["CV-B4", "ORGANISM", 163, 168], ["CV-B1", "ORGANISM", 179, 184], ["control antibodies", "PROTEIN", 13, 31], ["B1", "PROTEIN", 102, 104], ["B1", "PROTEIN", 120, 122], ["B4", "PROTEIN", 136, 138], ["B1", "PROTEIN", 182, 184], ["control antibodies", "TEST", 13, 31], ["high homotypic", "PROBLEM", 36, 50], ["neutralizing titers", "TEST", 73, 92], ["CV", "TEST", 117, 119], ["B1", "TEST", 120, 122], ["CV", "TEST", 133, 135], ["B4", "TEST", 136, 138], ["anti CV", "TEST", 141, 148], ["CV", "TEST", 163, 165], ["B4", "PROBLEM", 166, 168]]], ["Thus, the investigated monoclonals are devoid of neutralizing activity.DiscussionValidation of antibodies used to identify specific biomolecules is a critical issue in medicine33.", [["medicine33", "CHEMICAL", 168, 178], ["medicine33", "SIMPLE_CHEMICAL", 168, 178], ["antibodies", "PROTEIN", 95, 105], ["neutralizing activity", "PROBLEM", 49, 70], ["antibodies", "TREATMENT", 95, 105], ["neutralizing activity", "OBSERVATION", 49, 70]]], ["To this end, a variety of methods can be used, but it is recommended that rather than relying on a single antibody, researchers should have the possibility of using pairs of antibodies designed to bind different parts of the same target protein.", [["antibodies", "PROTEIN", 174, 184], ["target protein", "PROTEIN", 230, 244], ["methods", "TREATMENT", 26, 33], ["a single antibody", "TREATMENT", 97, 114], ["pairs of antibodies", "PROBLEM", 165, 184]]], ["The case of MAb 5D-8.1 is remarkable in the context of diabetes research.", [["diabetes", "DISEASE", 55, 63], ["MAb 5D", "TEST", 12, 18], ["diabetes research", "PROBLEM", 55, 72], ["diabetes", "OBSERVATION", 55, 63]]], ["In fact, numerous immunohistochemical studies with 5D-8.1 documented the presence of EV VP1 within the islets of Langerhans in a large proportion of T1D cases, but not in the pancreas of non-diabetic subjects28.", [["islets", "ANATOMY", 103, 109], ["Langerhans", "ANATOMY", 113, 123], ["pancreas", "ANATOMY", 175, 183], ["T1D", "DISEASE", 149, 152], ["EV VP1", "ORGANISM", 85, 91], ["islets", "MULTI-TISSUE_STRUCTURE", 103, 109], ["Langerhans", "MULTI-TISSUE_STRUCTURE", 113, 123], ["pancreas", "ORGAN", 175, 183], ["EV VP1", "PROTEIN", 85, 91], ["numerous immunohistochemical studies", "TEST", 9, 45], ["5D", "TEST", 51, 53], ["EV VP1", "PROBLEM", 85, 91], ["Langerhans", "PROBLEM", 113, 123], ["Langerhans", "OBSERVATION", 113, 123], ["large", "OBSERVATION_MODIFIER", 129, 134], ["T1D cases", "OBSERVATION", 149, 158], ["pancreas", "ANATOMY", 175, 183], ["non-diabetic", "OBSERVATION", 187, 199]]], ["These studies suggested that viral infection played a pathogenic role in T1D.", [["viral infection", "DISEASE", 29, 44], ["T1D", "DISEASE", 73, 76], ["These studies", "TEST", 0, 13], ["viral infection", "PROBLEM", 29, 44], ["viral", "OBSERVATION_MODIFIER", 29, 34], ["infection", "OBSERVATION", 35, 44], ["pathogenic", "OBSERVATION_MODIFIER", 54, 64]]], ["In 2013, it was shown that MAb 5D-8.1 could bind human islet proteins, specifically the mitochondrial proteins creatine kinase B-type and ATP synthase beta subunit27.", [["islet", "ANATOMY", 55, 60], ["mitochondrial", "ANATOMY", 88, 101], ["creatine", "CHEMICAL", 111, 119], ["ATP", "CHEMICAL", 138, 141], ["creatine", "CHEMICAL", 111, 119], ["ATP", "CHEMICAL", 138, 141], ["human", "ORGANISM", 49, 54], ["islet", "MULTI-TISSUE_STRUCTURE", 55, 60], ["mitochondrial", "CELLULAR_COMPONENT", 88, 101], ["creatine kinase B-type", "GENE_OR_GENE_PRODUCT", 111, 133], ["ATP synthase beta subunit27", "GENE_OR_GENE_PRODUCT", 138, 165], ["human islet proteins", "PROTEIN", 49, 69], ["mitochondrial proteins", "PROTEIN", 88, 110], ["creatine kinase B-type and ATP synthase beta subunit27", "PROTEIN", 111, 165], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 49, 54], ["MAb", "TEST", 27, 30], ["the mitochondrial proteins", "TEST", 84, 110], ["creatine kinase", "TEST", 111, 126], ["B", "TEST", 127, 128], ["ATP synthase beta subunit27", "TREATMENT", 138, 165]]], ["The finding triggered a reassessment of EV infection of pancreatic islets in T1D cases34.", [["pancreatic islets", "ANATOMY", 56, 73], ["infection", "DISEASE", 43, 52], ["T1D", "DISEASE", 77, 80], ["pancreatic islets", "MULTI-TISSUE_STRUCTURE", 56, 73], ["pancreatic islets", "CELL_TYPE", 56, 73], ["EV infection of pancreatic islets", "PROBLEM", 40, 73], ["infection", "OBSERVATION", 43, 52], ["pancreatic", "ANATOMY", 56, 66], ["islets", "OBSERVATION", 67, 73]]], ["Two subsequent publications settled the issue in part, convening that - under appropriate staining conditions - MAb 5D-8.1 was an adequate probe for EV infection2528.DiscussionAs virologists, we set out to validate the binding of 5D-8.1 and 9D5 to the EV VP1 capsid component and to identify the possible cross reactivity of these antibodies both with human proteins and viral agents.", [["infection", "DISEASE", 152, 161], ["human", "ORGANISM", 352, 357], ["5D", "PROTEIN", 230, 232], ["EV VP1 capsid component", "PROTEIN", 252, 275], ["antibodies", "PROTEIN", 331, 341], ["human proteins", "PROTEIN", 352, 366], ["human", "SPECIES", 352, 357], ["human", "SPECIES", 352, 357], ["MAb 5D", "TREATMENT", 112, 118], ["EV infection", "PROBLEM", 149, 161], ["the EV VP1 capsid component", "TEST", 248, 275], ["cross reactivity of these antibodies", "PROBLEM", 305, 341], ["human proteins", "TREATMENT", 352, 366], ["viral agents", "TREATMENT", 371, 383], ["infection", "OBSERVATION", 152, 161]]], ["Binding results and bioinformatics analyses confirmed that the epitopes of 5D-8.1 and 9D5 are distinct and located at the N- and C-terminal domains of VP1.", [["N", "CHEMICAL", 122, 123], ["C", "CHEMICAL", 129, 130], ["5D-8.1", "GENE_OR_GENE_PRODUCT", 75, 81], ["9D5", "GENE_OR_GENE_PRODUCT", 86, 89], ["VP1", "GENE_OR_GENE_PRODUCT", 151, 154], ["epitopes", "PROTEIN", 63, 71], ["5D", "PROTEIN", 75, 77], ["9D5", "PROTEIN", 86, 89], ["N- and C-terminal domains", "PROTEIN", 122, 147], ["VP1", "PROTEIN", 151, 154], ["bioinformatics analyses", "TEST", 20, 43], ["distinct", "OBSERVATION_MODIFIER", 94, 102], ["VP1", "ANATOMY", 151, 154]]], ["Both antibodies are directed to conserved domains of a capsid protein of picornaviruses, and recognize the majority of EV types.", [["antibodies", "PROTEIN", 5, 15], ["capsid protein", "PROTEIN", 55, 69], ["Both antibodies", "TREATMENT", 0, 15], ["a capsid protein of picornaviruses", "PROBLEM", 53, 87], ["picornaviruses", "OBSERVATION", 73, 87], ["EV types", "OBSERVATION", 119, 127]]], ["However, they are not neutralizing, as expected for antibodies targeting conserved regions of the viral shell.", [["antibodies", "PROTEIN", 52, 62], ["neutralizing", "PROBLEM", 22, 34], ["antibodies", "PROBLEM", 52, 62], ["not", "UNCERTAINTY", 18, 21], ["neutralizing", "OBSERVATION", 22, 34], ["viral shell", "OBSERVATION", 98, 109]]], ["Our data delineate the spectrum of EV types that each antibody binds to, thus confirming partial published results on the specificity of the two MAbs18202426.", [["Our data", "TEST", 0, 8], ["each antibody binds", "PROBLEM", 49, 68]]], ["Bioinformatics analysis indicated that the two antibodies cover EV types of the A species less well than those of the B, C, D species (Table 2).", [["B", "GENE_OR_GENE_PRODUCT", 118, 119], ["antibodies", "PROTEIN", 47, 57], ["Bioinformatics analysis", "TEST", 0, 23], ["the two antibodies", "PROBLEM", 39, 57], ["the A species", "PROBLEM", 76, 89], ["the B, C, D species", "PROBLEM", 114, 133]]], ["Since the binding spectra are not identical, the combined use of MAbs 5D-8.1 and 9D5 should allow to cover almost all EV types.", [["9D5", "PROTEIN", 81, 84], ["MAbs 5D", "TREATMENT", 65, 72]]], ["Notably, both antibodies are also predicted to cover Rabovirus and Sapeloviruses, animal viruses of the most recent genera within the Picornaviridae family.", [["antibodies", "PROTEIN", 14, 24], ["Rabovirus", "PROBLEM", 53, 62], ["Sapeloviruses", "PROBLEM", 67, 80], ["animal viruses", "PROBLEM", 82, 96]]], ["Immunofluorescence results confirmed that MAb 5D-8.1 (but not 9D5) may produce fine granular fluorescence in the cytoplasm of uninfected human and monkey cells.", [["cytoplasm", "ANATOMY", 113, 122], ["cells", "ANATOMY", 154, 159], ["MAb 5D", "GENE_OR_GENE_PRODUCT", 42, 48], ["cytoplasm", "ORGANISM_SUBSTANCE", 113, 122], ["human", "ORGANISM", 137, 142], ["monkey", "ORGANISM", 147, 153], ["cells", "CELL", 154, 159], ["9D5", "PROTEIN", 62, 65], ["uninfected human and monkey cells", "CELL_TYPE", 126, 159], ["human", "SPECIES", 137, 142], ["human", "SPECIES", 137, 142], ["Immunofluorescence", "TEST", 0, 18], ["MAb", "TEST", 42, 45], ["fine granular fluorescence", "PROBLEM", 79, 105], ["fine", "OBSERVATION_MODIFIER", 79, 83], ["granular fluorescence", "OBSERVATION", 84, 105], ["uninfected human", "OBSERVATION", 126, 142], ["monkey cells", "OBSERVATION", 147, 159]]], ["This, however, occurred only at elevated antibody concentrations (i.e., >1 \u03bcg/ml).", [["elevated antibody concentrations", "PROBLEM", 32, 64]]], ["The observation is in line with the lack of absolute specificity of EVs reported by Korsgren and collaborators27.", [["EVs", "CELL", 68, 71]]], ["We could however confirm that, when adequately diluted, the antibody produces specific staining of different EV types in cultured cells25 without fluorescent signals in uninfected cells.", [["cells25", "ANATOMY", 130, 137], ["cells", "ANATOMY", 180, 185], ["cells25", "CELL", 130, 137], ["cells", "CELL", 180, 185], ["cultured cells25", "CELL_LINE", 121, 137], ["uninfected cells", "CELL_TYPE", 169, 185], ["the antibody", "TEST", 56, 68], ["different EV types", "PROBLEM", 99, 117], ["cultured cells25", "TEST", 121, 137], ["fluorescent signals in uninfected cells", "PROBLEM", 146, 185], ["uninfected cells", "OBSERVATION", 169, 185]]], ["Of interest to diabetes research, the linear epitopes of both MAbs bear only marginal similarity with the human proteome, with a few possible exceptions.", [["diabetes", "DISEASE", 15, 23], ["MAbs", "GENE_OR_GENE_PRODUCT", 62, 66], ["human", "ORGANISM", 106, 111], ["MAbs", "PROTEIN", 62, 66], ["human", "SPECIES", 106, 111], ["human", "SPECIES", 106, 111], ["diabetes research", "PROBLEM", 15, 32]]], ["In particular, the 5D-8.1 epitope bears similarity with creatine kinase U-type (E value, 3.0), ATP synthase mitochondrial F1 complex assembly factor (E value, 12), creatine kinase B-type (E value, 66).DiscussionNotably, 9D5 - that has been used for a long time in diagnostic virology1820 \u2013does not produce background staining in uninfected cultured cells and delineates clearly the expression of VP1 in acutely- and persistently-infected cells.", [["cells", "ANATOMY", 349, 354], ["cells", "ANATOMY", 438, 443], ["creatine", "CHEMICAL", 56, 64], ["ATP", "CHEMICAL", 95, 98], ["creatine", "CHEMICAL", 164, 172], ["acutely- and persistently-infected", "DISEASE", 403, 437], ["creatine", "CHEMICAL", 56, 64], ["ATP", "CHEMICAL", 95, 98], ["creatine", "CHEMICAL", 164, 172], ["creatine kinase U", "GENE_OR_GENE_PRODUCT", 56, 73], ["ATP synthase", "GENE_OR_GENE_PRODUCT", 95, 107], ["mitochondrial F1 complex", "GENE_OR_GENE_PRODUCT", 108, 132], ["creatine kinase B", "GENE_OR_GENE_PRODUCT", 164, 181], ["9D5", "SIMPLE_CHEMICAL", 220, 223], ["cells", "CELL", 349, 354], ["VP1", "GENE_OR_GENE_PRODUCT", 396, 399], ["cells", "CELL", 438, 443], ["5D-8.1 epitope", "PROTEIN", 19, 33], ["creatine kinase U", "PROTEIN", 56, 73], ["ATP synthase", "PROTEIN", 95, 107], ["mitochondrial F1 complex assembly factor", "PROTEIN", 108, 148], ["creatine kinase B", "PROTEIN", 164, 181], ["9D5", "DNA", 220, 223], ["uninfected cultured cells", "CELL_LINE", 329, 354], ["VP1", "PROTEIN", 396, 399], ["acutely- and persistently-infected cells", "CELL_TYPE", 403, 443], ["creatine kinase U", "TEST", 56, 73], ["type (E value", "TEST", 74, 87], ["ATP synthase", "TEST", 95, 107], ["E value", "TEST", 150, 157], ["creatine kinase B", "TEST", 164, 181], ["E value", "TEST", 188, 195], ["background staining in uninfected cultured cells", "PROBLEM", 306, 354], ["VP1", "TEST", 396, 399], ["persistently-infected cells", "PROBLEM", 416, 443], ["infected cells", "OBSERVATION", 429, 443]]], ["Immunofluorescent staining of cultured cells cannot be compared directly with that of immunocytochemistry.", [["cells", "ANATOMY", 39, 44], ["cells", "CELL", 39, 44], ["cultured cells", "CELL_LINE", 30, 44], ["Immunofluorescent staining", "TEST", 0, 26], ["cultured cells", "PROBLEM", 30, 44], ["immunocytochemistry", "TEST", 86, 105], ["cultured cells", "OBSERVATION", 30, 44]]], ["In formalin-fixed, paraffin-embedded samples, antigen retrieval is mandatory for VP1 detection25 (suggesting that protein denaturation may favor antibody binding).", [["samples", "ANATOMY", 37, 44], ["formalin", "CHEMICAL", 3, 11], ["paraffin", "CHEMICAL", 19, 27], ["antigen", "GENE_OR_GENE_PRODUCT", 46, 53], ["VP1", "ORGANISM", 81, 84], ["VP1 detection25", "PROTEIN", 81, 96], ["antigen retrieval", "TREATMENT", 46, 63], ["VP1 detection25", "TEST", 81, 96], ["protein denaturation", "PROBLEM", 114, 134], ["antibody binding", "PROBLEM", 145, 161]]], ["In contrast, staining of cultured cells with either of these MAbs gives excellent results upon acetone or paraformaldehyde fixation (i.e., procedures not causing protein unfolding).", [["cells", "ANATOMY", 34, 39], ["acetone", "CHEMICAL", 95, 102], ["acetone", "CHEMICAL", 95, 102], ["paraformaldehyde", "CHEMICAL", 106, 122], ["cells", "CELL", 34, 39], ["acetone", "SIMPLE_CHEMICAL", 95, 102], ["paraformaldehyde", "SIMPLE_CHEMICAL", 106, 122], ["cultured cells", "CELL_LINE", 25, 39], ["cultured cells", "PROBLEM", 25, 39], ["these MAbs", "TEST", 55, 65], ["acetone", "TREATMENT", 95, 102], ["paraformaldehyde fixation", "TREATMENT", 106, 131], ["protein unfolding", "PROBLEM", 162, 179], ["paraformaldehyde fixation", "OBSERVATION", 106, 131]]], ["Whether the two MAbs can bind to VP1 in its native configuration35 within live virus particles is currently under investigation.DiscussionFinally, in persistently-infected cells, expression of VP1 was frequently seen in proliferating cells with both 5D-8.1 and 9D5.", [["cells", "ANATOMY", 172, 177], ["cells", "ANATOMY", 234, 239], ["MAbs", "GENE_OR_GENE_PRODUCT", 16, 20], ["VP1", "GENE_OR_GENE_PRODUCT", 33, 36], ["live virus particles", "ORGANISM", 74, 94], ["cells", "CELL", 172, 177], ["VP1", "GENE_OR_GENE_PRODUCT", 193, 196], ["cells", "CELL", 234, 239], ["MAbs", "PROTEIN", 16, 20], ["VP1", "DNA", 33, 36], ["VP1", "PROTEIN", 193, 196], ["proliferating cells", "CELL_TYPE", 220, 239], ["the two MAbs", "TREATMENT", 8, 20], ["VP1", "TEST", 33, 36], ["persistently-infected cells", "PROBLEM", 150, 177], ["VP1", "PROBLEM", 193, 196], ["proliferating cells", "PROBLEM", 220, 239], ["infected cells", "OBSERVATION", 163, 177], ["VP1", "ANATOMY", 193, 196], ["proliferating cells", "OBSERVATION", 220, 239]]], ["The finding may not be accidental.", [["may not be", "UNCERTAINTY", 12, 22]]], ["In fact, the cellular factor 68-kDa Src-associated protein in mitosis (Sam68) has been recently shown to interact with the EV IRES during infection, thus enhancing translation of virus proteins36.", [["cellular", "ANATOMY", 13, 21], ["infection", "DISEASE", 138, 147], ["cellular", "CELL", 13, 21], ["68-kDa", "GENE_OR_GENE_PRODUCT", 29, 35], ["mitosis", "CELLULAR_COMPONENT", 62, 69], ["Sam68", "GENE_OR_GENE_PRODUCT", 71, 76], ["EV", "GENE_OR_GENE_PRODUCT", 123, 125], ["cellular factor 68-kDa Src-associated protein", "PROTEIN", 13, 58], ["Sam68", "PROTEIN", 71, 76], ["EV IRES", "DNA", 123, 130], ["virus proteins36", "PROTEIN", 179, 195], ["the cellular factor", "TEST", 9, 28], ["protein in mitosis (Sam68", "PROBLEM", 51, 76], ["the EV IRES during infection", "PROBLEM", 119, 147], ["enhancing translation of virus proteins", "PROBLEM", 154, 193], ["infection", "OBSERVATION", 138, 147]]], ["This aspect merits further attention due to its possible impact on EV pathogenesis36DiscussionIn conclusion, both MAbs bind to the VP1 capsid protein of EVs and of phylogenetically-related picornaviruses.", [["EVs", "ANATOMY", 153, 156], ["EVs", "CELL", 153, 156], ["picornaviruses", "ORGANISM", 189, 203], ["MAbs", "PROTEIN", 114, 118], ["VP1 capsid protein", "PROTEIN", 131, 149], ["the VP1 capsid protein", "TEST", 127, 149], ["picornaviruses", "PROBLEM", 189, 203], ["picornaviruses", "OBSERVATION", 189, 203]]], ["Epitopes are located in distinct stretches of the VP1 protein.", [["VP1", "GENE_OR_GENE_PRODUCT", 50, 53], ["VP1 protein", "PROTEIN", 50, 61], ["Epitopes", "TREATMENT", 0, 8], ["distinct", "OBSERVATION_MODIFIER", 24, 32], ["stretches", "OBSERVATION_MODIFIER", 33, 42], ["VP1 protein", "OBSERVATION", 50, 61]]], ["The MAbs recognize both acute and persistent infection in cultured cells, and are devoid of EV-neutralizing activity.", [["cells", "ANATOMY", 67, 72], ["infection", "DISEASE", 45, 54], ["cells", "CELL", 67, 72], ["EV", "GENE_OR_GENE_PRODUCT", 92, 94], ["MAbs", "PROTEIN", 4, 8], ["cultured cells", "CELL_LINE", 58, 72], ["persistent infection in cultured cells", "PROBLEM", 34, 72], ["EV", "TEST", 92, 94], ["both", "OBSERVATION_MODIFIER", 19, 23], ["acute", "OBSERVATION_MODIFIER", 24, 29], ["persistent", "OBSERVATION_MODIFIER", 34, 44], ["infection", "OBSERVATION", 45, 54], ["neutralizing activity", "OBSERVATION", 95, 116]]], ["Thus, these distinct and independent probes will be useful for confirming histopathologic and virology data that indicate EV infection of islet cells as having a pathogenic role in diabetes.", [["islet cells", "ANATOMY", 138, 149], ["infection", "DISEASE", 125, 134], ["diabetes", "DISEASE", 181, 189], ["islet cells", "CELL", 138, 149], ["islet cells", "CELL_TYPE", 138, 149], ["histopathologic and virology data", "TEST", 74, 107], ["EV infection of islet cells", "PROBLEM", 122, 149], ["diabetes", "PROBLEM", 181, 189], ["infection", "OBSERVATION", 125, 134], ["diabetes", "OBSERVATION", 181, 189]]], ["Further virus searches in diabetes and other endocrine diseases are expected.Identification of linear epitopes in VP1 sequences of four enterovirus types ::: MethodsThe linear epitopes of MAbs 5D-8.1 and 9D5 in the VP1 capsid protein of enteroviruses were mapped using peptide microarray technology37.", [["endocrine", "ANATOMY", 45, 54], ["diabetes", "DISEASE", 26, 34], ["endocrine diseases", "DISEASE", 45, 63], ["endocrine", "ANATOMICAL_SYSTEM", 45, 54], ["VP1", "ORGANISM", 114, 117], ["enterovirus", "ORGANISM", 136, 147], ["9D5", "GENE_OR_GENE_PRODUCT", 204, 207], ["VP1", "ORGANISM", 215, 218], ["enteroviruses", "ORGANISM", 237, 250], ["VP1 sequences", "DNA", 114, 127], ["MAbs 5D", "PROTEIN", 188, 195], ["9D5", "PROTEIN", 204, 207], ["VP1 capsid protein", "PROTEIN", 215, 233], ["Further virus searches", "PROBLEM", 0, 22], ["diabetes", "PROBLEM", 26, 34], ["other endocrine diseases", "PROBLEM", 39, 63], ["linear epitopes in VP1 sequences", "PROBLEM", 95, 127], ["Methods", "TREATMENT", 158, 165], ["MAbs", "TEST", 188, 192], ["enteroviruses", "PROBLEM", 237, 250], ["peptide microarray technology37", "TREATMENT", 269, 300], ["virus", "OBSERVATION", 8, 13], ["endocrine diseases", "OBSERVATION", 45, 63], ["linear", "OBSERVATION_MODIFIER", 95, 101], ["epitopes", "OBSERVATION", 102, 110], ["linear", "OBSERVATION_MODIFIER", 169, 175], ["epitopes", "OBSERVATION_MODIFIER", 176, 184], ["VP1 capsid", "ANATOMY", 215, 225], ["enteroviruses", "OBSERVATION", 237, 250]]], ["The N- and C-termini of VP1 sequences of four enterovirus types [coxsackievirus B1 (CV-B1; K4N918), coxsackievirus-B4 (CV-B4; S5PU54), echovirus-30 (E-30; Q9YLK0), and coxsackievirus-A1 (CV-A1; Q9YLP4)] were elongated by neutral GSGSGSG linkers to avoid truncated peptides.", [["N", "CHEMICAL", 4, 5], ["coxsackievirus B1", "ORGANISM", 65, 82], ["CV-B1; K4N918", "ORGANISM", 84, 97], ["coxsackievirus-B4", "ORGANISM", 100, 117], ["CV-B4; S5PU54", "ORGANISM", 119, 132], ["echovirus-30", "ORGANISM", 135, 147], ["E-30; Q9YLK0", "ORGANISM", 149, 161], ["coxsackievirus-A1", "ORGANISM", 168, 185], ["Q9YLP4", "GENE_OR_GENE_PRODUCT", 194, 200], ["N- and C-termini", "PROTEIN", 4, 20], ["VP1 sequences", "DNA", 24, 37], ["coxsackievirus-B4", "SPECIES", 100, 117], ["coxsackievirus-", "SPECIES", 168, 183], ["coxsackievirus B1 (CV-B1; K4N918", "SPECIES", 65, 97], ["coxsackievirus-B4 (CV-B4; S5PU54), echovirus-30", "SPECIES", 100, 147], ["coxsackievirus-A1 (CV-A1; Q9YLP4", "SPECIES", 168, 200], ["The N", "TEST", 0, 5], ["VP1 sequences", "TEST", 24, 37], ["four enterovirus types", "TEST", 41, 63], ["coxsackievirus", "TEST", 65, 79], ["B1", "TEST", 80, 82], ["CV", "TEST", 84, 86], ["B1", "TEST", 87, 89], ["K4N918", "TEST", 91, 97], ["coxsackievirus", "TEST", 100, 114], ["B4", "TEST", 115, 117], ["CV", "TEST", 119, 121], ["B4", "TEST", 122, 124], ["echovirus", "TEST", 135, 144], ["coxsackievirus", "TEST", 168, 182], ["neutral GSGSGSG linkers", "TREATMENT", 221, 244], ["truncated peptides", "PROBLEM", 254, 272]]], ["Elongated sequences were linked to a single artificial sequence.", [["a single artificial sequence", "TEST", 35, 63]]], ["The elongated artificial sequence was translated into 15 AA peptides with a peptide-peptide overlap of 14 amino acids and bound to duplicate spots of silica microarrays.", [["amino acids", "CHEMICAL", 106, 117], ["amino acids", "CHEMICAL", 106, 117], ["silica", "CHEMICAL", 150, 156], ["amino acids", "AMINO_ACID", 106, 117], ["The elongated artificial sequence", "PROBLEM", 0, 33], ["15 AA peptides", "TREATMENT", 54, 68], ["a peptide-peptide overlap of 14 amino acids", "TREATMENT", 74, 117], ["silica microarrays", "TREATMENT", 150, 168], ["elongated", "OBSERVATION_MODIFIER", 4, 13], ["silica microarrays", "OBSERVATION", 150, 168]]], ["The resulting microarrays covered peptides of all four sequences (1,181 different peptides in duplicate).", [["all four sequences", "TEST", 46, 64]]], ["For control, microarrays were framed by HA (YPYDVPDYAG) and FLAG (DYKDDDDKGG) peptides (104 spots).", [["FLAG (DYKDDDDKGG) peptides", "GENE_OR_GENE_PRODUCT", 60, 86], ["YPYDVPDYAG", "PROTEIN", 44, 54], ["FLAG", "PROTEIN", 60, 64], ["DYKDDDDKGG", "PROTEIN", 66, 76], ["microarrays", "TEST", 13, 24], ["FLAG (DYKDDDDKGG) peptides", "TREATMENT", 60, 86]]], ["Rockland blocking buffer MB-070 (VWR International Frankfurt, DE), PBS plus 0.05% Tween 20, PBS-Tween plus 10% Rockland blocking buffer were used for blocking, washing, and incubation procedures, respectively.", [["MB-070", "CHEMICAL", 25, 31], ["Tween 20", "CHEMICAL", 82, 90], ["Tween", "CHEMICAL", 96, 101], ["Rockland", "SIMPLE_CHEMICAL", 0, 8], ["MB-070", "SIMPLE_CHEMICAL", 25, 31], ["Rockland", "SIMPLE_CHEMICAL", 111, 119], ["PBS", "TEST", 67, 70], ["PBS", "TREATMENT", 92, 95], ["Rockland blocking buffer", "TREATMENT", 111, 135], ["blocking, washing", "TREATMENT", 150, 167], ["incubation procedures", "TREATMENT", 173, 194]]], ["Mouse mAb 5D-8.1 (IgG2a; Dako, Cernusco sul Naviglio, Italy) and 9D5 (IgG3; Millipore, Livingstone, UK) were incubated at 10 \u03bcg/ml in the microarray for 16 h at 4 \u00b0C with shaking.", [["Mouse", "ORGANISM", 0, 5], ["IgG2a", "ORGANISM", 18, 23], ["Mouse mAb 5D", "PROTEIN", 0, 12], ["IgG2a", "PROTEIN", 18, 23], ["IgG3", "PROTEIN", 70, 74], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5], ["Mouse mAb 5D", "TEST", 0, 12], ["IgG2a", "TEST", 18, 23], ["shaking", "PROBLEM", 171, 178]]], ["Goat anti-mouse IgG-DyLight680 (New England Biolabs, Frankfurt, DE) served as secondary antibody and was incubated for 30 min at room temperature.", [["Goat anti-mouse IgG", "PROTEIN", 0, 19], ["secondary antibody", "PROTEIN", 78, 96], ["Goat", "SPECIES", 0, 4], ["anti-mouse", "SPECIES", 5, 15], ["Goat", "SPECIES", 0, 4], ["Goat anti-mouse IgG", "TEST", 0, 19]]], ["HA and FLAG control peptides framing the microarray were subsequently stained with MAb anti-HA-DyLight680 (red) and MAb anti-FLAG-DyLight800 (green).", [["HA", "GENE_OR_GENE_PRODUCT", 0, 2], ["FLAG", "GENE_OR_GENE_PRODUCT", 7, 11], ["anti-HA", "GENE_OR_GENE_PRODUCT", 87, 94], ["DyLight680", "GENE_OR_GENE_PRODUCT", 95, 105], ["MAb anti-HA", "PROTEIN", 83, 94], ["DyLight680", "PROTEIN", 95, 105], ["red", "PROTEIN", 107, 110], ["MAb anti-FLAG", "PROTEIN", 116, 129], ["DyLight800", "PROTEIN", 130, 140], ["HA", "PROBLEM", 0, 2], ["FLAG control peptides", "TREATMENT", 7, 28], ["the microarray", "TEST", 37, 51], ["MAb anti-HA", "TEST", 83, 94], ["MAb anti-FLAG", "TEST", 116, 129]]], ["Light emission was read with a LI-COR Odyssey Infrared Imaging System (resolution 21 \u03bcm; 700 nm; LI-COR Biosciences, Bad Homburg, DE).", [["Light emission", "TEST", 0, 14], ["resolution", "TEST", 71, 81], ["LI", "TEST", 97, 99]]], ["Staining with MAbs anti-HA and anti-FLAG confirmed the assay quality and microarray integrity (scanning intensities red/green 7/7).Substitution scan of the peptide SESIPALTAAETGHT against MAb 5D-81 ::: MethodsPeptide array synthesis and binding detection were performed by PEPperPRINT GmbH (PEPperPRINT, Heidelberg, Germany) as reported3839.", [["MAb 5D-81", "CHEMICAL", 188, 197], ["anti-HA", "GENE_OR_GENE_PRODUCT", 19, 26], ["anti-FLAG", "GENE_OR_GENE_PRODUCT", 31, 40], ["MAbs anti-HA", "PROTEIN", 14, 26], ["anti-FLAG", "PROTEIN", 31, 40], ["MAbs anti-HA", "TREATMENT", 14, 26], ["anti-FLAG", "TREATMENT", 31, 40], ["the assay quality", "TEST", 51, 68], ["microarray integrity", "TEST", 73, 93], ["scanning intensities", "TEST", 95, 115], ["Substitution scan", "TEST", 131, 148], ["binding detection", "TEST", 237, 254]]], ["Permutation scans were carried out on the peptide SESIPALTAAETGHT (containing the MAb 5D-8.1 epitope) and on its variants.", [["MAb 5D-8.1 epitope", "PROTEIN", 82, 100], ["Permutation scans", "TEST", 0, 17], ["the peptide SESIPALTAAETGHT", "TREATMENT", 38, 65], ["the MAb 5D", "TREATMENT", 78, 88]]], ["In the permutation scan, the effect on binding of replacing each of the 15 peptide positions by standard L-amino-acids was analyzed.", [["L-amino-acids", "CHEMICAL", 105, 118], ["L-amino-acids", "CHEMICAL", 105, 118], ["L-amino-acids", "SIMPLE_CHEMICAL", 105, 118], ["the permutation scan", "TEST", 3, 23], ["standard L-amino-acids", "TREATMENT", 96, 118]]], ["Each microarray contained 286 peptides printed in duplicate and was framed by HA and FLAG control peptides.", [["Each microarray", "TEST", 0, 15], ["FLAG control peptides", "TREATMENT", 85, 106]]], ["One peptide microarray copy was pre-stained with the secondary goat anti-mouse IgG (H+L) DyLight680 antibody (red) in the presence of the monoclonal anti-HA (12CA5)-DyLight800 antibody (green) followed by read-out at scanning intensities of 7/7 (red/green).", [["anti-HA", "GENE_OR_GENE_PRODUCT", 149, 156], ["12CA5", "SIMPLE_CHEMICAL", 158, 163], ["secondary goat anti-mouse IgG (H+L) DyLight680 antibody", "PROTEIN", 53, 108], ["red", "PROTEIN", 110, 113], ["monoclonal anti-HA", "PROTEIN", 138, 156], ["12CA5", "PROTEIN", 158, 163], ["DyLight800 antibody", "PROTEIN", 165, 184], ["goat", "SPECIES", 63, 67], ["anti-mouse", "SPECIES", 68, 78], ["goat", "SPECIES", 63, 67], ["One peptide microarray copy", "TEST", 0, 27], ["the secondary goat anti-mouse IgG", "TEST", 49, 82], ["DyLight680 antibody", "TEST", 89, 108], ["the monoclonal anti-HA", "TEST", 134, 156], ["DyLight800 antibody", "TEST", 165, 184], ["scanning intensities", "TEST", 217, 237]]], ["Incubation of a second peptide microarray with MAb 5D-8.1 (1 \u03bcg/ml) was followed by staining with the secondary antibody in the presence of the monoclonal anti-HA (12CA5)-DyLight800 control antibody and then read-out at scanning intensities of 7/7 (red/green).", [["MAb 5D-8.1", "CHEMICAL", 47, 57], ["anti-HA", "GENE_OR_GENE_PRODUCT", 155, 162], ["secondary antibody", "PROTEIN", 102, 120], ["monoclonal anti-HA (12CA5)-DyLight800 control antibody", "PROTEIN", 144, 198], ["a second peptide microarray", "TREATMENT", 14, 41], ["MAb 5D", "TREATMENT", 47, 53], ["the secondary antibody", "PROBLEM", 98, 120], ["the monoclonal anti-HA", "TEST", 140, 162], ["scanning intensities", "TEST", 220, 240]]], ["Finally, the FLAG control peptides framing the peptide arrays were stained as additional internal quality control to confirm the assay quality and the peptide microarray integrity (scanning intensities red/green: 7/7).Substitution scan of the peptide SESIPALTAAETGHT against MAb 5D-81 ::: MethodsQuantification of spot intensities and peptide annotation were based on 16-bit gray scale tiff files at scanning intensities of 7/7.", [["MAb 5D-81", "CHEMICAL", 275, 284], ["FLAG", "GENE_OR_GENE_PRODUCT", 13, 17], ["the FLAG control peptides", "TREATMENT", 9, 34], ["the peptide arrays", "TREATMENT", 43, 61], ["the assay quality", "TEST", 125, 142], ["the peptide microarray integrity", "TEST", 147, 179], ["scanning intensities", "TEST", 181, 201], ["Substitution scan", "TEST", 218, 235], ["spot intensities", "TEST", 314, 330], ["peptide annotation", "TEST", 335, 353], ["scanning intensities", "TEST", 400, 420]]], ["Microarray image analysis was done with PepSlide Analyzer.", [["Microarray image analysis", "TEST", 0, 25], ["PepSlide Analyzer", "TEST", 40, 57]]], ["A software algorithm broke down fluorescence intensities of each channel and spot into raw, foreground, background signal and calculated the standard deviation of median foreground intensities.", [["A software algorithm", "TEST", 0, 20], ["foreground, background signal", "PROBLEM", 92, 121], ["median foreground intensities", "OBSERVATION", 163, 192]]], ["Based on averaged median foreground intensities, an intensity map was generated and interactions in the peptide map were highlighted by an intensity color code with red for high and white for low spot intensities.", [["an intensity map", "TEST", 49, 65], ["the peptide map", "TEST", 100, 115], ["high and white for low spot intensities", "PROBLEM", 173, 212]]], ["To provide an in-depth view on the substitution scan, a heat map of the peptide microarray was generated as well as a substitution matrix and an AA plot reflecting the AA preferences at a given position.", [["the substitution scan", "TEST", 31, 52], ["a heat map", "TEST", 54, 64], ["the peptide microarray", "TEST", 68, 90], ["a substitution matrix", "TREATMENT", 116, 137], ["an AA plot", "TEST", 142, 152]]], ["Data sets were correlated with peptide and intensity maps to analyze the substitution pattern in consideration of conserved/variable amino acids and possible AA exchanges.Substitution scan of the peptide SESIPALTAAETGHT against MAb 5D-81 ::: MethodsThe substitution matrix highlighted the preference for a given AA by color codes (red: preferred AA; light blue: less preferred AAs) and was calculated by dividing the spot intensity of a given peptide (e.g., 1-YPYDVQDYA-9) by the averaged spot intensities of all 20 peptides that were substituted at the same position (1-YPYDVQDYA-9).", [["amino acids", "CHEMICAL", 133, 144], ["AA", "CHEMICAL", 158, 160], ["MAb 5D-81", "CHEMICAL", 228, 237], ["AA", "CHEMICAL", 312, 314], ["1-YPYDVQDYA-9", "CHEMICAL", 458, 471], ["1-YPYDVQDYA-9", "CHEMICAL", 569, 582], ["amino acids", "CHEMICAL", 133, 144], ["amino acids", "AMINO_ACID", 133, 144], ["AA", "SIMPLE_CHEMICAL", 158, 160], ["AA", "SIMPLE_CHEMICAL", 312, 314], ["Data sets", "TEST", 0, 9], ["intensity maps", "TEST", 43, 57], ["the substitution pattern", "PROBLEM", 69, 93], ["conserved/variable amino acids", "TREATMENT", 114, 144], ["AA exchanges", "TREATMENT", 158, 170], ["Substitution scan", "TEST", 171, 188], ["Methods", "TREATMENT", 242, 249], ["The substitution matrix", "TREATMENT", 249, 272], ["light blue", "TEST", 350, 360], ["peptide", "TEST", 443, 450], ["all 20 peptides", "TREATMENT", 509, 524], ["YPYDVQDYA", "TEST", 571, 580], ["substitution matrix", "OBSERVATION", 253, 272]]], ["The AA plot was calculated by dividing the spot intensity of a given peptide (1-YPYDVQDYA-9) by the spot intensity of the wild type epitope (1-YPYDVQDYA-9).", [["1-YPYDVQDYA-9", "CHEMICAL", 78, 91], ["1-YPYDVQDYA-9", "CHEMICAL", 141, 154], ["wild type epitope", "PROTEIN", 122, 139], ["The AA plot", "TEST", 0, 11], ["peptide", "TEST", 69, 76], ["the wild type epitope", "PROBLEM", 118, 139], ["YPYDVQDYA", "TEST", 143, 152]]], ["The position of an AA at a given position thus reflected the intensity ratio compared to the AA of the native epitope at the same position.Cell lines, viruses, indirect immunofluorescence (IIF) and neutralization assays ::: MethodsThe human cell lines AV3, HeLa, RD and the monkey line LLC-MK2 (ECAAC, Salisbury, UK) were cultured in DMEM/F12 medium supplemented with 10% FCS plus penicillin/streptomycin.", [["Cell lines", "ANATOMY", 139, 149], ["cell lines AV3", "ANATOMY", 241, 255], ["HeLa", "ANATOMY", 257, 261], ["AA", "CHEMICAL", 19, 21], ["FCS", "CHEMICAL", 372, 375], ["penicillin", "CHEMICAL", 381, 391], ["streptomycin", "CHEMICAL", 392, 404], ["penicillin", "CHEMICAL", 381, 391], ["streptomycin", "CHEMICAL", 392, 404], ["AA", "SIMPLE_CHEMICAL", 19, 21], ["Cell lines", "CELL", 139, 149], ["human", "ORGANISM", 235, 240], ["cell lines AV3", "CELL", 241, 255], ["HeLa", "CELL", 257, 261], ["RD", "CELL", 263, 265], ["monkey", "ORGANISM", 274, 280], ["LLC-MK2", "CELL", 286, 293], ["ECAAC", "CELL", 295, 300], ["UK", "GENE_OR_GENE_PRODUCT", 313, 315], ["FCS", "SIMPLE_CHEMICAL", 372, 375], ["penicillin", "SIMPLE_CHEMICAL", 381, 391], ["streptomycin", "SIMPLE_CHEMICAL", 392, 404], ["native epitope", "PROTEIN", 103, 117], ["human cell lines", "CELL_LINE", 235, 251], ["AV3", "CELL_LINE", 252, 255], ["HeLa", "CELL_LINE", 257, 261], ["RD", "CELL_LINE", 263, 265], ["MK2", "CELL_LINE", 290, 293], ["ECAAC", "CELL_LINE", 295, 300], ["human", "SPECIES", 235, 240], ["human", "SPECIES", 235, 240], ["an AA", "TREATMENT", 16, 21], ["the intensity ratio", "PROBLEM", 57, 76], ["Cell lines", "TREATMENT", 139, 149], ["indirect immunofluorescence", "TEST", 160, 187], ["Methods", "TREATMENT", 224, 231], ["The human cell lines AV3", "TEST", 231, 255], ["HeLa", "TEST", 257, 261], ["the monkey line LLC", "TEST", 270, 289], ["penicillin", "TREATMENT", 381, 391], ["streptomycin", "TREATMENT", 392, 404], ["position", "OBSERVATION_MODIFIER", 4, 12], ["native", "OBSERVATION_MODIFIER", 103, 109], ["epitope", "OBSERVATION", 110, 117], ["viruses", "OBSERVATION_MODIFIER", 151, 158], ["human cell lines", "OBSERVATION", 235, 251], ["LLC", "ANATOMY", 286, 289]]], ["EV types CV-B1 (Conn-5), CV-B4 (J.V.B.), E-30 (Bastianni), CV-A1 (Tompkins) obtained from ATCC (LGC Standards, Sesto San Giovanni, Italy) were amplified in vitro, titrated and stored at \u221270 \u00b0C. For acute infection, subconfluent cultures were infected at a multiplicity of infection of 0.5 and incubated 3\u20136 hours.", [["subconfluent cultures", "ANATOMY", 215, 236], ["acute infection", "DISEASE", 198, 213], ["infection", "DISEASE", 272, 281], ["Conn-5", "ORGANISM", 16, 22], ["CV-B4", "CELL", 25, 30], ["E-30", "ORGANISM", 41, 45], ["CV-A1", "CELL", 59, 64], ["ATCC", "CELL", 90, 94], ["subconfluent cultures", "CELL", 215, 236], ["subconfluent cultures", "CELL_LINE", 215, 236], ["E-30", "SPECIES", 41, 45], ["ATCC", "SPECIES", 90, 94], ["EV types CV", "TEST", 0, 11], ["CV", "TEST", 25, 27], ["E", "TEST", 41, 42], ["Bastianni", "TEST", 47, 56], ["CV", "TEST", 59, 61], ["acute infection", "PROBLEM", 198, 213], ["subconfluent cultures", "TEST", 215, 236], ["infection", "PROBLEM", 272, 281], ["acute", "OBSERVATION_MODIFIER", 198, 203], ["infection", "OBSERVATION", 204, 213], ["subconfluent", "OBSERVATION_MODIFIER", 215, 227], ["cultures", "OBSERVATION_MODIFIER", 228, 236], ["infection", "OBSERVATION", 272, 281]]], ["Persistent infection was investigated in the AV3 cell line that had been chronically infected with CV-B1pc (a virus strain isolated from tissue collateral to pancreatic carcinoma).", [["AV3 cell line", "ANATOMY", 45, 58], ["tissue collateral", "ANATOMY", 137, 154], ["pancreatic carcinoma", "ANATOMY", 158, 178], ["infection", "DISEASE", 11, 20], ["pancreatic carcinoma", "DISEASE", 158, 178], ["AV3 cell line", "CELL", 45, 58], ["CV-B1pc", "ORGANISM", 99, 106], ["tissue collateral", "MULTI-TISSUE_STRUCTURE", 137, 154], ["pancreatic carcinoma", "CANCER", 158, 178], ["AV3 cell line", "CELL_LINE", 45, 58], ["CV-B1pc", "SPECIES", 99, 106], ["Persistent infection", "PROBLEM", 0, 20], ["the AV3 cell line", "TREATMENT", 41, 58], ["CV", "TEST", 99, 101], ["a virus strain", "PROBLEM", 108, 122], ["pancreatic carcinoma", "PROBLEM", 158, 178], ["infection", "OBSERVATION", 11, 20], ["AV3 cell line", "OBSERVATION", 45, 58], ["chronically", "OBSERVATION_MODIFIER", 73, 84], ["infected", "OBSERVATION", 85, 93], ["pancreatic", "ANATOMY", 158, 168], ["carcinoma", "OBSERVATION", 169, 178]]], ["AV3 cells carrying CV-B1pc do not show evident CPE, maintain apparently normal replication rate, and release minimal amounts of virus in the medium as seen by RT-PCR and virus titration (\u2264100 TCID50/ml; manuscript in preparation).", [["AV3 cells", "ANATOMY", 0, 9], ["AV3 cells", "CELL", 0, 9], ["CV-B1pc", "GENE_OR_GENE_PRODUCT", 19, 26], ["AV3 cells", "CELL_LINE", 0, 9], ["B1pc", "PROTEIN", 22, 26], ["CV-B1pc", "TEST", 19, 26], ["CPE", "PROBLEM", 47, 50], ["virus", "PROBLEM", 128, 133], ["PCR", "TEST", 162, 165], ["virus titration", "TREATMENT", 170, 185]]], ["Persistently infected cells were at the 10th\u201320th passage.Cell lines, viruses, indirect immunofluorescence (IIF) and neutralization assays ::: MethodsFor IIF, cells were cultured in 4-well Millicell EZ Slides (Merck, Vimodrone, Italy).", [["cells", "ANATOMY", 22, 27], ["Cell lines", "ANATOMY", 58, 68], ["cells", "ANATOMY", 159, 164], ["cells", "CELL", 22, 27], ["Cell lines", "CELL", 58, 68], ["cells", "CELL", 159, 164], ["IIF", "PROTEIN", 154, 157], ["Persistently infected cells", "PROBLEM", 0, 27], ["Cell lines", "TREATMENT", 58, 68], ["indirect immunofluorescence", "TEST", 79, 106], ["IIF", "TEST", 154, 157], ["infected cells", "OBSERVATION", 13, 27], ["viruses", "OBSERVATION_MODIFIER", 70, 77]]], ["Cell monolayers were fixed in 4% paraformaldehyde in PBS (r.t., 30 min), washed 3\u00d7 in PBS-1% FCS, permeabilized with Triton X100 (0.05% in PBS; 10 min), washed 3\u00d7 in PBS-1% FCS, briefly immersed in distilled water and dried out.", [["Cell monolayers", "ANATOMY", 0, 15], ["Triton X100", "CHEMICAL", 117, 128], ["paraformaldehyde", "CHEMICAL", 33, 49], ["Triton X100", "CHEMICAL", 117, 128], ["Cell monolayers", "CELL", 0, 15], ["paraformaldehyde", "SIMPLE_CHEMICAL", 33, 49], ["FCS", "SIMPLE_CHEMICAL", 93, 96], ["Triton X100", "SIMPLE_CHEMICAL", 117, 128], ["Cell monolayers", "TEST", 0, 15], ["Triton", "TREATMENT", 117, 123]]], ["Fixed slides were incubated overnight at 4 \u00b0C with 0.5, 1, or 5 \u03bcg/ml of mouse pan-EV MAb 5D-8.1 (IgG2a) or MAb 9D5 (IgG3).", [["mouse", "ORGANISM", 73, 78], ["IgG2a", "GENE_OR_GENE_PRODUCT", 98, 103], ["MAb 9D5", "SIMPLE_CHEMICAL", 108, 115], ["IgG3", "GENE_OR_GENE_PRODUCT", 117, 121], ["mouse pan-EV MAb 5D-8.1", "PROTEIN", 73, 96], ["IgG2a", "PROTEIN", 98, 103], ["MAb 9D5", "PROTEIN", 108, 115], ["IgG3", "PROTEIN", 117, 121], ["mouse", "SPECIES", 73, 78], ["mouse", "SPECIES", 73, 78], ["Fixed slides", "TEST", 0, 12], ["mouse pan-EV MAb", "TEST", 73, 89], ["IgG2a", "TEST", 98, 103], ["MAb", "TEST", 108, 111]]], ["Staining was achieved with the secondary antibodies FITC-labeled goat anti-mouse IgG H+L (Merck), Alexa Fluor 488 goat anti-mouse IgG2a, or Alexa Fluor 594 goat anti-mouse IgG3 (ThermoFisher, Monza, Italy).", [["FITC", "CHEMICAL", 52, 56], ["Alexa Fluor 488", "CHEMICAL", 98, 113], ["FITC", "SIMPLE_CHEMICAL", 52, 56], ["goat", "ORGANISM", 65, 69], ["IgG H+L", "SIMPLE_CHEMICAL", 81, 88], ["Merck", "SIMPLE_CHEMICAL", 90, 95], ["Alexa Fluor", "SIMPLE_CHEMICAL", 98, 109], ["Alexa Fluor", "SIMPLE_CHEMICAL", 140, 151], ["secondary antibodies FITC-labeled goat anti-mouse IgG H+L", "PROTEIN", 31, 88], ["Merck", "PROTEIN", 90, 95], ["Alexa Fluor 488 goat anti-mouse IgG2a", "PROTEIN", 98, 135], ["Alexa Fluor 594 goat anti-mouse IgG3", "PROTEIN", 140, 176], ["goat", "SPECIES", 65, 69], ["anti-mouse", "SPECIES", 70, 80], ["goat", "SPECIES", 114, 118], ["anti-mouse", "SPECIES", 119, 129], ["goat", "SPECIES", 156, 160], ["anti-mouse", "SPECIES", 161, 171], ["goat", "SPECIES", 65, 69], ["Alexa Fluor 488", "SPECIES", 98, 113], ["goat", "SPECIES", 114, 118], ["Alexa Fluor 594", "SPECIES", 140, 155], ["goat", "SPECIES", 156, 160], ["Staining", "TEST", 0, 8], ["the secondary antibodies FITC", "TEST", 27, 56], ["Alexa Fluor", "TREATMENT", 98, 109]]], ["ProLong antifade (ThermoFisher) was used as mounting medium.", [["ProLong antifade (ThermoFisher)", "TREATMENT", 0, 31]]], ["Pictures were taken with either a Nikon E800 Eclipse microscope (Nikon, Firenze, Italy) or a Leica TCS SP8 confocal microscope (Leica, Milano, Italy).Cell lines, viruses, indirect immunofluorescence (IIF) and neutralization assays ::: MethodsIndirect immunofluorescence (IIF) inhibition assays of MAbs 5D-8.1 and 9D5 have been performed using different concentrations of the synthetic peptides SESIPALTAAETGHT (PEPperPRINT) and SIGNAYSCFYDG (Sigma-Aldrich, Milano, Italy) that encompass the epitopes of 5D-8.1 and 9D5, respectively.", [["Cell lines", "ANATOMY", 150, 160], ["TCS", "CHEMICAL", 99, 102], ["Cell lines", "CELL", 150, 160], ["9D5", "SIMPLE_CHEMICAL", 313, 316], ["epitopes", "PROTEIN", 491, 499], ["a Leica TCS", "TEST", 91, 102], ["Cell lines", "TREATMENT", 150, 160], ["indirect immunofluorescence", "TEST", 171, 198], ["MethodsIndirect immunofluorescence", "TEST", 235, 269], ["MAbs 5D", "TEST", 297, 304], ["the synthetic peptides", "TREATMENT", 371, 393], ["viruses", "OBSERVATION_MODIFIER", 162, 169]]], ["Each MAb (1 \u03bcg/ml) was pre-incubated with increasing concentrations (0, 2, 8, 32 \u03bcg/ml) of either the SESIPALTAAETGHT or the SIGNAYSCFYDG peptide (2 hrs at r.t.).", [["Each MAb", "TREATMENT", 0, 8], ["the SIGNAYSCFYDG peptide", "TREATMENT", 121, 145]]], ["Then, IIF staining was performed as above.Cell lines, viruses, indirect immunofluorescence (IIF) and neutralization assays ::: MethodsNeutralization assays were performed as reported40.", [["Cell lines", "ANATOMY", 42, 52], ["IIF", "GENE_OR_GENE_PRODUCT", 6, 9], ["Cell lines", "CELL", 42, 52], ["IIF", "PROTEIN", 6, 9], ["IIF staining", "TEST", 6, 18], ["Cell lines", "TREATMENT", 42, 52], ["indirect immunofluorescence", "TEST", 63, 90], ["MethodsNeutralization assays", "TEST", 127, 155], ["viruses", "OBSERVATION_MODIFIER", 54, 61]]], ["The following MAbs/antisera were used: MAb 5D-8.1, MAb 9D5, anti-CV-B4 MAb 35641, horse anti-CV-B1 serum (ATCC).", [["anti-CV-B1 serum", "ANATOMY", 88, 104], ["ATCC", "ANATOMY", 106, 110], ["MAb 9D5", "SIMPLE_CHEMICAL", 51, 58], ["horse", "ORGANISM", 82, 87], ["anti-CV-B1", "CELL", 88, 98], ["serum", "ORGANISM_SUBSTANCE", 99, 104], ["ATCC", "CELL", 106, 110], ["MAbs", "PROTEIN", 14, 18], ["horse", "SPECIES", 82, 87], ["The following MAbs/antisera", "TEST", 0, 27], ["MAb", "TEST", 39, 42], ["MAb", "TEST", 51, 54], ["anti-CV", "TEST", 60, 67], ["B4 MAb", "TEST", 68, 74], ["horse anti-CV", "TEST", 82, 95]]], ["Briefly, antibody dilutions in complete DMEM/F12 medium were made in triplicate in 96-well flat bottom plates.", [["antibody dilutions", "TREATMENT", 9, 27], ["complete DMEM/F12 medium", "TREATMENT", 31, 55]]], ["Then, 100 tissue culture infectious doses50 (TCID50) of CV-B1 or CV-B4 were dispensed into each well and mixed with antibody dilutions or control medium.", [["tissue culture", "ANATOMY", 10, 24], ["CV-B1", "CELL", 56, 61], ["CV-B4", "CELL", 65, 70], ["CV-B4", "SPECIES", 65, 70], ["tissue culture", "TEST", 10, 24], ["CV", "TEST", 56, 58], ["CV", "TEST", 65, 67], ["B4", "PROBLEM", 68, 70], ["antibody dilutions", "TREATMENT", 116, 134]]], ["After 1 hr incubation at r.t., 104 LLC-MK2 cells were added to each well.", [["LLC-MK2 cells", "ANATOMY", 35, 48], ["LLC-MK2 cells", "CELL", 35, 48], ["MK2 cells", "CELL_LINE", 39, 48], ["LLC-MK2 cells", "TREATMENT", 35, 48], ["LLC", "ANATOMY", 35, 38], ["MK2 cells", "OBSERVATION", 39, 48]]], ["Cytopathic effect (CPE) was read at 6\u20137 days with an inverted microscope.", [["Cytopathic effect (CPE", "PROBLEM", 0, 22], ["an inverted microscope", "TEST", 50, 72]]], ["Antibody titer is defined as the highest antibody dilution capable of preventing CPE.Bioinformatics analysis ::: MethodsA list of complete EV capsid structures were obtained from the advanced search method of the RSCB server42, and a selection of the resulting data were downloaded as monomer PDB files (1COV, 1H8T, 1D4M, 1EV1, 4GB3, 4Q4V).", [["RSCB server42", "DNA", 213, 226], ["1H8T", "PROTEIN", 310, 314], ["1D4M", "PROTEIN", 316, 320], ["1EV1", "PROTEIN", 322, 326], ["4GB3", "PROTEIN", 328, 332], ["4Q4V", "PROTEIN", 334, 338], ["Antibody titer", "TEST", 0, 14], ["the highest antibody dilution", "TEST", 29, 58], ["CPE", "PROBLEM", 81, 84], ["Bioinformatics analysis", "TEST", 85, 108], ["CPE", "OBSERVATION", 81, 84]]], ["For each monomer structure, the complete capsid was assembled based on its BIOMT REMARK included in the PDB file.", [["BIOMT REMARK", "PROTEIN", 75, 87], ["monomer structure", "OBSERVATION", 9, 26], ["PDB", "ANATOMY", 104, 107]]], ["The Visual Molecular Dynamics software (VMD)43 has been used for visualization, computation and analysis of structural data.", [["visualization", "TEST", 65, 78], ["structural data", "TEST", 108, 123]]], ["The Solvent-Accessible Surface area (SASA) was calculated for the VP1 monomer, the capsomer, the capsid.", [["VP1 monomer", "PROTEIN", 66, 77], ["capsomer", "PROTEIN", 83, 91], ["capsid", "PROTEIN", 97, 103], ["The Solvent", "TREATMENT", 0, 11], ["the VP1 monomer", "TREATMENT", 62, 77], ["Solvent", "OBSERVATION_MODIFIER", 4, 11], ["Accessible", "OBSERVATION_MODIFIER", 12, 22], ["Surface", "OBSERVATION_MODIFIER", 23, 30], ["VP1 monomer", "OBSERVATION", 66, 77], ["capsid", "OBSERVATION", 97, 103]]], ["For each epitope, BLASTp queries were performed in public databases (Homo sapiens, Viruses, Picornavirales, ssRNA viruses, enteroviruses, rhinoviruses).", [["enteroviruses", "DISEASE", 123, 136], ["Homo sapiens", "ORGANISM", 69, 81], ["Picornavirales", "GENE_OR_GENE_PRODUCT", 92, 106], ["enteroviruses", "ORGANISM", 123, 136], ["rhinoviruses", "ORGANISM", 138, 150], ["Homo sapiens", "SPECIES", 69, 81], ["Homo sapiens", "SPECIES", 69, 81], ["BLASTp queries", "TEST", 18, 32], ["Homo sapiens", "PROBLEM", 69, 81], ["Viruses", "PROBLEM", 83, 90], ["Picornavirales", "TREATMENT", 92, 106], ["ssRNA viruses", "TREATMENT", 108, 121], ["enteroviruses", "PROBLEM", 123, 136], ["rhinoviruses", "TREATMENT", 138, 150], ["ssRNA viruses", "OBSERVATION", 108, 121]]], ["A BLAST program employing the SEG algorithm44 was used to filter low complexity regions from proteins before executing a database search.", [["SEG algorithm44", "DNA", 30, 45], ["A BLAST program", "TREATMENT", 0, 15], ["the SEG algorithm44", "TREATMENT", 26, 45], ["a database search", "TEST", 119, 136], ["low complexity", "OBSERVATION_MODIFIER", 65, 79]]], ["The BLASTp results that produced significant alignments of the two MAb epitopes with human proteins or viral agents are reported along with the Expected(E) value.", [["human", "ORGANISM", 85, 90], ["MAb epitopes", "PROTEIN", 67, 79], ["human proteins", "PROTEIN", 85, 99], ["human", "SPECIES", 85, 90], ["human", "SPECIES", 85, 90], ["the two MAb epitopes", "PROBLEM", 59, 79], ["human proteins", "TREATMENT", 85, 99], ["viral agents", "TREATMENT", 103, 115], ["significant", "OBSERVATION_MODIFIER", 33, 44], ["alignments", "OBSERVATION_MODIFIER", 45, 55], ["viral agents", "OBSERVATION", 103, 115]]], ["E value is used as a measure of epitope specificity.", [["E value", "TEST", 0, 7]]], ["The lower the E-value, or the closer it is to zero, the more \u201csignificant\u201d the match is.", [["lower", "OBSERVATION_MODIFIER", 4, 9]]], ["Analysis of the predicted reactivity of the two MAbs with the different EV types is based on the alignments of epitope sequences with the VP1 sequence of EVs.", [["EVs", "ANATOMY", 154, 157], ["EVs", "CELL", 154, 157], ["MAbs", "PROTEIN", 48, 52], ["VP1 sequence", "DNA", 138, 150], ["the two MAbs", "TREATMENT", 40, 52], ["epitope sequences", "TEST", 111, 128], ["the VP1 sequence of EVs", "TEST", 134, 157]]], ["A cut off value of 70% AA identity has been used.Additional InformationHow to cite this article: Maccari, G. et al. Properties of Two Enterovirus Antibodies that are Utilized in Diabetes Research.", [["AA", "CHEMICAL", 23, 25], ["Diabetes", "DISEASE", 178, 186], ["Enterovirus Antibodies", "PROTEIN", 134, 156], ["A cut off value", "TEST", 0, 15], ["Two Enterovirus Antibodies", "PROBLEM", 130, 156], ["Two", "OBSERVATION_MODIFIER", 130, 133], ["Enterovirus Antibodies", "OBSERVATION", 134, 156]]], ["Rep.6, 24757; doi: 10.1038/srep24757 (2016).", [["Rep.6, 24757", "CHEMICAL", 0, 12]]]], "PMC7468182": [["IntroductionPatent protection gives market exclusivity to inventors.", [["IntroductionPatent protection", "TREATMENT", 0, 29]]], ["Such a monopolistic position usually translates into higher prices as compared to those that would prevail under competitive market settings.", [["a monopolistic position", "TREATMENT", 5, 28]]], ["Moreover, when the product in question is essential to human health, such as medicines, the issue of patenting itself becomes contentious.", [["human", "ORGANISM", 55, 60], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 55, 60], ["medicines", "TREATMENT", 77, 86]]], ["This debate with respect to medicines has been further intensified since 1995, when the international agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS) became effective.", [["medicines", "TREATMENT", 28, 37], ["Intellectual Property Rights (TRIPS)", "TREATMENT", 140, 176]]], ["While it was universally acknowledged that TRIPS would hike up the prices of patented medicines, there was no consensus on its likely final impact on access.", [["patented medicines", "TREATMENT", 77, 95]]], ["This was because TRIPS also included multiple instruments to promote access, such as issue of compulsory licenses, parallel imports, and incentivization of technology transfer (Scherer & Watal, 2002).", [["multiple instruments", "TREATMENT", 37, 57]]], ["So the moot question is: are these instruments sufficient to ensure adequate access to life-saving patented drugs in case of need?", [["these instruments", "TREATMENT", 29, 46], ["saving patented drugs", "TREATMENT", 92, 113]]], ["In an attempt to provide elements for a partial answer to this question, in this paper, we examine the role of compulsory license implementation as a means to lower the prices of patented medicines and thereby improve their access.IntroductionBefore the TRIPS Agreement, approximately 40 countries had forbidden patent protection for pharmaceutical products and/or processes (Boulet et al., 2000).", [["patented medicines", "TREATMENT", 179, 197], ["pharmaceutical products", "TREATMENT", 334, 357], ["patent", "OBSERVATION", 312, 318]]], ["Under this scenario, low-price copies of medicines developed by research-based pharmaceutical companies could be exported to international markets without the permission of the patent holders.", [["medicines", "TREATMENT", 41, 50], ["patent", "OBSERVATION", 177, 183]]], ["However, one of the main requirements of TRIPS is that all member nations have \u201cto make patents available for any inventions, whether products or processes, in all fields of technology without discrimination, subject to the normal tests of novelty, inventiveness and industrial applicability\u201d.", [["inventiveness", "DISEASE", 249, 262], ["main", "OBSERVATION_MODIFIER", 20, 24]]], ["The agreement also sets 20 years as the minimum period of patent protection in all World Trade Organisation (WTO) member nations and prohibits discrimination between domestic and imported products.", [["patent protection", "TREATMENT", 58, 75], ["patent", "OBSERVATION", 58, 64]]], ["Thus, as all WTO signatory countries are required to grant patent protection of pharmaceutical products and processes, TRIPS effectively removed the possibility for generic manufacturers to reverse-engineer pharmaceutical process in order to produce and sell medicines at lower prices.IntroductionAt the same time, TRIPS contains flexibilities that could be utilized to alleviate the negative impact of patents on access to pharmaceutical products, especially in low- and middle-income countries.", [["TRIPS", "CHEMICAL", 119, 124], ["TRIPS", "SIMPLE_CHEMICAL", 119, 124], ["pharmaceutical products", "TREATMENT", 80, 103], ["generic manufacturers", "TREATMENT", 165, 186], ["IntroductionAt", "TREATMENT", 285, 299], ["flexibilities", "TREATMENT", 330, 343], ["pharmaceutical products", "TREATMENT", 424, 447], ["patent", "OBSERVATION", 59, 65], ["pharmaceutical products", "OBSERVATION", 80, 103], ["middle", "ANATOMY_MODIFIER", 472, 478]]], ["For instance, developing countries that did not provide product patent protection for pharmaceuticals or any other knowledge intensive products when the TRIPS Agreement came into force could delay patent protection for those products until January 2005.", [["pharmaceuticals", "TREATMENT", 86, 101], ["those products", "TREATMENT", 219, 233], ["patent", "OBSERVATION", 197, 203]]], ["In November 2005, the transitional period for LDCs was extended to 1 July 2013, and, in June 2013, it was further shifted to 1 July 2021.", [["LDCs", "TEST", 46, 50]]], ["Specifically with respect to pharmaceutical patents, in 2002, the TRIPS Council pushed the period for LDCs to comply to 2016.", [["LDCs", "TEST", 102, 106], ["pharmaceutical patents", "OBSERVATION", 29, 51]]], ["This decision also keeps open the option for further extensions beyond that date.IntroductionBesides these flexibilities, the TRIPS Agreement includes the use of various instruments to improve access to medicines.", [["various instruments", "TREATMENT", 162, 181], ["access to medicines", "TREATMENT", 193, 212]]], ["Among these is the right of member states to grant compulsory licenses.", [["right", "ANATOMY_MODIFIER", 19, 24]]], ["Article 31 of the TRIPS agreement allows the issuance of a compulsory license under circumstances such as \u2018national emergencies\u2019, \u2018other circumstances of extreme urgency\u2019, \u2018public non-commercial use\u2019, or against \u2018anti-competitive\u2019 practices (WTO, 2006).", [["extreme urgency", "PROBLEM", 154, 169]]], ["This means that a member country can improve access to a particular patented medicine through making an exception to its existing patent without entering into a price negotiation with the patent holder.IntroductionOriginally, compulsory licensing was to be used predominantly for the purposes of supplying the domestic market of the country in which the license was issued.", [["a particular patented medicine", "TREATMENT", 55, 85], ["a price negotiation", "TREATMENT", 159, 178], ["the patent holder", "TREATMENT", 184, 201], ["patent", "OBSERVATION", 130, 136], ["patent", "OBSERVATION", 188, 194]]], ["This, however, posed a problem for countries that did not have sufficient manufacturing capacity to produce their own generic pharmaceuticals and, therefore, had to rely on imports of medicines.", [["medicines", "TREATMENT", 184, 193]]], ["In November 2001, the Declaration on the TRIPS Agreement and Public Health (also known as Doha Declaration) recognized that member states with insufficient or no technological capacity in pharmaceuticals could face difficulties in making effective use of compulsory licensing under the TRIPS Agreement.IntroductionFollowing the Doha Declaration, in 2003, the TRIPS Council made a first formal attempt, referred to as the \u2018August 30 Decision\u2019, to allow for exports under compulsory licenses to countries with no technological capacity to produce the drugs they needed.", [["technological capacity", "PROBLEM", 162, 184], ["technological capacity", "PROBLEM", 511, 533], ["the drugs", "TREATMENT", 545, 554]]], ["This was the first time that the WTO accords were amended since the organization opened in 1995.IntroductionCompulsory licensing is often advocated as the main alternative to circumvent the potential negative impact of patents on access to medicines.", [["medicines", "TREATMENT", 240, 249]]], ["For instance, a scoping review of the literature on how access to medicines can be improved under the current IPR system set by the TRIPS Agreement shows that compulsory licensing is the most advised TRIPS safeguard to improve access to medicines (Urias, 2015).", [["a scoping review", "TEST", 14, 30], ["medicines", "TREATMENT", 66, 75]]], ["Although lack of access to medicines is often associated with low- and middle-income countries, compulsory licensing of high-priced pharmaceuticals is also part of the policy agenda of high-income countries.", [["medicines", "TREATMENT", 27, 36], ["high-priced pharmaceuticals", "TREATMENT", 120, 147]]], ["For instance, in 2015, as the Veterans Administration stopped treating new hepatitis C patients due to lack of funds, Senator Bernie Sanders requested the Veterans Affairs Secretary to issue compulsory licenses for the patents of Sofosbuvir, which was costing about US$1000 per tablet at the time (Sanders, 2005).", [["hepatitis C", "DISEASE", 75, 86], ["Sofosbuvir", "CHEMICAL", 230, 240], ["Sofosbuvir", "CHEMICAL", 230, 240], ["patients", "ORGANISM", 87, 95], ["Sofosbuvir", "SIMPLE_CHEMICAL", 230, 240], ["patients", "SPECIES", 87, 95], ["the Veterans Administration", "TREATMENT", 26, 53], ["new hepatitis C", "PROBLEM", 71, 86], ["Sofosbuvir", "TREATMENT", 230, 240], ["hepatitis", "OBSERVATION", 75, 84]]], ["Also, in 2017, the German Federal Court of Justice confirmed a compulsory license granted for an antiretroviral drug for people living with HIV/AIDS, and the Minister for Health of the Netherlands announced his intention to explore the use of compulsory licensing for highly expensive medicines (Cappuyns & Vanherpe, 2018).IntroductionNonetheless, little is known about the extent to which the existing experiences with compulsory licensing have been effective in improving access to medicines.", [["HIV/AIDS", "DISEASE", 140, 148], ["people", "ORGANISM", 121, 127], ["people", "SPECIES", 121, 127], ["HIV", "SPECIES", 140, 143], ["an antiretroviral drug", "TREATMENT", 94, 116], ["compulsory licensing", "TREATMENT", 420, 440], ["medicines", "TREATMENT", 484, 493]]], ["In this article, we aim to fill this gap by conducting a systematic review and analysis of the existing evidence on the impact of compulsory licensing on drug prices.", [["a systematic review", "TEST", 55, 74], ["drug prices", "TREATMENT", 154, 165]]], ["Through an in-depth analysis of existing qualitative and quantitative data retrieved from selected studies, we hope to develop a deeper evidence-based understanding of the impact of compulsory license issuance on affordability.A Framework for Compulsory LicensingBy its very definition, the issuance of a compulsory license implicates three main actors:the government that issues the license;a third-party licensee which can import, manufacture, use, and/or sell copies of the patented medicine; andthe patentee which is entitled to compensation (i.e., royalties) \u2013 often a research-based pharmaceutical company.In Figure 1, we present the decision process involved in the use of compulsory licensing to improve access to medicines.", [["quantitative data", "TEST", 57, 74], ["selected studies", "TEST", 90, 106], ["compulsory licensing", "TREATMENT", 680, 700], ["medicines", "TREATMENT", 722, 731]]], ["As the focus of this article is on the impact of compulsory licensing on drug affordability, we start with the assumption that there are pharmaceutical products currently unaffordable due to patents1.", [["pharmaceutical products", "TREATMENT", 137, 160]]], ["Such drugs are the focus of the paper.A Framework for Compulsory LicensingTo improve access, some patent holders voluntarily license their products to generic manufacturers.", [["Such drugs", "TREATMENT", 0, 10], ["patent", "OBSERVATION", 98, 104]]], ["This is done either through direct contractual arrangements between patent holders and generic manufacturers or through mechanisms such as the Medicine Patent Pool2.", [["patent holders", "TREATMENT", 68, 82], ["generic manufacturers", "TREATMENT", 87, 108], ["patent", "OBSERVATION", 68, 74], ["Patent", "OBSERVATION", 152, 158]]], ["If there is no voluntary license for a given drug or a country is not included in a given voluntary license territory, then compulsory licensing can be a viable option for some countries under certain circumstances to improve access to patented medicines.", [["patented medicines", "TREATMENT", 236, 254], ["no", "UNCERTAINTY", 12, 14]]], ["At the outset, we must distinguish between LDCs and the rest.A Framework for Compulsory LicensingLet us start by considering a non-LDC country, say country A, which requires a branded drug.", [["LDCs", "ANATOMY", 43, 47], ["LDCs", "CANCER", 43, 47], ["a branded drug", "TREATMENT", 174, 188]]], ["If national firms have no capacity or inadequate capacity, and there are no international generic producers, the outcome with or without a compulsory license is bound to be sub-optimal.", [["capacity", "PROBLEM", 26, 34], ["inadequate capacity", "PROBLEM", 38, 57], ["no", "UNCERTAINTY", 23, 25], ["capacity", "OBSERVATION_MODIFIER", 26, 34]]], ["Country A must issue a compulsory license to import the drug, and country B must issue a compulsory license, under the Paragraph 6 system discussed in the previous section, to export the drug to country A. In other words, both the government of the non-LDC country demanding the generic and the government of the country supplying the generic must issue a compulsory license.A Framework for Compulsory LicensingIn addition to the requirements of compulsory licenses being issued by two countries in order to engage in trade of a branded drug, other binding IPR constraints linked to the scope of the license issued by the original innovator must be satisfied.", [["a branded drug", "TREATMENT", 527, 541]]], ["For instance, if the pharma firm in the exporter country firm B is a licensee or sub-licensee of a drug patent, and if this license excludes country A, then the potential exporter firm in country B cannot sell to country A, even if both countries issue a compulsory license.", [["a drug patent", "TREATMENT", 97, 110], ["patent", "OBSERVATION", 104, 110], ["firm", "OBSERVATION", 180, 184]]], ["Therefore, independently of the compulsory licenses themselves (in the importing and exporting countries), other IPR constraints on distribution must also be taken into account to enable access via trade.A Framework for Compulsory LicensingTurning now to the LDCs, it is to be noted that LDC members of the WTO have until January 2033 to implement patent protection or to enforce existing patents of pharmaceutical products.", [["patent protection", "TREATMENT", 348, 365], ["pharmaceutical products", "TREATMENT", 400, 423], ["patent", "OBSERVATION", 348, 354], ["pharmaceutical products", "OBSERVATION", 400, 423]]], ["For instance, India was a major generics supplier in the international market during the 1990s, and this industrial prowess had a dramatic impact on access to medicines, especially for HIV/AIDS patients in the developing world (Ramani & Mukherjee, 2014).A Framework for Compulsory LicensingThen, when India signed the TRIPS agreement, a \u2018mailbox\u2019 provision was included in its intellectual property rights framework.", [["HIV/AIDS", "DISEASE", 185, 193], ["patients", "ORGANISM", 194, 202], ["HIV", "SPECIES", 185, 188], ["patients", "SPECIES", 194, 202], ["HIV", "SPECIES", 185, 188], ["medicines", "TREATMENT", 159, 168], ["HIV/AIDS", "PROBLEM", 185, 193], ["a \u2018mailbox\u2019 provision", "TREATMENT", 335, 356]]], ["According to this provision, patent applications for medicines would be examined only after 2005, when the TRIPS treaty would be in force.", [["patent applications", "TREATMENT", 29, 48], ["medicines", "TREATMENT", 53, 62], ["patent", "OBSERVATION", 29, 35]]], ["The delay between the date of application and the actual examination and issuance of patent constrained the ability of the patent applicant to institute infringement actions against generic manufacturers (Gervais, 2003; Hason & Shimotake, 2006).", [["the actual examination", "TEST", 46, 68], ["patent", "OBSERVATION", 85, 91], ["patent", "OBSERVATION", 123, 129]]], ["This is because, for any patent granted under the mailbox provision, the patent holder could not initiate a patent infringement action against a company that was producing and manufacturing the corresponding product (Gervais, 2003; Hason & Shimotake, 2006).A Framework for Compulsory LicensingIn other words, between 1995 and 2005, if a patent had been granted to a product, the respective patent holder would only be entitled to receive \u2018reasonable royalty\u2019 from the manufacturers of generic drugs (Kale & Little, 2007).", [["the mailbox provision", "TREATMENT", 46, 67], ["the patent holder", "TREATMENT", 69, 86], ["the respective patent holder", "TREATMENT", 375, 403], ["patent", "OBSERVATION", 25, 31], ["patent", "OBSERVATION", 73, 79], ["patent", "OBSERVATION", 108, 114], ["patent", "OBSERVATION", 337, 343], ["patent", "OBSERVATION", 390, 396]]], ["For instance, in 2003, the Swiss-based company Novartis was awarded an Exclusive Marketing Rights (EMR) for the drug Glivec (imatinib mesylate), for which a patent application had been received in 1997 under the mailbox provision (Ecks, 2008).", [["Glivec", "CHEMICAL", 117, 123], ["imatinib mesylate", "CHEMICAL", 125, 142], ["Glivec", "CHEMICAL", 117, 123], ["imatinib mesylate", "CHEMICAL", 125, 142], ["Glivec", "SIMPLE_CHEMICAL", 117, 123], ["imatinib mesylate", "SIMPLE_CHEMICAL", 125, 142], ["the drug Glivec (imatinib mesylate", "TREATMENT", 108, 142], ["a patent application", "TREATMENT", 155, 175], ["patent", "OBSERVATION", 157, 163]]], ["Because of this mailbox provision, many drugs patented in India between 1995 and 2005 have affordable generic versions available worldwide, as Indian generic companies were able to continue to produce and export them, as long as they paid royalties to the patent holder(s) (Babovic & Wasan, 2011; Guennif & Ramani, 2012; Kale & Little, 2007).", [["this mailbox provision", "TREATMENT", 11, 33], ["many drugs", "TREATMENT", 35, 45], ["patent", "OBSERVATION", 256, 262]]], ["So, it is important to note that, from 2005, the rules of the game and the playing field itself changed, and this was mostly related to the end of the transitional period for India to become TRIPS-compliant.A Framework for Compulsory LicensingTherefore, after 2005, Indian firms have been able to develop generic versions of pharmaceutical products only if voluntary licenses are granted to them by the patent holders, or after patent expiration of the original branded drug or if Indian courts reject evergreening patents.", [["pharmaceutical products", "TREATMENT", 325, 348], ["patent", "OBSERVATION", 403, 409]]], ["The latter occurred in some cases of antiretrovirals like Tenofovir disoproxil fumarate, Darunavir, and Atazanavir sulfate.", [["Tenofovir disoproxil fumarate", "CHEMICAL", 58, 87], ["Darunavir", "CHEMICAL", 89, 98], ["Atazanavir sulfate", "CHEMICAL", 104, 122], ["Tenofovir disoproxil fumarate", "CHEMICAL", 58, 87], ["Darunavir", "CHEMICAL", 89, 98], ["Atazanavir sulfate", "CHEMICAL", 104, 122], ["Tenofovir disoproxil fumarate", "SIMPLE_CHEMICAL", 58, 87], ["Darunavir", "SIMPLE_CHEMICAL", 89, 98], ["Atazanavir sulfate", "SIMPLE_CHEMICAL", 104, 122], ["antiretrovirals", "TREATMENT", 37, 52], ["Tenofovir disoproxil fumarate", "TREATMENT", 58, 87], ["Darunavir", "TREATMENT", 89, 98], ["Atazanavir sulfate", "TREATMENT", 104, 122]]], ["Thus, given the inability of Indian firms to develop and to sell either at home or in international markets, drugs patented in India after January 2005 cannot be made available to a country, unless both the Indian government and the country\u2019s government are willing to issue a compulsory license for export and import, respectively.Systematic Reviews of Literature ::: MethodologyA literature review can be a research method in its own right and its format varies depending on its purpose (Jesson et al., 2011).", [["drugs", "TREATMENT", 109, 114], ["right", "ANATOMY_MODIFIER", 436, 441]]], ["Therefore, it is an appropriate method to assess the effectiveness of compulsory licensing based on the existing evidence.Systematic Reviews of Literature ::: MethodologySystematic reviews typically involve comprehensive search strategy with the goal of identifying, appraising, and synthesizing all relevant studies on a particular topic (Uman, 2011).", [["compulsory licensing", "TREATMENT", 70, 90]]], ["Jesson et al. (2011) argue that a systematic approach for literature reviews comprises the definition of a clear stated purpose, a question, a defined search approach, stating inclusion and exclusion criteria, and producing a qualitative appraisal of articlesSearch Approach ::: MethodologyThis systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement (www.prisma-statement.org).", [["Systematic Reviews", "TEST", 380, 398], ["Meta-Analysis", "TEST", 403, 416]]], ["A comprehensive search was performed in the bibliographic databases Web of Knowledge, PubMed, and Scopus.", [["A comprehensive search", "TEST", 0, 22]]], ["The full search strategies for all databases can be found in the Supplementary Information.Search Approach ::: MethodologyAfter removing duplicates, 425 articles were included for title and abstract screening.", [["abstract screening", "TEST", 190, 208]]], ["These studies were imported into Covidence, which is an online software to assist systematic reviews.", [["These studies", "TEST", 0, 13]]], ["All the studies were reviewed by both authors for relevance based on titles/abstracts and full text.", [["All the studies", "TEST", 0, 15]]], ["Therefore, studies that focused on cases wherein a compulsory license was considered, but not actually issued (as a consequence, for instance, of a donation, a voluntary license, or price reductions), were excluded from this review.", [["studies", "TEST", 11, 18]]], ["Second, only studies on compulsory licensing event of medicines after the TRIPS Agreement became effective in 1995 were included.", [["medicines", "TREATMENT", 54, 63]]], ["Thus, compulsory licensing of other types of goods, or instances that took place prior to TRIPS, were excluded.", [["goods", "OBSERVATION", 45, 50]]], ["However, it is important to mention that several eligible studies had collected their data from non-peer-reviewed, gray, and legal literature, which minimizes any bias against these types of sources.Data Extraction and Analysis ::: MethodologyData were extracted using a pre-designed form including fields such as: Country; Year; Drug; Brand; Manufacturer; Disease; Price before compulsory license; Price after compulsory license; Comparison with international prices; Source type (civil society report; industry report, official document, or academic publication); Compulsory license for local production (Yes/No), and Exporter country (if applicable).Data Extraction and Analysis ::: MethodologyThe data on prices were, therefore, extracted from the studies included in the review.", [["several eligible studies", "TEST", 41, 65], ["MethodologyData", "TREATMENT", 232, 247], ["the studies", "TEST", 748, 759]]], ["As these studies were not at all similar, the combination of the data in a meta-analysis was simply not possible (Jesson et al., 2011).", [["these studies", "TEST", 3, 16], ["a meta-analysis", "TEST", 73, 88]]], ["Alternatively, a thematic analysis was carried out and a narrative and tabular synthesis based on descriptive statistics was applied to derive the main results.Study Selection ::: ResultsA PRISMA flow-diagram shows the selection of papers for inclusion and exclusion (Figure 2).", [["a thematic analysis", "TEST", 15, 34], ["a narrative and tabular synthesis", "PROBLEM", 55, 88]]], ["In total, 86 articles have been considered eligible for full-text analysis.", [["full-text analysis", "TEST", 56, 74]]], ["Of these, 15 articles were included in this study.Study Selection ::: ResultsTable 1 summarizes the number of events, countries, and drugs covered in the final corpus of articles.", [["this study", "TEST", 39, 49], ["drugs", "TREATMENT", 133, 138]]], ["Four studies analyzed two compulsory licensing events each, whereas seven studies analyzed a single event each.Characteristics of the Compulsory Licensing Events ::: ResultsIn our review, we found 24 compulsory licensing events in eight countries (Brazil, Ecuador, India, Indonesia, Thailand, Malaysia, Rwanda, Zimbabwe) for which prices before and after the compulsory licensing were available (see Table 2).Characteristics of the Compulsory Licensing Events ::: ResultsThe 24 compulsory licensing events covered 16 different drug formulations, among which the following were the object of multiple compulsory licensing events: Lamivudine + Zidovudine|150 mg + 300 mg (n = 3), Efavirenz|600 mg\u2019 (n = 3), Lamivudine + Nevirapine + Zidovudine|150 mg + 200 mg + 300 mg (n = 2), and Atazanavir sulfate|150 mg (n = 2).", [["Lamivudine", "CHEMICAL", 629, 639], ["Zidovudine", "CHEMICAL", 642, 652], ["Efavirenz", "CHEMICAL", 678, 687], ["Lamivudine", "CHEMICAL", 705, 715], ["Nevirapine", "CHEMICAL", 718, 728], ["Zidovudine", "CHEMICAL", 731, 741], ["Atazanavir sulfate", "CHEMICAL", 780, 798], ["Lamivudine", "CHEMICAL", 629, 639], ["Zidovudine", "CHEMICAL", 642, 652], ["Efavirenz", "CHEMICAL", 678, 687], ["Lamivudine", "CHEMICAL", 705, 715], ["Nevirapine", "CHEMICAL", 718, 728], ["Zidovudine", "CHEMICAL", 731, 741], ["Atazanavir sulfate", "CHEMICAL", 780, 798], ["Lamivudine", "SIMPLE_CHEMICAL", 629, 639], ["Zidovudine", "SIMPLE_CHEMICAL", 642, 652], ["Efavirenz", "SIMPLE_CHEMICAL", 678, 687], ["Lamivudine", "SIMPLE_CHEMICAL", 705, 715], ["Nevirapine", "SIMPLE_CHEMICAL", 718, 728], ["Zidovudine", "SIMPLE_CHEMICAL", 731, 741], ["Atazanavir sulfate", "SIMPLE_CHEMICAL", 780, 798], ["Four studies", "TEST", 0, 12], ["seven studies", "TEST", 68, 81], ["16 different drug formulations", "TREATMENT", 514, 544], ["Lamivudine", "TREATMENT", 629, 639], ["Zidovudine", "TREATMENT", 642, 652], ["Efavirenz", "TREATMENT", 678, 687], ["Lamivudine", "TREATMENT", 705, 715], ["Nevirapine", "TREATMENT", 718, 728], ["Zidovudine", "TREATMENT", 731, 741], ["Atazanavir sulfate", "TREATMENT", 780, 798]]], ["Most of them were to treat HIV/AIDS (n = 11).", [["HIV/AIDS", "DISEASE", 27, 35], ["HIV", "SPECIES", 27, 30], ["HIV", "SPECIES", 27, 30], ["HIV", "PROBLEM", 27, 30], ["AIDS", "PROBLEM", 31, 35]]], ["The other drug formulations are to treat cancer (n = 4) and cardiovascular diseases (n = 1).Characteristics of the Compulsory Licensing Events ::: ResultsIn terms of price comparisons, the studies retrieved in this research gathered 51 observations of prices before and after compulsory licensing events (see Table 3).", [["cancer", "ANATOMY", 41, 47], ["cardiovascular", "ANATOMY", 60, 74], ["cancer", "DISEASE", 41, 47], ["cardiovascular diseases", "DISEASE", 60, 83], ["cancer", "CANCER", 41, 47], ["cardiovascular", "ANATOMICAL_SYSTEM", 60, 74], ["The other drug formulations", "TREATMENT", 0, 27], ["cancer (n = 4) and cardiovascular diseases", "PROBLEM", 41, 83], ["the studies", "TEST", 185, 196], ["cancer", "OBSERVATION", 41, 47], ["cardiovascular", "ANATOMY", 60, 74], ["diseases", "OBSERVATION", 75, 83]]], ["The compulsory licensing of Sorafenib in India (n = 8), Efavirenz 600 mg in Brazil (n = 7), and Efavirenz 600 mg in Thailand (n = 6) are the events reported most often in the literature.", [["Sorafenib", "CHEMICAL", 28, 37], ["Efavirenz", "CHEMICAL", 56, 65], ["Efavirenz", "CHEMICAL", 96, 105], ["Sorafenib", "CHEMICAL", 28, 37], ["Efavirenz", "CHEMICAL", 56, 65], ["Efavirenz", "CHEMICAL", 96, 105], ["Sorafenib", "SIMPLE_CHEMICAL", 28, 37], ["Efavirenz", "SIMPLE_CHEMICAL", 56, 65], ["Sorafenib in India (n", "TREATMENT", 28, 49], ["Efavirenz", "TREATMENT", 56, 65], ["Brazil (n", "TREATMENT", 76, 85], ["Efavirenz", "TREATMENT", 96, 105]]], ["In terms of compulsory licensing events, 13 out of the 24 identified events reported official governmental documents as data source.Result 1: Issuance of Compulsory Licensing or a Compulsory Licensing Event is Likely to Reduce Prices of Patented Drugs ::: Impact on Prices ::: ResultsFrom Table 2, the mean price reduction ranges between 66.2 and 73.9%, if we take, respectively, the minimum or the maximum price variation reported in the literature.", [["the mean price reduction", "TEST", 298, 322]]], ["The price reductions after compulsory license events range from 6.7% [Atazanavir sulfate in Brazil (2007)] to 98% [Lamivudine + Nevirapine + Zidovudine (2004)].Result 1: Issuance of Compulsory Licensing or a Compulsory Licensing Event is Likely to Reduce Prices of Patented Drugs ::: Impact on Prices ::: ResultsHaving noted the above, we again recall that a meta-analysis was not conducted because prices across events are not comparable due to many context-specific factors affecting the final price after a compulsory license (e.g., market structure, out-of-pocket payments, technological capacity).", [["Atazanavir sulfate", "CHEMICAL", 70, 88], ["Lamivudine", "CHEMICAL", 115, 125], ["Nevirapine", "CHEMICAL", 128, 138], ["Zidovudine", "CHEMICAL", 141, 151], ["Atazanavir sulfate", "CHEMICAL", 70, 88], ["Lamivudine", "CHEMICAL", 115, 125], ["Nevirapine", "CHEMICAL", 128, 138], ["Zidovudine", "CHEMICAL", 141, 151], ["Atazanavir sulfate", "SIMPLE_CHEMICAL", 70, 88], ["Lamivudine", "SIMPLE_CHEMICAL", 115, 125], ["The price reductions", "TREATMENT", 0, 20], ["Atazanavir sulfate in Brazil", "TREATMENT", 70, 98], ["Lamivudine", "TREATMENT", 115, 125], ["Nevirapine", "TREATMENT", 128, 138], ["Zidovudine", "TREATMENT", 141, 151], ["a meta-analysis", "TEST", 357, 372]]], ["Also, there was often no information about the price point (e.g., list price, price at dispensation) being used in each study included in this review.", [["each study", "TEST", 115, 125]]], ["However, for each compulsory licensing event identified in this review, it is reasonable to assume that prices pre- and post-compulsory licensing refer to the same price point, which makes the comparison of relative price change across events less problematic.Result 2: However, the Existing Public Knowledge on the Degree of Price Drop is Imperfect ::: Impact on Prices ::: ResultsIndeed, in the articles that specify the prices before and after, there are contradictions regarding the degree of price drop following an event.", [["price drop", "PROBLEM", 497, 507], ["price drop", "OBSERVATION", 497, 507]]], ["For instance, Beall et al. (2015) presented two compulsory licensing events for Atazanavir sulfate in Brazil, based on industry reports, However, Ramani and Urias (2018), relying on official documents and interviews with Brazilian authorities, show that the compulsory licensing for Efavirenz in 2007 was the only compulsory licensing event in that country.", [["Atazanavir sulfate", "CHEMICAL", 80, 98], ["Efavirenz", "CHEMICAL", 283, 292], ["Atazanavir sulfate", "CHEMICAL", 80, 98], ["Atazanavir sulfate", "SIMPLE_CHEMICAL", 80, 98], ["Atazanavir sulfate", "TREATMENT", 80, 98], ["Efavirenz", "TREATMENT", 283, 292]]], ["Indeed, according to the latter\u2019s findings, there was no compulsory license for Atazanavir sulfate in Brazil.", [["Atazanavir sulfate", "CHEMICAL", 80, 98], ["Atazanavir sulfate", "CHEMICAL", 80, 98], ["Atazanavir sulfate", "SIMPLE_CHEMICAL", 80, 98], ["Atazanavir sulfate", "TREATMENT", 80, 98]]], ["The price reduction (mis)reported by Beall et al. (2015) as a compulsory licensing event is, in fact, a discount given by the manufacturer of the original drug after a compulsory license threat (Ramani & Urias, 2018).", [["The price reduction", "TREATMENT", 0, 19]]], ["If these compulsory licensing events are removed from our sample, then the lowest price reduction resulting from a compulsory license is 15.6% [Malaysia Lamivudine + Zidovudine (2003)].Result 2: However, the Existing Public Knowledge on the Degree of Price Drop is Imperfect ::: Impact on Prices ::: ResultsSimilarly, the price before the compulsory licensing of Lamivudine + Nevirapine + Zidovudine|by the Canadian authorities is reported as US$20.00 in Beall et al. (2015) (source type industry report) and US$0.39 in Stirner & Thangaraj (2013) (source type civil society report), an extreme difference greater than 5000%.", [["Lamivudine", "CHEMICAL", 153, 163], ["Zidovudine", "CHEMICAL", 166, 176], ["Lamivudine", "CHEMICAL", 363, 373], ["Nevirapine", "CHEMICAL", 376, 386], ["Zidovudine|by", "CHEMICAL", 389, 402], ["Lamivudine", "CHEMICAL", 153, 163], ["Zidovudine", "CHEMICAL", 166, 176], ["Lamivudine", "CHEMICAL", 363, 373], ["Nevirapine", "CHEMICAL", 376, 386], ["Zidovudine|by", "CHEMICAL", 389, 402], ["Lamivudine", "SIMPLE_CHEMICAL", 363, 373], ["Nevirapine", "SIMPLE_CHEMICAL", 376, 386], ["the lowest price reduction", "TREATMENT", 71, 97], ["Lamivudine + Zidovudine", "TREATMENT", 153, 176], ["Lamivudine", "TREATMENT", 363, 373], ["Nevirapine", "TREATMENT", 376, 386], ["an extreme difference", "PROBLEM", 583, 604]]], ["If the two misreported compulsory licensing events for Atazanavir sulfate in Brazil are removed from the sample, then the price variation range increases, from 71 to 85.2%.", [["Atazanavir sulfate", "CHEMICAL", 55, 73], ["Atazanavir sulfate", "CHEMICAL", 55, 73], ["Atazanavir sulfate", "SIMPLE_CHEMICAL", 55, 73], ["Atazanavir sulfate", "TREATMENT", 55, 73]]], ["Then, turning to the local production option, the mean price reduction of drugs manufactured locally after a compulsory license (n = 10) ranges from 65 to 66.8% due to the discrepancies found in the reported price variations.", [["the mean price reduction of drugs", "TREATMENT", 46, 79], ["the discrepancies", "PROBLEM", 168, 185]]], ["Interestingly, for the compulsory license of Efavirenz in 2017 in Brazil, the drug was initially supplied by an Indian generic manufacturer until a local consortium could start production.", [["Efavirenz", "CHEMICAL", 45, 54], ["Efavirenz", "TREATMENT", 45, 54]]], ["So, for this single compulsory licensing event, there are data on prices for both the imported and the locally produced version of the licensed drug, with the former being lower than the latter.On the Role and Limitation of Compulsory Licenses to Improve Access ::: DiscussionThe utility of compulsory licensing threats as a tool to reduce drug prices in negotiations with patent holders is widely acknowledged (Beall & Kuhn, 2012; Ramani & Urias, 2015; Urias, 2015).", [["drug prices", "TREATMENT", 340, 351], ["patent", "OBSERVATION", 373, 379]]], ["Our evidence strongly suggests that compulsory licensing is indeed an effective mechanism to achieve price reductions of patented medicines.", [["patented medicines", "TREATMENT", 121, 139], ["strongly suggests", "UNCERTAINTY", 13, 30]]], ["Thus, in most cases, it was not possible to infer to what extent these licenses delivered the best outcome possible, in terms of improving the affordability of patented medicines vis-\u00e0-vis the lowest global price.On the Role and Limitation of Compulsory Licenses to Improve Access ::: DiscussionSecond, there are studies demonstrating that alternative approaches, such as price negotiations (with compulsory licensing threats, if needed) and voluntary licensing agreements, can be more effective than the actual issuance of compulsory licenses (Beall et al., 2015; Raju, 2017; Ramani & Urias, 2018; Urias, 2015).", [["patented medicines", "TREATMENT", 160, 178]]], ["For instance, Ramani and Urias (2018) compare the prices of Efavirenz 600 mg produced in Brazil after a compulsory licensing in 2007 to the lowest international price of a generic equivalent.", [["Efavirenz", "CHEMICAL", 60, 69], ["Efavirenz", "CHEMICAL", 60, 69], ["Efavirenz", "SIMPLE_CHEMICAL", 60, 69], ["Efavirenz", "TREATMENT", 60, 69]]], ["They show that, in 2009, when the local production of Efavirenz started, this medicine was 2.6 times more expensive than the cheapest generic version.", [["Efavirenz", "CHEMICAL", 54, 63], ["Efavirenz", "CHEMICAL", 54, 63], ["Efavirenz", "SIMPLE_CHEMICAL", 54, 63], ["Efavirenz", "TREATMENT", 54, 63], ["this medicine", "TREATMENT", 73, 86]]], ["The use of compulsory licensing as a price negotiation tool is mostly restricted either to drugs that are not protected by patents in India or to countries where there is sufficient local technological and productive capacity to produce pharmaceutical products (Ramani & Urias, 2015).", [["drugs", "TREATMENT", 91, 96], ["productive capacity", "PROBLEM", 206, 225]]], ["Similarly, the effectiveness of voluntary licensing is often hampered by geographical or economic limitations and other restrictive licensing terms imposed by pharmaceutical companies (Gold & Morin, 2012; \u2019t Hoen et al., 2011).", [["restrictive", "OBSERVATION_MODIFIER", 120, 131]]], ["For instance, China, Russia, Thailand, and Brazil are often excluded from voluntary licensing agreements under the Medicine Patent Pool (Luca, 2015).On the Role and Limitation of Compulsory Licenses to Improve Access ::: DiscussionBeyond price reduction, compulsory licensing can also be legitimized as an instrument of industrial policy to create local manufacturing capacity.", [["price reduction", "TREATMENT", 238, 253]]], ["Indeed, when the patent holder does not lower prices sufficiently, and is not willing to grant voluntary licenses, then compulsory licensing is the only option.", [["patent", "OBSERVATION", 17, 23]]], ["That said, when a license is contracted out to local firms, the price reduction may not be maximal as the local firms need to catch-up in terms of technological and manufacturing capabilities as compared to an international generics producer selling it at a lower price.", [["the price reduction", "TREATMENT", 60, 79]]], ["Although this could be perceived as a sub-optimal choice from a public health perspective in the short term, in the long term, it may be a relevant strategy to increase the bargaining power of countries when negotiating prices with patent holders.", [["short term", "OBSERVATION_MODIFIER", 97, 107], ["patent", "OBSERVATION", 232, 238]]], ["However, when compulsory licensing is issued for local production, it is important to track prices of licensed drugs over time, and more longitudinal studies are necessary to assess the long-term impact on access to medicines.On the Impact of TRIPS on the Incidence of Compulsory Licensing ::: DiscussionThe caveats with respect to the impact of compulsory licensing along evoked in the previous section, in conjunction with the three central global trends detailed below, raise doubts on the possible use of compulsory licensing by developing countries (not developed ones) to improve access to medicines in the future.On the Impact of TRIPS on the Incidence of Compulsory Licensing ::: DiscussionFirst, currently, the position of \u2018pharmacy of the developing world\u2019 is vacant for many drugs.", [["longitudinal studies", "TEST", 137, 157], ["access to medicines", "TREATMENT", 206, 225], ["medicines", "TREATMENT", 596, 605]]], ["By cross-checking the cases included in this review with the findings of Chaudhuri et al. (2010), we noted that, at the time of the respective compulsory licensing events, there were generic versions available in India for 15 out of the 16 drug formulations identified in this study.", [["the 16 drug formulations", "TREATMENT", 233, 257], ["this study", "TEST", 272, 282]]], ["The only exception was the compulsory license authorized by the Indian government in 2012 for the drug Sorafenib.", [["Sorafenib", "CHEMICAL", 103, 112], ["Sorafenib", "CHEMICAL", 103, 112], ["Sorafenib", "SIMPLE_CHEMICAL", 103, 112], ["the drug Sorafenib", "TREATMENT", 94, 112]]], ["In this event, the Indian Controller of Patents authorized the Indian generic manufacturer Natco to produce and supply to the domestic market a generic version of the drug priced at US$175 per patient per month.", [["patient", "ORGANISM", 193, 200], ["patient", "SPECIES", 193, 200]]], ["However, since India became TRIPS-compliant in 2005, Indian generic drug manufacturers cannot produce and sell any generic version of drugs patented there.On the Impact of TRIPS on the Incidence of Compulsory Licensing ::: DiscussionSecond, the protocol for implementation of compulsory licensing dissuades its application in developing countries.", [["drugs", "TREATMENT", 134, 139]]], ["In Rwanda in 2008, a Canadian generic manufacturer was authorized to export Lamivudine + Nevirapine + Zidovudine to the country.", [["Lamivudine", "CHEMICAL", 76, 86], ["Nevirapine", "CHEMICAL", 89, 99], ["Zidovudine", "CHEMICAL", 102, 112], ["Lamivudine", "CHEMICAL", 76, 86], ["Nevirapine", "CHEMICAL", 89, 99], ["Zidovudine", "CHEMICAL", 102, 112], ["Lamivudine", "SIMPLE_CHEMICAL", 76, 86], ["Nevirapine", "SIMPLE_CHEMICAL", 89, 99], ["Zidovudine", "SIMPLE_CHEMICAL", 102, 112], ["Lamivudine", "TREATMENT", 76, 86], ["Nevirapine", "TREATMENT", 89, 99], ["Zidovudine", "TREATMENT", 102, 112]]], ["To this date, this has been the first and only use of the Paragraph 6 system, which allows for compulsory licensing of essential medicines for exports.", [["essential medicines", "TREATMENT", 119, 138]]], ["Thus, given the limitations of the Paragraph 6 system, and the fact that most of the drugs invented after 2005 are protected by patents in India, we can infer that, under the current international IPR system, ceteris paribus, compulsory licensing is likely to play a more limited role in the future.On the Impact of TRIPS on the Incidence of Compulsory Licensing ::: DiscussionThird, even emerging countries do not have technological capabilities in biotechnology-based drugs of the future.", [["ceteris paribus", "ORGANISM", 209, 224], ["ceteris paribus", "SPECIES", 209, 224], ["the drugs", "TREATMENT", 81, 90]]], ["Increasingly, the drugs are being founded on modern biotechnology rather than synthetic chemistry.", [["synthetic chemistry", "TEST", 78, 97]]], ["In 2017, biologics accounted for about 26% of worldwide pharmaceutical sales (Diependaele et al., 2018).", [["biologics", "TREATMENT", 9, 18]]], ["Although biologics make up only a small proportion of the drug market based on the volume of physical units, the expenditure on them is significant in both developed and developing countries because of their high prices (Dowlat et al., 2016).", [["small", "OBSERVATION_MODIFIER", 34, 39], ["significant", "OBSERVATION_MODIFIER", 136, 147]]], ["This naturally affects the availability of these biologics to the patients, due to the increasingly burning question of health care financing.", [["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74]]], ["The higher price of biologics compared to small-molecule drugs has resulted in a significant burden for patients, health insurers, and public entities supporting medical costs (Chung, 2017).", [["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["The higher price of biologics", "TREATMENT", 0, 29], ["small-molecule drugs", "TREATMENT", 42, 62], ["higher", "OBSERVATION_MODIFIER", 4, 10], ["significant", "OBSERVATION_MODIFIER", 81, 92], ["burden", "OBSERVATION_MODIFIER", 93, 99]]], ["This is hampering access to those essential medicines in both high and low-income countries.", [["those essential medicines", "TREATMENT", 28, 53]]], ["At present, developing country firms do not have technological capabilities to manufacture most of these drugs and developed country firms are not incentivized to produce generic versions.", [["these drugs", "TREATMENT", 99, 110]]], ["Hence, unsurprisingly, our review does not contain any compulsory licensing event for a biologic drug.Compulsory licensing is also considered an important tool by developed countries when crisis hits them ::: The Race to Improve Remdesivir to Address the Covid-19 Challenge ::: DiscussionAlthough compulsory licensing is a TRIPS flexibility that is often perceived as the main mechanism to facilitate increased access to patented pharmaceutical products in developing countries under the coronavirus siege, only developed countries moved fast towards facilitating compulsory licensing.Compulsory licensing is also considered an important tool by developed countries when crisis hits them ::: The Race to Improve Remdesivir to Address the Covid-19 Challenge ::: DiscussionAs soon as Remdesivir was approved by the regulatory authorities, the Trump administration ordered the purchase of about 90% of Gilhead\u2019s targeted production in July, August, and September, leaving very little for the rest of the world.", [["Remdesivir", "CHEMICAL", 782, 792], ["coronavirus", "ORGANISM", 488, 499], ["patented pharmaceutical products", "TREATMENT", 421, 453], ["the coronavirus siege", "PROBLEM", 484, 505], ["the Trump administration", "TREATMENT", 837, 861], ["coronavirus siege", "OBSERVATION", 488, 505]]], ["Some countries, such as Canada, France, Germany, and Israel, also acted to improve access to vaccines, drugs, and other technologies, such as diagnostic kits, devices, and supplies, among others (\u2019t Hoen, 2020a).Compulsory licensing is also considered an important tool by developed countries when crisis hits them ::: The Race to Improve Remdesivir to Address the Covid-19 Challenge ::: DiscussionCanada enacted the COVID-19 Emergency Response Act as a law on 25 March, allowing the Canadian state to produce, sell, and use a patented invention.", [["vaccines", "TREATMENT", 93, 101], ["drugs", "TREATMENT", 103, 108], ["a patented invention", "TREATMENT", 525, 545]]], ["Under the new law, the production license can be issued without first negotiating with the rights holder or having local manufacturing ability, but the patentee must be compensated.", [["the rights holder", "TREATMENT", 87, 104], ["compensated", "OBSERVATION", 169, 180]]], ["Similarly, France passed a new law (No. 2020-290) on 23 March, whereby, under article L.3131-15, the Prime Minister can practice price control and launch generics to address the health crisis before expiry of the patent (Loi n\u00b02020-290 d\u2019urgence pour faire face \u00e0 l\u2019\u00e9pid\u00e9mie de covid-19, 2020).", [["the health crisis", "PROBLEM", 174, 191], ["patent", "OBSERVATION", 213, 219]]], ["Germany passed the Prevention and Control of Infectious Diseases in Humans Act on 28 March, permitting the issuance of compulsory licensing.Compulsory licensing is also considered an important tool by developed countries when crisis hits them ::: The Race to Improve Remdesivir to Address the Covid-19 Challenge ::: DiscussionIsrael issued a compulsory license on 18 March to get an HIV/AIDS antiretroviral called Kaletra, a combination of the antiviral drugs lopinavir and ritonavir developed by AbbVie.", [["Infectious Diseases", "DISEASE", 45, 64], ["AIDS", "DISEASE", 387, 391], ["Kaletra", "CHEMICAL", 414, 421], ["lopinavir", "CHEMICAL", 460, 469], ["ritonavir", "CHEMICAL", 474, 483], ["AbbVie", "CHEMICAL", 497, 503], ["lopinavir", "CHEMICAL", 460, 469], ["ritonavir", "CHEMICAL", 474, 483], ["Kaletra", "SIMPLE_CHEMICAL", 414, 421], ["lopinavir", "SIMPLE_CHEMICAL", 460, 469], ["ritonavir", "SIMPLE_CHEMICAL", 474, 483], ["AbbVie", "SIMPLE_CHEMICAL", 497, 503], ["HIV", "SPECIES", 383, 386], ["Infectious Diseases", "PROBLEM", 45, 64], ["an HIV/AIDS antiretroviral", "TREATMENT", 380, 406], ["Kaletra", "TREATMENT", 414, 421], ["the antiviral drugs lopinavir", "TREATMENT", 440, 469], ["ritonavir", "TREATMENT", 474, 483], ["Infectious", "OBSERVATION_MODIFIER", 45, 55], ["Diseases", "OBSERVATION", 56, 64]]], ["Again, although its positive impact on COVID-19 patients is unconfirmed, the patent for Kaletra expires in Israel only in 2024, while it has already expired in other countries, including India, where it has offices.Compulsory licensing is also considered an important tool by developed countries when crisis hits them ::: The Race to Improve Remdesivir to Address the Covid-19 Challenge ::: DiscussionThese acts confirm that changes in national legislation that allow for flexibilities to apply to patent protection, especially compulsory licensing, are an important means to promote quick access to treatment options under crisis situations (OECD, 2020).Compulsory licensing can be averted through voluntary licensing ::: The Race to Improve Remdesivir to Address the Covid-19 Challenge ::: DiscussionFollowing Figure 1, the important patent holders concerned have initiated voluntary licenses.", [["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["COVID", "TEST", 39, 44], ["flexibilities", "TREATMENT", 472, 485], ["positive", "OBSERVATION_MODIFIER", 20, 28], ["impact", "OBSERVATION_MODIFIER", 29, 35], ["patent", "OBSERVATION", 77, 83], ["patent", "OBSERVATION", 498, 504], ["patent", "OBSERVATION", 836, 842]]], ["Gilead has given voluntary licenses for Remdesivir production to three Indian companies, Cipla Ltd, Hetero Labs Ltd, and Jubilant Lifesciences, with a strong knowledge/technology capability base in antiretrovirals, the Pakistani pharmaceutical company, Ferozsons Laboratories, and the multinational Mylan Labs (Anglo-European).", [["Gilead", "CHEMICAL", 0, 6], ["Remdesivir production", "TREATMENT", 40, 61], ["antiretrovirals", "TREATMENT", 198, 213]]], ["The agreement between Gilead and Mylan allows the latter to manufacture and distribute Remdesivir in 127 low- and middle-income countries, including India (Rees, 2020).", [["Remdesivir", "CHEMICAL", 87, 97], ["Mylan", "TREATMENT", 33, 38]]], ["However, it is not clear which countries the Indian and Pakistani companies can supply according to the license with Gilead, as about 73 countries and territories including 30 low- and middle-income countries are excluded from the licensing agreement (Baker, 2020).", [["not", "UNCERTAINTY", 15, 18], ["clear", "OBSERVATION", 19, 24], ["middle", "ANATOMY_MODIFIER", 185, 191]]], ["At any rate, the international price cannot be paid by developing country patients.Addressing COVID-19 and future pandemics via compulsory licensing will depend upon bargaining versus collaboration ::: The Race to Improve Remdesivir to Address the Covid-19 Challenge ::: DiscussionCurrently, there is no vaccine to protect against the virus, and nor are there effective pharmaceutical treatments approved for this specific condition.", [["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["COVID", "TEST", 94, 99], ["vaccine", "TREATMENT", 304, 311], ["the virus", "PROBLEM", 331, 340], ["pharmaceutical treatments", "TREATMENT", 370, 395]]], ["Although existing drugs, including inexpensive generics, are being tested against Covid-19, the ultimate solution for this pandemic seems to rely on the research, development, production, and global distribution of a novel \u2013 and potentially patented \u2013 vaccine.", [["inexpensive generics", "TREATMENT", 35, 55], ["Covid", "TEST", 82, 87], ["the ultimate solution", "TREATMENT", 92, 113], ["this pandemic", "PROBLEM", 118, 131], ["patented \u2013 vaccine", "TREATMENT", 241, 259]]], ["Therefore, it is extremely important to consider how novel technologies yet to be developed can be made available globally.Addressing COVID-19 and future pandemics via compulsory licensing will depend upon bargaining versus collaboration ::: The Race to Improve Remdesivir to Address the Covid-19 Challenge ::: DiscussionWhat does this augur for compulsory licensing?", [["COVID", "TEST", 134, 139]]], ["In spite of this, it can be noted that none of the developing and emerging countries have issued compulsory licensing to access Remdesivir.", [["Remdesivir", "CHEMICAL", 128, 138], ["Remdesivir", "SIMPLE_CHEMICAL", 128, 138], ["access Remdesivir", "TREATMENT", 121, 138]]], ["On the other hand, the possibility of compulsory licensing in developed regions, such as the European Union, China and the United States, may undermine private investments in R&D. Because compulsory licenses can be issued unilaterally, their wider use as an instrument to fight the COVID-19 pandemic may have undesired effects on R&D, as it may lower incentives that IPRs create for innovation (OECD, 2020).Addressing COVID-19 and future pandemics via compulsory licensing will depend upon bargaining versus collaboration ::: The Race to Improve Remdesivir to Address the Covid-19 Challenge ::: DiscussionTo reconcile these two antagonistic forces, and to promote access, there is an urgent need for global collaboration, discussion on criteria for public funding, and upfront agreements on access and affordability with those engaged in the development of new medical technologies.", [["the COVID", "TEST", 278, 287], ["COVID", "TEST", 418, 423], ["public funding", "TREATMENT", 749, 763], ["new medical technologies", "TREATMENT", 857, 881]]], ["Alternative mechanisms, such as a possible international advance market commitment (OECD, 2020) or the COVID-19 Technology Access Pool launched by WHO (Medicines Law & Policy, 2020), could provide an alternative to patent-based incentives for innovation, and eventually reduce the need for compulsory licensing.Limitations of StudyIn our study, we could identify only 24 compulsory licensing events for which data were available on prices before and after the event.", [["compulsory licensing", "TREATMENT", 290, 310], ["StudyIn our study", "TEST", 326, 343]]], ["However, The TRIPS Flexibilities Database developed by Medicines Law & Policy reports 74 compulsory licensing events of medicines since the TRIPS Agreement came into force.", [["medicines", "TREATMENT", 120, 129]]], ["This method requires that the interventions be very similar so that the \u2018outcome measure\u2019 can be compared.", [["the interventions", "TREATMENT", 26, 43]]], ["Moreover, as reported in the Results, in the included studies, price data were obtained from a wide variety of sources with varying degrees of credibility, and there was no information available on the price component stages.Policy ImplicationsOur review highlights the following policy challenges for developing countries which need to be addressed with respect to compulsory licenses to improve their effectiveness with respect to access to medicines for improved health status.", [["price data", "TEST", 63, 73], ["medicines", "TREATMENT", 443, 452]]], ["Their resolution can then be interpreted as our policy recommendations.Policy ImplicationsFirst, the absolute majority of compulsory licensing events retrieved in this review refer to drug formulations to treat HIV/AIDS (n = 19).", [["HIV/AIDS", "DISEASE", 211, 219], ["HIV", "SPECIES", 211, 214], ["drug formulations", "TREATMENT", 184, 201], ["HIV/AIDS", "PROBLEM", 211, 219]]], ["The predominance of compulsory licensing events for HIV/AIDS drugs is not a surprise.", [["HIV/AIDS", "DISEASE", 52, 60], ["HIV", "ORGANISM", 52, 55], ["HIV", "SPECIES", 52, 55], ["HIV", "SPECIES", 52, 55], ["compulsory licensing events", "PROBLEM", 20, 47], ["HIV/AIDS drugs", "TREATMENT", 52, 66], ["predominance", "OBSERVATION_MODIFIER", 4, 16]]], ["The provisions of compulsory licensing in the TRIPS Agreement use terms like \u2018national emergency\u2019 or \u2018circumstances of extreme urgency\u2019 that are often associated with public health crisis caused by contagious diseases.", [["extreme urgency", "PROBLEM", 119, 134], ["contagious diseases", "PROBLEM", 198, 217], ["contagious diseases", "OBSERVATION", 198, 217]]], ["Furthermore, the Doha Declaration, which was influenced by a context of crisis over access to HIV/AIDS treatment in the developing world, specifies HIV/AIDS, tuberculosis, malaria, and other epidemics as particular diseases of concern.", [["HIV/AIDS", "DISEASE", 94, 102], ["HIV/AIDS", "DISEASE", 148, 156], ["tuberculosis", "DISEASE", 158, 170], ["malaria", "DISEASE", 172, 179], ["HIV", "SPECIES", 148, 151], ["HIV", "SPECIES", 94, 97], ["HIV", "SPECIES", 148, 151], ["crisis", "PROBLEM", 72, 78], ["HIV/AIDS treatment", "TREATMENT", 94, 112], ["HIV/AIDS", "PROBLEM", 148, 156], ["tuberculosis", "PROBLEM", 158, 170], ["malaria", "PROBLEM", 172, 179], ["other epidemics", "PROBLEM", 185, 200], ["tuberculosis", "OBSERVATION", 158, 170], ["malaria", "OBSERVATION", 172, 179]]], ["Therefore, the higher incidence of non-communicable diseases in the low- and middle-income countries brings important challenges in terms of improving access to medicines, and compulsory licensing should definitively remain a legitimate alternative for this goal.", [["non-communicable diseases", "DISEASE", 35, 60], ["non-communicable diseases", "PROBLEM", 35, 60], ["medicines", "TREATMENT", 161, 170], ["higher", "OBSERVATION_MODIFIER", 15, 21], ["non-communicable", "OBSERVATION_MODIFIER", 35, 51], ["diseases", "OBSERVATION", 52, 60], ["middle", "ANATOMY_MODIFIER", 77, 83]]], ["As our results show, compulsory licensing provisions are equally applicable and useful for non-communicable diseases.", [["non-communicable diseases", "PROBLEM", 91, 116]]], ["For that, developing countries have to implement adequate local IPR frameworks that allow them to make effective use of such flexibilities regardless of the disease type.Policy ImplicationsSecond, some scholars argue that stricter standards during the examination of patent applications can remove the need for compulsory licenses (Correa, 2006).", [["adequate local IPR frameworks", "TREATMENT", 49, 78], ["such flexibilities", "TREATMENT", 120, 138], ["the disease type", "PROBLEM", 153, 169], ["the examination", "TEST", 248, 263], ["patent applications", "TREATMENT", 267, 286], ["disease", "OBSERVATION", 157, 164], ["patent", "OBSERVATION", 267, 273]]], ["For instance, to fight against \u2018evergreening\u2019, the Indian IPR framework wards off patents for new forms or uses of existing pharmaceutical products that are simply minor modifications of existing products, unless they demonstrate improved efficacy (Rajkumar & Kesselheim, 2013).", [["existing pharmaceutical products", "TREATMENT", 115, 147], ["improved", "OBSERVATION_MODIFIER", 230, 238]]], ["Other developing countries, such as Argentina and the Philippines, have amended their IPR regulations to restrict the patentability of certain categories of pharmaceutical inventions (e.g., polymorphs, formulations, and additional uses of existing compounds) to avoid granting undeserved patents that can be detrimental to access to life-saving medicines (Amin & Kesselheim, 2012).Policy ImplicationsThird, it is difficult to identify and unravel the impact pathways of compulsory licenses, as information is simply not available.", [["their IPR regulations", "TREATMENT", 80, 101], ["pharmaceutical inventions", "TREATMENT", 157, 182], ["polymorphs, formulations", "TREATMENT", 190, 214], ["existing compounds", "TREATMENT", 239, 257]]], ["Analysis of 11 out of the 24 compulsory licensing events is not based on official sources at all.", [["Analysis", "TEST", 0, 8]]], ["Also, as discussed in the limitations, there are at least other 50 compulsory licensing events for which no price data could be retrieved.", [["price data", "TEST", 108, 118]]], ["Therefore, official information on prices pre- and post-compulsory licensing should be disclosed to prevent misuse and to ensure that private interests are not put before public interests.Policy ImplicationsFourth, industrial polices for creation and accumulation of technological capabilities in development and production of pharmaceutical products in developing countries are needed.", [["pharmaceutical products", "TREATMENT", 327, 350]]], ["As discussed, compulsory licensing itself can be a \u2018window of opportunity\u2019 for this purpose.ConclusionCompulsory licensing is often invoked as a panacea for the constraints imposed by TRIPS to ensure access to needed patented medicines during times of health crises.", [["patented medicines", "TREATMENT", 217, 235], ["health crises", "PROBLEM", 252, 265]]], ["In this regard, the objective of the present paper was to review the existing evidence on the impact of compulsory licensing events in order to assess its utility as an instrument to improve access.ConclusionIn our systematic review, we verified a mean price reduction between 66.2 and 73.9% for the 24 compulsory licensing events for which price data are available.", [["an instrument", "TREATMENT", 166, 179], ["a mean price reduction", "TREATMENT", 246, 268]]], ["Therefore, it would seem that compulsory licensing is indeed an effective mechanism for price reduction with increased availability.", [["price reduction", "TREATMENT", 88, 103]]], ["However, this result is modulated by the evaluation that it is not clear if compulsory licensing is the most effective alternative to make patented medicines more affordable.", [["the evaluation", "TEST", 37, 51], ["patented medicines", "TREATMENT", 139, 157]]], ["Nevertheless, it is still the only mechanism available to many developing countries without manufacturing capabilities in pharmaceuticals.ConclusionWhat about the effectiveness of compulsory licenses as an instrument to improve access to medicines in the future?", [["compulsory licenses", "TREATMENT", 180, 199], ["medicines", "TREATMENT", 238, 247]]], ["Thus, the future of compulsory licensing as an instrument of increasing access to medicines will be shaped by the evolution of two factors.", [["increasing access to medicines", "TREATMENT", 61, 91]]], ["First, under crisis situations, TRIPS has made the window of opportunity for generic producers to supply the rest of the world with drugs under patent, not only much smaller, but much more difficult to even open, given the cumbersomeness of the Paragraph 6 system.", [["TRIPS", "CHEMICAL", 32, 37], ["generic producers", "TREATMENT", 77, 94], ["drugs", "TREATMENT", 132, 137], ["patent", "OBSERVATION", 144, 150], ["much smaller", "OBSERVATION_MODIFIER", 161, 173]]], ["In the future, if there are other health crises, and activists force further refinements, this may change.", [["other health crises", "PROBLEM", 28, 47]]], ["Second, new drugs may be biologics in which emerging countries have an enormous technological (and often regulatory) retard.", [["new drugs", "TREATMENT", 8, 17], ["new", "OBSERVATION_MODIFIER", 8, 11], ["drugs", "OBSERVATION", 12, 17]]], ["This is even more extreme in the case of biologicals, for which the technological competence is concentrated in developed countries, mostly in companies that also manufacture innovative products.", [["more extreme", "OBSERVATION_MODIFIER", 13, 25]]], ["This calls for entrepreneurial state interventions towards technological capacity and promotion of innovative models for drug development, production, and distribution.", [["entrepreneurial state interventions", "TREATMENT", 15, 50], ["technological capacity", "TEST", 59, 81], ["innovative models", "TREATMENT", 99, 116], ["drug development", "PROBLEM", 121, 137]]], ["The use of compulsory licensing as an industrial policy instrument can be an important trigger of such a process of technological capacity building.", [["compulsory licensing", "TREATMENT", 11, 31], ["an industrial policy instrument", "TREATMENT", 35, 66], ["technological capacity building", "TREATMENT", 116, 147]]], ["For this, nevertheless, it is important to have other instruments and mechanisms to ensure competitiveness and compliance with safety and quality standards.Notes", [["other instruments", "TREATMENT", 48, 65]]]], "PMC6695463": [["IntroductionIn order to have a patient-tailored approach, choosing the right medication, the right dose at the right time point, the standardization and individualization should go hand in hand.", [["hand", "ANATOMY", 181, 185], ["hand", "ANATOMY", 189, 193], ["patient", "ORGANISM", 31, 38], ["hand", "ORGANISM_SUBDIVISION", 181, 185], ["hand", "ORGANISM_SUBDIVISION", 189, 193], ["patient", "SPECIES", 31, 38], ["a patient-tailored approach", "TREATMENT", 29, 56], ["the right medication", "TREATMENT", 67, 87], ["right", "ANATOMY_MODIFIER", 71, 76], ["right", "ANATOMY_MODIFIER", 93, 98], ["right", "ANATOMY_MODIFIER", 111, 116]]], ["Predictive diagnostics, targeted prevention, and personalization of medical services are the main objective of the predictive, preventive, and personalized medicine (PPPM).", [["Predictive diagnostics", "TEST", 0, 22], ["personalized medicine (PPPM)", "TREATMENT", 143, 171]]], ["Economic circumstances and missing political regulations are among the factors resulting in the blockage between the bench and bedside; to these, we should add the applicability of the bench studies as the foundation of clinical investigation and subsequent clinical trials.", [["Economic circumstances", "PROBLEM", 0, 22], ["the bench studies", "TEST", 181, 198], ["clinical investigation", "TEST", 220, 242], ["blockage", "OBSERVATION", 96, 104]]], ["Plenty of treatment modalities were developed on the basis of animal experimentations.", [["treatment modalities", "TREATMENT", 10, 30]]], ["Meanwhile, there is an increasing number of failed clinical trials, particularly on chronic and complex diseases that biased from the results of studies on inappropriate animal models [4, 5].", [["failed clinical trials", "PROBLEM", 44, 66], ["chronic and complex diseases", "PROBLEM", 84, 112], ["studies", "TEST", 145, 152], ["increasing", "OBSERVATION_MODIFIER", 23, 33], ["number", "OBSERVATION_MODIFIER", 34, 40], ["chronic", "OBSERVATION_MODIFIER", 84, 91], ["complex", "OBSERVATION_MODIFIER", 96, 103], ["diseases", "OBSERVATION", 104, 112]]], ["It is time to ask whether animal models truly predict human health conditions.IntroductionWhile validity and acceptability of current successful trials and guidelines are debated in the 21st century because they are not patient tailored, how could we rely on animal models as an appropriate predictor of human conditions?IntroductionSimplifying a complex system is inevitable to study the basis of a complex phenomenon.", [["human", "ORGANISM", 54, 59], ["patient", "ORGANISM", 220, 227], ["human", "ORGANISM", 304, 309], ["human", "SPECIES", 54, 59], ["patient", "SPECIES", 220, 227], ["human", "SPECIES", 304, 309], ["human", "SPECIES", 54, 59], ["human", "SPECIES", 304, 309], ["a complex phenomenon", "PROBLEM", 398, 418], ["complex", "OBSERVATION_MODIFIER", 400, 407], ["phenomenon", "OBSERVATION", 408, 418]]], ["When an animal model is used as the basis of a clinical trial, it is needed to mimic the complex properties of the patients.", [["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123]]], ["Otherwise, animal models might be misleading; consequently, a large number of therapeutic modalities might have lost in translation [7].", [["therapeutic modalities", "TREATMENT", 78, 100], ["large", "OBSERVATION_MODIFIER", 62, 67]]], ["This study was therefore undertaken to provide shreds of evidence against the validity of animal models.", [["This study", "TEST", 0, 10]]], ["It has been systematically discussed why the authors believe that it is time to re-evaluate the validity of animal experimentations.", [["animal experimentations", "PROBLEM", 108, 131]]], ["Although plenty of state-of-the-art disease modeling techniques have been introduced recently, their acceptance and application in the medical science society are scarce; nevertheless validity of these modern modeling techniques needs further evaluation as well.", [["further evaluation", "TEST", 235, 253]]], ["There is a gap between bench and bedside that, unfortunately, has not been appropriately filled with the animal models.", [["filled", "OBSERVATION", 89, 95]]], ["In our contribution, we want to provide relevant facts which clearly show that translational medicine and PPPM need accurate surrogate for misleading animal models in order to increase the level of the future healthcare.", [["translational medicine", "TREATMENT", 79, 101], ["PPPM", "TREATMENT", 106, 110], ["misleading animal models", "PROBLEM", 139, 163]]], ["In this article, we review the knowledge on inappropriate modeling of chronic and complex disorders, which is very important point for the predictive, preventive, and personalized medicine.", [["chronic and complex disorders", "PROBLEM", 70, 99], ["personalized medicine", "TREATMENT", 167, 188], ["chronic", "OBSERVATION_MODIFIER", 70, 77], ["complex", "OBSERVATION_MODIFIER", 82, 89], ["disorders", "OBSERVATION", 90, 99]]], ["The translation medicine in this point has to deal with this problem in order to support further and smooth development of PPPM.", [["PPPM", "DISEASE", 123, 127], ["PPPM", "CANCER", 123, 127], ["The translation medicine", "TREATMENT", 0, 24], ["PPPM", "TREATMENT", 123, 127], ["smooth", "OBSERVATION_MODIFIER", 101, 107]]], ["It is absolutely essential the experts in all fields of medicine, and beyond, are aware of the described problems.", [["essential", "OBSERVATION_MODIFIER", 17, 26]]], ["The predictions in PPPM and potential preventive actions may very well be compromised if inappropriate modeling is being widely used in numerous cases, let alone the creation of personalized models for an individual patient.", [["patient", "ORGANISM", 216, 223], ["patient", "SPECIES", 216, 223], ["PPPM", "TREATMENT", 19, 23], ["inappropriate modeling", "PROBLEM", 89, 111]]], ["There is a great need and potential for fundamental changes in strategies, leading to substantial improvements in future healthcare.Gene therapy: another illusion of scientific revolution ::: Examples of drug development failuresFrom 1990, only X-linked severe combined immunodeficiency (X-SCID) gene therapy showed near acceptable results; the other trials failed among several hundred successful gene therapies in animals; however, among ten successfully treated X-SCID children, three developed leukemia, and one of them died due to its complications.", [["leukemia", "ANATOMY", 498, 506], ["combined immunodeficiency (X-SCID", "DISEASE", 261, 294], ["X-SCID", "DISEASE", 465, 471], ["leukemia", "DISEASE", 498, 506], ["X-SCID children", "ORGANISM", 465, 480], ["leukemia", "CANCER", 498, 506], ["children", "SPECIES", 472, 480], ["fundamental changes in strategies", "PROBLEM", 40, 73], ["drug development failures", "PROBLEM", 204, 229], ["severe combined immunodeficiency", "PROBLEM", 254, 286], ["gene therapy", "TREATMENT", 296, 308], ["successful gene therapies", "TREATMENT", 387, 412], ["leukemia", "PROBLEM", 498, 506], ["its complications", "PROBLEM", 536, 553], ["great", "OBSERVATION_MODIFIER", 11, 16], ["substantial", "OBSERVATION_MODIFIER", 86, 97], ["improvements", "OBSERVATION_MODIFIER", 98, 110], ["severe", "OBSERVATION_MODIFIER", 254, 260], ["immunodeficiency", "OBSERVATION", 270, 286], ["leukemia", "OBSERVATION", 498, 506]]], ["None of these adverse effects were predicted by animal experiments and prompted the FDA to halt several gene therapy programs in the USA [14, 15].", [["several gene therapy programs", "TREATMENT", 96, 125]]], ["Hemophilia gene therapy programs were also discontinued in 2004 due to perilous complications such as liver damage which was not predicted in animal studies [15, 16].Myocardial infarction and stroke: just reading the last seen is not enough to comprehend a drama ::: Examples of drug development failuresAnimal models of myocardial infarction (MI) generally do not completely mimic the MI process.", [["liver", "ANATOMY", 102, 107], ["Myocardial", "ANATOMY", 166, 176], ["myocardial", "ANATOMY", 321, 331], ["Hemophilia", "DISEASE", 0, 10], ["liver damage", "DISEASE", 102, 114], ["Myocardial infarction", "DISEASE", 166, 187], ["stroke", "DISEASE", 192, 198], ["myocardial infarction", "DISEASE", 321, 342], ["MI", "DISEASE", 344, 346], ["MI", "DISEASE", 386, 388], ["liver", "ORGAN", 102, 107], ["Myocardial", "MULTI-TISSUE_STRUCTURE", 166, 176], ["myocardial", "MULTI-TISSUE_STRUCTURE", 321, 331], ["Hemophilia gene therapy programs", "TREATMENT", 0, 32], ["perilous complications", "PROBLEM", 71, 93], ["liver damage", "PROBLEM", 102, 114], ["Myocardial infarction", "PROBLEM", 166, 187], ["stroke", "PROBLEM", 192, 198], ["drug development failures", "PROBLEM", 279, 304], ["myocardial infarction", "PROBLEM", 321, 342], ["MI", "PROBLEM", 344, 346], ["the MI process", "PROBLEM", 382, 396], ["liver", "ANATOMY", 102, 107], ["damage", "OBSERVATION", 108, 114], ["infarction", "OBSERVATION", 177, 187], ["stroke", "OBSERVATION", 192, 198], ["failures", "OBSERVATION", 296, 304], ["myocardial", "ANATOMY", 321, 331], ["infarction", "OBSERVATION", 332, 342], ["MI", "OBSERVATION", 386, 388]]], ["Although atherosclerosis models are currently available, MI animal models are usually surgically mimicked by the clumping-reperfusion process.", [["atherosclerosis", "DISEASE", 9, 24], ["MI", "DISEASE", 57, 59], ["atherosclerosis models", "PROBLEM", 9, 31], ["MI animal models", "PROBLEM", 57, 73], ["the clumping-reperfusion process", "PROBLEM", 109, 141], ["atherosclerosis", "OBSERVATION", 9, 24], ["clumping", "OBSERVATION_MODIFIER", 113, 121], ["reperfusion process", "OBSERVATION", 122, 141]]], ["Hence, MI is synthesized with no previous hypoxia, no hypoperfusion, etc. Actually, acute myocardial infarction is the final sequence of the atherosclerosis drama as a chronic process.", [["myocardial", "ANATOMY", 90, 100], ["MI", "DISEASE", 7, 9], ["hypoxia", "DISEASE", 42, 49], ["hypoperfusion", "DISEASE", 54, 67], ["myocardial infarction", "DISEASE", 90, 111], ["atherosclerosis", "DISEASE", 141, 156], ["myocardial", "MULTI-TISSUE_STRUCTURE", 90, 100], ["MI", "PROBLEM", 7, 9], ["previous hypoxia", "PROBLEM", 33, 49], ["hypoperfusion", "PROBLEM", 54, 67], ["acute myocardial infarction", "PROBLEM", 84, 111], ["the atherosclerosis drama", "PROBLEM", 137, 162], ["a chronic process", "PROBLEM", 166, 183], ["hypoxia", "OBSERVATION", 42, 49], ["no", "UNCERTAINTY", 51, 53], ["hypoperfusion", "OBSERVATION", 54, 67], ["acute", "OBSERVATION_MODIFIER", 84, 89], ["myocardial", "ANATOMY", 90, 100], ["infarction", "OBSERVATION", 101, 111], ["atherosclerosis", "OBSERVATION", 141, 156], ["chronic", "OBSERVATION_MODIFIER", 168, 175], ["process", "OBSERVATION", 176, 183]]], ["In the case of MI modeling, the erythropoietin paradox certified inappropriate modeling of MI as a complex phenomenon [3].", [["MI", "DISEASE", 15, 17], ["MI", "DISEASE", 91, 93], ["erythropoietin", "GENE_OR_GENE_PRODUCT", 32, 46], ["erythropoietin", "PROTEIN", 32, 46], ["MI modeling", "PROBLEM", 15, 26], ["the erythropoietin paradox", "TREATMENT", 28, 54], ["MI", "PROBLEM", 91, 93], ["a complex phenomenon", "PROBLEM", 97, 117]]], ["Almost 500 drugs underwent trial for stroke; among them, only aspirin and early recombinant tissue plasminogen activator did not fail [17, 18].Diabetes mellitus: it is not all about the insulin ::: Examples of drug development failuresOperational implementation of PPPM perceptions to diabetes mellitus (DM) care is due long ago.", [["stroke", "DISEASE", 37, 43], ["aspirin", "CHEMICAL", 62, 69], ["Diabetes mellitus", "DISEASE", 143, 160], ["diabetes mellitus", "DISEASE", 285, 302], ["DM", "DISEASE", 304, 306], ["aspirin", "CHEMICAL", 62, 69], ["aspirin", "SIMPLE_CHEMICAL", 62, 69], ["tissue plasminogen activator", "GENE_OR_GENE_PRODUCT", 92, 120], ["insulin", "GENE_OR_GENE_PRODUCT", 186, 193], ["stroke", "PROBLEM", 37, 43], ["aspirin", "TREATMENT", 62, 69], ["early recombinant tissue plasminogen activator", "TREATMENT", 74, 120], ["Diabetes mellitus", "PROBLEM", 143, 160], ["drug development failures", "PROBLEM", 210, 235], ["diabetes mellitus", "PROBLEM", 285, 302], ["failures", "OBSERVATION", 227, 235]]], ["The European Association for Predictive, Preventive and Personalised Medicine (EPMA) emphasizes the need to debate the large-scale complex approach for diabetes care, especially those with comorbid pathologies such as cardiovascular disease (CVD), cancer, and neurological, neuropsychiatric, and neurodegenerative diseases (NNND) [1, 19, 20].Diabetes mellitus: it is not all about the insulin ::: Examples of drug development failuresStreptozotocin-induced diabetes models are one of the widely used diabetes models [21].", [["cardiovascular", "ANATOMY", 218, 232], ["cancer", "ANATOMY", 248, 254], ["neurological", "ANATOMY", 260, 272], ["diabetes", "DISEASE", 152, 160], ["cardiovascular disease", "DISEASE", 218, 240], ["CVD", "DISEASE", 242, 245], ["cancer", "DISEASE", 248, 254], ["neurological, neuropsychiatric, and neurodegenerative diseases", "DISEASE", 260, 322], ["NNND", "DISEASE", 324, 328], ["Diabetes mellitus", "DISEASE", 342, 359], ["Streptozotocin", "CHEMICAL", 434, 448], ["diabetes", "DISEASE", 457, 465], ["diabetes", "DISEASE", 500, 508], ["Streptozotocin", "CHEMICAL", 434, 448], ["cardiovascular", "ANATOMICAL_SYSTEM", 218, 232], ["cancer", "CANCER", 248, 254], ["insulin", "GENE_OR_GENE_PRODUCT", 385, 392], ["Streptozotocin", "SIMPLE_CHEMICAL", 434, 448], ["the large-scale complex approach", "TREATMENT", 115, 147], ["diabetes care", "TREATMENT", 152, 165], ["comorbid pathologies", "PROBLEM", 189, 209], ["cardiovascular disease (CVD)", "PROBLEM", 218, 246], ["cancer", "PROBLEM", 248, 254], ["neurological, neuropsychiatric, and neurodegenerative diseases", "PROBLEM", 260, 322], ["Diabetes mellitus", "PROBLEM", 342, 359], ["drug development failures", "PROBLEM", 409, 434], ["Streptozotocin", "TREATMENT", 434, 448], ["induced diabetes models", "PROBLEM", 449, 472], ["diabetes models", "PROBLEM", 500, 515], ["cancer", "OBSERVATION", 248, 254], ["neurodegenerative", "OBSERVATION_MODIFIER", 296, 313], ["diseases", "OBSERVATION", 314, 322], ["failures", "OBSERVATION", 426, 434]]], ["Diabetes is a chronic process with several genetic as well as environmental risk factors.", [["Diabetes", "DISEASE", 0, 8], ["Diabetes", "PROBLEM", 0, 8], ["a chronic process", "PROBLEM", 12, 29], ["chronic", "OBSERVATION_MODIFIER", 14, 21], ["process", "OBSERVATION", 22, 29]]], ["There are several abnormalities in diabetes patients, including impaired insulin secretion, increased insulin resistance, endothelial dysfunction, increased oxidative stress, and impaired antioxidant defense system, and all of them occur in a prolonged period of time [22].", [["endothelial", "ANATOMY", 122, 133], ["diabetes", "DISEASE", 35, 43], ["impaired insulin secretion", "DISEASE", 64, 90], ["endothelial dysfunction", "DISEASE", 122, 145], ["patients", "ORGANISM", 44, 52], ["insulin", "GENE_OR_GENE_PRODUCT", 73, 80], ["insulin", "GENE_OR_GENE_PRODUCT", 102, 109], ["endothelial", "TISSUE", 122, 133], ["patients", "SPECIES", 44, 52], ["several abnormalities in diabetes patients", "PROBLEM", 10, 52], ["impaired insulin secretion", "PROBLEM", 64, 90], ["increased insulin resistance", "PROBLEM", 92, 120], ["endothelial dysfunction", "PROBLEM", 122, 145], ["increased oxidative stress", "PROBLEM", 147, 173], ["impaired antioxidant defense system", "PROBLEM", 179, 214], ["several", "OBSERVATION_MODIFIER", 10, 17], ["abnormalities", "OBSERVATION", 18, 31], ["diabetes", "OBSERVATION", 35, 43], ["impaired", "OBSERVATION_MODIFIER", 64, 72], ["insulin secretion", "OBSERVATION", 73, 90], ["increased", "OBSERVATION_MODIFIER", 92, 101], ["insulin resistance", "OBSERVATION", 102, 120], ["endothelial dysfunction", "OBSERVATION", 122, 145], ["increased", "OBSERVATION_MODIFIER", 147, 156], ["oxidative stress", "OBSERVATION", 157, 173], ["impaired", "OBSERVATION_MODIFIER", 179, 187], ["antioxidant defense", "OBSERVATION", 188, 207]]], ["Additionally, diabetes is usually accompanied by a variety of comorbidities such as obesity, atherosclerosis, and other.", [["diabetes", "DISEASE", 14, 22], ["obesity", "DISEASE", 84, 91], ["atherosclerosis", "DISEASE", 93, 108], ["diabetes", "PROBLEM", 14, 22], ["comorbidities", "PROBLEM", 62, 75], ["obesity", "PROBLEM", 84, 91], ["atherosclerosis", "PROBLEM", 93, 108], ["diabetes", "OBSERVATION", 14, 22], ["variety", "OBSERVATION_MODIFIER", 51, 58], ["obesity", "OBSERVATION", 84, 91], ["atherosclerosis", "OBSERVATION", 93, 108]]], ["None of the abovementioned parameters has been reflected in the streptozotocin mouse model of diabetes.", [["streptozotocin", "CHEMICAL", 64, 78], ["diabetes", "DISEASE", 94, 102], ["streptozotocin", "CHEMICAL", 64, 78], ["streptozotocin", "ORGANISM", 64, 78], ["mouse", "ORGANISM", 79, 84], ["mouse", "SPECIES", 79, 84], ["mouse", "SPECIES", 79, 84], ["diabetes", "PROBLEM", 94, 102], ["diabetes", "OBSERVATION", 94, 102]]], ["Zucker rats are better examples of DM which could be replaced; at least, these obese animal models represent metabolic syndrome, and diabetes occurs after a period of time in these obese rats [23].Cancer: we are the underdog, with no doubt ::: Examples of drug development failuresDespite plenty of promising preclinical studies on cancer treatments, roughly 85% of early clinical trials for novel drugs fail, and only half of the medications that enter phase 3 studies will become approved for clinical application [7, 8, 24].", [["Cancer", "ANATOMY", 197, 203], ["cancer", "ANATOMY", 332, 338], ["DM", "DISEASE", 35, 37], ["metabolic syndrome", "DISEASE", 109, 127], ["diabetes", "DISEASE", 133, 141], ["Cancer", "DISEASE", 197, 203], ["cancer", "DISEASE", 332, 338], ["Zucker rats", "ORGANISM", 0, 11], ["rats", "ORGANISM", 187, 191], ["Cancer", "CANCER", 197, 203], ["cancer", "CANCER", 332, 338], ["rats", "SPECIES", 7, 11], ["rats", "SPECIES", 187, 191], ["DM", "PROBLEM", 35, 37], ["metabolic syndrome", "PROBLEM", 109, 127], ["diabetes", "PROBLEM", 133, 141], ["drug development failures", "PROBLEM", 256, 281], ["cancer treatments", "TREATMENT", 332, 349], ["novel drugs", "TREATMENT", 392, 403], ["the medications", "TREATMENT", 427, 442], ["obese", "OBSERVATION", 79, 84], ["metabolic syndrome", "OBSERVATION", 109, 127], ["failures", "OBSERVATION", 273, 281]]], ["Our efforts in the war against cancer were not encouraging in terms of therapeutic approaches; in fact, it was preventive approaches that showed promising effects.", [["cancer", "ANATOMY", 31, 37], ["cancer", "DISEASE", 31, 37], ["cancer", "CANCER", 31, 37], ["cancer", "PROBLEM", 31, 37]]], ["Genetic, molecular, cellular, and immunologic differences between models and human beings made them poor prognostic modalities [4].", [["cellular", "ANATOMY", 20, 28], ["cellular", "CELL", 20, 28], ["human", "ORGANISM", 77, 82], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 77, 82], ["cellular", "OBSERVATION_MODIFIER", 20, 28]]], ["False positivity of rodent studies in this case was around 95% [25, 26].", [["False positivity", "TEST", 0, 16], ["rodent studies", "TEST", 20, 34], ["rodent", "OBSERVATION_MODIFIER", 20, 26]]], ["In reality, rodent cancer models is believed to be invalid and financially indefensible [27].", [["cancer", "ANATOMY", 19, 25], ["cancer", "DISEASE", 19, 25], ["cancer", "CANCER", 19, 25], ["rodent cancer models", "PROBLEM", 12, 32], ["cancer", "OBSERVATION", 19, 25], ["believed to be", "UNCERTAINTY", 36, 50]]], ["Only 8% success rate in the translation of cancer studies has been reported; actually, 85% of all clinical trials failed before starting phase 3 trials.", [["cancer", "ANATOMY", 43, 49], ["cancer", "DISEASE", 43, 49], ["cancer", "CANCER", 43, 49], ["cancer studies", "TEST", 43, 57], ["phase 3 trials", "TREATMENT", 137, 151], ["cancer", "OBSERVATION", 43, 49]]], ["Among studies which enter phase 3, half of them were withdrawn [28, 29].", [["Among studies", "TEST", 0, 13]]], ["Only a little number of these studies are adopted and the others are being withdrawn after sacrificing their victims [7, 30].", [["these studies", "TEST", 24, 37]]], ["Most of the cancer animal models are suffering from inappropriate modeling.", [["cancer", "ANATOMY", 12, 18], ["cancer", "DISEASE", 12, 18], ["cancer", "CANCER", 12, 18], ["the cancer animal models", "PROBLEM", 8, 32], ["inappropriate modeling", "PROBLEM", 52, 74], ["cancer", "OBSERVATION", 12, 18], ["inappropriate modeling", "OBSERVATION", 52, 74]]], ["Inoculation of malignant cells (cell lines) is the most common current method of malignancy modeling.", [["malignant cells", "ANATOMY", 15, 30], ["cell lines", "ANATOMY", 32, 42], ["malignancy", "DISEASE", 81, 91], ["malignant cells", "CELL", 15, 30], ["cell lines", "CELL", 32, 42], ["malignancy", "CANCER", 81, 91], ["malignant cells", "CELL_TYPE", 15, 30], ["cell lines", "CELL_LINE", 32, 42], ["malignant cells (cell lines", "PROBLEM", 15, 42], ["malignancy modeling", "PROBLEM", 81, 100], ["malignant cells", "OBSERVATION", 15, 30], ["cell lines", "OBSERVATION", 32, 42], ["most common", "OBSERVATION_MODIFIER", 51, 62], ["malignancy", "OBSERVATION", 81, 91]]], ["This model does not reflect the prolonged complex process of developing a malignancy.", [["malignancy", "ANATOMY", 74, 84], ["malignancy", "DISEASE", 74, 84], ["malignancy", "CANCER", 74, 84], ["a malignancy", "PROBLEM", 72, 84], ["does not reflect", "UNCERTAINTY", 11, 27], ["prolonged", "OBSERVATION_MODIFIER", 32, 41], ["complex", "OBSERVATION_MODIFIER", 42, 49], ["malignancy", "OBSERVATION", 74, 84]]], ["Recently, knocked out animal models and animal models with special mutations have been introduced [7, 29, 31]; although these models sufficiently mimic genetic background of malignant tumors, the epigenetic role and the role of environment were not reflected in these models.", [["malignant tumors", "ANATOMY", 174, 190], ["malignant tumors", "DISEASE", 174, 190], ["malignant tumors", "CANCER", 174, 190], ["special mutations", "PROBLEM", 59, 76], ["malignant tumors", "PROBLEM", 174, 190], ["malignant", "OBSERVATION_MODIFIER", 174, 183], ["tumors", "OBSERVATION", 184, 190]]], ["Additionally, there are several probable genotypes for a single phenotype of malignancy.Cancer: we are the underdog, with no doubt ::: Examples of drug development failuresFor instance, extremely high heterogeneity among breast tumors is well documented.", [["Cancer", "ANATOMY", 88, 94], ["breast tumors", "ANATOMY", 221, 234], ["malignancy", "DISEASE", 77, 87], ["Cancer", "DISEASE", 88, 94], ["breast tumors", "DISEASE", 221, 234], ["malignancy", "CANCER", 77, 87], ["Cancer", "CANCER", 88, 94], ["breast tumors", "CANCER", 221, 234], ["a single phenotype of malignancy", "PROBLEM", 55, 87], ["drug development failures", "PROBLEM", 147, 172], ["extremely high heterogeneity among breast tumors", "PROBLEM", 186, 234], ["malignancy", "OBSERVATION", 77, 87], ["failures", "OBSERVATION", 164, 172], ["extremely", "OBSERVATION_MODIFIER", 186, 195], ["high", "OBSERVATION_MODIFIER", 196, 200], ["heterogeneity", "OBSERVATION_MODIFIER", 201, 214], ["breast", "ANATOMY", 221, 227], ["tumors", "OBSERVATION", 228, 234]]], ["Hence, Jaak Janssens beautifully stated the question as: \u201cshould we speak about breast cancers instead of cancer?\u201d [32, 33].Cancer: we are the underdog, with no doubt ::: Examples of drug development failuresGenomic guidance gradually becomes the standard for diagnostics in cancer care [33, 34].", [["breast cancers", "ANATOMY", 80, 94], ["cancer", "ANATOMY", 106, 112], ["Cancer", "ANATOMY", 124, 130], ["cancer", "ANATOMY", 275, 281], ["breast cancers", "DISEASE", 80, 94], ["cancer", "DISEASE", 106, 112], ["Cancer", "DISEASE", 124, 130], ["cancer", "DISEASE", 275, 281], ["breast cancers", "CANCER", 80, 94], ["cancer", "CANCER", 106, 112], ["Cancer", "CANCER", 124, 130], ["cancer", "CANCER", 275, 281], ["breast cancers", "PROBLEM", 80, 94], ["cancer", "PROBLEM", 106, 112], ["drug development failures", "PROBLEM", 183, 208], ["breast", "ANATOMY", 80, 86], ["cancers", "OBSERVATION", 87, 94], ["failures", "OBSERVATION", 200, 208]]], ["For example, in response to the growing knowledge about molecular characteristics of breast cancer subtypes and the need for personalized approach to the patients, the American Joint Committee on Cancer (AJCC) dramatically revised their latest edition (8th edition, last updated January 25, 2018) of breast cancer staging manual.", [["breast cancer", "ANATOMY", 85, 98], ["breast cancer", "ANATOMY", 300, 313], ["breast cancer", "DISEASE", 85, 98], ["Cancer", "DISEASE", 196, 202], ["AJCC", "DISEASE", 204, 208], ["breast cancer", "DISEASE", 300, 313], ["breast cancer", "CANCER", 85, 98], ["patients", "ORGANISM", 154, 162], ["Cancer", "CANCER", 196, 202], ["breast cancer", "CANCER", 300, 313], ["patients", "SPECIES", 154, 162], ["breast cancer subtypes", "PROBLEM", 85, 107], ["personalized approach", "TREATMENT", 125, 146], ["breast cancer", "PROBLEM", 300, 313], ["breast", "ANATOMY", 85, 91], ["cancer", "OBSERVATION", 92, 98], ["Joint", "ANATOMY", 177, 182], ["Cancer", "OBSERVATION", 196, 202], ["breast", "ANATOMY", 300, 306], ["cancer", "OBSERVATION", 307, 313]]], ["The 8th edition of the AJCC tumor, node, and metastase (TNM) breast cancer staging system delivers a flexible platform for prognostic classification based on traditional anatomic factors, which may be modified and enhanced with respect to patient biomarkers and other prognostic panel data.", [["AJCC tumor", "ANATOMY", 23, 33], ["node", "ANATOMY", 35, 39], ["metastase (TNM) breast cancer", "ANATOMY", 45, 74], ["tumor", "DISEASE", 28, 33], ["breast cancer", "DISEASE", 61, 74], ["AJCC tumor", "CANCER", 23, 33], ["node", "MULTI-TISSUE_STRUCTURE", 35, 39], ["breast cancer", "CANCER", 61, 74], ["patient", "ORGANISM", 239, 246], ["patient", "SPECIES", 239, 246], ["the AJCC tumor", "PROBLEM", 19, 33], ["node", "PROBLEM", 35, 39], ["metastase (TNM) breast cancer staging system", "PROBLEM", 45, 89], ["prognostic classification", "TEST", 123, 148], ["patient biomarkers", "TEST", 239, 257], ["prognostic panel data", "TEST", 268, 289], ["AJCC tumor", "OBSERVATION", 23, 33], ["node", "OBSERVATION", 35, 39], ["breast", "ANATOMY", 61, 67], ["cancer", "OBSERVATION", 68, 74]]], ["Compared to the previous version, a variety of genetic and molecular factors has been incorporated to the current version, among them are HER2, estrogen receptor (ER), progesterone receptor (PR), and also multigene panels such as Oncotype DX [35, 36].", [["estrogen", "CHEMICAL", 144, 152], ["progesterone", "CHEMICAL", 168, 180], ["estrogen", "CHEMICAL", 144, 152], ["progesterone", "CHEMICAL", 168, 180], ["HER2", "GENE_OR_GENE_PRODUCT", 138, 142], ["estrogen receptor", "GENE_OR_GENE_PRODUCT", 144, 161], ["ER", "GENE_OR_GENE_PRODUCT", 163, 165], ["progesterone receptor", "GENE_OR_GENE_PRODUCT", 168, 189], ["PR", "GENE_OR_GENE_PRODUCT", 191, 193], ["HER2", "PROTEIN", 138, 142], ["estrogen receptor", "PROTEIN", 144, 161], ["ER", "PROTEIN", 163, 165], ["progesterone receptor", "PROTEIN", 168, 189], ["PR", "PROTEIN", 191, 193], ["the previous version", "TEST", 12, 32], ["HER2, estrogen receptor", "TREATMENT", 138, 161], ["progesterone receptor (PR", "TREATMENT", 168, 193], ["multigene panels", "TEST", 205, 221]]], ["There is a difference between \u201csilent\u201d carriers of tumor lesions and patients who are predisposed to disease development and progression; a \u201cfertile\u201d microenvironment that supports the tumorigenesis, tumor invasion, and metastasis can distinguish between them.", [["tumor lesions", "ANATOMY", 51, 64], ["tumor", "ANATOMY", 200, 205], ["tumor", "DISEASE", 51, 56], ["tumor", "DISEASE", 200, 205], ["tumor lesions", "CANCER", 51, 64], ["patients", "ORGANISM", 69, 77], ["tumor", "CANCER", 200, 205], ["patients", "SPECIES", 69, 77], ["tumor lesions", "PROBLEM", 51, 64], ["disease development", "PROBLEM", 101, 120], ["progression", "PROBLEM", 125, 136], ["a \u201cfertile\u201d microenvironment", "PROBLEM", 138, 166], ["the tumorigenesis", "PROBLEM", 181, 198], ["tumor invasion", "PROBLEM", 200, 214], ["metastasis", "PROBLEM", 220, 230], ["tumor", "OBSERVATION", 51, 56], ["predisposed to", "UNCERTAINTY", 86, 100], ["disease", "OBSERVATION", 101, 108], ["progression", "OBSERVATION_MODIFIER", 125, 136], ["tumor", "OBSERVATION_MODIFIER", 200, 205], ["invasion", "OBSERVATION_MODIFIER", 206, 214], ["metastasis", "OBSERVATION", 220, 230]]], ["The mechanisms \u201cfertilizing\u201d the microenvironment for the cancer advancement are not addressed in animal models but it is very well addressed by innovative PPPM strategies in cancer [1, 37, 38].Depression: it is neither all about men nor about male rats ::: Neuroscience: we are human beings and it is because of our brains ::: Examples of drug development failuresDepression as a prevalent brain dysfunction in modern society is a real challenge for physicians and scientists.", [["cancer", "ANATOMY", 58, 64], ["cancer", "ANATOMY", 175, 181], ["brains", "ANATOMY", 317, 323], ["brain", "ANATOMY", 391, 396], ["cancer", "DISEASE", 58, 64], ["cancer", "DISEASE", 175, 181], ["Depression", "DISEASE", 194, 204], ["Depression", "DISEASE", 365, 375], ["brain dysfunction", "DISEASE", 391, 408], ["cancer", "CANCER", 58, 64], ["PPPM", "SIMPLE_CHEMICAL", 156, 160], ["cancer", "CANCER", 175, 181], ["men", "ORGANISM", 230, 233], ["rats", "ORGANISM", 249, 253], ["human", "ORGANISM", 279, 284], ["brains", "ORGANISM", 317, 323], ["brain", "ORGAN", 391, 396], ["men", "SPECIES", 230, 233], ["rats", "SPECIES", 249, 253], ["human", "SPECIES", 279, 284], ["human", "SPECIES", 279, 284], ["the cancer advancement", "TREATMENT", 54, 76], ["Depression", "PROBLEM", 194, 204], ["drug development failures", "PROBLEM", 340, 365], ["Depression", "PROBLEM", 365, 375], ["a prevalent brain dysfunction", "PROBLEM", 379, 408], ["cancer", "OBSERVATION", 58, 64], ["failures", "OBSERVATION", 357, 365], ["brain", "ANATOMY", 391, 396], ["dysfunction", "OBSERVATION", 397, 408]]], ["Stress exposure model, chronic unpredictable mild stress model (CUMS), maternal deprivation model, sleep deprivation model, and social defeat, are among the well-known animal models of depression.", [["depression", "DISEASE", 185, 195], ["Stress exposure model", "PROBLEM", 0, 21], ["chronic unpredictable mild stress model (CUMS)", "PROBLEM", 23, 69], ["maternal deprivation model", "PROBLEM", 71, 97], ["sleep deprivation model", "PROBLEM", 99, 122], ["depression", "PROBLEM", 185, 195], ["chronic", "OBSERVATION_MODIFIER", 23, 30], ["unpredictable", "OBSERVATION_MODIFIER", 31, 44], ["mild", "OBSERVATION_MODIFIER", 45, 49], ["stress model", "OBSERVATION", 50, 62], ["depression", "OBSERVATION", 185, 195]]], ["Almost always, rat and mouse are used to model depression [39\u201350].", [["depression", "DISEASE", 47, 57], ["rat", "ORGANISM", 15, 18], ["mouse", "ORGANISM", 23, 28], ["rat", "SPECIES", 15, 18], ["mouse", "SPECIES", 23, 28], ["rat", "SPECIES", 15, 18], ["mouse", "SPECIES", 23, 28], ["model depression", "PROBLEM", 41, 57]]], ["Forced swimming test, tail suspension test, open field test, and hot plate test are among the most known tests of evaluating depression in the previously mentioned models [50\u201354].", [["tail", "ANATOMY", 22, 26], ["depression", "DISEASE", 125, 135], ["Forced swimming test", "TEST", 0, 20], ["tail suspension test", "TEST", 22, 42], ["open field test", "TEST", 44, 59], ["hot plate test", "TEST", 65, 79], ["depression", "PROBLEM", 125, 135]]], ["Although these are creative and decent models, however, how could someone compare a so-called depressed male rat behavior and attitude with the depression in Franz Kafka or Friedrich Nietzsche?Depression: it is neither all about men nor about male rats ::: Neuroscience: we are human beings and it is because of our brains ::: Examples of drug development failuresAdditionally, depression is different in men and women, in terms of its perception as well as mechanisms.", [["brains", "ANATOMY", 316, 322], ["depressed", "DISEASE", 94, 103], ["depression", "DISEASE", 144, 154], ["Depression", "DISEASE", 193, 203], ["depression", "DISEASE", 378, 388], ["rat", "ORGANISM", 109, 112], ["men", "ORGANISM", 229, 232], ["rats", "ORGANISM", 248, 252], ["human", "ORGANISM", 278, 283], ["brains", "ORGANISM", 316, 322], ["men", "ORGANISM", 405, 408], ["women", "ORGANISM", 413, 418], ["rat", "SPECIES", 109, 112], ["men", "SPECIES", 229, 232], ["rats", "SPECIES", 248, 252], ["human", "SPECIES", 278, 283], ["men", "SPECIES", 405, 408], ["women", "SPECIES", 413, 418], ["human", "SPECIES", 278, 283], ["depressed male rat behavior", "PROBLEM", 94, 121], ["the depression", "PROBLEM", 140, 154], ["Depression", "PROBLEM", 193, 203], ["drug development failures", "PROBLEM", 339, 364], ["depression", "PROBLEM", 378, 388], ["failures", "OBSERVATION", 356, 364], ["different", "OBSERVATION_MODIFIER", 392, 401]]], ["Furthermore, post-menopausal depression is catecholamine-dependent, while depression in women in the productive age is serotonin prominent.", [["depression", "DISEASE", 29, 39], ["catecholamine", "CHEMICAL", 43, 56], ["depression", "DISEASE", 74, 84], ["serotonin", "CHEMICAL", 119, 128], ["catecholamine", "CHEMICAL", 43, 56], ["serotonin", "CHEMICAL", 119, 128], ["catecholamine", "SIMPLE_CHEMICAL", 43, 56], ["women", "ORGANISM", 88, 93], ["serotonin", "SIMPLE_CHEMICAL", 119, 128], ["women", "SPECIES", 88, 93], ["post-menopausal depression", "PROBLEM", 13, 39], ["catecholamine-dependent", "PROBLEM", 43, 66], ["depression", "PROBLEM", 74, 84], ["dependent", "OBSERVATION_MODIFIER", 57, 66], ["serotonin prominent", "OBSERVATION", 119, 138]]], ["That is why venlafaxine is suitable for elderly depressed women, and fluoxetine and sertraline have nothing to do with them but are the drug of choice for depressed men [51\u201353].", [["venlafaxine", "CHEMICAL", 12, 23], ["depressed", "DISEASE", 48, 57], ["fluoxetine", "CHEMICAL", 69, 79], ["sertraline", "CHEMICAL", 84, 94], ["depressed", "DISEASE", 155, 164], ["venlafaxine", "CHEMICAL", 12, 23], ["fluoxetine", "CHEMICAL", 69, 79], ["sertraline", "CHEMICAL", 84, 94], ["venlafaxine", "SIMPLE_CHEMICAL", 12, 23], ["women", "ORGANISM", 58, 63], ["fluoxetine", "SIMPLE_CHEMICAL", 69, 79], ["sertraline", "SIMPLE_CHEMICAL", 84, 94], ["men", "ORGANISM", 165, 168], ["women", "SPECIES", 58, 63], ["men", "SPECIES", 165, 168], ["venlafaxine", "TREATMENT", 12, 23], ["elderly depressed women", "PROBLEM", 40, 63], ["fluoxetine", "TREATMENT", 69, 79], ["sertraline", "TREATMENT", 84, 94]]], ["All these happened since studies on depression were almost always conducted exclusively on men; unfortunately, scientists preferred to avoid menstrual cyclic depressions, and eliminated women, even when raised FDA approval.Amyotrophic lateral sclerosis: animal models were based on the rare form of the disease instead of the prevalent form ::: Neuroscience: we are human beings and it is because of our brains ::: Examples of drug development failuresFor years, scientist studied amyotrophic lateral sclerosis (ALS) misleading model of superoxide dismutase 1 (SOD-1) which is responsible for only rare cases of ALS instead of transactive response DNA-binding protein 43 (TDP-43) which is responsible for the majority of cases.", [["brains", "ANATOMY", 404, 410], ["depression", "DISEASE", 36, 46], ["depressions", "DISEASE", 158, 169], ["Amyotrophic lateral sclerosis", "DISEASE", 223, 252], ["amyotrophic lateral sclerosis", "DISEASE", 481, 510], ["ALS", "DISEASE", 512, 515], ["superoxide", "CHEMICAL", 537, 547], ["ALS", "DISEASE", 612, 615], ["TDP-43", "CHEMICAL", 672, 678], ["superoxide", "CHEMICAL", 537, 547], ["men", "ORGANISM", 91, 94], ["women", "ORGANISM", 186, 191], ["human", "ORGANISM", 366, 371], ["brains", "ORGANISM", 404, 410], ["amyotrophic lateral sclerosis", "CANCER", 481, 510], ["superoxide dismutase 1", "GENE_OR_GENE_PRODUCT", 537, 559], ["SOD-1", "GENE_OR_GENE_PRODUCT", 561, 566], ["transactive response DNA-binding protein 43", "GENE_OR_GENE_PRODUCT", 627, 670], ["TDP-43", "GENE_OR_GENE_PRODUCT", 672, 678], ["superoxide dismutase 1", "PROTEIN", 537, 559], ["SOD", "PROTEIN", 561, 564], ["transactive response DNA-binding protein 43", "PROTEIN", 627, 670], ["TDP-43", "PROTEIN", 672, 678], ["men", "SPECIES", 91, 94], ["women", "SPECIES", 186, 191], ["human", "SPECIES", 366, 371], ["human", "SPECIES", 366, 371], ["depression", "PROBLEM", 36, 46], ["menstrual cyclic depressions", "PROBLEM", 141, 169], ["Amyotrophic lateral sclerosis", "PROBLEM", 223, 252], ["animal models", "PROBLEM", 254, 267], ["the disease", "PROBLEM", 299, 310], ["drug development failures", "PROBLEM", 427, 452], ["amyotrophic lateral sclerosis (ALS)", "PROBLEM", 481, 516], ["superoxide dismutase", "TREATMENT", 537, 557], ["ALS", "PROBLEM", 612, 615], ["transactive response DNA", "TEST", 627, 651], ["binding protein", "TEST", 652, 667], ["TDP", "TEST", 672, 675], ["lateral", "OBSERVATION_MODIFIER", 235, 242], ["sclerosis", "OBSERVATION", 243, 252], ["disease", "OBSERVATION", 303, 310], ["failures", "OBSERVATION", 444, 452], ["amyotrophic", "OBSERVATION_MODIFIER", 481, 492], ["lateral", "OBSERVATION_MODIFIER", 493, 500], ["sclerosis", "OBSERVATION", 501, 510]]], ["Hence, a large number of currently failed trials need re-evaluation with new models of the new gene [55\u201357]!HIV: where animal models were completely useless ::: Examples of drug development failuresUnfortunately, there is no acceptable animal model for human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) [58].", [["human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome", "DISEASE", 253, 326], ["AIDS", "DISEASE", 328, 332], ["HIV", "ORGANISM", 108, 111], ["human immunodeficiency virus", "ORGANISM", 253, 281], ["HIV", "ORGANISM", 283, 286], ["HIV", "SPECIES", 108, 111], ["human immunodeficiency virus", "SPECIES", 253, 281], ["HIV", "SPECIES", 283, 286], ["HIV", "SPECIES", 108, 111], ["human immunodeficiency virus", "SPECIES", 253, 281], ["HIV", "SPECIES", 283, 286], ["re-evaluation", "TEST", 54, 67], ["drug development failures", "PROBLEM", 173, 198], ["human immunodeficiency virus", "PROBLEM", 253, 281], ["HIV", "PROBLEM", 283, 286], ["acquired immunodeficiency syndrome", "PROBLEM", 292, 326], ["large", "OBSERVATION_MODIFIER", 9, 14], ["failures", "OBSERVATION", 190, 198], ["no", "UNCERTAINTY", 222, 224]]], ["Until the year 2006, more than fifty preventive vaccines and over thirty therapeutic vaccines were showed successful against HIV and AIDS in primate studies; regrettably all of them has failed in human clinical trials.", [["AIDS", "DISEASE", 133, 137], ["HIV", "ORGANISM", 125, 128], ["human", "ORGANISM", 196, 201], ["HIV", "SPECIES", 125, 128], ["human", "SPECIES", 196, 201], ["HIV", "SPECIES", 125, 128], ["human", "SPECIES", 196, 201], ["preventive vaccines", "TREATMENT", 37, 56], ["thirty therapeutic vaccines", "TREATMENT", 66, 93], ["HIV", "PROBLEM", 125, 128], ["AIDS", "PROBLEM", 133, 137], ["primate studies", "TEST", 141, 156]]], ["Both efficacy and toxicity of current known treatments for HIV such as zidovudine (AZT), lamivudine (3TC), and protease inhibitors are the results of in vitro studies using human white blood cells [59].Genetic diseases ::: Examples of drug development failuresAlthough called \u201cgenetic disease,\u201d they are also the consequence of interactions between the defected gene(s), and other genes, and also the environment, that is why so many of animal models failed to mimic phenotype of genetic disorders; for example, cystic fibrosis (CF) transgenic mice failed to mimic pancreas blockage and lung infections that happen in humans with CF [60, 61].Teratogenicity ::: Examples of drug development failuresAnimal models are used for understanding disease mechanisms and potential new treatments rather than predicting what will happen in humans.", [["white blood cells", "ANATOMY", 179, 196], ["pancreas", "ANATOMY", 565, 573], ["lung", "ANATOMY", 587, 591], ["toxicity", "DISEASE", 18, 26], ["zidovudine", "CHEMICAL", 71, 81], ["AZT", "CHEMICAL", 83, 86], ["lamivudine", "CHEMICAL", 89, 99], ["3TC", "CHEMICAL", 101, 104], ["Genetic diseases", "DISEASE", 202, 218], ["genetic disorders", "DISEASE", 480, 497], ["cystic fibrosis", "DISEASE", 512, 527], ["pancreas blockage", "DISEASE", 565, 582], ["lung infections", "DISEASE", 587, 602], ["CF", "DISEASE", 630, 632], ["Teratogenicity", "DISEASE", 642, 656], ["zidovudine", "CHEMICAL", 71, 81], ["AZT", "CHEMICAL", 83, 86], ["lamivudine", "CHEMICAL", 89, 99], ["3TC", "CHEMICAL", 101, 104], ["HIV", "ORGANISM", 59, 62], ["zidovudine", "SIMPLE_CHEMICAL", 71, 81], ["AZT", "SIMPLE_CHEMICAL", 83, 86], ["lamivudine", "SIMPLE_CHEMICAL", 89, 99], ["3TC", "SIMPLE_CHEMICAL", 101, 104], ["human", "ORGANISM", 173, 178], ["white blood cells", "CELL", 179, 196], ["cystic fibrosis", "PATHOLOGICAL_FORMATION", 512, 527], ["mice", "ORGANISM", 544, 548], ["pancreas", "ORGAN", 565, 573], ["lung", "ORGAN", 587, 591], ["humans", "ORGANISM", 618, 624], ["humans", "ORGANISM", 830, 836], ["human white blood cells", "CELL_TYPE", 173, 196], ["defected gene", "DNA", 353, 366], ["HIV", "SPECIES", 59, 62], ["human", "SPECIES", 173, 178], ["mice", "SPECIES", 544, 548], ["humans", "SPECIES", 618, 624], ["humans", "SPECIES", 830, 836], ["HIV", "SPECIES", 59, 62], ["human", "SPECIES", 173, 178], ["mice", "SPECIES", 544, 548], ["humans", "SPECIES", 618, 624], ["humans", "SPECIES", 830, 836], ["current known treatments", "TREATMENT", 30, 54], ["HIV", "PROBLEM", 59, 62], ["zidovudine (AZT)", "TREATMENT", 71, 87], ["lamivudine (3TC)", "TREATMENT", 89, 105], ["protease inhibitors", "TREATMENT", 111, 130], ["vitro studies", "TEST", 153, 166], ["human white blood cells", "TEST", 173, 196], ["drug development failures", "PROBLEM", 235, 260], ["genetic disorders", "PROBLEM", 480, 497], ["cystic fibrosis", "PROBLEM", 512, 527], ["transgenic mice", "PROBLEM", 533, 548], ["pancreas blockage", "PROBLEM", 565, 582], ["lung infections", "PROBLEM", 587, 602], ["drug development failures", "PROBLEM", 673, 698], ["understanding disease mechanisms", "PROBLEM", 725, 757], ["new treatments", "TREATMENT", 772, 786], ["diseases", "OBSERVATION", 210, 218], ["failures", "OBSERVATION", 252, 260], ["disease", "OBSERVATION", 285, 292], ["cystic", "OBSERVATION_MODIFIER", 512, 518], ["fibrosis", "OBSERVATION", 519, 527], ["pancreas", "ANATOMY", 565, 573], ["blockage", "OBSERVATION", 574, 582], ["lung", "ANATOMY", 587, 591], ["infections", "OBSERVATION", 592, 602], ["failures", "OBSERVATION", 690, 698]]], ["That is why toxicity and teratogenicity studies usually fail.", [["toxicity", "DISEASE", 12, 20], ["toxicity", "PROBLEM", 12, 20], ["teratogenicity studies", "TEST", 25, 47]]], ["Among 1396 different substances studied, it has been shown that half of the human teratogens are safe in animals.", [["human", "ORGANISM", 76, 81], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 76, 81]]], ["Conversely, almost half of the safe human agents are dangerous (teratogen) in animals, and 1/3 tested agents showed varying results in different species [62\u201364].Toxicity ::: Examples of drug development failuresTheralizumab (TGN1412) catastrophe is one of the best examples of low power of animal models in prediction of toxicity of drugs [65\u201367].", [["teratogen", "CHEMICAL", 64, 73], ["Toxicity", "DISEASE", 161, 169], ["Theralizumab", "CHEMICAL", 211, 223], ["TGN1412", "CHEMICAL", 225, 232], ["toxicity", "DISEASE", 321, 329], ["Theralizumab", "CHEMICAL", 211, 223], ["human", "ORGANISM", 36, 41], ["Theralizumab", "SIMPLE_CHEMICAL", 211, 223], ["TGN1412", "SIMPLE_CHEMICAL", 225, 232], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 36, 41], ["the safe human agents", "TREATMENT", 27, 48], ["drug development failures", "PROBLEM", 186, 211], ["catastrophe", "PROBLEM", 234, 245], ["toxicity of drugs", "PROBLEM", 321, 338], ["failures", "OBSERVATION", 203, 211], ["low power", "OBSERVATION_MODIFIER", 277, 286]]], ["Cigarette smoking failed to produce lung cancer in animals [4].", [["lung cancer", "ANATOMY", 36, 47], ["smoking", "CHEMICAL", 10, 17], ["lung cancer", "DISEASE", 36, 47], ["Cigarette", "ORGANISM", 0, 9], ["lung cancer", "CANCER", 36, 47], ["lung cancer", "PROBLEM", 36, 47], ["lung", "ANATOMY", 36, 40], ["cancer", "OBSERVATION", 41, 47]]], ["The same happened with asbestosis models [68, 69] and also diagnostic X-ray carcinogen effects [70, 71].", [["asbestosis", "DISEASE", 23, 33], ["diagnostic X-ray carcinogen effects", "TEST", 59, 94], ["asbestosis", "OBSERVATION", 23, 33]]], ["Effect of alcohol on fatty liver cirrhosis is another example [72].", [["fatty liver cirrhosis", "ANATOMY", 21, 42], ["alcohol", "CHEMICAL", 10, 17], ["fatty liver cirrhosis", "DISEASE", 21, 42], ["alcohol", "CHEMICAL", 10, 17], ["alcohol", "SIMPLE_CHEMICAL", 10, 17], ["liver", "ORGAN", 27, 32], ["fatty liver cirrhosis", "PROBLEM", 21, 42], ["liver", "ANATOMY", 27, 32], ["cirrhosis", "OBSERVATION", 33, 42]]], ["Animals\u2019 age, sex, strain, and weight have substantial effects on the results of toxicity studies, and due to huge differences of approximately all animal models, their results are extremely unreliable [73].", [["toxicity", "DISEASE", 81, 89], ["Animals", "ORGANISM", 0, 7], ["strain", "PROBLEM", 19, 25], ["toxicity studies", "TEST", 81, 97]]], ["In vitro studies have been recently validated to replace LD50 [74, 75].", [["vitro studies", "TEST", 3, 16]]], ["Among hundreds of known carcinogens in mice since 1980, only 15 proved to be a carcinogen in humans.Complexity ::: DiscussionGiven plenty of abovementioned examples, it is clear that the complex character of human diseases was not presented in most animal models.", [["mice", "ORGANISM", 39, 43], ["humans", "ORGANISM", 93, 99], ["human", "ORGANISM", 208, 213], ["mice", "SPECIES", 39, 43], ["humans", "SPECIES", 93, 99], ["human", "SPECIES", 208, 213], ["mice", "SPECIES", 39, 43], ["humans", "SPECIES", 93, 99], ["human", "SPECIES", 208, 213], ["known carcinogens", "PROBLEM", 18, 35], ["human diseases", "PROBLEM", 208, 222], ["carcinogens", "OBSERVATION", 24, 35], ["carcinogen", "OBSERVATION", 79, 89], ["diseases", "OBSERVATION", 214, 222]]], ["Diabetes, atherosclerosis, and dementia are all examples of chronic complex diseases that are modeled with extremely simplified acute approaches.Complexity ::: DiscussionWith no doubt, neuroscience is the most conflicting field of animal modeling.", [["Diabetes", "DISEASE", 0, 8], ["atherosclerosis", "DISEASE", 10, 25], ["dementia", "DISEASE", 31, 39], ["Diabetes", "PROBLEM", 0, 8], ["atherosclerosis", "PROBLEM", 10, 25], ["dementia", "PROBLEM", 31, 39], ["chronic complex diseases", "PROBLEM", 60, 84], ["atherosclerosis", "OBSERVATION", 10, 25], ["dementia", "OBSERVATION", 31, 39], ["chronic", "OBSERVATION_MODIFIER", 60, 67], ["complex", "OBSERVATION_MODIFIER", 68, 75], ["diseases", "OBSERVATION", 76, 84], ["acute", "OBSERVATION_MODIFIER", 128, 133]]], ["Compared to any other organ, complexity of the human brain is not comparable with animal models not even in primates.", [["organ", "ANATOMY", 22, 27], ["brain", "ANATOMY", 53, 58], ["organ", "ORGAN", 22, 27], ["human", "ORGANISM", 47, 52], ["brain", "ORGAN", 53, 58], ["primates", "ORGANISM", 108, 116], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 47, 52], ["human", "ANATOMY_MODIFIER", 47, 52], ["brain", "ANATOMY", 53, 58]]], ["Neuropsychological disorders in human are not comparable to animals at all.", [["Neuropsychological disorders", "DISEASE", 0, 28], ["human", "ORGANISM", 32, 37], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 32, 37], ["Neuropsychological disorders in human", "PROBLEM", 0, 37]]], ["That is why a large number of drug discoveries in this field were the result of direct human observations.", [["human", "ORGANISM", 87, 92], ["human", "SPECIES", 87, 92], ["human", "SPECIES", 87, 92], ["large", "OBSERVATION_MODIFIER", 14, 19], ["number", "OBSERVATION_MODIFIER", 20, 26]]], ["A large number of current neuropsychiatric medications were initially studied for other diseases and serendipitously discovered by observation of their side effects.", [["current neuropsychiatric medications", "TREATMENT", 18, 54], ["other diseases", "PROBLEM", 82, 96], ["their side effects", "PROBLEM", 146, 164], ["large", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14]]], ["For example, amantadine was originally developed to prevent influenza but was found to improve symptoms including tremor, akinesia, and rigidity in people with Parkinson disease [76\u201378].", [["amantadine", "CHEMICAL", 13, 23], ["influenza", "DISEASE", 60, 69], ["tremor", "DISEASE", 114, 120], ["akinesia", "DISEASE", 122, 130], ["rigidity", "DISEASE", 136, 144], ["Parkinson disease", "DISEASE", 160, 177], ["amantadine", "CHEMICAL", 13, 23], ["amantadine", "SIMPLE_CHEMICAL", 13, 23], ["people", "ORGANISM", 148, 154], ["people", "SPECIES", 148, 154], ["amantadine", "TREATMENT", 13, 23], ["influenza", "PROBLEM", 60, 69], ["symptoms", "PROBLEM", 95, 103], ["tremor", "PROBLEM", 114, 120], ["akinesia", "PROBLEM", 122, 130], ["rigidity", "PROBLEM", 136, 144], ["Parkinson disease", "PROBLEM", 160, 177], ["rigidity", "OBSERVATION_MODIFIER", 136, 144]]], ["Chlorpromazine, currently prescribed for its antipsychotic properties, was traditionally introduced as a possible additive to potentiate general anesthesia [79].Complexity ::: DiscussionFurthermore, familial, social, and cultural factors cannot be modeled in animals.Wrong nomination is misleading ::: DiscussionNominating a simplified model such as a transgenic mouse model as a true model of a given disease is dramatically misleading, especially when a complex multifactorial disease is being studied.", [["Chlorpromazine", "CHEMICAL", 0, 14], ["Chlorpromazine", "CHEMICAL", 0, 14], ["Chlorpromazine", "SIMPLE_CHEMICAL", 0, 14], ["mouse", "ORGANISM", 363, 368], ["mouse", "SPECIES", 363, 368], ["mouse", "SPECIES", 363, 368], ["Chlorpromazine", "TREATMENT", 0, 14], ["its antipsychotic properties", "TREATMENT", 41, 69], ["general anesthesia", "TREATMENT", 137, 155], ["a transgenic mouse model", "TREATMENT", 350, 374], ["disease", "PROBLEM", 402, 409], ["a complex multifactorial disease", "PROBLEM", 454, 486], ["multifactorial", "OBSERVATION_MODIFIER", 464, 478], ["disease", "OBSERVATION", 479, 486]]], ["As mentioned before, even single-gene diseases are the result of a transaction of a mutated gene with the wild genes and the environment.", [["mutated gene", "DNA", 84, 96], ["wild genes", "DNA", 106, 116], ["single-gene diseases", "PROBLEM", 26, 46], ["diseases", "OBSERVATION", 38, 46]]], ["SOD-1 mutation transgenic model of ALS is a good example.", [["ALS", "DISEASE", 35, 38], ["SOD-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["SOD", "PROTEIN", 0, 3]]], ["First of all, this model is extremely sensitive to infection; second, SOD-1 mutation is only responsible for less than 3% of the patients, and surprisingly, transgenic mouse which has 23 copies of this gene is known as the standard ALS model in the majority of studies.", [["infection", "DISEASE", 51, 60], ["ALS", "DISEASE", 232, 235], ["SOD-1", "GENE_OR_GENE_PRODUCT", 70, 75], ["patients", "ORGANISM", 129, 137], ["mouse", "ORGANISM", 168, 173], ["SOD", "PROTEIN", 70, 73], ["patients", "SPECIES", 129, 137], ["mouse", "SPECIES", 168, 173], ["mouse", "SPECIES", 168, 173], ["infection", "PROBLEM", 51, 60], ["SOD", "TEST", 70, 73], ["infection", "OBSERVATION", 51, 60]]], ["Conclusively, SOD-1 ALS transgenic models were representative of rare disease forms instead of prevalent mutations.", [["SOD-1", "GENE_OR_GENE_PRODUCT", 14, 19], ["SOD", "PROTEIN", 14, 17], ["1 ALS transgenic models", "PROBLEM", 18, 41], ["rare disease forms", "PROBLEM", 65, 83], ["prevalent mutations", "PROBLEM", 95, 114]]], ["This model represents a very aggressive presentation of ALS which does not respond to almost any treatment except for SOD inhibitors.", [["ALS", "DISEASE", 56, 59], ["SOD", "GENE_OR_GENE_PRODUCT", 118, 121], ["SOD", "PROTEIN", 118, 121], ["ALS", "PROBLEM", 56, 59], ["any treatment", "TREATMENT", 93, 106], ["SOD inhibitors", "TREATMENT", 118, 132], ["very", "OBSERVATION_MODIFIER", 24, 28], ["aggressive", "OBSERVATION_MODIFIER", 29, 39]]], ["Thus, current protocols of ALS treatment are a range of broad-spectrum antibiotics and general anti-inflammatory agents.", [["ALS", "DISEASE", 27, 30], ["ALS treatment", "TREATMENT", 27, 40], ["broad-spectrum antibiotics", "TREATMENT", 56, 82], ["general anti-inflammatory agents", "TREATMENT", 87, 119], ["anti-inflammatory agents", "OBSERVATION", 95, 119]]], ["Cochrane database analyses showed that even in the case of riluzole, the sole FDA-approved treatment of ALS, mean survival of the patients increased only up to 2\u20133 months [18].Wrong nomination is misleading ::: DiscussionThe same problem happens when we incorrectly call a streptozotocin model as a diabetes model, or clumping reperfusion procedure as a surrogate of a true myocardial infarction.Wrong nomination is misleading ::: DiscussionEven in the presence of similar phenotypes of diseases, different genotypes and different pathophysiologic mechanisms in the patients compared to the models could critically impair the models\u2019 prediction power that is essential for PPPM to work with.", [["myocardial", "ANATOMY", 374, 384], ["riluzole", "CHEMICAL", 59, 67], ["ALS", "DISEASE", 104, 107], ["streptozotocin", "CHEMICAL", 273, 287], ["diabetes", "DISEASE", 299, 307], ["myocardial infarction", "DISEASE", 374, 395], ["riluzole", "CHEMICAL", 59, 67], ["streptozotocin", "CHEMICAL", 273, 287], ["riluzole", "SIMPLE_CHEMICAL", 59, 67], ["patients", "ORGANISM", 130, 138], ["streptozotocin", "SIMPLE_CHEMICAL", 273, 287], ["myocardial", "MULTI-TISSUE_STRUCTURE", 374, 384], ["patients", "ORGANISM", 566, 574], ["patients", "SPECIES", 130, 138], ["patients", "SPECIES", 566, 574], ["Cochrane database analyses", "TEST", 0, 26], ["riluzole", "TREATMENT", 59, 67], ["the sole FDA", "TREATMENT", 69, 81], ["ALS", "PROBLEM", 104, 107], ["a streptozotocin model", "TREATMENT", 271, 293], ["a diabetes model", "TREATMENT", 297, 313], ["clumping reperfusion procedure", "TREATMENT", 318, 348], ["a true myocardial infarction", "PROBLEM", 367, 395], ["diseases", "PROBLEM", 487, 495], ["different genotypes", "PROBLEM", 497, 516], ["different pathophysiologic mechanisms", "PROBLEM", 521, 558], ["increased", "OBSERVATION_MODIFIER", 139, 148], ["myocardial", "ANATOMY", 374, 384], ["infarction", "OBSERVATION", 385, 395], ["diseases", "OBSERVATION", 487, 495]]], ["This issue is more challenging when we are studying diseases with vague and wide definition such as idiopathic pulmonary fibrosis (IPF).", [["pulmonary", "ANATOMY", 111, 120], ["idiopathic pulmonary fibrosis", "DISEASE", 100, 129], ["IPF", "DISEASE", 131, 134], ["pulmonary", "ORGAN", 111, 120], ["diseases", "PROBLEM", 52, 60], ["vague and wide definition", "PROBLEM", 66, 91], ["idiopathic pulmonary fibrosis", "PROBLEM", 100, 129], ["idiopathic", "OBSERVATION_MODIFIER", 100, 110], ["pulmonary", "ANATOMY", 111, 120], ["fibrosis", "OBSERVATION", 121, 129], ["IPF", "OBSERVATION", 131, 134]]], ["Idiopathic refers to our loss of knowledge about the exact mechanism of the disease; in fact, IPF might refer to several different unknown diseases with different mechanisms that were clustered under a sole name.", [["IPF", "DISEASE", 94, 97], ["Idiopathic refers", "PROBLEM", 0, 17], ["the disease", "PROBLEM", 72, 83], ["IPF", "PROBLEM", 94, 97], ["several different unknown diseases", "PROBLEM", 113, 147], ["disease", "OBSERVATION", 76, 83], ["IPF", "OBSERVATION", 94, 97], ["diseases", "OBSERVATION", 139, 147]]], ["Fibrosis could be the end-product of several unknown genetic, microbial, viral, and rheumatologic pathways yet to be discovered.", [["Fibrosis", "DISEASE", 0, 8], ["Fibrosis", "PROBLEM", 0, 8], ["microbial, viral, and rheumatologic pathways", "PROBLEM", 62, 106]]], ["Hence, how could we identify a bleomycin or paraquat-induced pulmonary fibrosis mouse model, like an IPF model?", [["pulmonary", "ANATOMY", 61, 70], ["bleomycin", "CHEMICAL", 31, 40], ["paraquat", "CHEMICAL", 44, 52], ["pulmonary fibrosis", "DISEASE", 61, 79], ["IPF", "DISEASE", 101, 104], ["bleomycin", "CHEMICAL", 31, 40], ["paraquat", "CHEMICAL", 44, 52], ["bleomycin", "SIMPLE_CHEMICAL", 31, 40], ["paraquat", "SIMPLE_CHEMICAL", 44, 52], ["pulmonary", "ORGAN", 61, 70], ["mouse", "ORGANISM", 80, 85], ["mouse", "SPECIES", 80, 85], ["mouse", "SPECIES", 80, 85], ["a bleomycin", "TREATMENT", 29, 40], ["pulmonary fibrosis mouse model", "PROBLEM", 61, 91], ["an IPF model", "TEST", 98, 110], ["bleomycin", "OBSERVATION", 31, 40], ["pulmonary", "ANATOMY", 61, 70], ["fibrosis", "OBSERVATION", 71, 79], ["IPF", "OBSERVATION", 101, 104]]], ["We should also keep in mind that pathophysiology of an idiopathic disease like IPF might be extremely diverse in different populations that further lower the predictability of our simplified models.Wrong nomination is misleading ::: DiscussionFrom a PPPM point of view, it is time to redefine medical terms.", [["idiopathic disease", "DISEASE", 55, 73], ["IPF", "DISEASE", 79, 82], ["an idiopathic disease", "PROBLEM", 52, 73], ["IPF", "PROBLEM", 79, 82], ["idiopathic", "OBSERVATION", 55, 65], ["IPF", "OBSERVATION", 79, 82], ["diverse", "OBSERVATION_MODIFIER", 102, 109]]], ["As stated by Janssens, \u201cShould we speak about breast cancers instead of cancer?\u201d [32, 33].", [["breast cancers", "ANATOMY", 46, 60], ["cancer", "ANATOMY", 72, 78], ["breast cancers", "DISEASE", 46, 60], ["cancer", "DISEASE", 72, 78], ["breast cancers", "CANCER", 46, 60], ["cancer", "CANCER", 72, 78], ["breast cancers", "PROBLEM", 46, 60], ["cancer", "PROBLEM", 72, 78], ["breast", "ANATOMY", 46, 52], ["cancers", "OBSERVATION", 53, 60]]], ["Parallel to the personalized clinical approach, our disease models should be defined precisely.", [["our disease models", "PROBLEM", 48, 66]]], ["Heterogeneity of cancer types that are currently mistakenly clustered in a single term calls for dedicated approaches with their characteristics from bench to bedside.", [["cancer", "ANATOMY", 17, 23], ["cancer", "DISEASE", 17, 23], ["cancer", "CANCER", 17, 23], ["Heterogeneity of cancer", "PROBLEM", 0, 23], ["cancer", "OBSERVATION", 17, 23]]], ["There is a significant difference between triple negative breast cancer in a premenopausal woman and triple positive breast cancer in a postmenopausal woman in terms of management planning, chemotherapy selection, chemotherapy response, metastasis tendency, and general outcome.", [["breast cancer", "ANATOMY", 58, 71], ["breast cancer", "ANATOMY", 117, 130], ["breast cancer", "DISEASE", 58, 71], ["breast cancer", "DISEASE", 117, 130], ["breast cancer", "CANCER", 58, 71], ["woman", "ORGANISM", 91, 96], ["breast cancer", "CANCER", 117, 130], ["woman", "ORGANISM", 151, 156], ["woman", "SPECIES", 91, 96], ["woman", "SPECIES", 151, 156], ["a significant difference between triple negative breast cancer", "PROBLEM", 9, 71], ["triple positive breast cancer", "PROBLEM", 101, 130], ["management planning", "TREATMENT", 169, 188], ["chemotherapy selection", "TREATMENT", 190, 212], ["chemotherapy response", "TREATMENT", 214, 235], ["metastasis tendency", "PROBLEM", 237, 256], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["difference", "OBSERVATION_MODIFIER", 23, 33], ["triple", "OBSERVATION_MODIFIER", 42, 48], ["negative", "OBSERVATION_MODIFIER", 49, 57], ["breast", "ANATOMY", 58, 64], ["cancer", "OBSERVATION", 65, 71], ["triple", "OBSERVATION_MODIFIER", 101, 107], ["positive", "OBSERVATION_MODIFIER", 108, 116], ["breast", "ANATOMY", 117, 123], ["cancer", "OBSERVATION", 124, 130], ["metastasis", "OBSERVATION", 237, 247]]], ["As a result, our models should reflect the differences appropriately to make the foundation of clinical research reliable and practical in PPPM.Chronicity is not reflected in most of the current models ::: DiscussionPlenty of human diseases are complex and chronic, while the counterpart models are not reflecting their chronic character.", [["Chronicity", "DISEASE", 144, 154], ["human diseases", "DISEASE", 226, 240], ["PPPM", "CANCER", 139, 143], ["human", "ORGANISM", 226, 231], ["human", "SPECIES", 226, 231], ["human", "SPECIES", 226, 231], ["practical in PPPM", "TREATMENT", 126, 143], ["human diseases", "PROBLEM", 226, 240], ["not reflected", "UNCERTAINTY", 158, 171], ["human diseases", "OBSERVATION", 226, 240], ["chronic", "OBSERVATION_MODIFIER", 257, 264], ["not reflecting", "UNCERTAINTY", 299, 313], ["chronic", "OBSERVATION_MODIFIER", 320, 327]]], ["Internal validity of experimental studies is dramatically affected by the ignorance of the chronic character of the diseases.Chronicity is not reflected in most of the current models ::: DiscussionMyocardial infarction models are the best example of a chronic process which was not modeled accurately.", [["Myocardial", "ANATOMY", 197, 207], ["Chronicity", "DISEASE", 125, 135], ["Myocardial infarction", "DISEASE", 197, 218], ["Myocardial", "MULTI-TISSUE_STRUCTURE", 197, 207], ["experimental studies", "TEST", 21, 41], ["the diseases", "PROBLEM", 112, 124], ["Myocardial infarction models", "PROBLEM", 197, 225], ["a chronic process", "PROBLEM", 250, 267], ["validity", "OBSERVATION_MODIFIER", 9, 17], ["experimental", "OBSERVATION", 21, 33], ["dramatically", "OBSERVATION_MODIFIER", 45, 57], ["chronic", "OBSERVATION_MODIFIER", 91, 98], ["diseases", "OBSERVATION", 116, 124], ["not reflected", "UNCERTAINTY", 139, 152], ["Myocardial", "ANATOMY", 197, 207], ["infarction", "OBSERVATION", 208, 218], ["chronic", "OBSERVATION_MODIFIER", 252, 259], ["process", "OBSERVATION", 260, 267]]], ["Myocytes which were exposed to chronic hypoxia due to hypoperfusion activate compensatory pathways to protect themselves from hypoxia.", [["Myocytes", "ANATOMY", 0, 8], ["hypoxia", "DISEASE", 39, 46], ["hypoperfusion", "DISEASE", 54, 67], ["hypoxia", "DISEASE", 126, 133], ["Myocytes", "CELL", 0, 8], ["Myocytes", "PROBLEM", 0, 8], ["chronic hypoxia", "PROBLEM", 31, 46], ["hypoperfusion activate compensatory pathways", "PROBLEM", 54, 98], ["hypoxia", "PROBLEM", 126, 133], ["chronic", "OBSERVATION_MODIFIER", 31, 38], ["hypoxia", "OBSERVATION", 39, 46], ["hypoperfusion", "OBSERVATION", 54, 67], ["hypoxia", "OBSERVATION", 126, 133]]], ["Hypoxemic preconditioning explains the reasoning behind the smokers\u2019 MI paradox.", [["MI", "DISEASE", 69, 71], ["Hypoxemic preconditioning", "PROBLEM", 0, 25]]], ["It also explains why erythropoietin (EPO) is a protector in acute-induced MI in healthy myocytes but not in the adapted myocytes.", [["myocytes", "ANATOMY", 88, 96], ["myocytes", "ANATOMY", 120, 128], ["MI", "DISEASE", 74, 76], ["erythropoietin", "GENE_OR_GENE_PRODUCT", 21, 35], ["EPO", "GENE_OR_GENE_PRODUCT", 37, 40], ["myocytes", "CELL", 88, 96], ["myocytes", "CELL", 120, 128], ["erythropoietin", "PROTEIN", 21, 35], ["EPO", "PROTEIN", 37, 40], ["erythropoietin (EPO", "TREATMENT", 21, 40], ["a protector", "TREATMENT", 45, 56], ["acute-induced MI in healthy myocytes", "PROBLEM", 60, 96], ["acute", "OBSERVATION_MODIFIER", 60, 65], ["MI", "OBSERVATION", 74, 76], ["healthy myocytes", "ANATOMY", 80, 96]]], ["Increased EPO secreted during chronic hypoxia previously saturated EPO receptors and implemented its cell protective effects; in fact, extra EPO, in this case, will not augment extra cell protection [3].Chronicity is not reflected in most of the current models ::: DiscussionAs another example, acute lesions produced by means of stereotaxic surgery or toxin infusion to mimic Parkinson in mice have almost nothing to share with progressive, chronic, degenerative pathophysiology of Parkinson in human beings.Age ::: DiscussionAge is one of the almost always ignored factors in disease modeling.", [["cell", "ANATOMY", 101, 105], ["cell", "ANATOMY", 183, 187], ["lesions", "ANATOMY", 301, 308], ["hypoxia", "DISEASE", 38, 45], ["Chronicity", "DISEASE", 203, 213], ["Parkinson", "DISEASE", 377, 386], ["Parkinson", "DISEASE", 483, 492], ["EPO", "GENE_OR_GENE_PRODUCT", 10, 13], ["EPO receptors", "GENE_OR_GENE_PRODUCT", 67, 80], ["cell", "CELL", 101, 105], ["EPO", "GENE_OR_GENE_PRODUCT", 141, 144], ["cell", "CELL", 183, 187], ["acute lesions", "CANCER", 295, 308], ["mice", "ORGANISM", 390, 394], ["human", "ORGANISM", 496, 501], ["EPO", "PROTEIN", 10, 13], ["EPO receptors", "PROTEIN", 67, 80], ["EPO", "PROTEIN", 141, 144], ["mice", "SPECIES", 390, 394], ["human", "SPECIES", 496, 501], ["mice", "SPECIES", 390, 394], ["human", "SPECIES", 496, 501], ["Increased EPO secreted", "PROBLEM", 0, 22], ["chronic hypoxia", "PROBLEM", 30, 45], ["EPO receptors", "TREATMENT", 67, 80], ["its cell protective effects", "TREATMENT", 97, 124], ["extra EPO", "TREATMENT", 135, 144], ["extra cell protection", "TREATMENT", 177, 198], ["acute lesions", "PROBLEM", 295, 308], ["stereotaxic surgery", "TREATMENT", 330, 349], ["toxin infusion", "TREATMENT", 353, 367], ["Parkinson in mice", "PROBLEM", 377, 394], ["progressive, chronic, degenerative pathophysiology of Parkinson in human beings", "PROBLEM", 429, 508], ["chronic", "OBSERVATION_MODIFIER", 30, 37], ["hypoxia", "OBSERVATION", 38, 45], ["not reflected", "UNCERTAINTY", 217, 230], ["acute", "OBSERVATION_MODIFIER", 295, 300], ["lesions", "OBSERVATION", 301, 308], ["progressive", "OBSERVATION_MODIFIER", 429, 440], ["chronic", "OBSERVATION_MODIFIER", 442, 449], ["degenerative", "OBSERVATION", 451, 463], ["Parkinson", "OBSERVATION", 483, 492]]], ["Even in a given species normal physiology, the pathophysiology of diseases and response of the organism to environment and drugs is different in young and old organism.", [["diseases", "PROBLEM", 66, 74], ["the organism", "PROBLEM", 91, 103], ["drugs", "TREATMENT", 123, 128], ["diseases", "OBSERVATION", 66, 74]]], ["And by adding to this fact also inter-species, intra-species discrepancies, you will find how current disease models are useless.", [["intra-species discrepancies", "PROBLEM", 47, 74]]], ["For example, clofibrate, nafenopin, phenobarbital, and reserpine cause cancer in old but not young rats [80\u201382].", [["cancer", "ANATOMY", 71, 77], ["clofibrate", "CHEMICAL", 13, 23], ["nafenopin", "CHEMICAL", 25, 34], ["phenobarbital", "CHEMICAL", 36, 49], ["reserpine", "CHEMICAL", 55, 64], ["cancer", "DISEASE", 71, 77], ["clofibrate", "CHEMICAL", 13, 23], ["nafenopin", "CHEMICAL", 25, 34], ["phenobarbital", "CHEMICAL", 36, 49], ["reserpine", "CHEMICAL", 55, 64], ["clofibrate", "SIMPLE_CHEMICAL", 13, 23], ["nafenopin", "SIMPLE_CHEMICAL", 25, 34], ["phenobarbital", "SIMPLE_CHEMICAL", 36, 49], ["reserpine", "SIMPLE_CHEMICAL", 55, 64], ["cancer", "CANCER", 71, 77], ["rats", "ORGANISM", 99, 103], ["rats", "SPECIES", 99, 103], ["clofibrate", "TREATMENT", 13, 23], ["nafenopin", "TREATMENT", 25, 34], ["phenobarbital", "TREATMENT", 36, 49], ["cancer", "PROBLEM", 71, 77], ["cancer", "OBSERVATION", 71, 77]]], ["Different depression pathophysiology in pre- and postmenopausal women is another example.", [["depression", "DISEASE", 10, 20], ["women", "ORGANISM", 64, 69], ["women", "SPECIES", 64, 69], ["Different depression pathophysiology", "PROBLEM", 0, 36], ["depression", "OBSERVATION", 10, 20]]], ["Menopausal status barely modeled if any in animal modeling.", [["Menopausal status", "PROBLEM", 0, 17]]], ["As another example, it has been repeatedly shown that premenopausal women with breast cancer have a higher risk for brain metastasis development.", [["breast cancer", "ANATOMY", 79, 92], ["brain", "ANATOMY", 116, 121], ["breast cancer", "DISEASE", 79, 92], ["brain metastasis", "DISEASE", 116, 132], ["women", "ORGANISM", 68, 73], ["breast cancer", "CANCER", 79, 92], ["brain", "ORGAN", 116, 121], ["women", "SPECIES", 68, 73], ["breast cancer", "PROBLEM", 79, 92], ["brain metastasis development", "PROBLEM", 116, 144], ["breast", "ANATOMY", 79, 85], ["cancer", "OBSERVATION", 86, 92], ["brain", "ANATOMY", 116, 121], ["metastasis", "OBSERVATION", 122, 132]]], ["Thus, the premenopausal status at the time of breast cancer diagnosis is considered as an additional risk factor for the brain metastatic lesions which were not reflected in animal models of breast cancer [32, 38].", [["breast cancer", "ANATOMY", 46, 59], ["brain metastatic lesions", "ANATOMY", 121, 145], ["breast cancer", "ANATOMY", 191, 204], ["breast cancer", "DISEASE", 46, 59], ["breast cancer", "DISEASE", 191, 204], ["breast cancer", "CANCER", 46, 59], ["brain metastatic lesions", "CANCER", 121, 145], ["breast cancer", "CANCER", 191, 204], ["the premenopausal status", "PROBLEM", 6, 30], ["breast cancer", "PROBLEM", 46, 59], ["the brain metastatic lesions", "PROBLEM", 117, 145], ["breast cancer", "PROBLEM", 191, 204], ["breast", "ANATOMY", 46, 52], ["cancer", "OBSERVATION", 53, 59], ["brain", "ANATOMY", 121, 126], ["metastatic", "OBSERVATION", 127, 137], ["breast", "ANATOMY", 191, 197], ["cancer", "OBSERVATION", 198, 204]]], ["It is time to ask how could we rely on the results of animal experiments with such significant inter- and intra-species discrepancies.Sex ::: DiscussionActually, disease perception and even definition in human beings might be different in either sex.", [["human", "ORGANISM", 204, 209], ["human", "SPECIES", 204, 209], ["human", "SPECIES", 204, 209], ["disease perception", "PROBLEM", 162, 180]]], ["Pathophysiology of diseases (i.e., depression), pharmacokinetic, and drug response in men and women is different.", [["depression", "DISEASE", 35, 45], ["men", "ORGANISM", 86, 89], ["women", "ORGANISM", 94, 99], ["men", "SPECIES", 86, 89], ["women", "SPECIES", 94, 99], ["diseases", "PROBLEM", 19, 27], ["depression", "PROBLEM", 35, 45], ["diseases", "OBSERVATION", 19, 27]]], ["In order to avoid menstrual cycles and mood disturbances of women, most of the studies on depression eliminated women from their study group.Mouse ::: DiscussionAvailability of rodents, short gestation and easy reproduction, resistance, costs, easy maintenance, and small size have made mouse the flagship of animal models.", [["mood disturbances", "DISEASE", 39, 56], ["depression", "DISEASE", 90, 100], ["women", "ORGANISM", 60, 65], ["women", "ORGANISM", 112, 117], ["Mouse", "ORGANISM", 141, 146], ["mouse", "ORGANISM", 287, 292], ["women", "SPECIES", 60, 65], ["women", "SPECIES", 112, 117], ["Mouse", "SPECIES", 141, 146], ["mouse", "SPECIES", 287, 292], ["Mouse", "SPECIES", 141, 146], ["mouse", "SPECIES", 287, 292], ["menstrual cycles", "PROBLEM", 18, 34], ["mood disturbances of women", "PROBLEM", 39, 65], ["the studies", "TEST", 75, 86], ["depression", "PROBLEM", 90, 100], ["short gestation", "PROBLEM", 186, 201], ["small", "OBSERVATION_MODIFIER", 266, 271], ["size", "OBSERVATION_MODIFIER", 272, 276]]], ["Compared to the larger animals such as primates who are much better representation of human beings, mice were much more widely used in experimental studies.", [["primates", "ORGANISM", 39, 47], ["human", "ORGANISM", 86, 91], ["mice", "ORGANISM", 100, 104], ["human", "SPECIES", 86, 91], ["mice", "SPECIES", 100, 104], ["human", "SPECIES", 86, 91], ["mice", "SPECIES", 100, 104], ["experimental studies", "TEST", 135, 155]]], ["Actually, a high percentage of our knowledge comes from male mouse studies which raise concerns for a so-called male mouse bias.Mouse ::: DiscussionAlthough in some single-gene disease such as Huntington\u2019s disease, there is a good correspondence between human and murine models.", [["Huntington\u2019s disease", "DISEASE", 193, 213], ["mouse", "ORGANISM", 61, 66], ["mouse", "ORGANISM", 117, 122], ["Mouse", "ORGANISM", 128, 133], ["human", "ORGANISM", 254, 259], ["murine", "ORGANISM", 264, 270], ["mouse", "SPECIES", 61, 66], ["mouse", "SPECIES", 117, 122], ["Mouse", "SPECIES", 128, 133], ["human", "SPECIES", 254, 259], ["murine", "SPECIES", 264, 270], ["mouse", "SPECIES", 61, 66], ["mouse", "SPECIES", 117, 122], ["human", "SPECIES", 254, 259], ["some single-gene disease", "PROBLEM", 160, 184], ["Huntington\u2019s disease", "PROBLEM", 193, 213], ["disease", "OBSERVATION", 177, 184]]], ["In terms of other environmental injuries such as trauma and burns, and also in systemic inflammation and endotoxemia, coefficient between human and murine models was less than 1% [28].", [["injuries", "DISEASE", 32, 40], ["trauma", "DISEASE", 49, 55], ["burns", "DISEASE", 60, 65], ["inflammation", "DISEASE", 88, 100], ["endotoxemia", "DISEASE", 105, 116], ["human", "ORGANISM", 138, 143], ["murine", "ORGANISM", 148, 154], ["human", "SPECIES", 138, 143], ["murine", "SPECIES", 148, 154], ["human", "SPECIES", 138, 143], ["other environmental injuries", "PROBLEM", 12, 40], ["trauma", "PROBLEM", 49, 55], ["burns", "PROBLEM", 60, 65], ["systemic inflammation", "PROBLEM", 79, 100], ["endotoxemia", "PROBLEM", 105, 116], ["environmental", "OBSERVATION_MODIFIER", 18, 31], ["injuries", "OBSERVATION", 32, 40], ["burns", "OBSERVATION", 60, 65], ["systemic", "OBSERVATION_MODIFIER", 79, 87], ["inflammation", "OBSERVATION", 88, 100], ["endotoxemia", "OBSERVATION", 105, 116]]], ["As another example, 18 out of 23 anticancer vaccines failed in clinical trials [7]; it has been hypothesized that these were due to higher levels of circulating immunosuppressive cytokines and several immunologic checkpoints in humans that might not be present in rodents.", [["anticancer", "ANATOMY", 33, 43], ["anticancer", "CANCER", 33, 43], ["humans", "ORGANISM", 228, 234], ["immunosuppressive cytokines", "PROTEIN", 161, 188], ["humans", "SPECIES", 228, 234], ["humans", "SPECIES", 228, 234], ["23 anticancer vaccines", "TREATMENT", 30, 52], ["circulating immunosuppressive cytokines", "TREATMENT", 149, 188], ["several immunologic checkpoints", "TREATMENT", 193, 224], ["might not be", "UNCERTAINTY", 240, 252]]], ["Males and mice are more resistant, compared to the other species (rabbit) and females.", [["mice", "ORGANISM", 10, 14], ["rabbit", "ORGANISM", 66, 72], ["mice", "SPECIES", 10, 14], ["rabbit", "SPECIES", 66, 72], ["mice", "SPECIES", 10, 14], ["rabbit", "SPECIES", 66, 72], ["more resistant", "OBSERVATION_MODIFIER", 19, 33]]], ["Additionally, they are cheaper, working with them is easier, and need smaller labs.Mouse ::: DiscussionAdditionally, inter-species genetic variations might further complicate the results of animal studies.", [["Mouse", "ORGANISM", 83, 88], ["Mouse", "SPECIES", 83, 88], ["Mouse", "SPECIES", 83, 88], ["smaller labs", "TEST", 70, 82], ["animal studies", "TEST", 190, 204]]], ["Genetic differences in mouse models might interfere with the results of animal experimentations.", [["mouse", "ORGANISM", 23, 28], ["mouse", "SPECIES", 23, 28], ["mouse", "SPECIES", 23, 28], ["Genetic differences in mouse models", "PROBLEM", 0, 35], ["animal experimentations", "PROBLEM", 72, 95]]], ["Although this might be decreased by increasing sample sizes and sacrificing more animals, but this trend is accompanied by several ethical concerns and is not recommended.Environment ::: DiscussionThere is an extremely sensitive interaction between genes, epigenetic regulations, and the environment that governs a sensitive balance between health and illness [6].", [["sample", "ANATOMY", 47, 53], ["illness", "DISEASE", 352, 359], ["increasing sample sizes", "PROBLEM", 36, 59], ["might be", "UNCERTAINTY", 14, 22], ["decreased", "OBSERVATION_MODIFIER", 23, 32], ["increasing", "OBSERVATION_MODIFIER", 36, 46], ["sample", "OBSERVATION_MODIFIER", 47, 53], ["sizes", "OBSERVATION_MODIFIER", 54, 59]]], ["Regrettably, environment and its effect on the organism have been tremendously neglected in healthcare and disease modeling.", [["the organism", "PROBLEM", 43, 55], ["disease modeling", "PROBLEM", 107, 123]]], ["\u201cPPPM approach aims to develop appropriate knowledge and technological skills for promoting affordable strategies in the emerging fields of environmental risk factors, epidemiology, healthy lifestyle, individualized nutrition, food technology and culture in a framework of cost-effective healthcare [1, 34].\u201dEnvironment ::: DiscussionMost of the animal models are kept in a clean standard environment, while this environment does not reflect the conditions in real life.", [["promoting affordable strategies", "TREATMENT", 82, 113], ["culture", "TEST", 247, 254]]], ["For example, smoking as a prevalent habit has not been reflected in most of the animal experiments.", [["smoking", "CHEMICAL", 13, 20]]], ["That is why oral contraceptives (OCP) killed plenty of women, most of them smokers, and that is why riluzole induced liver damage in smokers; all of these tragic events were not predicted in experimental studies [83, 84].", [["oral", "ANATOMY", 12, 16], ["liver", "ANATOMY", 117, 122], ["oral contraceptives", "CHEMICAL", 12, 31], ["OCP", "CHEMICAL", 33, 36], ["riluzole", "CHEMICAL", 100, 108], ["liver damage", "DISEASE", 117, 129], ["riluzole", "CHEMICAL", 100, 108], ["oral", "ORGANISM_SUBDIVISION", 12, 16], ["women", "ORGANISM", 55, 60], ["riluzole", "SIMPLE_CHEMICAL", 100, 108], ["liver", "ORGAN", 117, 122], ["women", "SPECIES", 55, 60], ["liver damage", "PROBLEM", 117, 129], ["liver", "ANATOMY", 117, 122], ["damage", "OBSERVATION", 123, 129]]], ["Interaction with the other widely used medications such as proton pump inhibitors is another example which is not generally studied in models.", [["medications", "TREATMENT", 39, 50], ["proton pump inhibitors", "TREATMENT", 59, 81]]], ["For instance, riluzole and pantoprazole co-consumption increases the likelihood of liver damage in ALS patients.Environment ::: DiscussionAnimals are maintaining in a standard clean environment which is not comparable to real life.", [["liver", "ANATOMY", 83, 88], ["riluzole", "CHEMICAL", 14, 22], ["pantoprazole", "CHEMICAL", 27, 39], ["liver damage", "DISEASE", 83, 95], ["ALS", "DISEASE", 99, 102], ["riluzole", "CHEMICAL", 14, 22], ["pantoprazole", "CHEMICAL", 27, 39], ["riluzole", "SIMPLE_CHEMICAL", 14, 22], ["pantoprazole", "SIMPLE_CHEMICAL", 27, 39], ["liver", "ORGAN", 83, 88], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 103, 111], ["riluzole", "TREATMENT", 14, 22], ["pantoprazole co-consumption", "TREATMENT", 27, 54], ["liver damage in ALS patients", "PROBLEM", 83, 111], ["liver", "ANATOMY", 83, 88], ["damage", "OBSERVATION", 89, 95]]], ["For instance, TGN1412 (anti-CD-28 monoclonal antibody) made an unpredicted human catastrophe.", [["TGN1412", "CHEMICAL", 14, 21], ["TGN1412", "CHEMICAL", 14, 21], ["anti-CD-28", "CHEMICAL", 23, 33], ["TGN1412", "SIMPLE_CHEMICAL", 14, 21], ["anti-CD-28", "GENE_OR_GENE_PRODUCT", 23, 33], ["human", "ORGANISM", 75, 80], ["TGN1412", "PROTEIN", 14, 21], ["anti-CD-28 monoclonal antibody", "PROTEIN", 23, 53], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 75, 80], ["instance", "TEST", 4, 12], ["TGN1412", "TEST", 14, 21], ["anti-CD", "TEST", 23, 30], ["monoclonal antibody", "TEST", 34, 53], ["an unpredicted human catastrophe", "PROBLEM", 60, 92], ["human catastrophe", "OBSERVATION", 75, 92]]], ["After administration, it tends to multi-organ failure due to an unpredicted immune response in the patients.", [["multi-organ", "ANATOMY", 34, 45], ["multi-organ failure", "DISEASE", 34, 53], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["administration", "TREATMENT", 6, 20], ["multi-organ failure", "PROBLEM", 34, 53], ["an unpredicted immune response", "PROBLEM", 61, 91], ["multi-organ", "ANATOMY", 34, 45], ["failure", "OBSERVATION", 46, 53], ["immune response", "OBSERVATION", 76, 91]]], ["Subsequently, it has been shown that CD4+ effector memory T cells (TEM) were responsible for the cytokine release syndrome (CRS) and multi-organ failure in the studied patients [28].", [["CD4+ effector memory T cells", "ANATOMY", 37, 65], ["multi-organ", "ANATOMY", 133, 144], ["CRS", "DISEASE", 124, 127], ["multi-organ failure", "DISEASE", 133, 152], ["CD4", "GENE_OR_GENE_PRODUCT", 37, 40], ["multi-organ", "ORGAN", 133, 144], ["patients", "ORGANISM", 168, 176], ["CD4", "PROTEIN", 37, 40], ["effector memory T cells", "CELL_TYPE", 42, 65], ["TEM", "CELL_TYPE", 67, 70], ["cytokine", "PROTEIN", 97, 105], ["patients", "SPECIES", 168, 176], ["CD4", "TEST", 37, 40], ["the cytokine release syndrome", "PROBLEM", 93, 122], ["CRS", "PROBLEM", 124, 127], ["multi-organ failure", "PROBLEM", 133, 152], ["multi-organ", "ANATOMY", 133, 144], ["failure", "OBSERVATION", 145, 152]]], ["As rodents were stored under very clean circumstances, they had no multiple exposures to infectious microorganisms; hence, TEM cell accumulation did not happen in them.", [["cell", "ANATOMY", 127, 131], ["TEM cell", "CELL", 123, 131], ["infectious microorganisms", "PROBLEM", 89, 114], ["TEM cell accumulation", "PROBLEM", 123, 144], ["infectious", "OBSERVATION", 89, 99]]], ["Unfortunately, studies in monkeys also failed to show these adverse effects because of the diversity of their immune system compared to the human.", [["immune system", "ANATOMY", 110, 123], ["monkeys", "ORGANISM", 26, 33], ["human", "ORGANISM", 140, 145], ["human", "SPECIES", 140, 145], ["human", "SPECIES", 140, 145], ["studies", "TEST", 15, 22], ["these adverse effects", "PROBLEM", 54, 75]]], ["Surprisingly, it was later discovered that in macaque monkeys (Cynomolgus macaques), CD4+ T cells lose CD-28 expression during differentiation into TEM cells [65\u201367].Dangers of animal modeling ::: DiscussionAs mentioned above, the most dangerous aspect of relying on animal models is their low, if any, predictive potential related to the toxicity of the therapeutic drugs.", [["CD4+ T cells", "ANATOMY", 85, 97], ["TEM cells", "ANATOMY", 148, 157], ["toxicity", "DISEASE", 339, 347], ["macaque monkeys", "ORGANISM", 46, 61], ["Cynomolgus macaques", "ORGANISM", 63, 82], ["CD4", "GENE_OR_GENE_PRODUCT", 85, 88], ["CD-28", "GENE_OR_GENE_PRODUCT", 103, 108], ["TEM cells", "CELL", 148, 157], ["CD4", "PROTEIN", 85, 88], ["T cells", "CELL_TYPE", 90, 97], ["CD", "PROTEIN", 103, 105], ["TEM cells", "CELL_TYPE", 148, 157], ["macaque monkeys", "SPECIES", 46, 61], ["Cynomolgus macaques", "SPECIES", 63, 82], ["macaque monkeys", "SPECIES", 46, 61], ["Cynomolgus macaques", "SPECIES", 63, 82], ["CD4", "TEST", 85, 88], ["CD", "TEST", 103, 105], ["TEM cells", "TEST", 148, 157], ["the toxicity", "PROBLEM", 335, 347], ["the therapeutic drugs", "TREATMENT", 351, 372]]], ["There are plenty of human catastrophes that happened because of this.", [["human", "ORGANISM", 20, 25], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 20, 25], ["human catastrophes", "PROBLEM", 20, 38], ["human catastrophes", "OBSERVATION", 20, 38]]], ["The other dangerous aspects of animal studies are infections that are transferred from animals to people working in the research facilities with these animals.", [["infections", "DISEASE", 50, 60], ["people", "ORGANISM", 98, 104], ["people", "SPECIES", 98, 104], ["animal studies", "TEST", 31, 45], ["infections", "PROBLEM", 50, 60], ["dangerous", "OBSERVATION_MODIFIER", 10, 19], ["infections", "OBSERVATION", 50, 60]]], ["Several animal-lab researchers suffered or died due to animal microbes.", [["microbes", "OBSERVATION", 62, 70]]], ["At least, 16 lab workers have been killed by the Marburg virus.", [["Marburg virus", "ORGANISM", 49, 62], ["Marburg virus", "SPECIES", 49, 62], ["the Marburg virus", "PROBLEM", 45, 62]]], ["Ebola outbreaks in American monkey colonies infected a number of lab workers [85].", [["colonies", "ANATOMY", 35, 43], ["Ebola outbreaks", "DISEASE", 0, 15], ["Ebola", "ORGANISM", 0, 5], ["monkey", "ORGANISM", 28, 34], ["American monkey", "SPECIES", 19, 34]]], ["Around 106,000 people die every year from adverse reactions to animal-tested drugs, while 2.2 million people are seriously injured annually.", [["people", "ORGANISM", 15, 21], ["people", "ORGANISM", 102, 108], ["people", "SPECIES", 15, 21], ["people", "SPECIES", 102, 108], ["adverse reactions", "PROBLEM", 42, 59], ["animal-tested drugs", "TREATMENT", 63, 82]]], ["Furthermore, working with animals is accompanied by several serious problems, such as the production of new serotypes, genetically drifted viruses, and contamination of biological products.", [["several serious problems", "PROBLEM", 52, 76], ["new serotypes", "PROBLEM", 104, 117], ["genetically drifted viruses", "PROBLEM", 119, 146], ["biological products", "TREATMENT", 169, 188]]], ["For example, Simian virus 40 infected polio vaccines; as a known carcinogen, it has infected millions of Americans [86].", [["Simian virus 40", "CHEMICAL", 13, 28], ["infected polio", "DISEASE", 29, 43], ["Simian virus 40", "ORGANISM", 13, 28], ["Simian virus", "SPECIES", 13, 25], ["Simian virus 40", "SPECIES", 13, 28], ["Simian virus 40 infected polio vaccines", "TREATMENT", 13, 52], ["infected", "OBSERVATION_MODIFIER", 84, 92]]], ["Although it is still doubtful, there are reports that hypothesized that HIV might be the result of polio vaccine production using monkey tissues or the product of cancer and biologic weapon research in the early 1970s [87\u201390].Dangers of animal modeling ::: DiscussionThere are several potentially infectious agents, especially virus and prions of nonhuman grafts and tissues that might be transmitted to humans.", [["tissues", "ANATOMY", 137, 144], ["cancer", "ANATOMY", 163, 169], ["grafts", "ANATOMY", 356, 362], ["tissues", "ANATOMY", 367, 374], ["cancer", "DISEASE", 163, 169], ["HIV", "ORGANISM", 72, 75], ["monkey", "ORGANISM", 130, 136], ["tissues", "TISSUE", 137, 144], ["cancer", "CANCER", 163, 169], ["nonhuman", "ORGANISM", 347, 355], ["grafts", "TISSUE", 356, 362], ["tissues", "TISSUE", 367, 374], ["humans", "ORGANISM", 404, 410], ["HIV", "SPECIES", 72, 75], ["humans", "SPECIES", 404, 410], ["HIV", "SPECIES", 72, 75], ["humans", "SPECIES", 404, 410], ["HIV", "PROBLEM", 72, 75], ["polio vaccine production", "TREATMENT", 99, 123], ["cancer", "PROBLEM", 163, 169], ["virus", "PROBLEM", 327, 332], ["prions of nonhuman grafts", "TREATMENT", 337, 362], ["cancer", "OBSERVATION", 163, 169], ["several", "OBSERVATION_MODIFIER", 277, 284], ["potentially", "OBSERVATION_MODIFIER", 285, 296], ["infectious", "OBSERVATION", 297, 307], ["nonhuman grafts", "OBSERVATION", 347, 362]]], ["Severe acute respiratory syndrome (SARS) outbreaks might be the results of remodeling and combination of zoonosis with human viruses.", [["acute respiratory syndrome", "DISEASE", 7, 33], ["SARS", "DISEASE", 35, 39], ["zoonosis", "DISEASE", 105, 113], ["human", "ORGANISM", 119, 124], ["human", "SPECIES", 119, 124], ["human viruses", "SPECIES", 119, 132], ["Severe acute respiratory syndrome", "PROBLEM", 0, 33], ["SARS) outbreaks", "PROBLEM", 35, 50], ["zoonosis", "PROBLEM", 105, 113], ["human viruses", "PROBLEM", 119, 132], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["respiratory syndrome", "OBSERVATION", 13, 33]]], ["Prion diseases are also extremely dangerous for us and there is a high likelihood of transfection to animal lab workers and receivers of animal lab products like animal-derived vaccines.", [["Prion diseases", "DISEASE", 0, 14], ["Prion diseases", "PROBLEM", 0, 14], ["animal lab products", "TREATMENT", 137, 156], ["animal-derived vaccines", "TREATMENT", 162, 185]]], ["The same might happen in genetic engineering labs, while during the production of recombinant proteins, other unknown infectious agents might contaminate their products.", [["recombinant proteins", "PROTEIN", 82, 102], ["genetic engineering labs", "TEST", 25, 49], ["recombinant proteins", "TREATMENT", 82, 102]]], ["Contamination with animal viruses and prions has been dramatically decreased after human tissue culture introduction [91].", [["tissue", "ANATOMY", 89, 95], ["human", "ORGANISM", 83, 88], ["tissue", "TISSUE", 89, 95], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 83, 88], ["animal viruses", "PROBLEM", 19, 33], ["human tissue culture", "TEST", 83, 103], ["viruses", "OBSERVATION", 26, 33], ["dramatically", "OBSERVATION_MODIFIER", 54, 66], ["decreased", "OBSERVATION_MODIFIER", 67, 76], ["human tissue", "OBSERVATION_MODIFIER", 83, 95]]], ["Meanwhile, animal cell cultures are still being practiced in several labs [92].Dangers of animal modeling ::: DiscussionPredictability of some models is assumed to be around 50%; instead of modeling, we might flip a coin and save money and innocent animals.", [["cell cultures", "ANATOMY", 18, 31], ["cell cultures", "CELL", 18, 31], ["animal cell cultures", "CELL_LINE", 11, 31], ["animal cell cultures", "TEST", 11, 31], ["several labs", "TEST", 61, 73], ["cell cultures", "OBSERVATION", 18, 31]]], ["Animal study designing is not as accurate as human trials, there is no registration for experimental studies, almost none of them is blind, and standard anesthesia is not practiced in many institutions.", [["human", "ORGANISM", 45, 50], ["human", "SPECIES", 45, 50], ["human", "SPECIES", 45, 50], ["Animal study", "TEST", 0, 12], ["experimental studies", "TEST", 88, 108], ["standard anesthesia", "TREATMENT", 144, 163], ["no", "UNCERTAINTY", 68, 70], ["blind", "OBSERVATION", 133, 138]]], ["Regrettably, more than 100 million animals are killed in animal labs annually.Dangers of animal modeling ::: DiscussionPublication bias is another critical concern of animal experiments.", [["animals", "ORGANISM", 35, 42], ["animal labs", "TEST", 57, 68]]], ["Even in clinical trials, fewer than one in five cancer RCTs are being published.", [["cancer", "ANATOMY", 48, 54], ["cancer", "DISEASE", 48, 54], ["cancer", "CANCER", 48, 54], ["five cancer RCTs", "TREATMENT", 43, 59], ["cancer", "OBSERVATION", 48, 54]]], ["Since negative results are not being published, animal studies generally overvalue, by about 30%, the likelihood that a treatment might be effective [7, 18].", [["animal studies", "TEST", 48, 62], ["a treatment", "TREATMENT", 118, 129]]], ["It is time to register animal studies, just like clinical trials.Neurosciences and Alzheimer ::: Three conclusive examplesA brief review of the literature will disclose several so-called animal models of Alzheimer, but a deeper look at Alzheimer models reveals that these models generally cover only one aspect of the complex character of this neurodegenerative disease [93].", [["Alzheimer", "DISEASE", 83, 92], ["Alzheimer", "DISEASE", 204, 213], ["Alzheimer", "DISEASE", 236, 245], ["neurodegenerative disease", "DISEASE", 344, 369], ["animal studies", "TEST", 23, 37], ["Alzheimer", "PROBLEM", 204, 213], ["a deeper look at Alzheimer models", "TEST", 219, 252], ["this neurodegenerative disease", "PROBLEM", 339, 369], ["neurodegenerative disease", "OBSERVATION", 344, 369]]], ["A large number of responsible factors have been suggested for developing Alzheimer and among them are aging, inflammation, oxidative stress, vascular abnormalities, and amyloid depositions.", [["vascular", "ANATOMY", 141, 149], ["Alzheimer", "DISEASE", 73, 82], ["inflammation", "DISEASE", 109, 121], ["vascular abnormalities", "DISEASE", 141, 163], ["vascular", "MULTI-TISSUE_STRUCTURE", 141, 149], ["amyloid", "GENE_OR_GENE_PRODUCT", 169, 176], ["Alzheimer", "PROBLEM", 73, 82], ["inflammation", "PROBLEM", 109, 121], ["oxidative stress", "PROBLEM", 123, 139], ["vascular abnormalities", "PROBLEM", 141, 163], ["amyloid depositions", "PROBLEM", 169, 188], ["large", "OBSERVATION_MODIFIER", 2, 7], ["Alzheimer", "OBSERVATION", 73, 82], ["inflammation", "OBSERVATION", 109, 121], ["oxidative stress", "OBSERVATION", 123, 139], ["vascular", "ANATOMY", 141, 149], ["abnormalities", "OBSERVATION", 150, 163], ["amyloid depositions", "OBSERVATION", 169, 188]]], ["Surprisingly, lifestyle, nutrition, education, academic achievements, and even career are also related to Alzheimer development [94\u201396].", [["Alzheimer", "DISEASE", 106, 115]]], ["Now it is time to ask, how could we synthesize such a complex, chronic, multi-factorial disease of an extremely complex organ (human brain) in a mouse model?", [["organ", "ANATOMY", 120, 125], ["brain", "ANATOMY", 133, 138], ["organ", "ORGAN", 120, 125], ["human", "ORGANISM", 127, 132], ["brain", "ORGAN", 133, 138], ["mouse", "ORGANISM", 145, 150], ["human", "SPECIES", 127, 132], ["mouse", "SPECIES", 145, 150], ["human", "SPECIES", 127, 132], ["mouse", "SPECIES", 145, 150], ["a complex, chronic, multi-factorial disease", "PROBLEM", 52, 95], ["an extremely complex organ (human brain", "PROBLEM", 99, 138], ["chronic", "OBSERVATION_MODIFIER", 63, 70], ["multi-factorial", "OBSERVATION_MODIFIER", 72, 87], ["disease", "OBSERVATION", 88, 95], ["brain", "ANATOMY", 133, 138]]], ["Is a transgenic model such as amyloid precursor protein transgenic mouse model a suitable model for human Alzheimer disease [97\u201399]?", [["Alzheimer disease", "DISEASE", 106, 123], ["amyloid precursor protein", "GENE_OR_GENE_PRODUCT", 30, 55], ["mouse", "ORGANISM", 67, 72], ["human", "ORGANISM", 100, 105], ["amyloid precursor protein", "PROTEIN", 30, 55], ["mouse", "SPECIES", 67, 72], ["human", "SPECIES", 100, 105], ["mouse", "SPECIES", 67, 72], ["human", "SPECIES", 100, 105], ["human Alzheimer disease", "PROBLEM", 100, 123]]], ["It has been shown that patients with Down syndrome develop Alzheimer earlier than the normal population due to having three copies of chromosome 21 and hence three copies of amyloid precursor protein (APP) gene.", [["chromosome 21", "ANATOMY", 134, 147], ["Down syndrome", "DISEASE", 37, 50], ["Alzheimer earlier than the normal population", "DISEASE", 59, 103], ["patients", "ORGANISM", 23, 31], ["chromosome 21", "CELLULAR_COMPONENT", 134, 147], ["amyloid precursor protein", "GENE_OR_GENE_PRODUCT", 174, 199], ["APP", "GENE_OR_GENE_PRODUCT", 201, 204], ["chromosome 21", "DNA", 134, 147], ["amyloid precursor protein (APP) gene", "DNA", 174, 210], ["patients", "SPECIES", 23, 31], ["Down syndrome", "PROBLEM", 37, 50], ["Alzheimer", "PROBLEM", 59, 68]]], ["However, does it mean that Alzheimer in Down syndrome is equal to Alzheimer in elderly?!", [["Alzheimer", "DISEASE", 27, 36], ["Down syndrome", "DISEASE", 40, 53], ["Alzheimer", "DISEASE", 66, 75], ["Alzheimer in Down syndrome", "PROBLEM", 27, 53], ["Alzheimer", "OBSERVATION", 27, 36]]], ["Does an Alzheimer model, which was developed by means of applying a mitochondrial toxin to a rat, is a good representative of Alzheimer in a Nobel laureate?", [["mitochondrial", "ANATOMY", 68, 81], ["Alzheimer", "DISEASE", 126, 135], ["mitochondrial", "CELLULAR_COMPONENT", 68, 81], ["rat", "ORGANISM", 93, 96], ["mitochondrial toxin", "PROTEIN", 68, 87], ["rat", "SPECIES", 93, 96], ["an Alzheimer model", "PROBLEM", 5, 23], ["a mitochondrial toxin", "PROBLEM", 66, 87], ["Alzheimer", "PROBLEM", 126, 135], ["Alzheimer model", "OBSERVATION", 8, 23]]], ["How could we compare cognitive impairment in animals and human beings?", [["cognitive impairment", "DISEASE", 21, 41], ["human", "ORGANISM", 57, 62], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 57, 62], ["cognitive impairment in animals", "PROBLEM", 21, 52]]], ["Amyloid precursor protein transgenic mouse model is not an Alzheimer model.", [["Alzheimer", "DISEASE", 59, 68], ["Amyloid precursor protein", "GENE_OR_GENE_PRODUCT", 0, 25], ["mouse", "ORGANISM", 37, 42], ["Amyloid precursor protein", "PROTEIN", 0, 25], ["mouse", "SPECIES", 37, 42], ["mouse", "SPECIES", 37, 42], ["Amyloid precursor", "TEST", 0, 17], ["an Alzheimer model", "PROBLEM", 56, 74], ["protein transgenic mouse model", "OBSERVATION", 18, 48], ["Alzheimer model", "OBSERVATION", 59, 74]]], ["It is nothing but three copies of amyloid precursor protein deposition in the brain of a mouse.", [["brain", "ANATOMY", 78, 83], ["amyloid precursor protein", "GENE_OR_GENE_PRODUCT", 34, 59], ["brain", "ORGAN", 78, 83], ["mouse", "ORGANISM", 89, 94], ["amyloid precursor protein", "PROTEIN", 34, 59], ["mouse", "SPECIES", 89, 94], ["mouse", "SPECIES", 89, 94], ["amyloid precursor protein deposition", "PROBLEM", 34, 70], ["amyloid precursor", "OBSERVATION", 34, 51], ["protein deposition", "OBSERVATION", 52, 70], ["brain", "ANATOMY", 78, 83]]], ["Conclusively, targeting a single aspect of a multifactorial disease such as Alzheimer will not appropriately model such a multifactorial chronic complex disease.", [["Alzheimer", "DISEASE", 76, 85], ["a multifactorial disease", "PROBLEM", 43, 67], ["Alzheimer", "PROBLEM", 76, 85], ["a multifactorial chronic complex disease", "PROBLEM", 120, 160], ["multifactorial", "OBSERVATION_MODIFIER", 45, 59], ["disease", "OBSERVATION", 60, 67], ["multifactorial", "OBSERVATION_MODIFIER", 122, 136], ["chronic", "OBSERVATION_MODIFIER", 137, 144], ["complex", "OBSERVATION_MODIFIER", 145, 152], ["disease", "OBSERVATION", 153, 160]]], ["In fact, none of age, oxidative stress, education, and other responsible genes were reflected in APP models of Alzheimer.", [["Alzheimer", "DISEASE", 111, 120], ["APP", "GENE_OR_GENE_PRODUCT", 97, 100], ["APP", "PROTEIN", 97, 100], ["Alzheimer", "PROBLEM", 111, 120]]], ["Weight of human trials is not comparable with the animal studies.", [["human", "ORGANISM", 10, 15], ["human", "SPECIES", 10, 15], ["human", "SPECIES", 10, 15], ["Weight", "TEST", 0, 6], ["human trials", "TEST", 10, 22], ["the animal studies", "TEST", 46, 64]]], ["Animal models might be misleading, if we do not revise our models\u2019 names and if not revising the concept of disease modeling instead of risk factor modeling.Neurosciences and Alzheimer ::: Three conclusive examplesPPPM approaches patients instead of diseases; for a patient-tailored approach, complex characteristics of the patients should be addressed precisely [1, 2, 34].", [["Alzheimer", "DISEASE", 175, 184], ["patients", "ORGANISM", 230, 238], ["patient", "ORGANISM", 266, 273], ["patients", "ORGANISM", 324, 332], ["patients", "SPECIES", 230, 238], ["patient", "SPECIES", 266, 273], ["patients", "SPECIES", 324, 332], ["disease modeling", "PROBLEM", 108, 124], ["risk factor modeling", "PROBLEM", 136, 156], ["diseases", "PROBLEM", 250, 258], ["a patient-tailored approach", "TREATMENT", 264, 291], ["diseases", "OBSERVATION", 250, 258]]], ["In order to provide reliable practical information, preclinical studies should implement PPPM concepts and hence model diseases with respect to their detailed characteristics of the patients.", [["patients", "ORGANISM", 182, 190], ["patients", "SPECIES", 182, 190], ["preclinical studies", "TEST", 52, 71], ["PPPM concepts", "TREATMENT", 89, 102], ["model diseases", "PROBLEM", 113, 127]]], ["It is quite sophisticated and literally impossible to model complex characteristics of human neuropsychiatric disorders in animal models.Wound healing ::: Three conclusive examplesBoth, modifiable risk factors (such as stress, smoking, inappropriate alcohol consumption, malnutrition, obesity, diabetes, and cardiovascular disease) and non-modifiable risk factors (such as genetic diseases and aging), have been identified in the process of impaired wound healing, which calls for implementation of PPPM approach in this area [100].", [["Wound", "ANATOMY", 137, 142], ["cardiovascular", "ANATOMY", 308, 322], ["wound", "ANATOMY", 450, 455], ["neuropsychiatric disorders", "DISEASE", 93, 119], ["alcohol", "CHEMICAL", 250, 257], ["malnutrition", "DISEASE", 271, 283], ["obesity", "DISEASE", 285, 292], ["diabetes", "DISEASE", 294, 302], ["cardiovascular disease", "DISEASE", 308, 330], ["impaired wound healing", "DISEASE", 441, 463], ["alcohol", "CHEMICAL", 250, 257], ["human", "ORGANISM", 87, 92], ["Wound", "PATHOLOGICAL_FORMATION", 137, 142], ["wound", "PATHOLOGICAL_FORMATION", 450, 455], ["human", "SPECIES", 87, 92], ["human", "SPECIES", 87, 92], ["human neuropsychiatric disorders", "PROBLEM", 87, 119], ["malnutrition", "PROBLEM", 271, 283], ["obesity", "PROBLEM", 285, 292], ["diabetes", "PROBLEM", 294, 302], ["cardiovascular disease)", "PROBLEM", 308, 331], ["non-modifiable risk factors", "PROBLEM", 336, 363], ["genetic diseases", "PROBLEM", 373, 389], ["impaired wound healing", "PROBLEM", 441, 463], ["implementation of PPPM approach", "TREATMENT", 481, 512], ["healing", "OBSERVATION", 143, 150], ["obesity", "OBSERVATION", 285, 292], ["cardiovascular", "ANATOMY", 308, 322], ["impaired", "OBSERVATION_MODIFIER", 441, 449], ["wound", "OBSERVATION_MODIFIER", 450, 455], ["healing", "OBSERVATION", 456, 463]]], ["Individual risk factors, causality, functional interrelationships, molecular signature, predictive diagnosis, and primary and secondary prevention are all crucial in approach to impaired wound healing [34].Wound healing ::: Three conclusive examplesOn the other hand, animal models of wound healing are extremely simplified; almost none of comorbidities and risk factors of impaired wound healing has been modeled on them.", [["wound", "ANATOMY", 187, 192], ["Wound", "ANATOMY", 206, 211], ["wound", "ANATOMY", 285, 290], ["wound", "ANATOMY", 383, 388], ["impaired wound healing", "DISEASE", 178, 200], ["impaired wound healing", "DISEASE", 374, 396], ["wound", "PATHOLOGICAL_FORMATION", 187, 192], ["Wound", "PATHOLOGICAL_FORMATION", 206, 211], ["wound", "PATHOLOGICAL_FORMATION", 285, 290], ["wound", "PATHOLOGICAL_FORMATION", 383, 388], ["Individual risk factors", "PROBLEM", 0, 23], ["impaired wound healing", "PROBLEM", 178, 200], ["wound healing", "PROBLEM", 285, 298], ["comorbidities", "PROBLEM", 340, 353], ["impaired wound healing", "PROBLEM", 374, 396], ["impaired", "OBSERVATION_MODIFIER", 178, 186], ["wound", "OBSERVATION_MODIFIER", 187, 192], ["healing", "OBSERVATION_MODIFIER", 193, 200], ["healing", "OBSERVATION", 212, 219], ["wound", "ANATOMY", 285, 290], ["healing", "OBSERVATION", 291, 298], ["impaired", "OBSERVATION_MODIFIER", 374, 382], ["wound healing", "OBSERVATION", 383, 396]]], ["Among the important risk factors that were not presented in the majority of models are aging, smoking, malnutrition, obesity, diabetes, and cardiovascular disorders [100, 101].Myocardial infarction ::: Three conclusive examplesAs a final example, let us take a short look to the MI/stroke models and evaluate the abovementioned confounding factors which were not taken into account while modeling MI/stroke.First of all, most of the patients with MI/stroke are old, while most of the animals are young.Most of the patients with stroke are suffering from several comorbidities such as hypertension, obesity, and diabetes while models are healthy animals which acutely underwent an arterial temporary blockage procedure.A large number of patients with stroke are smokers; none of the animals are.Female animals are usually underrepresented in experimental studies but the patients come from both sexes.Most of the models are rats and mice and biologically closer species have been rarely used, which increases inter-species discrepancies and decreases the validity of these biologically distant models.Timing is a matter of fact in MI/stroke treatment.", [["cardiovascular", "ANATOMY", 140, 154], ["Myocardial", "ANATOMY", 176, 186], ["arterial", "ANATOMY", 680, 688], ["smoking", "CHEMICAL", 94, 101], ["malnutrition", "DISEASE", 103, 115], ["obesity", "DISEASE", 117, 124], ["diabetes", "DISEASE", 126, 134], ["cardiovascular disorders", "DISEASE", 140, 164], ["Myocardial infarction", "DISEASE", 176, 197], ["MI", "DISEASE", 279, 281], ["stroke", "DISEASE", 282, 288], ["MI", "DISEASE", 397, 399], ["stroke", "DISEASE", 400, 406], ["MI", "DISEASE", 447, 449], ["stroke", "DISEASE", 450, 456], ["stroke", "DISEASE", 528, 534], ["hypertension", "DISEASE", 584, 596], ["obesity", "DISEASE", 598, 605], ["diabetes", "DISEASE", 611, 619], ["stroke", "DISEASE", 750, 756], ["MI", "DISEASE", 1130, 1132], ["stroke", "DISEASE", 1133, 1139], ["Myocardial", "MULTI-TISSUE_STRUCTURE", 176, 186], ["patients", "ORGANISM", 433, 441], ["animals", "ORGANISM", 484, 491], ["patients", "ORGANISM", 514, 522], ["arterial", "MULTI-TISSUE_STRUCTURE", 680, 688], ["patients", "ORGANISM", 736, 744], ["patients", "ORGANISM", 870, 878], ["rats", "ORGANISM", 923, 927], ["mice", "ORGANISM", 932, 936], ["patients", "SPECIES", 433, 441], ["patients", "SPECIES", 514, 522], ["patients", "SPECIES", 736, 744], ["patients", "SPECIES", 870, 878], ["rats", "SPECIES", 923, 927], ["mice", "SPECIES", 932, 936], ["mice", "SPECIES", 932, 936], ["malnutrition", "PROBLEM", 103, 115], ["obesity", "PROBLEM", 117, 124], ["diabetes", "PROBLEM", 126, 134], ["cardiovascular disorders", "PROBLEM", 140, 164], ["Myocardial infarction", "PROBLEM", 176, 197], ["the MI/stroke models", "PROBLEM", 275, 295], ["modeling MI", "PROBLEM", 388, 399], ["stroke", "PROBLEM", 400, 406], ["MI", "PROBLEM", 447, 449], ["stroke", "PROBLEM", 450, 456], ["stroke", "PROBLEM", 528, 534], ["several comorbidities", "PROBLEM", 554, 575], ["hypertension", "PROBLEM", 584, 596], ["obesity", "PROBLEM", 598, 605], ["diabetes", "PROBLEM", 611, 619], ["an arterial temporary blockage procedure", "TREATMENT", 677, 717], ["stroke", "PROBLEM", 750, 756], ["experimental studies", "TEST", 841, 861], ["MI", "PROBLEM", 1130, 1132], ["stroke treatment", "TREATMENT", 1133, 1149], ["malnutrition", "OBSERVATION", 103, 115], ["obesity", "OBSERVATION", 117, 124], ["diabetes", "OBSERVATION", 126, 134], ["cardiovascular", "ANATOMY", 140, 154], ["infarction", "OBSERVATION", 187, 197], ["stroke", "OBSERVATION", 400, 406], ["stroke", "OBSERVATION", 450, 456], ["stroke", "OBSERVATION", 528, 534], ["hypertension", "OBSERVATION", 584, 596], ["obesity", "OBSERVATION", 598, 605], ["diabetes", "OBSERVATION", 611, 619], ["arterial", "ANATOMY", 680, 688], ["temporary blockage", "OBSERVATION", 689, 707], ["large", "OBSERVATION_MODIFIER", 720, 725], ["number", "OBSERVATION_MODIFIER", 726, 732], ["stroke", "OBSERVATION", 750, 756], ["stroke", "OBSERVATION", 1133, 1139]]], ["Pretreatment and immediate treatment are prevalent in models, while in the real world, there is almost no pretreatment for MI/stroke.", [["MI", "DISEASE", 123, 125], ["stroke", "DISEASE", 126, 132], ["Pretreatment", "TREATMENT", 0, 12], ["immediate treatment", "TREATMENT", 17, 36], ["MI", "PROBLEM", 123, 125], ["stroke", "PROBLEM", 126, 132], ["stroke", "OBSERVATION", 126, 132]]], ["It happens suddenly and generally only hours after the MI/stroke, treatment will start for most of the patients.In experimental studies, the efficacy of treatment in models is evaluated by infarct volume, while the clinical relevance of infarct volume with the patients\u2019 outcome is in doubt.", [["infarct", "ANATOMY", 237, 244], ["MI", "DISEASE", 55, 57], ["stroke", "DISEASE", 58, 64], ["infarct", "DISEASE", 189, 196], ["infarct", "DISEASE", 237, 244], ["patients", "ORGANISM", 103, 111], ["patients", "ORGANISM", 261, 269], ["patients", "SPECIES", 103, 111], ["patients", "SPECIES", 261, 269], ["the MI", "PROBLEM", 51, 57], ["stroke", "PROBLEM", 58, 64], ["treatment", "TREATMENT", 66, 75], ["experimental studies", "TEST", 115, 135], ["treatment in models", "TREATMENT", 153, 172], ["infarct volume", "PROBLEM", 189, 203], ["infarct volume", "PROBLEM", 237, 251], ["stroke", "OBSERVATION", 58, 64], ["infarct", "OBSERVATION", 189, 196], ["infarct", "OBSERVATION", 237, 244]]], ["Infarct size has been shown to have a moderate correlation with the patients\u2019 clinical status and outcome [3].Preconditioning is of great importance specially in terms of applying recombinant cell protectors such as EPO; nevertheless, preconditioning has not been modeled in animal models of stroke and MI.Percentage of cells undergo stunning, and the location of the infarct plays a crucial role in clinical presentation and outcome of the patients.", [["Infarct", "ANATOMY", 0, 7], ["cell", "ANATOMY", 192, 196], ["cells", "ANATOMY", 320, 325], ["Infarct", "DISEASE", 0, 7], ["stroke", "DISEASE", 292, 298], ["MI", "DISEASE", 303, 305], ["infarct", "DISEASE", 368, 375], ["patients", "ORGANISM", 68, 76], ["cell", "CELL", 192, 196], ["EPO", "GENE_OR_GENE_PRODUCT", 216, 219], ["cells", "CELL", 320, 325], ["patients", "ORGANISM", 441, 449], ["EPO", "PROTEIN", 216, 219], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 441, 449], ["Infarct size", "PROBLEM", 0, 12], ["recombinant cell protectors", "TREATMENT", 180, 207], ["EPO", "TREATMENT", 216, 219], ["stroke", "PROBLEM", 292, 298], ["MI", "PROBLEM", 303, 305], ["stunning", "PROBLEM", 334, 342], ["the infarct", "PROBLEM", 364, 375], ["size", "OBSERVATION_MODIFIER", 8, 12], ["moderate", "OBSERVATION_MODIFIER", 38, 46], ["stroke", "OBSERVATION", 292, 298], ["cells", "OBSERVATION", 320, 325], ["stunning", "OBSERVATION", 334, 342], ["infarct", "OBSERVATION", 368, 375]]], ["None of these has been reflected in stroke models.Old habits die hard: why do animal models still exist? ::: Three conclusive examplesWhy do animal models still exist?", [["stroke", "DISEASE", 36, 42], ["stroke models", "OBSERVATION", 36, 49]]], ["People are happy with their routines.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6]]], ["Some people are making money with animal models; currently, animal production for experimental studies seems to be a treasured industry.Old habits die hard: why do animal models still exist? ::: Three conclusive examplesParticularly, animal experiments may provide a legal sanctuary for pharmaceutical companies.", [["people", "ORGANISM", 5, 11], ["people", "SPECIES", 5, 11], ["experimental studies", "TEST", 82, 102]]], ["Moreover, it seems that only after having their money back and when plenty of patients have suffered from unexpected side effects (as evidenced in plenty of phase 4 studies) they will withdraw selling their products, while, unfortunately, most of them are not willing to compensate for their fault.", [["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["unexpected side effects", "PROBLEM", 106, 129]]], ["Huge amounts of money and resources are wasted, and pharmaceutical companies are not those who missed their resources.", [["amounts", "OBSERVATION_MODIFIER", 5, 12]]], ["Experimental studies are also less expensive compared to human studies and less time-consuming.", [["human", "ORGANISM", 57, 62], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 57, 62], ["Experimental studies", "TEST", 0, 20], ["human studies", "TEST", 57, 70]]], ["Scientist could produce new and interesting findings in a short time with a small amount of money, time, and energy.", [["new", "OBSERVATION_MODIFIER", 24, 27]]], ["Furthermore, many of old-school researchers currently working with animals as experts in this field do not like to learn new methods such as tissue culture.", [["tissue culture", "ANATOMY", 141, 155], ["tissue", "TISSUE", 141, 147], ["tissue culture", "TEST", 141, 155]]], ["Additionally, there are less ethical investigations during the conduction of the study and at the time of publication.", [["the study", "TEST", 77, 86], ["less", "OBSERVATION_MODIFIER", 24, 28]]], ["Surprisingly, animal studies appear more scientific compared to clinical investigation.", [["animal studies", "TEST", 14, 28], ["clinical investigation", "TEST", 64, 86]]], ["A very small number of clinician scientists exist, and tunnel vision of PhDs and lack of holistic knowledge of the diseases and its complex character are real challenges for current investigations.", [["the diseases", "PROBLEM", 111, 123], ["current investigations", "TEST", 174, 196], ["very", "OBSERVATION_MODIFIER", 2, 6], ["small", "OBSERVATION_MODIFIER", 7, 12], ["number", "OBSERVATION_MODIFIER", 13, 19], ["tunnel vision", "OBSERVATION", 55, 68], ["diseases", "OBSERVATION", 115, 123]]], ["Finally, at the moment, there is still a vast lack of knowledge and expertise in cutting-edge non-animal techniques.Old habits die hard: why do animal models still exist? ::: Three conclusive examplesAlthough we have learned a lot from animal experiments, a large number of our studies are not fruitful and might be misleading.", [["our studies", "TEST", 274, 285], ["large", "OBSERVATION_MODIFIER", 258, 263]]], ["Careful application of animal models is advised and a replacement in the form of novel state-of-the-art technologies is required for disease modeling.", [["animal models", "TREATMENT", 23, 36], ["a replacement", "TREATMENT", 52, 65], ["the-art technologies", "TREATMENT", 96, 116], ["disease modeling", "PROBLEM", 133, 149]]], ["Malpractice in animal modeling was such a huge catastrophe that it made some scientist admit that \u201canimal experiments are part of medical history, but history is where they belong.\u201dImportance of clinical investigations ::: Recommendations and suggestions for solutionsUnderstanding and management of human diseases should start with and terminate in human observations [113].", [["human", "ORGANISM", 300, 305], ["human", "ORGANISM", 350, 355], ["human", "SPECIES", 300, 305], ["human", "SPECIES", 350, 355], ["human", "SPECIES", 300, 305], ["human", "SPECIES", 350, 355], ["a huge catastrophe", "PROBLEM", 40, 58], ["solutions", "TREATMENT", 259, 268], ["human diseases", "PROBLEM", 300, 314], ["huge", "OBSERVATION_MODIFIER", 42, 46], ["catastrophe", "OBSERVATION", 47, 58]]], ["Hepatitis, ulcerative colitis, rheumatic fever, typhoid fever, appendicitis, and hyperparathyroidism are all among samples of successful human-human study pathways.Epidemiologic population base studies ::: Recommendations and suggestions for solutionsFramingham identification of coronary heart disease risk factors is the best example of a critically important massive human cohort [114, 115].", [["ulcerative", "ANATOMY", 11, 21], ["coronary", "ANATOMY", 280, 288], ["heart", "ANATOMY", 289, 294], ["Hepatitis", "DISEASE", 0, 9], ["ulcerative colitis", "DISEASE", 11, 29], ["rheumatic fever", "DISEASE", 31, 46], ["typhoid fever", "DISEASE", 48, 61], ["appendicitis", "DISEASE", 63, 75], ["hyperparathyroidism", "DISEASE", 81, 100], ["coronary heart disease", "DISEASE", 280, 302], ["ulcerative colitis", "PATHOLOGICAL_FORMATION", 11, 29], ["human", "ORGANISM", 137, 142], ["human", "ORGANISM", 143, 148], ["coronary heart", "MULTI-TISSUE_STRUCTURE", 280, 294], ["human", "ORGANISM", 370, 375], ["human", "SPECIES", 137, 142], ["human", "SPECIES", 143, 148], ["human", "SPECIES", 370, 375], ["human", "SPECIES", 137, 142], ["human", "SPECIES", 143, 148], ["human", "SPECIES", 370, 375], ["Hepatitis", "PROBLEM", 0, 9], ["ulcerative colitis", "PROBLEM", 11, 29], ["rheumatic fever", "PROBLEM", 31, 46], ["typhoid fever", "PROBLEM", 48, 61], ["appendicitis", "PROBLEM", 63, 75], ["hyperparathyroidism", "PROBLEM", 81, 100], ["Epidemiologic population base studies", "TEST", 164, 201], ["coronary heart disease risk factors", "PROBLEM", 280, 315], ["ulcerative", "OBSERVATION_MODIFIER", 11, 21], ["colitis", "OBSERVATION", 22, 29], ["rheumatic", "OBSERVATION_MODIFIER", 31, 40], ["fever", "OBSERVATION", 41, 46], ["typhoid", "OBSERVATION_MODIFIER", 48, 55], ["appendicitis", "OBSERVATION", 63, 75], ["hyperparathyroidism", "OBSERVATION", 81, 100], ["coronary heart", "ANATOMY", 280, 294], ["disease", "OBSERVATION", 295, 302]]], ["Human observations, population-based studies, proteomics, next-generation sequencing, whole genome sequencing, post-marketing surveillance, phase 4 trials, side effects observations, network meta-analysis, and Mendelian randomization are among promising novel methods and techniques that can replace animal modeling.Mendelian randomization ::: Recommendations and suggestions for solutionsMendelian randomization, a novel genetic-epidemiologic approach, may identify a causal link between risk factor and disease, in the presence of confounding factors.", [["Human", "ORGANISM", 0, 5], ["Human", "SPECIES", 0, 5], ["based studies", "TEST", 31, 44], ["proteomics", "TEST", 46, 56], ["next-generation sequencing", "TREATMENT", 58, 84], ["post-marketing surveillance", "TEST", 111, 138], ["side effects observations", "PROBLEM", 156, 181], ["network meta-analysis", "TEST", 183, 204], ["Mendelian randomization", "TREATMENT", 210, 233], ["Mendelian randomization", "TREATMENT", 389, 412], ["disease", "PROBLEM", 505, 512], ["confounding factors", "PROBLEM", 533, 552], ["disease", "OBSERVATION", 505, 512]]], ["Mendelian randomization studies raised major concerns regarding what we believed to be a true causal relationship [116].", [["Mendelian randomization studies", "TEST", 0, 31]]], ["For example, courtesy of Mendelian randomization studies, the causal relationship between high-density lipoprotein cholesterol (HDL-C) and coronary heart disease (CHD) is in doubt now; this might explain why plenty of HDL-targeted medications failed to protect patients from developing CHD.", [["coronary", "ANATOMY", 139, 147], ["heart", "ANATOMY", 148, 153], ["cholesterol", "CHEMICAL", 115, 126], ["HDL-C", "CHEMICAL", 128, 133], ["coronary heart disease", "DISEASE", 139, 161], ["CHD", "DISEASE", 163, 166], ["CHD", "DISEASE", 286, 289], ["cholesterol", "CHEMICAL", 115, 126], ["high-density lipoprotein cholesterol", "SIMPLE_CHEMICAL", 90, 126], ["HDL-C", "SIMPLE_CHEMICAL", 128, 133], ["coronary heart", "MULTI-TISSUE_STRUCTURE", 139, 153], ["HDL", "SIMPLE_CHEMICAL", 218, 221], ["patients", "ORGANISM", 261, 269], ["HDL", "PROTEIN", 128, 131], ["HDL", "PROTEIN", 218, 221], ["patients", "SPECIES", 261, 269], ["Mendelian randomization studies", "TEST", 25, 56], ["coronary heart disease (CHD)", "PROBLEM", 139, 167], ["HDL", "TREATMENT", 218, 221], ["targeted medications", "TREATMENT", 222, 242], ["CHD", "PROBLEM", 286, 289], ["coronary heart", "ANATOMY", 139, 153], ["disease", "OBSERVATION", 154, 161], ["CHD", "OBSERVATION", 286, 289]]], ["Meanwhile, we should keep in mind that just like any other newly presented method, Mendelian randomization has its own limitations yet to be uncovered [117\u2013121].Autopsies and biopsies ::: Recommendations and suggestions for solutionsMost of our current knowledge in Alzheimer, DM, appendicitis, and heart disease is the result of studies on autopsies and biopsies.", [["biopsies", "ANATOMY", 175, 183], ["heart", "ANATOMY", 299, 304], ["Alzheimer", "DISEASE", 266, 275], ["DM", "DISEASE", 277, 279], ["appendicitis", "DISEASE", 281, 293], ["heart disease", "DISEASE", 299, 312], ["biopsies", "TISSUE", 175, 183], ["heart", "ORGAN", 299, 304], ["biopsies", "CANCER", 355, 363], ["Mendelian randomization", "TREATMENT", 83, 106], ["biopsies", "TEST", 175, 183], ["Alzheimer", "PROBLEM", 266, 275], ["DM", "PROBLEM", 277, 279], ["appendicitis", "PROBLEM", 281, 293], ["heart disease", "PROBLEM", 299, 312], ["autopsies", "TEST", 341, 350], ["biopsies", "TEST", 355, 363], ["biopsies", "OBSERVATION", 175, 183], ["appendicitis", "OBSERVATION", 281, 293], ["heart", "ANATOMY", 299, 304], ["disease", "OBSERVATION", 305, 312]]], ["For example, the development of colon cancers from adenomas was not observed in leading colon cancer animal models [122, 123].Medical education ::: Recommendations and suggestions for solutionsAnimal labs should be eliminated from educational programs.", [["colon cancers", "ANATOMY", 32, 45], ["adenomas", "ANATOMY", 51, 59], ["colon cancer", "ANATOMY", 88, 100], ["colon cancers", "DISEASE", 32, 45], ["adenomas", "DISEASE", 51, 59], ["colon cancer", "DISEASE", 88, 100], ["colon cancers", "CANCER", 32, 45], ["adenomas", "CANCER", 51, 59], ["colon cancer", "CANCER", 88, 100], ["colon cancers", "PROBLEM", 32, 45], ["adenomas", "PROBLEM", 51, 59], ["leading colon cancer", "PROBLEM", 80, 100], ["Animal labs", "TEST", 193, 204], ["colon", "ANATOMY", 32, 37], ["cancers", "OBSERVATION", 38, 45], ["adenomas", "OBSERVATION", 51, 59], ["colon", "ANATOMY", 88, 93], ["cancer", "OBSERVATION", 94, 100]]], ["For example, American College of Surgeons (ACS) presented trauma man simulator to replace animals and human cadavers for the Advanced Trauma Life Support (ATLS) program [124\u2013126].Phase 0 studies: microdosing ::: Recommendations and suggestions for solutionsOne out of four drug development failures is because of pharmacokinetic issues such as penetration into the target organ or absorption; microdosing with sensitive tests could solve this problem and eliminate these failures, and help us to save our patients, our money, and innocent animals in labs [127\u2013129].", [["organ", "ANATOMY", 372, 377], ["ACS", "DISEASE", 43, 46], ["trauma", "DISEASE", 58, 64], ["Trauma", "DISEASE", 134, 140], ["man", "ORGANISM", 65, 68], ["human", "ORGANISM", 102, 107], ["organ", "ORGAN", 372, 377], ["patients", "ORGANISM", 505, 513], ["man", "SPECIES", 65, 68], ["human", "SPECIES", 102, 107], ["patients", "SPECIES", 505, 513], ["human", "SPECIES", 102, 107], ["human cadavers", "TREATMENT", 102, 116], ["the Advanced Trauma Life Support", "TREATMENT", 121, 153], ["four drug development failures", "PROBLEM", 268, 298], ["pharmacokinetic issues", "PROBLEM", 313, 335], ["microdosing", "TREATMENT", 393, 404], ["sensitive tests", "TEST", 410, 425], ["these failures", "PROBLEM", 465, 479], ["labs", "TEST", 550, 554], ["failures", "OBSERVATION", 290, 298]]], ["The results of microdosing studies showed 70% correspondence with the results from full-dose studies.", [["microdosing studies", "TEST", 15, 34], ["full-dose studies", "TEST", 83, 100]]], ["Nevertheless, like any other novel technique, there is a likelihood of publication bias in the published literature.ConclusionPPPM calls for a patient-tailored approach as choosing the right medication, the right dose at the right time point.", [["patient", "ORGANISM", 143, 150], ["patient", "SPECIES", 143, 150], ["a patient-tailored approach", "TREATMENT", 141, 168], ["the right medication", "TREATMENT", 181, 201], ["right", "ANATOMY_MODIFIER", 207, 212], ["right", "ANATOMY_MODIFIER", 225, 230]]], ["This approach may not be achieved unless taking into account clinical, pathological, environmental, and psychosocial characteristics of the patients.", [["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 140, 148], ["This approach", "TREATMENT", 0, 13]]], ["In order to accurately model the patients and make relevant predictions, it is necessary to reflect all complex characteristics of the patients into our models.", [["patients", "ORGANISM", 33, 41], ["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 33, 41], ["patients", "SPECIES", 135, 143]]], ["Unfortunately, none of the complexity, chronicity, age, comorbidities, sex, genetic similarity, and environmental factors has been appropriately modeled in most of the current animal models.", [["chronicity", "DISEASE", 39, 49], ["comorbidities", "PROBLEM", 56, 69], ["chronicity", "OBSERVATION_MODIFIER", 39, 49]]], ["Hence, current animal models should be extensively revised and/or replaced by novel surrogates to achieve this goal.ConclusionThere might be plenty of agents, potentially safe in humans, that were not studied in people due to observed toxicity in animals.", [["toxicity", "DISEASE", 235, 243], ["humans", "ORGANISM", 179, 185], ["people", "ORGANISM", 212, 218], ["humans", "SPECIES", 179, 185], ["people", "SPECIES", 212, 218], ["humans", "SPECIES", 179, 185], ["current animal models", "TREATMENT", 7, 28], ["agents", "TREATMENT", 151, 157], ["observed toxicity in animals", "PROBLEM", 226, 254]]], ["Also, there might be plenty of missed potential treatments which did not show efficacy in animals and hence never studied clinically; as mentioned above, plenty of currently approved treatments were delayed because of misleading animal models.", [["missed potential treatments", "TREATMENT", 31, 58], ["treatments", "TREATMENT", 183, 193], ["misleading animal models", "PROBLEM", 218, 242]]], ["Hence, we have to look back and re-evaluate hundreds of potential treatments.", [["potential treatments", "TREATMENT", 56, 76]]], ["Some agents might not show efficacy in animals or might be lethal for them while they are well tolerated in humans and could be curative.ConclusionUsing inappropriate animal models can hardly be accepted if we want to improve the system of healthcare in the future.", [["humans", "ORGANISM", 108, 114], ["humans", "SPECIES", 108, 114], ["humans", "SPECIES", 108, 114]]], ["The surrogates for animal models are gradually emerging and we have to take care that they are vigorously tested and, if passed, used in predictive modeling, disease modeling, and therapy modeling.Study limitationsIn order to be as comprehensive as possible and cover a wide range of diseases, it was not possible to systematically review all the literature.", [["disease modeling", "PROBLEM", 158, 174], ["therapy modeling", "TREATMENT", 180, 196], ["Study limitations", "TEST", 197, 214], ["diseases", "PROBLEM", 284, 292]]], ["With plenty of keywords and diversity of discussed studies, it was inevitable to apply a narrative approach rather than a systematic approach to review the literature.", [["studies", "TEST", 51, 58], ["a narrative approach", "TREATMENT", 87, 107], ["a systematic approach", "TREATMENT", 120, 141]]], ["A narrative literature review can often include an element of selection bias.Study limitationsPlenty of suggested surrogates are still in their embryonic period and need further investigation.", [["embryonic", "ANATOMY", 144, 153], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 144, 153], ["Study limitations", "TEST", 77, 94], ["further investigation", "TEST", 170, 191]]]], "3907d9387d68b9df0359b4cd597389133e12461f": [["23Early detection of cancer often leads to better survival (1), because pre-malignant lesions and 24 early stage tumors can be more effectively treated (2).", [["cancer", "ANATOMY", 21, 27], ["pre-malignant lesions", "ANATOMY", 72, 93], ["tumors", "ANATOMY", 113, 119], ["cancer", "DISEASE", 21, 27], ["tumors", "DISEASE", 113, 119], ["cancer", "CANCER", 21, 27], ["pre-malignant lesions", "CANCER", 72, 93], ["tumors", "CANCER", 113, 119], ["cancer", "PROBLEM", 21, 27], ["pre-malignant lesions", "PROBLEM", 72, 93], ["24 early stage tumors", "PROBLEM", 98, 119], ["cancer", "OBSERVATION", 21, 27], ["pre-malignant", "OBSERVATION_MODIFIER", 72, 85], ["lesions", "OBSERVATION", 86, 93], ["24 early", "OBSERVATION_MODIFIER", 98, 106], ["stage", "OBSERVATION_MODIFIER", 107, 112], ["tumors", "OBSERVATION", 113, 119]]], ["Most pre-malignant lesions amenable to 25 early detection rely on targeted sampling and show only minor tissue changes on pathology as-26 sessment (3-5).", [["pre-malignant lesions", "ANATOMY", 5, 26], ["tissue", "ANATOMY", 104, 110], ["pre-malignant lesions", "CANCER", 5, 26], ["tissue", "TISSUE", 104, 110], ["Most pre-malignant lesions", "PROBLEM", 0, 26], ["targeted sampling", "TEST", 66, 83], ["minor tissue changes", "PROBLEM", 98, 118], ["pathology", "TEST", 122, 131], ["pre-malignant", "OBSERVATION_MODIFIER", 5, 18], ["lesions", "OBSERVATION", 19, 26], ["minor", "OBSERVATION_MODIFIER", 98, 103], ["tissue", "OBSERVATION", 104, 110]]], ["In addition, pathology procedures often involve laborious and time-consuming 27 steps which can lead to errors and adversely affect patient care (6).", [["patient", "ORGANISM", 132, 139], ["patient", "SPECIES", 132, 139], ["pathology procedures", "TEST", 13, 33]]], ["Recent developments in Ar- 28 tificial Intelligence (AI) have achieved excellent performance on diagnostic tasks (7-9).", [["Recent developments in Ar", "PROBLEM", 0, 25], ["diagnostic tasks", "TEST", 96, 112]]], ["The design of a clinical 31 decision support system needs to balance its performance against workload reduction and po-32 tential economic impact.", [["a clinical 31 decision support system", "TREATMENT", 14, 51], ["workload reduction", "TREATMENT", 93, 111], ["po", "TEST", 116, 118]]], ["Replacing pathologists entirely could lead to substantial workload 33 reduction, but such an approach would only be viable if performance remains comparable to 34 that of human experts.", [["human", "ORGANISM", 171, 176], ["human", "SPECIES", 171, 176], ["human", "SPECIES", 171, 176], ["substantial workload 33 reduction", "TREATMENT", 46, 79]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 17, 2020.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["Next, patient-level counts were compared to endoscopy ground truth for detecting BE on 149 the internal validation set (Methods).", [["BE", "CHEMICAL", 81, 83], ["patient", "ORGANISM", 6, 13], ["patient", "SPECIES", 6, 13], ["patient-level counts", "TEST", 6, 26], ["endoscopy", "TEST", 44, 53]]], ["This ground truth was defined according to the Prague 150 criteria (Methods) with confirmed IM on endoscopy biopsies (30).", [["endoscopy biopsies", "TEST", 98, 116]]], ["To calculate sensitivity and 151 specificity for the fully automated method on the internal validation cohort, we used operating 152 points determined on the calibration cohort (Table S2) CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted July 17, 2020. . https://doi.org/10.1101/2020.07.16.20154732 doi: medRxiv preprint We then explored whether a different modelling approach based on established decision path-164 ways could boost performance.", [["CC", "CHEMICAL", 188, 190], ["sensitivity", "TEST", 13, 24], ["medRxiv", "TREATMENT", 552, 559], ["a different modelling approach", "TREATMENT", 594, 624], ["med", "ANATOMY", 290, 293]]], ["Both approaches use the same 166 patient-level aggregations as input, but their outputs are different: the fully automated approach 167 tries to directly mimic pathology assessment by classifying patients as positive or negative for 168 BE.", [["BE", "CHEMICAL", 237, 239], ["patient", "ORGANISM", 33, 40], ["patients", "ORGANISM", 196, 204], ["patient", "SPECIES", 33, 40], ["patients", "SPECIES", 196, 204], ["pathology assessment", "TEST", 160, 180]]], ["In contrast, the triage approach defines different quality and diagnostic confidence classes 169 to select challenging patient samples for manual review.", [["patient", "ORGANISM", 119, 126], ["patient", "SPECIES", 119, 126], ["manual review", "TEST", 139, 152]]], ["Although it cannot reduce workload as 170 much as a fully automated approach, a triage approach keeps sample stratification more inter-171 pretable and transparent.", [["a triage approach", "TEST", 78, 95], ["sample stratification", "TEST", 102, 123]]], ["172 We first selected deep learning architectures and defined cut-offs for different quality and gastric-type columnar epithelium on H&E were classified as no confidence, low confidence, or 178 high confidence ( Figure S6a , Table S4 ).", [["gastric-type columnar epithelium", "ANATOMY", 97, 129], ["gastric-type columnar epithelium", "TISSUE", 97, 129], ["deep learning architectures", "TREATMENT", 22, 49], ["gastric", "ANATOMY", 97, 104], ["columnar epithelium", "OBSERVATION", 110, 129]]], ["For diagnostic confidence classes, the number of tiles 179 detected with TFF3-positive goblet cells were classified as high confidence negative, low confi-180 dence equivocal, or high confidence positive ( Figure S6b , Table S4 ).", [["goblet cells", "ANATOMY", 87, 99], ["TFF3", "GENE_OR_GENE_PRODUCT", 73, 77], ["goblet cells", "CELL", 87, 99], ["TFF3", "PROTEIN", 73, 77], ["positive goblet cells", "CELL_TYPE", 78, 99], ["TFF3", "TEST", 73, 77], ["high confidence positive", "PROBLEM", 179, 203], ["goblet cells", "OBSERVATION", 87, 99]]], ["On the internal validation 181 cohort, we observed a visual agreement between these confidence classes and pathology and 182 endoscopy ground truths ( Figure 3 , Table S5 ).", [["pathology", "TEST", 107, 116], ["endoscopy", "TEST", 125, 134]]], ["183 We then combined the quality and diagnostic classes into eight triage classes of varying 184 priority for manual review (Figure 4a ).", [["manual review", "TEST", 110, 123]]], ["The relative priority of each class was determined by 185 expert pathologists: Cases with low confidence in sample quality (none or few columnar ep-186 ithelium detected on H&E) or low confidence in diagnosis (few goblet cells detected on TFF3) 18710.", [["sample", "ANATOMY", 108, 114], ["goblet cells", "ANATOMY", 214, 226], ["goblet cells", "CELL", 214, 226], ["TFF3", "GENE_OR_GENE_PRODUCT", 239, 243], ["goblet cells", "CELL_TYPE", 214, 226], ["TFF3", "PROTEIN", 239, 243], ["sample quality", "TEST", 108, 122], ["columnar ep", "TEST", 136, 147], ["few goblet cells", "PROBLEM", 210, 226]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)10The copyright holder for this preprint this version posted July 17, 2020.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["Figure 3 : Application of quality control and diagnostic confidence class scheme to internal validation cohort. a Quality ground truth by pathologist from Cytosponge (top) compared with number of detected columnar epithelium (CE) tiles on H&E detected by VGG-16 (bottom). b Diagnosis ground truth by pathologist from Cytosponge (top), Endoscopy (with confirmed IM on biopsy) ground truth (middle) compared with number of detected TFF3-positive tiles on TFF3 detected by ResNet-18 (bottom) / eqv. = equivocal.11.", [["columnar epithelium", "ANATOMY", 205, 224], ["VGG-16", "CHEMICAL", 255, 261], ["columnar epithelium", "TISSUE", 205, 224], ["TFF3", "GENE_OR_GENE_PRODUCT", 430, 434], ["TFF3", "GENE_OR_GENE_PRODUCT", 453, 457], ["TFF3", "PROTEIN", 430, 434], ["TFF3", "PROTEIN", 453, 457], ["Application of quality control", "TREATMENT", 11, 41], ["internal validation cohort", "TREATMENT", 84, 110], ["columnar epithelium (CE) tiles", "PROBLEM", 205, 235], ["H&E", "TEST", 239, 242], ["VGG", "TEST", 255, 258], ["Endoscopy", "TEST", 335, 344], ["biopsy", "TEST", 367, 373], ["TFF3", "TEST", 430, 434], ["TFF3", "TEST", 453, 457], ["ResNet", "TEST", 470, 476], ["columnar epithelium", "OBSERVATION", 205, 224], ["ground truth", "OBSERVATION", 284, 296]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)11The copyright holder for this preprint this version posted July 17, 2020. . https://doi.org/10.1101/2020.07.16.20154732 doi: medRxiv preprint negative evidence.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["In our internal validation cohort, we find that only 13.0% of patients fall 189 into the triage classes with high priority (4 and 5), while 87.0% fall into the other six classes 190 (Figure 4a ).", [["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70]]], ["191 We next asked which classes can be substituted by automated review while retaining the 192 accuracy of full manual review by a human pathologist (sensitivity: 81.7%; specificity: 92.7%).", [["human", "ORGANISM", 131, 136], ["human", "SPECIES", 131, 136], ["human", "SPECIES", 131, 136], ["sensitivity", "TEST", 150, 161], ["specificity", "TEST", 170, 181]]], ["193 We applied a cumulative substitution scheme and started by substituting class 1 with automated 194 review, then classes 1 and 2, then classes 1, 2, and 3, and so on.", [["a cumulative substitution scheme", "TREATMENT", 15, 47]]], ["In the validation cohort, we 195 found that sensitivity and specificity remain stable if classes 1, 2, and 3 are substituted, but Our case-control cohort is not representative of a real-world population eligible for Cytosponge-208 TFF3 testing.", [["TFF3", "GENE_OR_GENE_PRODUCT", 231, 235], ["TFF3", "PROTEIN", 231, 235], ["sensitivity", "TEST", 44, 55], ["specificity", "TEST", 60, 71], ["Cytosponge", "TEST", 216, 226], ["TFF3 testing", "TEST", 231, 243]]], ["In our internal validation set we had a disease prevalence of 50.0%, while the 209 prevalence expected in a real-world population with GERD symptoms ranges from 3.0% to 210 7.5% (17, 31-33).", [["GERD", "DISEASE", 135, 139], ["a disease prevalence", "PROBLEM", 38, 58], ["GERD symptoms", "PROBLEM", 135, 148]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)11The copyright holder for this preprint this version posted July 17, 2020.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["Figure 4 : Triage-driven approach with incremental triage class substitution scheme on internal validation set a Table of quality control and diagnosis classes.", [["incremental triage class substitution scheme", "TREATMENT", 39, 83], ["internal validation", "TREATMENT", 87, 106]]], ["Each class has been assigned a qualitative priority for manual review.", [["manual review", "TEST", 56, 69]]], ["Asterisk (*): includes combination of no confidence (quality control) and high confidence positive (diagnosis) despite minimal likelihood of occurrence. b Cumulative substitution scheme starting with fully manual review, followed by substitution with automated review of class no. 1, then 1 and 2, etc. Red rectangle indicates a drop of performance at substitution stage. c Cumulative substitution scheme starting with fully manual review, followed by substitution with automated review of class no. 8, then 8 and 7, etc. Red rectangle indicates a drop of performance at substitution stage.13.", [["high confidence positive", "PROBLEM", 74, 98], ["b Cumulative substitution scheme", "TREATMENT", 153, 185], ["Red rectangle", "TEST", 303, 316], ["a drop of performance at substitution stage", "PROBLEM", 327, 370], ["Cumulative substitution scheme", "TREATMENT", 374, 404], ["Red rectangle", "TEST", 522, 535], ["a drop of performance at substitution stage", "PROBLEM", 546, 589], ["rectangle", "OBSERVATION_MODIFIER", 307, 316], ["drop", "OBSERVATION_MODIFIER", 329, 333], ["rectangle", "OBSERVATION_MODIFIER", 526, 535], ["drop", "OBSERVATION_MODIFIER", 548, 552]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)13The copyright holder for this preprint this version posted July 17, 2020. . https://doi.org/10.1101/2020.07.16.20154732 doi: medRxiv preprint the amount of sampled cellular material and the resulting sample confidence, which can vary 212 widely and might improve with future refinements of the device administration procedure.213To understand how our results generalize, we devised a simulation approach to vary how (determined by quality control and diagnostic class: 2 and 8) and lower sample confidence (1, 221 3, 4, 5, 6, and 7).", [["cellular", "ANATOMY", 365, 373], ["CC", "CHEMICAL", 0, 2], ["cellular", "CELL", 365, 373], ["medRxiv", "TREATMENT", 326, 333], ["the device administration procedure", "TREATMENT", 491, 526], ["med", "ANATOMY", 102, 105]]], ["We then modified the proportion of high confidence samples and inversely 222 adapted the proportion of lower confidence samples within a range from -25% to 25%.223Over a fine grid of varying disease prevalence and changes in sample confidence, we ob-224 served a negative impact of decreasing cohort BE prevalence and a positive impact of sample 225 confidence on the potential workload reduction (Figure 5a ).", [["BE", "CHEMICAL", 300, 302], ["varying disease prevalence", "PROBLEM", 183, 209], ["the potential workload reduction", "TREATMENT", 364, 396], ["high", "OBSERVATION_MODIFIER", 35, 39], ["lower", "OBSERVATION_MODIFIER", 103, 108], ["varying", "OBSERVATION_MODIFIER", 183, 190], ["disease", "OBSERVATION", 191, 198]]], ["According to this simulation, in 226 a realistic cohort with a BE prevalence of 7%, we would still be able to reduce the pathology 227 workload by 57%.", [["BE", "CHEMICAL", 63, 65]]], ["In order to retain the same workload reduction we observed in the validation 228 cohort, the proportion of samples with high confidence in a realistic cohort would need to be 229 increased by 15%.", [["samples", "ANATOMY", 107, 114], ["the same workload reduction", "TREATMENT", 19, 46]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)223The copyright holder for this preprint this version posted July 17, 2020.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["Li ne of eq ua l w or kl oa d re du ct io n Figure 5 : Triage model applied to external validation cohort and simulation of cohort variation Simulation of changes in cohort prevalence of BE and sample confidence with impact on workload reduction.", [["BE", "CHEMICAL", 187, 189], ["Li ne", "TEST", 0, 5], ["external validation cohort", "TREATMENT", 79, 105], ["workload reduction", "TREATMENT", 227, 245]]], ["Every contour line (blue) represents the same level of workload reduction as indicated by the percentages.", [["Every contour line (blue", "TREATMENT", 0, 24], ["workload reduction", "TREATMENT", 55, 73], ["contour line", "OBSERVATION", 6, 18]]], ["Solid black lines indicate the workload reduction of the validation cohort.", [["Solid black lines", "CELL", 0, 17], ["Solid black lines", "CELL_LINE", 0, 17], ["Solid black lines", "TREATMENT", 0, 17], ["the workload reduction", "TREATMENT", 27, 49], ["the validation cohort", "TREATMENT", 53, 74], ["black lines", "OBSERVATION", 6, 17], ["reduction", "OBSERVATION_MODIFIER", 40, 49]]], ["The dotted yellow line illustrates the workload reduction of a realistic primary care referral cohort (with 7% prevalence) with no change in sample confidence classes (lower yellow marker) and the confidence change required to match the same amount of workload reduction as in the validation cohort (upper yellow marker).", [["The dotted yellow line", "TREATMENT", 0, 22], ["the confidence change", "PROBLEM", 193, 214], ["workload reduction", "TREATMENT", 252, 270], ["yellow line", "OBSERVATION", 11, 22], ["no", "UNCERTAINTY", 128, 130], ["change", "OBSERVATION_MODIFIER", 131, 137]]], ["The results from the external validation cohort are shown in red.15.", [["the external validation cohort", "TREATMENT", 17, 47]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 17, 2020. . https://doi.org/10.1101/2020.07.16.20154732 doi: medRxiv preprint described in the previous section, we used manual pathologist reviews for samples that fell into 236 triage classes 4, 5 and 6.", [["samples", "ANATOMY", 414, 421], ["CC", "CHEMICAL", 0, 2], ["manual pathologist reviews", "TEST", 383, 409], ["samples", "TEST", 414, 421], ["med", "ANATOMY", 102, 105]]], ["In the BEST3 trial, endoscopy data was only available for positive 237 Cytosponge patients and those who had Barrett's diagnosed at follow-up as a result of standard 238 of care.", [["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["endoscopy data", "TEST", 20, 34], ["Barrett's", "PROBLEM", 109, 118]]], ["In addition, the trial was not designed to investigate sensitivity or specificity but positive 239 predictive value (PPV) instead.", [["sensitivity", "TEST", 55, 66], ["specificity", "TEST", 70, 81], ["PPV", "TEST", 117, 120]]], ["We also calculated the negative predictive value (NPV) based CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 17, 2020. . https://doi.org/10.1101/2020.07.16.20154732 doi: medRxiv preprint(which was not certified by peer review)We have presented a triage-driven approach that analyses samples of the Cytosponge-TFF3 test 254 using deep learning for the early detection of esophageal cancer.", [["esophageal cancer", "ANATOMY", 584, 601], ["esophageal cancer", "DISEASE", 584, 601], ["Cytosponge-TFF3", "GENE_OR_GENE_PRODUCT", 512, 527], ["esophageal cancer", "CANCER", 584, 601], ["Cytosponge-TFF3 test 254", "DNA", 512, 536], ["the Cytosponge", "TEST", 508, 522], ["TFF3 test", "TEST", 523, 532], ["esophageal cancer", "PROBLEM", 584, 601], ["med", "ANATOMY", 163, 166], ["esophageal", "ANATOMY", 584, 594], ["cancer", "OBSERVATION", 595, 601]]], ["Our approach combines quality 255 control and diagnostic metrics of pathology slides to stratify patients into 8 triage classes which 256 determine whether a patient sample requires manual or if automated review would suffice.257For the analysis of Cytosponge-TFF3 samples, our triaging approach has several benefits: 258 We are able to substantially reduce workload and match the sensitivity and specificity of expert 259 pathologists.", [["patients", "ORGANISM", 97, 105], ["patient", "ORGANISM", 158, 165], ["TFF3", "GENE_OR_GENE_PRODUCT", 260, 264], ["TFF3", "PROTEIN", 260, 264], ["patients", "SPECIES", 97, 105], ["patient", "SPECIES", 158, 165], ["pathology slides", "TEST", 68, 84], ["the analysis", "TEST", 233, 245], ["Cytosponge", "TEST", 249, 259], ["the sensitivity", "TEST", 377, 392]]], ["In our internal validation cohort, fully manual review by a pathologist achieves 260 81.7% sensitivity and 92.7% specificity.", [["sensitivity", "TEST", 91, 102]]], ["In a fully automated approach, we observed a sensitiv-261 ity of 72.6% and a specificity of 93.1%.", [["a sensitiv", "TEST", 43, 53], ["a specificity", "TEST", 75, 88]]], ["With our triage-driven approach, we demonstrate that 262 up to 66% of cases can be reviewed automatically while achieving a sensitivity of 82.5% and 263 specificity of 92.7%, a performance marginally superior to fully manual review by pathologists.", [["a sensitivity", "TEST", 122, 135], ["specificity", "TEST", 153, 164]]], ["In this more realistic cohort, 57.41% workload for the pathologists would have been reduced.269These results ( Figure 5 ) have several implications: First, a fully automated review would re-270 duce sensitivity (at fixed specificity) and therefore suffer from a loss of clinical utility.", [["a loss of clinical utility", "PROBLEM", 260, 286], ["reduced", "OBSERVATION_MODIFIER", 84, 91]]], ["Second, 271 while a triage-driven approach is not able to reduce workload as much as a fully automated ap-272 proach, the described triage classes provide a logical way for stage-wise clinical adoption and 273 performance testing in routine practice.274Another benefit of our approach is that we were able to directly adopt heuristics applied 275 by pathologists familiar with Cytosponge-TFF3 samples in our algorithmic design process.", [["TFF3", "GENE_OR_GENE_PRODUCT", 388, 392], ["ap-272 proach", "DNA", 103, 116], ["TFF3", "PROTEIN", 388, 392], ["a triage", "TEST", 18, 26], ["performance testing", "TEST", 210, 229]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 17, 2020. . https://doi.org/10.1101/2020.07.16.20154732 doi: medRxiv preprint a result, our approach demonstrates traceability and interpretability (8): First, we mimicked 277 the screening process of samples observed by expert pathologists by replicating their decision-278 making scheme (Figure 1c) .", [["samples", "ANATOMY", 463, 470], ["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["Second, the saliency maps we generated from deep learning mod-279 els to visualize learned features in the pathology images show strong agreement with manual 280 landmarks placed by pathologists ( Figure S2 ).281As a further benefit, our triage approach achieves strong performance from only 287 sam- is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 17, 2020. . https://doi.org/10.1101/2020.07.16.20154732 doi: medRxiv preprint assurance.", [["mod-279 els", "DNA", 58, 69], ["the saliency maps", "TEST", 8, 25], ["the pathology images", "TEST", 103, 123], ["medRxiv preprint assurance", "TREATMENT", 560, 586], ["med", "ANATOMY", 339, 342]]], ["In future work, we plan to test whether the superiority of the triage-driven approach 303 over fully manual pathologist review will generalize by incorporating multi-centre data from 304 ongoing and future Cytosponge-TFF3 studies to evaluate this effect more extensively.", [["Cytosponge-TFF3", "GENE_OR_GENE_PRODUCT", 206, 221], ["TFF3", "PROTEIN", 217, 221], ["the triage", "TEST", 59, 69], ["future Cytosponge", "TEST", 199, 216], ["TFF3 studies", "TEST", 217, 229]]], ["For example, 306 instead of using a transfer learning model based on pre-training with a primary dataset, we could 307 train a model from scratch, which has proven to improve results in some CNN applications (37).308In addition, the tile size needs further investigation because it determines the receptive field in In summary, our triage approach differs from previous applications of deep learning to medi-324 cal images (7,34) which used fully automated approaches on extremely large datasets.", [["a transfer learning model", "TREATMENT", 34, 59], ["further investigation", "TEST", 249, 270], ["scratch", "OBSERVATION", 138, 145], ["size", "OBSERVATION_MODIFIER", 238, 242]]], ["We show 325 that for a modest dataset size, leveraging existing heuristics of pathologist decision-making in a 32619.", [["size", "OBSERVATION_MODIFIER", 38, 42]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 17, 2020. . https://doi.org/10.1101/2020.07.16.20154732 doi: medRxiv preprint generalises well to an independent validation cohort.", [["CC", "CHEMICAL", 0, 2], ["medRxiv", "TREATMENT", 323, 330], ["med", "ANATOMY", 102, 105]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 17, 2020.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 17, 2020.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["All slides were annotated using the existing patient-level ground truth data for comparison.", [["patient", "ORGANISM", 45, 52], ["patient", "SPECIES", 45, 52]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 17, 2020. . https://doi.org/10.1101/2020.07.16.20154732 doi: medRxiv preprint(which was not certified by peer review)In order to compare the performance of all six deep learning architectures, we calculated class-450 specific performance in the quality control and diagnosis frameworks (Table S1 ).", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["To obtain 451 these numbers, we selected the epochs with the best weighted accuracy score on the develop- is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 17, 2020. .", [["med", "ANATOMY", 144, 147]]], ["We generated saliency maps for both models trained on H&E and TFF3, respectively.", [["H&E", "GENE_OR_GENE_PRODUCT", 54, 57], ["TFF3", "GENE_OR_GENE_PRODUCT", 62, 66], ["H&E", "DNA", 54, 57], ["TFF3", "PROTEIN", 62, 66], ["saliency maps", "TEST", 13, 26]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 17, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 17, 2020.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105], ["med", "ANATOMY", 310, 313]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 17, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 17, 2020.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105], ["med", "ANATOMY", 310, 313]]], ["(Table S5) .569The two operating points for quality control and diagnosis resulted in three tiers per frame- CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 17, 2020. . https://doi.org/10.1101/2020.07.16.20154732 doi: medRxiv preprint automated review were calculated and compared against the previous substitution steps.", [["med", "ANATOMY", 211, 214]]], ["The 589 substitution scheme was applied starting from both ends of the triage class list.", [["The 589 substitution scheme", "TREATMENT", 0, 27]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 17, 2020. . https://doi.org/10.1101/2020.07.16.20154732 doi: medRxiv preprint CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 17, 2020.41.", [["CC", "CHEMICAL", 0, 2], ["CC", "CHEMICAL", 340, 342], ["med", "ANATOMY", 102, 105], ["med", "ANATOMY", 442, 445]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 17, 2020.42.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 17, 2020.43.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 17, 2020.44.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 17, 2020.45.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 17, 2020.46.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 17, 2020.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["1, 2, 3 1, 2, 3, 4 1, 2, 3, 4, 5 1, 2, 3, 4, 5, 6 1, 2, 3, 4, 5, 6, 7 1, 2, 3, 4, 5, 6, 7 Figure S7 : Performance of semi-automated, triage-driven model on external validation cohort a Cumulative substitution scheme starting with fully manual review, followed by substitution with automated review of class no. 1, then 1 and 2, etc. b Cumulative substitution scheme starting with fully manual review, followed by substitution with automated review of class no. 8, then 8 and 7, etc.47.", [["triage", "TEST", 133, 139], ["external validation", "TREATMENT", 156, 175], ["a Cumulative substitution scheme", "TREATMENT", 183, 215], ["b Cumulative substitution scheme", "TREATMENT", 333, 365], ["4 1", "ANATOMY_MODIFIER", 17, 20]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)47The copyright holder for this preprint this version posted July 17, 2020.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["Table S1 : Tile-level precision and recall for all classes from H&E and TFF3 models.", [["TFF3", "GENE_OR_GENE_PRODUCT", 72, 76], ["TFF3", "PROTEIN", 72, 76]]], ["This data is derived from the tiles in the development set.", [["This data", "TEST", 0, 9]]], ["(DenseNet = DenseNet-121, Inception = Inception v3, ResNet = ResNet-18, VGG = VGG-16).", [["ResNet-18", "CHEMICAL", 61, 70], ["VGG-16", "CHEMICAL", 78, 84], ["Net", "TEST", 55, 58], ["ResNet", "TEST", 61, 67], ["VGG", "TEST", 72, 75], ["VGG", "TEST", 78, 81]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)48The copyright holder for this preprint this version posted July 17, 2020.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["Table S2 : Individual probability threshold calibration with associated performance based on differential ROC analysis for quality control and diagnosis.", [["differential ROC analysis", "TEST", 93, 118]]], ["The AUC for quality control relates to the performance on the calibration cohort at the given probability threshold for individual tiles containing columnar epithelium on H&E. The AUC for diagnosis relates to the performance on the calibration cohort at the given probability threshold for individual tiles containing positive goblet cells on TFF3.", [["columnar epithelium", "ANATOMY", 148, 167], ["goblet cells", "ANATOMY", 327, 339], ["columnar epithelium", "TISSUE", 148, 167], ["goblet cells", "CELL", 327, 339], ["TFF3", "GENE_OR_GENE_PRODUCT", 343, 347], ["positive goblet cells", "CELL_TYPE", 318, 339], ["TFF3", "PROTEIN", 343, 347], ["The AUC", "TEST", 0, 7], ["the calibration cohort", "TREATMENT", 58, 80], ["columnar epithelium on H&E", "PROBLEM", 148, 174], ["the calibration cohort", "TREATMENT", 228, 250], ["individual tiles", "PROBLEM", 290, 306], ["positive goblet cells", "PROBLEM", 318, 339], ["TFF3", "TEST", 343, 347], ["columnar epithelium", "OBSERVATION", 148, 167], ["positive goblet cells", "OBSERVATION", 318, 339]]], ["Sensitivity is based on a fixed value of specificity derived from the pathologist performance on the calibration cohort.", [["the calibration cohort", "TREATMENT", 97, 119]]], ["The tile number threshold is the resulting cutoff from the fixed specificity.49.", [["cutoff", "OBSERVATION", 43, 49]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)49The copyright holder for this preprint this version posted July 17, 2020. .", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["Table S3 : Performance of all architectures after application on the validation cohort.", [["all architectures", "TREATMENT", 26, 43], ["the validation cohort", "TREATMENT", 65, 86]]], ["Sensitivities or specificities were not determined due to irrelevance in the fully automated model approach.", [["Sensitivities", "TEST", 0, 13], ["specificities", "TEST", 17, 30]]], ["Diagnosis models relied on thresholds determined on the calibration cohort.50.", [["the calibration cohort", "TREATMENT", 52, 74]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)50The copyright holder for this preprint this version posted July 17, 2020.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["Table S4 : Characteristics of patients in quality control and diagnosis classes from calibration cohort.", [["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38]]], ["For each of the three quality control and diagnosis classes, the number of patients within the class and the paired ground truth is shown.", [["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["ground truth", "OBSERVATION", 116, 128]]], ["Table S5 : Characteristics of patients in quality control and diagnosis classes from validation cohort.", [["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38]]], ["For each of the three quality control and diagnosis classes, the number of patients within the class and the paired ground truth is shown.51.", [["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["ground truth", "OBSERVATION", 116, 128]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)51The copyright holder for this preprint this version posted July 17, 2020.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["Table S6 : Characteristics of patients in quality control and diagnosis classes from external validation cohort.", [["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["external validation cohort", "TREATMENT", 85, 111]]], ["For each of the three quality control and diagnosis classes, the number of patients within the class and the paired ground truth is shown.52.", [["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["ground truth", "OBSERVATION", 116, 128]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)52The copyright holder for this preprint this version posted July 17, 2020. . https://doi.org/10.1101/2020.07.16.20154732 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["medRxiv", "TREATMENT", 326, 333], ["med", "ANATOMY", 102, 105]]]], "d4bbd2413751fdb6e86c5f206aebd5820ecfe52d": [["Importance Statement: 28 The analysis of polymerase chain reaction amplicons derived from biological samples is the most 29 common modern method for detection and classification of infecting viral agents, such as 30 Coronaviruses .", [["samples", "ANATOMY", 101, 108], ["The analysis", "TEST", 25, 37], ["polymerase chain reaction amplicons", "PROBLEM", 41, 76], ["biological samples", "TEST", 90, 108], ["infecting viral agents", "TREATMENT", 181, 203], ["infecting viral agents", "OBSERVATION", 181, 203]]], ["Recent updates to the official standard for taxonomic classification of Coronaviruses, 31 however, may leave researchers unsure as to whether the viral sequences they obtain by these 32 methods can be classified into specific viral taxa due to variations in the sequences when compared 33 to type strains.", [["viral sequences", "DNA", 146, 161], ["Coronaviruses", "PROBLEM", 72, 85], ["the viral sequences", "TEST", 142, 161], ["the sequences", "TEST", 258, 271], ["type strains", "PROBLEM", 292, 304]]], ["To 35 assist in this, we also provide the R package 'MyCoV' which classifies user generated sequences.", [["the R package 'MyCoV'", "TREATMENT", 38, 59]]], ["36 the family Coronaviridae into two subfamilies -the amphibian-infecting Letovirinae, and 62", [["Letovirinae", "ORGANISM", 74, 85]]]], "e0d0ceb2658c588ef2f3549f2b9a928b441d94a6": [["IntroductionPorcine deltacoronavirus (PDCoV) is an emerging swine enteropathogenic coronavirus (CoV) belonging to the genus Deltacoronavirus of the family Coronaviridae within the order Nidovirales 1-4 .", [["deltacoronavirus", "CHEMICAL", 20, 36], ["PDCoV", "CHEMICAL", 38, 43], ["swine enteropathogenic coronavirus", "DISEASE", 60, 94], ["deltacoronavirus", "GENE_OR_GENE_PRODUCT", 20, 36], ["PDCoV", "GENE_OR_GENE_PRODUCT", 38, 43], ["swine enteropathogenic coronavirus", "ORGANISM", 60, 94], ["CoV", "ORGANISM", 96, 99], ["swine enteropathogenic coronavirus", "SPECIES", 60, 94], ["PDCoV", "SPECIES", 38, 43], ["swine enteropathogenic coronavirus", "SPECIES", 60, 94], ["CoV", "SPECIES", 96, 99], ["IntroductionPorcine deltacoronavirus (PDCoV", "TREATMENT", 0, 43], ["an emerging swine enteropathogenic coronavirus", "PROBLEM", 48, 94]]], ["Like other CoVs, PDCoV is an enveloped virus that contains positive, singlestranded genomic RNA 5, 6 .", [["PDCoV", "CHEMICAL", 17, 22], ["CoVs", "GENE_OR_GENE_PRODUCT", 11, 15], ["PDCoV", "GENE_OR_GENE_PRODUCT", 17, 22], ["CoVs", "DNA", 11, 15], ["PDCoV", "DNA", 17, 22], ["other CoVs", "PROBLEM", 5, 15], ["PDCoV", "TREATMENT", 17, 22], ["an enveloped virus", "PROBLEM", 26, 44], ["CoVs", "OBSERVATION", 11, 15], ["enveloped", "OBSERVATION_MODIFIER", 29, 38], ["virus", "OBSERVATION", 39, 44], ["positive", "OBSERVATION_MODIFIER", 59, 67]]], ["PDCoV was first identified in 2012 during molecular surveillance of CoVs in mammals and birds in Hong Kong 6 .", [["CoVs", "CANCER", 68, 72], ["PDCoV", "SPECIES", 0, 5], ["PDCoV", "TREATMENT", 0, 5]]], ["The first PDCoV outbreak was reported in 2014 in the United States 7 , causing severe diarrhea, vomiting, and mortality in piglets 3, 4, 8, 9 .", [["diarrhea", "DISEASE", 86, 94], ["vomiting", "DISEASE", 96, 104], ["severe diarrhea", "PROBLEM", 79, 94], ["vomiting", "PROBLEM", 96, 104], ["mortality in piglets", "PROBLEM", 110, 130], ["severe", "OBSERVATION_MODIFIER", 79, 85], ["diarrhea", "OBSERVATION", 86, 94]]], ["Thereafter, PDCoV was also detected in China 10-13 , Canada, South Korea 14, 15 , Lao People's Democratic Republic, Thailand 16 , and Vietnam 17, 18 , gaining considerable attention [19] [20] [21] .IntroductionIn general, CoVs have a limited host range and tissue tropism.", [["tissue", "ANATOMY", 257, 263], ["PDCoV", "GENE_OR_GENE_PRODUCT", 12, 17], ["CoVs", "GENE_OR_GENE_PRODUCT", 222, 226], ["tissue", "TISSUE", 257, 263], ["People", "SPECIES", 86, 92], ["tissue tropism", "PROBLEM", 257, 271]]], ["The interaction between CoV spike (S) proteins and specific cellular receptors on host cell surfaces mediates viral attachment and fusion of viral and cellular membranes, playing a vital role in successful infection in the host [22] [23] [24] .", [["cellular", "ANATOMY", 60, 68], ["cell surfaces", "ANATOMY", 87, 100], ["cellular membranes", "ANATOMY", 151, 169], ["infection", "DISEASE", 206, 215], ["CoV spike (S)", "GENE_OR_GENE_PRODUCT", 24, 37], ["cellular", "CELL", 60, 68], ["host cell", "CELL", 82, 91], ["cellular membranes", "CELLULAR_COMPONENT", 151, 169], ["CoV spike (S) proteins", "PROTEIN", 24, 46], ["cellular receptors", "PROTEIN", 60, 78], ["The interaction between CoV spike (S) proteins", "PROBLEM", 0, 46], ["specific cellular receptors", "PROBLEM", 51, 78], ["host cell surfaces", "TREATMENT", 82, 100], ["viral attachment", "PROBLEM", 110, 126], ["viral and cellular membranes", "PROBLEM", 141, 169], ["successful infection", "PROBLEM", 195, 215], ["cellular receptors", "OBSERVATION", 60, 78], ["host cell", "OBSERVATION_MODIFIER", 82, 91], ["viral attachment", "OBSERVATION", 110, 126], ["cellular membranes", "OBSERVATION", 151, 169], ["infection", "OBSERVATION", 206, 215]]], ["The CoV S protein is a type I transmembrane glycoprotein with high molecular weight that protrudes from the surface of virions.", [["surface", "ANATOMY", 108, 115], ["virions", "ANATOMY", 119, 126], ["CoV S", "GENE_OR_GENE_PRODUCT", 4, 9], ["surface", "CELLULAR_COMPONENT", 108, 115], ["virions", "CELLULAR_COMPONENT", 119, 126], ["CoV S protein", "PROTEIN", 4, 17], ["type I transmembrane glycoprotein", "PROTEIN", 23, 56], ["The CoV S protein", "TEST", 0, 17], ["a type I transmembrane glycoprotein", "PROBLEM", 21, 56], ["CoV", "OBSERVATION", 4, 7], ["surface", "OBSERVATION_MODIFIER", 108, 115], ["virions", "OBSERVATION", 119, 126]]], ["The amino-terminal S1 domain is responsible for the recognition of cellular receptors, and the carboxy-terminal S2 domain mediates the subsequent membrane fusion process 25 .", [["cellular", "ANATOMY", 67, 75], ["membrane", "ANATOMY", 146, 154], ["amino-terminal", "CHEMICAL", 4, 18], ["amino", "CHEMICAL", 4, 9], ["carboxy", "CHEMICAL", 95, 102], ["cellular", "CELL", 67, 75], ["membrane", "CELLULAR_COMPONENT", 146, 154], ["amino-terminal S1 domain", "PROTEIN", 4, 28], ["cellular receptors", "PROTEIN", 67, 85], ["carboxy-terminal S2 domain", "PROTEIN", 95, 121], ["The amino-terminal S1 domain", "PROBLEM", 0, 28], ["cellular receptors", "TEST", 67, 85], ["the carboxy-terminal S2 domain", "TREATMENT", 91, 121], ["the subsequent membrane fusion process", "TREATMENT", 131, 169], ["amino", "OBSERVATION", 4, 9], ["-terminal S1", "OBSERVATION", 9, 21], ["responsible for", "UNCERTAINTY", 32, 47], ["cellular receptors", "OBSERVATION", 67, 85], ["terminal S2", "OBSERVATION", 103, 114], ["membrane fusion", "OBSERVATION", 146, 161]]], ["Recently, two research groups independently resolved the structure of PDCoV S protein by cryo-electron microscopy 26, 27 .IntroductionPDCoV S protein is a trimer containing three receptorbinding S1 subunits and membrane-fusion S2 subunits 27 .", [["membrane", "ANATOMY", 211, 219], ["PDCoV S protein", "GENE_OR_GENE_PRODUCT", 70, 85], ["IntroductionPDCoV S protein", "GENE_OR_GENE_PRODUCT", 122, 149], ["membrane", "CELLULAR_COMPONENT", 211, 219], ["PDCoV S protein", "PROTEIN", 70, 85], ["IntroductionPDCoV S protein", "PROTEIN", 122, 149], ["receptorbinding S1 subunits", "PROTEIN", 179, 206], ["membrane-fusion S2 subunits 27", "PROTEIN", 211, 241], ["cryo-electron microscopy", "TEST", 89, 113], ["IntroductionPDCoV S protein", "TREATMENT", 122, 149], ["a trimer", "TREATMENT", 153, 161], ["three receptorbinding S1 subunits", "TREATMENT", 173, 206], ["membrane-fusion S2 subunits", "TREATMENT", 211, 238]]], ["The C-terminal domain (CTD) of the PDCoV S1 subunit that is responsible for receptor binding shares a similar structural fold with alphacoronavirus.IntroductionTo date, a series of cellular receptors for different genera of CoVs have been identified.", [["cellular", "ANATOMY", 181, 189], ["PDCoV S1", "GENE_OR_GENE_PRODUCT", 35, 43], ["alphacoronavirus", "CANCER", 131, 147], ["cellular", "CELL", 181, 189], ["CoVs", "GENE_OR_GENE_PRODUCT", 224, 228], ["C-terminal domain", "PROTEIN", 4, 21], ["CTD", "PROTEIN", 23, 26], ["PDCoV S1 subunit", "PROTEIN", 35, 51], ["alphacoronavirus", "PROTEIN", 131, 147], ["cellular receptors", "PROTEIN", 181, 199], ["CoVs", "PROTEIN", 224, 228], ["The C-terminal domain (CTD", "PROBLEM", 0, 26], ["receptor binding", "PROBLEM", 76, 92], ["alphacoronavirus", "PROBLEM", 131, 147], ["cellular receptors", "TREATMENT", 181, 199], ["different genera of CoVs", "PROBLEM", 204, 228], ["responsible for", "UNCERTAINTY", 60, 75], ["receptor binding", "OBSERVATION", 76, 92], ["CoVs", "OBSERVATION", 224, 228]]], ["For example, aminopeptidase N (APN, also called CD13) is the functional receptor for human coronavirus 229E (HCoV-229E) 28 , feline infectious peritonitis virus 29 , canine CoV 30 , and transmissible gastroenteritis virus (TGEV) 31 .", [["HCoV-229E", "CHEMICAL", 109, 118], ["feline infectious peritonitis", "DISEASE", 125, 154], ["transmissible gastroenteritis", "DISEASE", 186, 215], ["aminopeptidase N", "GENE_OR_GENE_PRODUCT", 13, 29], ["APN", "GENE_OR_GENE_PRODUCT", 31, 34], ["CD13", "GENE_OR_GENE_PRODUCT", 48, 52], ["human coronavirus 229E", "ORGANISM", 85, 107], ["HCoV-229E) 28", "ORGANISM", 109, 122], ["feline infectious peritonitis virus 29", "ORGANISM", 125, 163], ["canine CoV 30", "ORGANISM", 166, 179], ["transmissible gastroenteritis virus", "ORGANISM", 186, 221], ["TGEV", "ORGANISM", 223, 227], ["aminopeptidase N", "PROTEIN", 13, 29], ["APN", "PROTEIN", 31, 34], ["CD13", "PROTEIN", 48, 52], ["human", "SPECIES", 85, 90], ["coronavirus", "SPECIES", 91, 102], ["feline infectious peritonitis virus", "SPECIES", 125, 160], ["canine CoV", "SPECIES", 166, 176], ["transmissible gastroenteritis virus", "SPECIES", 186, 221], ["human coronavirus 229E (HCoV-229E)", "SPECIES", 85, 119], ["feline infectious peritonitis virus 29", "SPECIES", 125, 163], ["canine CoV 30", "SPECIES", 166, 179], ["transmissible gastroenteritis virus", "SPECIES", 186, 221], ["TGEV", "SPECIES", 223, 227], ["human coronavirus", "TEST", 85, 102], ["HCoV", "TEST", 109, 113], ["feline infectious peritonitis virus", "PROBLEM", 125, 160], ["canine CoV", "TEST", 166, 176], ["transmissible gastroenteritis virus", "PROBLEM", 186, 221], ["infectious", "OBSERVATION_MODIFIER", 132, 142], ["peritonitis", "OBSERVATION", 143, 154]]], ["Angiotensin-converting enzyme 2 is utilized by HCoV-NL63 and severe acute respiratory syndrome coronavirus (SARS-CoV) 24, 32 .", [["HCoV-NL63", "ANATOMY", 47, 56], ["Angiotensin", "CHEMICAL", 0, 11], ["acute respiratory syndrome coronavirus", "DISEASE", 68, 106], ["SARS", "DISEASE", 108, 112], ["Angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 0, 31], ["HCoV-NL63", "ORGANISM", 47, 56], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 61, 106], ["Angiotensin-converting enzyme 2", "PROTEIN", 0, 31], ["HCoV", "SPECIES", 47, 51], ["severe acute respiratory syndrome coronavirus", "SPECIES", 61, 106], ["SARS-CoV", "SPECIES", 108, 116], ["Angiotensin", "TEST", 0, 11], ["converting enzyme", "TEST", 12, 29], ["HCoV", "TEST", 47, 51], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 61, 106], ["severe", "OBSERVATION_MODIFIER", 61, 67], ["acute", "OBSERVATION_MODIFIER", 68, 73], ["respiratory syndrome", "OBSERVATION", 74, 94]]], ["Middle East respiratory syndrome coronavirus (MERS-CoV) S protein employs dipeptidyl peptidase 4 (also called CD26) as its receptor 33 .", [["respiratory syndrome coronavirus", "DISEASE", 12, 44], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 0, 44], ["MERS-CoV) S protein", "GENE_OR_GENE_PRODUCT", 46, 65], ["dipeptidyl peptidase 4", "GENE_OR_GENE_PRODUCT", 74, 96], ["CD26", "GENE_OR_GENE_PRODUCT", 110, 114], ["Middle East respiratory syndrome coronavirus (MERS-CoV) S protein", "PROTEIN", 0, 65], ["dipeptidyl peptidase 4", "PROTEIN", 74, 96], ["CD26", "PROTEIN", 110, 114], ["receptor 33", "PROTEIN", 123, 134], ["Middle East respiratory syndrome coronavirus", "SPECIES", 0, 44], ["MERS-CoV", "SPECIES", 46, 54], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 0, 44], ["dipeptidyl peptidase", "TREATMENT", 74, 94], ["respiratory syndrome", "OBSERVATION", 12, 32]]], ["Carcinoembryonic antigen-related cell adhesion molecule 1 is reported to mediate viral infection by interacting with mouse hepatitis virus (MHV) S protein 34 .", [["viral infection", "DISEASE", 81, 96], ["mouse hepatitis virus", "DISEASE", 117, 138], ["Carcinoembryonic antigen-related cell adhesion molecule 1", "GENE_OR_GENE_PRODUCT", 0, 57], ["mouse hepatitis virus", "ORGANISM", 117, 138], ["(MHV) S protein 34", "GENE_OR_GENE_PRODUCT", 139, 157], ["Carcinoembryonic antigen-related cell adhesion molecule 1", "PROTEIN", 0, 57], ["mouse hepatitis virus (MHV) S protein 34", "PROTEIN", 117, 157], ["mouse", "SPECIES", 117, 122], ["hepatitis virus", "SPECIES", 123, 138], ["mouse hepatitis virus", "SPECIES", 117, 138], ["MHV", "SPECIES", 140, 143], ["Carcinoembryonic antigen", "TEST", 0, 24], ["cell adhesion molecule", "PROBLEM", 33, 55], ["viral infection", "PROBLEM", 81, 96], ["mouse hepatitis virus", "PROBLEM", 117, 138], ["S protein", "TEST", 145, 154], ["cell", "OBSERVATION", 33, 37], ["adhesion molecule", "OBSERVATION", 38, 55], ["viral", "OBSERVATION_MODIFIER", 81, 86], ["infection", "OBSERVATION", 87, 96]]], ["However, the relationship between hosts and members of genus Deltacoronavirus remains unknown.IntroductionIn this study, we investigated the role of porcine APN (pAPN) in PDCoV infection.", [["PDCoV infection", "DISEASE", 171, 186], ["Deltacoronavirus", "GENE_OR_GENE_PRODUCT", 61, 77], ["porcine", "ORGANISM", 149, 156], ["APN", "GENE_OR_GENE_PRODUCT", 157, 160], ["pAPN", "GENE_OR_GENE_PRODUCT", 162, 166], ["PDCoV", "CANCER", 171, 176], ["porcine APN", "PROTEIN", 149, 160], ["pAPN", "PROTEIN", 162, 166], ["PDCoV", "SPECIES", 171, 176], ["genus Deltacoronavirus", "PROBLEM", 55, 77], ["this study", "TEST", 109, 119], ["porcine APN (pAPN", "TREATMENT", 149, 166], ["PDCoV infection", "PROBLEM", 171, 186], ["infection", "OBSERVATION", 177, 186]]], ["We found that ectopic expression of pAPN rendered non-susceptible cells susceptible to PDCoV infection and promoted PDCoV infection in poorly susceptible cells.", [["cells", "ANATOMY", 66, 71], ["cells", "ANATOMY", 154, 159], ["PDCoV", "CHEMICAL", 87, 92], ["infection", "DISEASE", 93, 102], ["PDCoV", "CHEMICAL", 116, 121], ["infection", "DISEASE", 122, 131], ["pAPN", "GENE_OR_GENE_PRODUCT", 36, 40], ["cells", "CELL", 66, 71], ["PDCoV", "GENE_OR_GENE_PRODUCT", 87, 92], ["PDCoV", "SIMPLE_CHEMICAL", 116, 121], ["cells", "CELL", 154, 159], ["pAPN", "PROTEIN", 36, 40], ["non-susceptible cells", "CELL_TYPE", 50, 71], ["PDCoV", "SPECIES", 87, 92], ["PDCoV", "SPECIES", 116, 121], ["ectopic expression of pAPN", "PROBLEM", 14, 40], ["non-susceptible cells", "PROBLEM", 50, 71], ["PDCoV infection", "PROBLEM", 87, 102], ["PDCoV infection", "PROBLEM", 116, 131], ["poorly susceptible cells", "PROBLEM", 135, 159], ["ectopic", "OBSERVATION", 14, 21], ["non-susceptible cells", "OBSERVATION", 50, 71], ["infection", "OBSERVATION", 93, 102], ["PDCoV infection", "OBSERVATION", 116, 131], ["poorly", "OBSERVATION_MODIFIER", 135, 141], ["susceptible cells", "OBSERVATION", 142, 159]]], ["However, pAPN knockout or treatment with APN-specific antibody and inhibitor only decreased PDCoV infection to some degree.", [["infection", "DISEASE", 98, 107], ["pAPN", "GENE_OR_GENE_PRODUCT", 9, 13], ["APN", "GENE_OR_GENE_PRODUCT", 41, 44], ["PDCoV", "CANCER", 92, 97], ["pAPN", "PROTEIN", 9, 13], ["APN", "PROTEIN", 41, 44], ["PDCoV", "SPECIES", 92, 97], ["treatment", "TREATMENT", 26, 35], ["APN", "TEST", 41, 44], ["specific antibody", "TEST", 45, 62], ["inhibitor", "TREATMENT", 67, 76], ["decreased PDCoV infection", "PROBLEM", 82, 107], ["infection", "OBSERVATION", 98, 107], ["some degree", "OBSERVATION_MODIFIER", 111, 122]]], ["Additionally, pAPN knockout in porcine intestinal epithelial (IPI-2I) cells, a cell line established from porcine ileum, did not completely block PDCoV infection but significantly affected viral replication.", [["intestinal epithelial (IPI-2I) cells", "ANATOMY", 39, 75], ["cell line", "ANATOMY", 79, 88], ["ileum", "ANATOMY", 114, 119], ["PDCoV", "CHEMICAL", 146, 151], ["infection", "DISEASE", 152, 161], ["pAPN", "GENE_OR_GENE_PRODUCT", 14, 18], ["porcine", "ORGANISM", 31, 38], ["intestinal epithelial (IPI-2I) cells", "CELL", 39, 75], ["cell line", "CELL", 79, 88], ["porcine", "ORGANISM", 106, 113], ["ileum", "ORGAN", 114, 119], ["PDCoV", "GENE_OR_GENE_PRODUCT", 146, 151], ["pAPN", "PROTEIN", 14, 18], ["porcine intestinal epithelial (IPI-2I) cells", "CELL_LINE", 31, 75], ["porcine", "SPECIES", 31, 38], ["porcine", "SPECIES", 106, 113], ["porcine", "SPECIES", 31, 38], ["porcine", "SPECIES", 106, 113], ["PDCoV", "SPECIES", 146, 151], ["pAPN knockout", "PROBLEM", 14, 27], ["porcine intestinal epithelial (IPI-2I) cells", "TREATMENT", 31, 75], ["a cell line", "TREATMENT", 77, 88], ["completely block PDCoV infection", "PROBLEM", 129, 161], ["significantly affected viral replication", "PROBLEM", 166, 206], ["pAPN knockout", "OBSERVATION", 14, 27], ["porcine", "ANATOMY_MODIFIER", 31, 38], ["intestinal epithelial", "ANATOMY", 39, 60], ["cell line", "OBSERVATION", 79, 88], ["ileum", "ANATOMY", 114, 119], ["PDCoV", "OBSERVATION_MODIFIER", 146, 151], ["infection", "OBSERVATION", 152, 161], ["significantly", "OBSERVATION_MODIFIER", 166, 179], ["affected", "OBSERVATION_MODIFIER", 180, 188], ["viral replication", "OBSERVATION", 189, 206]]], ["We also demonstrated that the APN enzymatic activity inhibitor did not disrupt PDCoV infection, indicating pAPN enzymatic activity is not involved in this process.", [["PDCoV", "CHEMICAL", 79, 84], ["infection", "DISEASE", 85, 94], ["APN", "GENE_OR_GENE_PRODUCT", 30, 33], ["PDCoV", "GENE_OR_GENE_PRODUCT", 79, 84], ["pAPN", "GENE_OR_GENE_PRODUCT", 107, 111], ["APN", "PROTEIN", 30, 33], ["pAPN", "PROTEIN", 107, 111], ["the APN enzymatic activity inhibitor", "PROBLEM", 26, 62], ["PDCoV infection", "PROBLEM", 79, 94], ["pAPN enzymatic activity", "PROBLEM", 107, 130], ["infection", "OBSERVATION", 85, 94], ["enzymatic activity", "OBSERVATION", 112, 130]]], ["Our work suggests pAPN is not a critical receptor but is an important factor during PDCoV infection.Phylogenetic analysis of PDCoV S proteinBecause of the dominant role of CoV S protein in receptor recognition and viral entry, we conducted amino acid sequence alignments of PDCoV S proteins, together with S proteins from three swine CoVs (TGEV; porcine epidemic diarrhea virus, PEDV; and porcine respiratory coronavirus, PRCV) and four representative CoVs from different genera (Betacoronavirus SARS-CoV, MERS-CoV, and MHV; Gammacoronavirus infectious bronchitis virus (IBV)).", [["infection", "DISEASE", 90, 99], ["amino acid", "CHEMICAL", 240, 250], ["porcine epidemic diarrhea", "DISEASE", 346, 371], ["infectious bronchitis virus", "DISEASE", 542, 569], ["amino acid", "CHEMICAL", 240, 250], ["pAPN", "GENE_OR_GENE_PRODUCT", 18, 22], ["PDCoV", "GENE_OR_GENE_PRODUCT", 84, 89], ["PDCoV S", "GENE_OR_GENE_PRODUCT", 125, 132], ["CoV S", "GENE_OR_GENE_PRODUCT", 172, 177], ["PDCoV S proteins", "GENE_OR_GENE_PRODUCT", 274, 290], ["swine CoVs", "ORGANISM", 328, 338], ["TGEV;", "ORGANISM", 340, 345], ["porcine epidemic diarrhea virus", "ORGANISM", 346, 377], ["PEDV", "ORGANISM", 379, 383], ["porcine respiratory coronavirus", "ORGANISM", 389, 420], ["PRCV", "CANCER", 422, 426], ["CoVs", "GENE_OR_GENE_PRODUCT", 452, 456], ["Betacoronavirus SARS-CoV", "ORGANISM", 480, 504], ["MERS-CoV", "ORGANISM", 506, 514], ["MHV;", "ORGANISM", 520, 524], ["Gammacoronavirus infectious bronchitis virus", "ORGANISM", 525, 569], ["IBV", "ORGANISM", 571, 574], ["pAPN", "PROTEIN", 18, 22], ["PDCoV S proteinBecause", "PROTEIN", 125, 147], ["CoV S protein", "PROTEIN", 172, 185], ["PDCoV S proteins", "PROTEIN", 274, 290], ["S proteins", "PROTEIN", 306, 316], ["swine", "SPECIES", 328, 333], ["TGEV", "SPECIES", 340, 344], ["porcine epidemic diarrhea virus", "SPECIES", 346, 377], ["porcine respiratory coronavirus", "SPECIES", 389, 420], ["Gammacoronavirus infectious bronchitis virus", "SPECIES", 525, 569], ["PDCoV", "SPECIES", 84, 89], ["swine CoVs", "SPECIES", 328, 338], ["TGEV", "SPECIES", 340, 344], ["porcine epidemic diarrhea virus", "SPECIES", 346, 377], ["PEDV", "SPECIES", 379, 383], ["porcine respiratory coronavirus", "SPECIES", 389, 420], ["PRCV", "SPECIES", 422, 426], ["Betacoronavirus SARS-CoV", "SPECIES", 480, 504], ["MERS-CoV", "SPECIES", 506, 514], ["MHV", "SPECIES", 520, 523], ["Gammacoronavirus infectious bronchitis virus", "SPECIES", 525, 569], ["IBV", "SPECIES", 571, 574], ["PDCoV infection", "PROBLEM", 84, 99], ["Phylogenetic analysis", "TEST", 100, 121], ["PDCoV S", "PROBLEM", 125, 132], ["CoV S protein in receptor recognition", "PROBLEM", 172, 209], ["viral entry", "PROBLEM", 214, 225], ["amino acid sequence alignments", "TEST", 240, 270], ["PDCoV S proteins", "PROBLEM", 274, 290], ["S proteins", "PROBLEM", 306, 316], ["three swine CoVs", "PROBLEM", 322, 338], ["TGEV", "PROBLEM", 340, 344], ["porcine epidemic diarrhea virus", "PROBLEM", 346, 377], ["PEDV", "PROBLEM", 379, 383], ["porcine respiratory coronavirus", "PROBLEM", 389, 420], ["four representative CoVs", "PROBLEM", 432, 456], ["different genera", "TEST", 462, 478], ["Betacoronavirus SARS", "TEST", 480, 500], ["CoV", "TEST", 501, 504], ["MHV", "TREATMENT", 520, 523], ["Gammacoronavirus infectious bronchitis virus", "PROBLEM", 525, 569], ["infection", "OBSERVATION", 90, 99], ["dominant", "OBSERVATION_MODIFIER", 155, 163], ["viral entry", "OBSERVATION", 214, 225], ["MHV", "ANATOMY", 520, 523], ["infectious bronchitis", "OBSERVATION", 542, 563]]], ["PDCoV S displayed higher homology with PEDV, PRCV, and TGEV (Fig. 1a) . pAPN acts as a functional cellular receptor for TGEV and PRCV infection 31, 35 .", [["cellular", "ANATOMY", 98, 106], ["pAPN", "CHEMICAL", 72, 76], ["infection", "DISEASE", 134, 143], ["PEDV", "GENE_OR_GENE_PRODUCT", 39, 43], ["TGEV", "ORGANISM", 55, 59], ["Fig. 1a", "ORGANISM", 61, 68], ["pAPN", "GENE_OR_GENE_PRODUCT", 72, 76], ["cellular", "CELL", 98, 106], ["TGEV", "ORGANISM", 120, 124], ["PEDV", "PROTEIN", 39, 43], ["PRCV", "PROTEIN", 45, 49], ["pAPN", "PROTEIN", 72, 76], ["TGEV", "SPECIES", 55, 59], ["PEDV", "SPECIES", 39, 43], ["PRCV", "SPECIES", 45, 49], ["TGEV", "SPECIES", 55, 59], ["TGEV", "SPECIES", 120, 124], ["PRCV", "SPECIES", 129, 133], ["PEDV", "PROBLEM", 39, 43], ["PRCV", "TREATMENT", 45, 49], ["TGEV", "PROBLEM", 120, 124], ["PRCV infection", "PROBLEM", 129, 143]]], ["Whether pAPN is indeed a functional receptor for PEDV remains controversial, but it is involved in PEDV infection [36] [37] [38] .", [["PEDV", "CHEMICAL", 49, 53], ["infection", "DISEASE", 104, 113], ["pAPN", "GENE_OR_GENE_PRODUCT", 8, 12], ["PEDV", "GENE_OR_GENE_PRODUCT", 49, 53], ["PEDV", "SIMPLE_CHEMICAL", 99, 103], ["pAPN", "PROTEIN", 8, 12], ["PEDV", "PROTEIN", 49, 53], ["PEDV", "SPECIES", 99, 103], ["PEDV", "PROBLEM", 49, 53], ["PEDV infection", "PROBLEM", 99, 113]]], ["Phylogenetic analysis indicated that PDCoV S is close to the cluster containing PEDV, TGEV, and PRCV (Fig. 1b) .", [["PDCoV S", "GENE_OR_GENE_PRODUCT", 37, 44], ["PEDV", "GENE_OR_GENE_PRODUCT", 80, 84], ["TGEV", "ORGANISM", 86, 90], ["PDCoV S", "DNA", 37, 44], ["PEDV", "DNA", 80, 84], ["PEDV", "SPECIES", 80, 84], ["TGEV", "SPECIES", 86, 90], ["PRCV", "SPECIES", 96, 100], ["Phylogenetic analysis", "TEST", 0, 21], ["PDCoV S", "PROBLEM", 37, 44], ["PEDV", "TREATMENT", 80, 84], ["TGEV", "TREATMENT", 86, 90], ["PRCV", "TREATMENT", 96, 100]]], ["Thus, we evaluated the role of pAPN in PDCoV infection.Non-susceptible cells expressing pAPN are susceptible to PDCoVTo determine whether pAPN contributes to PDCoV infection, we explored whether ectopic expression of pAPN in non-susceptible cells can cause PDCoV infection.", [["PDCoV", "ANATOMY", 39, 44], ["cells", "ANATOMY", 71, 76], ["cells", "ANATOMY", 241, 246], ["pAPN", "CHEMICAL", 31, 35], ["PDCoV infection", "DISEASE", 39, 54], ["pAPN", "CHEMICAL", 138, 142], ["infection", "DISEASE", 164, 173], ["pAPN", "CHEMICAL", 217, 221], ["infection", "DISEASE", 263, 272], ["pAPN", "GENE_OR_GENE_PRODUCT", 31, 35], ["PDCoV", "CANCER", 39, 44], ["cells", "CELL", 71, 76], ["pAPN", "GENE_OR_GENE_PRODUCT", 88, 92], ["PDCoVTo", "GENE_OR_GENE_PRODUCT", 112, 119], ["pAPN", "GENE_OR_GENE_PRODUCT", 138, 142], ["PDCoV", "GENE_OR_GENE_PRODUCT", 158, 163], ["pAPN", "GENE_OR_GENE_PRODUCT", 217, 221], ["cells", "CELL", 241, 246], ["PDCoV", "CANCER", 257, 262], ["pAPN", "PROTEIN", 31, 35], ["Non-susceptible cells", "CELL_LINE", 55, 76], ["pAPN", "PROTEIN", 88, 92], ["pAPN", "PROTEIN", 138, 142], ["pAPN", "PROTEIN", 217, 221], ["non-susceptible cells", "CELL_TYPE", 225, 246], ["PDCoV", "SPECIES", 39, 44], ["PDCoV", "SPECIES", 158, 163], ["PDCoV", "SPECIES", 257, 262], ["PDCoV infection", "PROBLEM", 39, 54], ["Non-susceptible cells", "PROBLEM", 55, 76], ["PDCoV infection", "PROBLEM", 158, 173], ["ectopic expression of pAPN in non-susceptible cells", "PROBLEM", 195, 246], ["PDCoV infection", "PROBLEM", 257, 272], ["infection", "OBSERVATION", 45, 54], ["infection", "OBSERVATION", 164, 173], ["infection", "OBSERVATION", 263, 272]]], ["Primary experiments showed that baby hamster kidney (BHK)-21 cells were non-susceptible and HeLa cells were slightly susceptible to PDCoV infection. pAPN overexpression in these cells was induced by transient transfection of the pAPN expression plasmid.", [["hamster kidney (BHK)-21 cells", "ANATOMY", 37, 66], ["HeLa cells", "ANATOMY", 92, 102], ["cells", "ANATOMY", 178, 183], ["PDCoV", "CHEMICAL", 132, 137], ["infection", "DISEASE", 138, 147], ["baby hamster kidney", "CELL", 32, 51], ["BHK)-21 cells", "CELL", 53, 66], ["HeLa cells", "CELL", 92, 102], ["pAPN", "GENE_OR_GENE_PRODUCT", 149, 153], ["cells", "CELL", 178, 183], ["pAPN", "GENE_OR_GENE_PRODUCT", 229, 233], ["baby hamster kidney (BHK)-21 cells", "CELL_LINE", 32, 66], ["HeLa cells", "CELL_LINE", 92, 102], ["pAPN", "PROTEIN", 149, 153], ["pAPN expression plasmid", "DNA", 229, 252], ["hamster", "SPECIES", 37, 44], ["hamster", "SPECIES", 37, 44], ["PDCoV", "SPECIES", 132, 137], ["Primary experiments", "TEST", 0, 19], ["baby hamster kidney (BHK)", "TEST", 32, 57], ["21 cells", "PROBLEM", 58, 66], ["non-susceptible", "PROBLEM", 72, 87], ["HeLa cells", "PROBLEM", 92, 102], ["PDCoV infection", "PROBLEM", 132, 147], ["pAPN overexpression in these cells", "PROBLEM", 149, 183], ["the pAPN expression plasmid", "TREATMENT", 225, 252], ["kidney", "ANATOMY", 45, 51], ["HeLa cells", "OBSERVATION", 92, 102], ["infection", "OBSERVATION", 138, 147], ["these cells", "OBSERVATION", 172, 183], ["transient", "OBSERVATION_MODIFIER", 199, 208], ["transfection", "OBSERVATION", 209, 221]]], ["PDCoV Sspecific fluorescence was observed in BHK-21 cells transfected with the pAPN expression plasmid, but not in cells transfected with control vector (Fig. 2a) .", [["BHK-21 cells", "ANATOMY", 45, 57], ["plasmid", "ANATOMY", 95, 102], ["cells", "ANATOMY", 115, 120], ["PDCoV", "SIMPLE_CHEMICAL", 0, 5], ["BHK-21 cells", "CELL", 45, 57], ["pAPN", "GENE_OR_GENE_PRODUCT", 79, 83], ["cells", "CELL", 115, 120], ["BHK-21 cells", "CELL_LINE", 45, 57], ["pAPN expression plasmid", "DNA", 79, 102], ["PDCoV", "SPECIES", 0, 5], ["BHK-21", "SPECIES", 45, 51], ["BHK", "TEST", 45, 48], ["the pAPN expression plasmid", "TREATMENT", 75, 102]]], ["Moreover, HeLa cells showed greater infection by PDCoV after transfection with pAPN expression plasmid compared with cells transfected with control vector (Fig. 2a) .Non-susceptible cells expressing pAPN are susceptible to PDCoVTo further investigate whether pAPN-mediated infection in transfected BHK-21 and HeLa cells is productive, quantitative real-time PCR (RT-qPCR) was performed to detect the PDCoV genome RNA copies at different time points post infection.", [["HeLa cells", "ANATOMY", 10, 20], ["cells", "ANATOMY", 117, 122], ["cells", "ANATOMY", 182, 187], ["BHK-21", "ANATOMY", 298, 304], ["HeLa cells", "ANATOMY", 309, 319], ["infection", "DISEASE", 36, 45], ["pAPN", "CHEMICAL", 259, 263], ["infection", "DISEASE", 273, 282], ["infection", "DISEASE", 454, 463], ["HeLa cells", "CELL", 10, 20], ["PDCoV", "SIMPLE_CHEMICAL", 49, 54], ["pAPN", "GENE_OR_GENE_PRODUCT", 79, 83], ["cells", "CELL", 117, 122], ["cells", "CELL", 182, 187], ["pAPN", "GENE_OR_GENE_PRODUCT", 199, 203], ["PDCoVTo", "GENE_OR_GENE_PRODUCT", 223, 230], ["pAPN", "GENE_OR_GENE_PRODUCT", 259, 263], ["BHK-21", "CELL", 298, 304], ["HeLa cells", "CELL", 309, 319], ["HeLa cells", "CELL_LINE", 10, 20], ["pAPN expression plasmid", "DNA", 79, 102], ["Non-susceptible cells", "CELL_LINE", 166, 187], ["pAPN", "PROTEIN", 199, 203], ["pAPN", "PROTEIN", 259, 263], ["transfected BHK-21", "CELL_LINE", 286, 304], ["HeLa cells", "CELL_LINE", 309, 319], ["PDCoV genome", "DNA", 400, 412], ["PDCoV", "SPECIES", 49, 54], ["BHK-21", "SPECIES", 298, 304], ["HeLa cells", "TEST", 10, 20], ["greater infection", "PROBLEM", 28, 45], ["transfection with pAPN expression plasmid", "TREATMENT", 61, 102], ["Non-susceptible cells", "PROBLEM", 166, 187], ["pAPN-mediated infection", "PROBLEM", 259, 282], ["transfected BHK", "TEST", 286, 301], ["HeLa cells", "TEST", 309, 319], ["PCR", "TEST", 358, 361], ["RT-qPCR", "TEST", 363, 370], ["the PDCoV genome RNA copies", "PROBLEM", 396, 423], ["infection", "PROBLEM", 454, 463], ["greater", "OBSERVATION_MODIFIER", 28, 35], ["infection", "OBSERVATION", 36, 45], ["infection", "OBSERVATION", 273, 282], ["HeLa cells", "OBSERVATION_MODIFIER", 309, 319], ["productive", "OBSERVATION_MODIFIER", 323, 333], ["infection", "OBSERVATION", 454, 463]]], ["In BHK-21 cells, ectopic expression Mouse monoclonal antibody against PDCoV S was used to detect PDCoV-infected cells (green).", [["BHK-21 cells", "ANATOMY", 3, 15], ["cells", "ANATOMY", 112, 117], ["BHK-21 cells", "CELL", 3, 15], ["Mouse", "ORGANISM", 36, 41], ["PDCoV", "GENE_OR_GENE_PRODUCT", 97, 102], ["cells", "CELL", 112, 117], ["BHK-21 cells", "CELL_LINE", 3, 15], ["Mouse monoclonal antibody", "PROTEIN", 36, 61], ["PDCoV S", "PROTEIN", 70, 77], ["PDCoV", "PROTEIN", 97, 102], ["infected cells", "CELL_TYPE", 103, 117], ["Mouse", "SPECIES", 36, 41], ["BHK-21", "SPECIES", 3, 9], ["Mouse", "SPECIES", 36, 41], ["PDCoV", "SPECIES", 70, 75], ["BHK", "TEST", 3, 6], ["ectopic expression", "PROBLEM", 17, 35], ["Mouse monoclonal antibody", "TEST", 36, 61], ["PDCoV S", "TEST", 70, 77], ["PDCoV", "TEST", 97, 102], ["infected cells", "PROBLEM", 103, 117], ["21 cells", "OBSERVATION_MODIFIER", 7, 15], ["infected cells", "OBSERVATION", 103, 117]]], ["The anti-Flag rabbit polyclonal antibody was used to stain for ectopic expression of APN protein (red).", [["anti-Flag", "GENE_OR_GENE_PRODUCT", 4, 13], ["APN", "GENE_OR_GENE_PRODUCT", 85, 88], ["anti-Flag rabbit polyclonal antibody", "PROTEIN", 4, 40], ["APN protein", "PROTEIN", 85, 96], ["rabbit", "SPECIES", 14, 20], ["rabbit", "SPECIES", 14, 20], ["The anti-Flag rabbit polyclonal antibody", "TEST", 0, 40], ["ectopic expression of APN protein", "PROBLEM", 63, 96]]], ["DAPI was applied to detect nuclei (blue). b, c BHK-21 cells (b) or HeLa cells (c) were transfected as described in a and then infected with PDCoV (MOI = 2).", [["nuclei", "ANATOMY", 27, 33], ["BHK-21 cells", "ANATOMY", 47, 59], ["b", "ANATOMY", 61, 62], ["HeLa cells", "ANATOMY", 67, 77], ["DAPI", "CHEMICAL", 0, 4], ["DAPI", "SIMPLE_CHEMICAL", 0, 4], ["nuclei", "CELLULAR_COMPONENT", 27, 33], ["c BHK-21 cells", "CELL", 45, 59], ["b", "CELL", 61, 62], ["HeLa cells", "CELL", 67, 77], ["c", "CELL", 79, 80], ["c BHK-21 cells", "CELL_LINE", 45, 59], ["HeLa cells", "CELL_LINE", 67, 77], ["DAPI", "TREATMENT", 0, 4], ["BHK", "TEST", 47, 50], ["HeLa cells", "PROBLEM", 67, 77], ["PDCoV (MOI", "TREATMENT", 140, 150]]], ["At different time points (0, 12, 24 h) post infection, cells were collected for RT-qPCR with primers targeting the PDCoV nsp16 gene to measure viral genome copies.", [["cells", "ANATOMY", 55, 60], ["infection", "DISEASE", 44, 53], ["cells", "CELL", 55, 60], ["PDCoV nsp16", "GENE_OR_GENE_PRODUCT", 115, 126], ["PDCoV nsp16 gene", "DNA", 115, 131], ["viral genome copies", "DNA", 143, 162], ["post infection, cells", "PROBLEM", 39, 60], ["RT", "TEST", 80, 82], ["primers", "TREATMENT", 93, 100], ["the PDCoV nsp16 gene", "TREATMENT", 111, 131], ["infection", "OBSERVATION", 44, 53], ["viral genome", "OBSERVATION", 143, 155]]], ["Statistical significance was determined by Student's t test; ns, P > 0.05; P < 0.05 \u03b2-turns (\u03b21-\u03b22 and \u03b23-\u03b24) between PDCoV and TGEV may determine their variability in pAPN usage during viral entry.DiscussionAs an emerging swine enteropathogenic CoV and the sole member of the genus Deltacoronavirus that has been successfully isolated by cell culture in vitro, PDCoV is a good model to study deltacoronaviruses.", [["cell culture", "ANATOMY", 339, 351], ["\u03b21-\u03b22", "GENE_OR_GENE_PRODUCT", 93, 98], ["\u03b23-\u03b24", "GENE_OR_GENE_PRODUCT", 103, 108], ["PDCoV", "GENE_OR_GENE_PRODUCT", 118, 123], ["TGEV", "ORGANISM", 128, 132], ["pAPN", "GENE_OR_GENE_PRODUCT", 168, 172], ["swine enteropathogenic CoV", "ORGANISM", 223, 249], ["Deltacoronavirus", "GENE_OR_GENE_PRODUCT", 283, 299], ["cell", "CELL", 339, 343], ["deltacoronaviruses", "GENE_OR_GENE_PRODUCT", 393, 411], ["\u03b21", "PROTEIN", 93, 95], ["\u03b22", "PROTEIN", 96, 98], ["\u03b23", "PROTEIN", 103, 105], ["\u03b24", "DNA", 106, 108], ["pAPN", "PROTEIN", 168, 172], ["swine", "SPECIES", 223, 228], ["TGEV", "SPECIES", 128, 132], ["swine enteropathogenic CoV", "SPECIES", 223, 249], ["PDCoV", "SPECIES", 362, 367], ["ns", "TEST", 61, 63], ["P", "TEST", 65, 66], ["P", "TEST", 75, 76], ["turns", "TEST", 86, 91], ["\u03b21", "TEST", 93, 95], ["PDCoV", "TREATMENT", 118, 123], ["TGEV", "TREATMENT", 128, 132], ["an emerging swine enteropathogenic CoV", "PROBLEM", 211, 249], ["the genus Deltacoronavirus", "PROBLEM", 273, 299], ["cell culture", "TEST", 339, 351]]], ["However, very little is known about this emerging virus, including its receptor and infection mechanisms.", [["infection", "DISEASE", 84, 93], ["this emerging virus", "PROBLEM", 36, 55], ["infection mechanisms", "PROBLEM", 84, 104], ["infection", "OBSERVATION", 84, 93]]], ["A recent study showed that the \u03b2-sandwich core structure of PDCoV S1-CTD, which may be responsible for receptor recognition, is similar to that of alphacoronaviruses, which mainly use APN as a cellular receptor 27 .", [["cellular", "ANATOMY", 193, 201], ["PDCoV S1-CTD", "GENE_OR_GENE_PRODUCT", 60, 72], ["alphacoronaviruses", "GENE_OR_GENE_PRODUCT", 147, 165], ["APN", "GENE_OR_GENE_PRODUCT", 184, 187], ["cellular", "CELL", 193, 201], ["\u03b2-sandwich core structure", "PROTEIN", 31, 56], ["PDCoV S1", "PROTEIN", 60, 68], ["CTD", "PROTEIN", 69, 72], ["alphacoronaviruses", "PROTEIN", 147, 165], ["APN", "PROTEIN", 184, 187], ["cellular receptor 27", "PROTEIN", 193, 213], ["A recent study", "TEST", 0, 14], ["PDCoV S1-CTD", "PROBLEM", 60, 72], ["receptor recognition", "PROBLEM", 103, 123], ["alphacoronaviruses", "PROBLEM", 147, 165], ["a cellular receptor", "TEST", 191, 210], ["S1", "ANATOMY", 66, 68], ["may be responsible", "UNCERTAINTY", 80, 98]]], ["Furthermore, PDCoV in infected pigs was primarily detected in the villous epithelium of the mid-jejunum to ileum 20 .", [["villous epithelium", "ANATOMY", 66, 84], ["mid-jejunum", "ANATOMY", 92, 103], ["ileum", "ANATOMY", 107, 112], ["PDCoV", "CHEMICAL", 13, 18], ["PDCoV", "GENE_OR_GENE_PRODUCT", 13, 18], ["pigs", "ORGANISM", 31, 35], ["villous epithelium", "TISSUE", 66, 84], ["ileum", "ORGAN", 107, 112], ["PDCoV", "PROTEIN", 13, 18], ["pigs", "SPECIES", 31, 35], ["pigs", "SPECIES", 31, 35], ["PDCoV", "TREATMENT", 13, 18], ["infected pigs", "TREATMENT", 22, 35], ["infected pigs", "OBSERVATION", 22, 35], ["villous", "ANATOMY_MODIFIER", 66, 73], ["epithelium", "ANATOMY_MODIFIER", 74, 84], ["mid-jejunum", "ANATOMY_MODIFIER", 92, 103], ["ileum", "ANATOMY", 107, 112]]], ["Large amounts of APN are also expressed on the surface of porcine small intestine enterocytes 31 .", [["surface", "ANATOMY", 47, 54], ["small intestine enterocytes", "ANATOMY", 66, 93], ["APN", "GENE_OR_GENE_PRODUCT", 17, 20], ["surface", "CELLULAR_COMPONENT", 47, 54], ["porcine", "ORGANISM", 58, 65], ["APN", "PROTEIN", 17, 20], ["porcine", "SPECIES", 58, 65], ["Large amounts of APN", "PROBLEM", 0, 20], ["amounts", "OBSERVATION_MODIFIER", 6, 13], ["APN", "OBSERVATION", 17, 20], ["surface", "ANATOMY_MODIFIER", 47, 54], ["porcine", "ANATOMY_MODIFIER", 58, 65], ["small", "ANATOMY_MODIFIER", 66, 71], ["intestine enterocytes", "ANATOMY", 72, 93]]], ["Thus, in this study, we investigated the role of pAPN in PDCoV infection.", [["PDCoV", "ANATOMY", 57, 62], ["pAPN", "CHEMICAL", 49, 53], ["PDCoV infection", "DISEASE", 57, 72], ["pAPN", "GENE_OR_GENE_PRODUCT", 49, 53], ["PDCoV", "CANCER", 57, 62], ["pAPN", "PROTEIN", 49, 53], ["PDCoV", "SPECIES", 57, 62], ["this study", "TEST", 9, 19], ["PDCoV infection", "PROBLEM", 57, 72], ["infection", "OBSERVATION", 63, 72]]], ["Interestingly, ectopic expression of pAPN successfully reestablished PDCoV infection in non-susceptible BHK-21 cells, and pAPN overexpression effectively promoted PDCoV infection in poorly susceptible HeLa cells expressing pAPN.", [["BHK-21 cells", "ANATOMY", 104, 116], ["HeLa cells", "ANATOMY", 201, 211], ["PDCoV", "CHEMICAL", 69, 74], ["infection", "DISEASE", 75, 84], ["PDCoV", "CHEMICAL", 163, 168], ["infection", "DISEASE", 169, 178], ["pAPN", "GENE_OR_GENE_PRODUCT", 37, 41], ["PDCoV", "GENE_OR_GENE_PRODUCT", 69, 74], ["BHK-21 cells", "CELL", 104, 116], ["pAPN", "GENE_OR_GENE_PRODUCT", 122, 126], ["PDCoV", "SIMPLE_CHEMICAL", 163, 168], ["HeLa cells", "CELL", 201, 211], ["pAPN", "GENE_OR_GENE_PRODUCT", 223, 227], ["pAPN", "PROTEIN", 37, 41], ["non-susceptible BHK-21 cells", "CELL_LINE", 88, 116], ["pAPN", "PROTEIN", 122, 126], ["HeLa cells", "CELL_LINE", 201, 211], ["pAPN", "PROTEIN", 223, 227], ["BHK-21", "SPECIES", 104, 110], ["PDCoV", "SPECIES", 163, 168], ["pAPN", "PROBLEM", 37, 41], ["PDCoV infection in non-susceptible BHK", "PROBLEM", 69, 107], ["pAPN overexpression", "TREATMENT", 122, 141], ["PDCoV infection", "PROBLEM", 163, 178], ["infection", "OBSERVATION", 75, 84], ["PDCoV infection", "OBSERVATION", 163, 178], ["poorly susceptible", "OBSERVATION_MODIFIER", 182, 200], ["HeLa cells", "OBSERVATION", 201, 211]]], ["However, pAPN knockout in IPI-2I cells, a cell line that was established from porcine ileum and is highly susceptible to PDCoV infection, did not completely block PDCoV infection.", [["IPI-2I cells", "ANATOMY", 26, 38], ["cell line", "ANATOMY", 42, 51], ["ileum", "ANATOMY", 86, 91], ["infection", "DISEASE", 127, 136], ["infection", "DISEASE", 169, 178], ["pAPN", "GENE_OR_GENE_PRODUCT", 9, 13], ["IPI-2I cells", "CELL", 26, 38], ["cell line", "CELL", 42, 51], ["porcine", "ORGANISM", 78, 85], ["ileum", "ORGAN", 86, 91], ["PDCoV", "GENE_OR_GENE_PRODUCT", 163, 168], ["pAPN", "PROTEIN", 9, 13], ["IPI-2I cells", "CELL_LINE", 26, 38], ["cell line", "CELL_LINE", 42, 51], ["porcine", "SPECIES", 78, 85], ["porcine", "SPECIES", 78, 85], ["PDCoV", "SPECIES", 121, 126], ["PDCoV", "SPECIES", 163, 168], ["pAPN knockout in IPI", "PROBLEM", 9, 29], ["2I cells", "PROBLEM", 30, 38], ["a cell line", "TREATMENT", 40, 51], ["PDCoV infection", "PROBLEM", 121, 136], ["completely block PDCoV infection", "PROBLEM", 146, 178], ["2I cells", "OBSERVATION", 30, 38], ["cell line", "OBSERVATION", 42, 51], ["ileum", "ANATOMY", 86, 91], ["highly susceptible to", "UNCERTAINTY", 99, 120], ["PDCoV", "OBSERVATION_MODIFIER", 121, 126], ["infection", "OBSERVATION", 127, 136], ["PDCoV", "OBSERVATION_MODIFIER", 163, 168], ["infection", "OBSERVATION", 169, 178]]], ["We also performed pAPN knock-down experiments with pAPN-specific siRNA in LLC-PK1 (porcine kidney) cells, and the viral titers were decreased by only 0.6 log in pAPN-knock-down LLC-PK1 cells compared to the LLC-PK1 cells transfected with control siRNA (data not shown).", [["LLC-PK1", "ANATOMY", 74, 81], ["kidney) cells", "ANATOMY", 91, 104], ["LLC-PK1 cells", "ANATOMY", 177, 190], ["LLC-PK1 cells", "ANATOMY", 207, 220], ["pAPN", "GENE_OR_GENE_PRODUCT", 51, 55], ["LLC-PK1", "CELL", 74, 81], ["porcine", "ORGANISM", 83, 90], ["kidney) cells", "CELL", 91, 104], ["LLC-PK1 cells", "CELL", 177, 190], ["LLC-PK1 cells", "CELL", 207, 220], ["pAPN", "PROTEIN", 18, 22], ["pAPN", "PROTEIN", 51, 55], ["LLC-PK1 (porcine kidney) cells", "CELL_LINE", 74, 104], ["pAPN", "PROTEIN", 161, 165], ["LLC-PK1 cells", "CELL_LINE", 177, 190], ["LLC-PK1 cells", "CELL_LINE", 207, 220], ["porcine", "SPECIES", 83, 90], ["pAPN knock", "TEST", 18, 28], ["pAPN", "TEST", 51, 55], ["PK1 (porcine kidney) cells", "TEST", 78, 104], ["the viral titers", "TEST", 110, 126], ["pAPN", "TEST", 161, 165], ["LLC", "TEST", 177, 180], ["PK1 cells", "PROBLEM", 181, 190], ["the LLC", "TEST", 203, 210], ["PK1 cells", "TEST", 211, 220], ["siRNA", "OBSERVATION", 65, 70], ["LLC", "ANATOMY", 74, 77], ["kidney", "ANATOMY", 91, 97], ["viral titers", "OBSERVATION", 114, 126], ["LLC", "ANATOMY", 177, 180], ["LLC", "ANATOMY", 207, 210]]], ["A recent study found no interaction between purified pAPN and PDCoV S1-CTD by dot-blot assay 27 .", [["pAPN", "GENE_OR_GENE_PRODUCT", 53, 57], ["pAPN", "PROTEIN", 53, 57], ["PDCoV S1", "PROTEIN", 62, 70], ["CTD", "PROTEIN", 71, 74], ["A recent study", "TEST", 0, 14], ["dot-blot assay", "TEST", 78, 92], ["no", "UNCERTAINTY", 21, 23]]], ["Although we detected a possible weak interaction with the purified full-length PDCoV S protein and pAPN through molecular sieve analysis, a direct interaction could not be confirmed by pull-down assay (data not shown).", [["PDCoV S", "GENE_OR_GENE_PRODUCT", 79, 86], ["pAPN", "GENE_OR_GENE_PRODUCT", 99, 103], ["purified full-length PDCoV S protein", "PROTEIN", 58, 94], ["pAPN", "PROTEIN", 99, 103], ["weak interaction", "PROBLEM", 32, 48], ["molecular sieve analysis", "TEST", 112, 136], ["pull-down assay", "TEST", 185, 200]]], ["In contrast, another CoV, TGEV, which uses pAPN as a functional receptor, failed to infect IPI-2I-APN KO cells, as demonstrated by CPE, viral protein expression, and viral genome replication.", [["IPI-2I-APN KO cells", "ANATOMY", 91, 110], ["CoV", "ORGANISM", 21, 24], ["TGEV", "ORGANISM", 26, 30], ["pAPN", "GENE_OR_GENE_PRODUCT", 43, 47], ["IPI-2I-APN KO cells", "CELL", 91, 110], ["pAPN", "PROTEIN", 43, 47], ["IPI-2I-APN KO cells", "CELL_LINE", 91, 110], ["TGEV", "SPECIES", 26, 30], ["TGEV", "PROBLEM", 26, 30], ["pAPN", "TREATMENT", 43, 47], ["IPI", "TEST", 91, 94], ["CPE", "TEST", 131, 134], ["viral protein expression", "PROBLEM", 136, 160], ["viral genome replication", "TREATMENT", 166, 190], ["viral protein expression", "OBSERVATION", 136, 160], ["viral genome replication", "OBSERVATION", 166, 190]]], ["These results indicate that pAPN plays a decisive role in TGEV infection and only a contributing role in PDCoV infection in IPI-2I cells.", [["PDCoV", "ANATOMY", 105, 110], ["IPI-2I cells", "ANATOMY", 124, 136], ["pAPN", "CHEMICAL", 28, 32], ["infection", "DISEASE", 63, 72], ["infection", "DISEASE", 111, 120], ["pAPN", "GENE_OR_GENE_PRODUCT", 28, 32], ["TGEV", "ORGANISM", 58, 62], ["PDCoV", "CANCER", 105, 110], ["IPI-2I cells", "CELL", 124, 136], ["pAPN", "PROTEIN", 28, 32], ["IPI-2I cells", "CELL_LINE", 124, 136], ["TGEV", "SPECIES", 58, 62], ["PDCoV", "SPECIES", 105, 110], ["TGEV infection", "PROBLEM", 58, 72], ["PDCoV infection", "PROBLEM", 105, 120], ["infection", "OBSERVATION", 63, 72], ["infection", "OBSERVATION", 111, 120]]], ["Coincidentally, pAPN was initially identified as a PEDV-binding protein in swine kidney cells by virus overlay protein binding assay, and non-susceptible cell lines expressing pAPN became susceptible to PEDV 40, 41 .", [["kidney cells", "ANATOMY", 81, 93], ["cell lines", "ANATOMY", 154, 164], ["pAPN", "GENE_OR_GENE_PRODUCT", 16, 20], ["PEDV", "GENE_OR_GENE_PRODUCT", 51, 55], ["swine", "ORGANISM", 75, 80], ["kidney cells", "CELL", 81, 93], ["cell lines", "CELL", 154, 164], ["pAPN", "GENE_OR_GENE_PRODUCT", 176, 180], ["pAPN", "PROTEIN", 16, 20], ["PEDV-binding protein", "PROTEIN", 51, 71], ["swine kidney cells", "CELL_TYPE", 75, 93], ["non-susceptible cell lines", "CELL_LINE", 138, 164], ["pAPN", "PROTEIN", 176, 180], ["swine", "SPECIES", 75, 80], ["swine", "SPECIES", 75, 80], ["PEDV", "SPECIES", 203, 207], ["a PEDV-binding protein in swine kidney cells", "PROBLEM", 49, 93], ["virus overlay protein binding assay", "TEST", 97, 132], ["non-susceptible cell lines", "TREATMENT", 138, 164], ["PEDV", "PROBLEM", 203, 207], ["kidney", "ANATOMY", 81, 87], ["non-susceptible cell lines", "OBSERVATION", 138, 164]]], ["However, more recent evidence showed that pAPN knockout did not decrease PEDV infection, and no interaction between PEDV S1 and pAPN was detected, implying that pAPN is not a functional receptor for PEDV entry 37 .", [["PEDV", "CHEMICAL", 73, 77], ["infection", "DISEASE", 78, 87], ["pAPN", "GENE_OR_GENE_PRODUCT", 42, 46], ["PEDV", "GENE_OR_GENE_PRODUCT", 73, 77], ["PEDV S1", "GENE_OR_GENE_PRODUCT", 116, 123], ["pAPN", "GENE_OR_GENE_PRODUCT", 128, 132], ["pAPN", "GENE_OR_GENE_PRODUCT", 161, 165], ["pAPN", "PROTEIN", 42, 46], ["PEDV S1", "PROTEIN", 116, 123], ["pAPN", "PROTEIN", 128, 132], ["pAPN", "PROTEIN", 161, 165], ["PEDV entry 37", "PROTEIN", 199, 212], ["PEDV", "SPECIES", 73, 77], ["PEDV", "SPECIES", 116, 120], ["pAPN knockout", "PROBLEM", 42, 55], ["PEDV infection", "PROBLEM", 73, 87], ["PEDV entry", "TEST", 199, 209], ["decrease", "OBSERVATION_MODIFIER", 64, 72], ["PEDV", "OBSERVATION_MODIFIER", 73, 77], ["infection", "OBSERVATION", 78, 87], ["no", "UNCERTAINTY", 93, 95]]], ["Thus, whether pAPN promotes PDCoV or PEDV infection through direct interaction with S protein or along with other cellular proteins requires further investigation.DiscussionAPN is a 150-kDa type II glycoprotein in the metalloprotease family 31 .", [["cellular", "ANATOMY", 114, 122], ["pAPN", "CHEMICAL", 14, 18], ["PDCoV", "CHEMICAL", 28, 33], ["infection", "DISEASE", 42, 51], ["pAPN", "GENE_OR_GENE_PRODUCT", 14, 18], ["PDCoV", "GENE_OR_GENE_PRODUCT", 28, 33], ["PEDV", "GENE_OR_GENE_PRODUCT", 37, 41], ["S protein", "GENE_OR_GENE_PRODUCT", 84, 93], ["cellular", "CELL", 114, 122], ["pAPN", "PROTEIN", 14, 18], ["S protein", "PROTEIN", 84, 93], ["cellular proteins", "PROTEIN", 114, 131], ["150-kDa type II glycoprotein", "PROTEIN", 182, 210], ["metalloprotease family 31", "PROTEIN", 218, 243], ["PDCoV", "SPECIES", 28, 33], ["PEDV", "SPECIES", 37, 41], ["pAPN promotes PDCoV", "PROBLEM", 14, 33], ["PEDV infection", "PROBLEM", 37, 51], ["S protein", "PROBLEM", 84, 93], ["other cellular proteins", "PROBLEM", 108, 131], ["further investigation", "TEST", 141, 162], ["PEDV", "OBSERVATION_MODIFIER", 37, 41], ["infection", "OBSERVATION", 42, 51]]], ["As a zinc-dependent metalloprotease, APN has multiple functions.", [["zinc", "CHEMICAL", 5, 9], ["zinc", "CHEMICAL", 5, 9], ["zinc", "SIMPLE_CHEMICAL", 5, 9], ["APN", "GENE_OR_GENE_PRODUCT", 37, 40], ["zinc-dependent metalloprotease", "PROTEIN", 5, 35], ["APN", "PROTEIN", 37, 40], ["a zinc-dependent metalloprotease", "TREATMENT", 3, 35], ["multiple", "OBSERVATION_MODIFIER", 45, 53]]], ["In its membrane-bound form, APN is involved in complex functions in cells, such as peptide cleavage, immune cell chemotaxis, and monocyte cell adhesion 42, 43 .", [["membrane", "ANATOMY", 7, 15], ["cells", "ANATOMY", 68, 73], ["immune cell", "ANATOMY", 101, 112], ["monocyte cell", "ANATOMY", 129, 142], ["membrane", "CELLULAR_COMPONENT", 7, 15], ["APN", "GENE_OR_GENE_PRODUCT", 28, 31], ["cells", "CELL", 68, 73], ["immune cell", "CELL", 101, 112], ["monocyte cell", "CELL", 129, 142], ["APN", "PROTEIN", 28, 31], ["complex functions in cells", "PROBLEM", 47, 73], ["peptide cleavage", "PROBLEM", 83, 99], ["immune cell chemotaxis", "TEST", 101, 123], ["monocyte cell adhesion", "TEST", 129, 151], ["immune cell chemotaxis", "OBSERVATION", 101, 123], ["monocyte cell", "OBSERVATION", 129, 142]]], ["One of the best-studied characterizations of APN is its receptor function in CoVs, including TGEV, HCoV-229E, feline infectious peritonitis virus, canine CoV, and PRCV from the genus Alphacoronavirus 31, 35, 44, 45 .", [["infectious peritonitis", "DISEASE", 117, 139], ["APN", "GENE_OR_GENE_PRODUCT", 45, 48], ["CoVs", "GENE_OR_GENE_PRODUCT", 77, 81], ["TGEV", "ORGANISM", 93, 97], ["HCoV-229E", "ORGANISM", 99, 108], ["feline infectious peritonitis virus", "ORGANISM", 110, 145], ["canine CoV", "ORGANISM", 147, 157], ["APN", "PROTEIN", 45, 48], ["feline infectious peritonitis virus", "SPECIES", 110, 145], ["canine", "SPECIES", 147, 153], ["TGEV", "SPECIES", 93, 97], ["HCoV-229E", "SPECIES", 99, 108], ["feline infectious peritonitis virus", "SPECIES", 110, 145], ["canine CoV", "SPECIES", 147, 157], ["PRCV", "SPECIES", 163, 167], ["APN", "PROBLEM", 45, 48], ["CoVs", "PROBLEM", 77, 81], ["TGEV", "TEST", 93, 97], ["HCoV", "TEST", 99, 103], ["feline infectious peritonitis virus", "PROBLEM", 110, 145], ["canine CoV", "TEST", 147, 157], ["PRCV", "TEST", 163, 167], ["the genus Alphacoronavirus", "TEST", 173, 199], ["infectious", "OBSERVATION_MODIFIER", 117, 127], ["peritonitis", "OBSERVATION", 128, 139], ["genus Alphacoronavirus", "ANATOMY", 177, 199]]], ["In this study, bestatin, an APN inhibitor that binds to its catalytic site, failed to affect PDCoV infection.", [["bestatin", "CHEMICAL", 15, 23], ["infection", "DISEASE", 99, 108], ["bestatin", "CHEMICAL", 15, 23], ["bestatin", "SIMPLE_CHEMICAL", 15, 23], ["APN", "GENE_OR_GENE_PRODUCT", 28, 31], ["PDCoV", "GENE_OR_GENE_PRODUCT", 93, 98], ["this study", "TEST", 3, 13], ["bestatin", "TREATMENT", 15, 23], ["an APN inhibitor", "TREATMENT", 25, 41], ["PDCoV infection", "PROBLEM", 93, 108], ["infection", "OBSERVATION", 99, 108]]], ["However, two inhibitors that alter APN epitope conformation both decreased PDCoV infection in IPI-2I cells.", [["IPI-2I cells", "ANATOMY", 94, 106], ["PDCoV", "CHEMICAL", 75, 80], ["infection", "DISEASE", 81, 90], ["APN", "GENE_OR_GENE_PRODUCT", 35, 38], ["PDCoV", "SIMPLE_CHEMICAL", 75, 80], ["IPI-2I cells", "CELL", 94, 106], ["APN", "PROTEIN", 35, 38], ["IPI-2I cells", "CELL_LINE", 94, 106], ["two inhibitors", "TREATMENT", 9, 23], ["APN epitope conformation", "PROBLEM", 35, 59], ["PDCoV infection in IPI", "PROBLEM", 75, 97], ["decreased", "OBSERVATION_MODIFIER", 65, 74], ["PDCoV", "OBSERVATION_MODIFIER", 75, 80], ["infection", "OBSERVATION", 81, 90], ["2I cells", "OBSERVATION", 98, 106]]], ["These data suggest that a specific conformation of the pAPN epitopes, not its enzymatic activity, is required in PDCoV infection.DiscussionCoV S proteins contribute to the first step of viral infection and seem to be a vital determinant of host range and tissue tropism.", [["tissue", "ANATOMY", 255, 261], ["infection", "DISEASE", 119, 128], ["viral infection", "DISEASE", 186, 201], ["pAPN", "GENE_OR_GENE_PRODUCT", 55, 59], ["PDCoV", "CANCER", 113, 118], ["DiscussionCoV S proteins", "GENE_OR_GENE_PRODUCT", 129, 153], ["tissue", "TISSUE", 255, 261], ["pAPN epitopes", "PROTEIN", 55, 68], ["DiscussionCoV S proteins", "PROTEIN", 129, 153], ["PDCoV", "SPECIES", 113, 118], ["the pAPN epitopes", "PROBLEM", 51, 68], ["PDCoV infection", "PROBLEM", 113, 128], ["DiscussionCoV S proteins", "PROBLEM", 129, 153], ["viral infection", "PROBLEM", 186, 201], ["tissue tropism", "PROBLEM", 255, 269], ["infection", "OBSERVATION", 119, 128], ["viral", "OBSERVATION_MODIFIER", 186, 191], ["infection", "OBSERVATION", 192, 201]]], ["Considering that pAPN is a functional receptor for TGEV, but not for PDCoV, we analyzed differences between PDCoV and TGEV S protein structures.", [["pAPN", "GENE_OR_GENE_PRODUCT", 17, 21], ["TGEV", "ORGANISM", 51, 55], ["PDCoV", "GENE_OR_GENE_PRODUCT", 69, 74], ["PDCoV", "CANCER", 108, 113], ["TGEV", "ORGANISM", 118, 122], ["pAPN", "PROTEIN", 17, 21], ["PDCoV", "PROTEIN", 69, 74], ["TGEV", "SPECIES", 51, 55], ["TGEV", "SPECIES", 118, 122], ["TGEV", "PROBLEM", 51, 55], ["PDCoV", "PROBLEM", 69, 74], ["PDCoV", "TEST", 108, 113]]], ["In general, S protein S1 subunits, which contain two independent, functional subdomains S1-NTD and S1-CTD, mediate viral entry into cells during CoV infection.", [["cells", "ANATOMY", 132, 137], ["infection", "DISEASE", 149, 158], ["S protein S1", "GENE_OR_GENE_PRODUCT", 12, 24], ["S1-NTD", "GENE_OR_GENE_PRODUCT", 88, 94], ["S1-CTD", "GENE_OR_GENE_PRODUCT", 99, 105], ["cells", "CELL", 132, 137], ["CoV", "ORGANISM", 145, 148], ["S protein S1 subunits", "PROTEIN", 12, 33], ["S1", "PROTEIN", 88, 90], ["NTD", "PROTEIN", 91, 94], ["S1", "PROTEIN", 99, 101], ["CTD", "PROTEIN", 102, 105], ["CTD", "PROBLEM", 102, 105], ["CoV infection", "PROBLEM", 145, 158], ["S1", "ANATOMY", 88, 90], ["S1", "ANATOMY", 99, 101], ["CoV", "OBSERVATION_MODIFIER", 145, 148], ["infection", "OBSERVATION", 149, 158]]], ["Although MHV S1-NTD is reported to recognize sugar receptors and a unique protein receptor carcinoembryonic antigen-related cell adhesion molecule 1 34 , protein receptor recognition for most CoVs depends on S1-CTD 46 .", [["sugar", "CHEMICAL", 45, 50], ["MHV S1", "ORGANISM", 9, 15], ["sugar receptors", "GENE_OR_GENE_PRODUCT", 45, 60], ["carcinoembryonic antigen-related cell adhesion molecule 1 34", "GENE_OR_GENE_PRODUCT", 91, 151], ["CoVs", "CANCER", 192, 196], ["MHV S1", "PROTEIN", 9, 15], ["NTD", "PROTEIN", 16, 19], ["sugar receptors", "PROTEIN", 45, 60], ["protein receptor carcinoembryonic antigen-related cell adhesion molecule 1 34", "PROTEIN", 74, 151], ["protein receptor", "PROTEIN", 154, 170], ["CoVs", "PROTEIN", 192, 196], ["S1", "PROTEIN", 208, 210], ["CTD 46", "PROTEIN", 211, 217], ["MHV", "SPECIES", 9, 12], ["sugar receptors", "TEST", 45, 60], ["a unique protein receptor carcinoembryonic antigen", "TEST", 65, 115], ["cell adhesion molecule", "TEST", 124, 146], ["protein receptor recognition", "TEST", 154, 182], ["cell adhesion", "OBSERVATION", 124, 137], ["S1", "ANATOMY", 208, 210]]], ["In particular, APN receptor in several alphacoronaviruses, such as TGEV and PRCV, interacts with S1-CTD 35 .", [["APN receptor", "GENE_OR_GENE_PRODUCT", 15, 27], ["alphacoronaviruses", "GENE_OR_GENE_PRODUCT", 39, 57], ["TGEV", "ORGANISM", 67, 71], ["PRCV", "GENE_OR_GENE_PRODUCT", 76, 80], ["S1-CTD", "GENE_OR_GENE_PRODUCT", 97, 103], ["APN receptor", "PROTEIN", 15, 27], ["alphacoronaviruses", "PROTEIN", 39, 57], ["PRCV", "PROTEIN", 76, 80], ["S1", "PROTEIN", 97, 99], ["CTD 35", "PROTEIN", 100, 106], ["TGEV", "SPECIES", 67, 71], ["several alphacoronaviruses", "PROBLEM", 31, 57], ["TGEV", "PROBLEM", 67, 71]]], ["Understanding the differences between S1-CTD structures of various CoVs is helpful to explain the role of pAPN in viral infection.", [["pAPN", "CHEMICAL", 106, 110], ["viral infection", "DISEASE", 114, 129], ["CoVs", "GENE_OR_GENE_PRODUCT", 67, 71], ["pAPN", "GENE_OR_GENE_PRODUCT", 106, 110], ["S1", "PROTEIN", 38, 40], ["CoVs", "PROTEIN", 67, 71], ["pAPN", "PROTEIN", 106, 110], ["various CoVs", "PROBLEM", 59, 71], ["viral infection", "PROBLEM", 114, 129], ["viral", "OBSERVATION_MODIFIER", 114, 119], ["infection", "OBSERVATION", 120, 129]]], ["Therefore, we analyzed the possible recognition of pAPN by PDCoV and TGEV S1-CTD.", [["pAPN", "GENE_OR_GENE_PRODUCT", 51, 55], ["PDCoV", "SIMPLE_CHEMICAL", 59, 64], ["TGEV", "ORGANISM", 69, 73], ["pAPN", "PROTEIN", 51, 55], ["PDCoV", "PROTEIN", 59, 64], ["TGEV S1-CTD", "PROTEIN", 69, 80], ["TGEV", "SPECIES", 69, 73], ["pAPN", "PROBLEM", 51, 55], ["CTD", "PROBLEM", 77, 80]]], ["We found that the \u03b21-\u03b22 and \u03b23-\u03b24 turns in TGEV S1-CTD strongly supported its interaction with pAPN.", [["\u03b21-\u03b22", "GENE_OR_GENE_PRODUCT", 18, 23], ["\u03b23-\u03b24", "GENE_OR_GENE_PRODUCT", 28, 33], ["TGEV", "ORGANISM", 43, 47], ["S1-CTD", "GENE_OR_GENE_PRODUCT", 48, 54], ["pAPN", "GENE_OR_GENE_PRODUCT", 95, 99], ["\u03b21", "PROTEIN", 18, 20], ["\u03b22", "PROTEIN", 21, 23], ["\u03b23", "PROTEIN", 28, 30], ["\u03b24", "PROTEIN", 31, 33], ["TGEV S1", "PROTEIN", 43, 50], ["CTD", "PROTEIN", 51, 54], ["pAPN", "PROTEIN", 95, 99], ["TGEV", "SPECIES", 43, 47], ["the \u03b21", "TEST", 14, 20], ["\u03b23", "TEST", 28, 30], ["TGEV S1", "ANATOMY", 43, 50]]], ["However, for PDCoV S1-CTD, only residues at the top of the \u03b21-\u03b22 turn contacted pAPN.", [["PDCoV S1", "GENE_OR_GENE_PRODUCT", 13, 21], ["\u03b21-\u03b22", "GENE_OR_GENE_PRODUCT", 59, 64], ["pAPN", "GENE_OR_GENE_PRODUCT", 80, 84], ["PDCoV S1", "PROTEIN", 13, 21], ["CTD", "PROTEIN", 22, 25], ["\u03b21", "PROTEIN", 59, 61], ["\u03b22", "PROTEIN", 62, 64], ["pAPN", "PROTEIN", 80, 84], ["CTD", "PROBLEM", 22, 25]]], ["The markedly shorter \u03b21-\u03b22 and \u03b23-\u03b24 turns in PDCoV S1-CTD may cause insufficient contact with pAPN during viral attachment.", [["\u03b21-\u03b22", "GENE_OR_GENE_PRODUCT", 21, 26], ["\u03b23-\u03b24", "GENE_OR_GENE_PRODUCT", 31, 36], ["PDCoV S1-CTD", "GENE_OR_GENE_PRODUCT", 46, 58], ["pAPN", "GENE_OR_GENE_PRODUCT", 95, 99], ["\u03b21", "PROTEIN", 21, 23], ["\u03b22", "PROTEIN", 24, 26], ["\u03b23", "PROTEIN", 31, 33], ["\u03b24", "PROTEIN", 34, 36], ["PDCoV S1", "PROTEIN", 46, 54], ["CTD", "PROTEIN", 55, 58], ["pAPN", "PROTEIN", 95, 99], ["viral attachment", "PROBLEM", 107, 123], ["markedly", "OBSERVATION_MODIFIER", 4, 12], ["shorter", "OBSERVATION_MODIFIER", 13, 20], ["S1", "ANATOMY", 52, 54], ["viral attachment", "OBSERVATION", 107, 123]]], ["These findings may help explain the limited role of pAPN in PDCoV infection.", [["PDCoV", "ANATOMY", 60, 65], ["pAPN", "CHEMICAL", 52, 56], ["infection", "DISEASE", 66, 75], ["pAPN", "GENE_OR_GENE_PRODUCT", 52, 56], ["PDCoV", "CANCER", 60, 65], ["pAPN", "PROTEIN", 52, 56], ["PDCoV", "SPECIES", 60, 65], ["PDCoV infection", "PROBLEM", 60, 75], ["infection", "OBSERVATION", 66, 75]]], ["PDCoV can be detected in other tissues of infected pigs 1, 4, 10, 47 , suggesting that another, unidentified protein may contribute to the PDCoV recognition and entry processes.", [["tissues", "ANATOMY", 31, 38], ["PDCoV", "CHEMICAL", 0, 5], ["PDCoV", "GENE_OR_GENE_PRODUCT", 0, 5], ["tissues", "TISSUE", 31, 38], ["pigs", "ORGANISM", 51, 55], ["PDCoV", "PROTEIN", 0, 5], ["pigs", "SPECIES", 51, 55], ["PDCoV", "TREATMENT", 0, 5], ["unidentified protein", "PROBLEM", 96, 116], ["the PDCoV recognition", "PROBLEM", 135, 156], ["infected", "OBSERVATION", 42, 50]]], ["In addition, the S gene of CoV has been shaped by recombination and positive selection that may have led to changes in receptorbinding affinity 48, 49 .", [["CoV", "GENE_OR_GENE_PRODUCT", 27, 30], ["S gene", "DNA", 17, 23], ["CoV", "DNA", 27, 30], ["changes in receptorbinding affinity", "PROBLEM", 108, 143]]], ["For example, isolated MERS-CoV strains from a recent outbreak in South Korea had point mutations in S1-CTD and showed decreased binding ability to the cellular receptor 50 .", [["cellular", "ANATOMY", 151, 159], ["MERS-CoV strains", "ORGANISM", 22, 38], ["S1-CTD", "GENE_OR_GENE_PRODUCT", 100, 106], ["cellular", "CELL", 151, 159], ["S1", "PROTEIN", 100, 102], ["CTD", "PROTEIN", 103, 106], ["cellular receptor 50", "PROTEIN", 151, 171], ["MERS-CoV", "SPECIES", 22, 30], ["isolated MERS", "PROBLEM", 13, 26], ["CoV strains", "PROBLEM", 27, 38], ["point mutations in S1-CTD", "PROBLEM", 81, 106], ["decreased binding ability", "PROBLEM", 118, 143], ["CoV strains", "OBSERVATION", 27, 38], ["decreased", "OBSERVATION", 118, 127]]], ["A highly neurotropic MHV JHMV strain infected host cells through a carcinoembryonic antigen-related cell adhesion molecule 1 receptor-independent manner 51 .", [["cells", "ANATOMY", 51, 56], ["MHV JHMV", "ORGANISM", 21, 29], ["host cells", "CELL", 46, 56], ["carcinoembryonic antigen-related cell adhesion molecule 1 receptor", "GENE_OR_GENE_PRODUCT", 67, 133], ["carcinoembryonic antigen-related cell adhesion molecule 1 receptor", "PROTEIN", 67, 133], ["MHV", "SPECIES", 21, 24], ["JHMV", "SPECIES", 25, 29], ["A highly neurotropic MHV JHMV strain infected host cells", "PROBLEM", 0, 56], ["a carcinoembryonic antigen", "TEST", 65, 91], ["cell adhesion molecule", "TREATMENT", 100, 122], ["highly", "OBSERVATION_MODIFIER", 2, 8], ["neurotropic MHV", "OBSERVATION", 9, 24], ["infected", "OBSERVATION_MODIFIER", 37, 45], ["host cells", "OBSERVATION", 46, 56], ["cell adhesion", "OBSERVATION", 100, 113]]], ["However, whether the evolution of PDCoV S1-CTD is responsible for the shorter \u03b21-\u03b22 and \u03b23-\u03b24 turns and impaired ability to use pAPN requires further investigation.", [["PDCoV S1", "GENE_OR_GENE_PRODUCT", 34, 42], ["CTD", "GENE_OR_GENE_PRODUCT", 43, 46], ["\u03b21-\u03b22", "GENE_OR_GENE_PRODUCT", 78, 83], ["\u03b23-\u03b24", "GENE_OR_GENE_PRODUCT", 88, 93], ["pAPN", "GENE_OR_GENE_PRODUCT", 128, 132], ["PDCoV S1", "PROTEIN", 34, 42], ["CTD", "PROTEIN", 43, 46], ["\u03b21", "PROTEIN", 78, 80], ["\u03b22", "PROTEIN", 81, 83], ["\u03b23", "PROTEIN", 88, 90], ["\u03b24", "PROTEIN", 91, 93], ["pAPN", "PROTEIN", 128, 132], ["PDCoV S1-CTD", "PROBLEM", 34, 46], ["pAPN", "TREATMENT", 128, 132], ["further investigation", "TEST", 142, 163]]], ["Moreover, the receptor-binding region of CTD is believed to bear mainly Fig. 8 Homologous modeling of PDCoV or TGEV S1-CTD with pAPN. a Sequence alignment was conducted with PDCoV S1-CTD (GenBank accession no. ALS54086.1) and TGEV S1-CTD (GenBank accession no. ADY39740.1).", [["ADY39740.1", "CHEMICAL", 261, 271], ["ADY39740.1", "CHEMICAL", 261, 271], ["CTD", "GENE_OR_GENE_PRODUCT", 41, 44], ["PDCoV", "CANCER", 102, 107], ["TGEV", "ORGANISM", 111, 115], ["pAPN", "GENE_OR_GENE_PRODUCT", 128, 132], ["receptor-binding region", "PROTEIN", 14, 37], ["CTD", "PROTEIN", 41, 44], ["CTD", "PROTEIN", 119, 122], ["pAPN", "PROTEIN", 128, 132], ["PDCoV S1", "DNA", 174, 182], ["CTD", "PROTEIN", 183, 186], ["ALS54086.1", "PROTEIN", 210, 220], ["TGEV S1", "DNA", 226, 233], ["CTD", "PROTEIN", 234, 237], ["TGEV", "SPECIES", 111, 115], ["PDCoV", "SPECIES", 102, 107], ["TGEV", "SPECIES", 111, 115], ["TGEV", "SPECIES", 226, 230], ["PDCoV", "TREATMENT", 102, 107], ["pAPN", "TREATMENT", 128, 132], ["a Sequence alignment", "TEST", 134, 154], ["CTD", "OBSERVATION", 41, 44], ["believed to bear", "UNCERTAINTY", 48, 64]]], ["The secondary structures of S1-CTD were analyzed using the ESPript website (http://espript.ibcp.fr/ESPript/ESPript/index.php). b, c The three-dimensional structures of PDCoV S1-CTD (yellow; PDB ID 6B7N), TGEV S1-CTD (red; PDB ID 4F2M), and pAPN (blue; PDB ID 4F5C) obtained from the Protein Data Bank were analyzed with PyMOL software epitopes recognized by CoV neutralizing antibodies 35, 50, 52, 53 .", [["S1-CTD", "GENE_OR_GENE_PRODUCT", 28, 34], ["S1", "PROTEIN", 28, 30], ["CTD", "PROTEIN", 31, 34], ["PDCoV S1", "PROTEIN", 168, 176], ["CTD", "PROTEIN", 177, 180], ["PDB", "PROTEIN", 190, 193], ["6B7N", "PROTEIN", 197, 201], ["TGEV S1", "PROTEIN", 204, 211], ["CTD", "PROTEIN", 212, 215], ["red", "PROTEIN", 217, 220], ["PDB", "PROTEIN", 222, 225], ["4F2M", "PROTEIN", 229, 233], ["pAPN", "PROTEIN", 240, 244], ["PDB", "PROTEIN", 252, 255], ["4F5C", "PROTEIN", 259, 263], ["CoV neutralizing antibodies 35, 50, 52, 53", "PROTEIN", 358, 400], ["PDCoV", "TEST", 168, 173], ["CTD", "TEST", 177, 180], ["yellow", "TEST", 182, 188], ["PDB ID 6B7N", "TEST", 190, 201], ["TGEV", "TEST", 204, 208], ["CTD", "PROBLEM", 212, 215], ["PDB ID 4F2M", "TEST", 222, 233], ["CoV neutralizing antibodies", "TEST", 358, 385], ["S1", "ANATOMY", 28, 30], ["PDCoV S1", "ANATOMY", 168, 176]]], ["Thus, the receptor-binding regions of CoVs are under selective pressure from the host immune system.", [["immune system", "ANATOMY", 86, 99], ["CoVs", "GENE_OR_GENE_PRODUCT", 38, 42], ["immune system", "ANATOMICAL_SYSTEM", 86, 99], ["receptor-binding regions", "PROTEIN", 10, 34], ["CoVs", "PROTEIN", 38, 42], ["CoVs", "PROBLEM", 38, 42], ["CoVs", "OBSERVATION", 38, 42], ["host immune system", "OBSERVATION", 81, 99]]], ["We speculate that the shorter \u03b21-\u03b22 and \u03b23-\u03b24 turns in PDCoV S1-CTD compared with TGEV S1-CTD may be the result of positive immune pressure from the host.", [["\u03b21-\u03b22", "GENE_OR_GENE_PRODUCT", 30, 35], ["\u03b23-\u03b24", "GENE_OR_GENE_PRODUCT", 40, 45], ["PDCoV S1-CTD", "GENE_OR_GENE_PRODUCT", 55, 67], ["TGEV S1-CTD", "ORGANISM", 82, 93], ["\u03b21", "PROTEIN", 30, 32], ["\u03b22", "PROTEIN", 33, 35], ["\u03b23", "PROTEIN", 40, 42], ["\u03b24", "PROTEIN", 43, 45], ["PDCoV S1", "PROTEIN", 55, 63], ["CTD", "PROTEIN", 64, 67], ["CTD", "PROTEIN", 90, 93], ["TGEV", "SPECIES", 82, 86], ["\u03b23", "TEST", 40, 42], ["CTD", "PROBLEM", 64, 67], ["CTD", "PROBLEM", 90, 93], ["positive immune pressure", "PROBLEM", 115, 139], ["S1", "ANATOMY", 61, 63], ["positive immune pressure", "OBSERVATION", 115, 139]]], ["Conformational changes help PDCoV to evade host immune surveillance, while the ability of PDCoV to hijack pAPN may be impaired.", [["PDCoV", "GENE_OR_GENE_PRODUCT", 28, 33], ["PDCoV", "GENE_OR_GENE_PRODUCT", 90, 95], ["pAPN", "GENE_OR_GENE_PRODUCT", 106, 110], ["pAPN", "PROTEIN", 106, 110], ["Conformational changes", "PROBLEM", 0, 22], ["host immune surveillance", "TEST", 43, 67], ["PDCoV", "TREATMENT", 90, 95], ["impaired", "OBSERVATION", 118, 126]]], ["These findings imply that a yet unidentified receptor may be utilized by PDCoV in the process of viral evolution and variation.DiscussionIn this study, PDCoV exhibited a low level of infection in HeLa cells, a human cell line.", [["HeLa cells", "ANATOMY", 196, 206], ["cell line", "ANATOMY", 216, 225], ["infection", "DISEASE", 183, 192], ["PDCoV", "GENE_OR_GENE_PRODUCT", 73, 78], ["HeLa cells", "CELL", 196, 206], ["human", "ORGANISM", 210, 215], ["cell line", "CELL", 216, 225], ["HeLa cells", "CELL_LINE", 196, 206], ["human cell line", "CELL_LINE", 210, 225], ["human", "SPECIES", 210, 215], ["human", "SPECIES", 210, 215], ["this study", "TEST", 140, 150], ["a low level of infection in HeLa cells", "PROBLEM", 168, 206], ["a human cell line", "TREATMENT", 208, 225], ["viral evolution", "OBSERVATION", 97, 112], ["low level", "OBSERVATION_MODIFIER", 170, 179], ["infection", "OBSERVATION", 183, 192], ["HeLa cells", "OBSERVATION", 196, 206], ["human cell line", "OBSERVATION", 210, 225]]], ["Purified PDCoV S1-CTD binds to both human and porcine cells with high affinity 27 , suggesting that a co-receptor(s) exists on the surface of both human and porcine cells.", [["cells", "ANATOMY", 54, 59], ["surface", "ANATOMY", 131, 138], ["cells", "ANATOMY", 165, 170], ["PDCoV S1-CTD", "GENE_OR_GENE_PRODUCT", 9, 21], ["human", "ORGANISM", 36, 41], ["porcine", "ORGANISM", 46, 53], ["cells", "CELL", 54, 59], ["surface", "CELLULAR_COMPONENT", 131, 138], ["human", "ORGANISM", 147, 152], ["porcine", "ORGANISM", 157, 164], ["cells", "CELL", 165, 170], ["PDCoV S1", "PROTEIN", 9, 17], ["CTD", "PROTEIN", 18, 21], ["human and porcine cells", "CELL_TYPE", 36, 59], ["co-receptor", "PROTEIN", 102, 113], ["human and porcine cells", "CELL_TYPE", 147, 170], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 147, 152], ["porcine", "SPECIES", 157, 164], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 147, 152], ["CTD binds", "PROBLEM", 18, 27], ["high affinity", "PROBLEM", 65, 78], ["high affinity", "OBSERVATION", 65, 78], ["porcine cells", "OBSERVATION", 157, 170]]], ["We therefore evaluated the role of hAPN in PDCoV infection.", [["PDCoV", "ANATOMY", 43, 48], ["hAPN", "CHEMICAL", 35, 39], ["PDCoV infection", "DISEASE", 43, 58], ["hAPN", "GENE_OR_GENE_PRODUCT", 35, 39], ["PDCoV", "CANCER", 43, 48], ["hAPN", "PROTEIN", 35, 39], ["PDCoV", "SPECIES", 43, 48], ["PDCoV infection", "PROBLEM", 43, 58], ["infection", "OBSERVATION", 49, 58]]], ["PDCoV efficiently infected non-susceptible BHK-21 cells expressing hAPN by transient transfection, as demonstrated by detection of PDCoV S protein-specific fluorescence.", [["BHK-21 cells", "ANATOMY", 43, 55], ["PDCoV", "CHEMICAL", 0, 5], ["PDCoV", "SIMPLE_CHEMICAL", 0, 5], ["BHK-21 cells", "CELL", 43, 55], ["hAPN", "CELL", 67, 71], ["PDCoV S", "GENE_OR_GENE_PRODUCT", 131, 138], ["PDCoV", "CELL_LINE", 0, 5], ["BHK-21 cells", "CELL_LINE", 43, 55], ["hAPN", "PROTEIN", 67, 71], ["PDCoV S protein", "PROTEIN", 131, 146], ["PDCoV", "SPECIES", 0, 5], ["BHK-21", "SPECIES", 43, 49], ["PDCoV efficiently infected non-susceptible BHK", "PROBLEM", 0, 46], ["transient transfection", "PROBLEM", 75, 97], ["PDCoV S protein", "TEST", 131, 146], ["infected", "OBSERVATION_MODIFIER", 18, 26], ["non-susceptible BHK", "OBSERVATION", 27, 46], ["21 cells", "OBSERVATION_MODIFIER", 47, 55], ["transient", "OBSERVATION_MODIFIER", 75, 84], ["transfection", "OBSERVATION", 85, 97]]], ["However, TGEV failed to infect BHK-21 cells overexpressing hAPN (data not shown).", [["BHK-21 cells", "ANATOMY", 31, 43], ["TGEV", "ORGANISM", 9, 13], ["BHK-21 cells", "CELL", 31, 43], ["hAPN", "CELL", 59, 63], ["BHK-21 cells", "CELL_LINE", 31, 43], ["hAPN", "PROTEIN", 59, 63], ["TGEV", "SPECIES", 9, 13], ["BHK-21", "SPECIES", 31, 37], ["TGEV", "PROBLEM", 9, 13], ["BHK", "TEST", 31, 34]]], ["These observations suggest that PDCoV may employ both pAPN and hAPN, while TGEV can only employ pAPN.", [["PDCoV", "CHEMICAL", 32, 37], ["PDCoV", "SIMPLE_CHEMICAL", 32, 37], ["pAPN", "GENE_OR_GENE_PRODUCT", 54, 58], ["hAPN", "GENE_OR_GENE_PRODUCT", 63, 67], ["TGEV", "ORGANISM", 75, 79], ["pAPN", "GENE_OR_GENE_PRODUCT", 96, 100], ["pAPN", "PROTEIN", 54, 58], ["hAPN", "PROTEIN", 63, 67], ["pAPN", "PROTEIN", 96, 100], ["TGEV", "SPECIES", 75, 79], ["PDCoV", "TREATMENT", 32, 37], ["hAPN", "TREATMENT", 63, 67], ["TGEV", "PROBLEM", 75, 79]]], ["In addition, a previous study suggested that calves are also susceptible to PDCoV infection 54 .", [["infection", "DISEASE", 82, 91], ["calves", "ORGANISM", 45, 51], ["calves", "SPECIES", 45, 51], ["calves", "SPECIES", 45, 51], ["PDCoV", "SPECIES", 76, 81], ["a previous study", "TEST", 13, 29], ["PDCoV infection", "PROBLEM", 76, 91], ["calves", "ANATOMY", 45, 51], ["infection", "OBSERVATION", 82, 91]]], ["Although no diarrhea or other clinical signs were observed in PDCoV-inoculated calves, persistent fecal viral RNA shedding and serum IgG antibody responses against PDCoV were detected 54 .", [["calves", "ANATOMY", 79, 85], ["fecal", "ANATOMY", 98, 103], ["serum", "ANATOMY", 127, 132], ["diarrhea", "DISEASE", 12, 20], ["PDCoV", "CHEMICAL", 62, 67], ["PDCoV", "SIMPLE_CHEMICAL", 62, 67], ["calves", "ORGANISM", 79, 85], ["fecal", "ORGANISM_SUBSTANCE", 98, 103], ["serum", "ORGANISM_SUBSTANCE", 127, 132], ["IgG", "GENE_OR_GENE_PRODUCT", 133, 136], ["PDCoV", "CANCER", 164, 169], ["serum IgG antibody", "PROTEIN", 127, 145], ["calves", "SPECIES", 79, 85], ["PDCoV", "SPECIES", 164, 169], ["diarrhea", "PROBLEM", 12, 20], ["other clinical signs", "PROBLEM", 24, 44], ["inoculated calves", "PROBLEM", 68, 85], ["persistent fecal viral RNA shedding", "PROBLEM", 87, 122], ["serum IgG antibody responses", "TEST", 127, 155], ["PDCoV", "TEST", 164, 169], ["no", "UNCERTAINTY", 9, 11], ["diarrhea", "OBSERVATION", 12, 20], ["inoculated calves", "OBSERVATION", 68, 85], ["persistent", "OBSERVATION_MODIFIER", 87, 97], ["fecal", "ANATOMY", 98, 103], ["viral RNA", "OBSERVATION", 104, 113]]], ["These phenomena remind us of the potential risk for PDCoV infection with cross-species transmission.DiscussionIn addition to the protein receptor that is responsible for CoV S1-CTD, host sugar receptors also interact with S1-NTD to facilitate initial viral attachment to cells in some alpha-and betacoronaviruses 55, 56 .", [["cells", "ANATOMY", 271, 276], ["infection", "DISEASE", 58, 67], ["sugar", "CHEMICAL", 187, 192], ["PDCoV", "CANCER", 52, 57], ["CoV S1", "GENE_OR_GENE_PRODUCT", 170, 176], ["S1-NTD", "GENE_OR_GENE_PRODUCT", 222, 228], ["cells", "CELL", 271, 276], ["protein receptor", "PROTEIN", 129, 145], ["CoV S1", "PROTEIN", 170, 176], ["CTD", "PROTEIN", 177, 180], ["host sugar receptors", "PROTEIN", 182, 202], ["S1", "PROTEIN", 222, 224], ["NTD", "PROTEIN", 225, 228], ["PDCoV", "SPECIES", 52, 57], ["These phenomena", "PROBLEM", 0, 15], ["PDCoV infection", "PROBLEM", 52, 67], ["the protein receptor", "TREATMENT", 125, 145], ["CTD", "PROBLEM", 177, 180], ["host sugar receptors", "TEST", 182, 202], ["NTD", "PROBLEM", 225, 228], ["initial viral attachment to cells", "PROBLEM", 243, 276], ["infection", "OBSERVATION", 58, 67]]], ["The structural model of PDCoV S1-NTD presents a similar galectin fold to that of alpha-and betacoronaviruses, and the sugarbinding capability of PDCoV S1-NTD to mucin has been demonstrated through enzyme-linked immunosorbent assay 27 .", [["PDCoV S1", "GENE_OR_GENE_PRODUCT", 24, 32], ["galectin", "GENE_OR_GENE_PRODUCT", 56, 64], ["alpha", "GENE_OR_GENE_PRODUCT", 81, 86], ["betacoronaviruses", "GENE_OR_GENE_PRODUCT", 91, 108], ["PDCoV S1-NTD", "GENE_OR_GENE_PRODUCT", 145, 157], ["mucin", "GENE_OR_GENE_PRODUCT", 161, 166], ["PDCoV S1", "PROTEIN", 24, 32], ["NTD", "PROTEIN", 33, 36], ["alpha", "PROTEIN", 81, 86], ["PDCoV S1", "PROTEIN", 145, 153], ["NTD", "PROTEIN", 154, 157], ["mucin", "PROTEIN", 161, 166], ["alpha", "TEST", 81, 86], ["enzyme", "TEST", 197, 203], ["immunosorbent assay", "TEST", 211, 230]]], ["The specific effects of sugar receptors in PDCoV infection deserve deeper study.DiscussionIn summary, our results illustrate that pAPN could support PDCoV infection, independent of its enzymatic activity.", [["infection", "DISEASE", 49, 58], ["pAPN", "CHEMICAL", 130, 134], ["PDCoV", "CHEMICAL", 149, 154], ["infection", "DISEASE", 155, 164], ["sugar", "CHEMICAL", 24, 29], ["sugar receptors", "GENE_OR_GENE_PRODUCT", 24, 39], ["pAPN", "GENE_OR_GENE_PRODUCT", 130, 134], ["PDCoV", "GENE_OR_GENE_PRODUCT", 149, 154], ["sugar receptors", "PROTEIN", 24, 39], ["pAPN", "PROTEIN", 130, 134], ["PDCoV", "SPECIES", 149, 154], ["sugar receptors", "PROBLEM", 24, 39], ["PDCoV infection", "PROBLEM", 43, 58], ["deeper study", "TEST", 67, 79], ["PDCoV infection", "PROBLEM", 149, 164], ["infection", "OBSERVATION", 49, 58], ["infection", "OBSERVATION", 155, 164]]], ["However, whether pAPN promotes PDCoV infection through direct interaction with PDCoV S protein or with the cooperation of other host proteins must be further elucidated.", [["pAPN", "CHEMICAL", 17, 21], ["infection", "DISEASE", 37, 46], ["pAPN", "GENE_OR_GENE_PRODUCT", 17, 21], ["PDCoV", "GENE_OR_GENE_PRODUCT", 31, 36], ["PDCoV S protein", "GENE_OR_GENE_PRODUCT", 79, 94], ["pAPN", "PROTEIN", 17, 21], ["PDCoV S protein", "PROTEIN", 79, 94], ["host proteins", "PROTEIN", 128, 141], ["PDCoV infection", "PROBLEM", 31, 46], ["PDCoV S protein", "TREATMENT", 79, 94], ["other host proteins", "TREATMENT", 122, 141], ["PDCoV", "OBSERVATION_MODIFIER", 31, 36], ["infection", "OBSERVATION", 37, 46]]], ["The findings of slight infection in HeLa cells and successful infection in non-susceptible BHK-21 cells expressing hAPN suggest that a possible co-receptor exists in both porcine and human cells, revealing the potential risk for PDCoV cross-species transmission.", [["HeLa cells", "ANATOMY", 36, 46], ["BHK-21 cells", "ANATOMY", 91, 103], ["cells", "ANATOMY", 189, 194], ["infection", "DISEASE", 23, 32], ["infection", "DISEASE", 62, 71], ["HeLa cells", "CELL", 36, 46], ["BHK-21 cells", "CELL", 91, 103], ["hAPN", "GENE_OR_GENE_PRODUCT", 115, 119], ["porcine", "ORGANISM", 171, 178], ["human", "ORGANISM", 183, 188], ["cells", "CELL", 189, 194], ["HeLa cells", "CELL_LINE", 36, 46], ["non-susceptible BHK-21 cells", "CELL_LINE", 75, 103], ["hAPN", "PROTEIN", 115, 119], ["porcine and human cells", "CELL_TYPE", 171, 194], ["porcine", "SPECIES", 171, 178], ["human", "SPECIES", 183, 188], ["BHK-21", "SPECIES", 91, 97], ["porcine", "SPECIES", 171, 178], ["human", "SPECIES", 183, 188], ["slight infection in HeLa cells", "PROBLEM", 16, 46], ["successful infection in non-susceptible BHK", "PROBLEM", 51, 94], ["slight", "OBSERVATION_MODIFIER", 16, 22], ["infection", "OBSERVATION", 23, 32], ["HeLa cells", "OBSERVATION", 36, 46], ["successful", "OBSERVATION_MODIFIER", 51, 61], ["infection", "OBSERVATION", 62, 71]]], ["Therefore, detailed study focused on virus-host interactions and identification of critical functional receptor usage is necessary to increase the understanding of PDCoV infection.Construction of plasmidspAPN and human APN (hAPN) eukaryotic expression plasmids were constructed by cloning pAPN or hAPN cDNA into vector pCAGGS-Flag with an N-terminal Flag tag.", [["plasmids", "ANATOMY", 252, 260], ["infection", "DISEASE", 170, 179], ["PDCoV", "GENE_OR_GENE_PRODUCT", 164, 169], ["plasmidspAPN", "GENE_OR_GENE_PRODUCT", 196, 208], ["human", "ORGANISM", 213, 218], ["APN", "GENE_OR_GENE_PRODUCT", 219, 222], ["hAPN", "GENE_OR_GENE_PRODUCT", 224, 228], ["pAPN", "GENE_OR_GENE_PRODUCT", 289, 293], ["hAPN", "GENE_OR_GENE_PRODUCT", 297, 301], ["pCAGGS-Flag", "GENE_OR_GENE_PRODUCT", 319, 330], ["plasmidspAPN and human APN (hAPN) eukaryotic expression plasmids", "DNA", 196, 260], ["pAPN", "DNA", 289, 293], ["hAPN cDNA", "DNA", 297, 306], ["pCAGGS", "DNA", 319, 325], ["Flag", "PROTEIN", 326, 330], ["N-terminal Flag tag", "PROTEIN", 339, 358], ["human", "SPECIES", 213, 218], ["PDCoV", "SPECIES", 164, 169], ["human", "SPECIES", 213, 218], ["detailed study", "TEST", 11, 25], ["virus", "TREATMENT", 37, 42], ["PDCoV infection", "PROBLEM", 164, 179], ["plasmidspAPN", "TREATMENT", 196, 208], ["human APN (hAPN)", "TREATMENT", 213, 229], ["eukaryotic expression plasmids", "TREATMENT", 230, 260], ["cloning pAPN", "TREATMENT", 281, 293], ["an N-terminal Flag tag", "PROBLEM", 336, 358], ["infection", "OBSERVATION", 170, 179], ["Flag tag", "OBSERVATION", 350, 358]]], ["To knockout the pAPN gene in IPI-2I cells, two single-guide RNAs (sgRNAs) targeting exon 1 (5\u2032-GGTAGGCGGTACCGGTTCCA-3\u2032 and 5\u2032-GTCTGTCTGTGGTGTACGCCC-3\u2032) were designed and inserted into the PX459 background to generate sgRNA1 and sgRNA2 expression plasmids.", [["IPI-2I cells", "ANATOMY", 29, 41], ["pAPN", "GENE_OR_GENE_PRODUCT", 16, 20], ["IPI-2I cells", "CELL", 29, 41], ["5\u2032-GTCTGTCTGTGGTGTACGCCC-3", "GENE_OR_GENE_PRODUCT", 123, 149], ["PX459", "GENE_OR_GENE_PRODUCT", 188, 193], ["sgRNA1", "GENE_OR_GENE_PRODUCT", 217, 223], ["sgRNA2", "GENE_OR_GENE_PRODUCT", 228, 234], ["pAPN gene", "DNA", 16, 25], ["IPI-2I cells", "CELL_LINE", 29, 41], ["sgRNAs", "DNA", 66, 72], ["exon 1", "DNA", 84, 90], ["PX459", "DNA", 188, 193], ["sgRNA1 and sgRNA2 expression plasmids", "DNA", 217, 254], ["exon", "TEST", 84, 88], ["GGTAGGCGGTACCGGTTCCA", "TEST", 95, 115], ["sgRNA2 expression plasmids", "TREATMENT", 228, 254], ["expression plasmids", "OBSERVATION", 235, 254]]], ["All plasmids used were confirmed by sequencing.Treatment with APN-specific inhibitors or antibodyAPN inhibitors bestatin (TargetMol, USA), 2,2\u2032-dipyridyl, and 1,10-phenanthroline (Sigma, USA) were each dissolved in water at a concentration of 200 mM.", [["plasmids", "ANATOMY", 4, 12], ["bestatin", "CHEMICAL", 112, 120], ["TargetMol", "CHEMICAL", 122, 131], ["2,2\u2032-dipyridyl", "CHEMICAL", 139, 153], ["1,10-phenanthroline", "CHEMICAL", 159, 178], ["bestatin", "CHEMICAL", 112, 120], ["TargetMol", "CHEMICAL", 122, 131], ["2,2\u2032-dipyridyl", "CHEMICAL", 139, 153], ["1,10-phenanthroline", "CHEMICAL", 159, 178], ["APN", "GENE_OR_GENE_PRODUCT", 62, 65], ["antibodyAPN", "SIMPLE_CHEMICAL", 89, 100], ["bestatin", "SIMPLE_CHEMICAL", 112, 120], ["TargetMol", "SIMPLE_CHEMICAL", 122, 131], ["USA", "SIMPLE_CHEMICAL", 133, 136], ["2,2\u2032-dipyridyl", "SIMPLE_CHEMICAL", 139, 153], ["1,10-phenanthroline", "SIMPLE_CHEMICAL", 159, 178], ["Sigma, USA", "SIMPLE_CHEMICAL", 180, 190], ["water", "SIMPLE_CHEMICAL", 215, 220], ["plasmids", "DNA", 4, 12], ["APN", "PROTEIN", 62, 65], ["All plasmids", "TREATMENT", 0, 12], ["APN", "TREATMENT", 62, 65], ["specific inhibitors", "TREATMENT", 66, 85], ["antibodyAPN inhibitors bestatin", "TREATMENT", 89, 120], ["dipyridyl", "TREATMENT", 144, 153], ["phenanthroline", "TREATMENT", 164, 178], ["plasmids", "OBSERVATION", 4, 12]]], ["The inhibitors were then diluted to various concentrations for use at 300 \u03bcM (bestatin), 250 \u03bcM (2,2\u2032-dipyridyl), and 15 \u03bcM (1,10-phenanthroline) as previously described 36 .", [["bestatin", "CHEMICAL", 78, 86], ["2,2\u2032-dipyridyl", "CHEMICAL", 97, 111], ["1,10-phenanthroline", "CHEMICAL", 125, 144], ["bestatin", "CHEMICAL", 78, 86], ["(2,2\u2032-dipyridyl)", "CHEMICAL", 96, 112], ["(1,10-phenanthroline", "CHEMICAL", 124, 144], ["bestatin", "SIMPLE_CHEMICAL", 78, 86], ["2,2\u2032-dipyridyl", "SIMPLE_CHEMICAL", 97, 111], ["1,10-phenanthroline", "SIMPLE_CHEMICAL", 125, 144], ["The inhibitors", "TREATMENT", 0, 14], ["phenanthroline", "TREATMENT", 130, 144]]], ["IPI-2I cells cultured in 24-well plates were pre-incubated with inhibitors, rabbit polyclonal antibody against APN, or anti-Flag rabbit polyclonal antibody (control) for 1 h and subsequently infected with PDCoV [multiplicity of infection (MOI) = 2] for 1 h.", [["IPI-2I cells", "ANATOMY", 0, 12], ["PDCoV", "CHEMICAL", 205, 210], ["infection", "DISEASE", 228, 237], ["IPI-2I cells", "CELL", 0, 12], ["rabbit", "ORGANISM", 76, 82], ["APN", "GENE_OR_GENE_PRODUCT", 111, 114], ["IPI-2I cells", "CELL_LINE", 0, 12], ["rabbit polyclonal antibody", "PROTEIN", 76, 102], ["APN", "PROTEIN", 111, 114], ["anti-Flag rabbit polyclonal antibody", "PROTEIN", 119, 155], ["rabbit", "SPECIES", 76, 82], ["rabbit", "SPECIES", 129, 135], ["rabbit", "SPECIES", 76, 82], ["rabbit", "SPECIES", 129, 135], ["PDCoV", "SPECIES", 205, 210], ["IPI", "TEST", 0, 3], ["2I cells cultured", "TEST", 4, 21], ["inhibitors", "TREATMENT", 64, 74], ["rabbit polyclonal antibody", "TEST", 76, 102], ["APN", "TEST", 111, 114], ["anti-Flag rabbit polyclonal antibody", "TREATMENT", 119, 155], ["PDCoV", "TREATMENT", 205, 210], ["infection", "PROBLEM", 228, 237], ["infection", "OBSERVATION", 228, 237]]], ["The cells were further washed three times with Dulbecco's modified Eagle medium and maintained with inhibitors, APN antibody, or control antibody in cell culture containing 2.5 \u03bcg/ml trypsin.", [["cells", "ANATOMY", 4, 9], ["cell", "ANATOMY", 149, 153], ["cells", "CELL", 4, 9], ["APN", "GENE_OR_GENE_PRODUCT", 112, 115], ["cell", "CELL", 149, 153], ["trypsin", "GENE_OR_GENE_PRODUCT", 183, 190], ["APN antibody", "PROTEIN", 112, 124], ["trypsin", "PROTEIN", 183, 190], ["The cells", "TREATMENT", 0, 9], ["Dulbecco's modified Eagle medium", "TREATMENT", 47, 79], ["inhibitors", "TREATMENT", 100, 110], ["APN antibody", "TEST", 112, 124], ["control antibody in cell culture", "TEST", 129, 161]]], ["At 24 h post infection, cells were collected for IFA, and PDCoV titers in LLC-PK1 cells were determined by 50% tissue culture infective dose (TCID 50 ).Treatment with APN-specific inhibitors or antibodyInternalization assay IPI-2I-APN WT and IPI-2I-APN KO cells in 24-well plates with 90% confluence were inoculated with PDCoV (MOI = 30) for virus attachment at 4\u00b0C. After 1 h, the infected cells were washed three times with cold PBS and cultured at 37\u00b0C for another 1 h to allow virus internalization.", [["cells", "ANATOMY", 24, 29], ["LLC-PK1 cells", "ANATOMY", 74, 87], ["tissue culture", "ANATOMY", 111, 125], ["IPI-2I-APN KO cells", "ANATOMY", 242, 261], ["cells", "ANATOMY", 391, 396], ["PDCoV", "CHEMICAL", 321, 326], ["cells", "CELL", 24, 29], ["PDCoV", "SIMPLE_CHEMICAL", 58, 63], ["LLC-PK1 cells", "CELL", 74, 87], ["tissue", "TISSUE", 111, 117], ["APN", "GENE_OR_GENE_PRODUCT", 167, 170], ["IPI-2I-APN KO cells", "CELL", 242, 261], ["cells", "CELL", 391, 396], ["PDCoV", "PROTEIN", 58, 63], ["LLC-PK1 cells", "CELL_LINE", 74, 87], ["APN", "PROTEIN", 167, 170], ["IPI", "PROTEIN", 224, 227], ["APN", "PROTEIN", 231, 234], ["IPI-2I-APN KO cells", "CELL_LINE", 242, 261], ["infected cells", "CELL_TYPE", 382, 396], ["PDCoV", "SPECIES", 58, 63], ["infection", "PROBLEM", 13, 22], ["cells", "PROBLEM", 24, 29], ["IFA", "TEST", 49, 52], ["PDCoV titers", "TEST", 58, 70], ["PK1 cells", "TEST", 78, 87], ["APN", "TREATMENT", 167, 170], ["specific inhibitors", "TREATMENT", 171, 190], ["antibody", "TREATMENT", 194, 202], ["Internalization", "TEST", 202, 217], ["IPI", "TEST", 224, 227], ["APN WT", "TEST", 231, 237], ["IPI", "TEST", 242, 245], ["APN KO cells", "TEST", 249, 261], ["PDCoV", "TEST", 321, 326], ["MOI", "TEST", 328, 331], ["virus attachment", "PROBLEM", 342, 358], ["the infected cells", "PROBLEM", 378, 396], ["cold PBS", "TREATMENT", 426, 434], ["virus internalization", "TREATMENT", 481, 502], ["infection", "OBSERVATION", 13, 22], ["infected cells", "OBSERVATION", 382, 396]]], ["Then, the infected cells were washed with citrate buffer solution (pH = 3) to remove the bound but noninternalized virus particles.", [["cells", "ANATOMY", 19, 24], ["citrate", "CHEMICAL", 42, 49], ["citrate", "CHEMICAL", 42, 49], ["cells", "CELL", 19, 24], ["citrate", "SIMPLE_CHEMICAL", 42, 49], ["infected cells", "CELL_TYPE", 10, 24], ["the infected cells", "TREATMENT", 6, 24], ["citrate buffer solution", "TREATMENT", 42, 65], ["pH", "TEST", 67, 69], ["the bound", "PROBLEM", 85, 94], ["noninternalized virus particles", "PROBLEM", 99, 130], ["infected cells", "OBSERVATION", 10, 24]]], ["The cells were harvested for RT-qPCR and western blot to evaluate the effect of pAPN on PDCoV internalization.IPI-2I cells, BHK-21 cells, or HeLa cells in 24-well plateswere seeded on glass coverslips (NEST).", [["cells", "ANATOMY", 4, 9], ["IPI-2I cells", "ANATOMY", 110, 122], ["BHK-21 cells", "ANATOMY", 124, 136], ["HeLa cells", "ANATOMY", 141, 151], ["pAPN", "CHEMICAL", 80, 84], ["pAPN", "CHEMICAL", 80, 84], ["cells", "CELL", 4, 9], ["pAPN", "SIMPLE_CHEMICAL", 80, 84], ["PDCoV", "SIMPLE_CHEMICAL", 88, 93], ["IPI-2I cells", "CELL", 110, 122], ["BHK-21 cells", "CELL", 124, 136], ["HeLa cells", "CELL", 141, 151], ["pAPN", "PROTEIN", 80, 84], ["IPI-2I cells", "CELL_LINE", 110, 122], ["BHK-21 cells", "CELL_LINE", 124, 136], ["HeLa cells", "CELL_LINE", 141, 151], ["RT-qPCR", "TEST", 29, 36], ["western blot", "TEST", 41, 53], ["pAPN", "TREATMENT", 80, 84], ["PDCoV internalization", "TREATMENT", 88, 109], ["IPI", "TEST", 110, 113], ["BHK", "TEST", 124, 127], ["HeLa cells", "TEST", 141, 151]]], ["Cells were washed three times with phosphate-buffered saline (PBS) and then sealed with 4% paraformaldehyde in methanol for 15 min and methanol for 15 min.", [["Cells", "ANATOMY", 0, 5], ["phosphate", "CHEMICAL", 35, 44], ["methanol", "CHEMICAL", 111, 119], ["methanol", "CHEMICAL", 135, 143], ["phosphate", "CHEMICAL", 35, 44], ["paraformaldehyde", "CHEMICAL", 91, 107], ["methanol", "CHEMICAL", 111, 119], ["methanol", "CHEMICAL", 135, 143], ["Cells", "CELL", 0, 5], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 35, 60], ["paraformaldehyde", "SIMPLE_CHEMICAL", 91, 107], ["methanol", "SIMPLE_CHEMICAL", 111, 119], ["methanol", "SIMPLE_CHEMICAL", 135, 143], ["Cells", "TEST", 0, 5], ["phosphate-buffered saline (PBS", "TREATMENT", 35, 65], ["4% paraformaldehyde in methanol", "TREATMENT", 88, 119], ["methanol", "TREATMENT", 135, 143]]], ["Bovine serum albumin (5%) diluted in PBS was used to block cells for 1 h, and mouse monoclonal antibody against PDCoV S, TGEV M, or anti-Flag rabbit polyclonal antibody was then added and incubated for 1 h.", [["serum", "ANATOMY", 7, 12], ["cells", "ANATOMY", 59, 64], ["Bovine", "ORGANISM", 0, 6], ["serum", "ORGANISM_SUBSTANCE", 7, 12], ["albumin", "ORGANISM_SUBSTANCE", 13, 20], ["PBS", "SIMPLE_CHEMICAL", 37, 40], ["cells", "CELL", 59, 64], ["mouse", "ORGANISM", 78, 83], ["PDCoV S", "GENE_OR_GENE_PRODUCT", 112, 119], ["TGEV", "ORGANISM", 121, 125], ["anti-Flag", "GENE_OR_GENE_PRODUCT", 132, 141], ["mouse monoclonal antibody", "PROTEIN", 78, 103], ["PDCoV S", "PROTEIN", 112, 119], ["TGEV M", "PROTEIN", 121, 127], ["anti-Flag rabbit polyclonal antibody", "PROTEIN", 132, 168], ["Bovine", "SPECIES", 0, 6], ["mouse", "SPECIES", 78, 83], ["rabbit", "SPECIES", 142, 148], ["Bovine", "SPECIES", 0, 6], ["mouse", "SPECIES", 78, 83], ["PDCoV", "SPECIES", 112, 117], ["TGEV", "SPECIES", 121, 125], ["rabbit", "SPECIES", 142, 148], ["Bovine serum albumin", "TEST", 0, 20], ["PBS", "TREATMENT", 37, 40], ["block cells", "PROBLEM", 53, 64], ["mouse monoclonal antibody", "TEST", 78, 103], ["PDCoV S", "TEST", 112, 119], ["TGEV M", "TEST", 121, 127], ["anti-Flag rabbit polyclonal antibody", "TREATMENT", 132, 168]]], ["After three washes with PBS, Alexa Fluor-conjugated secondary antibodies were added and incubated for 1 h, followed by 0.01% 4\u2032,6-diamidino-2-phenylindole (DAPI) staining for 15 min to detect nuclei.", [["nuclei", "ANATOMY", 192, 198], ["4\u2032,6-diamidino-2-phenylindole", "CHEMICAL", 125, 154], ["DAPI", "CHEMICAL", 156, 160], ["4\u2032,6-diamidino-2-phenylindole", "CHEMICAL", 125, 154], ["DAPI", "CHEMICAL", 156, 160], ["Alexa Fluor", "SIMPLE_CHEMICAL", 29, 40], ["4\u2032,6-diamidino-2-phenylindole", "SIMPLE_CHEMICAL", 125, 154], ["DAPI", "SIMPLE_CHEMICAL", 156, 160], ["nuclei", "CELLULAR_COMPONENT", 192, 198], ["Alexa Fluor-conjugated secondary antibodies", "PROTEIN", 29, 72], ["Alexa", "SPECIES", 29, 34], ["PBS", "TREATMENT", 24, 27], ["Alexa Fluor-conjugated secondary antibodies", "TREATMENT", 29, 72], ["diamidino", "TREATMENT", 130, 139], ["nuclei", "ANATOMY", 192, 198]]], ["After three washes with PBS, fluorescent images were examined by confocal laser scanning microscopy (LSM 510 Meta, Carl Zeiss).IPI-2I cells, BHK-21 cells, or HeLa cells in 24-well platespAPN knockout by CRISPR/Cas9 genome-editing system Knockout of the pAPN gene in IPI-2I cells was performed as previously described 57 . sgRNA1 and sgRNA2 expression plasmids targeting exon 1 of pAPN gene were constructed.", [["IPI-2I cells", "ANATOMY", 127, 139], ["BHK-21 cells", "ANATOMY", 141, 153], ["HeLa cells", "ANATOMY", 158, 168], ["IPI-2I cells", "ANATOMY", 266, 278], ["IPI-2I cells", "CELL", 127, 139], ["BHK-21 cells", "CELL", 141, 153], ["HeLa cells", "CELL", 158, 168], ["platespAPN", "GENE_OR_GENE_PRODUCT", 180, 190], ["CRISPR/Cas9", "GENE_OR_GENE_PRODUCT", 203, 214], ["pAPN", "GENE_OR_GENE_PRODUCT", 253, 257], ["IPI-2I cells", "CELL", 266, 278], ["sgRNA1", "GENE_OR_GENE_PRODUCT", 322, 328], ["sgRNA2", "GENE_OR_GENE_PRODUCT", 333, 339], ["exon 1", "GENE_OR_GENE_PRODUCT", 370, 376], ["pAPN", "GENE_OR_GENE_PRODUCT", 380, 384], ["IPI-2I cells", "CELL_LINE", 127, 139], ["BHK-21 cells", "CELL_LINE", 141, 153], ["HeLa cells", "CELL_LINE", 158, 168], ["CRISPR/Cas9 genome", "DNA", 203, 221], ["pAPN gene", "DNA", 253, 262], ["IPI-2I cells", "CELL_LINE", 266, 278], ["sgRNA1 and sgRNA2 expression plasmids", "DNA", 322, 359], ["exon 1", "DNA", 370, 376], ["pAPN gene", "DNA", 380, 389], ["PBS", "TREATMENT", 24, 27], ["fluorescent images", "TEST", 29, 47], ["confocal laser scanning microscopy", "TEST", 65, 99], ["IPI", "TEST", 127, 130], ["BHK", "TEST", 141, 144], ["cells", "TEST", 148, 153], ["HeLa cells", "TEST", 158, 168], ["sgRNA1", "TEST", 322, 328], ["sgRNA2 expression plasmids", "TREATMENT", 333, 359]]], ["The two sgRNA expression plasmids (each 0.5 \u00b5g) were mixed and transfected into IPI-2I cells cultured in 24-well plates.", [["IPI-2I cells", "ANATOMY", 80, 92], ["IPI-2I cells", "CELL", 80, 92], ["sgRNA expression plasmids", "DNA", 8, 33], ["IPI-2I cells", "CELL_LINE", 80, 92], ["The two sgRNA expression plasmids", "TREATMENT", 0, 33], ["IPI", "TEST", 80, 83], ["sgRNA expression plasmids", "OBSERVATION", 8, 33]]], ["After 24 h, 1 \u00b5g/ml of puromycin (Sigma, USA) for IPI-2I cells was added to the cell culture for positive cell selection.", [["IPI-2I cells", "ANATOMY", 50, 62], ["cell", "ANATOMY", 80, 84], ["cell", "ANATOMY", 106, 110], ["puromycin", "CHEMICAL", 23, 32], ["puromycin", "CHEMICAL", 23, 32], ["puromycin", "SIMPLE_CHEMICAL", 23, 32], ["IPI-2I cells", "CELL", 50, 62], ["cell", "CELL", 80, 84], ["cell", "CELL", 106, 110], ["IPI-2I cells", "CELL_LINE", 50, 62], ["puromycin", "TREATMENT", 23, 32], ["IPI-2I cells", "TREATMENT", 50, 62], ["the cell culture", "TEST", 76, 92], ["positive cell selection", "PROBLEM", 97, 120], ["positive cell selection", "OBSERVATION", 97, 120]]], ["After 48 h incubation, surviving cells were treated with trypsin and harvested to detect indel mutations by the surveyor nuclease assay.", [["cells", "ANATOMY", 33, 38], ["cells", "CELL", 33, 38], ["trypsin", "GENE_OR_GENE_PRODUCT", 57, 64], ["surviving cells", "CELL_TYPE", 23, 38], ["trypsin", "PROTEIN", 57, 64], ["surviving cells", "PROBLEM", 23, 38], ["trypsin", "TREATMENT", 57, 64], ["indel mutations", "PROBLEM", 89, 104], ["the surveyor nuclease assay", "TEST", 108, 135]]], ["Clonal cell lines were isolated by dilution.", [["Clonal cell lines", "ANATOMY", 0, 17], ["Clonal cell lines", "CELL", 0, 17], ["Clonal cell lines", "CELL_LINE", 0, 17], ["Clonal cell lines", "TREATMENT", 0, 17], ["cell lines", "OBSERVATION", 7, 17]]], ["Approximately 60 cells in 10 ml of Dulbecco's modified Eagle medium were plated in each 96-well plate. pAPN knockout clonal cell lines were confirmed by sequencing and western blot.RNA extraction and RT-qPCRTotal RNA was extracted from PDCoV-infected cells by TRIzol reagent (Promega, USA).", [["cells", "ANATOMY", 17, 22], ["clonal cell lines", "ANATOMY", 117, 134], ["cells", "ANATOMY", 251, 256], ["cells", "CELL", 17, 22], ["pAPN", "GENE_OR_GENE_PRODUCT", 103, 107], ["clonal cell lines", "CELL", 117, 134], ["PDCoV", "SIMPLE_CHEMICAL", 236, 241], ["cells", "CELL", 251, 256], ["pAPN knockout clonal cell lines", "CELL_LINE", 103, 134], ["RT-qPCRTotal RNA", "RNA", 200, 216], ["PDCoV-infected cells", "CELL_LINE", 236, 256], ["Dulbecco's modified Eagle medium", "TREATMENT", 35, 67], ["pAPN knockout clonal cell lines", "TREATMENT", 103, 134], ["western blot", "TEST", 168, 180], ["RNA extraction", "TREATMENT", 181, 195], ["RT-qPCRTotal RNA", "TREATMENT", 200, 216], ["infected cells", "PROBLEM", 242, 256], ["TRIzol reagent", "TREATMENT", 260, 274], ["60 cells", "OBSERVATION_MODIFIER", 14, 22], ["clonal cell lines", "OBSERVATION", 117, 134], ["qPCRTotal RNA", "ANATOMY", 203, 216], ["infected cells", "OBSERVATION", 242, 256]]], ["Using AMV reverse transcriptase (Takara, Japan), RNA (1 \u03bcg) was then reverse-transcribed into cDNA, which acted as the template in the SYBR Green PCR assay.", [["AMV reverse transcriptase", "GENE_OR_GENE_PRODUCT", 6, 31], ["SYBR", "GENE_OR_GENE_PRODUCT", 135, 139], ["AMV reverse transcriptase", "PROTEIN", 6, 31], ["RNA", "RNA", 49, 52], ["cDNA", "DNA", 94, 98], ["AMV reverse transcriptase", "TREATMENT", 6, 31]]], ["RT-qPCR primers targeting PDCoV nsp16 (nsp16-F: 5\u2032-GCCCTCGGTGGTTCTATCTT-3\u2032, nsp16-R: 5\u2032-TCCTTAGCTTGCCCCAAATA-3\u2032) were used to measure PDCoV genome RNA copies.Western blot analysesCells cultured in six-well plates were harvested with lysis buffer (Beyotime, China) and boiled for 10 min with sample loading buffer (Beyotime, China).", [["Cells", "ANATOMY", 179, 184], ["sample", "ANATOMY", 291, 297], ["PDCoV nsp16", "GENE_OR_GENE_PRODUCT", 26, 37], ["nsp16-F", "GENE_OR_GENE_PRODUCT", 39, 46], ["nsp16-R", "GENE_OR_GENE_PRODUCT", 76, 83], ["PDCoV", "GENE_OR_GENE_PRODUCT", 134, 139], ["Cells", "CELL", 179, 184], ["RT-qPCR primers", "DNA", 0, 15], ["PDCoV nsp16", "DNA", 26, 37], ["nsp16", "DNA", 39, 44], ["nsp16", "DNA", 76, 81], ["PDCoV genome RNA copies", "DNA", 134, 157], ["RT", "TEST", 0, 2], ["qPCR primers", "TEST", 3, 15], ["PDCoV", "TEST", 26, 31], ["nsp16", "TEST", 39, 44], ["GCCCTCGGTGGTTCTATCTT", "TEST", 51, 71], ["nsp16", "TEST", 76, 81], ["TCCTTAGCTTGCCCCAAATA", "TEST", 88, 108], ["blot analyses", "TEST", 166, 179], ["Cells", "TEST", 179, 184], ["lysis buffer", "TREATMENT", 233, 245], ["sample loading buffer", "TREATMENT", 291, 312]]], ["The samples were then resolved by sodium dodecyl sulfatepolyacrylamide gel electrophoresis, and proteins were transferred to polyvinylidene difluoride membranes (Millipore, USA).", [["samples", "ANATOMY", 4, 11], ["sodium dodecyl sulfatepolyacrylamide", "CHEMICAL", 34, 70], ["sodium dodecyl sulfatepolyacrylamide", "CHEMICAL", 34, 70], ["polyvinylidene difluoride", "CHEMICAL", 125, 150], ["sodium dodecyl sulfatepolyacrylamide", "SIMPLE_CHEMICAL", 34, 70], ["membranes", "CELLULAR_COMPONENT", 151, 160], ["The samples", "TEST", 0, 11], ["sodium dodecyl sulfatepolyacrylamide gel electrophoresis", "TREATMENT", 34, 90], ["polyvinylidene difluoride membranes", "TREATMENT", 125, 160]]], ["The membranes were blocked with 5% bovine serum albumin at room temperature for 2 h and incubated with rabbit polyclonal antibody against APN or mouse monoclonal antibody against PDCoV N or TGEV N for 3 h.", [["membranes", "ANATOMY", 4, 13], ["serum", "ANATOMY", 42, 47], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["bovine", "ORGANISM", 35, 41], ["serum", "ORGANISM_SUBSTANCE", 42, 47], ["albumin", "ORGANISM_SUBSTANCE", 48, 55], ["rabbit", "ORGANISM", 103, 109], ["APN", "GENE_OR_GENE_PRODUCT", 138, 141], ["mouse", "ORGANISM", 145, 150], ["TGEV", "ORGANISM", 190, 194], ["rabbit polyclonal antibody", "PROTEIN", 103, 129], ["APN", "PROTEIN", 138, 141], ["mouse monoclonal antibody", "PROTEIN", 145, 170], ["PDCoV N", "PROTEIN", 179, 186], ["bovine", "SPECIES", 35, 41], ["rabbit", "SPECIES", 103, 109], ["mouse", "SPECIES", 145, 150], ["rabbit", "SPECIES", 103, 109], ["mouse", "SPECIES", 145, 150], ["PDCoV", "SPECIES", 179, 184], ["TGEV", "SPECIES", 190, 194], ["5% bovine serum albumin", "TREATMENT", 32, 55], ["rabbit polyclonal antibody", "TREATMENT", 103, 129], ["APN", "PROBLEM", 138, 141], ["mouse monoclonal antibody", "TREATMENT", 145, 170], ["PDCoV N", "TREATMENT", 179, 186], ["TGEV N", "TREATMENT", 190, 196]]], ["After washing three times, the membranes were incubated with horseradish peroxidase-conjugated antipolyclonal or -monoclonal antibody for another 1 h and washed three times.", [["membranes", "ANATOMY", 31, 40], ["membranes", "CELLULAR_COMPONENT", 31, 40], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 61, 83], ["conjugated antipolyclonal", "SIMPLE_CHEMICAL", 84, 109], ["horseradish peroxidase", "PROTEIN", 61, 83], ["conjugated antipolyclonal or -monoclonal antibody", "PROTEIN", 84, 133], ["horseradish", "SPECIES", 61, 72], ["horseradish peroxidase", "TREATMENT", 61, 83], ["conjugated antipolyclonal", "TREATMENT", 84, 109], ["monoclonal antibody", "TREATMENT", 114, 133]]], ["Proteins were detected using a western blot analysis system (Bio-Rad).Homology modelingThe structure information of proteins evaluated in our study was obtained from the Protein Data Bank (PDB) library. pAPN (PDB ID 4F5C), TGEV S (PDB ID 4F2M), and PDCoV S (PDB ID 6B7N) were chosen for analysis of S1-CTD and pAPN using PyMOL software (https:// pymol.org/2/).Statistical analysisAll experiments were performed in triplicate.", [["PDCoV S", "GENE_OR_GENE_PRODUCT", 249, 256], ["PDB ID 6B7N", "GENE_OR_GENE_PRODUCT", 258, 269], ["S1-CTD", "GENE_OR_GENE_PRODUCT", 299, 305], ["pAPN", "SIMPLE_CHEMICAL", 310, 314], ["Protein Data Bank (PDB) library", "DNA", 170, 201], ["pAPN", "PROTEIN", 203, 207], ["PDB ID 4F5C", "PROTEIN", 209, 220], ["TGEV S", "PROTEIN", 223, 229], ["4F2M", "PROTEIN", 238, 242], ["PDCoV S", "DNA", 249, 256], ["PDB ID 6B7N", "PROTEIN", 258, 269], ["S1", "PROTEIN", 299, 301], ["CTD", "PROTEIN", 302, 305], ["pAPN", "PROTEIN", 310, 314], ["pymol", "PROTEIN", 346, 351], ["Proteins", "TEST", 0, 8], ["a western blot analysis system", "TEST", 29, 59], ["our study", "TEST", 138, 147], ["PDCoV S", "TREATMENT", 249, 256], ["analysis", "TEST", 287, 295], ["CTD", "PROBLEM", 302, 305], ["Statistical analysis", "TEST", 360, 380]]], ["Student's t test was used to measure significant differences between groups.", [["Student's t test", "TEST", 0, 16]]], ["P values < 0.05 were considered statistically significant.", [["P values", "TEST", 0, 8]]]], "013d9fb8719d3d3d47738f9f0604f3b643c4df57": [["INTRODUCTIONNovel influenza virus strains have resulted in pandemics costing millions of lives 1 and the possible occurrence of a highly pathogenic virus strain is of concern to health authorities worldwide.ARTICLE SUMMARYArticle focus \u25aa This modelling study investigated the impact of an influenza pandemic on a community in Papua New Guinea (PNG) and compared it with that in a similar-sized community in Australia. \u25aa The effectiveness of social distancing interventions was determined using the PNG model and contrasted with the Australian model.Key messages\u25aa A moderately transmissible pandemic occurring in PNG may be expected to result in a larger illness attack rate compared with that in a developed country setting. \u25aa Feasible social distancing intervention strategies may be significantly less effective in PNG compared with the Australian setting. \u25aa Compared with Australia, the larger household sizes contribute both to the larger attack rates in PNG and to the lower effectiveness of the interventions. \u25aa The larger proportion of children in PNG and the fact that 50% do not attend school lessen the effectiveness of school closure interventions.Key messagesStrength and limitations of this study \u25aa The findings are a first step in understanding how an influenza pandemic will impact on a lowincome country. \u25aa As with all modelling studies obtaining highquality field data with which to 'populate' models is crucial and accessing such data in countries such as PNG is a challenge. \u25aa These results and those from future research will permit better pandemic planning and allow intervention strategies to be tailored to the specific demographics and resource constraints found in developing countries.Key messagesIt has been shown under laboratory conditions that the highly pathogenic H5N1 avian influenza strain may reassort or mutate to become readily transmissible between humans.", [["influenza pandemic", "DISEASE", 289, 307], ["illness", "DISEASE", 654, 661], ["influenza", "DISEASE", 1266, 1275], ["influenza", "DISEASE", 1807, 1816], ["INTRODUCTIONNovel influenza virus", "ORGANISM", 0, 33], ["children", "ORGANISM", 1043, 1051], ["H5N1", "ORGANISM", 1796, 1800], ["avian influenza strain", "ORGANISM", 1801, 1823], ["humans", "ORGANISM", 1887, 1893], ["influenza virus", "SPECIES", 18, 33], ["children", "SPECIES", 1043, 1051], ["H5N1 avian influenza", "SPECIES", 1796, 1816], ["humans", "SPECIES", 1887, 1893], ["humans", "SPECIES", 1887, 1893], ["influenza virus strains", "PROBLEM", 18, 41], ["a highly pathogenic virus strain", "PROBLEM", 128, 160], ["This modelling study", "TEST", 238, 258], ["an influenza pandemic", "PROBLEM", 286, 307], ["social distancing interventions", "TREATMENT", 441, 472], ["the PNG model", "TREATMENT", 494, 507], ["A moderately transmissible pandemic", "PROBLEM", 563, 598], ["a larger illness attack rate", "PROBLEM", 645, 673], ["Feasible social distancing intervention strategies", "TREATMENT", 727, 777], ["the interventions", "TREATMENT", 997, 1014], ["school closure interventions", "TREATMENT", 1130, 1158], ["this study", "TEST", 1199, 1209], ["an influenza pandemic", "PROBLEM", 1263, 1284], ["all modelling studies", "TEST", 1331, 1352], ["pandemic planning", "TREATMENT", 1560, 1577], ["intervention strategies", "TREATMENT", 1588, 1611], ["the highly pathogenic H5N1 avian influenza strain", "PROBLEM", 1774, 1823], ["pathogenic", "OBSERVATION_MODIFIER", 137, 147], ["virus", "OBSERVATION", 148, 153], ["influenza", "OBSERVATION", 289, 298], ["moderately", "OBSERVATION_MODIFIER", 565, 575], ["transmissible", "OBSERVATION_MODIFIER", 576, 589], ["pandemic", "OBSERVATION", 590, 598], ["larger", "OBSERVATION_MODIFIER", 647, 653], ["illness", "OBSERVATION", 654, 661], ["larger", "OBSERVATION_MODIFIER", 890, 896], ["sizes", "OBSERVATION_MODIFIER", 907, 912], ["larger", "OBSERVATION_MODIFIER", 936, 942], ["attack", "OBSERVATION_MODIFIER", 943, 949], ["rates", "OBSERVATION_MODIFIER", 950, 955], ["lower", "OBSERVATION_MODIFIER", 974, 979], ["larger", "OBSERVATION_MODIFIER", 1022, 1028], ["proportion", "OBSERVATION_MODIFIER", 1029, 1039]]], ["2 In response to the threat of influenza pandemics, most countries have developed pandemic preparedness plans.", [["influenza pandemics", "DISEASE", 31, 50], ["influenza pandemics", "PROBLEM", 31, 50]]], ["[3] [4] [5] [6] [7] [8] However, the level of completeness of these plans with regard to WHO guidelines 9 varies dramatically between developed high-income countries and developing low-income countries.", [["[3] [4] [5] [6] [7] [8]", "SIMPLE_CHEMICAL", 0, 23]]], ["7 8 Low-income countries suffer the highest rates of morbidity and mortality from influenza pandemics.", [["influenza pandemics", "DISEASE", 82, 101], ["morbidity", "PROBLEM", 53, 62], ["influenza pandemics", "PROBLEM", 82, 101]]], ["Data from the 1918/1919 pandemic suggest much higher death rates in India compared with Europe and the USA.", [["death", "DISEASE", 53, 58]]], ["While in northern Europe and the USA death rates were consistently below 1%, over 4.3% average mortality was reported from India, with some Indian provinces exceeding death rates of 7%.", [["death", "DISEASE", 37, 42], ["death", "DISEASE", 167, 172], ["the USA death rates", "TEST", 29, 48], ["death rates", "TEST", 167, 178]]], ["10 11 Even in the mild H1N1 pandemic of 2009, 59% of the estimated 284 500 deaths occurred in Africa and South-East Asia.", [["H1N1", "DISEASE", 23, 27], ["deaths", "DISEASE", 75, 81], ["the mild H1N1 pandemic", "PROBLEM", 14, 36], ["mild", "OBSERVATION_MODIFIER", 18, 22], ["H1N1", "OBSERVATION", 23, 27]]], ["2 These differences are most likely due to the significant association of influenza mortality with comorbidities usually absent in the developed countries (such as chronic malnutrition, malaria, tuberculosis, pneumonia and HIV).", [["influenza", "DISEASE", 74, 83], ["chronic malnutrition", "DISEASE", 164, 184], ["malaria", "DISEASE", 186, 193], ["tuberculosis", "DISEASE", 195, 207], ["pneumonia", "DISEASE", 209, 218], ["HIV", "DISEASE", 223, 226], ["HIV", "SPECIES", 223, 226], ["HIV", "SPECIES", 223, 226], ["influenza mortality", "PROBLEM", 74, 93], ["comorbidities", "PROBLEM", 99, 112], ["chronic malnutrition", "PROBLEM", 164, 184], ["malaria", "PROBLEM", 186, 193], ["tuberculosis", "PROBLEM", 195, 207], ["pneumonia", "PROBLEM", 209, 218], ["HIV", "PROBLEM", 223, 226], ["most likely due to", "UNCERTAINTY", 24, 42], ["influenza", "OBSERVATION", 74, 83], ["chronic", "OBSERVATION_MODIFIER", 164, 171], ["malnutrition", "OBSERVATION", 172, 184], ["malaria", "OBSERVATION", 186, 193], ["tuberculosis", "OBSERVATION", 195, 207], ["pneumonia", "OBSERVATION", 209, 218]]], ["12 Furthermore it has been shown that the increased death rate due to an influenza pandemic is strongly associated with per capita income.", [["death", "DISEASE", 52, 57], ["influenza pandemic", "DISEASE", 73, 91], ["the increased death rate", "PROBLEM", 38, 62], ["an influenza pandemic", "PROBLEM", 70, 91], ["increased", "OBSERVATION_MODIFIER", 42, 51], ["influenza", "OBSERVATION", 73, 82]]], ["5 11 13-15 A substantial number of pandemic influenza models have been constructed in the past decade.", [["influenza", "DISEASE", 44, 53], ["pandemic influenza models", "PROBLEM", 35, 60], ["substantial", "OBSERVATION_MODIFIER", 13, 24], ["number", "OBSERVATION_MODIFIER", 25, 31], ["pandemic influenza", "OBSERVATION", 35, 53]]], ["A key goal of this effort is to determine the effectiveness of interventions, in terms of their ability to reduce infection and consequential death rates.", [["infection", "DISEASE", 114, 123], ["death", "DISEASE", 142, 147], ["interventions", "TREATMENT", 63, 76], ["infection", "PROBLEM", 114, 123], ["consequential death rates", "PROBLEM", 128, 153], ["infection", "OBSERVATION", 114, 123]]], ["Although it has been recognised that the major burden of mortality from influenza pandemics is suffered by low-income countries, 5 11 16 the primary focus of the vast majority of these models is on examining intervention effectiveness in developed (eg, the USA and European countries [17] [18] [19] [20] and middle-income countries (eg, Thailand 21 22 ).", [["influenza pandemics", "DISEASE", 72, 91], ["influenza pandemics", "PROBLEM", 72, 91], ["intervention effectiveness", "TREATMENT", 208, 234], ["European countries", "TEST", 265, 283]]], ["Given the markedly different demographic and community structure, as well as resource and infrastructural constraints in comparison with developed countries, these models have limited capability to predict the impact of an influenza pandemic on low-income countries.", [["influenza", "DISEASE", 223, 232], ["an influenza pandemic", "PROBLEM", 220, 241], ["markedly", "OBSERVATION_MODIFIER", 10, 18], ["different", "OBSERVATION_MODIFIER", 19, 28], ["influenza", "OBSERVATION", 223, 232]]], ["23 In addition, many low-income countries are located in tropical or subtropical regions where the timing and impact of influenza epidemics are more poorly understood than in temperate regions, where they are known to have a well-defined winter season.", [["influenza", "DISEASE", 120, 129], ["influenza epidemics", "PROBLEM", 120, 139], ["many", "OBSERVATION_MODIFIER", 16, 20], ["low", "OBSERVATION_MODIFIER", 21, 24], ["tropical", "ANATOMY_MODIFIER", 57, 65], ["subtropical", "ANATOMY_MODIFIER", 69, 80], ["influenza", "OBSERVATION", 120, 129]]], ["15 To address this 'modelling gap' an individual-based disease transmission model of pandemic influenza has been developed for Papua New Guinea (PNG), based on the methods used previously to develop a pandemic influenza model of Albany, Western Australia.", [["influenza", "DISEASE", 94, 103], ["influenza", "DISEASE", 210, 219], ["this 'modelling gap", "PROBLEM", 14, 33], ["an individual-based disease", "PROBLEM", 35, 62], ["pandemic influenza", "PROBLEM", 85, 103], ["disease", "OBSERVATION", 55, 62]]], ["20 24 25 The chosen location of Madang, a town of approximately 35 000 on the northern coast of the island of New Guinea has, along with all of PNG, different demographics and individual-to-individual contact patterns compared with those in developed countries.", [["New", "OBSERVATION_MODIFIER", 110, 113], ["Guinea", "OBSERVATION", 114, 120]]], ["26 The model was used to describe the spread of a novel influenza strain after introduction into the community.", [["influenza", "DISEASE", 56, 65], ["a novel influenza strain", "PROBLEM", 48, 72]]], ["The resulting illness attack rate was determined together with data indicating where person-to-person transmission occurred.", [["illness", "DISEASE", 14, 21], ["person", "SPECIES", 85, 91], ["person", "SPECIES", 95, 101], ["The resulting illness attack rate", "PROBLEM", 0, 33]]], ["An unmitigated outbreak and two outbreaks with PNG-feasible intervention strategies activated were simulated and the results compared with those obtained using the Albany, Australia model.METHODSCensus and country-wide data from the PNG National Statistics Office 27 together with data collected in a field survey in Madang were used to construct the Madang model.", [["An unmitigated outbreak", "PROBLEM", 0, 23], ["PNG-feasible intervention strategies", "TREATMENT", 47, 83]]], ["Using virus intrinsic transmission characteristics calibrated with the Australian model, simulations were performed using the Madang model.", [["the Madang model", "TREATMENT", 122, 138]]], ["These simulations captured the day-to-day susceptible, exposed, infectious and recovered/immune infection profile of the population following introduction of a novel strain of influenza into the modelled community, assuming no existing immunity.", [["infection", "DISEASE", 96, 105], ["influenza", "DISEASE", 176, 185], ["infectious", "PROBLEM", 64, 74], ["immune infection profile", "PROBLEM", 89, 113], ["influenza", "PROBLEM", 176, 185], ["infectious", "OBSERVATION", 64, 74]]], ["28Madang demographicsMadang model development used the most recent census data from 2001, other PNG government data and additional data collected in our field survey.", [["additional data", "TEST", 120, 135]]], ["The specific demographics of each household in Madang in terms of number of individuals, their ages and occupation of adults was also provided by the census and each individual is uniquely identified in the model.Madang demographicsFrom July to September 2011 we also conducted a survey in Madang to obtain data on the number of people working in smaller workplaces, school class sizes, market sizes and the number of people attending the major tertiary education centres in Madang (Divine Word University (DWU), Madang Teachers College, Madang Technical College and Madang Maritime College).", [["people", "ORGANISM", 329, 335], ["people", "ORGANISM", 418, 424], ["people", "SPECIES", 329, 335], ["people", "SPECIES", 418, 424], ["sizes", "OBSERVATION_MODIFIER", 380, 385], ["sizes", "OBSERVATION_MODIFIER", 394, 399]]], ["We asked the headmasters of schools and colleges, the human resource department at DWU and business owners of small-to-medium scale businesses about the respective numbers and, if no records existed relied on their estimates.", [["human", "ORGANISM", 54, 59], ["human", "SPECIES", 54, 59], ["human", "SPECIES", 54, 59]]], ["We also obtained estimates on the size of informal settlements within the town boundaries from the Madang provincial government.", [["size", "OBSERVATION_MODIFIER", 34, 38]]], ["The data obtained in the survey are presented in online supplementary table A1.Madang demographicsThese data allowed for the construction of an explicit contact network linking households, schools, workplaces and other meeting places by allocating individuals to workplaces and schools, as with the Albany model.", [["A1", "PROTEIN", 76, 78], ["The data", "TEST", 0, 8]]], ["10Contact networkThe model captures explicit person-to-person contact with the contact network describing population mobility occurring between households, schools, workplaces and the wider community as shown in figure 1 .", [["person", "SPECIES", 45, 51]]], ["The virus spreads through the community due to this mobility, as transmission occurs between individuals when they are co-located, possibly following a move from one location to another.Contact networkThe number of contacts made by each individual each day in school, work and community settings were adjusted to reproduce the proportion of cases occurring in different settings as reported by empirical studies, specifically 40% of infections occurred in households, 30% in schools and workplaces and 30% in the wider community.", [["infections", "DISEASE", 433, 443], ["The virus", "PROBLEM", 0, 9], ["empirical studies", "TEST", 394, 411], ["infections", "PROBLEM", 433, 443], ["virus", "OBSERVATION", 4, 9], ["mobility", "OBSERVATION", 52, 60], ["infections", "OBSERVATION", 433, 443]]], ["[30] [31] [32] Contacts within schools and workplaces occurred in fixed-size mixing groups of maximum size 10.", [["size", "OBSERVATION_MODIFIER", 72, 76]]], ["Within mixing groups contact was assumed to be homogeneous.", [["assumed to be", "UNCERTAINTY", 33, 46], ["homogeneous", "OBSERVATION_MODIFIER", 47, 58]]], ["Children and adults are assigned by an allocation algorithm to school classes and workplaces according to age based on class sizes and employee numbers obtained in the field survey.", [["Children", "ORGANISM", 0, 8], ["adults", "ORGANISM", 13, 19], ["Children", "SPECIES", 0, 8]]], ["The field survey described above revealed that 50% of school-age children do not attend school, and this percentage is thought to be similar to most urban areas in PNG, with still lower rates in rural areas.", [["children", "ORGANISM", 65, 73], ["children", "SPECIES", 65, 73], ["The field survey", "TEST", 0, 16], ["rural", "ANATOMY_MODIFIER", 195, 200]]], ["Of those children not attending school 50% are allocated to neighbourhood hubs, as described below.", [["children", "ORGANISM", 9, 17], ["children", "SPECIES", 9, 17]]], ["The numbers in this census category exceeded those found in the survey of major workplaces and knowledge of Madang suggested the creation of small, local workplaces to locate these additional adults and those in the business category.", [["numbers", "OBSERVATION_MODIFIER", 4, 11], ["small", "OBSERVATION_MODIFIER", 141, 146]]], ["Adults with gardening as their occupation work in family-owned gardens, subsistence farming and generating produce for sale.", [["Adults", "ORGANISM", 0, 6], ["Adults", "SPECIES", 0, 6]]], ["For each household containing a garden worker, a garden workplace was created whose members matched those of the household.Madang-specific contact locationsThree significant populations in Madang were not counted in the 2001 census, namely, those in settlements (unofficial housing areas also found in other parts of the developing world), those in the University and Chinese workers at a mine/processing site on the edge of the town.", [["Three significant populations in Madang", "PROBLEM", 156, 195], ["significant", "OBSERVATION_MODIFIER", 162, 173], ["populations", "OBSERVATION", 174, 185]]], ["The populations at the University and the mine-site had virtual households created to replicate friendship groups of average size 7, and these locations were also designated as the workplace for these individuals.", [["size", "OBSERVATION_MODIFIER", 125, 129]]], ["Contact between the mine-site and the town was also restricted to community contact.Madang-specific contact locationsCensus data classified a significant proportion (16.2%) of adults as unemployed and not attending a designated workplace.", [["mine-site", "DNA", 20, 29], ["Census data", "TEST", 117, 128], ["significant", "OBSERVATION_MODIFIER", 142, 153]]], ["27 Knowledge gathered from the field survey in Madang indicated that these adults do have daytime contact with others outwith the home, such as working or visiting the two informal markets.", [["adults", "ORGANISM", 75, 81]]], ["In addition, these hubs also have 25% of all local school age pupils allocated to them, accounting for half of the 50% of school age children which do not attend school.Madang-specific contact locationsThe introduction of neighbourhood hubs, which do not exist in the Albany model, give a model which the field survey and local knowledge indicate is representative of the contact patterns found in urban PNG.", [["children", "ORGANISM", 133, 141], ["children", "SPECIES", 133, 141]]], ["This allows influenza spread dynamics within the three models to be compared and indicates the sensitivity of the Madang model to the presence of the neighbourhood hubs.Madang-specific contact locationsThe number of individuals in each of the daytime locations for the Albany, Madang and Madang-nnh models are presented in online supplementary table A1.", [["A1", "PROTEIN", 350, 352], ["influenza spread dynamics", "PROBLEM", 12, 37], ["number", "OBSERVATION_MODIFIER", 206, 212]]], ["Additional information on the data used to construct the Madang model is given in.", [["the data", "TEST", 26, 34]]], ["33Influenza transmissionEach individual has their influenza infection history modelled using an SEIR approach and are in one of four infection states, namely susceptible, exposed, infectious or recovered and thus immune.", [["influenza infection", "DISEASE", 50, 69], ["infection", "DISEASE", 133, 142], ["their influenza infection", "PROBLEM", 44, 69], ["an SEIR approach", "TREATMENT", 93, 109], ["four infection", "PROBLEM", 128, 142], ["influenza", "OBSERVATION_MODIFIER", 50, 59], ["infection", "OBSERVATION", 60, 69], ["infection", "OBSERVATION", 133, 142], ["infectious", "OBSERVATION", 180, 190]]], ["28 The passage of infection in each individual reflects the known timechanging infectiousness profile (ie, virus shedding 34 ) of influenza at two discrete points-of-time every 24 h, during a day-time and a night-time period.Influenza transmissionDisease transmission is realised using a probabilistic transmission function, implemented by the simulation algorithm.", [["infection", "DISEASE", 18, 27], ["influenza", "DISEASE", 130, 139], ["Influenza transmission", "DISEASE", 225, 247], ["infection", "PROBLEM", 18, 27], ["the known timechanging infectiousness profile", "PROBLEM", 56, 101], ["influenza", "PROBLEM", 130, 139], ["Influenza transmission", "PROBLEM", 225, 247], ["Disease transmission", "PROBLEM", 247, 267], ["the simulation algorithm", "TEST", 340, 364], ["passage", "OBSERVATION_MODIFIER", 7, 14], ["infection", "OBSERVATION", 18, 27]]], ["Together with mobility data, the transmission function captures disease spread throughout the modelled community and may be adjusted to reflect pandemics with various transmission characteristics, corresponding to the basic reproduction number R 0 of a particular influenza strain, as discussed further in.", [["influenza", "DISEASE", 264, 273], ["mobility data", "TEST", 14, 27], ["disease spread", "PROBLEM", 64, 78], ["pandemics", "PROBLEM", 144, 153], ["a particular influenza strain", "PROBLEM", 251, 280]]], ["20 24 25 It is assumed that infection transmission may occur when an infectious and a susceptible individual come into contact, in a stochastic fashion.", [["infection", "DISEASE", 28, 37], ["infection transmission", "PROBLEM", 28, 50], ["an infectious", "PROBLEM", 66, 79], ["infection", "OBSERVATION", 28, 37], ["infectious", "OBSERVATION", 69, 79]]], ["Once infected, an individual progresses through a series of infectious states according to a fixed timeline, taking them from susceptible, to exposed state, to infectious and then to an immune, recovered state.", [["infected", "PROBLEM", 5, 13], ["infectious states", "PROBLEM", 60, 77], ["infected", "OBSERVATION", 5, 13], ["infectious", "OBSERVATION", 60, 70]]], ["28 The probability that an infectious individual infects a susceptible was calculated using the following function.Influenza transmissionThe factors which determine probability of transmission from an infectious individual (I i ) to a susceptible individual (I s ) are the basic virus transmissibility (\u03b2 v ), the age-based susceptibility of I s the current level of infectiousness of I i , and, if the contact between I i and I s occurs in a household, the household size Household(I i , I s ).", [["Influenza transmission", "DISEASE", 115, 137], ["an infectious individual infects", "PROBLEM", 24, 56], ["Influenza transmission", "PROBLEM", 115, 137], ["infectious", "OBSERVATION_MODIFIER", 27, 37], ["infectious", "OBSERVATION", 201, 211]]], ["Details of the household size factor are given below; further details of the influenza transmission model can be found in ref.", [["influenza", "DISEASE", 77, 86], ["household size factor", "PROTEIN", 15, 36], ["the influenza transmission model", "TREATMENT", 73, 105]]], ["35 .Influenza transmissionTo achieve simulations for a particular basic reproduction number R 0 , \u03b2 v was adjusted; details of the procedure for estimating \u03b2 v and R 0 are given in ref.", [["Influenza transmission", "DISEASE", 4, 26], ["\u03b2 v", "GENE_OR_GENE_PRODUCT", 98, 101], ["\u03b2 v", "GENE_OR_GENE_PRODUCT", 156, 159], ["\u03b2 v", "PROTEIN", 156, 159], ["Influenza transmission", "PROBLEM", 4, 26], ["the procedure", "TREATMENT", 127, 140], ["estimating \u03b2 v and R 0", "TREATMENT", 145, 167]]], ["A pandemic with a basic reproduction number of 1.5 is used in this study, and corresponds to some estimations of the 2009 H1N1 pandemic [36] [37] [38] [39] and the 1957 and 1968 pandemics.", [["pandemic", "DISEASE", 127, 135], ["A pandemic", "PROBLEM", 0, 10], ["this study", "TEST", 62, 72], ["pandemic", "OBSERVATION", 2, 10]]], ["40 41 Since it is virus intrinsic, we assumed that \u03b2 v was similar in Madang and thus calculated R 0 in the Madang and Madang-nnh models using the \u03b2 v corresponding to an R 0 of 1.5 in the Albany model.", [["\u03b2 v", "GENE_OR_GENE_PRODUCT", 51, 54], ["\u03b2 v", "GENE_OR_GENE_PRODUCT", 147, 150], ["\u03b2 v", "PROTEIN", 51, 54], ["virus", "OBSERVATION", 18, 23]]], ["Details of parameter settings used in each model are given in online supplementary table A2.SimulationA simulation algorithm, realised in the C++ programming language, manipulates the underlying demographic model and captures both population mobility and the time-changing infectivity profile of each individual.", [["A2", "PROTEIN", 89, 91], ["SimulationA simulation algorithm", "TEST", 92, 124]]], ["Each individual has their infectivity status denoted by one of the four (S, E, I, R) states at any time point during the duration of the simulated period.", [["infectivity", "OBSERVATION", 26, 37]]], ["The simulation algorithm captures the state of the whole population twice per day, a daytime point-in-time snapshot and an evening snapshot, with individuals ( possibly) moving locations between successive day or night periods, such as household to school or workplace for the day phase, returning home for the night period.", [["The simulation algorithm", "TEST", 0, 24]]], ["Individuals come into contact with other individuals on a one-to-one basis in each location, with possible influenza transmission then occurring.SimulationIndividuals in each household and contact hub make contacts within a close-contact mixing group, taken to be the entire household or a subset of larger hubs, and also make additional non hub-based random community contacts.", [["influenza", "DISEASE", 107, 116], ["influenza transmission", "PROBLEM", 107, 129], ["possible", "UNCERTAINTY", 98, 106], ["influenza", "OBSERVATION", 107, 116]]], ["The individual-to-individual transmission probability in larger households was moderated by household size using data from a study by Cauchemez et al 42 The reduction of the probability of within-household transmission with household size is also shown in online supplementary figure A1.", [["A1", "PROTEIN", 284, 286], ["a study", "TEST", 123, 130]]], ["This reflects the assumed reduction in pairwise contact in households with greater than three members and is significant in the Madang context, where the average household size is 6.32 compared with 2.54 in Albany.SimulationUsing the contact, mobility and transmission features described above, stochastic simulations of influenza spread in Madang were conducted.", [["influenza", "DISEASE", 321, 330], ["influenza spread", "PROBLEM", 321, 337], ["reduction", "OBSERVATION_MODIFIER", 26, 35], ["significant", "OBSERVATION_MODIFIER", 109, 120], ["size", "OBSERVATION_MODIFIER", 172, 176]]], ["All simulations were repeated 40 times with random numbers controlling the outcome of stochastic events (the locality of seeded infected individuals and the probability of transmission) and the results were averaged.", [["All simulations", "TREATMENT", 0, 15], ["stochastic events", "PROBLEM", 86, 103]]], ["Analysis of this simulation model has shown that the 40-run mean attack rate is highly unlikely (95% CI) to differ by more than 1.2% from the mean attack rate of a much larger set of experiment repeats.", [["this simulation model", "TEST", 12, 33], ["highly unlikely", "UNCERTAINTY", 80, 95]]], ["20 Where 95% CIs are reported in the results, these were calculated from the mean and SD of 40 randomly seeded simulation runs, using the normal approximation method.SimulationOne new infection per day was introduced into the population during the whole period of the simulations, and randomly allocated to a household.SimulationThis seeding assumption of one case per day was chosen to reliably begin a local epidemic in every stochastic simulation.", [["infection", "DISEASE", 184, 193], ["normal", "OBSERVATION", 138, 144], ["new", "OBSERVATION_MODIFIER", 180, 183], ["infection", "OBSERVATION", 184, 193]]], ["For the transmission characteristics described above, analysis shows that seeding at this rate Mean simulation outcomes of no intervention, school closure and rigorous social distancing presented as percentages and their corresponding 95% CI (presented in parentheses, shaded rows).", [["analysis", "TEST", 54, 62], ["seeding", "PROBLEM", 74, 81], ["intervention", "TREATMENT", 126, 138], ["school closure", "TREATMENT", 140, 154], ["no", "UNCERTAINTY", 123, 125]]], ["WR, workforce reduction and CCR, community contact reduction; Hubs represent schools, workplaces and neighbourhoods together; Community represents general community; Imported represents seeded cases.Simulationfor 7 days results in a sustained epidemic in >97% of the simulation runs and 100% with 2 weeks of seeding, with higher percentages for the higher transmissibility scenarios.", [["workforce reduction", "TREATMENT", 4, 23], ["community contact reduction", "TREATMENT", 33, 60], ["the simulation runs", "TEST", 263, 282], ["seeding", "PROBLEM", 308, 315], ["the higher transmissibility scenarios", "PROBLEM", 345, 382]]], ["Seeding at this rate is continued throughout the simulation to capture the case where an epidemic may be initially suppressed by a rigorous intervention strategy, but may subsequently break out if intervention measures are relaxed.SimulationAfter the beginning of a sustained local epidemic, any subsequent variation in the amount of seeding has very little effect on the progress of the local epidemic, as the number of imported cases is much smaller than those generated by the local epidemic.", [["a rigorous intervention strategy", "TREATMENT", 129, 161], ["intervention measures", "TREATMENT", 197, 218], ["a sustained local epidemic", "PROBLEM", 264, 290], ["seeding", "PROBLEM", 334, 341], ["amount", "OBSERVATION_MODIFIER", 324, 330], ["seeding", "OBSERVATION", 334, 341], ["very", "OBSERVATION_MODIFIER", 346, 350], ["little", "OBSERVATION_MODIFIER", 351, 357], ["effect", "OBSERVATION_MODIFIER", 358, 364], ["local", "OBSERVATION_MODIFIER", 388, 393], ["epidemic", "OBSERVATION", 394, 402], ["much smaller", "OBSERVATION_MODIFIER", 439, 451], ["local", "OBSERVATION_MODIFIER", 480, 485], ["epidemic", "OBSERVATION", 486, 494]]], ["Preliminary analyses using the present model have shown that even if the seeding rate is increased to five infections per day, after 7 days the number of infections generated from the selfsustained local epidemic is twice the number of imported infections, and by 14 days local infections outnumber imported infections by a factor of 8.SimulationThe simulation period was divided into 12 h day/night periods and during each period a nominal location for each individual was determined.", [["infections", "DISEASE", 107, 117], ["infections", "DISEASE", 154, 164], ["infections", "DISEASE", 245, 255], ["infections", "DISEASE", 278, 288], ["infections", "DISEASE", 308, 318], ["Preliminary analyses", "TEST", 0, 20], ["the seeding rate", "PROBLEM", 69, 85], ["infections", "PROBLEM", 154, 164], ["imported infections", "PROBLEM", 236, 255], ["increased", "OBSERVATION_MODIFIER", 89, 98], ["infections", "OBSERVATION", 154, 164], ["infections", "OBSERVATION", 245, 255], ["infections", "OBSERVATION", 308, 318]]], ["This took into consideration the cycle type (day/night, weekday/weekend), infection state of each individual and whether child supervision was needed to look after a child at home.", [["infection", "DISEASE", 74, 83], ["infection", "PROBLEM", 74, 83], ["infection", "OBSERVATION", 74, 83]]], ["Details of the simulation procedure are presented in ref.", [["the simulation procedure", "TREATMENT", 11, 35]]], ["20 .InterventionsThe effectiveness of social distancing interventions, such as school or workplace closure, may be quantified by comparing the passage of the influenza virus in the community with and without interventions activated, and presented as the reduction in the daily and cumulative illness attack rates.", [["influenza", "DISEASE", 158, 167], ["illness", "DISEASE", 292, 299], ["Interventions", "TREATMENT", 4, 17], ["social distancing interventions", "TREATMENT", 38, 69], ["closure", "TREATMENT", 99, 106], ["the influenza virus", "PROBLEM", 154, 173], ["interventions", "TREATMENT", 208, 221], ["the reduction", "TREATMENT", 250, 263]]], ["Pharmaceutical-based interventions were not considered as antiviral agents may only be available in limited quantities in a PNG setting, while a vaccination campaign would face significant delay, supply and delivery constraints.", [["Pharmaceutical-based interventions", "TREATMENT", 0, 34], ["antiviral agents", "TREATMENT", 58, 74], ["a vaccination campaign", "TREATMENT", 143, 165], ["delivery constraints", "TREATMENT", 207, 227]]], ["Two intervention strategies considered feasible in a PNG setting were examined.", [["Two intervention strategies", "TREATMENT", 0, 27]]], ["These were: school closure involving all schools, with home isolation of all affected children; and a more rigorous strategy involving school closure coupled with 50% reductions in community-wide contact, workplace participation and contact in neighbourhood hubs.InterventionsBoth Madang models, (with and without neighbourhood hubs), were used to compare a pandemic in PNG with one occurring in Albany, Australia.", [["children", "ORGANISM", 86, 94], ["children", "SPECIES", 86, 94], ["school closure", "TREATMENT", 12, 26], ["home isolation", "TREATMENT", 55, 69], ["school closure", "TREATMENT", 135, 149]]], ["Simulations were conducted involving: no interventions; only school closure applied; and rigorous social distancing, for each of the three models.SynopsisGeneral comparative trends are presented in table 1, were the Albany and Madang models are compared.", [["interventions", "TREATMENT", 41, 54], ["school closure", "TREATMENT", 61, 75]]], ["For a pandemic in a developed country setting having a basic reproduction number R 0 of 1.5 and an illness attack rate of 31.7%, the same pandemic characteristics applied in a PNG setting with no interventions activated resulted in higher rates of influenza transmission, with an attack rate of 46.6% and reproduction number R 0 =1.88 (table 1) .", [["influenza transmission", "DISEASE", 248, 270], ["an illness attack rate", "TEST", 96, 118], ["interventions", "TREATMENT", 196, 209], ["influenza transmission", "PROBLEM", 248, 270], ["an attack rate", "TEST", 277, 291]]], ["Comparing the attack rates when interventions were activated, both intervention strategies (solely school closure and rigorous social distancing) were much less effective in the PNG setting compared with the Australian one.", [["interventions", "TREATMENT", 32, 45], ["both intervention strategies", "TREATMENT", 62, 90], ["solely school closure", "TREATMENT", 92, 113]]], ["The mitigated illness attack rates in the PNG model were approximately three times higher than those in the Australian model with the interventions being 60-70% less effective.", [["illness", "DISEASE", 14, 21], ["The mitigated illness attack rates", "PROBLEM", 0, 34], ["the PNG model", "TEST", 38, 51], ["the interventions", "TREATMENT", 130, 147], ["mitigated", "OBSERVATION_MODIFIER", 4, 13], ["illness", "OBSERVATION", 14, 21]]], ["Table 2 indicates where transmission that resulted in illness occurred, showing a significantly higher number and proportion of transmissions occurring in households, as opposed to other contact/transmission locations, in the Madang compared with the Australian model (table 1) .", [["illness", "PROBLEM", 54, 61]]], ["The average household size in the PNG model is 2.5 times larger than that in Albany and this had a significant impact on the overall infection rate, making it noticeably higher in the PNG model.SynopsisWe also conducted experiments with the Madang-nnh model, where neighbourhood contact hubs were omitted, to contrast the transmission characteristics with and without these contact hubs.", [["infection", "DISEASE", 133, 142], ["the overall infection rate", "PROBLEM", 121, 147], ["average", "OBSERVATION_MODIFIER", 4, 11], ["household", "OBSERVATION_MODIFIER", 12, 21], ["size", "OBSERVATION_MODIFIER", 22, 26], ["2.5 times larger", "OBSERVATION_MODIFIER", 47, 63], ["significant", "OBSERVATION_MODIFIER", 99, 110], ["infection", "OBSERVATION", 133, 142], ["noticeably", "OBSERVATION_MODIFIER", 159, 169], ["higher", "OBSERVATION_MODIFIER", 170, 176]]], ["The results of these simulation experiments are included in tables 1 and 2.", [["these simulation experiments", "TEST", 15, 43]]], ["Neighbourhood hubs were introduced to reflect the known mixing patterns occurring with adults not working in designated workplaces, such as those found in the regular contact which may occur among individuals in marketplaces.", [["mixing patterns", "OBSERVATION", 56, 71]]], ["The addition of such contact hubs increased individual-to-individual contacts and hence infection transmission opportunities (see table 2 ) with approximately 2000 additional symptomatic infections resulting, for all three (mitigated and non-mitigated) scenarios.", [["infection", "DISEASE", 88, 97], ["infections", "DISEASE", 187, 197], ["symptomatic infections", "PROBLEM", 175, 197], ["symptomatic", "OBSERVATION_MODIFIER", 175, 186], ["infections", "OBSERVATION", 187, 197]]], ["In terms of cumulative illness attack rate, the Madang model gave a basic reproduction number R 0 of 1.88 and an illness attack rate of 46.6%, compared with that of the Madang-nnh (no neighbourhood hub) model with R 0 =1.74 and an illness attack rate of 40.8%.", [["illness", "DISEASE", 23, 30], ["illness", "DISEASE", 113, 120], ["cumulative illness attack rate", "PROBLEM", 12, 42], ["an illness attack rate", "TEST", 110, 132], ["an illness attack rate", "TEST", 228, 250], ["cumulative", "OBSERVATION_MODIFIER", 12, 22], ["illness", "OBSERVATION", 23, 30]]], ["The daily case incidence resulting from simulating the Albany, Madang and Madang-nnh models is presented in figure 2 for the three scenarios.No intervention scenarioThe results given in table 1 show that there is an approximately 47% increase in the illness attack rate in the Madang setting compared with that resulting from the Albany model; from 31.7% to 46.6%.", [["illness", "DISEASE", 250, 257], ["intervention scenario", "TREATMENT", 144, 165], ["the illness attack rate", "PROBLEM", 246, 269], ["the Albany model", "TEST", 326, 342], ["approximately", "OBSERVATION_MODIFIER", 216, 229], ["47%", "OBSERVATION_MODIFIER", 230, 233], ["increase", "OBSERVATION_MODIFIER", 234, 242], ["illness", "OBSERVATION", 250, 257]]], ["If no neighbourhood hub contact occurs, as with the Madang-nnh model, there is still an increase in illness attack rate compared with that resulting from the Albany model, with an approximately 29% increase in the attack rate; from 31.7% to 40.8%.No intervention scenarioIt is apparent from the results presented in table 1 that there is a greater proportion of influenza cases occurring within households in both Madang models compared with that of the Albany model.", [["illness", "DISEASE", 100, 107], ["influenza", "DISEASE", 362, 371], ["illness attack rate", "PROBLEM", 100, 119], ["the attack rate", "TEST", 210, 225], ["intervention scenarioIt", "TREATMENT", 250, 273], ["influenza cases", "PROBLEM", 362, 377], ["increase", "OBSERVATION_MODIFIER", 88, 96], ["illness", "OBSERVATION", 100, 107], ["increase", "OBSERVATION_MODIFIER", 198, 206], ["greater", "OBSERVATION_MODIFIER", 340, 347], ["influenza", "OBSERVATION", 362, 371]]], ["This arises from the average Madang household size being larger than that in Albany.", [["size", "OBSERVATION_MODIFIER", 46, 50], ["larger", "OBSERVATION_MODIFIER", 57, 63]]], ["The number of cases occurring in Madang due to household transmission is \u223c8000 compared with \u223c3500 in Albany; note that Madang has a total population of \u223c35 000 compared with \u223c30 000 in Albany.School closure scenarioThe school closure intervention in the Madang model is found to be approximately five times less effective Mean number (italic face) of symptomatic influenza cases and their corresponding 95% CI (in parentheses) at different locations for no intervention, school closure and rigorous social distancing presented.", [["influenza", "DISEASE", 364, 373], ["The school closure intervention", "TREATMENT", 216, 247], ["symptomatic influenza cases", "PROBLEM", 352, 379], ["intervention", "TREATMENT", 458, 470], ["school closure", "TREATMENT", 472, 486], ["symptomatic", "OBSERVATION_MODIFIER", 352, 363], ["influenza", "OBSERVATION", 364, 373]]], ["WR, workforce reduction and CCR, community contact reduction.Figure 2Daily case incidence for different intervention scenarios.", [["workforce reduction", "TREATMENT", 4, 23], ["community contact reduction", "TREATMENT", 33, 60], ["different intervention scenarios", "TREATMENT", 94, 126]]], ["Daily case incidence for the no intervention, school closure and rigorous social distancing (school closure and workplace and community contact reductions) scenarios is shown.", [["intervention", "TREATMENT", 32, 44], ["school closure", "TREATMENT", 46, 60]]], ["The blue, red and green curves represent the Albany, Madang and Madang-nnh models, respectively. compared with that of the Albany model.", [["The blue, red and green curves", "PROBLEM", 0, 30], ["blue", "OBSERVATION_MODIFIER", 4, 8], ["green curves", "OBSERVATION", 18, 30]]], ["Simulation results suggest a 9.4% reduction (46.6% to 42.2%) in the illness attack rate can be achieved in Madang due to school closure whereas a 48.6% reduction (31.7-16.3%) can be achieved in Albany (see table 1 ).", [["illness", "DISEASE", 68, 75], ["a 9.4% reduction", "PROBLEM", 27, 43], ["the illness attack rate", "PROBLEM", 64, 87]]], ["Table 2 (middle panel) indicates an illness attack rate of \u223c15 000 in Madang compared with \u223c4800 in Albany.", [["illness", "DISEASE", 36, 43], ["an illness attack rate", "PROBLEM", 33, 55], ["illness", "OBSERVATION", 36, 43]]], ["Much higher case numbers occur in households, workplaces and the wider community (including neighbourhood hubs) than in Albany, highlighting the poorer efficacy of this intervention strategy in a PNG setting.", [["this intervention strategy", "TREATMENT", 164, 190]]], ["Note that while there is a significantly higher proportion of under 17-year-old children in Madang (40%) compared with Albany (28%), our field survey indicates that 50% of school age children in Madang do not attend school, hence school closure is less effective in disrupting the transmission chain (ie, household 1-to-school-to-household 2) compared with Australia.", [["children", "ORGANISM", 80, 88], ["children", "ORGANISM", 183, 191], ["children", "SPECIES", 80, 88], ["children", "SPECIES", 183, 191]]], ["This feature is also present in the rigorous social distancing intervention.Rigorous social distancing scenarioPrevious simulation studies 20 43 44 show that rigorous social distancing interventions involving school closure coupled to contact reductions in other locations may be highly effective in reducing the attack rate within a developed country setting.", [["distancing intervention", "TREATMENT", 52, 75], ["school closure", "TREATMENT", 209, 223]]], ["Comparing the effectiveness of rigorous social distancing between the Albany and Madang models, an \u223c83% reduction (from 31.7% to 5.4%) reduction may be achieved in Albany whereas a smaller \u223c62.7% reduction (from 46.6% to 17.4%), is achieved in the Madang model; see table 1.", [["smaller", "OBSERVATION_MODIFIER", 181, 188]]], ["In the Madang-nnh model a \u223c69.4% reduction in the attack rate (40.8-12.5%) can be achieved by this rigorous social distancing intervention.", [["the attack rate", "TEST", 46, 61], ["this rigorous social distancing intervention", "TREATMENT", 94, 138]]], ["Table 2 (bottom panel) indicates an illness attack rate of \u223c6000 in Madang (and \u223c4400 for Madang-nnh) compared with \u223c1600 for the Albany model.", [["illness", "DISEASE", 36, 43]]], ["Workplace and community-wide transmission are also higher in the two Madang models compared with Albany.Rigorous social distancing scenarioThese results suggest that both social distancing strategies are much less effective in a PNG setting compared with what might be achieved in a developed country.", [["wide", "OBSERVATION_MODIFIER", 24, 28], ["higher", "OBSERVATION_MODIFIER", 51, 57]]], ["Figure 2 also reveals this clear trend, with peak case incidence and the area under the curves (the attack rate) being higher in both Madang models compared with the Albany model.Sensitivity analysisThe sensitivity of key model parameters, such as school contact group size, illness withdrawal rates and intervention duration have been extensively examined for the Albany model.", [["illness", "DISEASE", 275, 282], ["the attack rate", "TEST", 96, 111], ["Sensitivity analysis", "TEST", 179, 199], ["key model parameters", "TEST", 218, 238], ["illness withdrawal rates", "PROBLEM", 275, 299], ["intervention duration", "TREATMENT", 304, 325], ["higher", "OBSERVATION_MODIFIER", 119, 125], ["both Madang", "ANATOMY", 129, 140]]], ["44 45 These indicate that while the model is sensitive to some parameter settings, the relative effectiveness of social distancing interventions remains unchanged, a feature also shared by the Madang models.Sensitivity analysisThe major difference between the Albany and Madang models is the presence of neighbourhood hubs.", [["some parameter settings", "TREATMENT", 58, 81], ["social distancing interventions", "TREATMENT", 113, 144], ["Sensitivity analysis", "TEST", 207, 227], ["unchanged", "OBSERVATION_MODIFIER", 153, 162], ["major", "OBSERVATION_MODIFIER", 231, 236], ["difference", "OBSERVATION_MODIFIER", 237, 247]]], ["Simulations comparing neighbourhood mixing group sizes 10 (baseline), 20 and 30 indicate that for hubs of size 20 and 30, the increased transmission results in higher attack rates, as expected (see online supplementary table A3).Sensitivity analysisThe effect of varying compliance with home isolation of school children following school closure on attack rate was examined.", [["children", "ORGANISM", 312, 320], ["children", "SPECIES", 312, 320], ["the increased transmission", "PROBLEM", 122, 148], ["higher attack rates", "PROBLEM", 160, 179], ["Sensitivity analysis", "TEST", 229, 249], ["home isolation of school children", "TREATMENT", 287, 320], ["school closure", "TREATMENT", 331, 345], ["attack rate", "TEST", 349, 360], ["varying", "OBSERVATION_MODIFIER", 263, 270], ["compliance", "OBSERVATION_MODIFIER", 271, 281]]], ["Compliance was reduced from 100% to 50%.", [["reduced", "OBSERVATION_MODIFIER", 15, 22]]], ["Reduced compliance increased the attack rate in Albany as those children affected made additional daytime contacts with other children.", [["children", "ORGANISM", 64, 72], ["children", "ORGANISM", 126, 134], ["children", "SPECIES", 64, 72], ["children", "SPECIES", 126, 134], ["compliance", "OBSERVATION_MODIFIER", 8, 18], ["increased", "OBSERVATION_MODIFIER", 19, 28]]], ["In Madang, the reduction in compliance had only minimal effect since approximately 50% of school age children do not attend school and continue to make daytime contacts in neighbourhood hubs (see online supplementary table A4).Sensitivity analysisThe effect of using different probabilities of voluntary withdrawal to the home of symptomatic adults and children is presented in online supplementary table A5.", [["children", "ORGANISM", 101, 109], ["children", "ORGANISM", 353, 361], ["children", "SPECIES", 101, 109], ["children", "SPECIES", 353, 361], ["Sensitivity analysis", "TEST", 227, 247], ["voluntary withdrawal", "PROBLEM", 294, 314], ["reduction", "OBSERVATION_MODIFIER", 15, 24], ["minimal", "OBSERVATION_MODIFIER", 48, 55], ["voluntary withdrawal", "OBSERVATION", 294, 314]]], ["Lower rates of voluntary withdrawal lead to higher attack rates in all three models.", [["voluntary withdrawal", "PROBLEM", 15, 35], ["higher attack rates", "PROBLEM", 44, 63], ["voluntary withdrawal", "OBSERVATION", 15, 35]]], ["Voluntary withdrawal from work or school has a more pronounced effect in the Albany model, as a significant proportion of children in Madang still transmit through daytime contacts in neighbourhood hubs.Sensitivity analysisThe effects of variation of the timing of intervention initiation are presented in online supplementary table A6.", [["children", "ORGANISM", 122, 130], ["children", "SPECIES", 122, 130], ["Voluntary withdrawal", "PROBLEM", 0, 20], ["Sensitivity analysis", "TEST", 203, 223], ["intervention initiation", "TREATMENT", 265, 288], ["variation", "OBSERVATION_MODIFIER", 238, 247]]], ["In the school closure scenario, delayed response had the most severe impact on the attack rates in Albany, whereas for the Madang models the changes in attack rate were marginal.", [["most severe", "OBSERVATION_MODIFIER", 57, 68]]], ["This is again due to a large fraction of children not attending school and the existence of neighbourhood hubs.", [["children", "ORGANISM", 41, 49], ["children", "SPECIES", 41, 49], ["large", "OBSERVATION_MODIFIER", 23, 28], ["fraction", "OBSERVATION", 29, 37]]], ["Similarly, in the rigorous contact reduction scenario the effect of delayed response on attack rate was more pronounced in the Albany model, due to lower effectiveness of interventions in a PNG setting.DISCUSSIONIntroduction of a pandemic influenza strain with identical transmissibility characteristics results in a significantly higher infection and illness rate in a PNG setting when compared with that of a developed country.", [["influenza", "DISEASE", 239, 248], ["infection", "DISEASE", 338, 347], ["illness", "DISEASE", 352, 359], ["delayed response on attack rate", "PROBLEM", 68, 99], ["interventions", "TREATMENT", 171, 184], ["a pandemic influenza strain", "PROBLEM", 228, 255], ["a significantly higher infection", "PROBLEM", 315, 347], ["illness rate", "PROBLEM", 352, 364], ["contact reduction", "OBSERVATION", 27, 44], ["delayed", "OBSERVATION_MODIFIER", 68, 75], ["response", "OBSERVATION_MODIFIER", 76, 84], ["more pronounced", "OBSERVATION_MODIFIER", 104, 119], ["lower", "OBSERVATION_MODIFIER", 148, 153], ["effectiveness", "OBSERVATION", 154, 167], ["higher", "OBSERVATION_MODIFIER", 331, 337], ["infection", "OBSERVATION", 338, 347]]], ["Social distancing intervention strategies suitable for a developing country may be significantly less effective in reducing the attack rate when compared with the outcomes expected in an Australian setting.", [["Social distancing intervention strategies", "TREATMENT", 0, 41]]], ["Substantially more infections occurred in PNG households compared with that of the Australian model.", [["infections", "DISEASE", 19, 29], ["Substantially more infections", "PROBLEM", 0, 29], ["more", "OBSERVATION_MODIFIER", 14, 18], ["infections", "OBSERVATION", 19, 29]]], ["The significantly larger size of households, a feature shared by many developing countries, together with higher community-wide contact in PNG, contributed to the higher infection rates.", [["infection", "DISEASE", 170, 179], ["the higher infection rates", "PROBLEM", 159, 185], ["significantly", "OBSERVATION_MODIFIER", 4, 17], ["larger", "OBSERVATION_MODIFIER", 18, 24], ["size", "OBSERVATION_MODIFIER", 25, 29], ["higher", "OBSERVATION_MODIFIER", 163, 169], ["infection", "OBSERVATION", 170, 179]]], ["Interventions are less effective in a PNG setting since they are not targeted at household transmission, and given the larger household sizes, are applicable to a smaller proportion of transmissions compared with the Australian scenario.", [["Interventions", "TREATMENT", 0, 13], ["less effective", "OBSERVATION_MODIFIER", 18, 32], ["larger", "OBSERVATION_MODIFIER", 119, 125], ["sizes", "OBSERVATION_MODIFIER", 136, 141], ["smaller", "OBSERVATION_MODIFIER", 163, 170]]], ["In addition, as only half the schoolage children in Madang attend school, the two school closure based interventions impact fewer individuals.DISCUSSIONWhile care was taken to obtain detailed data used to populate the Madang and Albany models, government data was found to be more limited in PNG.", [["children", "ORGANISM", 40, 48], ["children", "SPECIES", 40, 48], ["the two school closure based interventions", "TREATMENT", 74, 116]]], ["While a field survey was conducted in Madang to fill in missing data and make the models as directly comparable as possible, there is still scope for conducting further data collection.", [["a field survey", "TEST", 6, 20], ["conducting further data collection", "TEST", 150, 184]]], ["As with all modelling studies, the accuracy of results is limited by the quality of data used to construct the model.", [["all modelling studies", "TEST", 8, 29]]], ["In the case of influenza epidemic modelling, outcomes are dependent on assumptions about the number, duration and physical closeness of contacts between people and how these attributes of contact affect transmission probability.", [["people", "ORGANISM", 153, 159], ["people", "SPECIES", 153, 159], ["influenza", "PROBLEM", 15, 24], ["influenza", "OBSERVATION", 15, 24]]], ["46 The lack of similar low-income modelling studies prevents comparison with related studies, and suggests that this is an area requiring further attention.", [["related studies", "TEST", 77, 92]]], ["Research studies expanding on that reported here suggest themselves: the construction and use of a number of additional PNG models capturing different population structures, such as rural villages and island communities; and the determination of health outcomes following a moderately severe influenza pandemic, taking into account comorbidities with extant diseases such as malaria and tuberculosis, diseases common to many low-income countries.DISCUSSIONThe interventions used in the present study are based on social distancing.", [["influenza pandemic", "DISEASE", 292, 310], ["malaria", "DISEASE", 375, 382], ["tuberculosis", "DISEASE", 387, 399], ["Research studies", "TEST", 0, 16], ["additional PNG models", "TREATMENT", 109, 130], ["a moderately severe influenza pandemic", "PROBLEM", 272, 310], ["extant diseases", "PROBLEM", 351, 366], ["malaria", "PROBLEM", 375, 382], ["tuberculosis", "PROBLEM", 387, 399], ["diseases", "PROBLEM", 401, 409], ["The interventions", "TREATMENT", 456, 473], ["the present study", "TEST", 482, 499], ["malaria", "OBSERVATION", 375, 382], ["tuberculosis", "OBSERVATION", 387, 399]]], ["Surveys have shown that a higher proportion of low-income countries have social distancing interventions planned in the case of a pandemic, compared with high-income European countries due to their feasibility and cost-effectiveness.", [["social distancing interventions", "TREATMENT", 73, 104], ["a pandemic", "PROBLEM", 128, 138]]], ["3 4 6 8 47 48 Pharmaceutical-based interventions were not considered in this study due to cost and delivery issues found with low-income countries.", [["Pharmaceutical-based interventions", "TREATMENT", 14, 48], ["this study", "TEST", 72, 82], ["cost and delivery issues", "PROBLEM", 90, 114]]], ["4 8 Consideration may need to be given to some form of antiviral agent use, possibly for case treatment, given the poor performance of purely social distancing interventions in developing countries as suggested by this study.", [["antiviral agent", "TREATMENT", 55, 70], ["case treatment", "TREATMENT", 89, 103], ["distancing interventions", "TREATMENT", 149, 173], ["this study", "TEST", 214, 224]]], ["The advantage of antiviral use is that it may be targeted at reducing within-household transmission, a location of transmission otherwise not impacted by social distancing interventions.", [["antiviral use", "TREATMENT", 17, 30], ["social distancing interventions", "TREATMENT", 154, 185]]], ["The present study shows that larger numbers of transmissions occur within households due to the larger household sizes in countries such as PNG.", [["The present study", "TEST", 0, 17], ["larger", "OBSERVATION_MODIFIER", 29, 35], ["numbers", "OBSERVATION_MODIFIER", 36, 43], ["larger", "OBSERVATION_MODIFIER", 96, 102], ["sizes", "OBSERVATION_MODIFIER", 113, 118]]], ["Furthermore, low-income countries generally have population health profiles not seen in developed countries, including the prevalence of diseases such as malaria, tuberculosis and HIV.", [["malaria", "DISEASE", 154, 161], ["tuberculosis", "DISEASE", 163, 175], ["HIV", "DISEASE", 180, 183], ["HIV", "SPECIES", 180, 183], ["HIV", "SPECIES", 180, 183], ["diseases", "PROBLEM", 137, 145], ["malaria", "PROBLEM", 154, 161], ["tuberculosis", "PROBLEM", 163, 175], ["HIV", "PROBLEM", 180, 183], ["low", "OBSERVATION_MODIFIER", 13, 16], ["diseases", "OBSERVATION", 137, 145], ["malaria", "OBSERVATION", 154, 161], ["tuberculosis", "OBSERVATION", 163, 175]]], ["49 Antiviral treatment of influenza cases coinfected with such diseases may be an appropriate intervention strategy given the poorer health outcomes which comorbidity may impose.", [["influenza", "DISEASE", 26, 35], ["influenza", "ORGANISM", 26, 35], ["Antiviral treatment", "TREATMENT", 3, 22], ["influenza cases", "PROBLEM", 26, 41], ["such diseases", "PROBLEM", 58, 71], ["an appropriate intervention strategy", "TREATMENT", 79, 115]]], ["12 The provision and use of antiviral agents will have challenges not faced by industrialised countries, due to the cost of providing an antiviral stockpile and subsequent distribution of antivirals in countries which have health systems already stretched to capacity.", [["antiviral agents", "TREATMENT", 28, 44], ["an antiviral stockpile", "TREATMENT", 134, 156], ["antivirals", "TREATMENT", 188, 198], ["antiviral stockpile", "OBSERVATION", 137, 156]]], ["15 The importance of suitable pandemic influenza preparedness plans for low-income countries is recognised by the WHO.", [["influenza", "DISEASE", 39, 48], ["suitable pandemic influenza preparedness", "TREATMENT", 21, 61]]], ["50 51 Disease transmission models will play a role in guiding policy makers in determining the effectiveness of possible pandemic countermeasures.", [["pandemic countermeasures", "TREATMENT", 121, 145]]], ["History tells us that low-income countries are likely to be more affected, yet almost all models deal with mitigation strategies for developed nations with good health infrastructure and low prevalence of endemic diseases.", [["mitigation strategies", "TREATMENT", 107, 128], ["endemic diseases", "PROBLEM", 205, 221], ["low prevalence", "OBSERVATION_MODIFIER", 187, 201], ["endemic diseases", "OBSERVATION", 205, 221]]], ["These countries have poorer access to antiviral drug and vaccine-based interventions and higher extant disease burdens, compared with developed countries.", [["antiviral drug", "TREATMENT", 38, 52], ["vaccine", "TREATMENT", 57, 64], ["based interventions", "TREATMENT", 65, 84], ["higher extant disease burdens", "PROBLEM", 89, 118], ["higher extant", "OBSERVATION_MODIFIER", 89, 102], ["disease", "OBSERVATION", 103, 110]]], ["For the reasons, development of appropriate intervention strategies focused on countries such as PNG needs to occur.", [["appropriate intervention strategies", "TREATMENT", 32, 67]]]], "4ae8c9c942c792ce0361cf661e563c012f22bb9b": [["Healthcare-associated infections (HCAIs) are unintended consequences of care which are recognized as a public health problem [1, 2] .", [["infections", "DISEASE", 22, 32], ["HCAIs", "DISEASE", 34, 39], ["associated infections", "PROBLEM", 11, 32], ["infections", "OBSERVATION", 22, 32]]], ["They demand implementation of preventive measures and many large-scale institutional changes.", [["preventive measures", "TREATMENT", 30, 49], ["many large-scale institutional changes", "TREATMENT", 54, 92], ["large", "OBSERVATION_MODIFIER", 59, 64]]], ["However, around two-thirds of organizations' efforts to implement changes fail due to barriers at various levels of healthcare delivery such as the provider team, the healthcare organization, the market, patients, and policy [3] .", [["patients", "ORGANISM", 204, 212], ["patients", "SPECIES", 204, 212], ["healthcare delivery", "TREATMENT", 116, 135]]]], "PMC7310636": [["IntroductionCoronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus, is an ongoing global pandemic.", [["IntroductionCoronavirus disease", "DISEASE", 0, 31], ["COVID-19", "CHEMICAL", 38, 46], ["SARS-CoV-2 virus", "ORGANISM", 63, 79], ["CoV-2 virus", "SPECIES", 68, 79], ["IntroductionCoronavirus disease 2019 (COVID-19", "SPECIES", 0, 46], ["SARS-CoV-2 virus", "SPECIES", 63, 79], ["IntroductionCoronavirus disease", "PROBLEM", 0, 31], ["COVID", "TEST", 38, 43], ["the SARS-CoV-2 virus", "PROBLEM", 59, 79], ["an ongoing global pandemic", "PROBLEM", 84, 110], ["global", "OBSERVATION_MODIFIER", 95, 101], ["pandemic", "OBSERVATION", 102, 110]]], ["Neutralizing the virus is the focus of a multi-pronged approach, including behavioral, medical, and basic research efforts around the world.", [["Neutralizing the virus", "PROBLEM", 0, 22], ["a multi-pronged approach", "TREATMENT", 39, 63], ["virus", "OBSERVATION", 17, 22]]], ["Vaccine and therapeutic development are predominantly focused on the essential virus-encoded Spike, main protease, and RNA-dependent RNA polymerase proteins.", [["Spike", "GENE_OR_GENE_PRODUCT", 93, 98], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 119, 147], ["Spike", "PROTEIN", 93, 98], ["protease", "PROTEIN", 105, 113], ["RNA-dependent RNA polymerase proteins", "PROTEIN", 119, 156], ["Vaccine", "TREATMENT", 0, 7], ["the essential virus", "PROBLEM", 65, 84], ["main protease", "TREATMENT", 100, 113], ["RNA", "TEST", 119, 122], ["dependent RNA polymerase proteins", "PROBLEM", 123, 156]]], ["These targets have well characterized functions and, particularly for Spike, evidence for neutralizing antibodies in con-valescent patient serum.", [["serum", "ANATOMY", 139, 144], ["Spike", "GENE_OR_GENE_PRODUCT", 70, 75], ["patient", "ORGANISM", 131, 138], ["serum", "ORGANISM_SUBSTANCE", 139, 144], ["Spike", "PROTEIN", 70, 75], ["neutralizing antibodies", "PROTEIN", 90, 113], ["patient", "SPECIES", 131, 138], ["Spike", "PROBLEM", 70, 75], ["neutralizing antibodies in con-valescent patient serum", "PROBLEM", 90, 144]]], ["The availability of high-resolution structures of these targets, some in complex with drug candidates or neutralizing antibodies, has yielded mechanistic insight into their function and provided a platform for structure-guided drug design1\u20136.", [["neutralizing antibodies", "PROTEIN", 105, 128], ["drug candidates", "TREATMENT", 86, 101], ["neutralizing antibodies", "PROBLEM", 105, 128], ["structure-guided drug design1\u20136", "TREATMENT", 210, 241], ["high-resolution", "OBSERVATION_MODIFIER", 20, 35]]], ["However, expanding of the range of SARS-CoV-2 drug targets may accelerate therapeutic discovery and increase diversity of available drugs to mitigate against the potential evolution of drug-resistant viral strains7.IntroductionThe SARS-CoV-2 genome encodes three putative ion channels (viroporins)8, E, 3a, and 8a9.", [["SARS", "DISEASE", 35, 39], ["SARS-CoV-2", "ORGANISM", 35, 45], ["SARS-CoV-2", "ORGANISM", 231, 241], ["viroporins)8", "GENE_OR_GENE_PRODUCT", 286, 298], ["E", "GENE_OR_GENE_PRODUCT", 300, 301], ["3", "GENE_OR_GENE_PRODUCT", 303, 304], ["8a9", "GENE_OR_GENE_PRODUCT", 311, 314], ["SARS-CoV-2 genome", "DNA", 231, 248], ["putative ion channels (viroporins)8, E, 3a, and 8a9", "PROTEIN", 263, 314], ["SARS-CoV", "SPECIES", 231, 239], ["SARS", "PROBLEM", 35, 39], ["CoV-2 drug targets", "TREATMENT", 40, 58], ["available drugs", "TREATMENT", 122, 137], ["drug-resistant viral strains7", "PROBLEM", 185, 214], ["The SARS", "TEST", 227, 235], ["putative ion channels (viroporins)", "TREATMENT", 263, 297], ["resistant", "OBSERVATION_MODIFIER", 190, 199], ["viral strains7", "OBSERVATION", 200, 214]]], ["Viroporins are generally believed to modify host membrane permeability to promote viral assembly and release, among other functions8,10.", [["membrane", "ANATOMY", 49, 57], ["Viroporins", "GENE_OR_GENE_PRODUCT", 0, 10], ["host membrane", "CELLULAR_COMPONENT", 44, 57], ["Viroporins", "PROTEIN", 0, 10], ["Viroporins", "TREATMENT", 0, 10], ["host membrane permeability", "PROBLEM", 44, 70], ["viral", "OBSERVATION", 82, 87]]], ["Many successful drugs targeting ion channels have been developed11 and targeting viroporins with small molecule inhibitors, in particular the influenza M2 proton channel, has demonstrated therapeutic success12\u201314.IntroductionIn this study, we focus on the SARS-CoV-2 3a channel15.", [["SARS", "DISEASE", 256, 260], ["viroporins", "GENE_OR_GENE_PRODUCT", 81, 91], ["channel15", "GENE_OR_GENE_PRODUCT", 270, 279], ["viroporins", "PROTEIN", 81, 91], ["influenza M2 proton channel", "PROTEIN", 142, 169], ["channel15", "DNA", 270, 279], ["SARS-CoV", "SPECIES", 256, 264], ["Many successful drugs targeting ion channels", "TREATMENT", 0, 44], ["small molecule inhibitors", "TREATMENT", 97, 122], ["the influenza M2 proton channel", "TREATMENT", 138, 169], ["this study", "TEST", 228, 238], ["the SARS", "TEST", 252, 260]]], ["The ORF3 genomic region contains coding sequence for multiple open reading frames and exhibits high diversity among coronaviruses compared to neighboring regions16.", [["ORF3", "GENE_OR_GENE_PRODUCT", 4, 8], ["ORF3 genomic region", "DNA", 4, 23], ["multiple open reading frames", "DNA", 53, 81], ["neighboring regions16", "DNA", 142, 163], ["The ORF3 genomic region", "PROBLEM", 0, 23], ["coding sequence", "TEST", 33, 48], ["multiple open reading frames", "PROBLEM", 53, 81], ["high diversity among coronaviruses", "PROBLEM", 95, 129], ["ORF3 genomic", "OBSERVATION", 4, 16], ["region", "ANATOMY_MODIFIER", 17, 23], ["multiple", "OBSERVATION_MODIFIER", 53, 61], ["open", "OBSERVATION_MODIFIER", 62, 66], ["high", "OBSERVATION_MODIFIER", 95, 99], ["diversity", "OBSERVATION_MODIFIER", 100, 109], ["coronaviruses", "OBSERVATION", 116, 129]]], ["Notably, 3a is highly conserved within the Betacoronavirus subgenus Sarbecovirus which includes SARS-CoV-1 and related bat coronaviruses that are thought to be the zoonotic source of human-infecting SARS coronaviruses (Fig. S1)17.", [["SARS coronaviruses", "DISEASE", 199, 217], ["Betacoronavirus subgenus Sarbecovirus", "ORGANISM", 43, 80], ["SARS-CoV-1", "ORGANISM", 96, 106], ["bat coronaviruses", "ORGANISM", 119, 136], ["human", "ORGANISM", 183, 188], ["SARS coronaviruses", "ORGANISM", 199, 217], ["CoV-1", "SPECIES", 101, 106], ["bat coronaviruses", "SPECIES", 119, 136], ["human", "SPECIES", 183, 188], ["SARS-CoV-1", "SPECIES", 96, 106], ["bat coronaviruses", "SPECIES", 119, 136], ["human", "SPECIES", 183, 188], ["SARS coronaviruses", "SPECIES", 199, 217], ["the Betacoronavirus subgenus Sarbecovirus", "PROBLEM", 39, 80], ["SARS", "PROBLEM", 96, 100], ["CoV", "TEST", 101, 104], ["bat coronaviruses", "PROBLEM", 119, 136], ["infecting SARS coronaviruses", "PROBLEM", 189, 217], ["subgenus Sarbecovirus", "OBSERVATION", 59, 80], ["bat", "ANATOMY", 119, 122], ["coronaviruses", "OBSERVATION", 123, 136], ["thought to be", "UNCERTAINTY", 146, 159]]], ["SARS-CoV-1 3a has been reported to form an emodin-sensitive K+-permeable cation channel15,18 and has been implicated in inflammasome activation19 and both apoptotic20 and necrotic cell death21.", [["necrotic cell", "ANATOMY", 171, 184], ["SARS", "DISEASE", 0, 4], ["emodin", "CHEMICAL", 43, 49], ["necrotic", "DISEASE", 171, 179], ["emodin", "CHEMICAL", 43, 49], ["SARS-CoV-1 3a", "GENE_OR_GENE_PRODUCT", 0, 13], ["emodin", "SIMPLE_CHEMICAL", 43, 49], ["apoptotic20", "GENE_OR_GENE_PRODUCT", 155, 166], ["necrotic cell", "CELL", 171, 184], ["K+-permeable cation channel15,18", "PROTEIN", 60, 92], ["inflammasome activation19", "PROTEIN", 120, 145], ["apoptotic20", "PROTEIN", 155, 166], ["necrotic cell death21", "PROTEIN", 171, 192], ["an emodin", "TEST", 40, 49], ["necrotic cell death21", "PROBLEM", 171, 192], ["necrotic cell death21", "OBSERVATION", 171, 192]]], ["In mouse models of SARSCoV-1 infection, genomic deletion of ORF3a reduced viral titer and morbidity9.", [["infection", "DISEASE", 29, 38], ["mouse", "ORGANISM", 3, 8], ["SARSCoV-1", "GENE_OR_GENE_PRODUCT", 19, 28], ["ORF3a", "GENE_OR_GENE_PRODUCT", 60, 65], ["ORF3a", "DNA", 60, 65], ["mouse", "SPECIES", 3, 8], ["mouse", "SPECIES", 3, 8], ["SARSCoV-1", "SPECIES", 19, 28], ["SARSCoV", "PROBLEM", 19, 26], ["1 infection", "PROBLEM", 27, 38], ["genomic deletion", "PROBLEM", 40, 56], ["ORF3a reduced viral titer", "PROBLEM", 60, 85], ["infection", "OBSERVATION", 29, 38]]], ["SARS-CoV-1 3a has therefore been considered a potential target for therapeutics to treat SARS.Introduction3a has three predicted transmembrane helices followed by a cytosolic domain with multiple \u03b2-strands per protomer chain15.", [["transmembrane", "ANATOMY", 129, 142], ["cytosolic", "ANATOMY", 165, 174], ["SARS", "DISEASE", 0, 4], ["SARS", "DISEASE", 89, 93], ["SARS-CoV-1 3a", "GENE_OR_GENE_PRODUCT", 0, 13], ["transmembrane helices", "PROTEIN", 129, 150], ["cytosolic domain", "PROTEIN", 165, 181], ["\u03b2-strands", "PROTEIN", 196, 205], ["protomer chain15", "PROTEIN", 210, 226], ["therapeutics", "TREATMENT", 67, 79], ["SARS", "PROBLEM", 89, 93], ["three predicted transmembrane helices", "TREATMENT", 113, 150], ["a cytosolic domain", "PROBLEM", 163, 181], ["multiple \u03b2-strands per protomer chain15", "TREATMENT", 187, 226]]], ["Each of its domains: N-terminal, Transmembrane, and C-terminal have been proposed to play roles in SARS biology and pathogenesis15,19.", [["SARS", "DISEASE", 99, 103], ["N", "CHEMICAL", 21, 22], ["C", "CHEMICAL", 52, 53], ["Transmembrane", "CELLULAR_COMPONENT", 33, 46], ["N-terminal, Transmembrane, and C-terminal", "PROTEIN", 21, 62]]], ["3a has been shown to form dimers, tetramers, and potentially higher order oligomers of 31 kDa subunits15,21.", [["tetramers", "PROTEIN", 34, 43], ["31 kDa subunits15,21", "PROTEIN", 87, 107], ["tetramers", "TREATMENT", 34, 43]]], ["No structural information exists for 3a proteins nor are there structures of close homologs that could be used to generate structural models, impeding both computational discovery and design of inhibitors as well as a mechanistic understanding of 3a function.", [["3a proteins", "PROTEIN", 37, 48], ["3a proteins", "PROBLEM", 37, 48], ["design of inhibitors", "TREATMENT", 184, 204]]], ["To better understand the basis for 3a function, we have determined structures of dimeric and tetrameric SARSCoV-2 3a in lipid nanodiscs by cryo-electron microscopy (cryo-EM) and characterized 3a channel activity in a reconstituted system.", [["lipid nanodiscs", "ANATOMY", 120, 135], ["SARSCoV-2 3a", "GENE_OR_GENE_PRODUCT", 104, 116], ["lipid nanodiscs", "SIMPLE_CHEMICAL", 120, 135], ["dimeric and tetrameric SARSCoV-2 3a", "PROTEIN", 81, 116], ["tetrameric SARSCoV", "TEST", 93, 111], ["cryo-electron microscopy", "TEST", 139, 163]]], ["This could provide a framework for the design of drugs which target 3a and have the potential to serve as COVID-19 therapeutics.ResultsFull length SARS-CoV-2 3a was heterologously expressed in Spodoptera frugiperda (Sf9) cells with a cleavable C-terminal GFP tag.", [["Sf9) cells", "ANATOMY", 216, 226], ["C", "CHEMICAL", 244, 245], ["SARS-CoV-2 3a", "GENE_OR_GENE_PRODUCT", 147, 160], ["Spodoptera frugiperda", "ORGANISM", 193, 214], ["Sf9) cells", "CELL", 216, 226], ["SARS-CoV-2 3a", "DNA", 147, 160], ["Spodoptera frugiperda (Sf9) cells", "CELL_LINE", 193, 226], ["cleavable C-terminal GFP tag", "PROTEIN", 234, 262], ["Spodoptera frugiperda", "SPECIES", 193, 214], ["Spodoptera frugiperda", "SPECIES", 193, 214], ["drugs", "TREATMENT", 49, 54], ["COVID", "TEST", 106, 111], ["Full length SARS", "TEST", 135, 151], ["CoV", "TEST", 152, 155], ["a cleavable C-terminal GFP tag", "PROBLEM", 232, 262], ["Spodoptera frugiperda", "ANATOMY", 193, 214], ["GFP tag", "OBSERVATION", 255, 262]]], ["Whole cell currents recorded from 3a-expressing cells were difficult to distinguish from control cells, likely because the majority of 3a protein is present in intracellular membranes.", [["cell", "ANATOMY", 6, 10], ["cells", "ANATOMY", 48, 53], ["cells", "ANATOMY", 97, 102], ["intracellular membranes", "ANATOMY", 160, 183], ["cell", "CELL", 6, 10], ["cells", "CELL", 48, 53], ["cells", "CELL", 97, 102], ["3a", "GENE_OR_GENE_PRODUCT", 135, 137], ["intracellular membranes", "CELLULAR_COMPONENT", 160, 183], ["3a-expressing cells", "CELL_LINE", 34, 53], ["control cells", "CELL_TYPE", 89, 102], ["3a protein", "PROTEIN", 135, 145], ["Whole cell currents", "TEST", 0, 19], ["intracellular membranes", "OBSERVATION", 160, 183]]], ["To better assess 3a channel function, we purified 3a in detergent, reconstituted it into phosphatidylcholine lipids, and recorded currents across excised patches pulled from proteoliposome blisters.Results3a-containing patches generated currents with modest outward rectification in symmetric [K+] (rectification index = 1.28\u00b10.02, mean \u00b1s.e.m. (n=5)), consistent with preferential sidedness of rectifying channels in the membrane after reconstitution (Fig. 1A,B).", [["patches", "ANATOMY", 154, 161], ["proteoliposome blisters", "ANATOMY", 174, 197], ["membrane", "ANATOMY", 422, 430], ["phosphatidylcholine", "CHEMICAL", 89, 108], ["K", "CHEMICAL", 294, 295], ["phosphatidylcholine", "CHEMICAL", 89, 108], ["phosphatidylcholine lipids", "SIMPLE_CHEMICAL", 89, 115], ["Results3a", "SIMPLE_CHEMICAL", 198, 207], ["membrane", "CELLULAR_COMPONENT", 422, 430], ["Results3a", "PROTEIN", 198, 207], ["rectifying channels", "PROTEIN", 395, 414], ["detergent", "TREATMENT", 56, 65], ["phosphatidylcholine lipids", "TREATMENT", 89, 115], ["proteoliposome blisters", "PROBLEM", 174, 197], ["Results3a", "TEST", 198, 207], ["modest outward rectification", "PROBLEM", 251, 279], ["K", "TEST", 294, 295], ["rectification index", "TEST", 299, 318], ["mean \u00b1s.e.m.", "TEST", 332, 344], ["proteoliposome", "OBSERVATION_MODIFIER", 174, 188], ["blisters", "OBSERVATION", 189, 197], ["consistent with", "UNCERTAINTY", 353, 368], ["preferential sidedness", "OBSERVATION", 369, 391], ["rectifying channels", "OBSERVATION", 395, 414], ["membrane", "ANATOMY_MODIFIER", 422, 430]]], ["We evaluated selectivity of 3a for different cations by replacing the K+-containing bath solution with solutions containing Na+, NMDG+, or Ca2+.", [["K", "CHEMICAL", 70, 71], ["Na+", "CHEMICAL", 124, 127], ["NMDG", "CHEMICAL", 129, 133], ["Ca2", "CHEMICAL", 139, 142], ["K", "CHEMICAL", 70, 71], ["Na+", "CHEMICAL", 124, 127], ["NMDG+", "CHEMICAL", 129, 134], ["Ca2+", "CHEMICAL", 139, 143], ["cations", "SIMPLE_CHEMICAL", 45, 52], ["K+-", "SIMPLE_CHEMICAL", 70, 73], ["Na+", "SIMPLE_CHEMICAL", 124, 127], ["NMDG+", "SIMPLE_CHEMICAL", 129, 134], ["Ca2+", "SIMPLE_CHEMICAL", 139, 143], ["different cations", "TREATMENT", 35, 52], ["the K+-containing bath solution with solutions", "TREATMENT", 66, 112], ["Na+", "TEST", 124, 127], ["NMDG", "TEST", 129, 133]]], ["Solution exchange resulted in reversal potential shifts from 0.3\u00b10.3 mV in K+ to \u22126.7\u00b10.5 mV in Ca2+, \u221213.5\u00b11.8 mV in Na+, and \u221231.0\u00b11.1 mV in NMDG+ (Fig. 1A,C).", [["K", "CHEMICAL", 75, 76], ["Ca2", "CHEMICAL", 96, 99], ["Ca2+", "CHEMICAL", 96, 100], ["Ca2+", "SIMPLE_CHEMICAL", 96, 100], ["Ca2", "PROTEIN", 96, 99], ["NMDG", "PROTEIN", 143, 147], ["Solution exchange", "TREATMENT", 0, 17], ["mV", "TEST", 69, 71], ["K", "TEST", 75, 76], ["mV", "TEST", 90, 92], ["Ca2", "TEST", 96, 99], ["\u2212", "TEST", 102, 103], ["mV", "TEST", 112, 114], ["Na+", "TEST", 118, 121], ["\u2212", "TEST", 127, 128], ["mV", "TEST", 137, 139], ["NMDG", "TEST", 143, 147]]], ["These shifts correspond to the following permeability ratios (PX/PK+): Ca2+ (2.04\u00b10.06) > K+ (1.0) > Na+ (0.59\u00b10.04) > NMDG+ (0.29\u00b10.01) (Fig. 1D).", [["Ca2", "CHEMICAL", 71, 74], ["K", "CHEMICAL", 90, 91], ["Na", "CHEMICAL", 101, 103], ["Ca2+", "CHEMICAL", 71, 75], ["K+", "CHEMICAL", 90, 92], ["Na+", "CHEMICAL", 101, 104], ["NMDG", "CHEMICAL", 119, 123], ["Ca2+", "SIMPLE_CHEMICAL", 71, 75], ["K+", "SIMPLE_CHEMICAL", 90, 92], ["Na+", "SIMPLE_CHEMICAL", 101, 104], ["NMDG+", "SIMPLE_CHEMICAL", 119, 124], ["the following permeability ratios", "TEST", 27, 60], ["PX", "TEST", 62, 64], ["PK", "TEST", 65, 67], ["Ca2", "TEST", 71, 74], ["K", "TEST", 90, 91], ["Na", "TEST", 101, 103], ["NMDG", "TEST", 119, 123]]], ["We conclude that SARS-CoV-2 3a is a cation channel with modest selectivity for Ca2+ and K+ over Na+.ResultsIn K+- and Na+- containing solutions, channels remained open for long durations with infrequent closures.", [["SARS", "DISEASE", 17, 21], ["Ca2", "CHEMICAL", 79, 82], ["K", "CHEMICAL", 88, 89], ["K", "CHEMICAL", 110, 111], ["Na", "CHEMICAL", 118, 120], ["Ca2+", "CHEMICAL", 79, 83], ["K+", "CHEMICAL", 88, 90], ["Na+.", "CHEMICAL", 96, 100], ["K", "CHEMICAL", 110, 111], ["Na", "CHEMICAL", 118, 120], ["SARS-CoV-2 3a", "GENE_OR_GENE_PRODUCT", 17, 30], ["cation", "SIMPLE_CHEMICAL", 36, 42], ["Ca2+", "SIMPLE_CHEMICAL", 79, 83], ["K+", "SIMPLE_CHEMICAL", 88, 90], ["K+-", "SIMPLE_CHEMICAL", 110, 113], ["Na+-", "SIMPLE_CHEMICAL", 118, 122], ["Ca2", "PROTEIN", 79, 82], ["a cation channel", "TREATMENT", 34, 50], ["Ca2", "TEST", 79, 82], ["K", "TEST", 88, 89], ["K", "TEST", 110, 111], ["Na+- containing solutions", "TREATMENT", 118, 143], ["infrequent closures", "TREATMENT", 192, 211], ["closures", "OBSERVATION", 203, 211]]], ["In contrast, in Ca2+-containing solutions, channels exhibited \u201cflickery\u201d behavior with frequent transitions to closed or subconductance states (Fig. 1F).", [["Ca2", "CHEMICAL", 16, 19], ["Ca2+", "CHEMICAL", 16, 20], ["Ca2+", "SIMPLE_CHEMICAL", 16, 20], ["Ca2", "PROTEIN", 16, 19]]], ["Contrary to previous studies of SARSCoV-1 3a in cells, SARS-CoV-2 3a activity was not inhibited by Ba2+(15) or by the small molecule emodin18 (Fig. S2F,G).", [["cells", "ANATOMY", 48, 53], ["Ba2", "CHEMICAL", 99, 102], ["Ba2+", "CHEMICAL", 99, 103], ["SARSCoV-1 3a", "GENE_OR_GENE_PRODUCT", 32, 44], ["cells", "CELL", 48, 53], ["SARS-CoV-2 3", "GENE_OR_GENE_PRODUCT", 55, 67], ["Ba2+(15)", "GENE_OR_GENE_PRODUCT", 99, 107], ["SARSCoV-1 3a", "DNA", 32, 44], ["Ba2", "PROTEIN", 99, 102], ["small molecule emodin18", "PROTEIN", 118, 141], ["S2F,G", "PROTEIN", 148, 153], ["previous studies", "TEST", 12, 28], ["SARSCoV", "TEST", 32, 39], ["SARS", "TEST", 55, 59], ["CoV", "TEST", 60, 63], ["Ba2", "TEST", 99, 102]]], ["Alkaline pH modestly increased channel activity (by 31 \u00b1 2% at \u221280 mV in symmetric K+, Fig. S2H,I,J).", [["K", "CHEMICAL", 83, 84], ["Alkaline", "SIMPLE_CHEMICAL", 0, 8], ["K+", "SIMPLE_CHEMICAL", 83, 85], ["S2H", "SIMPLE_CHEMICAL", 92, 95], ["Alkaline pH", "TEST", 0, 11], ["channel activity", "TEST", 31, 47], ["symmetric K", "TEST", 73, 84], ["modestly", "OBSERVATION_MODIFIER", 12, 20], ["increased", "OBSERVATION_MODIFIER", 21, 30], ["channel activity", "OBSERVATION_MODIFIER", 31, 47]]], ["Gating was not observed in response to acidic pH (Fig. S2J).", [["acidic pH", "TEST", 39, 48]]], ["After a variable amount of time (on the order of minutes), we observed an increase in \u201cflickery\u201d closures followed by loss of channel activity in each patch, perhaps as a result of channel inactivation (Fig. 1G).", [["\u201cflickery\u201d closures", "TREATMENT", 86, 105], ["loss of channel activity in each patch", "PROBLEM", 118, 156], ["channel inactivation", "PROBLEM", 181, 201], ["increase", "OBSERVATION_MODIFIER", 74, 82], ["channel activity", "OBSERVATION_MODIFIER", 126, 142]]], ["The basis for this loss of channel activity remains to be determined.", [["this loss of channel activity", "PROBLEM", 14, 43]]], ["Current reduction occurred in discrete steps of 30.0 \u00b1 0.8 pA from which we estimate the single channel conductance of 3a to be 375 pS at \u221280 mV under bi-ionic conditions with K+ in the pipette and Na+ in the bath (Fig. 1E,G).ResultsPurification of 3a in detergent resulted in two species separable by gel filtration (Fig. S3).", [["K", "CHEMICAL", 176, 177], ["Na", "CHEMICAL", 198, 200], ["K+", "CHEMICAL", 176, 178], ["Na+", "CHEMICAL", 198, 201], ["K+", "SIMPLE_CHEMICAL", 176, 178], ["Na+", "SIMPLE_CHEMICAL", 198, 201], ["Current reduction", "TREATMENT", 0, 17], ["pS", "TEST", 132, 134], ["K", "TEST", 176, 177], ["Na", "TEST", 198, 200], ["two species", "PROBLEM", 277, 288], ["gel filtration", "TREATMENT", 302, 316], ["reduction", "OBSERVATION_MODIFIER", 8, 17], ["discrete", "OBSERVATION_MODIFIER", 30, 38], ["steps", "OBSERVATION_MODIFIER", 39, 44]]], ["A majority of 3a runs at a position consistent with a dimer of 62 kDa (Fig. S3A) and 5\u201310% runs as a 124 kDa tetramer (Fig. S3D).", [["dimer", "PROTEIN", 54, 59], ["62 kDa", "PROTEIN", 63, 69], ["S3A", "PROTEIN", 76, 79], ["124 kDa tetramer", "PROTEIN", 101, 117], ["S3D", "PROTEIN", 124, 127], ["a 124 kDa tetramer", "TREATMENT", 99, 117]]], ["A similar degree of tetramer formation was observed at low concentrations of 3a by florescence size-exclusion chromatography, indicative of a biochemically stable species rather than concentration-dependent nonspecific aggregation (Fig. S3E).", [["florescence", "SIMPLE_CHEMICAL", 83, 94], ["tetramer formation", "PROBLEM", 20, 38], ["exclusion chromatography", "TEST", 100, 124], ["a biochemically stable species", "PROBLEM", 140, 170], ["dependent nonspecific aggregation", "PROBLEM", 197, 230], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["degree", "OBSERVATION_MODIFIER", 10, 16], ["tetramer formation", "OBSERVATION", 20, 38], ["size", "OBSERVATION_MODIFIER", 95, 99], ["indicative of", "UNCERTAINTY", 126, 139], ["biochemically", "OBSERVATION_MODIFIER", 142, 155], ["stable", "OBSERVATION_MODIFIER", 156, 162], ["species", "OBSERVATION", 163, 170], ["nonspecific", "OBSERVATION_MODIFIER", 207, 218], ["aggregation", "OBSERVATION", 219, 230]]], ["These data are consistent with previous reports of dimeric and tetrameric SARS-CoV-1 3a observed by western blot15,21.ResultsWe separately reconstituted dimeric and tetrameric SARS-CoV-2 3a into nanodiscs made from the scaffold protein MSP1E3D1 and a mixture of POPC, DOPE, and POPS lipids and determined their structures by cryo-EM (Fig. 2A\u2013H).", [["POPC", "CHEMICAL", 262, 266], ["DOPE", "CHEMICAL", 268, 272], ["POPC", "CHEMICAL", 262, 266], ["DOPE", "CHEMICAL", 268, 272], ["SARS-CoV-1 3", "GENE_OR_GENE_PRODUCT", 74, 86], ["nanodiscs", "CANCER", 195, 204], ["MSP1E3D1", "SIMPLE_CHEMICAL", 236, 244], ["POPC", "SIMPLE_CHEMICAL", 262, 266], ["DOPE", "SIMPLE_CHEMICAL", 268, 272], ["POPS lipids", "SIMPLE_CHEMICAL", 278, 289], ["tetrameric SARS-CoV-2 3a", "PROTEIN", 165, 189], ["scaffold protein MSP1E3D1", "PROTEIN", 219, 244], ["dimeric and tetrameric SARS", "PROBLEM", 51, 78], ["CoV", "TEST", 79, 82], ["tetrameric SARS", "TEST", 165, 180], ["CoV", "TEST", 181, 184], ["the scaffold protein MSP1E3D1", "TREATMENT", 215, 244], ["POPC", "TEST", 262, 266], ["DOPE", "TREATMENT", 268, 272], ["POPS lipids", "TEST", 278, 289], ["consistent with", "UNCERTAINTY", 15, 30]]], ["We also determined the structure of dimeric 3a in the presence of 100 \u03bcM emodin, but observed no significant structural changes from dimeric apo 3a or any indication of bound emodin.", [["emodin", "CHEMICAL", 73, 79], ["emodin", "CHEMICAL", 175, 181], ["emodin", "CHEMICAL", 73, 79], ["emodin", "CHEMICAL", 175, 181], ["emodin", "SIMPLE_CHEMICAL", 73, 79], ["dimeric apo 3a", "GENE_OR_GENE_PRODUCT", 133, 147], ["emodin", "SIMPLE_CHEMICAL", 175, 181], ["dimeric 3a", "PROTEIN", 36, 46], ["dimeric apo 3a", "PROTEIN", 133, 147], ["emodin", "TREATMENT", 73, 79], ["significant structural changes from dimeric apo 3a", "PROBLEM", 97, 147], ["bound emodin", "PROBLEM", 169, 181], ["no", "UNCERTAINTY", 94, 96], ["significant", "OBSERVATION_MODIFIER", 97, 108], ["structural", "OBSERVATION", 109, 119], ["bound emodin", "OBSERVATION", 169, 181]]], ["This is consistent with the lack of emodin inhibition observed in proteoliposome recordings (Fig. S2F,J).", [["proteoliposome", "ANATOMY", 66, 80], ["emodin", "CHEMICAL", 36, 42], ["emodin", "CHEMICAL", 36, 42], ["emodin", "SIMPLE_CHEMICAL", 36, 42], ["emodin inhibition", "PROBLEM", 36, 53], ["proteoliposome recordings", "TEST", 66, 91], ["consistent with", "UNCERTAINTY", 8, 23], ["emodin inhibition", "OBSERVATION", 36, 53]]], ["The final dimeric reconstruction (with C2 symmetry applied) had an overall resolution of 2.9 \u00c5 and permitted de novo modeling of 195 of the 275 amino acids per protomer chain (Fig. 2B).", [["amino acids", "CHEMICAL", 144, 155], ["amino acids", "CHEMICAL", 144, 155], ["amino acids", "AMINO_ACID", 144, 155], ["protomer chain", "PROTEIN", 160, 174], ["Fig. 2B", "PROTEIN", 176, 183], ["The final dimeric reconstruction", "TREATMENT", 0, 32], ["amino acids", "TEST", 144, 155]]], ["The N-terminus (amino acids 1\u201339), C-terminus (amino acids 239\u2013275), and a short cytoplasmic loop (amino acids 175\u2013180) are either not observed or weakly resolved in the density map, presumably due to conformational differences between particles or because they are disordered.Results3a adopts a fold that is, to our knowledge, novel among available protein structures.", [["cytoplasmic", "ANATOMY", 81, 92], ["amino acids", "CHEMICAL", 16, 27], ["amino acids 239\u2013275", "CHEMICAL", 47, 66], ["amino acids 175\u2013180", "CHEMICAL", 99, 118], ["amino acids", "CHEMICAL", 16, 27], ["C", "CHEMICAL", 35, 36], ["amino acids", "CHEMICAL", 47, 58], ["amino acids", "CHEMICAL", 99, 110], ["amino acids", "AMINO_ACID", 16, 27], ["1\u201339", "AMINO_ACID", 28, 32], ["C-terminus", "GENE_OR_GENE_PRODUCT", 35, 45], ["amino acids", "AMINO_ACID", 47, 58], ["239\u2013275", "AMINO_ACID", 59, 66], ["cytoplasmic", "ORGANISM_SUBSTANCE", 81, 92], ["amino acids", "AMINO_ACID", 99, 110], ["175\u2013180", "AMINO_ACID", 111, 118], ["N-terminus", "PROTEIN", 4, 14], ["amino acids 1\u201339", "PROTEIN", 16, 32], ["C-terminus", "PROTEIN", 35, 45], ["amino acids 239\u2013275", "PROTEIN", 47, 66], ["cytoplasmic loop", "PROTEIN", 81, 97], ["amino acids 175\u2013180", "PROTEIN", 99, 118], ["Results3a", "PROTEIN", 277, 286], ["The N-terminus (amino acids", "TEST", 0, 27], ["C-terminus (amino acids", "TEST", 35, 58], ["a short cytoplasmic loop (amino acids", "TEST", 73, 110], ["the density map", "TEST", 166, 181], ["conformational differences between particles", "PROBLEM", 201, 245], ["not observed", "UNCERTAINTY", 131, 143], ["weakly", "OBSERVATION_MODIFIER", 147, 153], ["resolved", "OBSERVATION", 154, 162], ["presumably due to", "UNCERTAINTY", 183, 200]]], ["Querying the protein structure database for structural homologs with DALI returned only weak hits for fragments of 3a domains22.", [["DALI", "PROTEIN", 69, 73], ["3a domains22", "PROTEIN", 115, 127], ["weak hits", "PROBLEM", 88, 97], ["fragments of 3a domains", "PROBLEM", 102, 125], ["weak", "OBSERVATION_MODIFIER", 88, 92], ["hits", "OBSERVATION", 93, 97]]], ["Viewed from the membrane plane, 3a is approximately 70 \u00c5 tall with a 40 \u00c5 high transmembrane region and a cytosolic domain (CD) extending 30 \u00c5 out of the membrane (Fig. 2B).", [["membrane plane", "ANATOMY", 16, 30], ["cytosolic", "ANATOMY", 106, 115], ["membrane", "ANATOMY", 154, 162], ["membrane plane", "CELLULAR_COMPONENT", 16, 30], ["membrane", "CELLULAR_COMPONENT", 154, 162], ["40 \u00c5 high transmembrane region", "PROTEIN", 69, 99], ["cytosolic domain", "PROTEIN", 106, 122], ["CD", "PROTEIN", 124, 126], ["Fig. 2B", "PROTEIN", 164, 171], ["a 40 \u00c5 high transmembrane region", "PROBLEM", 67, 99], ["a cytosolic domain (CD)", "TREATMENT", 104, 127]]], ["The transmembrane region is composed of three helices per protomer.", [["transmembrane", "ANATOMY", 4, 17], ["transmembrane", "CELLULAR_COMPONENT", 4, 17], ["transmembrane region", "PROTEIN", 4, 24], ["helices per protomer", "PROTEIN", 46, 66], ["transmembrane", "ANATOMY_MODIFIER", 4, 17], ["region", "ANATOMY_MODIFIER", 18, 24]]], ["The N-termini are oriented on the extracellular or lumenal side and C-termini on the cytosolic side of the bilayer.", [["extracellular", "ANATOMY", 34, 47], ["lumenal", "ANATOMY", 51, 58], ["cytosolic", "ANATOMY", 85, 94], ["N", "CHEMICAL", 4, 5], ["C", "CHEMICAL", 68, 69], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 34, 47], ["lumenal side", "CELLULAR_COMPONENT", 51, 63], ["C-termini", "SIMPLE_CHEMICAL", 68, 77], ["bilayer", "CELLULAR_COMPONENT", 107, 114], ["N-termini", "PROTEIN", 4, 13], ["extracellular or lumenal side and C-termini", "PROTEIN", 34, 77], ["N-termini", "OBSERVATION_MODIFIER", 4, 13], ["oriented", "OBSERVATION_MODIFIER", 18, 26], ["extracellular", "ANATOMY_MODIFIER", 34, 47], ["lumenal", "ANATOMY_MODIFIER", 51, 58], ["bilayer", "ANATOMY_MODIFIER", 107, 114]]], ["3a is thus a Class IIIA viroporin according to the classification system of Nieva et al10.", [["Class IIIA viroporin", "PROTEIN", 13, 33], ["a Class IIIA viroporin", "TREATMENT", 11, 33]]], ["Viewed from the extracellular side, the transmembrane helices (TMs) trace the circumference of an ellipse with TM1\u20133 from one protomer followed by TM1\u20133 of the second protomer in a clockwise order (Fig. 2C).", [["extracellular", "ANATOMY", 16, 29], ["transmembrane helices", "ANATOMY", 40, 61], ["extracellular side", "CELLULAR_COMPONENT", 16, 34], ["TM1\u20133", "GENE_OR_GENE_PRODUCT", 111, 116], ["transmembrane helices", "PROTEIN", 40, 61], ["TMs", "PROTEIN", 63, 66], ["TM1\u20133", "PROTEIN", 111, 116], ["TM1\u20133", "PROTEIN", 147, 152]]], ["TM1s and TM2s pack against each other across the elliptical minor axis with TM3s positioned at the major axis vertices.", [["TM1s", "PROTEIN", 0, 4], ["TM2s", "PROTEIN", 9, 13], ["TM3s", "DNA", 76, 80], ["TM1s", "TEST", 0, 4], ["TM2s pack", "TREATMENT", 9, 18], ["TM3s", "TREATMENT", 76, 80], ["elliptical", "ANATOMY_MODIFIER", 49, 59], ["minor axis", "ANATOMY", 60, 70], ["major axis", "ANATOMY", 99, 109], ["vertices", "ANATOMY_MODIFIER", 110, 118]]], ["TM1-TM2 and TM2-TM3 are joined by short intracellular and extracellular linkers, respectively.", [["TM2-TM3", "ANATOMY", 12, 19], ["intracellular", "ANATOMY", 40, 53], ["extracellular", "ANATOMY", 58, 71], ["TM1-TM2", "GENE_OR_GENE_PRODUCT", 0, 7], ["TM2-TM3", "GENE_OR_GENE_PRODUCT", 12, 19], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 40, 53], ["extracellular linkers", "CELLULAR_COMPONENT", 58, 79], ["TM1", "PROTEIN", 0, 3], ["TM2", "PROTEIN", 4, 7], ["TM2", "PROTEIN", 12, 15], ["TM3", "PROTEIN", 16, 19], ["TM1", "TEST", 0, 3], ["TM2", "TEST", 12, 15]]], ["The transmembrane region connects to the CD through a turn-helix-turn motif following TM3.", [["transmembrane region", "ANATOMY", 4, 24], ["transmembrane", "CELLULAR_COMPONENT", 4, 17], ["CD", "GENE_OR_GENE_PRODUCT", 41, 43], ["TM3", "AMINO_ACID", 86, 89], ["transmembrane region", "PROTEIN", 4, 24], ["turn-helix-turn motif", "PROTEIN", 54, 75], ["TM3", "PROTEIN", 86, 89], ["The transmembrane region", "PROBLEM", 0, 24]]], ["Each protomer chain forms a pair of opposing \u03b2-sheets packed against one another in an eight stranded \u03b2-sandwich (Fig. 2B,D).", [["protomer chain", "PROTEIN", 5, 19], ["opposing \u03b2-sheets", "TREATMENT", 36, 53]]], ["The outer sheet is formed by strands \u03b21, \u03b22, \u03b26 and the N-terminal half of \u03b27.", [["outer sheet", "ANATOMY", 4, 15], ["N", "CHEMICAL", 56, 57], ["outer sheet", "CELLULAR_COMPONENT", 4, 15], ["\u03b21", "GENE_OR_GENE_PRODUCT", 37, 39], ["\u03b22", "GENE_OR_GENE_PRODUCT", 41, 43], ["\u03b26", "GENE_OR_GENE_PRODUCT", 45, 47], ["\u03b27", "GENE_OR_GENE_PRODUCT", 75, 77], ["\u03b21", "PROTEIN", 37, 39], ["\u03b22", "PROTEIN", 41, 43], ["\u03b26", "PROTEIN", 45, 47], ["N-terminal half", "PROTEIN", 56, 71], ["\u03b27", "PROTEIN", 75, 77], ["The outer sheet", "TEST", 0, 15], ["outer", "ANATOMY_MODIFIER", 4, 9], ["formed", "OBSERVATION", 19, 25], ["strands", "OBSERVATION", 29, 36], ["terminal", "ANATOMY_MODIFIER", 58, 66]]], ["The inner sheet is formed by strands \u03b23, \u03b24, \u03b25, \u03b28, and C-terminal half of \u03b27.", [["inner sheet", "ANATOMY", 4, 15], ["C", "CHEMICAL", 57, 58], ["inner sheet", "TISSUE", 4, 15], ["\u03b23", "GENE_OR_GENE_PRODUCT", 37, 39], ["\u03b24", "GENE_OR_GENE_PRODUCT", 41, 43], ["\u03b25", "GENE_OR_GENE_PRODUCT", 45, 47], ["\u03b28", "GENE_OR_GENE_PRODUCT", 49, 51], ["\u03b27", "GENE_OR_GENE_PRODUCT", 76, 78], ["\u03b23", "PROTEIN", 37, 39], ["\u03b24", "PROTEIN", 41, 43], ["\u03b25", "PROTEIN", 45, 47], ["\u03b28", "PROTEIN", 49, 51], ["C-terminal half", "PROTEIN", 57, 72], ["\u03b27", "PROTEIN", 76, 78], ["strands", "TEST", 29, 36], ["inner", "ANATOMY_MODIFIER", 4, 9], ["formed", "OBSERVATION", 19, 25], ["strands", "OBSERVATION", 29, 36], ["terminal", "ANATOMY_MODIFIER", 59, 67]]], ["The inner sheets from each protomer interact through a large ( 940 \u00c52 of buried surface area per chain) and highly complementary interface with residues V168, V225, F230, and I232 forming a continuous buried hydrophobic core (Fig. 2D).", [["inner sheets", "ANATOMY", 4, 16], ["surface area", "ANATOMY", 80, 92], ["inner sheets", "TISSUE", 4, 16], ["F230", "PROTEIN", 165, 169], ["I232", "PROTEIN", 175, 179], ["The inner sheets", "TREATMENT", 0, 16], ["inner", "OBSERVATION_MODIFIER", 4, 9], ["large", "OBSERVATION_MODIFIER", 55, 60]]], ["The interaction between \u03b2-sandwiches from each protomer thus forms a strong and stable link between monomers in the dimer.ResultsTwo-dimensional class averages of tetrameric 3a show a side by side arrangement of two dimers with well-separated TMs and close juxtaposition of CDs (Fig. 2F).", [["\u03b2-sandwiches", "SIMPLE_CHEMICAL", 24, 36], ["\u03b2-sandwiches", "PROTEIN", 24, 36], ["dimer", "PROTEIN", 116, 121], ["tetrameric 3a", "PROTEIN", 163, 176], ["TMs", "PROTEIN", 243, 246], ["CDs", "PROTEIN", 274, 277]]], ["However, the tetrameric map was sufficiently featured in the ICDs to enable rigid-body docking of two copies of the 3a dimer model (Fig. 2G).", [["body", "ANATOMY", 82, 86], ["the tetrameric map", "TEST", 9, 27], ["the ICDs", "TREATMENT", 57, 65]]], ["The best fit models show that TM3-CTD linkers and \u03b21-\u03b22 linkers from neighboring dimers form a continuous interface ( 300 \u00c52 buried surface area per dimer).", [["\u03b21-\u03b22", "GENE_OR_GENE_PRODUCT", 50, 55], ["TM3", "PROTEIN", 30, 33], ["CTD linkers", "PROTEIN", 34, 45], ["\u03b21", "PROTEIN", 50, 52], ["\u03b22 linkers", "PROTEIN", 53, 63], ["dimer", "PROTEIN", 149, 154], ["TM3", "TEST", 30, 33], ["CTD linkers", "TEST", 34, 45], ["\u03b21", "TEST", 50, 52]]], ["While the exact positions of side chains cannot be determined at this resolution, residues W131, R134, K136, H150, T151, N152, C153, and D155 are poised to form a network of hydrophobic, polar, and electrostatic interactions which could mediate tetramerization (Fig. 2H).ResultsTetramerization of SARS-CoV-1 3a observed by western blot was abolished by reducing agents and a C133A mutation resulted in the loss of tetramerization, membrane localization, and whole-cell currents15.", [["membrane", "ANATOMY", 431, 439], ["whole-cell", "ANATOMY", 458, 468], ["SARS", "DISEASE", 297, 301], ["W131, R134, K136, H150, T151, N152, C153, and D155", "CHEMICAL", 91, 141], ["D155", "AMINO_ACID", 137, 141], ["SARS-CoV-1 3a", "GENE_OR_GENE_PRODUCT", 297, 310], ["C133A", "GENE_OR_GENE_PRODUCT", 375, 380], ["membrane", "CELLULAR_COMPONENT", 431, 439], ["D155", "PROTEIN", 137, 141], ["residues", "TEST", 82, 90], ["K136", "TEST", 103, 107], ["H150", "TEST", 109, 113], ["electrostatic interactions", "PROBLEM", 198, 224], ["SARS", "PROBLEM", 297, 301], ["CoV", "TEST", 302, 305], ["a C133A mutation", "TREATMENT", 373, 389], ["the loss of tetramerization", "PROBLEM", 402, 429], ["membrane localization", "TEST", 431, 452], ["electrostatic interactions", "OBSERVATION", 198, 224], ["SARS", "OBSERVATION", 297, 301]]], ["However, expression of the C133A mutant was also dramatically reduced, so it may be that these results are a consequence of destabilizing 3a15.", [["C133A", "GENE_OR_GENE_PRODUCT", 27, 32], ["3a15", "GENE_OR_GENE_PRODUCT", 138, 142], ["C133A mutant", "PROTEIN", 27, 39], ["3a15", "PROTEIN", 138, 142], ["dramatically", "OBSERVATION_MODIFIER", 49, 61], ["reduced", "OBSERVATION_MODIFIER", 62, 69]]], ["In SARS-CoV-2 3a, C133 is located in a notable cysteine-rich pocket adjacent to the tetramerization interface (Fig. S11A).", [["SARS", "DISEASE", 3, 7], ["cysteine", "CHEMICAL", 47, 55], ["SARS-CoV-2 3a", "ORGANISM", 3, 16], ["C133", "GENE_OR_GENE_PRODUCT", 18, 22], ["cysteine", "AMINO_ACID", 47, 55], ["C133", "DNA", 18, 22], ["cysteine-rich pocket", "PROTEIN", 47, 67], ["tetramerization interface", "PROTEIN", 84, 109], ["S11A", "PROTEIN", 116, 120], ["SARS-CoV", "SPECIES", 3, 11], ["CoV", "TEST", 8, 11], ["a notable cysteine-rich pocket", "PROBLEM", 37, 67], ["notable", "OBSERVATION_MODIFIER", 39, 46], ["cysteine", "OBSERVATION", 47, 55], ["rich pocket", "OBSERVATION", 56, 67], ["tetramerization interface", "OBSERVATION", 84, 109]]], ["At the base of TM3, C133 projects back towards the top faces of \u03b21 and \u03b22 in close proximity to solvent exposed C148 and buried C157.", [["TM3", "CHEMICAL", 15, 18], ["C133", "CHEMICAL", 20, 24], ["C148", "CHEMICAL", 112, 116], ["C157", "CHEMICAL", 128, 132], ["\u03b21", "GENE_OR_GENE_PRODUCT", 64, 66], ["\u03b22", "GENE_OR_GENE_PRODUCT", 71, 73], ["\u03b21", "PROTEIN", 64, 66], ["\u03b22", "PROTEIN", 71, 73], ["base", "ANATOMY_MODIFIER", 7, 11], ["TM3", "ANATOMY_MODIFIER", 15, 18], ["top", "ANATOMY_MODIFIER", 51, 54]]], ["Due to geometric considerations, we modeled C133 and C157 as reduced sulfhydryls, but note that they are nearly within disulfide-bonding distance (C\u03b1 distance 6.9 \u00c5) (Fig. S11A).", [["C133", "CHEMICAL", 44, 48], ["sulfhydryls", "CHEMICAL", 69, 80], ["C133", "CHEMICAL", 44, 48], ["C157", "CHEMICAL", 53, 57], ["sulfhydryls", "CHEMICAL", 69, 80], ["disulfide", "CHEMICAL", 119, 128], ["C133", "SIMPLE_CHEMICAL", 44, 48], ["C157", "SIMPLE_CHEMICAL", 53, 57], ["sulfhydryls", "SIMPLE_CHEMICAL", 69, 80], ["C\u03b1 distance", "TEST", 147, 158]]], ["While it is unlikely a single conserved disulfide mediates tetramerization in SARSCoV-1 3a and SARS-CoV-2 3a, it may be that disruption of this cysteine-rich pocket with cysteine modifying agents or mutations disfavor oligomerization in both channels.ResultsAnalysis of possible conduction pathways through 3a reveals a narrow, bifurcated pore which stretches through the outer half of the TM region and is connected to a large and polar cavity open to the cytosol (Fig. 3).", [["pore", "ANATOMY", 339, 343], ["cytosol", "ANATOMY", 457, 464], ["cysteine", "CHEMICAL", 170, 178], ["disulfide", "CHEMICAL", 40, 49], ["cysteine", "CHEMICAL", 144, 152], ["cysteine", "CHEMICAL", 170, 178], ["SARSCoV-1 3a", "GENE_OR_GENE_PRODUCT", 78, 90], ["SARS-CoV-2 3a", "GENE_OR_GENE_PRODUCT", 95, 108], ["cysteine", "AMINO_ACID", 144, 152], ["cysteine", "AMINO_ACID", 170, 178], ["cytosol", "CELLULAR_COMPONENT", 457, 464], ["SARSCoV", "PROTEIN", 78, 85], ["TM region", "PROTEIN", 390, 399], ["a single conserved disulfide mediates tetramerization", "PROBLEM", 21, 74], ["SARSCoV", "TEST", 78, 85], ["SARS", "TEST", 95, 99], ["this cysteine-rich pocket", "TREATMENT", 139, 164], ["cysteine modifying agents", "TREATMENT", 170, 195], ["mutations disfavor oligomerization", "PROBLEM", 199, 233], ["conduction pathways", "TEST", 279, 298], ["a narrow, bifurcated pore", "PROBLEM", 318, 343], ["a large and polar cavity", "TREATMENT", 420, 444], ["narrow", "OBSERVATION_MODIFIER", 320, 326], ["bifurcated", "OBSERVATION_MODIFIER", 328, 338], ["pore", "OBSERVATION_MODIFIER", 339, 343], ["outer", "ANATOMY_MODIFIER", 372, 377], ["TM", "ANATOMY", 390, 392], ["region", "ANATOMY_MODIFIER", 393, 399], ["large", "OBSERVATION_MODIFIER", 422, 427], ["polar", "OBSERVATION_MODIFIER", 432, 437], ["cavity", "OBSERVATION", 438, 444], ["cytosol", "ANATOMY", 457, 464]]], ["The pore has a series of six constrictions and narrows to 1 \u00c5 in radius, too small for the conduction of permeant cations.", [["pore", "ANATOMY", 4, 8], ["cations", "SIMPLE_CHEMICAL", 114, 121], ["six constrictions", "PROBLEM", 25, 42], ["permeant cations", "TREATMENT", 105, 121], ["pore", "OBSERVATION_MODIFIER", 4, 8], ["narrows", "OBSERVATION_MODIFIER", 47, 54], ["radius", "ANATOMY", 65, 71], ["too small", "OBSERVATION_MODIFIER", 73, 82], ["permeant cations", "OBSERVATION", 105, 121]]], ["We therefore conclude this 3a structure represents either a closed or inactivated channel conformation.ResultsFrom the extracellular side, the first four constrictions are hydrophobic (Fig. 3A\u2013F).", [["extracellular", "ANATOMY", 119, 132], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 119, 132], ["a closed or inactivated channel conformation", "PROBLEM", 58, 102], ["closed", "OBSERVATION", 60, 66], ["hydrophobic", "OBSERVATION_MODIFIER", 172, 183]]], ["Opposing F43 residues at the top of TM1 create two paths into the channel which taper to 1.5 \u00c5 in radius.", [["TM1", "AMINO_ACID", 36, 39], ["F43 residues", "PROTEIN", 9, 21], ["TM1", "PROTEIN", 36, 39], ["Opposing F43 residues", "PROBLEM", 0, 21], ["F43 residues", "OBSERVATION", 9, 21], ["top", "OBSERVATION_MODIFIER", 29, 32], ["TM1", "ANATOMY_MODIFIER", 36, 39], ["two", "OBSERVATION_MODIFIER", 47, 50], ["paths", "OBSERVATION_MODIFIER", 51, 56], ["channel", "OBSERVATION_MODIFIER", 66, 73], ["taper", "OBSERVATION_MODIFIER", 80, 85], ["radius", "ANATOMY", 98, 104]]], ["The paths then merge and go through a series of tight ( 1\u00c5 radius) constrictions lined by L46 and I47, V50 and V58, and finally L53 and L85.", [["V50", "PROTEIN", 103, 106], ["V58", "PROTEIN", 111, 114], ["L53", "PROTEIN", 128, 131], ["L85", "PROTEIN", 136, 139], ["tight ( 1\u00c5 radius) constrictions", "TREATMENT", 48, 80], ["V50", "TEST", 103, 106]]], ["The final two constrictions are polar (Fig. 3G,H).", [["constrictions", "OBSERVATION_MODIFIER", 14, 27], ["polar", "OBSERVATION_MODIFIER", 32, 37]]], ["The close juxtaposition of Q57s from opposing TM1s splits the pore into two paths of 1 \u00c5 radius lined by C81s from TM2s.", [["pore", "ANATOMY", 62, 66], ["TM1s", "CANCER", 46, 50], ["Q57s", "DNA", 27, 31], ["TM1s", "DNA", 46, 50], ["C81s", "PROTEIN", 105, 109], ["TM2s", "PROTEIN", 115, 119], ["opposing TM1s", "TREATMENT", 37, 50], ["pore", "OBSERVATION_MODIFIER", 62, 66], ["two", "OBSERVATION_MODIFIER", 72, 75], ["paths", "OBSERVATION_MODIFIER", 76, 81]]], ["The final and widest constriction ( 2 \u00c5 radius) before the pore opens to the cavity is lined by S60, H78 and K61 from TM1 and H78 from TM2.", [["pore", "ANATOMY", 59, 63], ["TM1", "AMINO_ACID", 118, 121], ["TM2", "AMINO_ACID", 135, 138], ["S60", "PROTEIN", 96, 99], ["H78", "PROTEIN", 101, 104], ["K61", "PROTEIN", 109, 112], ["TM1", "PROTEIN", 118, 121], ["H78", "PROTEIN", 126, 129], ["TM2", "PROTEIN", 135, 138], ["widest constriction ( 2 \u00c5 radius)", "TREATMENT", 14, 47], ["TM1", "TEST", 118, 121], ["widest", "OBSERVATION_MODIFIER", 14, 20], ["constriction", "OBSERVATION_MODIFIER", 21, 33], ["cavity", "ANATOMY", 77, 83]]], ["Opening the channel would require conformational changes in TM1 and/or TM2 to both expand the hydrophobic constrictions and rearrange Q57 at the inner hydrophilic constriction.ResultsThe polar cavity within the inner half of the TM region is continuous with the cytosol and surrounding bilayer through three pairs of openings: the upper, intersubunit, and lower tunnels (Fig. 3I\u2013R).", [["inner half", "ANATOMY", 211, 221], ["cytosol", "ANATOMY", 262, 269], ["TM1", "AMINO_ACID", 60, 63], ["TM2", "AMINO_ACID", 71, 74], ["cavity", "PATHOLOGICAL_FORMATION", 193, 199], ["cytosol", "CELLULAR_COMPONENT", 262, 269], ["surrounding bilayer", "CELLULAR_COMPONENT", 274, 293], ["TM1", "PROTEIN", 60, 63], ["TM2", "PROTEIN", 71, 74], ["Q57", "PROTEIN", 134, 137], ["TM region", "PROTEIN", 229, 238], ["Fig. 3I\u2013R", "PROTEIN", 371, 380], ["conformational changes in TM1", "TREATMENT", 34, 63], ["TM2", "TREATMENT", 71, 74], ["the hydrophobic constrictions", "PROBLEM", 90, 119], ["the inner hydrophilic constriction", "TREATMENT", 141, 175], ["hydrophobic constrictions", "OBSERVATION", 94, 119], ["hydrophilic constriction", "OBSERVATION", 151, 175], ["polar", "ANATOMY_MODIFIER", 187, 192], ["cavity", "OBSERVATION", 193, 199], ["inner", "ANATOMY_MODIFIER", 211, 216], ["half", "ANATOMY_MODIFIER", 217, 221], ["TM", "ANATOMY", 229, 231], ["region", "ANATOMY_MODIFIER", 232, 238], ["openings", "OBSERVATION_MODIFIER", 317, 325], ["upper", "ANATOMY_MODIFIER", 331, 336], ["lower tunnels", "ANATOMY", 356, 369]]], ["The upper tunnels are formed between TM2 and TM3 within each protomer and narrow to 2 \u00c5 in radius (Fig. 3J,K,L).", [["upper tunnels", "MULTI-TISSUE_STRUCTURE", 4, 17], ["TM3", "AMINO_ACID", 45, 48], ["TM2", "PROTEIN", 37, 40], ["TM3", "PROTEIN", 45, 48], ["The upper tunnels", "TREATMENT", 0, 17], ["K", "TEST", 107, 108], ["upper", "ANATOMY_MODIFIER", 4, 9], ["tunnels", "OBSERVATION", 10, 17], ["TM2", "ANATOMY_MODIFIER", 37, 40], ["narrow", "OBSERVATION_MODIFIER", 74, 80]]], ["Judging by the relative position of the nanodisc in the EM maps and hydrophobic character of the upper tunnel exterior, in a cell membrane they likely open to the surrounding lipid bilayer.", [["cell membrane", "ANATOMY", 125, 138], ["lipid bilayer", "ANATOMY", 175, 188], ["cell membrane", "CELLULAR_COMPONENT", 125, 138], ["lipid bilayer", "CELLULAR_COMPONENT", 175, 188], ["a cell membrane", "TREATMENT", 123, 138], ["position", "OBSERVATION_MODIFIER", 24, 32], ["hydrophobic character", "OBSERVATION", 68, 89], ["upper", "ANATOMY_MODIFIER", 97, 102], ["tunnel", "ANATOMY_MODIFIER", 103, 109], ["cell membrane", "OBSERVATION", 125, 138], ["lipid bilayer", "OBSERVATION", 175, 188]]], ["The intersubunit tunnels run between TM1 and TM3 from different protomers, just above the CD, and narrow to 2.5 \u00c5 in radius (Fig. 3M,N,O).", [["N", "CHEMICAL", 133, 134], ["TM3", "AMINO_ACID", 45, 48], ["TM1", "PROTEIN", 37, 40], ["TM3", "PROTEIN", 45, 48], ["CD", "PROTEIN", 90, 92], ["TM1 and TM3 from different protomers", "TREATMENT", 37, 73], ["intersubunit tunnels", "OBSERVATION", 4, 24], ["CD", "OBSERVATION", 90, 92], ["narrow", "OBSERVATION_MODIFIER", 98, 104], ["radius", "ANATOMY", 117, 123]]], ["With a modest expansion, the intersubunit tunnels could permit even large cations like NMDG to access the channel cavity.", [["NMDG", "CHEMICAL", 87, 91], ["NMDG", "CHEMICAL", 87, 91], ["cations", "SIMPLE_CHEMICAL", 74, 81], ["NMDG", "SIMPLE_CHEMICAL", 87, 91], ["NMDG", "PROTEIN", 87, 91], ["a modest expansion", "PROBLEM", 5, 23], ["the intersubunit tunnels", "TREATMENT", 25, 49], ["large cations", "TREATMENT", 68, 81], ["modest", "OBSERVATION_MODIFIER", 7, 13], ["expansion", "OBSERVATION_MODIFIER", 14, 23], ["intersubunit tunnels", "OBSERVATION", 29, 49], ["channel cavity", "ANATOMY", 106, 120]]], ["The intersubunit tunnels open to the membrane-cytosol interface.", [["membrane-cytosol", "ANATOMY", 37, 53], ["membrane", "CELLULAR_COMPONENT", 37, 45], ["cytosol", "CELLULAR_COMPONENT", 46, 53], ["The intersubunit tunnels", "TREATMENT", 0, 24], ["intersubunit tunnels", "OBSERVATION", 4, 24], ["cytosol interface", "OBSERVATION", 46, 63]]], ["Tubular shaped-densities are present in both the upper and intersubunit which are consistent with lipid acyl chains, but are not sufficiently featured to confidently model as such (Fig. S11B).", [["Tubular", "ANATOMY", 0, 7], ["acyl", "CHEMICAL", 104, 108], ["upper", "ORGANISM_SUBDIVISION", 49, 54], ["lipid acyl chains", "SIMPLE_CHEMICAL", 98, 115], ["Tubular shaped-densities", "PROBLEM", 0, 24], ["lipid acyl chains", "PROBLEM", 98, 115], ["shaped", "OBSERVATION_MODIFIER", 8, 14], ["densities", "OBSERVATION", 15, 24], ["both", "ANATOMY_MODIFIER", 40, 44], ["upper", "ANATOMY_MODIFIER", 49, 54], ["intersubunit", "ANATOMY_MODIFIER", 59, 71], ["consistent with", "UNCERTAINTY", 82, 97], ["lipid", "OBSERVATION", 98, 103], ["acyl chains", "OBSERVATION", 104, 115]]], ["The lower tunnels run underneath the TM1-TM2 linker and above the CD and narrow to 2 \u00c5 in radius (Fig. 3P,Q,R).", [["TM1", "PROTEIN", 37, 40], ["TM2 linker", "PROTEIN", 41, 51], ["CD", "PROTEIN", 66, 68], ["The lower tunnels", "TREATMENT", 0, 17], ["the TM1-TM2 linker", "TREATMENT", 33, 51], ["lower", "ANATOMY_MODIFIER", 4, 9], ["tunnels", "OBSERVATION", 10, 17], ["TM1", "ANATOMY", 37, 40], ["TM2 linker", "OBSERVATION", 41, 51], ["CD", "ANATOMY", 66, 68], ["narrow", "OBSERVATION_MODIFIER", 73, 79], ["radius", "ANATOMY_MODIFIER", 90, 96]]], ["The lower tunnels open well into the cytosol and are open paths for ion movement between the cell interior and channel cavity.ResultsThe N-terminal 41 residues of each chain constitute the majority of the extracellularly or lumenally exposed 3a protein and thus could be involved in retention of 3a to internal membranes in cultured cells.", [["cytosol", "ANATOMY", 37, 44], ["cell", "ANATOMY", 93, 97], ["channel cavity", "ANATOMY", 111, 125], ["internal membranes", "ANATOMY", 302, 320], ["cells", "ANATOMY", 333, 338], ["cytosol", "CELLULAR_COMPONENT", 37, 44], ["cell interior", "CELLULAR_COMPONENT", 93, 106], ["channel cavity", "CELLULAR_COMPONENT", 111, 125], ["membranes", "CELLULAR_COMPONENT", 311, 320], ["cells", "CELL", 333, 338], ["N-terminal 41 residues", "PROTEIN", 137, 159], ["cultured cells", "CELL_LINE", 324, 338], ["The lower tunnels", "TREATMENT", 0, 17], ["the cytosol", "TREATMENT", 33, 44], ["open paths", "TREATMENT", 53, 63], ["The N-terminal 41 residues of each chain", "PROBLEM", 133, 173], ["lower", "ANATOMY_MODIFIER", 4, 9], ["tunnels", "OBSERVATION", 10, 17], ["cytosol", "ANATOMY", 37, 44], ["cell", "ANATOMY", 93, 97], ["interior", "ANATOMY_MODIFIER", 98, 106], ["channel cavity", "ANATOMY", 111, 125], ["internal membranes", "ANATOMY", 302, 320], ["cultured cells", "OBSERVATION", 324, 338]]], ["To test this, we generated an N-terminal deletion construct lacking the first 41 amino acids (3a\u0394N) and compared its localization to wild-type 3a in HEK cells.", [["HEK cells", "ANATOMY", 149, 158], ["amino acids", "CHEMICAL", 81, 92], ["N", "CHEMICAL", 30, 31], ["amino acids", "CHEMICAL", 81, 92], ["amino acids", "AMINO_ACID", 81, 92], ["HEK cells", "CELL", 149, 158], ["N-terminal deletion construct", "DNA", 30, 59], ["41 amino acids", "PROTEIN", 78, 92], ["3a\u0394N", "PROTEIN", 94, 98], ["HEK cells", "CELL_LINE", 149, 158], ["an N-terminal deletion construct", "TREATMENT", 27, 59]]], ["Indeed, 3a\u0394N-EGFP shows reduced localization to internal membranes and bright foci and increased plasma membrane expression (Fig. 4A and Fig. S12).", [["internal membranes", "ANATOMY", 48, 66], ["foci", "ANATOMY", 78, 82], ["plasma membrane", "ANATOMY", 97, 112], ["3a\u0394N-EGFP", "CHEMICAL", 8, 17], ["3a\u0394N-EGFP", "GENE_OR_GENE_PRODUCT", 8, 17], ["internal membranes", "CELLULAR_COMPONENT", 48, 66], ["plasma membrane", "CELLULAR_COMPONENT", 97, 112], ["3a\u0394N", "PROTEIN", 8, 12], ["EGFP", "PROTEIN", 13, 17], ["Fig. S12", "PROTEIN", 137, 145], ["reduced localization to internal membranes", "PROBLEM", 24, 66], ["bright foci", "PROBLEM", 71, 82], ["increased plasma membrane expression", "PROBLEM", 87, 123], ["reduced", "OBSERVATION_MODIFIER", 24, 31], ["internal membranes", "ANATOMY", 48, 66], ["bright", "OBSERVATION_MODIFIER", 71, 77], ["foci", "OBSERVATION", 78, 82], ["increased", "OBSERVATION_MODIFIER", 87, 96], ["plasma membrane expression", "OBSERVATION", 97, 123]]], ["While we were unable to model the N-terminal 39 residues of 3a, an unassigned density feature in the cryo-EM maps that stretches between subunits just above the extracellular entrance to the pore that could correspond to a portion of these unmodeled N-terminal residues (Fig. 4B).", [["extracellular", "ANATOMY", 161, 174], ["pore", "ANATOMY", 191, 195], ["N", "CHEMICAL", 34, 35], ["N", "CHEMICAL", 250, 251], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 161, 174], ["pore", "CELLULAR_COMPONENT", 191, 195], ["N-terminal 39 residues", "PROTEIN", 34, 56], ["cryo-EM maps", "PROTEIN", 101, 113], ["unmodeled N-terminal residues", "PROTEIN", 240, 269], ["the N-terminal 39 residues of 3a", "PROBLEM", 30, 62], ["an unassigned density feature", "PROBLEM", 64, 93], ["terminal residues", "PROBLEM", 252, 269], ["unassigned density", "OBSERVATION", 67, 85], ["extracellular", "ANATOMY_MODIFIER", 161, 174], ["entrance", "ANATOMY_MODIFIER", 175, 183], ["pore", "ANATOMY_MODIFIER", 191, 195], ["terminal residues", "OBSERVATION", 252, 269]]], ["We speculated that if the N-terminal region was stably positioned above the mouth of the pore it could influence channel properties.", [["pore", "ANATOMY", 89, 93], ["N", "CHEMICAL", 26, 27], ["N-terminal region", "PROTEIN", 26, 43], ["the N-terminal region", "TREATMENT", 22, 43], ["terminal", "ANATOMY_MODIFIER", 28, 36]]], ["3a\u0394N was therefore purified, reconstituted into proteoliposomes and compared to wild type 3a in patch recordings.", [["proteoliposomes", "ANATOMY", 48, 63], ["3a\u0394N", "SIMPLE_CHEMICAL", 0, 4], ["3a\u0394N", "PROTEIN", 0, 4], ["patch recordings", "TEST", 96, 112]]], ["Aside from a modest decrease in the relative permeability of Ca2+ to K+, no significant differences were observed in 3a\u0394N properties compared to wild-type 3a (Fig. 4C,D,E).", [["Ca2", "CHEMICAL", 61, 64], ["K", "CHEMICAL", 69, 70], ["Ca2+", "CHEMICAL", 61, 65], ["K+", "CHEMICAL", 69, 71], ["Ca2+", "SIMPLE_CHEMICAL", 61, 65], ["K+", "SIMPLE_CHEMICAL", 69, 71], ["D,E", "SIMPLE_CHEMICAL", 167, 170], ["Ca2", "PROTEIN", 61, 64], ["3a\u0394N", "PROTEIN", 117, 121], ["a modest decrease", "PROBLEM", 11, 28], ["K", "TEST", 69, 70], ["significant differences", "PROBLEM", 76, 99], ["modest", "OBSERVATION_MODIFIER", 13, 19], ["decrease", "OBSERVATION_MODIFIER", 20, 28], ["permeability", "OBSERVATION_MODIFIER", 45, 57], ["no", "UNCERTAINTY", 73, 75], ["significant", "OBSERVATION_MODIFIER", 76, 87]]], ["These results are consistent with the N-terminal region of 3a being a determinant of its subcellular localization without influencing channel properties.ResultsOver forty thousand SARS-CoV-2 genomes have been sequenced to date and analyses of mutations across time and geography have identified a large number of coding variants, some of which may have experienced selective pressure during viral evolution.", [["subcellular", "ANATOMY", 89, 100], ["N", "CHEMICAL", 38, 39], ["N-terminal region", "PROTEIN", 38, 55], ["SARS-CoV-2 genomes", "DNA", 180, 198], ["the N-terminal region", "PROBLEM", 34, 55], ["SARS", "TEST", 180, 184], ["CoV-2 genomes", "PROBLEM", 185, 198], ["mutations", "PROBLEM", 243, 252], ["coding variants", "PROBLEM", 313, 328], ["selective pressure during viral evolution", "PROBLEM", 365, 406], ["consistent with", "UNCERTAINTY", 18, 33], ["large", "OBSERVATION_MODIFIER", 297, 302], ["selective", "OBSERVATION_MODIFIER", 365, 374], ["pressure", "OBSERVATION_MODIFIER", 375, 383], ["viral evolution", "OBSERVATION", 391, 406]]], ["To date, mutations that result in amino acid changes at 17 residues in 3a have been observed in different SARS-CoV-2 genomes23.", [["amino acid", "CHEMICAL", 34, 44], ["amino acid", "CHEMICAL", 34, 44], ["amino acid", "AMINO_ACID", 34, 44], ["SARS-CoV-2 genomes23", "ORGANISM", 106, 126], ["SARS-CoV-2 genomes23", "DNA", 106, 126], ["SARS-CoV", "SPECIES", 106, 114], ["amino acid changes", "PROBLEM", 34, 52], ["CoV", "TEST", 111, 114]]], ["Thirteen of these residues are represented with colored spheres overlaid on the 3a structure in Figure 5A (the remaining four positions: K16N/L, P36L, P240L/S/H, and P258L are unresolved in our structure).", [["P240L", "PROTEIN", 151, 156], ["P258L", "PROTEIN", 166, 171], ["colored spheres", "PROBLEM", 48, 63], ["K16N", "TEST", 137, 141], ["P36L", "TEST", 145, 149], ["P240L", "TEST", 151, 156], ["P258L", "TEST", 166, 171], ["colored spheres", "OBSERVATION", 48, 63]]], ["The most prevalent is a Q57H variant found in 25% of sequenced viruses, yet not observed in the earliest sequences or in related bat coronaviruses.", [["bat coronaviruses", "ORGANISM", 129, 146], ["bat coronaviruses", "SPECIES", 129, 146], ["a Q57H variant", "PROBLEM", 22, 36], ["sequenced viruses", "PROBLEM", 53, 70], ["most prevalent", "OBSERVATION_MODIFIER", 4, 18], ["viruses", "OBSERVATION", 63, 70]]], ["Strikingly, as described above, Q57 forms the major hydrophilic constriction in the 3a pore (Fig. 3G and Fig. 5A).", [["3a pore", "ANATOMY", 84, 91], ["Q57", "PROTEIN", 32, 35], ["the major hydrophilic constriction", "PROBLEM", 42, 76], ["hydrophilic constriction", "OBSERVATION", 52, 76]]], ["We asked whether this mutation had functional consequences by purifying 3a-Q57H, reconstituting it into proteoliposomes, and comparing channel activity to wild-type (Fig. 5B,C,D).", [["proteoliposomes", "ANATOMY", 104, 119], ["3a-Q57H", "GENE_OR_GENE_PRODUCT", 72, 79], ["proteoliposomes", "GENE_OR_GENE_PRODUCT", 104, 119], ["Q57H", "PROTEIN", 75, 79], ["this mutation", "PROBLEM", 17, 30]]], ["No significant difference was observed in the expression, stability, conductance, selectivity, or gating behavior of 3a-Q57H (Fig. 5B,C,D and Fig. S13A,B,C) .", [["3a-Q57H", "SIMPLE_CHEMICAL", 117, 124], ["B,C", "GENE_OR_GENE_PRODUCT", 152, 155], ["Q57H", "PROTEIN", 120, 124], ["S13A", "PROTEIN", 147, 151], ["gating behavior", "TEST", 98, 113], ["3a", "TEST", 117, 119], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION", 15, 25], ["stability", "OBSERVATION_MODIFIER", 58, 67]]], ["We conclude that the presence of a histidine at this position does not influence channel properties.", [["histidine", "CHEMICAL", 35, 44], ["histidine", "CHEMICAL", 35, 44], ["histidine", "AMINO_ACID", 35, 44], ["a histidine", "TREATMENT", 33, 44]]], ["The remaining variants are much less common, being observed in <0.1% of sequenced viruses to date.", [["remaining variants", "OBSERVATION", 4, 22], ["much", "OBSERVATION_MODIFIER", 27, 31], ["less common", "OBSERVATION_MODIFIER", 32, 43]]], ["Nine of these are unlikely to impact 3a structure or funcion as they are located in loops, lipid facing positions on TMs, and/or are conservative in nature (L41F/I/P, L53F, L96F/H, P104L/S/H, A110V/S, I123V, M125K/L/T, I232F/K/T and N234I/K).", [["H", "PROTEIN", 178, 179], ["P104L", "PROTEIN", 181, 186], ["H", "PROTEIN", 189, 190], ["A110V", "PROTEIN", 192, 197], ["I123V", "PROTEIN", 201, 206], ["M125K", "PROTEIN", 208, 213], ["T", "PROTEIN", 216, 217], ["I232F", "PROTEIN", 219, 224], ["TMs", "TEST", 117, 120], ["L41F", "TEST", 157, 161], ["L53F", "TEST", 167, 171], ["I232F", "TEST", 219, 224], ["K", "TEST", 225, 226], ["unlikely to", "UNCERTAINTY", 18, 29]]], ["Whether these influence oligomerization or channel function remains to be determined.Results3a is very well conserved in the Betacoronavirus subgenus Sarbecovirus that includes SARS-CoV-1 and SARS-CoV-2 (Fig. S1).", [["Results3a", "GENE_OR_GENE_PRODUCT", 85, 94], ["SARS-CoV-1", "ORGANISM", 177, 187], ["SARS-CoV-2", "ORGANISM", 192, 202], ["Results3a", "PROTEIN", 85, 94], ["CoV-1", "SPECIES", 182, 187], ["SARS-CoV-1", "SPECIES", 177, 187], ["SARS-CoV", "SPECIES", 192, 200], ["the Betacoronavirus subgenus Sarbecovirus", "TEST", 121, 162], ["SARS", "PROBLEM", 177, 181], ["CoV", "TEST", 182, 185], ["SARS", "PROBLEM", 192, 196], ["CoV", "TEST", 197, 200], ["S1", "ANATOMY", 209, 211]]], ["Structurally related proteins have not been identified in other coronaviruses (including the other five species known infect humans: MERS-CoV, HCoV-NL63, HCoV-229E, HCoV-HKU1, and HCoV-OC43) by sequence homology.", [["coronaviruses", "ORGANISM", 64, 77], ["humans", "ORGANISM", 125, 131], ["MERS-CoV", "ORGANISM", 133, 141], ["HCoV-NL63", "ORGANISM", 143, 152], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 154, 163], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 165, 174], ["HCoV-OC43", "GENE_OR_GENE_PRODUCT", 180, 189], ["HCoV", "PROTEIN", 143, 147], ["NL63", "PROTEIN", 148, 152], ["HCoV", "PROTEIN", 154, 158], ["229E", "PROTEIN", 159, 163], ["HCoV", "PROTEIN", 165, 169], ["HKU1", "DNA", 170, 174], ["HCoV", "DNA", 180, 184], ["OC43", "DNA", 185, 189], ["humans", "SPECIES", 125, 131], ["humans", "SPECIES", 125, 131], ["MERS-CoV", "SPECIES", 133, 141], ["Structurally related proteins", "PROBLEM", 0, 29], ["other coronaviruses", "PROBLEM", 58, 77], ["MERS", "TEST", 133, 137], ["CoV", "TEST", 138, 141], ["HCoV", "TEST", 143, 147], ["HCoV", "TEST", 154, 158], ["HCoV", "TEST", 165, 169], ["HKU1", "TEST", 170, 174], ["HCoV", "TEST", 180, 184]]], ["We asked whether we could identify more distant homologs using structure prediction algorithms and the SARS-CoV-2 3a structure.", [["SARS-CoV-2 3a structure", "DNA", 103, 126], ["structure prediction algorithms", "TEST", 63, 94], ["the SARS", "TEST", 99, 107]]], ["Coronaviridae are classified into 4 genera: Alphacoronavirus, Betacoronavirus, Gammacoronavirus, and Deltacoronavirus.", [["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 44, 60], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 62, 77], ["Gammacoronavirus", "GENE_OR_GENE_PRODUCT", 79, 95], ["Coronaviridae", "TREATMENT", 0, 13], ["Alphacoronavirus", "TREATMENT", 44, 60], ["Betacoronavirus", "TREATMENT", 62, 77], ["Gammacoronavirus", "TREATMENT", 79, 95], ["Deltacoronavirus", "TREATMENT", 101, 117]]], ["3a homologs were not detected in any Gammacoronavirus or Deltacoronavirus species or in the Betacoronavirus subgenus Embecovirus (which includes HCoV-HKU1 and HCoV-OC43).", [["3a", "GENE_OR_GENE_PRODUCT", 0, 2], ["Gammacoronavirus", "GENE_OR_GENE_PRODUCT", 37, 53], ["Betacoronavirus subgenus Embecovirus", "ORGANISM", 92, 128], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 145, 154], ["HCoV-OC43", "GENE_OR_GENE_PRODUCT", 159, 168], ["HCoV", "PROTEIN", 145, 149], ["HKU1", "PROTEIN", 150, 154], ["HCoV", "PROTEIN", 159, 163], ["OC43", "PROTEIN", 164, 168], ["Deltacoronavirus species", "PROBLEM", 57, 81], ["the Betacoronavirus subgenus Embecovirus", "PROBLEM", 88, 128], ["HCoV", "TEST", 145, 149], ["not detected", "UNCERTAINTY", 17, 29]]], ["Distant homology to the CD was identified in the membrane protein ORF5 found in Betacoronavirus subgenus Merbecovirus species including MERS-CoV.", [["membrane", "ANATOMY", 49, 57], ["CD", "GENE_OR_GENE_PRODUCT", 24, 26], ["membrane", "CELLULAR_COMPONENT", 49, 57], ["ORF5", "GENE_OR_GENE_PRODUCT", 66, 70], ["Betacoronavirus subgenus Merbecovirus species", "ORGANISM", 80, 125], ["MERS-CoV", "ORGANISM", 136, 144], ["CD", "DNA", 24, 26], ["membrane protein", "PROTEIN", 49, 65], ["ORF5", "PROTEIN", 66, 70], ["MERS-CoV", "SPECIES", 136, 144], ["the membrane protein ORF5", "TEST", 45, 70], ["Betacoronavirus subgenus Merbecovirus species", "PROBLEM", 80, 125], ["subgenus Merbecovirus", "OBSERVATION", 96, 117]]], ["In contrast, high confidence structural homologs were predicted in all remaining Betacoronavirus subgenera in proteins annotated ORF3 or NS3 and in all Alphacoronavirus subgenera in proteins annotated ORF3, NS3, ORF4, or NSP3B (including in HCoV-229E and HCoV-NL63 (Fig. S14)).", [["ORF3", "GENE_OR_GENE_PRODUCT", 129, 133], ["NS3", "GENE_OR_GENE_PRODUCT", 137, 140], ["ORF3", "GENE_OR_GENE_PRODUCT", 201, 205], ["NS3", "GENE_OR_GENE_PRODUCT", 207, 210], ["ORF4", "GENE_OR_GENE_PRODUCT", 212, 216], ["NSP3B", "GENE_OR_GENE_PRODUCT", 221, 226], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 241, 250], ["HCoV-NL63", "GENE_OR_GENE_PRODUCT", 255, 264], ["Betacoronavirus subgenera", "PROTEIN", 81, 106], ["ORF3", "DNA", 129, 133], ["NS3", "PROTEIN", 137, 140], ["Alphacoronavirus subgenera", "PROTEIN", 152, 178], ["ORF3", "DNA", 201, 205], ["NS3", "PROTEIN", 207, 210], ["ORF4", "PROTEIN", 212, 216], ["NSP3B", "PROTEIN", 221, 226], ["HCoV", "PROTEIN", 241, 245], ["229E", "PROTEIN", 246, 250], ["HCoV", "PROTEIN", 255, 259], ["NL63", "PROTEIN", 260, 264], ["HCoV-229E", "SPECIES", 241, 250], ["high confidence structural homologs", "PROBLEM", 13, 48], ["NS3", "PROBLEM", 137, 140], ["ORF3", "TEST", 201, 205], ["NS3", "TEST", 207, 210], ["ORF4", "TEST", 212, 216], ["NSP3B", "TEST", 221, 226], ["HCoV", "TEST", 241, 245], ["HCoV", "TEST", 255, 259]]], ["Several of these homologs have been previously demonstrated to have ion channel activity24\u201326.", [["ion channel activity24", "TEST", 68, 90]]], ["Strikingly, all coronaviruses with 3a structural homologs are derived from the bat gene pool, while all those without 3a structural homologs derive from rodent, avian, or pig gene pools.", [["pig", "ORGANISM", 171, 174], ["rodent", "SPECIES", 153, 159], ["pig", "SPECIES", 171, 174], ["pig", "SPECIES", 171, 174], ["coronaviruses", "OBSERVATION", 16, 29]]], ["This suggests coevolution of 3a with coronaviruses that have bats as their principal reservoir and may reflect a unique aspect of bat coronavirus biology.", [["coronaviruses", "ORGANISM", 37, 50], ["bat coronavirus", "ORGANISM", 130, 145], ["bat coronavirus", "SPECIES", 130, 145], ["bat coronavirus", "SPECIES", 130, 145], ["coronaviruses", "PROBLEM", 37, 50], ["coronaviruses", "OBSERVATION", 37, 50], ["may reflect", "UNCERTAINTY", 99, 110], ["bat coronavirus", "OBSERVATION", 130, 145]]], ["The true extent of 3a structural and functional conservation awaits further experimental confirmation.", [["further experimental confirmation", "TEST", 68, 101], ["true extent", "OBSERVATION_MODIFIER", 4, 15]]], ["Still, this analysis suggests 3a or 3a-like proteins are more broadly present in coronaviruses than previously recognized and antiviral drugs targeting these proteins could potentially treat diseases associated with multiple known human coronavirus.", [["3a", "GENE_OR_GENE_PRODUCT", 30, 32], ["3a", "GENE_OR_GENE_PRODUCT", 36, 38], ["coronaviruses", "ORGANISM", 81, 94], ["human", "ORGANISM", 231, 236], ["coronavirus", "ORGANISM", 237, 248], ["3a or 3a-like proteins", "PROTEIN", 30, 52], ["human", "SPECIES", 231, 236], ["human coronavirus", "SPECIES", 231, 248], ["this analysis", "TEST", 7, 20], ["3a-like proteins", "PROBLEM", 36, 52], ["coronaviruses", "PROBLEM", 81, 94], ["antiviral drugs", "TREATMENT", 126, 141], ["diseases", "PROBLEM", 191, 199], ["multiple known human coronavirus", "PROBLEM", 216, 248], ["more broadly", "OBSERVATION_MODIFIER", 57, 69], ["human coronavirus", "OBSERVATION", 231, 248]]], ["Further experiments are that resolve the role of 3a in coronavirus biology and pathology could aid in the development of therapeutics targeting 3a channels.Protein purification ::: Cloning and protein expression ::: MethodsFor preparation of the 3a dimer and mutant constructs, infected Sf9 cells from 1 L of culture ( 15\u201320 mL of cell pellet) were thawed in 100 mL of Lysis Buffer containing 50 mM Tris, 150 mM KCl, 1mM EDTA pH 8.", [["Sf9 cells", "ANATOMY", 287, 296], ["cell pellet", "ANATOMY", 331, 342], ["KCl", "CHEMICAL", 412, 415], ["Tris", "CHEMICAL", 399, 403], ["KCl", "CHEMICAL", 412, 415], ["EDTA", "CHEMICAL", 421, 425], ["coronavirus", "ORGANISM", 55, 66], ["Sf9 cells", "CELL", 287, 296], ["cell", "CELL", 331, 335], ["3a channels", "PROTEIN", 144, 155], ["mutant constructs", "DNA", 259, 276], ["Sf9 cells", "CELL_LINE", 287, 296], ["Sf9", "SPECIES", 287, 290], ["the 3a dimer", "TREATMENT", 242, 254], ["mutant constructs", "PROBLEM", 259, 276], ["infected Sf9 cells", "PROBLEM", 278, 296], ["culture", "TEST", 309, 316], ["cell pellet", "TEST", 331, 342], ["Lysis Buffer", "TREATMENT", 369, 381], ["150 mM KCl", "TREATMENT", 405, 415], ["mM EDTA pH", "TEST", 418, 428], ["infected", "OBSERVATION_MODIFIER", 278, 286], ["Sf9 cells", "OBSERVATION", 287, 296]]], ["Protease inhibitors (Final Concentrations: E64 (1 \u03bcM), Pepstatin A (1 \u03bcg/mL), Soy Trypsin Inhibitor (10 \u03bcg/mL), Benzimidine (1 mM), Aprotinin (1 \u03bcg/mL), Leupeptin (1\u03bcg/mL), AEBSF (1mM), and PMSF (1mM)) were added to the lysis buffer immediately before use.", [["Pepstatin A", "CHEMICAL", 55, 66], ["Benzimidine", "CHEMICAL", 112, 123], ["Aprotinin", "CHEMICAL", 132, 141], ["Leupeptin", "CHEMICAL", 153, 162], ["AEBSF", "CHEMICAL", 173, 178], ["Pepstatin A", "CHEMICAL", 55, 66], ["Benzimidine", "CHEMICAL", 112, 123], ["Aprotinin", "CHEMICAL", 132, 141], ["Leupeptin", "CHEMICAL", 153, 162], ["AEBSF", "CHEMICAL", 173, 178], ["PMSF", "CHEMICAL", 190, 194], ["Protease", "GENE_OR_GENE_PRODUCT", 0, 8], ["Pepstatin A", "SIMPLE_CHEMICAL", 55, 66], ["Benzimidine", "SIMPLE_CHEMICAL", 112, 123], ["Aprotinin", "SIMPLE_CHEMICAL", 132, 141], ["Leupeptin", "SIMPLE_CHEMICAL", 153, 162], ["AEBSF", "SIMPLE_CHEMICAL", 173, 178], ["PMSF", "SIMPLE_CHEMICAL", 190, 194], ["Protease inhibitors", "TREATMENT", 0, 19], ["Pepstatin A", "TREATMENT", 55, 66], ["Soy Trypsin Inhibitor", "TREATMENT", 78, 99], ["Benzimidine", "TREATMENT", 112, 123], ["Aprotinin", "TREATMENT", 132, 141], ["Leupeptin", "TREATMENT", 153, 162], ["PMSF (1mM)", "TREATMENT", 190, 200], ["the lysis buffer", "TREATMENT", 216, 232]]], ["Benzonase (4 \u03bcl) was added after the cell pellet thawed.", [["cell", "ANATOMY", 37, 41], ["Benzonase", "CHEMICAL", 0, 9], ["Benzonase", "CHEMICAL", 0, 9], ["Benzonase", "SIMPLE_CHEMICAL", 0, 9], ["cell", "CELL", 37, 41], ["Benzonase (4 \u03bcl)", "TREATMENT", 0, 16], ["the cell pellet", "TREATMENT", 33, 48]]], ["Cells were then lysed by sonication and centrifuged at 150,000 \u00d7 g for 45 minutes.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5]]], ["The supernatant was discarded and residual nucleic acid was removed from the top of the membrane pellet using DPBS.", [["supernatant", "ANATOMY", 4, 15], ["membrane pellet", "ANATOMY", 88, 103], ["nucleic acid", "CHEMICAL", 43, 55], ["nucleic acid", "SIMPLE_CHEMICAL", 43, 55], ["membrane", "CELLULAR_COMPONENT", 88, 96], ["The supernatant", "TREATMENT", 0, 15], ["residual nucleic acid", "PROBLEM", 34, 55], ["DPBS", "TREATMENT", 110, 114], ["residual", "OBSERVATION_MODIFIER", 34, 42], ["nucleic acid", "OBSERVATION", 43, 55], ["membrane pellet", "OBSERVATION", 88, 103]]], ["Membrane pellets were scooped into a dounce homogenizer containing Extraction Buffer (50 mM Tris, 150 mM KCl, 1 mM EDTA, 1% n-Dodecyl-\u03b2-D-Maltopyranoside (DDM, Anatrace, Maumee, OH), pH 8).", [["Membrane pellets", "ANATOMY", 0, 16], ["KCl", "CHEMICAL", 105, 108], ["n-Dodecyl-\u03b2-D-Maltopyranoside", "CHEMICAL", 124, 153], ["Tris", "CHEMICAL", 92, 96], ["KCl", "CHEMICAL", 105, 108], ["EDTA", "CHEMICAL", 115, 119], ["n-Dodecyl-\u03b2-D-Maltopyranoside", "CHEMICAL", 124, 153], ["DDM", "CHEMICAL", 155, 158], ["Anatrace", "CHEMICAL", 160, 168], ["Maumee", "CHEMICAL", 170, 176], ["OH", "CHEMICAL", 178, 180], ["EDTA", "SIMPLE_CHEMICAL", 115, 119], ["n-Dodecyl-\u03b2-D-Maltopyranoside", "SIMPLE_CHEMICAL", 124, 153], ["DDM", "SIMPLE_CHEMICAL", 155, 158], ["Anatrace", "SIMPLE_CHEMICAL", 160, 168], ["Membrane pellets", "PROBLEM", 0, 16], ["a dounce homogenizer", "TREATMENT", 35, 55], ["Extraction Buffer", "TREATMENT", 67, 84], ["Tris", "TEST", 92, 96], ["KCl", "TEST", 105, 108], ["EDTA", "TEST", 115, 119], ["n-Dodecyl", "TEST", 124, 133], ["Maltopyranoside (DDM", "TREATMENT", 138, 158], ["Anatrace", "TEST", 160, 168]]], ["A 10% solution of DDM was dissolved and clarified by bath sonication in 200 mM Tris pH 8 prior to addition to buffer to the indicated final concentration.", [["DDM", "CHEMICAL", 18, 21], ["DDM", "SIMPLE_CHEMICAL", 18, 21], ["A 10% solution of DDM", "TREATMENT", 0, 21], ["Tris pH", "TEST", 79, 86], ["buffer", "TREATMENT", 110, 116]]], ["Membrane pellets were then homogenized in Extraction Buffer and this mixture (150 mL final volume) was gently stirred at 4\u00b0C for 1 hour.", [["Membrane", "ANATOMY", 0, 8], ["Membrane pellets", "PROBLEM", 0, 16], ["Extraction Buffer", "TREATMENT", 42, 59], ["this mixture", "TREATMENT", 64, 76]]], ["The extraction mixture was centrifuged at 33,000 \u00d7 g for 45 minutes and the supernatant, containing solubilized membrane protein, was bound to 4 mL of Sepharose resin coupled to anti-GFP nanobody for 1 hour at 4\u00b0C. The resin was then collected in a column and washed with 10 mL of Buffer 1 (20 mM HEPES, 150 mM KCl, 1 mM EDTA, 0.025% DDM, pH 7.4), 40 mL of Buffer 2 (20 mM HEPES, 500 mM KCl, 1 mM EDTA, 0.025% DDM, pH 7.4), and 10 mL of Buffer 1.", [["supernatant", "ANATOMY", 76, 87], ["membrane", "ANATOMY", 112, 120], ["KCl", "CHEMICAL", 311, 314], ["KCl", "CHEMICAL", 387, 390], ["HEPES", "CHEMICAL", 297, 302], ["KCl", "CHEMICAL", 311, 314], ["EDTA", "CHEMICAL", 321, 325], ["HEPES", "CHEMICAL", 373, 378], ["KCl", "CHEMICAL", 387, 390], ["EDTA", "CHEMICAL", 397, 401], ["membrane", "CELLULAR_COMPONENT", 112, 120], ["Sepharose", "SIMPLE_CHEMICAL", 151, 160], ["solubilized membrane protein", "PROTEIN", 100, 128], ["anti-GFP nanobody", "PROTEIN", 178, 195], ["The extraction mixture", "TREATMENT", 0, 22], ["solubilized membrane protein", "TREATMENT", 100, 128], ["Sepharose resin", "TREATMENT", 151, 166], ["anti-GFP nanobody", "TREATMENT", 178, 195], ["The resin", "TREATMENT", 215, 224], ["a column", "TREATMENT", 247, 255], ["20 mM HEPES", "TREATMENT", 291, 302], ["150 mM KCl", "TREATMENT", 304, 314], ["1 mM EDTA", "TREATMENT", 316, 325], ["pH", "TEST", 339, 341], ["20 mM HEPES", "TREATMENT", 367, 378], ["500 mM KCl", "TREATMENT", 380, 390], ["1 mM EDTA", "TREATMENT", 392, 401], ["pH", "TEST", 415, 417]]], ["The resin was then resuspended in 6 mL of Buffer 1 with 0.5 mg of PPX protease and rocked gently in the capped column for 2 hours.", [["PPX", "CHEMICAL", 66, 69], ["PPX protease", "PROTEIN", 66, 78], ["The resin", "TREATMENT", 0, 9], ["Buffer", "TREATMENT", 42, 48], ["PPX protease", "TREATMENT", 66, 78]]], ["Cleaved 3a protein was then eluted with an additional 8 mL of Wash Buffer, spin concentrated to 500 \u03bcl with Amicon Ultra spin concentrator 10 kDa cutoff (Millipore), and then loaded onto a Superdex 200 increase column (GE Healthcare, Chicago, IL) on an NGC system (Bio-Rad, Hercules, CA) equilibrated in Buffer 1.", [["Cleaved 3a", "GENE_OR_GENE_PRODUCT", 0, 10], ["Cleaved 3a protein", "PROTEIN", 0, 18], ["Wash Buffer", "TREATMENT", 62, 73], ["Amicon Ultra spin concentrator", "TREATMENT", 108, 138], ["a Superdex", "TREATMENT", 187, 197], ["an NGC system", "TREATMENT", 250, 263]]], ["Peak fractions containing 3a channel were then collected and spin concentrated prior to incorporation into proteoliposomes or nanodiscs.", [["proteoliposomes", "ANATOMY", 107, 122], ["Peak fractions", "PROBLEM", 0, 14], ["a channel", "TREATMENT", 27, 36]]], ["For the tetramer, the preparation was carried out in a similar manner, except with overnight protease cleavage and collection of a peak of larger hydrodynamic radius (see Fig. S2).Proteoliposome formation ::: MethodsFor proteoliposome patching experiments, we incorporated protein into lipid and generated proteoliposome blisters for patch recordings using dehydration and rehydration as described previously with the following modifications27.", [["Proteoliposome", "ANATOMY", 180, 194], ["proteoliposome blisters", "ANATOMY", 306, 329], ["dehydration", "DISEASE", 357, 368], ["Proteoliposome", "SIMPLE_CHEMICAL", 180, 194], ["lipid", "SIMPLE_CHEMICAL", 286, 291], ["protease", "PROTEIN", 93, 101], ["S2", "PROTEIN", 176, 178], ["overnight protease cleavage", "TREATMENT", 83, 110], ["a peak of larger hydrodynamic radius", "PROBLEM", 129, 165], ["Methods", "TREATMENT", 209, 216], ["proteoliposome patching experiments", "TREATMENT", 220, 255], ["protein into lipid", "TREATMENT", 273, 291], ["generated proteoliposome blisters", "TREATMENT", 296, 329], ["patch recordings", "TREATMENT", 334, 350], ["dehydration", "PROBLEM", 357, 368], ["rehydration", "TREATMENT", 373, 384], ["peak", "OBSERVATION_MODIFIER", 131, 135], ["larger", "OBSERVATION_MODIFIER", 139, 145], ["hydrodynamic radius", "OBSERVATION", 146, 165]]], ["Protein was then exchanged into lipid with the addition of Biobeads SM2 and an overnight incubation at a protein:lipid ratio of 1:10 (corresponding to 0.5 mg purified 3a dimer and 5 mg of cleared Soybean L-\u03b1-phosphatidylcholine (Soy PC, MillaporeSigma, Burlington, MA) in DR Buffer (5 mM HEPES, 200 mM KCl, pH7.2).Electrophysiology ::: MethodsAll electrophysiology recordings were made from 3a-reconstituted L-\u03b1-Phosphatidylcholine (Sigma P5638) proteoliposomes.", [["L-\u03b1-phosphatidylcholine", "CHEMICAL", 204, 227], ["KCl", "CHEMICAL", 302, 305], ["Phosphatidylcholine", "CHEMICAL", 412, 431], ["L-\u03b1-phosphatidylcholine", "CHEMICAL", 204, 227], ["HEPES", "CHEMICAL", 288, 293], ["KCl", "CHEMICAL", 302, 305], ["Phosphatidylcholine", "CHEMICAL", 412, 431], ["lipid", "SIMPLE_CHEMICAL", 32, 37], ["SM2", "SIMPLE_CHEMICAL", 68, 71], ["lipid", "SIMPLE_CHEMICAL", 113, 118], ["Soybean L-\u03b1-phosphatidylcholine", "SIMPLE_CHEMICAL", 196, 227], ["L-\u03b1-Phosphatidylcholine", "SIMPLE_CHEMICAL", 408, 431], ["Sigma P5638", "SIMPLE_CHEMICAL", 433, 444], ["Soybean", "SPECIES", 196, 203], ["Protein", "TEST", 0, 7], ["Biobeads SM2", "TREATMENT", 59, 71], ["an overnight incubation", "TREATMENT", 76, 99], ["lipid ratio", "TEST", 113, 124], ["Soybean L-\u03b1-phosphatidylcholine (Soy PC", "TREATMENT", 196, 235], ["MillaporeSigma", "TREATMENT", 237, 251], ["5 mM HEPES", "TREATMENT", 283, 293], ["200 mM KCl", "TREATMENT", 295, 305], ["All electrophysiology recordings", "TEST", 343, 375]]], ["Patches formed in an inside-out configuration and were quickly (within 5\u201310 seconds) transferred to a solution exchange chamber.", [["a solution exchange chamber", "TREATMENT", 100, 127], ["out configuration", "OBSERVATION_MODIFIER", 28, 45]]], ["Recordings were made at room temperature using Clampex 10.7 data acquisition software with an Axopatch 200B Patch Clamp amplifier and Digidata 1550B digitizer (Molecular Devices) at a bandwidth of 1 kHz and digitized at 500 kHz.", [["Recordings", "TEST", 0, 10], ["Clampex", "TREATMENT", 47, 54], ["an Axopatch 200B Patch Clamp amplifier", "TREATMENT", 91, 129], ["Digidata 1550B digitizer (Molecular Devices", "TREATMENT", 134, 177]]], ["A pressure clamp (ALA Scientific) was used to form seals.", [["A pressure clamp (ALA Scientific)", "TREATMENT", 0, 33], ["pressure clamp", "OBSERVATION", 2, 16]]], ["Potassium pipette and bath solution was 5 mM HEPES pH 7.2, 150 mM KCl, 5 mM EGTA, 1 mM MgCl2 .", [["Potassium", "CHEMICAL", 0, 9], ["KCl", "CHEMICAL", 66, 69], ["EGTA", "CHEMICAL", 76, 80], ["MgCl2", "CHEMICAL", 87, 92], ["Potassium", "CHEMICAL", 0, 9], ["KCl", "CHEMICAL", 66, 69], ["EGTA", "CHEMICAL", 76, 80], ["MgCl2", "CHEMICAL", 87, 92], ["Potassium", "SIMPLE_CHEMICAL", 0, 9], ["EGTA", "SIMPLE_CHEMICAL", 76, 80], ["Potassium pipette", "TREATMENT", 0, 17], ["bath solution", "TREATMENT", 22, 35], ["pH", "TEST", 51, 53], ["150 mM KCl", "TREATMENT", 59, 69], ["5 mM EGTA", "TREATMENT", 71, 80], ["1 mM MgCl2", "TREATMENT", 82, 92]]], ["Sodium bath solution was 5 mM HEPES pH 7.2, 150 mM KCl, 1 mM MgCl2, 1 mM CaCl2.", [["Sodium bath", "CHEMICAL", 0, 11], ["KCl", "CHEMICAL", 51, 54], ["MgCl2", "CHEMICAL", 61, 66], ["CaCl2", "CHEMICAL", 73, 78], ["Sodium", "CHEMICAL", 0, 6], ["KCl", "CHEMICAL", 51, 54], ["MgCl2", "CHEMICAL", 61, 66], ["CaCl2", "CHEMICAL", 73, 78], ["Sodium", "SIMPLE_CHEMICAL", 0, 6], ["CaCl2", "SIMPLE_CHEMICAL", 73, 78], ["Sodium bath solution", "TREATMENT", 0, 20], ["pH", "TEST", 36, 38], ["KCl", "TEST", 51, 54], ["1 mM MgCl2", "TREATMENT", 56, 66], ["1 mM CaCl2", "TREATMENT", 68, 78]]], ["NaCl in the bath solution was substituted for 150 mM NMDG-Cl or 75 mM CaCl2 for permeability experiments.", [["NaCl", "CHEMICAL", 0, 4], ["NMDG-Cl", "CHEMICAL", 53, 60], ["CaCl2", "CHEMICAL", 70, 75], ["NaCl", "CHEMICAL", 0, 4], ["NMDG", "CHEMICAL", 53, 57], ["Cl", "CHEMICAL", 58, 60], ["CaCl2", "CHEMICAL", 70, 75], ["NaCl", "SIMPLE_CHEMICAL", 0, 4], ["NMDG-Cl", "SIMPLE_CHEMICAL", 53, 60], ["CaCl2", "SIMPLE_CHEMICAL", 70, 75], ["NaCl in the bath solution", "TREATMENT", 0, 25], ["NMDG", "TEST", 53, 57], ["permeability experiments", "TEST", 80, 104]]], ["Borosilicate glass pipettes were pulled and polished to a resistance of 2\u20135 M\u2126 when filled with pipette solution.", [["Borosilicate", "CHEMICAL", 0, 12], ["Borosilicate glass pipettes", "TREATMENT", 0, 27], ["pipette solution", "TREATMENT", 96, 112], ["glass pipettes", "OBSERVATION", 13, 27]]], ["For cation permeability experiments, liquid junction potentials were calculated and data were corrected offline.", [["liquid junction", "ANATOMY", 37, 52], ["cation", "SIMPLE_CHEMICAL", 4, 10], ["cation permeability experiments", "TREATMENT", 4, 35], ["liquid junction potentials", "TEST", 37, 63]]], ["For current-voltage plots, the following voltage protocol was applied: Vhold= 0 mV mV; Vtest= \u2212100 to +100 mV, \u039420 mV, ttest = 1 second.", [["the following voltage protocol", "TREATMENT", 27, 57], ["Vhold", "TEST", 71, 76], ["mV mV", "TEST", 80, 85], ["Vtest", "TEST", 87, 92], ["mV", "TEST", 107, 109], ["mV", "TEST", 115, 117], ["ttest", "TEST", 119, 124]]], ["Currents from each patch correspond to mean values during the step to the indicated voltage.Electrophysiology ::: MethodsPermeability ratios were calculated according to Goldman-Hodgkin-Katz relationship.", [["mean values", "TEST", 39, 50], ["MethodsPermeability ratios", "TEST", 114, 140]]], ["For monovalent cations, permeability ratios were calculated as PX+/PK+ = exp(\u0394VrevF/RT).", [["cations", "SIMPLE_CHEMICAL", 15, 22], ["PX", "PROTEIN", 63, 65], ["monovalent cations", "TREATMENT", 4, 22], ["permeability ratios", "TEST", 24, 43], ["PX", "TEST", 63, 65], ["PK", "TEST", 67, 69]]], ["For divalent cations, permeability ratios were calculated as: PX2+/PK+=\u03b1K+K+exp\u0394VrevF/RT1+exp\u0394VrevF/RT/4\u03b1X2+X2+ Where Vrev is the reversal potential, F is Faraday\u2019s constant, R is the universal gas constant, and T is absolute temperature (where RT/F = 25.2 mV at room temperature), and \u03b1is the ion activity coefficient (assumed to be 0.75 for K+ and 0.25 for Ca2+).Nanodisc formation ::: MethodsFreshly purified 3a dimer in Buffer 1 was reconstituted into MSP1E3D1 nanodiscs with a mixture of lipids (DOPE:POPS:POPC at a 2:1:1 molar ratio, Avanti, Alabaster, Alabama) at a final molar ratio of 1:4:400 (Monomer Ratio: 3a, MSP1E3D1, lipid mixture).", [["Nanodisc", "ANATOMY", 365, 373], ["K", "CHEMICAL", 343, 344], ["Ca2", "CHEMICAL", 359, 362], ["DOPE", "CHEMICAL", 501, 505], ["POPC", "CHEMICAL", 511, 515], ["K+", "CHEMICAL", 343, 345], ["Ca2+", "CHEMICAL", 359, 363], ["DOPE", "CHEMICAL", 501, 505], ["POPC", "CHEMICAL", 511, 515], ["cations", "SIMPLE_CHEMICAL", 13, 20], ["Vrev", "GENE_OR_GENE_PRODUCT", 118, 122], ["K+", "SIMPLE_CHEMICAL", 343, 345], ["Ca2+", "SIMPLE_CHEMICAL", 359, 363], ["Nanodisc", "SIMPLE_CHEMICAL", 365, 373], ["MSP1E3D1", "ORGANISM", 456, 464], ["lipids", "SIMPLE_CHEMICAL", 493, 499], ["DOPE", "SIMPLE_CHEMICAL", 501, 505], ["POPS", "SIMPLE_CHEMICAL", 506, 510], ["POPC", "SIMPLE_CHEMICAL", 511, 515], ["MSP1E3D1", "SIMPLE_CHEMICAL", 622, 630], ["lipid", "SIMPLE_CHEMICAL", 632, 637], ["PX2", "PROTEIN", 62, 65], ["PK", "PROTEIN", 67, 69], ["exp\u0394VrevF", "PROTEIN", 76, 85], ["RT1+exp\u0394VrevF", "PROTEIN", 86, 99], ["/RT", "PROTEIN", 99, 102], ["/4\u03b1X2", "PROTEIN", 102, 107], ["X2", "PROTEIN", 108, 110], ["Vrev", "PROTEIN", 118, 122], ["K", "PROTEIN", 343, 344], ["Ca2", "PROTEIN", 359, 362], ["MethodsFreshly purified 3a dimer", "PROTEIN", 388, 420], ["MSP1E3D1 nanodiscs", "CELL_LINE", 456, 474], ["divalent cations", "TREATMENT", 4, 20], ["permeability ratios", "TEST", 22, 41], ["PX2", "TEST", 62, 65], ["PK", "TEST", 67, 69], ["K+K+", "TEST", 72, 76], ["exp\u0394VrevF", "TEST", 76, 85], ["RT1+exp\u0394VrevF", "TEST", 86, 99], ["/RT", "TEST", 99, 102], ["absolute temperature", "PROBLEM", 217, 237], ["K", "TEST", 343, 344], ["POPC", "TEST", 511, 515], ["a final molar ratio", "TEST", 571, 590]]], ["First, 20 mM solubilized lipid in Column Buffer (20 mM HEPES, 150 mM KCl, 1 mM EDTA pH 7.4) was mixed with additional DDM detergent and 3a protein.", [["KCl", "CHEMICAL", 69, 72], ["HEPES", "CHEMICAL", 55, 60], ["KCl", "CHEMICAL", 69, 72], ["EDTA", "CHEMICAL", 79, 83], ["20 mM solubilized lipid in Column Buffer (20 mM HEPES", "TREATMENT", 7, 60], ["150 mM KCl", "TREATMENT", 62, 72], ["1 mM EDTA pH", "TREATMENT", 74, 86], ["additional DDM detergent", "TREATMENT", 107, 131]]], ["This solution was mixed at 4\u00b0C for 30 minutes before addition of purified MSP1E3D1.", [["MSP1E3D1", "GENE_OR_GENE_PRODUCT", 74, 82], ["MSP1E3D1", "PROTEIN", 74, 82], ["This solution", "TREATMENT", 0, 13]]], ["This addition brought the final concentrations to approximately 15 \u03bcM 3a, 60 \u03bcM MSP1E3D1, 6 mM lipid mix, and 10 mM DDM in Column Buffer.", [["MSP1E3D1", "SIMPLE_CHEMICAL", 80, 88], ["6 mM lipid mix", "TREATMENT", 90, 104], ["10 mM DDM in Column Buffer", "TREATMENT", 110, 136], ["10 mM", "OBSERVATION_MODIFIER", 110, 115]]], ["The solution with MSP1E3D1 was mixed at 4\u00b0C for 10 minutes before addition of 200 mg of Biobeads SM2 (Bio-Rad).", [["MSP1E3D1", "SIMPLE_CHEMICAL", 18, 26], ["Bio-Rad", "GENE_OR_GENE_PRODUCT", 102, 109], ["The solution", "TREATMENT", 0, 12], ["MSP1E3D1", "TREATMENT", 18, 26], ["Biobeads SM2", "TREATMENT", 88, 100]]], ["Biobeads (washed into methanol, water, and then Column Buffer) were weighed after liquid was removed by P1000 tip (damp weight).", [["methanol", "CHEMICAL", 22, 30], ["methanol", "SIMPLE_CHEMICAL", 22, 30], ["Biobeads", "TREATMENT", 0, 8], ["methanol", "TREATMENT", 22, 30], ["Column Buffer)", "TREATMENT", 48, 62]]], ["This mix was incubated at 4\u00b0C for 30 minutes before addition of another 200 mg of Biobeads (for a total 400 mg of Biobeads per 0.5 mL reaction).", [["Biobeads", "CHEMICAL", 82, 90], ["Biobeads", "SIMPLE_CHEMICAL", 82, 90], ["Biobeads", "TREATMENT", 82, 90], ["Biobeads", "TREATMENT", 114, 122]]], ["Supernatant was cleared of beads by letting large beads settle and carefully removing liquid with a pipette.", [["Supernatant", "ANATOMY", 0, 11], ["beads", "ANATOMY", 27, 32], ["Supernatant", "ORGANISM_SUBSTANCE", 0, 11], ["a pipette", "TREATMENT", 98, 107]]], ["Sample was spun for 10 minutes at 21,000 \u00d7 g before loading onto a Superdex 200 increase column in 20 mM HEPES, 150 mM KCl, pH 7.4.", [["KCl", "CHEMICAL", 119, 122], ["HEPES", "CHEMICAL", 105, 110], ["KCl", "CHEMICAL", 119, 122], ["Sample", "TEST", 0, 6], ["a Superdex", "TREATMENT", 65, 75], ["20 mM HEPES", "TREATMENT", 99, 110], ["150 mM KCl", "TREATMENT", 112, 122], ["pH", "TEST", 124, 126]]], ["Peak fractions corresponding to 3a protein in MSP1E3D1 were collected, 10 kDa cutoff spin concentrated and used for grid preparation.", [["MSP1E3D1", "GENE_OR_GENE_PRODUCT", 46, 54], ["3a protein", "PROTEIN", 32, 42], ["MSP1E3D1", "PROTEIN", 46, 54], ["Peak fractions", "TEST", 0, 14], ["3a protein", "TEST", 32, 42], ["grid preparation", "TREATMENT", 116, 132]]], ["MSP1E3D1 was prepared as described28 without cleavage of the His-tag.", [["His", "CHEMICAL", 61, 64], ["MSP1E3D1", "GENE_OR_GENE_PRODUCT", 0, 8], ["MSP1E3D1", "PROTEIN", 0, 8], ["His-tag", "DNA", 61, 68]]], ["Tetrameric 3a in nanodiscs was prepared similarly, except with a ratio of 1:2:200 (Monomer Ratio: 3a, MSP1E3D1, lipid mixture).Grid preparation ::: MethodsDimeric 3a in MSP1E3D1 was prepared at final concentration of 1.1 mg/mL.", [["MethodsDimeric 3a", "CHEMICAL", 148, 165], ["nanodiscs", "SIMPLE_CHEMICAL", 17, 26], ["MSP1E3D1", "SIMPLE_CHEMICAL", 102, 110], ["lipid", "SIMPLE_CHEMICAL", 112, 117], ["MSP1E3D1", "SIMPLE_CHEMICAL", 169, 177], ["MSP1E3D1", "CELL_LINE", 169, 177], ["a ratio", "TEST", 63, 70]]], ["For the sample with emodin (MillaporeSigma, Burlington, MA, Catalog E7881), a stock solution of 50 mM emodin in DMSO added to protein sample for final concentrations of 1.1 mg/mL 3a and 100 \u03bcM emodin and 1% DMSO.", [["sample", "ANATOMY", 8, 14], ["emodin", "CHEMICAL", 20, 26], ["emodin", "CHEMICAL", 102, 108], ["DMSO", "CHEMICAL", 112, 116], ["emodin", "CHEMICAL", 193, 199], ["DMSO", "CHEMICAL", 207, 211], ["emodin", "CHEMICAL", 20, 26], ["emodin", "CHEMICAL", 102, 108], ["DMSO", "CHEMICAL", 112, 116], ["emodin", "CHEMICAL", 193, 199], ["DMSO", "CHEMICAL", 207, 211], ["emodin", "SIMPLE_CHEMICAL", 20, 26], ["emodin", "SIMPLE_CHEMICAL", 102, 108], ["DMSO", "SIMPLE_CHEMICAL", 112, 116], ["emodin", "SIMPLE_CHEMICAL", 193, 199], ["DMSO", "SIMPLE_CHEMICAL", 207, 211], ["emodin", "TREATMENT", 20, 26], ["a stock solution", "TREATMENT", 76, 92], ["DMSO", "TREATMENT", 112, 116], ["emodin", "TREATMENT", 193, 199]]], ["Concentrated sample was cleared by a 10 minute 21,000 \u00d7 g spin at 4\u00b0C prior to grid making.", [["sample", "ANATOMY", 13, 19]]], ["For freezing grids, a 3 \u03bcl drop of protein was applied to freshly glow discharged Holey Carbon, 300 mesh R 1.2/1.3 gold grids (Quantifoil, Gro\u00dfl\u00f6bichau, Germany).", [["Carbon", "CHEMICAL", 88, 94], ["freezing grids", "PROBLEM", 4, 18], ["a 3 \u03bcl drop of protein", "TREATMENT", 20, 42], ["Holey Carbon", "TREATMENT", 82, 94], ["mesh R", "TEST", 100, 106]]], ["A FEI Vitrobot Mark IV (ThermoFisher Scientific) was used with 4\u00b0C, 100% humidity, 1 blot force, a wait time of 5 seconds, and a 3 second blot time, before plunge freezing in liquid ethane.", [["ethane", "CHEMICAL", 182, 188], ["ethane", "CHEMICAL", 182, 188], ["ethane", "SIMPLE_CHEMICAL", 182, 188], ["A FEI Vitrobot Mark IV", "TREATMENT", 0, 22], ["plunge freezing in liquid ethane", "TREATMENT", 156, 188]]], ["Grids were then clipped and used for data collection.", [["data collection", "TEST", 37, 52]]], ["Tetrameric 3a in MSP1E3D1 was frozen at 0.7 mg/mL with the same grid preparation.Cryo-EM data processing ::: Cryo-EM data acquisition ::: MethodsFor the apo 3a dimer, motion-correction and dose-weighting were performed on all 6,309 movies using RELION 3.1\u2019s implementation of MotionCor2, and 2x \u201cbinned\u201d to 1.137 \u00c5 per pixel30\u201332.", [["Tetrameric 3a", "GENE_OR_GENE_PRODUCT", 0, 13], ["MSP1E3D1", "SIMPLE_CHEMICAL", 17, 25], ["apo 3a", "GENE_OR_GENE_PRODUCT", 153, 159], ["MSP1E3D1", "DNA", 17, 25], ["apo 3a dimer", "PROTEIN", 153, 165], ["MotionCor2", "PROTEIN", 276, 286], ["Tetrameric 3a in MSP1E3D1", "TREATMENT", 0, 25], ["RELION", "TEST", 245, 251], ["MotionCor2", "TEST", 276, 286]]], ["CTFFIND-4.1 was used to estimate the contrast transfer function (CTF) parameters33.", [["CTFFIND", "PROTEIN", 0, 7], ["CTFFIND", "TEST", 0, 7]]], ["Micrographs were then manually sorted to eliminate subjectively bad micrographs, such as empty or contaminated holes, resulting in 3,611 good micrographs.", [["Micrographs", "TEST", 0, 11], ["subjectively bad micrographs", "PROBLEM", 51, 79], ["empty or contaminated holes", "PROBLEM", 89, 116], ["contaminated holes", "OBSERVATION", 98, 116]]], ["Additionally, micrographs with a CTF maximum resolution lower than 4 \u00c5 were discarded, resulting in 2,595 remaining micrographs.", [["CTF", "PROTEIN", 33, 36], ["micrographs", "TEST", 14, 25], ["a CTF maximum resolution", "TEST", 31, 55]]], ["Template-free auto-picking of particles was performed with RELION3.1\u2019s Laplacian-of-Gaussian (LoG) filter yielding an initial set of particles.", [["Template", "TEST", 0, 8], ["free auto-picking of particles", "PROBLEM", 9, 39], ["Laplacian", "TEST", 71, 80], ["Gaussian (LoG) filter", "TREATMENT", 84, 105], ["particles", "OBSERVATION", 133, 142]]], ["This initial set of particles were iteratively classified to generate templates, which were subsequently used to template-based auto-pick 1,750,730 particles.Cryo-EM data processing ::: Cryo-EM data acquisition ::: MethodsTemplate picked particles were iteratively 2D-classified in RELION3.1 and then in cryoSPARC v234, resulting in 820,543 particles.", [["cryoSPARC v", "TEST", 304, 315]]], ["These particles were subsequently 3D-classified in cryoSPARC v2 with iterative ab-initio and heterogeneous refinement jobs.", [["cryoSPARC v2", "CELL_LINE", 51, 63], ["3D", "TEST", 34, 36], ["iterative ab-initio", "TREATMENT", 69, 88], ["heterogeneous", "OBSERVATION_MODIFIER", 93, 106], ["refinement jobs", "OBSERVATION", 107, 122]]], ["The resulting maps were visually evaluated with regard to the transmembrane domain density.", [["transmembrane", "ANATOMY", 62, 75], ["The resulting maps", "TEST", 0, 18], ["the transmembrane domain density", "PROBLEM", 58, 90], ["density", "OBSERVATION", 83, 90]]], ["A set of 86,479 particles were identified, polished in RELION3.1 and refined in cryoSPARC v2 with subsequent homogeneous and non-uniform refinement35 jobs (maps were low-pass filtered to an initial resolution where TM density was still visible (6\u20139 \u00c5), and the dynamic mask was tightened with the near (2\u20135 \u00c5) and far (3\u20139 \u00c5) parameters), yielding a map with overall resolution of 3.6 \u00c5.Cryo-EM data processing ::: Cryo-EM data acquisition ::: MethodsFrom this set of 86,479 particles, 2D-classification was performed in RELION3.1 to identify a set of particles with subjectively equal view distribution.", [["RELION3.1", "DNA", 55, 64], ["cryoSPARC v2", "CELL_LINE", 80, 92], ["RELION3.1", "CELL_LINE", 521, 530], ["A set", "TEST", 0, 5], ["maps", "TEST", 156, 160], ["TM density", "TEST", 215, 225], ["the dynamic mask", "TREATMENT", 257, 273], ["a map", "TEST", 348, 353], ["overall resolution", "TEST", 359, 377], ["homogeneous", "OBSERVATION_MODIFIER", 109, 120], ["density", "OBSERVATION", 218, 225], ["dynamic mask", "OBSERVATION", 261, 273]]], ["From the resulting set, 1,000 particles were randomly sampled and their coordinates used for training in the Topaz particle-picking pipeline36.", [["the Topaz particle", "TREATMENT", 105, 123]]], ["Training, picking, and extraction were performed independently on each subset of the micrographs.", [["extraction", "TREATMENT", 23, 33]]], ["4,134,279 total particles were extracted in RELION3.1 with a box size of 256 pixels and \u201cbinned\u201d 4x to 4.548 \u00c5/pixel.", [["total particles", "TEST", 10, 25], ["a box size", "TEST", 59, 69], ["pixels", "TEST", 77, 83], ["size", "OBSERVATION_MODIFIER", 65, 69]]], ["These particles were then iteratively 2D-classified in RELION3.1 resulting in 2,674,606 particles which were extracted at 2.274 \u00c5/pixel.", [["RELION3.1", "CELL_LINE", 55, 64]]], ["Further classification was performed in cryoSPARC v2 with subsequent ab-initio (4 classes, max resolution 8 \u00c5) and heterogeneous refinement (8 \u00c5 initial resolution) jobs.", [["cryoSPARC v2", "CELL_LINE", 40, 52], ["Further classification", "TEST", 0, 22], ["heterogeneous", "OBSERVATION_MODIFIER", 115, 128]]], ["The two best classes were selected and the particles pooled resulting in 743,800 particles which were extracted in RELION3.1 at 1.137 \u00c5/pixel.Cryo-EM data processing ::: Cryo-EM data acquisition ::: MethodsIterative 3D-classification was performed with subsequent ab-initio and heterogeneous refinement jobs as described above.", [["heterogeneous refinement jobs", "TREATMENT", 278, 307], ["particles", "OBSERVATION_MODIFIER", 81, 90], ["heterogeneous", "OBSERVATION_MODIFIER", 278, 291], ["refinement jobs", "OBSERVATION", 292, 307]]], ["Following each round, 2D classification jobs were used to \u201crescue\u201d good particles from the worst classes before the next round.", [["2D classification jobs", "TREATMENT", 22, 44]]], ["After 3 rounds, a final 2D-classificaiton job was used to identify 112,502 particles, which were subsequently pooled with the previous 86,479 RELION3.1 template-picked particles, resulting in 185,871 particles after duplicates were removed.Cryo-EM data processing ::: Cryo-EM data acquisition ::: MethodsThese particles were then refined with subsequent homogeneous and non-uniform refinement jobs resulting in a map with overall resolution of 3.4 \u00c5.", [["RELION3.1 template", "DNA", 142, 160], ["Methods", "TREATMENT", 297, 304], ["a map", "TEST", 411, 416], ["homogeneous", "OBSERVATION_MODIFIER", 354, 365]]], ["This map was post-processed in RELION3.1 using a mask with a soft edge (5 pixel extension, 7 pixel soft-edge), the output of which was used for Bayesian particle polishing in RELION3.1 (training and polishing were each performed independently on each subset of the micrographs).", [["RELION3.1", "CELL_LINE", 31, 40], ["This map", "TEST", 0, 8], ["a mask", "TREATMENT", 47, 53], ["a soft edge (5 pixel extension", "TREATMENT", 59, 89], ["the output", "TEST", 111, 121], ["Bayesian particle polishing", "TREATMENT", 144, 171], ["polishing", "TREATMENT", 199, 208], ["soft edge", "OBSERVATION_MODIFIER", 61, 70]]], ["The resulting \u201cshiny\u201d particles were then refined in cryoSPARC v2 with subsequent homogenous refinement (1 extra pass, 7 \u00c5 initial resolution) and non-uniform refinement (C2, 1 extra pass, 9 \u00c5 initial resolution) to yield a map with 2.9 \u00c5 overall resolution.Cryo-EM data processing ::: Cryo-EM data acquisition ::: MethodsFor 3a dimer with added 100 \u03bcM emodin, initial processing was similar to the dimer without added drug (see processing supplement).", [["emodin", "CHEMICAL", 353, 359], ["emodin", "CHEMICAL", 353, 359], ["emodin", "SIMPLE_CHEMICAL", 353, 359], ["cryoSPARC v2", "CELL_LINE", 53, 65], ["C2", "PROTEIN", 171, 173], ["The resulting \u201cshiny\u201d particles", "PROBLEM", 0, 31], ["non-uniform refinement (C2, 1 extra pass", "TREATMENT", 147, 187], ["a map", "TEST", 222, 227], ["100 \u03bcM emodin", "TREATMENT", 346, 359], ["homogenous", "OBSERVATION_MODIFIER", 82, 92], ["resolution", "OBSERVATION_MODIFIER", 247, 257]]], ["As with the apo 3a dimer, the critical steps included Topaz particle picking, particle clean-up with cryoSPARC v2 ab-initio and heterogeneous refinement, non-uniform refinement with tightened masking, and RELION3.1 Bayesian particle polishing.", [["apo 3a", "GENE_OR_GENE_PRODUCT", 12, 18], ["Topaz", "SIMPLE_CHEMICAL", 54, 59], ["apo 3a dimer", "PROTEIN", 12, 24], ["Topaz particle picking", "TREATMENT", 54, 76], ["cryoSPARC v2 ab", "TREATMENT", 101, 116], ["heterogeneous refinement", "TREATMENT", 128, 152], ["tightened masking", "TREATMENT", 182, 199]]], ["However, in contrast to the apo dataset, we observed a set of particles that were included in < 4 \u00c5 reconstructions that had discontinuous transmembrane domain density.", [["transmembrane", "ANATOMY", 139, 152], ["apo", "GENE_OR_GENE_PRODUCT", 28, 31], ["discontinuous transmembrane domain density", "PROBLEM", 125, 167], ["transmembrane domain density", "OBSERVATION", 139, 167]]], ["Removal of these particles with RELION3.1 3D classification without angular sampling led to the best map from the emodin-added dataset.", [["emodin", "CHEMICAL", 114, 120], ["emodin", "CHEMICAL", 114, 120], ["emodin", "SIMPLE_CHEMICAL", 114, 120], ["Removal of these particles", "TREATMENT", 0, 26], ["angular sampling", "TEST", 68, 84], ["particles", "OBSERVATION_MODIFIER", 17, 26]]], ["We did not see any evidence of bound emodin, but the 1% DMSO added with drug addition may have contributed to subtle map differences (Fig. S8,S9).Cryo-EM data processing ::: Cryo-EM data acquisition ::: MethodsFor the 3a tetramer, the initial 7,092 micrographs were first cleaned using manual inspection and removal of images with < 4 \u00c5 CtfMaxResolution to obtain a set of 4,324 micrographs.", [["emodin", "CHEMICAL", 37, 43], ["DMSO", "CHEMICAL", 56, 60], ["emodin", "CHEMICAL", 37, 43], ["DMSO", "CHEMICAL", 56, 60], ["emodin", "SIMPLE_CHEMICAL", 37, 43], ["DMSO", "SIMPLE_CHEMICAL", 56, 60], ["S8", "PROTEIN", 139, 141], ["S9", "PROTEIN", 142, 144], ["bound emodin", "PROBLEM", 31, 43], ["the 1% DMSO", "TREATMENT", 49, 60], ["subtle map differences (Fig", "PROBLEM", 110, 137], ["manual inspection", "TEST", 286, 303], ["images", "TEST", 319, 325], ["emodin", "OBSERVATION", 37, 43]]], ["Reference particles for Topaz particle picking were generated by first template picking in RELION3.1, followed by 2D classification in both RELION3.1 and cryoSPARC v2, and subsequent ab-initio in cryoSPARC v2.", [["RELION3.1", "CELL_LINE", 91, 100], ["RELION3.1", "CELL_LINE", 140, 149], ["cryoSPARC v2", "CELL_LINE", 196, 208], ["Topaz particle picking", "TREATMENT", 24, 46]]], ["Using these coordinates for training, Topaz particle picking was then performed to generate a set of 1,282,913 initial particles.", [["training", "TREATMENT", 28, 36], ["Topaz particle picking", "TREATMENT", 38, 60]]], ["These particles were then cleaned using 2D classification in RELION3.1 and cryoSPARC v2, followed by rounds of cryoSPARC v2 ab-initio and RELION3.1 3D classification.", [["RELION3.1", "CELL_LINE", 61, 70], ["cryoSPARC v2", "CELL_LINE", 75, 87], ["2D classification", "TEST", 40, 57]]], ["A major hurdle for tetramer processing was obtaining a reconstruction where most particles were properly oriented in the same direction (i.e. CD domains on the same side of the nanodisc as seen in the 2D classes, see Fig. 2F).", [["CD domains", "PROTEIN", 142, 152], ["tetramer processing", "TREATMENT", 19, 38], ["a reconstruction", "TREATMENT", 53, 69]]], ["Reconstructions with C1 or C2 symmetry looked similar (see Fig. S10), although no tetramer reconstruction went to high enough resolution to determine symmetry with certainty.", [["C1", "PROTEIN", 21, 23], ["Reconstructions with C1 or C2 symmetry", "TEST", 0, 38], ["tetramer reconstruction", "TREATMENT", 82, 105], ["C2", "ANATOMY", 27, 29], ["no", "UNCERTAINTY", 79, 81]]], ["Therefore, it is possible that either the tetramer is pseudosymmetric or that different particles have heterogeneous orientations between dimer pairs.", [["dimer pairs", "PROTEIN", 138, 149], ["pseudosymmetric", "PROBLEM", 54, 69], ["heterogeneous orientations between dimer pairs", "PROBLEM", 103, 149], ["heterogeneous", "OBSERVATION_MODIFIER", 103, 116]]], ["For the tetramer, the highest resolution reconstruction came from cryoSPARC v2 non-uniform refinement with a tightened mask, which was subsequently used for dimer-docking and figure preparation.Fluorescence Size Exclusion Chromatography (FSEC) ::: Modeling, Refinement, and Analysis ::: MethodsSf9 cells ( 4 million) from the third day of infection were pelleted, frozen, and then thawed into extraction buffer (20mM Tris pH 8, 150 mM KCl, all protease inhibitors used for protein purification, 1 mM EDTA, 1% DDM).", [["Sf9 cells", "ANATOMY", 294, 303], ["infection", "DISEASE", 339, 348], ["KCl", "CHEMICAL", 435, 438], ["KCl", "CHEMICAL", 435, 438], ["EDTA", "CHEMICAL", 500, 504], ["Sf9 cells", "CELL", 294, 303], ["EDTA", "SIMPLE_CHEMICAL", 500, 504], ["dimer", "PROTEIN", 157, 162], ["Sf9 cells", "CELL_LINE", 294, 303], ["the tetramer", "TREATMENT", 4, 16], ["the highest resolution reconstruction", "TREATMENT", 18, 55], ["a tightened mask", "TREATMENT", 107, 123], ["dimer-docking and figure preparation", "TREATMENT", 157, 193], ["Fluorescence Size Exclusion Chromatography", "TEST", 194, 236], ["MethodsSf9 cells", "TREATMENT", 287, 303], ["infection", "PROBLEM", 339, 348], ["extraction buffer", "TREATMENT", 393, 410], ["mM Tris pH", "TEST", 414, 424], ["150 mM KCl", "TREATMENT", 428, 438], ["all protease inhibitors", "TREATMENT", 440, 463], ["protein purification", "TREATMENT", 473, 493], ["tightened mask", "OBSERVATION", 109, 123], ["infection", "OBSERVATION", 339, 348]]], ["Extraction was performed at 4\u00b0C for 1 hour and lysate was then pelleted at 21,000 \u00d7 g at 4\u00b0C for 1 hour to clear supernatant.", [["lysate", "ANATOMY", 47, 53], ["supernatant", "ANATOMY", 113, 124], ["Extraction", "TREATMENT", 0, 10], ["lysate", "TREATMENT", 47, 53]]], ["Supernatant was then run on a Superose 6 Increase column with fluorescence detection for GFP into column buffer (20 mM HEPES pH 7.4, 150 mM KCl, 0.025% DDM).Transfection and Imaging ::: Modeling, Refinement, and Analysis ::: MethodsThe constructs for full length 3a and 3a\u0394N were cloned into a vector with a CMV-promoter and C-terminal EGFP.", [["Supernatant", "ANATOMY", 0, 11], ["KCl", "CHEMICAL", 140, 143], ["KCl", "CHEMICAL", 140, 143], ["C", "CHEMICAL", 325, 326], ["Supernatant", "ORGANISM_SUBSTANCE", 0, 11], ["GFP", "GENE_OR_GENE_PRODUCT", 89, 92], ["3a", "GENE_OR_GENE_PRODUCT", 263, 265], ["3a\u0394N", "GENE_OR_GENE_PRODUCT", 270, 274], ["CMV", "ORGANISM", 308, 311], ["C-terminal EGFP", "GENE_OR_GENE_PRODUCT", 325, 340], ["3a\u0394N", "DNA", 270, 274], ["CMV-promoter", "DNA", 308, 320], ["C-terminal EGFP", "DNA", 325, 340], ["a Superose 6 Increase column", "TREATMENT", 28, 56], ["fluorescence detection", "TEST", 62, 84], ["GFP into column buffer", "TREATMENT", 89, 111], ["mM HEPES pH", "TEST", 116, 127], ["150 mM KCl", "TREATMENT", 133, 143], ["Imaging", "TEST", 174, 181], ["Methods", "TREATMENT", 225, 232], ["a CMV-promoter", "TREATMENT", 306, 320], ["C-terminal EGFP", "TREATMENT", 325, 340], ["terminal EGFP", "OBSERVATION", 327, 340]]], ["Constructs (2 \u03bcg) were transfected into HEK293 cells on glass coverslips using Fugene HD (Promega, Madison, WI) per manufacturer\u2019s instructions.", [["HEK293 cells", "ANATOMY", 40, 52], ["HEK293 cells", "CELL", 40, 52], ["HEK293 cells", "CELL_LINE", 40, 52], ["glass coverslips", "TREATMENT", 56, 72], ["Fugene HD", "TREATMENT", 79, 88]]], ["Two days after transfection cells were washed with DPBS and then fixed in 4% Formaldehyde in DPBS for 10 minutes.", [["cells", "ANATOMY", 28, 33], ["Formaldehyde", "CHEMICAL", 77, 89], ["Formaldehyde", "CHEMICAL", 77, 89], ["cells", "CELL", 28, 33], ["Formaldehyde", "SIMPLE_CHEMICAL", 77, 89], ["transfection cells", "TREATMENT", 15, 33], ["DPBS", "TREATMENT", 51, 55]]], ["Cells were then washed with DPBS before mounting the coverslip with Prolong Glass Antifade with NucBlue (ThermoFisher Scientific) per manufacturer\u2019s instructions.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["DPBS", "TREATMENT", 28, 32]]], ["Fluorescent images were collected using a Zeiss LSM 880 NLO AxioExaminer confocal microscope at either 20X (NA 1.0) or 63X oil immersion objective (NA 1.4).", [["Fluorescent images", "TEST", 0, 18], ["NA", "TEST", 108, 110], ["NA", "TEST", 148, 150]]], ["The samples were excited with 488nm argon laser and image analysis was performed using ImageJ.Data and reagent availability ::: MethodsAll data and reagents associated with this study are publicly available.", [["samples", "ANATOMY", 4, 11], ["488nm argon laser", "TREATMENT", 30, 47], ["image analysis", "TEST", 52, 66], ["ImageJ", "TEST", 87, 93], ["Methods", "TREATMENT", 128, 135], ["All data", "TEST", 135, 143], ["this study", "TEST", 173, 183]]], ["For dimeric apo 3a, the final model is in the PDB under 6XDC, the final map is in the EMDB under EMD-22136, and the original micrograph movies and final particle stack is in EMPIAR under EMPIAR-10439.", [["EMD-22136", "CHEMICAL", 97, 106], ["EMPIAR-10439", "CHEMICAL", 187, 199], ["EMD-22136", "CHEMICAL", 97, 106], ["EMPIAR-10439", "CHEMICAL", 187, 199], ["apo 3", "GENE_OR_GENE_PRODUCT", 12, 17]]], ["For tetrameric apo 3a, the final map is in the EMDB under EMD-22138 and the original micrograph movies and final particle stack is in EMPIAR under EMPIAR-10441.", [["EMD-22138", "CHEMICAL", 58, 67], ["EMPIAR-10441", "CHEMICAL", 147, 159], ["EMD-22138", "CHEMICAL", 58, 67], ["EMPIAR-10441", "CHEMICAL", 147, 159], ["tetrameric apo 3", "GENE_OR_GENE_PRODUCT", 4, 20]]], ["For dimeric 3a in the presence of emodin, the final map is in the EMDB under EMD-22139 and the original micrograph movies and final particle stack is in EMPIAR under EMPIAR-10440.", [["emodin", "CHEMICAL", 34, 40], ["EMD-22139", "CHEMICAL", 77, 86], ["EMPIAR-10440", "CHEMICAL", 166, 178], ["emodin", "CHEMICAL", 34, 40], ["EMD-22139", "CHEMICAL", 77, 86], ["EMPIAR-10440", "CHEMICAL", 166, 178], ["emodin", "SIMPLE_CHEMICAL", 34, 40], ["dimeric 3a", "PROTEIN", 4, 14], ["emodin", "TREATMENT", 34, 40]]]], "976f10c43bb5da18802d81b6c4a48fcb3c6a2732": [["IntroductionPig (Sus scrofa domesticus) was domesticated more than 9000 years ago in multiple areas of the world including the Near-Tigris Basin-and the Far East (Barrios-Rodiles et al., 2005; Epstein and Bichard, 1984) .", [["Sus scrofa domesticus", "ORGANISM", 17, 38], ["Sus", "SPECIES", 17, 20], ["scrofa domesticus", "SPECIES", 21, 38], ["Sus scrofa domesticus", "SPECIES", 17, 38]]], ["Pigs arrived in America with Hernando de Soto around 1539.", [["Pigs", "ORGANISM", 0, 4], ["Pigs", "SPECIES", 0, 4]]], ["Over the last few years the demand for pigs in biomedical research has considerably increased, particularly with the implementation of transgenesis and the release of the swine genome assembly 10.2 (Sscrofa10.2) (Dawson et al., 2013; Groenen et al., 2012) .", [["pigs", "ORGANISM", 39, 43], ["pigs", "SPECIES", 39, 43], ["pigs", "SPECIES", 39, 43], ["swine", "SPECIES", 171, 176], ["pigs", "TREATMENT", 39, 43], ["transgenesis", "TREATMENT", 135, 147], ["considerably", "OBSERVATION_MODIFIER", 71, 83], ["increased", "OBSERVATION_MODIFIER", 84, 93]]], ["The porcine immune system has been shown to be very similar to its human counterpart in terms of anatomy, organization, and response (Dawson, 2011; Dawson et al., 2013; Rothkotter, 2009) .", [["porcine", "ORGANISM", 4, 11], ["human", "ORGANISM", 67, 72], ["porcine", "SPECIES", 4, 11], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 67, 72], ["The porcine immune system", "TREATMENT", 0, 25], ["porcine immune", "OBSERVATION", 4, 18], ["anatomy", "OBSERVATION", 97, 104]]], ["However, to our knowledge there is no comprehensive review focusing specifically on the innate arm of the porcine immune system.", [["immune system", "ANATOMY", 114, 127], ["porcine", "ORGANISM", 106, 113], ["immune system", "ANATOMICAL_SYSTEM", 114, 127], ["porcine", "SPECIES", 106, 113], ["porcine", "SPECIES", 106, 113], ["no", "UNCERTAINTY", 35, 37]]], ["With the current review we aim at presenting the main features of the porcine innate immune system and at comparing it to its human counterpart.", [["porcine", "ORGANISM", 70, 77], ["human", "ORGANISM", 126, 131], ["human", "SPECIES", 126, 131], ["human", "SPECIES", 126, 131], ["the porcine innate immune system", "TREATMENT", 66, 98]]], ["We start with a brief section highlighting the relevance of the pig model, and then describe the main anatomical particularities of its innate immune system.", [["pig", "ORGANISM", 64, 67], ["immune system", "ANATOMICAL_SYSTEM", 143, 156], ["pig", "SPECIES", 64, 67], ["a brief section", "TREATMENT", 14, 29], ["the pig model", "TREATMENT", 60, 73], ["main", "OBSERVATION_MODIFIER", 97, 101]]], ["After we focus on the principal structures involved in the triggering of innate response, we present the main cellular and molecular players of both humoral and cellular responses, with the exception of cytokines, which already have been presented in other reviews.Introduction2.", [["cellular", "ANATOMY", 110, 118], ["cellular", "ANATOMY", 161, 169], ["cellular", "CELL", 110, 118], ["cellular", "CELL", 161, 169], ["cytokines", "PROTEIN", 203, 212], ["cytokines", "PROBLEM", 203, 212], ["main", "OBSERVATION_MODIFIER", 105, 109], ["both", "ANATOMY_MODIFIER", 144, 148], ["humoral", "ANATOMY", 149, 156], ["cellular responses", "OBSERVATION", 161, 179], ["cytokines", "OBSERVATION", 203, 212]]], ["Relevance of the pig as a large animal model to study the innate immune system Pigs are of proven relevance for use in the study of human health priorities such as obesity (Brambilla and Cantafora, 2004) , cardio-vascular disease (Boluyt et al., 2007) , nutritional studies (Puiman and Stoll, 2008) , and communicable diseases as pigs have anatomical (Swindle et al., 2012) and physiologic (Kuzmuk and Schook, 2011) characteristics comparable to humans.", [["vascular", "ANATOMY", 213, 221], ["obesity", "DISEASE", 164, 171], ["cardio-vascular disease", "DISEASE", 206, 229], ["communicable diseases", "DISEASE", 305, 326], ["pig", "ORGANISM", 17, 20], ["human", "ORGANISM", 132, 137], ["vascular", "MULTI-TISSUE_STRUCTURE", 213, 221], ["pigs", "ORGANISM", 330, 334], ["humans", "ORGANISM", 446, 452], ["pig", "SPECIES", 17, 20], ["human", "SPECIES", 132, 137], ["pigs", "SPECIES", 330, 334], ["humans", "SPECIES", 446, 452], ["pig", "SPECIES", 17, 20], ["human", "SPECIES", 132, 137], ["humans", "SPECIES", 446, 452], ["the pig", "TREATMENT", 13, 20], ["obesity", "PROBLEM", 164, 171], ["cardio-vascular disease", "PROBLEM", 206, 229], ["nutritional studies", "TEST", 254, 273], ["communicable diseases", "PROBLEM", 305, 326], ["obesity", "OBSERVATION", 164, 171], ["cardio", "ANATOMY", 206, 212], ["vascular", "ANATOMY", 213, 221], ["disease", "OBSERVATION", 222, 229]]], ["Due to their long-standing domestication (Barrios-Rodiles et al., 2005) , there is a substantial amount of information regarding their husbandry making them a particularly attractive animal model.", [["substantial", "OBSERVATION_MODIFIER", 85, 96], ["amount", "OBSERVATION_MODIFIER", 97, 103]]], ["As a litter bearing species with an average litter size of twelve and a gestation of 114 days, swine allow for models involving familial, gender, and sibling matching.", [["swine", "SPECIES", 95, 100], ["swine", "SPECIES", 95, 100], ["a litter bearing species", "PROBLEM", 3, 27], ["size", "OBSERVATION_MODIFIER", 51, 55]]], ["This relatively short gestational period affords the opportunity to enrol and follow to farrowing a reasonable number of pregnant sows.", [["sows", "ORGANISM", 130, 134]]], ["Postnatally, piglets grow rapidly reaching sexual maturity around 6 months of age (Reiland, 1978) .", [["piglets", "ORGANISM", 13, 20], ["piglets", "SPECIES", 13, 20], ["rapidly", "OBSERVATION_MODIFIER", 26, 33]]], ["The pig model enables clear discernment of maternal and foetal contributions to immune responses due to the epitheliochorial placenta (three maternal layers and three foetal layers) (Kim, 1975) , which prevents the transfer of maternal cells and immunoglobulins (Igs) into the embryo/foetus.", [["foetal", "ANATOMY", 56, 62], ["epitheliochorial placenta", "ANATOMY", 108, 133], ["foetal layers", "ANATOMY", 167, 180], ["cells", "ANATOMY", 236, 241], ["embryo", "ANATOMY", 277, 283], ["foetus", "ANATOMY", 284, 290], ["pig", "ORGANISM", 4, 7], ["foetal", "ORGANISM_SUBDIVISION", 56, 62], ["epitheliochorial placenta", "TISSUE", 108, 133], ["maternal layers", "TISSUE", 141, 156], ["foetal layers", "TISSUE", 167, 180], ["maternal cells", "CELL", 227, 241], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 246, 261], ["Igs", "GENE_OR_GENE_PRODUCT", 263, 266], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 277, 283], ["foetus", "ORGAN", 284, 290], ["maternal cells", "CELL_TYPE", 227, 241], ["immunoglobulins", "PROTEIN", 246, 261], ["Igs", "PROTEIN", 263, 266], ["pig", "SPECIES", 4, 7], ["pig", "SPECIES", 4, 7], ["maternal and foetal contributions", "PROBLEM", 43, 76], ["immune responses", "PROBLEM", 80, 96], ["the epitheliochorial placenta", "PROBLEM", 104, 133], ["maternal cells", "PROBLEM", 227, 241], ["immunoglobulins (Igs", "TREATMENT", 246, 266], ["the embryo/foetus", "PROBLEM", 273, 290], ["clear", "OBSERVATION", 22, 27], ["epitheliochorial placenta", "ANATOMY", 108, 133]]], ["Moreover, placenta and endometrium are easily separated allowing the interactions between each foetus and the uterus to be easily identified and analysed.", [["placenta", "ANATOMY", 10, 18], ["endometrium", "ANATOMY", 23, 34], ["foetus", "ANATOMY", 95, 101], ["uterus", "ANATOMY", 110, 116], ["placenta", "MULTI-TISSUE_STRUCTURE", 10, 18], ["endometrium", "MULTI-TISSUE_STRUCTURE", 23, 34], ["foetus", "ORGAN", 95, 101], ["uterus", "ORGAN", 110, 116], ["placenta", "ANATOMY", 10, 18], ["endometrium", "ANATOMY", 23, 34], ["uterus", "ANATOMY", 110, 116]]], ["Importantly, each foetus' placenta can be matched permitting correlation of placenta-specific differences with differences in the foetuses.", [["foetus' placenta", "ANATOMY", 18, 34], ["placenta", "ANATOMY", 76, 84], ["foetuses", "ANATOMY", 130, 138], ["placenta", "ORGAN", 26, 34], ["placenta", "TISSUE", 76, 84], ["foetuses", "ORGANISM", 130, 138], ["the foetuses", "PROBLEM", 126, 138], ["placenta", "ANATOMY", 26, 34], ["placenta", "OBSERVATION", 76, 84]]], ["Further, it has been shown that pig immune responses resemble humans for 80% of analysed parameters whereas mice are similar in less than 10% (Dawson, 2011; Dawson et al., 2013) .", [["pig", "ORGANISM", 32, 35], ["humans", "ORGANISM", 62, 68], ["mice", "ORGANISM", 108, 112], ["pig", "SPECIES", 32, 35], ["humans", "SPECIES", 62, 68], ["mice", "SPECIES", 108, 112], ["pig", "SPECIES", 32, 35], ["humans", "SPECIES", 62, 68], ["mice", "SPECIES", 108, 112]]], ["Although genetically modified mice have played a prominent and extremely valuable role in basic research, the results obtained from mice often failed translation into clinically relevant applications in humans.", [["mice", "ORGANISM", 30, 34], ["mice", "ORGANISM", 132, 136], ["humans", "ORGANISM", 203, 209], ["mice", "SPECIES", 30, 34], ["mice", "SPECIES", 132, 136], ["humans", "SPECIES", 203, 209], ["mice", "SPECIES", 30, 34], ["mice", "SPECIES", 132, 136], ["humans", "SPECIES", 203, 209]]], ["Moving beyond the mouse into the pig animal model should allow us better translation from the laboratory into clinical research.", [["mouse", "ORGANISM", 18, 23], ["pig", "ORGANISM", 33, 36], ["mouse", "SPECIES", 18, 23], ["pig", "SPECIES", 33, 36], ["mouse", "SPECIES", 18, 23], ["pig", "SPECIES", 33, 36], ["the pig animal model", "TREATMENT", 29, 49]]], ["For instance, because of its comparable size to humans, the pig may be a better model than the mouse for modelling radiation or photodynamic tumour therapy (Adam et al., 2006) .", [["tumour", "ANATOMY", 141, 147], ["tumour", "DISEASE", 141, 147], ["humans", "ORGANISM", 48, 54], ["pig", "ORGANISM", 60, 63], ["mouse", "ORGANISM", 95, 100], ["tumour", "CANCER", 141, 147], ["humans", "SPECIES", 48, 54], ["pig", "SPECIES", 60, 63], ["mouse", "SPECIES", 95, 100], ["humans", "SPECIES", 48, 54], ["pig", "SPECIES", 60, 63], ["mouse", "SPECIES", 95, 100], ["the pig", "TREATMENT", 56, 63], ["modelling radiation", "TREATMENT", 105, 124], ["photodynamic tumour therapy", "TREATMENT", 128, 155], ["size", "OBSERVATION_MODIFIER", 40, 44]]], ["Indeed, in this species scaling of energy dose and tumour size is easier.", [["tumour", "ANATOMY", 51, 57], ["tumour", "DISEASE", 51, 57], ["tumour", "CANCER", 51, 57], ["tumour", "OBSERVATION", 51, 57], ["size", "OBSERVATION_MODIFIER", 58, 62]]], ["Therefore, the pig has definitely many advantages as an animal model.", [["pig", "ORGANISM", 15, 18], ["pig", "SPECIES", 15, 18], ["pig", "SPECIES", 15, 18], ["the pig", "TREATMENT", 11, 18]]], ["Table 1 Pros and cons for the use of the pig model.Introduction-All season breeding species -Large litter size (10-12 piglets/litter), 24-36 piglets/year -Gestation (115 days) -Short generation interval (12 months) -Lifespan (10-20 years) -Omnivorous like humans -Size, similar to humans, especially miniature Hanford pig -Various surgical procedures can be performed and many samples can be collected -Availability, outbred and inbred, more than 500 breeds -Breeding conditions are very standardized -High genome and protein sequence homologies with humans -More tools available -Cheaper and ethically more acceptable than primates -Required bigger and more expensive facilities than mouse -Still some differences with humans -Still limited access to inbred pigs for basic research -Less close to humans than monkeys -More expensive than mice -Less tools than mice -Ethically a little bit less accepted than mice -Genome still not fully annotated -Pig research community smaller than its mouse counterpart 2.1.", [["pig", "ORGANISM", 41, 44], ["litter", "ORGANISM_SUBDIVISION", 99, 105], ["piglets", "ORGANISM", 118, 125], ["piglets", "ORGANISM", 141, 148], ["humans", "ORGANISM", 256, 262], ["humans", "ORGANISM", 281, 287], ["pig", "ORGANISM", 318, 321], ["humans", "ORGANISM", 551, 557], ["mouse", "ORGANISM", 685, 690], ["humans", "ORGANISM", 720, 726], ["pigs", "ORGANISM", 759, 763], ["humans", "ORGANISM", 798, 804], ["monkeys", "ORGANISM", 810, 817], ["mice", "ORGANISM", 839, 843], ["mice", "ORGANISM", 861, 865], ["mice", "ORGANISM", 909, 913], ["Pig", "ORGANISM", 949, 952], ["mouse", "ORGANISM", 989, 994], ["piglets", "SPECIES", 141, 148], ["humans", "SPECIES", 256, 262], ["humans", "SPECIES", 281, 287], ["pig", "SPECIES", 318, 321], ["humans", "SPECIES", 551, 557], ["mouse", "SPECIES", 685, 690], ["humans", "SPECIES", 720, 726], ["pigs", "SPECIES", 759, 763], ["humans", "SPECIES", 798, 804], ["mice", "SPECIES", 839, 843], ["mice", "SPECIES", 861, 865], ["mice", "SPECIES", 909, 913], ["mouse", "SPECIES", 989, 994], ["pig", "SPECIES", 41, 44], ["humans", "SPECIES", 256, 262], ["humans", "SPECIES", 281, 287], ["pig", "SPECIES", 318, 321], ["humans", "SPECIES", 551, 557], ["mouse", "SPECIES", 685, 690], ["humans", "SPECIES", 720, 726], ["pigs", "SPECIES", 759, 763], ["humans", "SPECIES", 798, 804], ["mice", "SPECIES", 839, 843], ["mice", "SPECIES", 861, 865], ["mice", "SPECIES", 909, 913], ["mouse", "SPECIES", 989, 994], ["the pig model", "TREATMENT", 37, 50], ["Large litter size", "PROBLEM", 93, 110], ["Various surgical procedures", "TREATMENT", 323, 350], ["High genome and protein sequence homologies", "PROBLEM", 502, 545], ["Cheaper", "TREATMENT", 581, 588], ["inbred pigs", "TREATMENT", 752, 763], ["basic research", "TREATMENT", 768, 782], ["Large", "OBSERVATION_MODIFIER", 93, 98], ["litter", "OBSERVATION_MODIFIER", 99, 105], ["size", "OBSERVATION_MODIFIER", 106, 110], ["Size", "OBSERVATION_MODIFIER", 264, 268]]], ["Anatomical particularities of the porcine immune system Since a comprehensive review on that specific subject has already been published (Rothkotter, 2009) , only the main anatomical particularities of the porcine immune system will be briefly presented in this section.", [["porcine", "ORGANISM", 34, 41], ["porcine", "ORGANISM", 206, 213], ["porcine immune", "OBSERVATION", 34, 48], ["main", "OBSERVATION_MODIFIER", 167, 171], ["porcine immune", "OBSERVATION", 206, 220]]], ["The porcine thymus is similar to the thymus of other mammals (Rothkotter, 2009; Swindle et al., 2012) acting as a primary lymphoid organ principally involved in primary T cell development ).", [["thymus", "ANATOMY", 12, 18], ["thymus", "ANATOMY", 37, 43], ["lymphoid organ", "ANATOMY", 122, 136], ["primary T cell", "ANATOMY", 161, 175], ["porcine", "ORGANISM", 4, 11], ["thymus", "ORGAN", 12, 18], ["thymus", "ORGAN", 37, 43], ["lymphoid", "MULTI-TISSUE_STRUCTURE", 122, 130], ["organ", "ORGAN", 131, 136], ["T cell", "CELL", 169, 175], ["porcine", "SPECIES", 4, 11], ["a primary lymphoid organ", "PROBLEM", 112, 136], ["porcine thymus", "OBSERVATION", 4, 18], ["similar", "OBSERVATION_MODIFIER", 22, 29], ["thymus", "ANATOMY", 37, 43], ["lymphoid organ", "OBSERVATION", 122, 136], ["cell", "OBSERVATION", 171, 175]]], ["Its' size and surgical accessibility has enabled numerous studies about thymic lymphocyte immigration and emigration ).", [["thymic lymphocyte", "ANATOMY", 72, 89], ["thymic lymphocyte", "CELL", 72, 89], ["numerous studies", "TEST", 49, 65], ["thymic lymphocyte immigration", "TREATMENT", 72, 101], ["size", "OBSERVATION_MODIFIER", 5, 9], ["surgical accessibility", "OBSERVATION", 14, 36], ["thymic lymphocyte immigration", "OBSERVATION", 72, 101]]], ["Lymphoid tissues associated to the oral cavity and upper respiratory tracts are anatomically similar in pigs and humans.", [["Lymphoid tissues", "ANATOMY", 0, 16], ["oral cavity", "ANATOMY", 35, 46], ["upper respiratory tracts", "ANATOMY", 51, 75], ["Lymphoid tissues", "TISSUE", 0, 16], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 35, 46], ["upper respiratory", "ORGANISM_SUBDIVISION", 51, 68], ["tracts", "PATHOLOGICAL_FORMATION", 69, 75], ["pigs", "ORGANISM", 104, 108], ["humans", "ORGANISM", 113, 119], ["pigs", "SPECIES", 104, 108], ["humans", "SPECIES", 113, 119], ["pigs", "SPECIES", 104, 108], ["humans", "SPECIES", 113, 119], ["Lymphoid tissues", "PROBLEM", 0, 16], ["the oral cavity and upper respiratory tracts", "PROBLEM", 31, 75], ["oral cavity", "ANATOMY", 35, 46], ["upper", "ANATOMY_MODIFIER", 51, 56], ["respiratory tracts", "ANATOMY", 57, 75], ["anatomically", "OBSERVATION_MODIFIER", 80, 92], ["similar", "OBSERVATION_MODIFIER", 93, 100]]], ["For example, the human Waldeyer's ring most closely resembles the anatomical arrangement of the porcine lymphoid tissues in the nasopharynx (Horter et al., 2003) .", [["Waldeyer's ring", "ANATOMY", 23, 38], ["lymphoid tissues", "ANATOMY", 104, 120], ["nasopharynx", "ANATOMY", 128, 139], ["human", "ORGANISM", 17, 22], ["porcine", "ORGANISM", 96, 103], ["lymphoid tissues", "TISSUE", 104, 120], ["nasopharynx", "ORGAN", 128, 139], ["human", "SPECIES", 17, 22], ["human", "SPECIES", 17, 22], ["the human Waldeyer's ring", "TREATMENT", 13, 38], ["anatomical arrangement", "OBSERVATION", 66, 88], ["porcine lymphoid tissues", "OBSERVATION", 96, 120], ["nasopharynx", "ANATOMY", 128, 139]]], ["Unlike mice where these organs are absent, pigs possess palatine and pharyngeal tonsils.", [["organs", "ANATOMY", 24, 30], ["palatine", "ANATOMY", 56, 64], ["pharyngeal tonsils", "ANATOMY", 69, 87], ["mice", "ORGANISM", 7, 11], ["organs", "ORGAN", 24, 30], ["pigs", "ORGANISM", 43, 47], ["palatine", "ORGAN", 56, 64], ["pharyngeal tonsils", "MULTI-TISSUE_STRUCTURE", 69, 87], ["mice", "SPECIES", 7, 11], ["pigs", "SPECIES", 43, 47], ["mice", "SPECIES", 7, 11], ["pigs", "SPECIES", 43, 47], ["organs", "ANATOMY", 24, 30], ["palatine", "ANATOMY", 56, 64], ["pharyngeal tonsils", "ANATOMY", 69, 87]]], ["Their spleen is tightly attached to the stomach by the short gastric blood vessels and therefore is not as pedunculate as it is in species like dog.", [["spleen", "ANATOMY", 6, 12], ["stomach", "ANATOMY", 40, 47], ["gastric blood vessels", "ANATOMY", 61, 82], ["spleen", "ORGAN", 6, 12], ["stomach", "ORGAN", 40, 47], ["gastric blood vessels", "MULTI-TISSUE_STRUCTURE", 61, 82], ["dog", "ORGANISM", 144, 147], ["dog", "SPECIES", 144, 147], ["spleen", "ANATOMY", 6, 12], ["tightly", "OBSERVATION_MODIFIER", 16, 23], ["attached", "OBSERVATION", 24, 32], ["stomach", "ANATOMY", 40, 47], ["short", "OBSERVATION_MODIFIER", 55, 60], ["gastric", "ANATOMY", 61, 68], ["blood vessels", "ANATOMY", 69, 82]]], ["Because of its similarities with human spleen, pigs have been used extensively to assess the impact of splenectomy (Reihner and Brismar, 1995; Rothkotter, 2009 ).", [["spleen", "ANATOMY", 39, 45], ["human", "ORGANISM", 33, 38], ["spleen", "ORGAN", 39, 45], ["pigs", "ORGANISM", 47, 51], ["human", "SPECIES", 33, 38], ["pigs", "SPECIES", 47, 51], ["human", "SPECIES", 33, 38], ["pigs", "SPECIES", 47, 51], ["pigs", "TREATMENT", 47, 51], ["splenectomy", "TREATMENT", 103, 114], ["spleen", "ANATOMY", 39, 45], ["splenectomy", "OBSERVATION", 103, 114]]], ["The porcine peripheral and mucosaassociated lymph nodes have a specific structure that is called inverted (Rothkotter, 2009 ), a general organisation that is shared with the rhinoceros, the dolphin, and the elephant.", [["peripheral", "ANATOMY", 12, 22], ["lymph nodes", "ANATOMY", 44, 55], ["porcine", "ORGANISM", 4, 11], ["peripheral", "TISSUE", 12, 22], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 44, 55], ["rhinoceros", "ORGANISM_SUBDIVISION", 174, 184], ["dolphin", "ORGANISM", 190, 197], ["The porcine peripheral and mucosaassociated lymph nodes", "PROBLEM", 0, 55], ["porcine", "OBSERVATION_MODIFIER", 4, 11], ["peripheral", "OBSERVATION_MODIFIER", 12, 22], ["mucosaassociated", "OBSERVATION_MODIFIER", 27, 43], ["lymph nodes", "OBSERVATION", 44, 55], ["elephant", "OBSERVATION_MODIFIER", 207, 215]]], ["The lymph nodes lack a larger medullary area and are preferentially composed of cortical areas and paracortex and the majority of the lymphocytes exit in the blood directly.", [["lymph nodes", "ANATOMY", 4, 15], ["medullary area", "ANATOMY", 30, 44], ["cortical areas", "ANATOMY", 80, 94], ["paracortex", "ANATOMY", 99, 109], ["lymphocytes", "ANATOMY", 134, 145], ["blood", "ANATOMY", 158, 163], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 4, 15], ["medullary area", "CANCER", 30, 44], ["cortical areas", "MULTI-TISSUE_STRUCTURE", 80, 94], ["paracortex", "CANCER", 99, 109], ["lymphocytes", "CELL", 134, 145], ["blood", "ORGANISM_SUBSTANCE", 158, 163], ["lymphocytes", "CELL_TYPE", 134, 145], ["a larger medullary area", "PROBLEM", 21, 44], ["lymph nodes", "OBSERVATION", 4, 15], ["larger", "OBSERVATION_MODIFIER", 23, 29], ["medullary", "ANATOMY", 30, 39], ["area", "ANATOMY_MODIFIER", 40, 44], ["cortical", "ANATOMY_MODIFIER", 80, 88], ["areas", "ANATOMY_MODIFIER", 89, 94], ["paracortex", "ANATOMY_MODIFIER", 99, 109], ["majority", "OBSERVATION_MODIFIER", 118, 126], ["lymphocytes", "OBSERVATION", 134, 145], ["blood", "ANATOMY", 158, 163]]], ["The reason for developing and flourishing with an inverted lymph node structure still remains unclear and calls for further research.", [["lymph node", "ANATOMY", 59, 69], ["lymph node", "MULTI-TISSUE_STRUCTURE", 59, 69], ["an inverted lymph node structure", "PROBLEM", 47, 79], ["lymph node", "OBSERVATION", 59, 69]]], ["Lymphoid tissue is also present in the small intestine wall as single follicles or as aggregated lymphoid follicles named Peyer's patches (PP) in reference to Johan Conrad Peyer (Schaffhausen, Switzerland, 17th century).", [["Lymphoid tissue", "ANATOMY", 0, 15], ["small intestine wall", "ANATOMY", 39, 59], ["follicles", "ANATOMY", 70, 79], ["lymphoid follicles", "ANATOMY", 97, 115], ["Lymphoid tissue", "TISSUE", 0, 15], ["intestine wall", "MULTI-TISSUE_STRUCTURE", 45, 59], ["follicles", "MULTI-TISSUE_STRUCTURE", 70, 79], ["lymphoid follicles", "MULTI-TISSUE_STRUCTURE", 97, 115], ["PP", "MULTI-TISSUE_STRUCTURE", 139, 141], ["Lymphoid tissue", "PROBLEM", 0, 15], ["single follicles", "PROBLEM", 63, 79], ["tissue", "OBSERVATION", 9, 15], ["small", "ANATOMY_MODIFIER", 39, 44], ["intestine", "ANATOMY", 45, 54], ["wall", "ANATOMY_MODIFIER", 55, 59], ["single", "OBSERVATION_MODIFIER", 63, 69], ["follicles", "OBSERVATION", 70, 79], ["lymphoid follicles", "OBSERVATION", 97, 115]]], ["Two types of PPs are described in pigs; jejunal (JPP) and ileal PPs (IPP).", [["jejunal", "ANATOMY", 40, 47], ["ileal PPs", "ANATOMY", 58, 67], ["PPs", "MULTI-TISSUE_STRUCTURE", 13, 16], ["pigs", "ORGANISM", 34, 38], ["jejunal", "MULTI-TISSUE_STRUCTURE", 40, 47], ["JPP", "MULTI-TISSUE_STRUCTURE", 49, 52], ["ileal PPs", "MULTI-TISSUE_STRUCTURE", 58, 67], ["IPP", "SIMPLE_CHEMICAL", 69, 72], ["pigs", "SPECIES", 34, 38], ["PPs", "TREATMENT", 13, 16], ["jejunal (JPP)", "TREATMENT", 40, 53], ["ileal PPs (IPP", "TREATMENT", 58, 72], ["PPs", "OBSERVATION", 13, 16], ["jejunal", "ANATOMY", 40, 47], ["ileal PPs", "ANATOMY", 58, 67]]], ["Unlike the Bursa of Fabricus (chicken) and IPP in sheep (Gerber et al., 1986) , porcine IPP are not primary lymphoid organs (Butler and Sinkora, 2013; Sinkora et al., 2000b) as they are neither required to maintain the systemic B cell pool nor are they a site of B cell lymphogenesis.Pattern recognition receptors and inflammationPattern recognition receptors (PRRs) are evolutionarily conserved, germline-encoded host sensors mainly expressed on innate immune cells such as dendritic cells, macrophages, and neutrophils (Kumar et al., 2011) .", [["primary lymphoid organs", "ANATOMY", 100, 123], ["B cell", "ANATOMY", 228, 234], ["B cell", "ANATOMY", 263, 269], ["immune cells", "ANATOMY", 454, 466], ["dendritic cells", "ANATOMY", 475, 490], ["macrophages", "ANATOMY", 492, 503], ["neutrophils", "ANATOMY", 509, 520], ["IPP", "CHEMICAL", 43, 46], ["inflammation", "DISEASE", 318, 330], ["Fabricus", "GENE_OR_GENE_PRODUCT", 20, 28], ["chicken", "ORGANISM", 30, 37], ["IPP", "SIMPLE_CHEMICAL", 43, 46], ["sheep", "ORGANISM", 50, 55], ["porcine", "ORGANISM", 80, 87], ["IPP", "SIMPLE_CHEMICAL", 88, 91], ["lymphoid organs", "TISSUE", 108, 123], ["B cell", "CELL", 228, 234], ["B cell", "CELL", 263, 269], ["Pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 284, 313], ["Pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 330, 359], ["PRRs", "GENE_OR_GENE_PRODUCT", 361, 365], ["innate immune cells", "CELL", 447, 466], ["dendritic cells", "CELL", 475, 490], ["macrophages", "CELL", 492, 503], ["neutrophils", "CELL", 509, 520], ["systemic B cell pool", "CELL_TYPE", 219, 239], ["Pattern recognition receptors", "PROTEIN", 284, 313], ["Pattern recognition receptors", "PROTEIN", 330, 359], ["PRRs", "PROTEIN", 361, 365], ["germline", "DNA", 397, 405], ["innate immune cells", "CELL_TYPE", 447, 466], ["dendritic cells", "CELL_TYPE", 475, 490], ["macrophages", "CELL_TYPE", 492, 503], ["neutrophils", "CELL_TYPE", 509, 520], ["chicken", "SPECIES", 30, 37], ["sheep", "SPECIES", 50, 55], ["porcine", "SPECIES", 80, 87], ["chicken", "SPECIES", 30, 37], ["sheep", "SPECIES", 50, 55], ["porcine", "SPECIES", 80, 87], ["porcine IPP", "TREATMENT", 80, 91], ["B cell lymphogenesis", "PROBLEM", 263, 283], ["Pattern recognition receptors", "PROBLEM", 284, 313], ["inflammation", "PROBLEM", 318, 330], ["dendritic cells", "PROBLEM", 475, 490], ["macrophages", "PROBLEM", 492, 503], ["neutrophils", "TEST", 509, 520], ["Bursa", "ANATOMY", 11, 16], ["not", "UNCERTAINTY", 96, 99], ["primary lymphoid organs", "OBSERVATION", 100, 123], ["B cell lymphogenesis", "OBSERVATION", 263, 283], ["inflammation", "OBSERVATION", 318, 330], ["dendritic cells", "OBSERVATION", 475, 490], ["macrophages", "ANATOMY", 492, 503], ["neutrophils", "ANATOMY", 509, 520]]], ["Recent data provide evidence that they also play a role in cells from the adaptive immune system such as T cells.", [["cells", "ANATOMY", 59, 64], ["immune system", "ANATOMY", 83, 96], ["T cells", "ANATOMY", 105, 112], ["cells", "CELL", 59, 64], ["T cells", "CELL", 105, 112], ["T cells", "CELL_TYPE", 105, 112], ["a role in cells", "PROBLEM", 49, 64]]], ["PRRs detect pathogen-associated molecular patterns (PAMPs) expressed by pathogens as well as commensal flora.", [["pathogen-associated molecular patterns", "GENE_OR_GENE_PRODUCT", 12, 50], ["PAMPs", "GENE_OR_GENE_PRODUCT", 52, 57], ["PRRs", "PROTEIN", 0, 4], ["pathogen-associated molecular patterns", "PROTEIN", 12, 50], ["PAMPs", "PROTEIN", 52, 57], ["pathogen", "PROBLEM", 12, 20], ["pathogens", "PROBLEM", 72, 81], ["commensal flora", "PROBLEM", 93, 108], ["flora", "OBSERVATION", 103, 108]]], ["PRRs include different classes of cellular receptors: The Toll-like receptors (TLRs), the nucleotide-binding oligomerization domain (NODs)-like receptors (NLRs), the retinoic acid-inducible gene (RIG)-I-like receptors (RLRs), membrane C-type lectin receptors (CLRs), and DNA receptors (cytosolic sensors for DNA) (Kumar et al., 2011) .", [["cellular", "ANATOMY", 34, 42], ["cytosolic", "ANATOMY", 286, 295], ["nucleotide", "CHEMICAL", 90, 100], ["nucleotide", "CHEMICAL", 90, 100], ["cellular", "CELL", 34, 42], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 58, 77], ["TLRs", "GENE_OR_GENE_PRODUCT", 79, 83], ["nucleotide-binding oligomerization domain (NODs)-like receptors", "GENE_OR_GENE_PRODUCT", 90, 153], ["NLRs", "GENE_OR_GENE_PRODUCT", 155, 159], ["retinoic acid-inducible gene (RIG)-I-like receptors", "GENE_OR_GENE_PRODUCT", 166, 217], ["RLRs", "GENE_OR_GENE_PRODUCT", 219, 223], ["membrane C-type lectin receptors", "GENE_OR_GENE_PRODUCT", 226, 258], ["CLRs", "GENE_OR_GENE_PRODUCT", 260, 264], ["DNA", "CELLULAR_COMPONENT", 271, 274], ["DNA", "CELLULAR_COMPONENT", 308, 311], ["PRRs", "PROTEIN", 0, 4], ["cellular receptors", "PROTEIN", 34, 52], ["Toll-like receptors", "PROTEIN", 58, 77], ["TLRs", "PROTEIN", 79, 83], ["nucleotide-binding oligomerization domain (NODs)-like receptors", "PROTEIN", 90, 153], ["NLRs", "PROTEIN", 155, 159], ["retinoic acid-inducible gene (RIG)-I-like receptors", "PROTEIN", 166, 217], ["RLRs", "PROTEIN", 219, 223], ["membrane C-type lectin receptors", "PROTEIN", 226, 258], ["CLRs", "PROTEIN", 260, 264], ["DNA receptors", "PROTEIN", 271, 284], ["the nucleotide-binding oligomerization domain", "TEST", 86, 131], ["the retinoic acid-inducible gene (RIG)-I-like receptors", "PROBLEM", 162, 217], ["RLRs", "TEST", 219, 223], ["membrane C-type lectin receptors", "PROBLEM", 226, 258], ["DNA receptors", "PROBLEM", 271, 284], ["cellular receptors", "OBSERVATION", 34, 52]]], ["Additionally, PAMPs can also be bound by soluble PRRs such as surfactant proteins (SPs) and mannan-binding lectins (MBLs).Toll-like receptorsToll-like receptors are the best studied PRRs and to date twelve functional TLRs are known in mice and ten in humans.", [["PAMPs", "GENE_OR_GENE_PRODUCT", 14, 19], ["surfactant proteins", "GENE_OR_GENE_PRODUCT", 62, 81], ["SPs", "GENE_OR_GENE_PRODUCT", 83, 86], ["mannan-binding lectins", "GENE_OR_GENE_PRODUCT", 92, 114], ["MBLs", "GENE_OR_GENE_PRODUCT", 116, 120], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 122, 141], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 141, 160], ["PRRs", "GENE_OR_GENE_PRODUCT", 182, 186], ["TLRs", "GENE_OR_GENE_PRODUCT", 217, 221], ["mice", "ORGANISM", 235, 239], ["humans", "ORGANISM", 251, 257], ["PAMPs", "PROTEIN", 14, 19], ["soluble PRRs", "PROTEIN", 41, 53], ["surfactant proteins", "PROTEIN", 62, 81], ["SPs", "PROTEIN", 83, 86], ["mannan-binding lectins", "PROTEIN", 92, 114], ["MBLs", "PROTEIN", 116, 120], ["Toll-like receptors", "PROTEIN", 122, 141], ["Toll-like receptors", "PROTEIN", 141, 160], ["PRRs", "PROTEIN", 182, 186], ["TLRs", "PROTEIN", 217, 221], ["mice", "SPECIES", 235, 239], ["humans", "SPECIES", 251, 257], ["mice", "SPECIES", 235, 239], ["humans", "SPECIES", 251, 257], ["PAMPs", "PROBLEM", 14, 19], ["soluble PRRs", "TREATMENT", 41, 53], ["surfactant proteins", "TREATMENT", 62, 81]]], ["TLR1-10 are also known in swine and therefore, this section focusses on these TLRs.", [["TLR1-10", "GENE_OR_GENE_PRODUCT", 0, 7], ["swine", "ORGANISM", 26, 31], ["TLRs", "GENE_OR_GENE_PRODUCT", 78, 82], ["TLR1", "PROTEIN", 0, 4], ["TLRs", "PROTEIN", 78, 82], ["swine", "SPECIES", 26, 31], ["swine", "SPECIES", 26, 31]]], ["TLRs are type I membrane glycoproteins that recognize extracellular or endosomal/endolysosomal PAMPs via leucine rich repeats (LRRs).", [["extracellular", "ANATOMY", 54, 67], ["endosomal", "ANATOMY", 71, 80], ["endolysosomal", "ANATOMY", 81, 94], ["leucine", "CHEMICAL", 105, 112], ["leucine", "CHEMICAL", 105, 112], ["TLRs", "GENE_OR_GENE_PRODUCT", 0, 4], ["type I membrane glycoproteins", "GENE_OR_GENE_PRODUCT", 9, 38], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 54, 67], ["endosomal", "CELLULAR_COMPONENT", 71, 80], ["endolysosomal", "CELLULAR_COMPONENT", 81, 94], ["leucine", "AMINO_ACID", 105, 112], ["TLRs", "PROTEIN", 0, 4], ["type I membrane glycoproteins", "PROTEIN", 9, 38], ["extracellular or endosomal/endolysosomal PAMPs", "PROTEIN", 54, 100], ["leucine rich repeats", "PROTEIN", 105, 125], ["LRRs", "PROTEIN", 127, 131], ["type I membrane glycoproteins", "PROBLEM", 9, 38], ["endosomal/endolysosomal PAMPs", "TREATMENT", 71, 100]]], ["They can form homodimers 7, 9) , heterodimers (TLR1 and TLR6 with TLR2) or complex with other factors (i.e. TLR4 can complex with myeloid differentiation factor 2 -MD2-and CD14) to sense pathogens.", [["TLR1", "GENE_OR_GENE_PRODUCT", 47, 51], ["TLR6", "GENE_OR_GENE_PRODUCT", 56, 60], ["TLR2", "GENE_OR_GENE_PRODUCT", 66, 70], ["TLR4", "GENE_OR_GENE_PRODUCT", 108, 112], ["myeloid differentiation factor 2", "GENE_OR_GENE_PRODUCT", 130, 162], ["MD2", "GENE_OR_GENE_PRODUCT", 164, 167], ["CD14", "GENE_OR_GENE_PRODUCT", 172, 176], ["homodimers 7, 9", "PROTEIN", 14, 29], ["heterodimers", "PROTEIN", 33, 45], ["TLR1", "PROTEIN", 47, 51], ["TLR6", "PROTEIN", 56, 60], ["TLR2", "PROTEIN", 66, 70], ["TLR4", "PROTEIN", 108, 112], ["myeloid differentiation factor 2", "PROTEIN", 130, 162], ["MD2", "PROTEIN", 164, 167], ["CD14", "PROTEIN", 172, 176], ["homodimers", "TEST", 14, 24], ["heterodimers (TLR1 and TLR6 with TLR2)", "TREATMENT", 33, 71], ["other factors", "PROBLEM", 88, 101], ["myeloid differentiation factor", "TEST", 130, 160], ["MD2", "TEST", 164, 167], ["sense pathogens", "PROBLEM", 181, 196]]], ["After ligand binding, TLRs initiate downstream signalling cascades through a cytoplasmic Toll/interleukin-1 receptor (TIR) domain depending on the recognized pathogen and its location (Kumar et al., 2011) .", [["cytoplasmic", "ANATOMY", 77, 88], ["TLRs", "GENE_OR_GENE_PRODUCT", 22, 26], ["cytoplasmic", "ORGANISM_SUBSTANCE", 77, 88], ["interleukin-1 receptor", "GENE_OR_GENE_PRODUCT", 94, 116], ["TIR", "GENE_OR_GENE_PRODUCT", 118, 121], ["TLRs", "PROTEIN", 22, 26], ["cytoplasmic Toll/interleukin-1 receptor (TIR) domain", "PROTEIN", 77, 129], ["downstream signalling cascades", "TREATMENT", 36, 66], ["a cytoplasmic Toll/interleukin-1 receptor (TIR) domain", "TREATMENT", 75, 129]]], ["Extracellular PAMPs (e.g. LPS, lipopeptides or flaggelin) from bacteria, fungi and protozoa are recognized by TLRs expressed on the cell surface such as TLR1, 2, 4, 5 and 6 followed by downstream signalling through the myeloid differentiation primary response gene 88 (MyD88) to translocate nuclear factor kappa B (NFjB) to the nucleus and enable the production of inflammatory cytokines.", [["Extracellular", "ANATOMY", 0, 13], ["cell surface", "ANATOMY", 132, 144], ["nucleus", "ANATOMY", 328, 335], ["LPS", "CHEMICAL", 26, 29], ["flaggelin", "CHEMICAL", 47, 56], ["Extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 13], ["LPS", "SIMPLE_CHEMICAL", 26, 29], ["flaggelin", "GENE_OR_GENE_PRODUCT", 47, 56], ["TLRs", "GENE_OR_GENE_PRODUCT", 110, 114], ["cell surface", "CELLULAR_COMPONENT", 132, 144], ["TLR1", "GENE_OR_GENE_PRODUCT", 153, 157], ["2", "GENE_OR_GENE_PRODUCT", 159, 160], ["4", "GENE_OR_GENE_PRODUCT", 162, 163], ["5", "GENE_OR_GENE_PRODUCT", 165, 166], ["6", "GENE_OR_GENE_PRODUCT", 171, 172], ["myeloid differentiation primary response gene 88", "GENE_OR_GENE_PRODUCT", 219, 267], ["MyD88", "GENE_OR_GENE_PRODUCT", 269, 274], ["nuclear factor kappa B", "GENE_OR_GENE_PRODUCT", 291, 313], ["NFjB", "GENE_OR_GENE_PRODUCT", 315, 319], ["nucleus", "CELLULAR_COMPONENT", 328, 335], ["Extracellular PAMPs", "PROTEIN", 0, 19], ["TLRs", "PROTEIN", 110, 114], ["TLR1, 2, 4, 5 and 6", "PROTEIN", 153, 172], ["myeloid differentiation primary response gene 88", "DNA", 219, 267], ["MyD88", "DNA", 269, 274], ["nuclear factor kappa B", "PROTEIN", 291, 313], ["NFjB", "PROTEIN", 315, 319], ["inflammatory cytokines", "PROTEIN", 365, 387], ["Extracellular PAMPs", "TEST", 0, 19], ["LPS", "PROBLEM", 26, 29], ["lipopeptides", "PROBLEM", 31, 43], ["flaggelin", "PROBLEM", 47, 56], ["bacteria", "PROBLEM", 63, 71], ["fungi", "PROBLEM", 73, 78], ["protozoa", "PROBLEM", 83, 91], ["the cell surface", "TEST", 128, 144], ["TLR1", "TEST", 153, 157], ["nuclear factor kappa", "TEST", 291, 311], ["inflammatory cytokines", "PROBLEM", 365, 387], ["PAMPs", "OBSERVATION", 14, 19], ["TLR1", "ANATOMY_MODIFIER", 153, 157], ["myeloid differentiation", "OBSERVATION", 219, 242], ["nucleus", "ANATOMY", 328, 335], ["inflammatory cytokines", "OBSERVATION", 365, 387]]], ["TLR4 can also signal through TIR-domain-containing adapter-inducing interferon-b (TRIF) and the interferon regulatory factors (IRF) 3/7 to induce type I interferon (IFN) production to combat pathogens.", [["TLR4", "GENE_OR_GENE_PRODUCT", 0, 4], ["TIR-domain-containing adapter-inducing interferon-b", "GENE_OR_GENE_PRODUCT", 29, 80], ["TRIF", "GENE_OR_GENE_PRODUCT", 82, 86], ["interferon regulatory factors", "GENE_OR_GENE_PRODUCT", 96, 125], ["IRF) 3/7", "GENE_OR_GENE_PRODUCT", 127, 135], ["type I interferon", "GENE_OR_GENE_PRODUCT", 146, 163], ["IFN", "GENE_OR_GENE_PRODUCT", 165, 168], ["TLR4", "PROTEIN", 0, 4], ["TIR-domain-containing adapter-inducing interferon-b", "PROTEIN", 29, 80], ["TRIF", "PROTEIN", 82, 86], ["interferon regulatory factors (IRF) 3/7", "PROTEIN", 96, 135], ["type I interferon", "PROTEIN", 146, 163], ["IFN", "PROTEIN", 165, 168], ["adapter", "TREATMENT", 51, 58], ["interferon-b (TRIF)", "TREATMENT", 68, 87], ["the interferon regulatory factors", "TREATMENT", 92, 125], ["type I interferon (IFN)", "TREATMENT", 146, 169], ["pathogens", "PROBLEM", 191, 200]]], ["TLR10 can be expressed both on the cell surface as well as intracellularly in epithelial cells.", [["cell surface", "ANATOMY", 35, 47], ["epithelial cells", "ANATOMY", 78, 94], ["TLR10", "GENE_OR_GENE_PRODUCT", 0, 5], ["cell surface", "CELLULAR_COMPONENT", 35, 47], ["epithelial cells", "CELL", 78, 94], ["TLR10", "PROTEIN", 0, 5], ["epithelial cells", "CELL_TYPE", 78, 94], ["TLR10", "TREATMENT", 0, 5], ["both", "OBSERVATION_MODIFIER", 23, 27], ["epithelial cells", "OBSERVATION", 78, 94]]], ["Signalling is thought to involve MyD88.", [["MyD88", "GENE_OR_GENE_PRODUCT", 33, 38], ["MyD88", "PROTEIN", 33, 38]]], ["Although the specific ligand for TLR10 is so far not determined ) a novel study from Regan et al. found TLR10 involved in sensing and responding to the cell-invasive pathogen Listeria monocytogenes (Regan et al., 2013) .", [["cell", "ANATOMY", 152, 156], ["TLR10", "GENE_OR_GENE_PRODUCT", 33, 38], ["TLR10", "GENE_OR_GENE_PRODUCT", 104, 109], ["cell", "CELL", 152, 156], ["Listeria monocytogenes", "ORGANISM", 175, 197], ["TLR10", "PROTEIN", 33, 38], ["TLR10", "PROTEIN", 104, 109], ["Listeria monocytogenes", "SPECIES", 175, 197], ["Listeria monocytogenes", "SPECIES", 175, 197], ["a novel study", "TEST", 66, 79]]], ["TLR3, 7, 8, and 9 are classically but not exclusively (Ioannidis et al., 2013) expressed intracellularly and mainly recognize nucleic acids from viruses and intracellular bacteria in endosomes or endolysosomes.", [["intracellular", "ANATOMY", 157, 170], ["endosomes", "ANATOMY", 183, 192], ["endolysosomes", "ANATOMY", 196, 209], ["nucleic acids", "CHEMICAL", 126, 139], ["TLR3", "GENE_OR_GENE_PRODUCT", 0, 4], ["7", "GENE_OR_GENE_PRODUCT", 6, 7], ["8", "GENE_OR_GENE_PRODUCT", 9, 10], ["9", "GENE_OR_GENE_PRODUCT", 16, 17], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 157, 170], ["endosomes", "CELLULAR_COMPONENT", 183, 192], ["endolysosomes", "CELLULAR_COMPONENT", 196, 209], ["TLR3, 7, 8, and 9", "PROTEIN", 0, 17], ["nucleic acids", "TEST", 126, 139], ["viruses", "PROBLEM", 145, 152], ["intracellular bacteria in endosomes", "PROBLEM", 157, 192], ["endolysosomes", "PROBLEM", 196, 209], ["nucleic acids", "OBSERVATION", 126, 139], ["bacteria", "OBSERVATION_MODIFIER", 171, 179]]], ["Signalling through TLR3 involves the TRIF and IRF3/7 pathway and induces type I IFNs while TLR7 and 9 signal through MyD88 and can activate further downstream IRF7, as well as NFjB to induce the production of both type I IFNs and pro-inflammatory cytokines (Kumar et al., 2011) .", [["TLR3", "GENE_OR_GENE_PRODUCT", 19, 23], ["TRIF", "GENE_OR_GENE_PRODUCT", 37, 41], ["IRF3", "GENE_OR_GENE_PRODUCT", 46, 50], ["7", "GENE_OR_GENE_PRODUCT", 51, 52], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 73, 84], ["TLR7", "GENE_OR_GENE_PRODUCT", 91, 95], ["9", "GENE_OR_GENE_PRODUCT", 100, 101], ["MyD88", "GENE_OR_GENE_PRODUCT", 117, 122], ["IRF7", "GENE_OR_GENE_PRODUCT", 159, 163], ["NFjB", "GENE_OR_GENE_PRODUCT", 176, 180], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 214, 225], ["TLR3", "PROTEIN", 19, 23], ["TRIF", "PROTEIN", 37, 41], ["IRF3", "PROTEIN", 46, 50], ["type I IFNs", "PROTEIN", 73, 84], ["TLR7 and 9", "PROTEIN", 91, 101], ["MyD88", "PROTEIN", 117, 122], ["IRF7", "PROTEIN", 159, 163], ["NFjB", "PROTEIN", 176, 180], ["type I IFNs", "PROTEIN", 214, 225], ["pro-inflammatory cytokines", "PROTEIN", 230, 256], ["type I IFNs", "PROBLEM", 73, 84], ["TLR7", "TEST", 91, 95], ["further downstream IRF7", "PROBLEM", 140, 163], ["NFjB", "TREATMENT", 176, 180]]], ["Details on the individual TLR ligands and signalling pathways are summarized in Table 2 .Toll-like receptorsInterestingly, TIR domains are not only expressed by eukaryotic cells but were also found in various bacteria.", [["cells", "ANATOMY", 172, 177], ["TLR", "GENE_OR_GENE_PRODUCT", 26, 29], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 89, 108], ["cells", "CELL", 172, 177], ["TLR", "PROTEIN", 26, 29], ["Toll-like receptors", "PROTEIN", 89, 108], ["TIR domains", "PROTEIN", 123, 134], ["eukaryotic cells", "CELL_TYPE", 161, 177], ["eukaryotic cells", "PROBLEM", 161, 177], ["various bacteria", "PROBLEM", 201, 217], ["not only", "UNCERTAINTY", 139, 147], ["eukaryotic cells", "OBSERVATION", 161, 177], ["various", "OBSERVATION_MODIFIER", 201, 208], ["bacteria", "OBSERVATION", 209, 217]]], ["Bacterial pathogens may express TIR domains to manipulate TLR signalling and/or to limit the NFjB expression thereby decreasing the innate immune response (Patterson and Werling, 2013) .Toll-like receptorsIn swine, cDNA analysis and sequencing discovered a significant homology of porcine TLRs with their human counterparts ($80% for TLR1, 3, and 10; 85% for TLR7; and 73% for TLR8) and that they share typical functional TLR domains (Sang et al., 2008; Shinkai et al., 2006a; Zhu et al., 2008) .", [["TLR", "GENE_OR_GENE_PRODUCT", 58, 61], ["NFjB", "GENE_OR_GENE_PRODUCT", 93, 97], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 186, 205], ["swine", "ORGANISM", 208, 213], ["porcine", "ORGANISM", 281, 288], ["TLRs", "GENE_OR_GENE_PRODUCT", 289, 293], ["human", "ORGANISM", 305, 310], ["TLR1", "GENE_OR_GENE_PRODUCT", 334, 338], ["3", "GENE_OR_GENE_PRODUCT", 340, 341], ["TLR7", "GENE_OR_GENE_PRODUCT", 359, 363], ["TLR8", "GENE_OR_GENE_PRODUCT", 377, 381], ["TLR", "GENE_OR_GENE_PRODUCT", 422, 425], ["TIR domains", "PROTEIN", 32, 43], ["TLR", "PROTEIN", 58, 61], ["NFjB", "PROTEIN", 93, 97], ["Toll-like receptors", "PROTEIN", 186, 205], ["porcine TLRs", "PROTEIN", 281, 293], ["TLR1", "PROTEIN", 334, 338], ["TLR7", "PROTEIN", 359, 363], ["TLR8", "PROTEIN", 377, 381], ["TLR domains", "PROTEIN", 422, 433], ["swine", "SPECIES", 208, 213], ["human", "SPECIES", 305, 310], ["swine", "SPECIES", 208, 213], ["human", "SPECIES", 305, 310], ["Bacterial pathogens", "PROBLEM", 0, 19], ["cDNA analysis", "TEST", 215, 228], ["sequencing", "TEST", 233, 243], ["TLR1", "TEST", 334, 338], ["TLR7", "TEST", 359, 363], ["TLR8", "TEST", 377, 381], ["pathogens", "OBSERVATION", 10, 19]]], ["Studies on the genetic diversity of TLRs including single-nucleotide polymorphisms (SNPs) identified pronounced differences between wild boars and domestic pigs (Bergman et al., 2010) but also between different pig breeds with several clusters of variation supporting the documented history of pig breed domestication (Palermo et al., 2009) .", [["TLRs", "GENE_OR_GENE_PRODUCT", 36, 40], ["pigs", "ORGANISM", 156, 160], ["pig", "ORGANISM", 211, 214], ["pig", "ORGANISM", 294, 297], ["TLRs", "PROTEIN", 36, 40], ["boars", "SPECIES", 137, 142], ["pigs", "SPECIES", 156, 160], ["pig", "SPECIES", 211, 214], ["pig", "SPECIES", 294, 297], ["pigs", "SPECIES", 156, 160], ["pig", "SPECIES", 211, 214], ["pig", "SPECIES", 294, 297], ["TLRs", "TEST", 36, 40], ["single-nucleotide polymorphisms (SNPs)", "TREATMENT", 51, 89], ["different pig breeds", "TREATMENT", 201, 221], ["pig breed domestication", "TREATMENT", 294, 317], ["pronounced", "OBSERVATION_MODIFIER", 101, 111], ["pig breeds", "OBSERVATION", 211, 221]]], ["Furthermore, SNP studies located 'hotspots' of variation in various functional domains.", [["SNP", "CHEMICAL", 13, 16], ["SNP studies", "TEST", 13, 24], ["variation", "OBSERVATION_MODIFIER", 47, 56], ["functional domains", "OBSERVATION", 68, 86]]], ["Many SNPs were shown to be located in the LRR domain but these SNPs were biased in the analysed animals so breeding did not seem to have an impact on the heterogeneity of TLRs (Shinkai et al., 2006b ).", [["TLRs", "GENE_OR_GENE_PRODUCT", 171, 175], ["LRR domain", "DNA", 42, 52], ["TLRs", "PROTEIN", 171, 175], ["Many SNPs", "TREATMENT", 0, 9], ["these SNPs", "TREATMENT", 57, 67]]], ["In addition, three missense mutations were identified in the extracellular domain with one of them shown to be important for flagellin recognition.", [["extracellular", "ANATOMY", 61, 74], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 61, 74], ["flagellin", "GENE_OR_GENE_PRODUCT", 125, 134], ["extracellular domain", "PROTEIN", 61, 81], ["flagellin", "PROTEIN", 125, 134], ["three missense mutations", "PROBLEM", 13, 37], ["flagellin recognition", "PROBLEM", 125, 146]]], ["SNPs have implications in various human diseases and although this relation has not be described for swine so far, analysis of polymorphism may provide a useful tool in the selection of disease-resistant animals in future (Yang et al., 2013) .Toll-like receptorsIn conjunction with these genetic studies, porcine TLR expression patterns and function have been analysed.", [["human", "ORGANISM", 34, 39], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 243, 262], ["porcine", "ORGANISM", 305, 312], ["TLR", "GENE_OR_GENE_PRODUCT", 313, 316], ["Toll-like receptors", "PROTEIN", 243, 262], ["TLR", "PROTEIN", 313, 316], ["human", "SPECIES", 34, 39], ["swine", "SPECIES", 101, 106], ["human", "SPECIES", 34, 39], ["swine", "SPECIES", 101, 106], ["SNPs", "TREATMENT", 0, 4], ["various human diseases", "PROBLEM", 26, 48], ["polymorphism", "PROBLEM", 127, 139], ["disease", "PROBLEM", 186, 193], ["these genetic studies", "TEST", 282, 303], ["various human", "OBSERVATION_MODIFIER", 26, 39], ["diseases", "OBSERVATION", 40, 48]]], ["The porcine intestinal epithelial cell line IPEC-J2 has been shown to express TLR2, TLR4, and TLR9 (Burkey et al., 2009) and is a valuable tool for the study of these porcine TLRs.", [["intestinal epithelial cell line IPEC-J2", "ANATOMY", 12, 51], ["porcine", "ORGANISM", 4, 11], ["intestinal epithelial cell line IPEC-J2", "CELL", 12, 51], ["TLR2", "GENE_OR_GENE_PRODUCT", 78, 82], ["TLR4", "GENE_OR_GENE_PRODUCT", 84, 88], ["TLR9", "GENE_OR_GENE_PRODUCT", 94, 98], ["porcine", "ORGANISM", 167, 174], ["TLRs", "GENE_OR_GENE_PRODUCT", 175, 179], ["porcine intestinal epithelial cell line", "CELL_LINE", 4, 43], ["IPEC", "CELL_LINE", 44, 48], ["J2", "CELL_LINE", 49, 51], ["TLR2", "PROTEIN", 78, 82], ["TLR4", "PROTEIN", 84, 88], ["TLR9", "PROTEIN", 94, 98], ["porcine TLRs", "PROTEIN", 167, 179], ["porcine", "SPECIES", 4, 11], ["The porcine intestinal epithelial cell line IPEC", "TREATMENT", 0, 48], ["TLR2", "TEST", 78, 82], ["TLR4", "TEST", 84, 88], ["the study", "TEST", 148, 157], ["these porcine TLRs", "TREATMENT", 161, 179], ["porcine", "ANATOMY_MODIFIER", 4, 11], ["intestinal", "ANATOMY", 12, 22], ["epithelial cell line", "OBSERVATION", 23, 43], ["TLR2", "ANATOMY_MODIFIER", 78, 82], ["TLR4", "OBSERVATION_MODIFIER", 84, 88]]], ["In vivo, TLR2 has been shown to be expressed in the porcine thymus, spleen, IPPs, mesenteric lymph nodes (MLNs), and palatine tonsil (Wilson et al., 2007) as well as being expressed to a lower level on columnar membranous Hardison and Brown (2012) and Lepenies et al. (2013) (M) cells and innate immune cells such as macrophages and epithelial cells but not on peripheral blood lymphocytes (Alvarez et al., 2008; Tohno et al., 2006) .", [["thymus", "ANATOMY", 60, 66], ["spleen", "ANATOMY", 68, 74], ["IPPs", "ANATOMY", 76, 80], ["mesenteric lymph nodes", "ANATOMY", 82, 104], ["MLNs", "ANATOMY", 106, 110], ["palatine tonsil", "ANATOMY", 117, 132], ["M) cells", "ANATOMY", 276, 284], ["immune cells", "ANATOMY", 296, 308], ["macrophages", "ANATOMY", 317, 328], ["epithelial cells", "ANATOMY", 333, 349], ["peripheral blood lymphocytes", "ANATOMY", 361, 389], ["TLR2", "GENE_OR_GENE_PRODUCT", 9, 13], ["porcine", "ORGANISM", 52, 59], ["thymus", "ORGAN", 60, 66], ["spleen", "ORGAN", 68, 74], ["IPPs", "CELL", 76, 80], ["mesenteric lymph nodes", "MULTI-TISSUE_STRUCTURE", 82, 104], ["MLNs", "MULTI-TISSUE_STRUCTURE", 106, 110], ["palatine tonsil", "MULTI-TISSUE_STRUCTURE", 117, 132], ["M) cells", "CELL", 276, 284], ["innate immune cells", "CELL", 289, 308], ["macrophages", "CELL", 317, 328], ["epithelial cells", "CELL", 333, 349], ["peripheral blood lymphocytes", "CELL", 361, 389], ["TLR2", "PROTEIN", 9, 13], ["innate immune cells", "CELL_TYPE", 289, 308], ["macrophages", "CELL_TYPE", 317, 328], ["epithelial cells", "CELL_TYPE", 333, 349], ["peripheral blood lymphocytes", "CELL_TYPE", 361, 389], ["porcine", "SPECIES", 52, 59], ["innate immune cells", "PROBLEM", 289, 308], ["macrophages", "PROBLEM", 317, 328], ["epithelial cells", "PROBLEM", 333, 349], ["peripheral blood lymphocytes", "TEST", 361, 389], ["porcine", "ANATOMY_MODIFIER", 52, 59], ["thymus", "ANATOMY", 60, 66], ["spleen", "ANATOMY", 68, 74], ["mesenteric", "ANATOMY", 82, 92], ["lymph nodes", "OBSERVATION", 93, 104], ["MLNs", "ANATOMY", 106, 110], ["palatine tonsil", "ANATOMY", 117, 132], ["immune cells", "OBSERVATION", 296, 308], ["epithelial cells", "OBSERVATION", 333, 349], ["peripheral", "ANATOMY_MODIFIER", 361, 371], ["blood lymphocytes", "ANATOMY", 372, 389]]], ["Reduction of TLR3 expression via RNA interference has been shown to trigger an increase in porcine reproductive and respiratory syndrome virus (PRRSV) replication which suggests that TLR3 may play an important role in the porcine innate antiviral response (Miller et al., 2009; Sang et al., 2008) .", [["porcine reproductive and respiratory syndrome", "DISEASE", 91, 136], ["TLR3", "GENE_OR_GENE_PRODUCT", 13, 17], ["porcine reproductive and respiratory syndrome virus", "ORGANISM", 91, 142], ["PRRSV", "ORGANISM", 144, 149], ["TLR3", "GENE_OR_GENE_PRODUCT", 183, 187], ["porcine", "ORGANISM", 222, 229], ["TLR3", "PROTEIN", 13, 17], ["TLR3", "PROTEIN", 183, 187], ["PRRSV", "SPECIES", 144, 149], ["porcine", "SPECIES", 222, 229], ["TLR3 expression", "TREATMENT", 13, 28], ["RNA interference", "PROBLEM", 33, 49], ["porcine reproductive and respiratory syndrome virus", "PROBLEM", 91, 142], ["the porcine innate antiviral response", "TREATMENT", 218, 255], ["TLR3 expression", "OBSERVATION", 13, 28], ["increase", "OBSERVATION_MODIFIER", 79, 87], ["porcine reproductive", "OBSERVATION", 91, 111], ["respiratory syndrome", "OBSERVATION", 116, 136]]], ["TLR4, 5, and 9 are up-regulated on monocytes and dendritic cells (DCs) after stimulation with various TLR ligands like lipopolysaccharide (LPS), lipoteichoic acid (LTA), and cytosine-phosphateguanine oligodeoxynucleotides (CpG ODNs) (Raymond and Wilkie, 2005) .", [["monocytes", "ANATOMY", 35, 44], ["dendritic cells", "ANATOMY", 49, 64], ["DCs", "ANATOMY", 66, 69], ["lipopolysaccharide", "CHEMICAL", 119, 137], ["LPS", "CHEMICAL", 139, 142], ["lipoteichoic acid", "CHEMICAL", 145, 162], ["LTA", "CHEMICAL", 164, 167], ["cytosine", "CHEMICAL", 174, 182], ["cytosine", "CHEMICAL", 174, 182], ["phosphateguanine", "CHEMICAL", 183, 199], ["CpG", "CHEMICAL", 223, 226], ["TLR4", "GENE_OR_GENE_PRODUCT", 0, 4], ["5", "GENE_OR_GENE_PRODUCT", 6, 7], ["9", "GENE_OR_GENE_PRODUCT", 13, 14], ["monocytes", "CELL", 35, 44], ["dendritic cells", "CELL", 49, 64], ["DCs", "CELL", 66, 69], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 119, 137], ["LPS", "SIMPLE_CHEMICAL", 139, 142], ["lipoteichoic acid", "SIMPLE_CHEMICAL", 145, 162], ["LTA", "SIMPLE_CHEMICAL", 164, 167], ["cytosine-phosphateguanine oligodeoxynucleotides", "SIMPLE_CHEMICAL", 174, 221], ["CpG ODNs", "SIMPLE_CHEMICAL", 223, 231], ["TLR4, 5, and 9", "PROTEIN", 0, 14], ["monocytes", "CELL_TYPE", 35, 44], ["dendritic cells", "CELL_TYPE", 49, 64], ["DCs", "CELL_TYPE", 66, 69], ["TLR ligands", "PROTEIN", 102, 113], ["TLR4", "TEST", 0, 4], ["monocytes", "TEST", 35, 44], ["dendritic cells", "PROBLEM", 49, 64], ["stimulation", "TREATMENT", 77, 88], ["various TLR ligands", "TREATMENT", 94, 113], ["lipopolysaccharide (LPS", "TREATMENT", 119, 142], ["lipoteichoic acid (LTA", "TEST", 145, 167], ["cytosine-phosphateguanine oligodeoxynucleotides (CpG ODNs", "TREATMENT", 174, 231], ["dendritic cells", "OBSERVATION", 49, 64]]], ["Alves et al. studied the role of TLR7 and MyD88 in porcine DCs by lentiviral-mediated RNA interference to reduce the expression of TLR7 and MyD88 (Alves et al., 2007) .", [["DCs", "ANATOMY", 59, 62], ["TLR7", "GENE_OR_GENE_PRODUCT", 33, 37], ["MyD88", "GENE_OR_GENE_PRODUCT", 42, 47], ["porcine", "ORGANISM", 51, 58], ["DCs", "CELL", 59, 62], ["lentiviral", "ORGANISM", 66, 76], ["TLR7", "GENE_OR_GENE_PRODUCT", 131, 135], ["MyD88", "GENE_OR_GENE_PRODUCT", 140, 145], ["TLR7", "PROTEIN", 33, 37], ["MyD88", "PROTEIN", 42, 47], ["porcine DCs", "CELL_TYPE", 51, 62], ["TLR7", "PROTEIN", 131, 135], ["MyD88", "PROTEIN", 140, 145], ["MyD88 in porcine DCs", "TREATMENT", 42, 62], ["lentiviral-mediated RNA interference", "TREATMENT", 66, 102], ["TLR7", "ANATOMY", 131, 135]]], ["In both knockdown models, IL-6 production was substantially decreased after stimulation with the TLR7-ligand imiquimod (R837) (Alves et al., 2007) .", [["imiquimod", "CHEMICAL", 109, 118], ["imiquimod", "CHEMICAL", 109, 118], ["IL-6", "GENE_OR_GENE_PRODUCT", 26, 30], ["TLR7", "GENE_OR_GENE_PRODUCT", 97, 101], ["imiquimod", "SIMPLE_CHEMICAL", 109, 118], ["R837", "SIMPLE_CHEMICAL", 120, 124], ["IL-6", "PROTEIN", 26, 30], ["TLR7", "PROTEIN", 97, 101], ["stimulation", "TREATMENT", 76, 87], ["the TLR7-ligand imiquimod", "TREATMENT", 93, 118], ["both", "ANATOMY_MODIFIER", 3, 7], ["knockdown models", "OBSERVATION", 8, 24], ["decreased", "OBSERVATION_MODIFIER", 60, 69]]], ["Porcine TLR7 and 8 could be found intracellularly and mainly in the endoplasmatic reticulum.", [["endoplasmatic reticulum", "ANATOMY", 68, 91], ["Porcine", "ORGANISM", 0, 7], ["TLR7", "GENE_OR_GENE_PRODUCT", 8, 12], ["8", "GENE_OR_GENE_PRODUCT", 17, 18], ["endoplasmatic reticulum", "CELLULAR_COMPONENT", 68, 91], ["Porcine TLR7 and 8", "PROTEIN", 0, 18], ["Porcine", "SPECIES", 0, 7], ["Porcine", "SPECIES", 0, 7], ["Porcine TLR7 and 8", "TREATMENT", 0, 18], ["intracellularly", "OBSERVATION_MODIFIER", 34, 49], ["endoplasmatic reticulum", "ANATOMY", 68, 91]]], ["Their stimulatory activity was analysed in transfected Cos-7 and HEK-293 cells using an NFjB reporter assay.", [["Cos-7", "ANATOMY", 55, 60], ["HEK-293 cells", "ANATOMY", 65, 78], ["Cos-7", "CELL", 55, 60], ["HEK-293 cells", "CELL", 65, 78], ["NFjB", "GENE_OR_GENE_PRODUCT", 88, 92], ["Cos-7", "CELL_LINE", 55, 60], ["HEK-293 cells", "CELL_LINE", 65, 78], ["HEK-293", "SPECIES", 65, 72], ["transfected Cos", "TEST", 43, 58], ["HEK", "TEST", 65, 68], ["an NFjB reporter assay", "TEST", 85, 107]]], ["In contrast to humans, imiquimod could not only activate TLR7 but also TLR8 in the pig, showing altered receptor specificity across species (Zhu et al., 2008) .", [["imiquimod", "CHEMICAL", 23, 32], ["imiquimod", "CHEMICAL", 23, 32], ["humans", "ORGANISM", 15, 21], ["imiquimod", "SIMPLE_CHEMICAL", 23, 32], ["TLR7", "GENE_OR_GENE_PRODUCT", 57, 61], ["TLR8", "GENE_OR_GENE_PRODUCT", 71, 75], ["pig", "ORGANISM", 83, 86], ["TLR7", "PROTEIN", 57, 61], ["TLR8", "PROTEIN", 71, 75], ["humans", "SPECIES", 15, 21], ["pig", "SPECIES", 83, 86], ["humans", "SPECIES", 15, 21], ["pig", "SPECIES", 83, 86], ["imiquimod", "TREATMENT", 23, 32], ["altered receptor specificity across species", "PROBLEM", 96, 139]]], ["Calzada-Nova et al. found an enhanced production of various cytokines (IFN-a, IFN-c, IL-2, IL-6, IL-8, IL-12, and TNF-a) after plasmacytoid DCs (pDCs) were stimulated with both imiquimod and the TLR9 ligand CpG ODN (Calzada-Nova et al., 2010) .", [["plasmacytoid DCs", "ANATOMY", 127, 143], ["pDCs", "ANATOMY", 145, 149], ["imiquimod", "CHEMICAL", 177, 186], ["ODN", "CHEMICAL", 211, 214], ["imiquimod", "CHEMICAL", 177, 186], ["IFN-a", "GENE_OR_GENE_PRODUCT", 71, 76], ["IFN-c", "GENE_OR_GENE_PRODUCT", 78, 83], ["IL-2", "GENE_OR_GENE_PRODUCT", 85, 89], ["IL-6", "GENE_OR_GENE_PRODUCT", 91, 95], ["IL-8", "GENE_OR_GENE_PRODUCT", 97, 101], ["IL-12", "GENE_OR_GENE_PRODUCT", 103, 108], ["TNF-a", "GENE_OR_GENE_PRODUCT", 114, 119], ["plasmacytoid DCs", "CELL", 127, 143], ["pDCs", "CELL", 145, 149], ["imiquimod", "SIMPLE_CHEMICAL", 177, 186], ["TLR9", "GENE_OR_GENE_PRODUCT", 195, 199], ["cytokines", "PROTEIN", 60, 69], ["IFN", "PROTEIN", 71, 74], ["IFN", "PROTEIN", 78, 81], ["IL", "PROTEIN", 103, 105], ["TNF", "PROTEIN", 114, 117], ["plasmacytoid DCs", "CELL_TYPE", 127, 143], ["pDCs", "CELL_TYPE", 145, 149], ["TLR9", "PROTEIN", 195, 199], ["Calzada", "TREATMENT", 0, 7], ["various cytokines", "TEST", 52, 69], ["IFN", "TEST", 71, 74], ["IFN", "TEST", 78, 81], ["IL", "TEST", 85, 87], ["IL", "TEST", 91, 93], ["IL", "TEST", 97, 99], ["IL", "TEST", 103, 105], ["TNF", "TEST", 114, 117], ["plasmacytoid DCs (pDCs)", "TREATMENT", 127, 150], ["both imiquimod", "TREATMENT", 172, 186], ["the TLR9 ligand CpG ODN", "TREATMENT", 191, 214], ["enhanced", "OBSERVATION_MODIFIER", 29, 37], ["production", "OBSERVATION_MODIFIER", 38, 48]]], ["CpG ODN additionally increased the expression of chemokine receptors on monocyte derived DCs (MoDCs) and blood DCs (bDCs) (Auray et al., 2010) as well as altering the general DC morphology of cultured sorted plasmacytoid (pDCs) compared to unstimulated cultures (Calzada-Nova et al., 2010) .", [["monocyte", "ANATOMY", 72, 80], ["DCs", "ANATOMY", 89, 92], ["MoDCs", "ANATOMY", 94, 99], ["blood DCs", "ANATOMY", 105, 114], ["bDCs", "ANATOMY", 116, 120], ["DC", "ANATOMY", 175, 177], ["plasmacytoid", "ANATOMY", 208, 220], ["pDCs", "ANATOMY", 222, 226], ["cultures", "ANATOMY", 253, 261], ["ODN", "CHEMICAL", 4, 7], ["CpG", "CHEMICAL", 0, 3], ["ODN", "SIMPLE_CHEMICAL", 4, 7], ["monocyte derived DCs", "CELL", 72, 92], ["MoDCs", "CELL", 94, 99], ["blood DCs", "CELL", 105, 114], ["bDCs", "CELL", 116, 120], ["DC", "CELL", 175, 177], ["plasmacytoid", "CELL", 208, 220], ["pDCs", "CELL", 222, 226], ["chemokine receptors", "PROTEIN", 49, 68], ["monocyte derived DCs", "CELL_TYPE", 72, 92], ["MoDCs", "CELL_TYPE", 94, 99], ["blood DCs", "CELL_TYPE", 105, 114], ["bDCs", "CELL_TYPE", 116, 120], ["cultured sorted plasmacytoid", "CELL_LINE", 192, 220], ["pDCs", "CELL_TYPE", 222, 226], ["unstimulated cultures", "CELL_LINE", 240, 261], ["CpG ODN", "TREATMENT", 0, 7], ["chemokine receptors", "TREATMENT", 49, 68], ["blood DCs", "TEST", 105, 114], ["unstimulated cultures", "TEST", 240, 261]]], ["A more detailed study including different CpG ODNs revealed that the three classes of CpG ODN (A-C) induce different cytokines (Dar et al., 2010) .", [["ODN", "CHEMICAL", 90, 93], ["CpG", "CHEMICAL", 42, 45], ["CpG", "CHEMICAL", 86, 89], ["CpG ODN", "SIMPLE_CHEMICAL", 86, 93], ["A-C", "SIMPLE_CHEMICAL", 95, 98], ["cytokines", "PROTEIN", 117, 126], ["A more detailed study", "TEST", 0, 21], ["different CpG ODNs", "TREATMENT", 32, 50], ["CpG ODN", "TREATMENT", 86, 93]]], ["All three CpG ODN classes trigger up-regulation of the IFN-c inducible protein 10 (IP-10) suggesting its use as a biomarker for TLR9 immune activity induced by CpG ODNs in pigs (Dar et al., 2010) .", [["ODN", "CHEMICAL", 14, 17], ["CpG", "CHEMICAL", 10, 13], ["CpG", "CHEMICAL", 160, 163], ["IFN-c inducible protein 10", "GENE_OR_GENE_PRODUCT", 55, 81], ["IP-10", "GENE_OR_GENE_PRODUCT", 83, 88], ["TLR9", "GENE_OR_GENE_PRODUCT", 128, 132], ["pigs", "ORGANISM", 172, 176], ["IFN-c inducible protein 10", "PROTEIN", 55, 81], ["IP-10", "PROTEIN", 83, 88], ["TLR9", "PROTEIN", 128, 132], ["pigs", "SPECIES", 172, 176], ["pigs", "SPECIES", 172, 176], ["All three CpG ODN", "TREATMENT", 0, 17], ["the IFN", "TEST", 51, 58], ["inducible protein", "TEST", 61, 78], ["IP", "TEST", 83, 85], ["a biomarker", "TEST", 112, 123], ["TLR9 immune activity", "TREATMENT", 128, 148]]], ["Beyond the basic characteristics and functions of TLRs, their role in various viral, bacterial, and fungal diseases have been investigated.", [["viral, bacterial, and fungal diseases", "DISEASE", 78, 115], ["TLRs", "GENE_OR_GENE_PRODUCT", 50, 54], ["TLRs", "PROTEIN", 50, 54], ["various viral, bacterial, and fungal diseases", "PROBLEM", 70, 115], ["bacterial", "OBSERVATION_MODIFIER", 85, 94], ["fungal diseases", "OBSERVATION", 100, 115]]], ["PRRSV infection increased the expression of TLR3, 4, and 7 as well as the production of the pro-inflammatory cytokines IL-1b, IL-6, TNFa, and IFN-c in tracheobronchial lymph nodes (Miguel et al., 2010) .", [["tracheobronchial lymph nodes", "ANATOMY", 151, 179], ["PRRSV infection", "DISEASE", 0, 15], ["PRRSV", "ORGANISM", 0, 5], ["TLR3", "GENE_OR_GENE_PRODUCT", 44, 48], ["4", "GENE_OR_GENE_PRODUCT", 50, 51], ["7", "GENE_OR_GENE_PRODUCT", 57, 58], ["IL-1b", "GENE_OR_GENE_PRODUCT", 119, 124], ["IL-6", "GENE_OR_GENE_PRODUCT", 126, 130], ["TNFa", "GENE_OR_GENE_PRODUCT", 132, 136], ["IFN-c", "GENE_OR_GENE_PRODUCT", 142, 147], ["tracheobronchial lymph nodes", "MULTI-TISSUE_STRUCTURE", 151, 179], ["TLR3, 4, and 7", "PROTEIN", 44, 58], ["pro-inflammatory cytokines", "PROTEIN", 92, 118], ["IL", "PROTEIN", 119, 121], ["IL-6", "PROTEIN", 126, 130], ["TNFa", "PROTEIN", 132, 136], ["IFN-c", "PROTEIN", 142, 147], ["PRRSV", "SPECIES", 0, 5], ["PRRSV infection", "PROBLEM", 0, 15], ["the pro-inflammatory cytokines IL", "TEST", 88, 121], ["IL", "TEST", 126, 128], ["TNFa", "TEST", 132, 136], ["IFN", "TEST", 142, 145], ["infection", "OBSERVATION", 6, 15], ["TLR3", "ANATOMY_MODIFIER", 44, 48], ["pro-inflammatory", "OBSERVATION_MODIFIER", 92, 108], ["tracheobronchial", "ANATOMY", 151, 167], ["lymph nodes", "OBSERVATION", 168, 179]]], ["However, activation of TLR3, but not TLR4, could decrease the infectivity of PRRSV in porcine alveolar macrophages (PAMs) (Miller et al., 2009) .", [["alveolar macrophages", "ANATOMY", 94, 114], ["TLR3", "GENE_OR_GENE_PRODUCT", 23, 27], ["TLR4", "GENE_OR_GENE_PRODUCT", 37, 41], ["PRRSV", "ORGANISM", 77, 82], ["porcine", "ORGANISM", 86, 93], ["alveolar macrophages", "CELL", 94, 114], ["PAMs", "CELL", 116, 120], ["TLR3", "PROTEIN", 23, 27], ["TLR4", "PROTEIN", 37, 41], ["porcine alveolar macrophages", "CELL_TYPE", 86, 114], ["PAMs", "CELL_TYPE", 116, 120], ["porcine", "SPECIES", 86, 93], ["PRRSV", "SPECIES", 77, 82], ["porcine", "SPECIES", 86, 93], ["activation of TLR3", "PROBLEM", 9, 27], ["TLR4", "PROBLEM", 37, 41], ["infectivity", "OBSERVATION_MODIFIER", 62, 73], ["alveolar macrophages", "OBSERVATION", 94, 114]]], ["A comparison of high (HP) and low pathogenic (LP) PRRSV strains revealed that relative to LP strains, HP PRRSV strains suppress ERK phosphorylation at early time points and impair LPS-and poly I:C-stimulated TNF-a release (Hou et al., 2012) .", [["LPS", "CHEMICAL", 180, 183], ["poly I:C", "CHEMICAL", 188, 196], ["LP strains", "ORGANISM", 90, 100], ["HP PRRSV", "ORGANISM", 102, 110], ["strains", "ORGANISM", 111, 118], ["ERK", "GENE_OR_GENE_PRODUCT", 128, 131], ["LPS", "SIMPLE_CHEMICAL", 180, 183], ["poly I:C", "SIMPLE_CHEMICAL", 188, 196], ["TNF", "GENE_OR_GENE_PRODUCT", 208, 211], ["ERK", "PROTEIN", 128, 131], ["TNF", "PROTEIN", 208, 211], ["PRRSV", "SPECIES", 50, 55], ["PRRSV", "SPECIES", 105, 110], ["high (HP)", "PROBLEM", 16, 25], ["low pathogenic (LP) PRRSV strains", "PROBLEM", 30, 63], ["LP strains", "PROBLEM", 90, 100], ["HP PRRSV strains", "PROBLEM", 102, 118], ["ERK phosphorylation", "PROBLEM", 128, 147], ["LPS", "TEST", 180, 183], ["high", "OBSERVATION_MODIFIER", 16, 20], ["low pathogenic", "OBSERVATION_MODIFIER", 30, 44]]], ["HP PRRSV strains also lead to high serum levels of pro-inflammatory cytokines but lower IL-10 levels compared to LP PRRSV strains (Zhang et al., 2013a) .", [["serum", "ANATOMY", 35, 40], ["HP PRRSV", "ORGANISM", 0, 8], ["serum", "ORGANISM_SUBSTANCE", 35, 40], ["IL-10", "GENE_OR_GENE_PRODUCT", 88, 93], ["LP PRRSV", "ORGANISM", 113, 121], ["pro-inflammatory cytokines", "PROTEIN", 51, 77], ["IL", "PROTEIN", 88, 90], ["PRRSV", "SPECIES", 3, 8], ["PRRSV", "SPECIES", 116, 121], ["HP PRRSV strains", "PROBLEM", 0, 16], ["high serum levels of pro-inflammatory cytokines", "PROBLEM", 30, 77], ["lower IL", "TEST", 82, 90], ["LP PRRSV strains", "PROBLEM", 113, 129], ["PRRSV strains", "OBSERVATION", 3, 16], ["pro-inflammatory cytokines", "OBSERVATION", 51, 77]]], ["The stronger inflammation induced by HP PRRSV likely contributes to increased tissue damage and clinical signs.", [["tissue", "ANATOMY", 78, 84], ["inflammation", "DISEASE", 13, 25], ["tissue damage", "DISEASE", 78, 91], ["HP PRRSV", "ORGANISM", 37, 45], ["tissue", "TISSUE", 78, 84], ["PRRSV", "SPECIES", 40, 45], ["The stronger inflammation", "PROBLEM", 0, 25], ["HP PRRSV", "PROBLEM", 37, 45], ["increased tissue damage", "PROBLEM", 68, 91], ["clinical signs", "TEST", 96, 110], ["stronger", "OBSERVATION_MODIFIER", 4, 12], ["inflammation", "OBSERVATION", 13, 25], ["HP PRRSV", "OBSERVATION", 37, 45], ["increased tissue damage", "OBSERVATION", 68, 91]]], ["Furthermore, HP PRRSV strains have decreased amounts of SARM1, a TIR-domain containing adaptor protein involved in TLR signalling transduction (Zhou et al., 2013) which may decrease the ability to mount an immune response against PRRSV.", [["HP PRRSV", "ORGANISM", 13, 21], ["SARM1", "GENE_OR_GENE_PRODUCT", 56, 61], ["TLR", "GENE_OR_GENE_PRODUCT", 115, 118], ["PRRSV", "ORGANISM", 230, 235], ["SARM1", "PROTEIN", 56, 61], ["TIR-domain containing adaptor protein", "PROTEIN", 65, 102], ["TLR", "PROTEIN", 115, 118], ["PRRSV", "SPECIES", 16, 21], ["PRRSV", "SPECIES", 230, 235], ["HP PRRSV strains", "PROBLEM", 13, 29], ["SARM1", "PROBLEM", 56, 61], ["adaptor protein", "TREATMENT", 87, 102], ["PRRSV", "PROBLEM", 230, 235], ["decreased", "OBSERVATION_MODIFIER", 35, 44], ["amounts", "OBSERVATION_MODIFIER", 45, 52]]], ["The African swine fever virus (ASFV) also inhibits poly I:C-mediated NFjB activation via TLR3 and the IFN-b promoter at the level of TRIF (de Oliveira et al., 2011) .", [["swine fever", "DISEASE", 12, 23], ["poly I:C", "CHEMICAL", 51, 59], ["African swine fever virus", "ORGANISM", 4, 29], ["ASFV", "ORGANISM", 31, 35], ["poly I:C", "GENE_OR_GENE_PRODUCT", 51, 59], ["NFjB", "GENE_OR_GENE_PRODUCT", 69, 73], ["TLR3", "GENE_OR_GENE_PRODUCT", 89, 93], ["IFN-b", "GENE_OR_GENE_PRODUCT", 102, 107], ["TRIF", "GENE_OR_GENE_PRODUCT", 133, 137], ["poly I:C", "PROTEIN", 51, 59], ["NFjB", "PROTEIN", 69, 73], ["TLR3", "PROTEIN", 89, 93], ["IFN-b promoter", "DNA", 102, 116], ["TRIF", "PROTEIN", 133, 137], ["African swine fever virus", "SPECIES", 4, 29], ["African swine fever virus", "SPECIES", 4, 29], ["ASFV", "SPECIES", 31, 35], ["The African swine fever virus", "PROBLEM", 0, 29], ["TLR3", "TREATMENT", 89, 93], ["the IFN-b promoter", "TREATMENT", 98, 116]]], ["H\u00fcsser et al. showed that TLR3 is involved in sensing classical swine fever virus (CSFV) but not food and mouth disease virus (FMDV), vesicular stomatitis virus (VSV), and influenza A virus (IAV) (H\u00fcsser et al., 2011) .Toll-like receptorsThe role of TLRs in porcine bacterial diseases was analysed in Salmonella and hog cholera vaccines.", [["swine fever", "DISEASE", 64, 75], ["food and mouth disease", "DISEASE", 97, 119], ["vesicular stomatitis", "DISEASE", 134, 154], ["influenza A virus", "DISEASE", 172, 189], ["bacterial diseases", "DISEASE", 266, 284], ["TLR3", "GENE_OR_GENE_PRODUCT", 26, 30], ["classical swine fever virus", "ORGANISM", 54, 81], ["CSFV", "ORGANISM", 83, 87], ["food and mouth disease virus", "ORGANISM", 97, 125], ["FMDV", "ORGANISM", 127, 131], ["vesicular stomatitis virus", "ORGANISM", 134, 160], ["VSV", "ORGANISM", 162, 165], ["influenza A virus", "ORGANISM", 172, 189], ["IAV", "ORGANISM", 191, 194], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 219, 238], ["TLRs", "GENE_OR_GENE_PRODUCT", 250, 254], ["porcine", "ORGANISM", 258, 265], ["hog cholera", "ORGANISM", 316, 327], ["TLR3", "PROTEIN", 26, 30], ["Toll-like receptors", "PROTEIN", 219, 238], ["TLRs", "PROTEIN", 250, 254], ["swine fever virus", "SPECIES", 64, 81], ["FMDV", "SPECIES", 127, 131], ["stomatitis virus", "SPECIES", 144, 160], ["influenza A virus", "SPECIES", 172, 189], ["porcine", "SPECIES", 258, 265], ["hog", "SPECIES", 316, 319], ["swine fever virus", "SPECIES", 64, 81], ["CSFV", "SPECIES", 83, 87], ["FMDV", "SPECIES", 127, 131], ["stomatitis virus", "SPECIES", 144, 160], ["VSV", "SPECIES", 162, 165], ["influenza A virus", "SPECIES", 172, 189], ["IAV", "SPECIES", 191, 194], ["Salmonella", "SPECIES", 301, 311], ["hog", "SPECIES", 316, 319], ["sensing classical swine fever virus (CSFV)", "PROBLEM", 46, 88], ["mouth disease virus (FMDV)", "PROBLEM", 106, 132], ["vesicular stomatitis virus (VSV)", "PROBLEM", 134, 166], ["influenza", "PROBLEM", 172, 181], ["porcine bacterial diseases", "PROBLEM", 258, 284], ["Salmonella", "PROBLEM", 301, 311], ["hog cholera vaccines", "TREATMENT", 316, 336], ["TLR3", "OBSERVATION", 26, 30], ["mouth", "ANATOMY", 106, 111], ["vesicular stomatitis", "ANATOMY", 134, 154], ["bacterial diseases", "OBSERVATION", 266, 284]]], ["Burkey et al. found that pigs infected with Salmonella enterica subspecies enterica serovar Typhimurium (commonly called Salmonella Typhimurium) showed increased TLR2 and 4 expression 24 and 48 h later, in vivo (Burkey showed increased expression of TLR1, 2, 3, 4, 6, and 9 but the porcine ileum cell line IPI-21 expressed more TLR8 and 10 after stimulation with LPS from S. Typhimurium (Arce et al., 2010) .", [["ileum cell line IPI-21", "ANATOMY", 290, 312], ["LPS", "CHEMICAL", 363, 366], ["pigs", "ORGANISM", 25, 29], ["Salmonella enterica subspecies enterica serovar Typhimurium", "ORGANISM", 44, 103], ["Salmonella Typhimurium", "ORGANISM", 121, 143], ["TLR2", "GENE_OR_GENE_PRODUCT", 162, 166], ["4", "GENE_OR_GENE_PRODUCT", 171, 172], ["TLR1", "GENE_OR_GENE_PRODUCT", 250, 254], ["2", "GENE_OR_GENE_PRODUCT", 256, 257], ["3", "GENE_OR_GENE_PRODUCT", 259, 260], ["4", "GENE_OR_GENE_PRODUCT", 262, 263], ["6", "GENE_OR_GENE_PRODUCT", 265, 266], ["porcine", "ORGANISM", 282, 289], ["ileum cell line IPI-21", "CELL", 290, 312], ["TLR8", "GENE_OR_GENE_PRODUCT", 328, 332], ["10", "GENE_OR_GENE_PRODUCT", 337, 339], ["LPS", "SIMPLE_CHEMICAL", 363, 366], ["S. Typhimurium", "ORGANISM", 372, 386], ["TLR2", "PROTEIN", 162, 166], ["TLR1", "PROTEIN", 250, 254], ["porcine ileum cell line IPI-21", "CELL_LINE", 282, 312], ["TLR8 and 10", "PROTEIN", 328, 339], ["pigs", "SPECIES", 25, 29], ["Salmonella enterica", "SPECIES", 44, 63], ["subspecies enterica", "SPECIES", 64, 83], ["serovar Typhimurium", "SPECIES", 84, 103], ["Salmonella Typhimurium", "SPECIES", 121, 143], ["porcine", "SPECIES", 282, 289], ["S. Typhimurium", "SPECIES", 372, 386], ["pigs", "SPECIES", 25, 29], ["Salmonella enterica subspecies enterica serovar Typhimurium", "SPECIES", 44, 103], ["Salmonella Typhimurium", "SPECIES", 121, 143], ["S. Typhimurium", "SPECIES", 372, 386], ["Salmonella enterica subspecies enterica serovar Typhimurium", "PROBLEM", 44, 103], ["Salmonella Typhimurium", "TEST", 121, 143], ["increased TLR2", "PROBLEM", 152, 166], ["increased expression of TLR1", "PROBLEM", 226, 254], ["the porcine ileum cell line IPI", "TEST", 278, 309], ["TLR8", "TEST", 328, 332], ["LPS", "TEST", 363, 366], ["pigs", "ANATOMY", 25, 29], ["infected", "OBSERVATION", 30, 38], ["Salmonella", "OBSERVATION_MODIFIER", 44, 54], ["enterica", "OBSERVATION_MODIFIER", 55, 63], ["subspecies", "OBSERVATION_MODIFIER", 64, 74], ["enterica", "OBSERVATION_MODIFIER", 75, 83], ["serovar Typhimurium", "OBSERVATION", 84, 103], ["increased", "OBSERVATION_MODIFIER", 152, 161], ["TLR2", "OBSERVATION_MODIFIER", 162, 166], ["increased", "OBSERVATION_MODIFIER", 226, 235], ["TLR1", "ANATOMY_MODIFIER", 250, 254], ["ileum", "ANATOMY", 290, 295], ["cell line", "OBSERVATION", 296, 305], ["more TLR8", "OBSERVATION_MODIFIER", 323, 332]]], ["Li et al. used a plasmid encoding the pig IL-6 gene and eleven CpG motifs in combination with chitosan nanoparticles as an adjuvant to boost the porcine immune system against an attenuated classical hog cholera vaccine.", [["plasmid", "ANATOMY", 17, 24], ["Li", "CHEMICAL", 0, 2], ["chitosan nanoparticles", "CHEMICAL", 94, 116], ["CpG", "CHEMICAL", 63, 66], ["pig", "ORGANISM", 38, 41], ["IL-6", "GENE_OR_GENE_PRODUCT", 42, 46], ["chitosan nanoparticles", "SIMPLE_CHEMICAL", 94, 116], ["porcine", "ORGANISM", 145, 152], ["immune system", "ANATOMICAL_SYSTEM", 153, 166], ["hog", "ORGANISM", 199, 202], ["plasmid", "DNA", 17, 24], ["pig IL-6 gene", "DNA", 38, 51], ["CpG motifs", "DNA", 63, 73], ["pig", "SPECIES", 38, 41], ["hog", "SPECIES", 199, 202], ["pig", "SPECIES", 38, 41], ["porcine", "SPECIES", 145, 152], ["hog", "SPECIES", 199, 202], ["a plasmid encoding the pig IL", "TREATMENT", 15, 44], ["eleven CpG motifs", "TREATMENT", 56, 73], ["chitosan nanoparticles", "TREATMENT", 94, 116], ["an adjuvant", "TREATMENT", 120, 131], ["the porcine immune system", "TREATMENT", 141, 166]]], ["Inclusion of the adjuvant plasmid was shown to increase the T cell frequency, the amount of antibody as well as the serum levels of IL-2, IL-6, and IFN-c .", [["plasmid", "ANATOMY", 26, 33], ["T cell", "ANATOMY", 60, 66], ["serum", "ANATOMY", 116, 121], ["T cell", "CELL", 60, 66], ["serum", "ORGANISM_SUBSTANCE", 116, 121], ["IL-2", "GENE_OR_GENE_PRODUCT", 132, 136], ["IL-6", "GENE_OR_GENE_PRODUCT", 138, 142], ["IFN-c", "GENE_OR_GENE_PRODUCT", 148, 153], ["adjuvant plasmid", "DNA", 17, 33], ["IL", "PROTEIN", 132, 134], ["IL-6", "PROTEIN", 138, 142], ["IFN", "PROTEIN", 148, 151], ["the adjuvant plasmid", "TREATMENT", 13, 33], ["the T cell frequency", "PROBLEM", 56, 76], ["the serum levels", "TEST", 112, 128], ["IL", "TEST", 132, 134], ["IL", "TEST", 138, 140], ["IFN", "TREATMENT", 148, 151], ["adjuvant plasmid", "OBSERVATION", 17, 33], ["T cell", "OBSERVATION", 60, 66], ["amount", "OBSERVATION_MODIFIER", 82, 88]]], ["Thus, they showed a possible role for TLR ligands as adjuvants in vaccines against pig bacterial diseases.", [["bacterial diseases", "DISEASE", 87, 105], ["TLR ligands", "GENE_OR_GENE_PRODUCT", 38, 49], ["pig", "ORGANISM", 83, 86], ["TLR", "PROTEIN", 38, 41], ["pig", "SPECIES", 83, 86], ["pig", "SPECIES", 83, 86], ["TLR ligands", "TREATMENT", 38, 49], ["adjuvants in vaccines", "TREATMENT", 53, 74], ["pig bacterial diseases", "PROBLEM", 83, 105]]], ["TLR expression has been also assessed in various types of cells such as alveolar macrophages in response to many other important porcine bacterial pathogens including Streptococcus suis (de Greeff et al., 2010) .", [["cells", "ANATOMY", 58, 63], ["alveolar macrophages", "ANATOMY", 72, 92], ["Streptococcus suis", "DISEASE", 167, 185], ["TLR", "GENE_OR_GENE_PRODUCT", 0, 3], ["cells", "CELL", 58, 63], ["alveolar macrophages", "CELL", 72, 92], ["porcine", "ORGANISM", 129, 136], ["Streptococcus suis", "ORGANISM", 167, 185], ["TLR", "PROTEIN", 0, 3], ["alveolar macrophages", "CELL_TYPE", 72, 92], ["Streptococcus suis", "SPECIES", 167, 185], ["Streptococcus suis", "SPECIES", 167, 185], ["alveolar macrophages", "PROBLEM", 72, 92], ["many other important porcine bacterial pathogens", "PROBLEM", 108, 156], ["Streptococcus suis", "PROBLEM", 167, 185], ["alveolar macrophages", "OBSERVATION", 72, 92]]], ["Fungal pathogens are also able to manipulate TLR signalling (Seeboth et al., 2012) .", [["TLR", "GENE_OR_GENE_PRODUCT", 45, 48], ["TLR", "PROTEIN", 45, 48], ["Fungal pathogens", "PROBLEM", 0, 16]]], ["T-2, a fungal toxin, was shown to decrease the production of the inflammatory mediators IL-1b, TNF-a, and nitric oxide (NO) in PAMs in response to LPS (via TLR4) and synthetic diacylated lipoprotein FSL-1 (via TLR2/6).", [["nitric oxide", "CHEMICAL", 106, 118], ["NO", "CHEMICAL", 120, 122], ["LPS", "CHEMICAL", 147, 150], ["nitric oxide", "CHEMICAL", 106, 118], ["NO", "CHEMICAL", 120, 122], ["T-2", "GENE_OR_GENE_PRODUCT", 0, 3], ["IL-1b", "GENE_OR_GENE_PRODUCT", 88, 93], ["TNF-a", "GENE_OR_GENE_PRODUCT", 95, 100], ["nitric oxide", "SIMPLE_CHEMICAL", 106, 118], ["NO", "SIMPLE_CHEMICAL", 120, 122], ["PAMs", "CELL", 127, 131], ["LPS", "SIMPLE_CHEMICAL", 147, 150], ["TLR4", "GENE_OR_GENE_PRODUCT", 156, 160], ["diacylated lipoprotein FSL-1", "GENE_OR_GENE_PRODUCT", 176, 204], ["TLR2", "GENE_OR_GENE_PRODUCT", 210, 214], ["inflammatory mediators", "PROTEIN", 65, 87], ["IL-1b", "PROTEIN", 88, 93], ["TNF", "PROTEIN", 95, 98], ["PAMs", "CELL_TYPE", 127, 131], ["TLR4", "PROTEIN", 156, 160], ["TLR2", "PROTEIN", 210, 214], ["T", "TEST", 0, 1], ["a fungal toxin", "TEST", 5, 19], ["the inflammatory mediators IL", "TREATMENT", 61, 90], ["TNF", "TEST", 95, 98], ["nitric oxide", "TREATMENT", 106, 118], ["LPS", "TEST", 147, 150], ["TLR4", "TEST", 156, 160], ["synthetic diacylated lipoprotein FSL", "TEST", 166, 202], ["inflammatory", "OBSERVATION_MODIFIER", 65, 77]]], ["This reduced pro-inflammatory response was associated with a decline of TLR mRNA expression.", [["TLR", "GENE_OR_GENE_PRODUCT", 72, 75], ["TLR mRNA", "RNA", 72, 80], ["This reduced pro-inflammatory response", "PROBLEM", 0, 38], ["a decline of TLR mRNA expression", "PROBLEM", 59, 91], ["pro-inflammatory response", "OBSERVATION", 13, 38]]], ["Interestingly, the activation of TLR7 by singlestranded RNA (ssRNA) was not modulated by T-2 toxin pre-treatment.", [["T-2 toxin", "CHEMICAL", 89, 98], ["TLR7", "GENE_OR_GENE_PRODUCT", 33, 37], ["singlestranded RNA", "GENE_OR_GENE_PRODUCT", 41, 59], ["T-2 toxin", "GENE_OR_GENE_PRODUCT", 89, 98], ["TLR7", "PROTEIN", 33, 37], ["singlestranded RNA", "RNA", 41, 59], ["singlestranded RNA (ssRNA", "PROBLEM", 41, 66]]], ["These data suggest that fungal pathogens might decrease pattern recognition of pathogens and therefore interfere with the initiation of an effective immune response (Seeboth et al., 2012) .Nucleotide-binding oligomerization domain (NODs)-like receptorsThe NLR family is the largest group of PRRs and they detect PAMPs within the cytosol.", [["cytosol", "ANATOMY", 329, 336], ["fungal pathogens", "DISEASE", 24, 40], ["Nucleotide", "CHEMICAL", 189, 199], ["Nucleotide-binding oligomerization domain (NODs)-like receptors", "GENE_OR_GENE_PRODUCT", 189, 252], ["NLR", "GENE_OR_GENE_PRODUCT", 256, 259], ["PRRs", "GENE_OR_GENE_PRODUCT", 291, 295], ["PAMPs", "GENE_OR_GENE_PRODUCT", 312, 317], ["cytosol", "CELLULAR_COMPONENT", 329, 336], ["Nucleotide-binding oligomerization domain (NODs)-like receptors", "PROTEIN", 189, 252], ["NLR family", "PROTEIN", 256, 266], ["PRRs", "PROTEIN", 291, 295], ["PAMPs", "PROTEIN", 312, 317], ["These data", "TEST", 0, 10], ["fungal pathogens", "PROBLEM", 24, 40], ["pathogens", "PROBLEM", 79, 88], ["Nucleotide-binding oligomerization domain", "TREATMENT", 189, 230], ["fungal", "OBSERVATION", 24, 30]]], ["Nearly all of its members have a C-terminal leucine-rich repeat (LRR) responsible for the detection of diverse PAMPs, a central NOD (NACHT) domain able to induce oligomerization upon PAMP detection.", [["C", "CHEMICAL", 33, 34], ["leucine", "CHEMICAL", 44, 51], ["PAMPs", "GENE_OR_GENE_PRODUCT", 111, 116], ["NOD", "GENE_OR_GENE_PRODUCT", 128, 131], ["NACHT", "GENE_OR_GENE_PRODUCT", 133, 138], ["PAMP", "GENE_OR_GENE_PRODUCT", 183, 187], ["C-terminal leucine-rich repeat", "PROTEIN", 33, 63], ["LRR", "PROTEIN", 65, 68], ["PAMPs", "PROTEIN", 111, 116], ["central NOD (NACHT) domain", "PROTEIN", 120, 146], ["PAMP", "PROTEIN", 183, 187], ["diverse PAMPs", "PROBLEM", 103, 116], ["a central NOD (NACHT) domain", "TREATMENT", 118, 146], ["PAMP detection", "TEST", 183, 197]]], ["Different N-terminal domains divide the NLRs into different subfamilies: NLRA (MHC class II transactivator -CIITA-) has an acid transactivation domain, NLRB has a baculovirus inhibitor of apoptosis protein repeat (BIR), NLRC has a caspase-recruitment domain (CARD) (this subfamily includes NLRX1, NLRC3, and NLRC5 which contain a CARD-related X effector domain) and NLRP has a pyrin domain (PYD).", [["NLRA", "GENE_OR_GENE_PRODUCT", 73, 77], ["CIITA", "GENE_OR_GENE_PRODUCT", 108, 113], ["NLRB", "GENE_OR_GENE_PRODUCT", 152, 156], ["NLRC", "GENE_OR_GENE_PRODUCT", 220, 224], ["caspase", "GENE_OR_GENE_PRODUCT", 231, 238], ["CARD", "GENE_OR_GENE_PRODUCT", 259, 263], ["NLRX1", "GENE_OR_GENE_PRODUCT", 290, 295], ["NLRC3", "GENE_OR_GENE_PRODUCT", 297, 302], ["NLRC5", "GENE_OR_GENE_PRODUCT", 308, 313], ["CARD", "GENE_OR_GENE_PRODUCT", 330, 334], ["NLRP", "GENE_OR_GENE_PRODUCT", 366, 370], ["pyrin", "GENE_OR_GENE_PRODUCT", 377, 382], ["PYD", "GENE_OR_GENE_PRODUCT", 391, 394], ["N-terminal domains", "PROTEIN", 10, 28], ["NLRs", "PROTEIN", 40, 44], ["NLRA", "PROTEIN", 73, 77], ["MHC class II transactivator", "PROTEIN", 79, 106], ["CIITA", "PROTEIN", 108, 113], ["acid transactivation domain", "PROTEIN", 123, 150], ["NLRB", "PROTEIN", 152, 156], ["baculovirus inhibitor of apoptosis protein repeat", "PROTEIN", 163, 212], ["BIR", "PROTEIN", 214, 217], ["NLRC", "PROTEIN", 220, 224], ["caspase-recruitment domain", "PROTEIN", 231, 257], ["CARD", "PROTEIN", 259, 263], ["NLRX1", "PROTEIN", 290, 295], ["NLRC3", "PROTEIN", 297, 302], ["NLRC5", "PROTEIN", 308, 313], ["CARD", "PROTEIN", 330, 334], ["X effector domain", "PROTEIN", 343, 360], ["NLRP", "PROTEIN", 366, 370], ["pyrin domain", "PROTEIN", 377, 389], ["PYD", "PROTEIN", 391, 394], ["baculovirus", "SPECIES", 163, 174], ["Different N-terminal domains", "PROBLEM", 0, 28], ["an acid transactivation domain", "PROBLEM", 120, 150], ["NLRB", "TREATMENT", 152, 156], ["a baculovirus inhibitor", "TREATMENT", 161, 184], ["a caspase", "TREATMENT", 229, 238], ["NLRC3", "TREATMENT", 297, 302], ["NLRP", "TREATMENT", 366, 370]]], ["Upon NLR-ligand binding to the distinct N-terminal domains, specific signalling cascades are triggered to determine the immunological response (Benko et al., 2008; Kumar et al., 2011; Zhong et al., 2013) .", [["N", "CHEMICAL", 40, 41], ["NLR", "GENE_OR_GENE_PRODUCT", 5, 8], ["NLR", "PROTEIN", 5, 8], ["N-terminal domains", "PROTEIN", 40, 58], ["NLR", "TEST", 5, 8], ["specific signalling cascades", "PROBLEM", 60, 88], ["signalling cascades", "OBSERVATION", 69, 88]]], ["NLRs are able to induce an inflammatory response in two ways.", [["NLRs", "GENE_OR_GENE_PRODUCT", 0, 4], ["NLRs", "PROTEIN", 0, 4], ["an inflammatory response", "PROBLEM", 24, 48], ["inflammatory", "OBSERVATION", 27, 39]]], ["On one hand, NLRP1, NLRP3, NLRP6, NLRP7, NLRP12, NLRC4 (IPAF), and the NLR family, apoptosis inhibitory protein (NAIP), recruit protease caspase-1 and activate inflammasomes.", [["NLRP1", "GENE_OR_GENE_PRODUCT", 13, 18], ["NLRP3", "GENE_OR_GENE_PRODUCT", 20, 25], ["NLRP6", "GENE_OR_GENE_PRODUCT", 27, 32], ["NLRP7", "GENE_OR_GENE_PRODUCT", 34, 39], ["NLRP12", "GENE_OR_GENE_PRODUCT", 41, 47], ["NLRC4", "GENE_OR_GENE_PRODUCT", 49, 54], ["IPAF", "GENE_OR_GENE_PRODUCT", 56, 60], ["NLR", "GENE_OR_GENE_PRODUCT", 71, 74], ["apoptosis inhibitory protein", "GENE_OR_GENE_PRODUCT", 83, 111], ["NAIP", "GENE_OR_GENE_PRODUCT", 113, 117], ["protease caspase-1", "GENE_OR_GENE_PRODUCT", 128, 146], ["NLRP1", "PROTEIN", 13, 18], ["NLRP3", "PROTEIN", 20, 25], ["NLRP6", "PROTEIN", 27, 32], ["NLRP7", "PROTEIN", 34, 39], ["NLRP12", "PROTEIN", 41, 47], ["NLRC4", "PROTEIN", 49, 54], ["IPAF", "PROTEIN", 56, 60], ["NLR family", "PROTEIN", 71, 81], ["apoptosis inhibitory protein", "PROTEIN", 83, 111], ["NAIP", "PROTEIN", 113, 117], ["protease caspase-1", "PROTEIN", 128, 146], ["inflammasomes", "PROTEIN", 160, 173], ["NLRP1", "TREATMENT", 13, 18], ["NLRP3", "TREATMENT", 20, 25], ["NLRP6", "TREATMENT", 27, 32], ["NLRP7", "TREATMENT", 34, 39], ["NLRP12", "TREATMENT", 41, 47], ["NLRC4", "TREATMENT", 49, 54], ["apoptosis inhibitory protein (NAIP", "TREATMENT", 83, 117], ["recruit protease caspase", "TREATMENT", 120, 144]]], ["Inflammasomes promote the processing and maturation of the inflammatory cytokines IL-1b and IL-18 and induce pyroptosis -an inflammatory form of cell death.", [["cell", "ANATOMY", 145, 149], ["pyroptosis", "DISEASE", 109, 119], ["death", "DISEASE", 150, 155], ["IL-1b", "GENE_OR_GENE_PRODUCT", 82, 87], ["IL-18", "GENE_OR_GENE_PRODUCT", 92, 97], ["cell", "CELL", 145, 149], ["inflammatory cytokines IL-1b and IL-18", "PROTEIN", 59, 97], ["Inflammasomes", "PROBLEM", 0, 13], ["the processing", "TREATMENT", 22, 36], ["the inflammatory cytokines IL", "TEST", 55, 84], ["IL", "TEST", 92, 94], ["pyroptosis", "PROBLEM", 109, 119], ["cell death", "PROBLEM", 145, 155], ["inflammatory", "OBSERVATION_MODIFIER", 59, 71], ["pyroptosis", "OBSERVATION", 109, 119], ["inflammatory", "OBSERVATION", 124, 136], ["cell death", "OBSERVATION", 145, 155]]], ["On the other hand, NOD1, NOD2, NLRP10, and NLRX1 induce the transcription of inflammatory cytokines through NFjB, mitogen-activated protein kinases (MAPKs) and IRFs (Zhong et al., 2013) .", [["NOD1", "GENE_OR_GENE_PRODUCT", 19, 23], ["NOD2", "GENE_OR_GENE_PRODUCT", 25, 29], ["NLRP10", "GENE_OR_GENE_PRODUCT", 31, 37], ["NLRX1", "GENE_OR_GENE_PRODUCT", 43, 48], ["NFjB", "GENE_OR_GENE_PRODUCT", 108, 112], ["mitogen-activated protein kinases", "GENE_OR_GENE_PRODUCT", 114, 147], ["MAPKs", "GENE_OR_GENE_PRODUCT", 149, 154], ["NOD1", "PROTEIN", 19, 23], ["NOD2", "PROTEIN", 25, 29], ["NLRP10", "PROTEIN", 31, 37], ["NLRX1", "PROTEIN", 43, 48], ["inflammatory cytokines", "PROTEIN", 77, 99], ["NFjB", "PROTEIN", 108, 112], ["mitogen-activated protein kinases", "PROTEIN", 114, 147], ["MAPKs", "PROTEIN", 149, 154], ["IRFs", "PROTEIN", 160, 164], ["NOD2", "TEST", 25, 29], ["NLRP10", "TEST", 31, 37], ["NLRX1", "TREATMENT", 43, 48], ["inflammatory cytokines", "PROBLEM", 77, 99], ["NFjB", "TEST", 108, 112], ["mitogen", "TEST", 114, 121], ["IRFs", "PROBLEM", 160, 164], ["inflammatory", "OBSERVATION_MODIFIER", 77, 89]]], ["In contrast, NLRC5 and CIITA seem to be master regulators of MHC-I and MHC-II expression, respectively, and thereby strongly influence antigen presentation (Kobayashi and van den Elsen, 2012) .", [["NLRC5", "GENE_OR_GENE_PRODUCT", 13, 18], ["CIITA", "GENE_OR_GENE_PRODUCT", 23, 28], ["MHC-I", "GENE_OR_GENE_PRODUCT", 61, 66], ["MHC-II", "GENE_OR_GENE_PRODUCT", 71, 77], ["NLRC5", "PROTEIN", 13, 18], ["CIITA", "PROTEIN", 23, 28], ["MHC", "PROTEIN", 61, 64], ["MHC", "PROTEIN", 71, 74]]], ["Details on the individual NLR ligands and signalling pathways are summarized in Table 2 .Nucleotide-binding oligomerization domain (NODs)-like receptorsIn swine, NOD1 and NOD2 were cloned and functionally characterized (Tohno et al., 2008a,b) .", [["Nucleotide", "CHEMICAL", 89, 99], ["NLR", "GENE_OR_GENE_PRODUCT", 26, 29], ["Nucleotide-binding oligomerization domain (NODs)-like receptors", "GENE_OR_GENE_PRODUCT", 89, 152], ["swine", "ORGANISM", 155, 160], ["NOD1", "GENE_OR_GENE_PRODUCT", 162, 166], ["NOD2", "GENE_OR_GENE_PRODUCT", 171, 175], ["NLR", "PROTEIN", 26, 29], ["Nucleotide-binding oligomerization domain (NODs)-like receptors", "PROTEIN", 89, 152], ["NOD1", "PROTEIN", 162, 166], ["NOD2", "PROTEIN", 171, 175], ["swine", "SPECIES", 155, 160], ["swine", "SPECIES", 155, 160], ["Nucleotide-binding oligomerization domain", "TREATMENT", 89, 130]]], ["Porcine NOD (poNOD) 1 and 2 have an 83.8% and 81.6% amino acid identity with human NOD2, respectively (Tohno et al., 2008a,b) .", [["amino acid", "CHEMICAL", 52, 62], ["amino acid", "CHEMICAL", 52, 62], ["Porcine", "ORGANISM", 0, 7], ["NOD (poNOD) 1", "GENE_OR_GENE_PRODUCT", 8, 21], ["2", "GENE_OR_GENE_PRODUCT", 26, 27], ["amino acid", "AMINO_ACID", 52, 62], ["human", "ORGANISM", 77, 82], ["NOD2", "GENE_OR_GENE_PRODUCT", 83, 87], ["Porcine NOD (poNOD) 1 and 2", "PROTEIN", 0, 27], ["human NOD2", "PROTEIN", 77, 87], ["Porcine", "SPECIES", 0, 7], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 77, 82], ["amino acid identity", "TEST", 52, 71], ["human NOD2", "ANATOMY", 77, 87]]], ["Both poNODs were expressed in numerous tissues.", [["tissues", "ANATOMY", 39, 46], ["poNODs", "GENE_OR_GENE_PRODUCT", 5, 11], ["tissues", "TISSUE", 39, 46], ["poNODs", "PROTEIN", 5, 11], ["numerous tissues", "OBSERVATION", 30, 46]]], ["In newborn piglets, poNOD1 expression was shown to be highly elevated in MLN and the oesophagus while poNOD2 expression was elevated in MLN and the spleen.", [["MLN", "ANATOMY", 73, 76], ["oesophagus", "ANATOMY", 85, 95], ["MLN", "ANATOMY", 136, 139], ["spleen", "ANATOMY", 148, 154], ["piglets", "ORGANISM", 11, 18], ["poNOD1", "GENE_OR_GENE_PRODUCT", 20, 26], ["MLN", "CELL", 73, 76], ["oesophagus", "ORGAN", 85, 95], ["poNOD2", "GENE_OR_GENE_PRODUCT", 102, 108], ["MLN", "CELL", 136, 139], ["spleen", "ORGAN", 148, 154], ["poNOD1", "PROTEIN", 20, 26], ["poNOD2", "PROTEIN", 102, 108], ["MLN", "CELL_TYPE", 136, 139], ["piglets", "SPECIES", 11, 18], ["elevated in MLN and the spleen", "PROBLEM", 124, 154], ["elevated", "OBSERVATION", 61, 69], ["MLN", "ANATOMY", 73, 76], ["oesophagus", "ANATOMY", 85, 95], ["elevated", "OBSERVATION_MODIFIER", 124, 132], ["MLN", "ANATOMY", 136, 139], ["spleen", "ANATOMY", 148, 154]]], ["In adult pigs, poNOD1 expression remained highly elevated but poNOD2 expression was much more dispersed among various tissues.", [["tissues", "ANATOMY", 118, 125], ["pigs", "ORGANISM", 9, 13], ["poNOD1", "GENE_OR_GENE_PRODUCT", 15, 21], ["poNOD2", "GENE_OR_GENE_PRODUCT", 62, 68], ["tissues", "TISSUE", 118, 125], ["poNOD1", "PROTEIN", 15, 21], ["poNOD2", "PROTEIN", 62, 68], ["pigs", "SPECIES", 9, 13], ["pigs", "SPECIES", 9, 13], ["highly elevated", "PROBLEM", 42, 57], ["poNOD2 expression", "PROBLEM", 62, 79], ["highly", "OBSERVATION_MODIFIER", 42, 48], ["elevated", "OBSERVATION", 49, 57], ["various tissues", "OBSERVATION", 110, 125]]], ["Fur-thermore, TLR and NOD ligands as well as immunobiotic lactic acid bacteria strongly increased poNOD1 and 2 expressions in the gutassociated lymphoid tissues (GALT).", [["gutassociated lymphoid tissues", "ANATOMY", 130, 160], ["GALT", "ANATOMY", 162, 166], ["lactic acid", "CHEMICAL", 58, 69], ["lactic acid", "CHEMICAL", 58, 69], ["TLR", "GENE_OR_GENE_PRODUCT", 14, 17], ["immunobiotic lactic acid", "SIMPLE_CHEMICAL", 45, 69], ["NOD1", "GENE_OR_GENE_PRODUCT", 100, 104], ["2", "GENE_OR_GENE_PRODUCT", 109, 110], ["gutassociated lymphoid tissues", "TISSUE", 130, 160], ["GALT", "TISSUE", 162, 166], ["TLR", "PROTEIN", 14, 17], ["NOD1", "PROTEIN", 100, 104], ["NOD ligands", "TEST", 22, 33], ["immunobiotic lactic acid bacteria", "TEST", 45, 78], ["increased", "OBSERVATION_MODIFIER", 88, 97], ["poNOD1", "OBSERVATION", 98, 104], ["lymphoid tissues", "ANATOMY", 144, 160]]], ["For functional analysis of poN-ODs, Tohno et al. transfected HEK-293 cells with poNOD sequences.", [["HEK-293 cells", "ANATOMY", 61, 74], ["HEK-293 cells", "CELL", 61, 74], ["poNOD", "GENE_OR_GENE_PRODUCT", 80, 85], ["HEK-293 cells", "CELL_LINE", 61, 74], ["poNOD sequences", "DNA", 80, 95], ["poN-ODs", "TREATMENT", 27, 34], ["poNOD sequences", "TEST", 80, 95]]], ["Transfected HEK293 cells expressed both poNODs as an intracellular membrane-bound molecule and poNOD2 also in the cytoplasm.", [["HEK293 cells", "ANATOMY", 12, 24], ["intracellular membrane", "ANATOMY", 53, 75], ["cytoplasm", "ANATOMY", 114, 123], ["HEK293 cells", "CELL", 12, 24], ["poNODs", "GENE_OR_GENE_PRODUCT", 40, 46], ["intracellular membrane", "CELLULAR_COMPONENT", 53, 75], ["poNOD2", "GENE_OR_GENE_PRODUCT", 95, 101], ["cytoplasm", "ORGANISM_SUBSTANCE", 114, 123], ["HEK293 cells", "CELL_LINE", 12, 24], ["poNODs", "PROTEIN", 40, 46], ["intracellular membrane-bound molecule", "PROTEIN", 53, 90], ["poNOD2", "PROTEIN", 95, 101], ["an intracellular membrane", "TEST", 50, 75], ["HEK293 cells", "OBSERVATION", 12, 24], ["intracellular membrane", "OBSERVATION", 53, 75], ["bound molecule", "OBSERVATION", 76, 90], ["cytoplasm", "ANATOMY_MODIFIER", 114, 123]]], ["Upon stimulation with gamma-D-glutamyl-mesodiaminopimelic acid, meso-diaminopimelic acid and meso-lanthionine for poNOD1, and muramyl dipeptide (MDP) for poNOD2, both transfected HEK-293 cells responded with the activation of NFjB (Tohno et al., 2008b) .", [["HEK-293 cells", "ANATOMY", 179, 192], ["gamma-D-glutamyl-mesodiaminopimelic acid", "CHEMICAL", 22, 62], ["meso-diaminopimelic acid", "CHEMICAL", 64, 88], ["meso-lanthionine", "CHEMICAL", 93, 109], ["poNOD1", "CHEMICAL", 114, 120], ["muramyl dipeptide", "CHEMICAL", 126, 143], ["MDP", "CHEMICAL", 145, 148], ["gamma-D-glutamyl-mesodiaminopimelic acid", "CHEMICAL", 22, 62], ["meso-diaminopimelic acid", "CHEMICAL", 64, 88], ["meso-lanthionine", "CHEMICAL", 93, 109], ["muramyl dipeptide", "CHEMICAL", 126, 143], ["MDP", "CHEMICAL", 145, 148], ["gamma-D-glutamyl-mesodiaminopimelic acid", "SIMPLE_CHEMICAL", 22, 62], ["meso-diaminopimelic acid", "SIMPLE_CHEMICAL", 64, 88], ["meso-lanthionine", "SIMPLE_CHEMICAL", 93, 109], ["poNOD1", "SIMPLE_CHEMICAL", 114, 120], ["muramyl dipeptide", "SIMPLE_CHEMICAL", 126, 143], ["MDP", "SIMPLE_CHEMICAL", 145, 148], ["poNOD2", "SIMPLE_CHEMICAL", 154, 160], ["HEK-293 cells", "CELL", 179, 192], ["NFjB", "GENE_OR_GENE_PRODUCT", 226, 230], ["poNOD1", "PROTEIN", 114, 120], ["poNOD2", "PROTEIN", 154, 160], ["transfected HEK-293 cells", "CELL_LINE", 167, 192], ["NFjB", "PROTEIN", 226, 230], ["stimulation", "TEST", 5, 16], ["gamma-D", "TEST", 22, 29], ["glutamyl", "TEST", 30, 38], ["mesodiaminopimelic acid", "TREATMENT", 39, 62], ["meso-diaminopimelic acid", "TREATMENT", 64, 88], ["meso-lanthionine", "TREATMENT", 93, 109], ["poNOD1", "TREATMENT", 114, 120], ["muramyl dipeptide", "TREATMENT", 126, 143]]], ["These data demonstrate the potential of poNODs in the innate immune response against bacterial infections.", [["bacterial infections", "DISEASE", 85, 105], ["poNODs", "GENE_OR_GENE_PRODUCT", 40, 46], ["These data", "TEST", 0, 10], ["poNODs", "PROBLEM", 40, 46], ["bacterial infections", "PROBLEM", 85, 105], ["bacterial", "OBSERVATION_MODIFIER", 85, 94], ["infections", "OBSERVATION", 95, 105]]], ["Furthermore, Jozaki et al. found a reduced MBL binding capacity for a SNP in the poNOD2 hinge region emphasizing the role of PRR polymorphism studies in selection for disease resistance in pig production (Jozaki et al., 2009 ).Retinoic acid-inducible gene (RIG)-I-like receptorsRIG-1, melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2) are the three members of the RLR family and they are responsible for the detection of RNA viruses within the cytoplasm.", [["melanoma", "ANATOMY", 285, 293], ["cytoplasm", "ANATOMY", 498, 507], ["SNP", "CHEMICAL", 70, 73], ["MBL", "GENE_OR_GENE_PRODUCT", 43, 46], ["PRR", "GENE_OR_GENE_PRODUCT", 125, 128], ["pig", "ORGANISM", 189, 192], ["Retinoic acid-inducible gene (RIG)-I-like receptorsRIG-1", "GENE_OR_GENE_PRODUCT", 227, 283], ["melanoma differentiation-associated protein 5", "GENE_OR_GENE_PRODUCT", 285, 330], ["MDA5", "GENE_OR_GENE_PRODUCT", 332, 336], ["physiology 2", "GENE_OR_GENE_PRODUCT", 369, 381], ["LGP2", "GENE_OR_GENE_PRODUCT", 383, 387], ["RLR", "GENE_OR_GENE_PRODUCT", 418, 421], ["cytoplasm", "ORGANISM_SUBSTANCE", 498, 507], ["MBL", "PROTEIN", 43, 46], ["poNOD2 hinge region", "DNA", 81, 100], ["PRR", "PROTEIN", 125, 128], ["Retinoic acid-inducible gene (RIG)-I-like receptors", "PROTEIN", 227, 278], ["RIG-1", "PROTEIN", 278, 283], ["melanoma differentiation-associated protein 5", "PROTEIN", 285, 330], ["MDA5", "PROTEIN", 332, 336], ["RLR family", "PROTEIN", 418, 428], ["pig", "SPECIES", 189, 192], ["pig", "SPECIES", 189, 192], ["a reduced MBL binding capacity", "PROBLEM", 33, 63], ["a SNP in the poNOD2 hinge region", "TREATMENT", 68, 100], ["PRR polymorphism studies", "TREATMENT", 125, 149], ["disease resistance", "PROBLEM", 167, 185], ["Retinoic acid-inducible gene (RIG)", "PROBLEM", 227, 261], ["receptorsRIG", "TEST", 269, 281], ["melanoma differentiation", "PROBLEM", 285, 309], ["associated protein", "PROBLEM", 310, 328], ["RNA viruses within the cytoplasm", "PROBLEM", 475, 507], ["reduced", "OBSERVATION_MODIFIER", 35, 42], ["MBL", "OBSERVATION", 43, 46], ["melanoma", "OBSERVATION", 285, 293]]], ["They bind doublestranded RNA during the replication cycle of RNA viruses by an RNA helicase domain and, upon ligand binding, the CARD domains in RIG-1 and MDA5 associate with the adaptor protein IPS1.", [["RIG-1", "GENE_OR_GENE_PRODUCT", 145, 150], ["MDA5", "GENE_OR_GENE_PRODUCT", 155, 159], ["IPS1", "GENE_OR_GENE_PRODUCT", 195, 199], ["doublestranded RNA", "RNA", 10, 28], ["RNA helicase domain", "PROTEIN", 79, 98], ["CARD domains", "PROTEIN", 129, 141], ["RIG-1", "PROTEIN", 145, 150], ["MDA5", "PROTEIN", 155, 159], ["adaptor protein", "PROTEIN", 179, 194], ["IPS1", "PROTEIN", 195, 199], ["RNA viruses", "PROBLEM", 61, 72], ["RIG", "TEST", 145, 148], ["the adaptor protein IPS1", "TREATMENT", 175, 199], ["RNA viruses", "OBSERVATION", 61, 72]]], ["This association induces a signalling cascade to activate the expression of inflammatory cytokines and type-I IFNs through NFjB and IRF3/ 7 and leads to the induction of an antiviral state in virus-infected cells.", [["cells", "ANATOMY", 207, 212], ["type-I IFNs", "GENE_OR_GENE_PRODUCT", 103, 114], ["NFjB", "GENE_OR_GENE_PRODUCT", 123, 127], ["IRF3/ 7", "GENE_OR_GENE_PRODUCT", 132, 139], ["cells", "CELL", 207, 212], ["inflammatory cytokines", "PROTEIN", 76, 98], ["type-I IFNs", "PROTEIN", 103, 114], ["NFjB", "PROTEIN", 123, 127], ["IRF3/ 7", "PROTEIN", 132, 139], ["virus-infected cells", "CELL_TYPE", 192, 212], ["a signalling cascade", "PROBLEM", 25, 45], ["inflammatory cytokines", "PROBLEM", 76, 98], ["type-I IFNs through NFjB", "PROBLEM", 103, 127], ["IRF3/ 7", "TREATMENT", 132, 139], ["an antiviral state in virus", "PROBLEM", 170, 197], ["infected cells", "PROBLEM", 198, 212], ["inflammatory", "OBSERVATION_MODIFIER", 76, 88], ["infected cells", "OBSERVATION", 198, 212]]], ["The role of LGP2 is still controversial (Szabo and Rajnavolgyi, 2013) .Retinoic acid-inducible gene (RIG)-I-like receptorsLGP2 lacks a CARD domain and was therefore thought to have a negative regulatory role in RNA virus sensing but recent data showed that LGP2 \u00c0/\u00c0 mice showed a decreased production of IFNs upon RNA virus infection suggesting a positive role of LGP2 in RNA virus detection (Szabo and Rajnavolgyi, 2013) .", [["infection", "DISEASE", 324, 333], ["LGP2", "GENE_OR_GENE_PRODUCT", 12, 16], ["Retinoic acid-inducible gene (RIG)-I-", "GENE_OR_GENE_PRODUCT", 71, 108], ["receptorsLGP2", "GENE_OR_GENE_PRODUCT", 113, 126], ["CARD", "GENE_OR_GENE_PRODUCT", 135, 139], ["LGP2", "GENE_OR_GENE_PRODUCT", 257, 261], ["IFNs", "GENE_OR_GENE_PRODUCT", 304, 308], ["RNA virus", "ORGANISM", 314, 323], ["LGP2", "GENE_OR_GENE_PRODUCT", 364, 368], ["LGP2", "PROTEIN", 12, 16], ["Retinoic acid-inducible gene (RIG)-I-like receptorsLGP2", "PROTEIN", 71, 126], ["CARD domain", "PROTEIN", 135, 146], ["LGP2", "PROTEIN", 257, 261], ["IFNs", "PROTEIN", 304, 308], ["LGP2", "PROTEIN", 364, 368], ["mice", "SPECIES", 266, 270], ["mice", "SPECIES", 266, 270], ["Retinoic acid-inducible gene (RIG)-I-like receptorsLGP2", "PROBLEM", 71, 126], ["RNA virus sensing", "PROBLEM", 211, 228], ["recent data", "TEST", 233, 244], ["LGP2", "TEST", 257, 261], ["a decreased production of IFNs", "PROBLEM", 278, 308], ["RNA virus infection", "PROBLEM", 314, 333], ["negative", "OBSERVATION", 183, 191], ["decreased", "OBSERVATION", 280, 289], ["positive", "OBSERVATION_MODIFIER", 347, 355]]], ["In pigs, an induction of LGP2 has been observed in alveolar macrophages and lung explants in response to influenza virus (Dobrescu et al., 2014) .", [["alveolar macrophages", "ANATOMY", 51, 71], ["lung explants", "ANATOMY", 76, 89], ["influenza virus", "DISEASE", 105, 120], ["pigs", "ORGANISM", 3, 7], ["LGP2", "GENE_OR_GENE_PRODUCT", 25, 29], ["alveolar macrophages", "CELL", 51, 71], ["lung explants", "TISSUE", 76, 89], ["influenza virus", "ORGANISM", 105, 120], ["LGP2", "PROTEIN", 25, 29], ["alveolar macrophages", "CELL_TYPE", 51, 71], ["pigs", "SPECIES", 3, 7], ["pigs", "SPECIES", 3, 7], ["an induction of LGP2", "TREATMENT", 9, 29], ["alveolar macrophages", "PROBLEM", 51, 71], ["lung explants", "PROBLEM", 76, 89], ["influenza virus", "PROBLEM", 105, 120], ["alveolar macrophages", "OBSERVATION", 51, 71], ["lung", "ANATOMY", 76, 80]]], ["Details on the individual RLR ligands and signalling pathways are summarized in Table 2 .Retinoic acid-inducible gene (RIG)-I-like receptorsH\u00fcsser et al. described the role played by RIG-1 and MDA-5 (and TLR-3) in porcine RNA virus infections (H\u00fcsser et al., 2011) .", [["infections", "DISEASE", 232, 242], ["RLR", "GENE_OR_GENE_PRODUCT", 26, 29], ["Retinoic acid-inducible gene (RIG)-I-", "GENE_OR_GENE_PRODUCT", 89, 126], ["RIG-1", "GENE_OR_GENE_PRODUCT", 183, 188], ["MDA-5", "GENE_OR_GENE_PRODUCT", 193, 198], ["TLR-3", "GENE_OR_GENE_PRODUCT", 204, 209], ["porcine RNA virus", "ORGANISM", 214, 231], ["RLR ligands", "PROTEIN", 26, 37], ["Retinoic acid-inducible gene (RIG)-I-like receptors", "PROTEIN", 89, 140], ["RIG", "PROTEIN", 183, 186], ["MDA", "PROTEIN", 193, 196], ["TLR", "PROTEIN", 204, 207], ["Retinoic acid-inducible gene (RIG)", "PROBLEM", 89, 123], ["MDA", "TEST", 193, 196], ["porcine RNA virus infections", "PROBLEM", 214, 242]]], ["They analysed their recognition of CSFV, FMDV, VSV, and IAV and used small interfering RNA to knockdown RIG-1 and MDA-5 expression in the porcine epithelial cell line porcine kidney 15 (PK15).", [["epithelial cell line porcine kidney", "ANATOMY", 146, 181], ["CSFV", "ORGANISM", 35, 39], ["FMDV", "ORGANISM", 41, 45], ["VSV", "ORGANISM", 47, 50], ["IAV", "ORGANISM", 56, 59], ["RIG-1", "GENE_OR_GENE_PRODUCT", 104, 109], ["MDA-5", "GENE_OR_GENE_PRODUCT", 114, 119], ["porcine", "ORGANISM", 138, 145], ["epithelial cell line porcine kidney 15", "CELL", 146, 184], ["PK15", "CELL", 186, 190], ["small interfering RNA", "RNA", 69, 90], ["RIG", "PROTEIN", 104, 107], ["MDA", "PROTEIN", 114, 117], ["porcine epithelial cell line porcine kidney 15", "CELL_LINE", 138, 184], ["PK15", "CELL_LINE", 186, 190], ["FMDV", "SPECIES", 41, 45], ["VSV", "SPECIES", 47, 50], ["porcine", "SPECIES", 167, 174], ["CSFV", "SPECIES", 35, 39], ["FMDV", "SPECIES", 41, 45], ["VSV", "SPECIES", 47, 50], ["IAV", "SPECIES", 56, 59], ["CSFV", "PROBLEM", 35, 39], ["VSV", "TREATMENT", 47, 50], ["IAV", "PROBLEM", 56, 59], ["small interfering RNA", "PROBLEM", 69, 90], ["knockdown RIG", "TEST", 94, 107], ["MDA", "TEST", 114, 117], ["the porcine epithelial cell line porcine kidney", "TREATMENT", 134, 181], ["CSFV", "OBSERVATION", 35, 39], ["small", "OBSERVATION_MODIFIER", 69, 74], ["interfering", "OBSERVATION", 75, 86], ["porcine", "ANATOMY_MODIFIER", 138, 145], ["epithelial cell line", "OBSERVATION", 146, 166], ["kidney", "ANATOMY", 175, 181]]], ["These knockdown cell lines were then analysed for their IFN-b responses after stimulation with the various RNA viruses.", [["cell lines", "ANATOMY", 16, 26], ["cell lines", "CELL", 16, 26], ["IFN-b", "GENE_OR_GENE_PRODUCT", 56, 61], ["knockdown cell lines", "CELL_LINE", 6, 26], ["IFN", "PROTEIN", 56, 59], ["These knockdown cell lines", "TREATMENT", 0, 26], ["stimulation", "TREATMENT", 78, 89], ["the various RNA viruses", "PROBLEM", 95, 118], ["knockdown cell lines", "OBSERVATION", 6, 26], ["RNA viruses", "OBSERVATION", 107, 118]]], ["Their results indicated that VSV and IAV are largely detected by RIG-I with a minor contribution of MDA-5 while CSFV is sensed by MDA-5 and RIG-I (and TLR3).", [["VSV", "ORGANISM", 29, 32], ["IAV", "ORGANISM", 37, 40], ["RIG-I", "GENE_OR_GENE_PRODUCT", 65, 70], ["MDA-5", "GENE_OR_GENE_PRODUCT", 100, 105], ["CSFV", "ORGANISM", 112, 116], ["MDA-5", "GENE_OR_GENE_PRODUCT", 130, 135], ["RIG-I", "GENE_OR_GENE_PRODUCT", 140, 145], ["TLR3", "GENE_OR_GENE_PRODUCT", 151, 155], ["RIG-I", "PROTEIN", 65, 70], ["MDA", "PROTEIN", 130, 133], ["RIG-I", "PROTEIN", 140, 145], ["TLR3", "PROTEIN", 151, 155], ["VSV", "SPECIES", 29, 32], ["IAV", "SPECIES", 37, 40], ["CSFV", "SPECIES", 112, 116], ["VSV", "PROBLEM", 29, 32], ["IAV", "PROBLEM", 37, 40], ["MDA", "TEST", 100, 103], ["CSFV", "PROBLEM", 112, 116], ["MDA", "TEST", 130, 133], ["RIG", "TEST", 140, 143], ["VSV", "OBSERVATION", 29, 32], ["IAV", "OBSERVATION", 37, 40]]], ["The response to FMDV-infection seems to be solely mediated by MDA-5 (H\u00fcsser et al., 2011) .", [["FMDV-infection", "DISEASE", 16, 30], ["MDA-5", "CHEMICAL", 62, 67], ["FMDV", "ORGANISM", 16, 20], ["MDA-5", "GENE_OR_GENE_PRODUCT", 62, 67], ["FMDV", "SPECIES", 16, 20], ["FMDV", "SPECIES", 16, 20], ["FMDV", "PROBLEM", 16, 20], ["infection", "PROBLEM", 21, 30], ["infection", "OBSERVATION", 21, 30]]], ["The lack of RIG-1 response upon FMDV-infection is supported by a study from Wang et al. who demonstrated that FMDV is able to inhibit the activation of RIG-1 .", [["FMDV-infection", "DISEASE", 32, 46], ["RIG-1", "GENE_OR_GENE_PRODUCT", 12, 17], ["FMDV", "ORGANISM", 32, 36], ["FMDV", "ORGANISM", 110, 114], ["RIG-1", "GENE_OR_GENE_PRODUCT", 152, 157], ["RIG", "PROTEIN", 12, 15], ["RIG-1", "PROTEIN", 152, 157], ["FMDV", "SPECIES", 32, 36], ["FMDV", "SPECIES", 110, 114], ["FMDV", "SPECIES", 32, 36], ["FMDV", "SPECIES", 110, 114], ["FMDV", "PROBLEM", 32, 36], ["infection", "PROBLEM", 37, 46], ["a study", "TEST", 63, 70], ["FMDV", "PROBLEM", 110, 114], ["RIG-1 response", "OBSERVATION_MODIFIER", 12, 26], ["infection", "OBSERVATION", 37, 46], ["FMDV", "OBSERVATION", 110, 114]]], ["Additionally, FMDV dampened the ubiquitination of TANK-binding kinase 1 (TBK1), TNF receptor-associated factor 3 (TRAF3), and TRAF6.", [["FMDV", "ORGANISM", 14, 18], ["TANK-binding kinase 1", "GENE_OR_GENE_PRODUCT", 50, 71], ["TBK1", "GENE_OR_GENE_PRODUCT", 73, 77], ["TNF receptor-associated factor 3", "GENE_OR_GENE_PRODUCT", 80, 112], ["TRAF3", "GENE_OR_GENE_PRODUCT", 114, 119], ["TRAF6", "GENE_OR_GENE_PRODUCT", 126, 131], ["TANK-binding kinase 1", "PROTEIN", 50, 71], ["TBK1", "PROTEIN", 73, 77], ["TNF receptor-associated factor 3", "PROTEIN", 80, 112], ["TRAF3", "PROTEIN", 114, 119], ["TRAF6", "PROTEIN", 126, 131], ["FMDV", "SPECIES", 14, 18], ["FMDV", "SPECIES", 14, 18], ["FMDV", "PROBLEM", 14, 18], ["TANK-binding kinase", "TEST", 50, 69], ["TBK1", "TEST", 73, 77], ["TNF receptor", "TEST", 80, 92], ["TRAF6", "PROBLEM", 126, 131], ["FMDV", "OBSERVATION", 14, 18]]], ["By suppressing these key signalling molecules of the type I IFN response, FMDV might counteract the host antiviral innate immune response .DNA sensorsWhile TLR9 senses DNA in the endosome, DNA sensors like the DNA-dependent activator of IFN-regulatory factors (DAI; also DM1 or ZBP1) screen the cytoplasm for the presence of DNA (Kumar et al., 2011) .", [["endosome", "ANATOMY", 179, 187], ["cytoplasm", "ANATOMY", 295, 304], ["type I IFN", "GENE_OR_GENE_PRODUCT", 53, 63], ["FMDV", "ORGANISM", 74, 78], ["DNA", "CELLULAR_COMPONENT", 139, 142], ["TLR9", "GENE_OR_GENE_PRODUCT", 156, 160], ["DNA", "CELLULAR_COMPONENT", 168, 171], ["endosome", "CELLULAR_COMPONENT", 179, 187], ["DNA", "CELLULAR_COMPONENT", 189, 192], ["DNA", "CELLULAR_COMPONENT", 210, 213], ["-dependent activator of IFN-regulatory factors", "GENE_OR_GENE_PRODUCT", 213, 259], ["DM1", "GENE_OR_GENE_PRODUCT", 271, 274], ["ZBP1", "GENE_OR_GENE_PRODUCT", 278, 282], ["cytoplasm", "ORGANISM_SUBSTANCE", 295, 304], ["DNA", "CELLULAR_COMPONENT", 325, 328], ["type I IFN", "PROTEIN", 53, 63], ["TLR9", "PROTEIN", 156, 160], ["DNA-dependent activator of IFN-regulatory factors", "PROTEIN", 210, 259], ["DAI", "PROTEIN", 261, 264], ["DM1", "PROTEIN", 271, 274], ["ZBP1", "PROTEIN", 278, 282], ["FMDV", "SPECIES", 74, 78], ["FMDV", "SPECIES", 74, 78], ["the type I IFN response", "PROBLEM", 49, 72], ["FMDV", "PROBLEM", 74, 78], ["DNA sensors", "TEST", 139, 150], ["DNA sensors", "TEST", 189, 200], ["the DNA", "TEST", 206, 213], ["DM1", "PROBLEM", 271, 274], ["ZBP1", "TEST", 278, 282]]], ["DAI-DNA binding triggers type-I IFN production via TBK1/IKKi.", [["DNA", "CELLULAR_COMPONENT", 4, 7], ["type-I IFN", "GENE_OR_GENE_PRODUCT", 25, 35], ["TBK1", "GENE_OR_GENE_PRODUCT", 51, 55], ["IKKi", "GENE_OR_GENE_PRODUCT", 56, 60], ["IFN", "PROTEIN", 32, 35], ["TBK1", "PROTEIN", 51, 55], ["IKKi", "PROTEIN", 56, 60], ["DAI", "PROBLEM", 0, 3], ["DNA binding", "PROBLEM", 4, 15], ["type-I IFN production", "PROBLEM", 25, 46], ["TBK1", "PROBLEM", 51, 55]]], ["Additionally, after DNA transcription into double stranded RNA by polymerase III, the RLR RIG-1 can be activated by the presence of DNA to induce type-I IFNs (Kumar et al., 2011) .", [["DNA", "CELLULAR_COMPONENT", 20, 23], ["polymerase III", "GENE_OR_GENE_PRODUCT", 66, 80], ["RLR RIG-1", "GENE_OR_GENE_PRODUCT", 86, 95], ["DNA", "CELLULAR_COMPONENT", 132, 135], ["type-I IFNs", "GENE_OR_GENE_PRODUCT", 146, 157], ["double stranded RNA", "RNA", 43, 62], ["polymerase III", "PROTEIN", 66, 80], ["RLR RIG-1", "PROTEIN", 86, 95], ["type-I IFNs", "PROTEIN", 146, 157], ["DNA transcription", "TREATMENT", 20, 37], ["double stranded RNA", "TREATMENT", 43, 62], ["the RLR RIG", "TREATMENT", 82, 93]]], ["Unfortunately, the role of DNA sensors in pigs has not yet been investigated in details.", [["DNA", "CELLULAR_COMPONENT", 27, 30], ["pigs", "ORGANISM", 42, 46], ["pigs", "SPECIES", 42, 46], ["pigs", "SPECIES", 42, 46], ["DNA sensors", "TREATMENT", 27, 38]]], ["Information about the individual DNA sensors and signalling pathways are summarized in Table 2 .Membrane C-type lectin receptorsMembrane C-type lectin receptors (CLRs) are a large receptor family including collectins, selectins, lymphocyte lectins, and proteoglycans which recognize PAMPs by a carbohydrate-recognition domain (CRD) (Hardison and Brown, 2012; Lepenies et al., 2013) .", [["lymphocyte", "ANATOMY", 229, 239], ["carbohydrate", "CHEMICAL", 294, 306], ["DNA", "CELLULAR_COMPONENT", 33, 36], ["C-type lectin receptorsMembrane C-type lectin receptors", "GENE_OR_GENE_PRODUCT", 105, 160], ["CLRs", "GENE_OR_GENE_PRODUCT", 162, 166], ["collectins", "GENE_OR_GENE_PRODUCT", 206, 216], ["selectins", "GENE_OR_GENE_PRODUCT", 218, 227], ["lymphocyte lectins", "GENE_OR_GENE_PRODUCT", 229, 247], ["proteoglycans", "GENE_OR_GENE_PRODUCT", 253, 266], ["PAMPs", "GENE_OR_GENE_PRODUCT", 283, 288], ["Membrane C-type lectin receptors", "PROTEIN", 96, 128], ["Membrane C-type lectin receptors", "PROTEIN", 128, 160], ["CLRs", "PROTEIN", 162, 166], ["collectins", "PROTEIN", 206, 216], ["selectins", "PROTEIN", 218, 227], ["lymphocyte lectins", "PROTEIN", 229, 247], ["proteoglycans", "PROTEIN", 253, 266], ["PAMPs", "PROTEIN", 283, 288], ["carbohydrate-recognition domain", "PROTEIN", 294, 325], ["CRD", "PROTEIN", 327, 330], ["Membrane C", "TEST", 96, 106], ["selectins, lymphocyte lectins", "TREATMENT", 218, 247], ["proteoglycans", "TREATMENT", 253, 266]]], ["They are involved in the immune response against bacteria, viruses, and parasites but their central role is to induce immunity to fungal pathogens.", [["bacteria", "PROBLEM", 49, 57], ["viruses", "PROBLEM", 59, 66], ["parasites", "PROBLEM", 72, 81], ["fungal pathogens", "PROBLEM", 130, 146]]], ["Therefore, several CLRs such as Dectin-1 sense b-glucan and mannose-based structures of the mannan part of the fungal cell wall (DC-specific intercellular adhesion molecule-3grabbing non-integrin -DC-SIGN-, Dectin-2, MBL, macrophage inducible C-type ''calcium-dependent'' lectin -Mincle-, surfactant protein-A and D).", [["cell wall", "ANATOMY", 118, 127], ["DC", "ANATOMY", 129, 131], ["mannose", "CHEMICAL", 60, 67], ["calcium", "CHEMICAL", 252, 259], ["b-glucan", "CHEMICAL", 47, 55], ["mannose", "CHEMICAL", 60, 67], ["calcium", "CHEMICAL", 252, 259], ["CLRs", "GENE_OR_GENE_PRODUCT", 19, 23], ["Dectin-1", "GENE_OR_GENE_PRODUCT", 32, 40], ["b-glucan", "SIMPLE_CHEMICAL", 47, 55], ["mannose", "SIMPLE_CHEMICAL", 60, 67], ["mannan", "GENE_OR_GENE_PRODUCT", 92, 98], ["cell wall", "TISSUE", 118, 127], ["intercellular adhesion molecule-3grabbing", "GENE_OR_GENE_PRODUCT", 141, 182], ["SIGN", "GENE_OR_GENE_PRODUCT", 200, 204], ["Dectin-2", "GENE_OR_GENE_PRODUCT", 207, 215], ["MBL", "GENE_OR_GENE_PRODUCT", 217, 220], ["macrophage", "CELL", 222, 232], ["calcium", "SIMPLE_CHEMICAL", 252, 259], ["surfactant protein-A", "GENE_OR_GENE_PRODUCT", 289, 309], ["D", "SIMPLE_CHEMICAL", 314, 315], ["CLRs", "PROTEIN", 19, 23], ["Dectin-1", "PROTEIN", 32, 40], ["mannan part", "PROTEIN", 92, 103], ["DC", "CELL_TYPE", 129, 131], ["intercellular adhesion molecule", "PROTEIN", 141, 172], ["non-integrin", "PROTEIN", 183, 195], ["DC", "PROTEIN", 197, 199], ["SIGN", "PROTEIN", 200, 204], ["Dectin", "PROTEIN", 207, 213], ["MBL", "PROTEIN", 217, 220], ["macrophage inducible C-type ''calcium-dependent'' lectin", "PROTEIN", 222, 278], ["Mincle", "PROTEIN", 280, 286], ["surfactant protein", "PROTEIN", 289, 307], ["several CLRs", "TEST", 11, 23], ["Dectin", "TEST", 32, 38], ["the fungal cell wall", "TEST", 107, 127], ["intercellular adhesion molecule", "TEST", 141, 172], ["non-integrin", "TEST", 183, 195], ["DC", "TEST", 197, 199], ["SIGN", "TEST", 200, 204], ["Dectin", "TEST", 207, 213], ["MBL", "TEST", 217, 220], ["macrophage", "TEST", 222, 232], ["C", "TEST", 243, 244], ["calcium", "TEST", 252, 259], ["lectin", "TEST", 272, 278], ["Mincle", "TEST", 280, 286], ["surfactant protein", "TEST", 289, 307], ["fungal cell", "OBSERVATION", 111, 122], ["wall", "ANATOMY_MODIFIER", 123, 127]]], ["Binding occurs in a Ca 2+ dependent manner and PAMP recognition either induces phagocytosis only or can also activate signalling pathways in an immunoreceptor tyrosine-based activation motifs (ITAM)-dependent, immunoreceptor tyrosinebased inhibitory motifs (ITIM)-dependent or ITAM/ITIM-independent way.", [["Ca", "CHEMICAL", 20, 22], ["tyrosine", "CHEMICAL", 159, 167], ["Ca 2+", "CHEMICAL", 20, 25], ["tyrosine", "CHEMICAL", 159, 167], ["Ca 2+", "SIMPLE_CHEMICAL", 20, 25], ["PAMP", "GENE_OR_GENE_PRODUCT", 47, 51], ["ITAM", "GENE_OR_GENE_PRODUCT", 193, 197], ["ITIM", "GENE_OR_GENE_PRODUCT", 258, 262], ["ITAM", "GENE_OR_GENE_PRODUCT", 277, 281], ["ITIM", "GENE_OR_GENE_PRODUCT", 282, 286], ["immunoreceptor tyrosine-based activation motifs", "PROTEIN", 144, 191], ["ITAM", "PROTEIN", 193, 197], ["immunoreceptor tyrosinebased inhibitory motifs", "PROTEIN", 210, 256], ["ITIM", "PROTEIN", 258, 262], ["ITAM", "PROTEIN", 277, 281], ["ITIM", "PROTEIN", 282, 286], ["PAMP recognition", "TEST", 47, 63], ["phagocytosis", "PROBLEM", 79, 91], ["signalling pathways", "PROBLEM", 118, 137], ["an immunoreceptor tyrosine", "TREATMENT", 141, 167], ["activation motifs (ITAM)", "TREATMENT", 174, 198], ["immunoreceptor tyrosinebased inhibitory motifs", "TREATMENT", 210, 256]]], ["ITAM-dependent signalling can recruit and activate the spleen tyrosine kinase (Syk).", [["spleen", "ANATOMY", 55, 61], ["tyrosine", "CHEMICAL", 62, 70], ["tyrosine", "CHEMICAL", 62, 70], ["ITAM", "GENE_OR_GENE_PRODUCT", 0, 4], ["spleen tyrosine kinase", "GENE_OR_GENE_PRODUCT", 55, 77], ["Syk", "GENE_OR_GENE_PRODUCT", 79, 82], ["ITAM", "PROTEIN", 0, 4], ["spleen tyrosine kinase", "PROTEIN", 55, 77], ["Syk", "PROTEIN", 79, 82], ["dependent signalling", "PROBLEM", 5, 25], ["spleen", "ANATOMY", 55, 61]]], ["Syk can mediate inflammasome activation and/or signal through protein kinase C (PKC)d and the Card9 complex to induce the production of various inflammatory cytokines and stimulate and direct cellular immune responses mainly towards T-helper 1 (Th1) and Th17.", [["cellular", "ANATOMY", 192, 200], ["Syk", "GENE_OR_GENE_PRODUCT", 0, 3], ["protein kinase C", "GENE_OR_GENE_PRODUCT", 62, 78], ["PKC", "GENE_OR_GENE_PRODUCT", 80, 83], ["Card9", "GENE_OR_GENE_PRODUCT", 94, 99], ["cellular", "CELL", 192, 200], ["T-helper 1", "GENE_OR_GENE_PRODUCT", 233, 243], ["Th1", "GENE_OR_GENE_PRODUCT", 245, 248], ["Th17", "GENE_OR_GENE_PRODUCT", 254, 258], ["Syk", "PROTEIN", 0, 3], ["protein kinase C", "PROTEIN", 62, 78], ["PKC", "PROTEIN", 80, 83], ["Card9 complex", "PROTEIN", 94, 107], ["inflammatory cytokines", "PROTEIN", 144, 166], ["T-helper 1 (Th1) and Th17", "CELL_TYPE", 233, 258], ["signal through protein kinase C (PKC)d", "PROBLEM", 47, 85], ["the Card9 complex", "PROBLEM", 90, 107], ["various inflammatory cytokines", "PROBLEM", 136, 166], ["direct cellular immune responses", "TEST", 185, 217], ["T", "TEST", 233, 234]]], ["Contrary, ITIM-dependent signalling can downregulate the production of inflammatory cytokines.", [["ITIM", "GENE_OR_GENE_PRODUCT", 10, 14], ["ITIM", "PROTEIN", 10, 14], ["inflammatory cytokines", "PROTEIN", 71, 93], ["inflammatory cytokines", "PROBLEM", 71, 93], ["inflammatory cytokines", "OBSERVATION", 71, 93]]], ["The mannose receptor (MR) is an example for ITAM/ITIMindependent signalling but the mechanisms involved are so far unknown (Hardison and Brown, 2012; Lepenies et al., 2013) .", [["mannose", "CHEMICAL", 4, 11], ["mannose receptor", "GENE_OR_GENE_PRODUCT", 4, 20], ["ITAM", "GENE_OR_GENE_PRODUCT", 44, 48], ["ITIMindependent", "GENE_OR_GENE_PRODUCT", 49, 64], ["mannose receptor", "PROTEIN", 4, 20], ["MR", "PROTEIN", 22, 24], ["ITAM", "PROTEIN", 44, 48], ["ITIMindependent", "PROTEIN", 49, 64]]], ["Details on the individual CLR ligands and signalling pathways are summarized in Table 2 .Membrane C-type lectin receptorsSeveral porcine CLRs have been identified such as CD69, CD205, CD207 (Langerin), CLEC4G, DC-SIGN, and Dectin-1.", [["Membrane", "ANATOMY", 89, 97], ["CLR", "GENE_OR_GENE_PRODUCT", 26, 29], ["C-type lectin receptors", "GENE_OR_GENE_PRODUCT", 98, 121], ["porcine", "ORGANISM", 129, 136], ["CLRs", "GENE_OR_GENE_PRODUCT", 137, 141], ["CD69", "GENE_OR_GENE_PRODUCT", 171, 175], ["CD205", "GENE_OR_GENE_PRODUCT", 177, 182], ["CD207", "GENE_OR_GENE_PRODUCT", 184, 189], ["Langerin", "GENE_OR_GENE_PRODUCT", 191, 199], ["CLEC4G", "GENE_OR_GENE_PRODUCT", 202, 208], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 210, 217], ["Dectin-1", "GENE_OR_GENE_PRODUCT", 223, 231], ["Membrane C-type lectin receptors", "PROTEIN", 89, 121], ["CLRs", "PROTEIN", 137, 141], ["CD69", "PROTEIN", 171, 175], ["CD205", "PROTEIN", 177, 182], ["CD207", "PROTEIN", 184, 189], ["Langerin", "PROTEIN", 191, 199], ["CLEC4G", "PROTEIN", 202, 208], ["DC", "PROTEIN", 210, 212], ["SIGN", "PROTEIN", 213, 217], ["Dectin-1", "PROTEIN", 223, 231], ["porcine", "SPECIES", 129, 136], ["Membrane C-type lectin receptors", "TREATMENT", 89, 121], ["Several porcine CLRs", "TREATMENT", 121, 141], ["CD69", "TEST", 171, 175], ["CD205", "TEST", 177, 182], ["CLEC4G", "TEST", 202, 208], ["Dectin", "TEST", 223, 229]]], ["With the exception of the Ca 2+ -dependent binding of DC-SIGN, detailed mechanisms of PAMP recognition or signal transduction including the immunological responses are missing in swine (Flores-Mendoza et al., 2010 Nfon et al., 2008) .Surfactant proteinsSurfactant proteins (SP) were discovered by their essential role in reducing surface tension at the air-liquid interface of the lung.", [["DC", "ANATOMY", 54, 56], ["surface", "ANATOMY", 330, 337], ["lung", "ANATOMY", 381, 385], ["Ca", "CHEMICAL", 26, 28], ["Ca 2+", "CHEMICAL", 26, 31], ["Ca 2+", "SIMPLE_CHEMICAL", 26, 31], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 54, 61], ["PAMP", "GENE_OR_GENE_PRODUCT", 86, 90], ["swine", "ORGANISM", 179, 184], ["Surfactant proteins", "GENE_OR_GENE_PRODUCT", 253, 272], ["lung", "ORGAN", 381, 385], ["DC", "CELL_TYPE", 54, 56], ["SIGN", "PROTEIN", 57, 61], ["PAMP", "PROTEIN", 86, 90], ["Surfactant proteins", "PROTEIN", 234, 253], ["Surfactant proteins", "PROTEIN", 253, 272], ["SP", "PROTEIN", 274, 276], ["swine", "SPECIES", 179, 184], ["swine", "SPECIES", 179, 184], ["PAMP recognition", "PROBLEM", 86, 102], ["signal transduction", "PROBLEM", 106, 125], ["Surfactant proteinsSurfactant proteins", "TREATMENT", 234, 272], ["essential", "OBSERVATION_MODIFIER", 303, 312], ["reducing", "OBSERVATION_MODIFIER", 321, 329], ["surface tension", "OBSERVATION", 330, 345], ["air-liquid interface", "OBSERVATION", 353, 373], ["lung", "ANATOMY", 381, 385]]], ["It is known that two hydrophobic SPs (SP-B and SP-C) are in charge of this lung stabilizing function.", [["lung", "ANATOMY", 75, 79], ["SP-B", "GENE_OR_GENE_PRODUCT", 38, 42], ["SP-C", "GENE_OR_GENE_PRODUCT", 47, 51], ["lung", "ORGAN", 75, 79], ["SP", "PROTEIN", 38, 40], ["B", "PROTEIN", 41, 42], ["SP", "PROTEIN", 47, 49], ["C", "PROTEIN", 50, 51], ["hydrophobic SPs", "TEST", 21, 36], ["hydrophobic", "OBSERVATION_MODIFIER", 21, 32], ["lung", "ANATOMY", 75, 79], ["stabilizing function", "OBSERVATION", 80, 100]]], ["Pig serves as a donor of these important surfactants and as an animal model to study their function (Parra et al., 2013) and their possible medical applications as such lung transplantation (Inci et al., 2013) , lung emphysema (Bruun et al., 2013) , and neonatal acute respiratory distress syndrome (ARDS) (Hilgendorff et al., 2008) .", [["lung", "ANATOMY", 169, 173], ["lung", "ANATOMY", 212, 216], ["lung emphysema", "DISEASE", 212, 226], ["acute respiratory distress syndrome", "DISEASE", 263, 298], ["ARDS", "DISEASE", 300, 304], ["Pig", "ORGANISM", 0, 3], ["lung", "ORGAN", 169, 173], ["lung", "ORGAN", 212, 216], ["these important surfactants", "TREATMENT", 25, 52], ["medical applications", "TREATMENT", 140, 160], ["such lung transplantation", "TREATMENT", 164, 189], ["lung emphysema", "PROBLEM", 212, 226], ["neonatal acute respiratory distress syndrome", "PROBLEM", 254, 298], ["ARDS", "PROBLEM", 300, 304], ["lung", "ANATOMY", 169, 173], ["transplantation", "OBSERVATION", 174, 189], ["lung", "ANATOMY", 212, 216], ["emphysema", "OBSERVATION", 217, 226], ["neonatal", "OBSERVATION_MODIFIER", 254, 262], ["acute", "OBSERVATION_MODIFIER", 263, 268], ["respiratory distress syndrome", "OBSERVATION", 269, 298]]], ["SP-A and SP-D play important roles in the lung host defence.", [["lung", "ANATOMY", 42, 46], ["SP-A", "CHEMICAL", 0, 4], ["SP-D", "CHEMICAL", 9, 13], ["SP-A", "GENE_OR_GENE_PRODUCT", 0, 4], ["SP-D", "GENE_OR_GENE_PRODUCT", 9, 13], ["lung", "ORGAN", 42, 46], ["SP", "PROTEIN", 0, 2], ["SP", "PROTEIN", 9, 11], ["lung", "ANATOMY", 42, 46], ["host defence", "OBSERVATION", 47, 59]]], ["SP-A and -D belong to the C-type lectins and recognize bacterial, viral, and fungal PAMPs via a CRD.", [["CRD", "DISEASE", 96, 99], ["SP-A", "GENE_OR_GENE_PRODUCT", 0, 4], ["-D", "SIMPLE_CHEMICAL", 9, 11], ["C-type lectins", "GENE_OR_GENE_PRODUCT", 26, 40], ["PAMPs", "GENE_OR_GENE_PRODUCT", 84, 89], ["SP", "PROTEIN", 0, 2], ["C-type lectins", "PROTEIN", 26, 40], ["bacterial, viral, and fungal PAMPs", "PROTEIN", 55, 89], ["CRD", "PROTEIN", 96, 99], ["bacterial, viral, and fungal PAMPs", "PROBLEM", 55, 89], ["a CRD", "PROBLEM", 94, 99], ["bacterial", "OBSERVATION", 55, 64], ["fungal PAMPs", "OBSERVATION", 77, 89]]], ["They form oligomers to bind and opsonize microorganisms to increase their aggregation, phagocytosis, and lysis.", [["opsonize microorganisms", "PROBLEM", 32, 55], ["their aggregation", "PROBLEM", 68, 85], ["phagocytosis", "PROBLEM", 87, 99], ["lysis", "TREATMENT", 105, 110]]], ["Furthermore, SP-D binding can facilitate the phagocytosis of apoptotic cells (Pastva et al., 2007) .", [["cells", "ANATOMY", 71, 76], ["SP-D", "CHEMICAL", 13, 17], ["SP-D", "GENE_OR_GENE_PRODUCT", 13, 17], ["cells", "CELL", 71, 76], ["SP", "PROTEIN", 13, 15], ["apoptotic cells", "CELL_TYPE", 61, 76], ["SP-D binding", "PROBLEM", 13, 25], ["apoptotic cells", "OBSERVATION", 61, 76]]], ["The pig is frequently used to study the role of SPs in innate immune responses.", [["pig", "ORGANISM", 4, 7], ["SPs", "GENE_OR_GENE_PRODUCT", 48, 51], ["pig", "SPECIES", 4, 7], ["pig", "SPECIES", 4, 7], ["The pig", "TREATMENT", 0, 7]]], ["Hillaire et al. demonstrated the potent antiviral activity of porcine SP-D against various influenza A viruses including H1N1 (Hillaire et al., 2011) .", [["SP-D", "CHEMICAL", 70, 74], ["influenza A viruses", "DISEASE", 91, 110], ["H1N1", "DISEASE", 121, 125], ["porcine", "ORGANISM", 62, 69], ["SP-D", "SIMPLE_CHEMICAL", 70, 74], ["influenza A viruses", "ORGANISM", 91, 110], ["H1N1", "ORGANISM", 121, 125], ["porcine", "SPECIES", 62, 69], ["porcine SP", "TREATMENT", 62, 72], ["various influenza A viruses", "PROBLEM", 83, 110], ["H1N1", "PROBLEM", 121, 125], ["potent", "OBSERVATION_MODIFIER", 33, 39], ["antiviral activity", "OBSERVATION", 40, 58]]], ["Therefore, SP-D seems to be a promising novel antiviral agent against pulmonary human diseases (Hillaire et al., 2011).", [["pulmonary", "ANATOMY", 70, 79], ["SP-D", "CHEMICAL", 11, 15], ["pulmonary human diseases", "DISEASE", 70, 94], ["SP-D", "SIMPLE_CHEMICAL", 11, 15], ["human", "ORGANISM", 80, 85], ["SP", "PROTEIN", 11, 13], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 80, 85], ["a promising novel antiviral agent", "TREATMENT", 28, 61], ["pulmonary human diseases", "PROBLEM", 70, 94], ["antiviral", "OBSERVATION", 46, 55], ["pulmonary", "ANATOMY", 70, 79], ["human diseases", "OBSERVATION", 80, 94]]], ["Furthermore, SNPs in SP-A seems to correlate with common porcine diseases and might thereby serve as a genetic marker of impaired innate immune function (Keirstead et al., 2011) .Mannan-binding lectinsMannan-binding lectins MBL-A and -C have a cysteine-rich Nterminal region and they recognize PAMPs via a C-terminal CRD, an intermediate collagen-like domain which enables MBLs to form a trimer triple-helix (Juul-Madsen et al., 2006) .", [["porcine diseases", "DISEASE", 57, 73], ["Mannan", "CHEMICAL", 179, 185], ["cysteine", "CHEMICAL", 244, 252], ["C", "CHEMICAL", 306, 307], ["SP-A", "GENE_OR_GENE_PRODUCT", 21, 25], ["porcine", "ORGANISM", 57, 64], ["Mannan", "SIMPLE_CHEMICAL", 179, 185], ["MBL-A", "GENE_OR_GENE_PRODUCT", 224, 229], ["-C", "SIMPLE_CHEMICAL", 234, 236], ["cysteine", "AMINO_ACID", 244, 252], ["PAMPs", "GENE_OR_GENE_PRODUCT", 294, 299], ["collagen", "GENE_OR_GENE_PRODUCT", 338, 346], ["MBLs", "GENE_OR_GENE_PRODUCT", 373, 377], ["SP", "PROTEIN", 21, 23], ["Mannan-binding lectins", "PROTEIN", 179, 201], ["Mannan-binding lectins MBL-A and -C", "PROTEIN", 201, 236], ["cysteine-rich Nterminal region", "PROTEIN", 244, 274], ["PAMPs", "PROTEIN", 294, 299], ["C-terminal CRD", "PROTEIN", 306, 320], ["intermediate collagen-like domain", "PROTEIN", 325, 358], ["MBLs", "PROTEIN", 373, 377], ["common porcine diseases", "PROBLEM", 50, 73], ["Mannan-binding lectins", "TEST", 179, 201], ["Mannan", "TEST", 201, 207], ["MBL", "TEST", 224, 227], ["a cysteine-rich Nterminal region", "TREATMENT", 242, 274], ["a C-terminal CRD", "PROBLEM", 304, 320], ["an intermediate collagen-like domain", "PROBLEM", 322, 358], ["diseases", "OBSERVATION", 65, 73], ["intermediate collagen", "OBSERVATION_MODIFIER", 325, 346]]], ["In serum, MBLs are complexed with MBL-associated serine proteases (MASPs), and a small MBL-associated protein (sMAP) which bind PAMP and then activate the complement cascade by triggering the lectin activation pathway of complement (Bergman, 2011) .", [["serum", "ANATOMY", 3, 8], ["serine", "CHEMICAL", 49, 55], ["serum", "ORGANISM_SUBSTANCE", 3, 8], ["MBLs", "SIMPLE_CHEMICAL", 10, 14], ["MBL-associated serine proteases", "GENE_OR_GENE_PRODUCT", 34, 65], ["MASPs", "GENE_OR_GENE_PRODUCT", 67, 72], ["MBL", "GENE_OR_GENE_PRODUCT", 87, 90], ["MAP", "GENE_OR_GENE_PRODUCT", 112, 115], ["PAMP", "GENE_OR_GENE_PRODUCT", 128, 132], ["lectin", "GENE_OR_GENE_PRODUCT", 192, 198], ["MBLs", "PROTEIN", 10, 14], ["MBL", "PROTEIN", 34, 37], ["serine proteases", "PROTEIN", 49, 65], ["MASPs", "PROTEIN", 67, 72], ["MBL", "PROTEIN", 87, 90], ["associated protein", "PROTEIN", 91, 109], ["MAP", "PROTEIN", 112, 115], ["PAMP", "PROTEIN", 128, 132], ["lectin", "PROTEIN", 192, 198], ["serum, MBLs", "TEST", 3, 14], ["MBL", "TEST", 34, 37], ["serine proteases", "PROBLEM", 49, 65], ["MASPs", "TEST", 67, 72], ["a small MBL-associated protein", "PROBLEM", 79, 109], ["bind PAMP", "TEST", 123, 132], ["small", "OBSERVATION_MODIFIER", 81, 86], ["MBL", "OBSERVATION", 87, 90]]], ["The effect of this cascade will be discussed in detail in the section ''The complement system'' below.", [["this cascade", "TREATMENT", 14, 26]]], ["Porcine MBLs were isolated, cloned, and functionally analysed and cDNA analysis revealed a 64.9% identity with human MBL (Agah et al., 2001) .", [["MBLs", "ANATOMY", 8, 12], ["Porcine", "ORGANISM", 0, 7], ["MBLs", "GENE_OR_GENE_PRODUCT", 8, 12], ["human", "ORGANISM", 111, 116], ["MBL", "GENE_OR_GENE_PRODUCT", 117, 120], ["Porcine MBLs", "DNA", 0, 12], ["human MBL", "PROTEIN", 111, 120], ["Porcine", "SPECIES", 0, 7], ["human", "SPECIES", 111, 116], ["Porcine", "SPECIES", 0, 7], ["human", "SPECIES", 111, 116], ["Porcine MBLs", "TEST", 0, 12], ["cDNA analysis", "TEST", 66, 79], ["human MBL", "TEST", 111, 120]]], ["Low serum concentrations of MBL-A and -C are responsible for increased susceptibility to bacterial and viral pathogens in humans as well as in pig (Juul-Madsen et al., 2011; Lillie et al., 2007) .", [["serum", "ANATOMY", 4, 9], ["bacterial and viral pathogens", "DISEASE", 89, 118], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["MBL-A", "GENE_OR_GENE_PRODUCT", 28, 33], ["-C", "GENE_OR_GENE_PRODUCT", 38, 40], ["humans", "ORGANISM", 122, 128], ["pig", "ORGANISM", 143, 146], ["MBL", "PROTEIN", 28, 31], ["humans", "SPECIES", 122, 128], ["pig", "SPECIES", 143, 146], ["humans", "SPECIES", 122, 128], ["pig", "SPECIES", 143, 146], ["Low serum concentrations", "PROBLEM", 0, 24], ["MBL", "TEST", 28, 31], ["increased susceptibility to bacterial and viral pathogens in humans", "PROBLEM", 61, 128], ["bacterial", "OBSERVATION_MODIFIER", 89, 98], ["viral pathogens", "OBSERVATION", 103, 118]]], ["Serum MBL concentration was found to be highly heritable in some although not all breeds (Juul-Madsen et al., 2006) .", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["MBL", "GENE_OR_GENE_PRODUCT", 6, 9], ["MBL", "PROTEIN", 6, 9], ["Serum MBL concentration", "TEST", 0, 23]]], ["Additionally, SNPs in both MBLs may be correlated with decreased serum concentrations in pigs (Bongoni et al., 2013; Lillie et al., 2007) suggesting that MBLs levels may be a possible target for pig breed selection to improve disease resistance.SummaryWhile some PRRs such as TLRs are well-studied in the pig, many others lack even basic knowledge in this species.", [["serum", "ANATOMY", 65, 70], ["MBLs", "GENE_OR_GENE_PRODUCT", 27, 31], ["serum", "ORGANISM_SUBSTANCE", 65, 70], ["pigs", "ORGANISM", 89, 93], ["MBLs", "GENE_OR_GENE_PRODUCT", 154, 158], ["pig", "ORGANISM", 195, 198], ["TLRs", "GENE_OR_GENE_PRODUCT", 276, 280], ["pig", "ORGANISM", 305, 308], ["MBLs", "PROTEIN", 154, 158], ["PRRs", "PROTEIN", 263, 267], ["TLRs", "PROTEIN", 276, 280], ["pigs", "SPECIES", 89, 93], ["pig", "SPECIES", 305, 308], ["pigs", "SPECIES", 89, 93], ["pig", "SPECIES", 195, 198], ["pig", "SPECIES", 305, 308], ["SNPs in both MBLs", "PROBLEM", 14, 31], ["decreased serum concentrations", "PROBLEM", 55, 85], ["MBLs levels", "TEST", 154, 165], ["pig breed selection", "TREATMENT", 195, 214], ["disease resistance", "PROBLEM", 226, 244]]], ["The examples mentioned above emphasize the potential of porcine PRRs to improve porcine health and resistance to various pathogens.", [["porcine", "ORGANISM", 56, 63], ["PRRs", "GENE_OR_GENE_PRODUCT", 64, 68], ["porcine", "ORGANISM", 80, 87], ["porcine PRRs", "PROTEIN", 56, 68], ["porcine", "SPECIES", 56, 63], ["porcine", "SPECIES", 80, 87], ["porcine PRRs", "TREATMENT", 56, 68], ["porcine health", "TREATMENT", 80, 94], ["various pathogens", "PROBLEM", 113, 130]]], ["Due to the high sequence homology shared by PRRs among species, synthetic/purified PAMPs used in murine or human studies stimulate also innate receptors in swine like peptidoglycan (PGN), lipoteichoic acid (LTA ?", [["PGN", "CHEMICAL", 182, 185], ["lipoteichoic acid", "CHEMICAL", 188, 205], ["LTA", "CHEMICAL", 207, 210], ["PRRs", "GENE_OR_GENE_PRODUCT", 44, 48], ["murine", "ORGANISM", 97, 103], ["human", "ORGANISM", 107, 112], ["swine", "ORGANISM", 156, 161], ["peptidoglycan", "SIMPLE_CHEMICAL", 167, 180], ["PGN", "SIMPLE_CHEMICAL", 182, 185], ["lipoteichoic acid", "SIMPLE_CHEMICAL", 188, 205], ["LTA", "SIMPLE_CHEMICAL", 207, 210], ["PRRs", "PROTEIN", 44, 48], ["synthetic/purified PAMPs", "PROTEIN", 64, 88], ["innate receptors", "PROTEIN", 136, 152], ["murine", "SPECIES", 97, 103], ["human", "SPECIES", 107, 112], ["swine", "SPECIES", 156, 161], ["human", "SPECIES", 107, 112], ["swine", "SPECIES", 156, 161], ["the high sequence homology", "PROBLEM", 7, 33], ["synthetic/purified PAMPs", "TREATMENT", 64, 88], ["human studies", "TEST", 107, 120], ["peptidoglycan (PGN", "TREATMENT", 167, 185], ["lipoteichoic acid (LTA", "TEST", 188, 210]]], ["TLR2), poly(I:C) (?TLR3) (Auray et al., 2010) , lipopolysaccharide (LPS ?", [["poly(I:C", "CHEMICAL", 7, 15], ["lipopolysaccharide", "CHEMICAL", 48, 66], ["LPS", "CHEMICAL", 68, 71], ["poly(I:C)", "CHEMICAL", 7, 16], ["TLR2", "GENE_OR_GENE_PRODUCT", 0, 4], ["poly(I:C", "SIMPLE_CHEMICAL", 7, 15], ["TLR3", "GENE_OR_GENE_PRODUCT", 19, 23], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 48, 66], ["LPS", "SIMPLE_CHEMICAL", 68, 71], ["TLR2", "PROTEIN", 0, 4], ["TLR3", "PROTEIN", 19, 23], ["lipopolysaccharide (LPS", "TREATMENT", 48, 71]]], ["TLR4) Uddin et al., 2012) , imiquimod (?TLR7/8) (Calzada-Nova et al., 2010) , CpG ODN (?TLR9) (Auray et al., 2010; Calzada-Nova et al., 2010; Dar et al., 2010) , and muramil dipeptide (MDP ?", [["imiquimod", "CHEMICAL", 28, 37], ["ODN", "CHEMICAL", 82, 85], ["muramil dipeptide", "CHEMICAL", 166, 183], ["MDP", "CHEMICAL", 185, 188], ["imiquimod", "CHEMICAL", 28, 37], ["muramil dipeptide", "CHEMICAL", 166, 183], ["MDP", "CHEMICAL", 185, 188], ["TLR4", "GENE_OR_GENE_PRODUCT", 0, 4], ["imiquimod", "SIMPLE_CHEMICAL", 28, 37], ["TLR7", "GENE_OR_GENE_PRODUCT", 40, 44], ["8", "GENE_OR_GENE_PRODUCT", 45, 46], ["TLR9", "GENE_OR_GENE_PRODUCT", 88, 92], ["muramil dipeptide", "SIMPLE_CHEMICAL", 166, 183], ["MDP", "SIMPLE_CHEMICAL", 185, 188], ["TLR4", "PROTEIN", 0, 4], ["TLR7", "PROTEIN", 40, 44], ["TLR9", "PROTEIN", 88, 92], ["imiquimod", "TREATMENT", 28, 37], ["CpG ODN", "TREATMENT", 78, 85], ["muramil dipeptide", "TREATMENT", 166, 183]]], ["This high level of homology may facilitate research on the other PRR members and might encourage the porcine research community to widen our knowledge on these important factors in the innate immune response against all kinds of pathogens.Humoral innate responseThe humoral innate immune system is comprised of soluble plasma components that include, but are not exclusive to, complement, natural antibodies, acute phase proteins, and antimicrobial peptides as well as proteins/peptides involved in the contact system (Shishido et al., 2012) .", [["plasma", "ANATOMY", 319, 325], ["PRR", "GENE_OR_GENE_PRODUCT", 65, 68], ["plasma", "ORGANISM_SUBSTANCE", 319, 325], ["PRR members", "PROTEIN", 65, 76], ["natural antibodies", "PROTEIN", 389, 407], ["acute phase proteins", "PROTEIN", 409, 429], ["pathogens", "PROBLEM", 229, 238], ["soluble plasma components", "PROBLEM", 311, 336], ["natural antibodies", "TEST", 389, 407], ["acute phase proteins", "PROBLEM", 409, 429], ["antimicrobial peptides", "TREATMENT", 435, 457], ["proteins/peptides", "PROBLEM", 469, 486], ["pathogens", "OBSERVATION", 229, 238], ["soluble plasma", "OBSERVATION", 311, 325], ["antimicrobial peptides", "OBSERVATION", 435, 457]]], ["These innate molecules play a role in prevention and control of disease which 'complements' cellular innate immunity.The complement systemThe complement cascade is an ancient immunological system responsible for the recognition and elimination of microorganisms, apoptotic cells, and infected or cancerous cells as well as mediation of inflammation processes.", [["cellular", "ANATOMY", 92, 100], ["cells", "ANATOMY", 273, 278], ["cancerous cells", "ANATOMY", 296, 311], ["inflammation", "DISEASE", 336, 348], ["cellular", "CELL", 92, 100], ["cells", "CELL", 273, 278], ["cancerous cells", "CELL", 296, 311], ["apoptotic cells", "CELL_TYPE", 263, 278], ["infected or cancerous cells", "CELL_TYPE", 284, 311], ["disease", "PROBLEM", 64, 71], ["microorganisms", "PROBLEM", 247, 261], ["apoptotic cells", "PROBLEM", 263, 278], ["infected or cancerous cells", "PROBLEM", 284, 311], ["inflammation processes", "PROBLEM", 336, 358], ["apoptotic cells", "OBSERVATION", 263, 278], ["infected", "OBSERVATION_MODIFIER", 284, 292], ["cancerous cells", "OBSERVATION", 296, 311], ["inflammation", "OBSERVATION", 336, 348]]], ["This complex system is activated through three independent pathways using >30 soluble-and membrane-anchored proteins that together constitute a proteolytic cascade (Shishido et al., 2012) .", [["membrane", "ANATOMY", 90, 98], ["membrane", "CELLULAR_COMPONENT", 90, 98], ["membrane-anchored proteins", "PROTEIN", 90, 116], ["30 soluble-and membrane-anchored proteins", "TREATMENT", 75, 116], ["a proteolytic cascade", "TREATMENT", 142, 163]]], ["It ultimately leads to C3 convertase cleaving C3 to produce C3b.", [["C3 convertase", "GENE_OR_GENE_PRODUCT", 23, 36], ["C3", "GENE_OR_GENE_PRODUCT", 46, 48], ["C3b", "GENE_OR_GENE_PRODUCT", 60, 63], ["C3 convertase", "PROTEIN", 23, 36], ["C3", "PROTEIN", 46, 48], ["C3b", "PROTEIN", 60, 63]]], ["Next, C3b promotes cleavage of C5 by C5 convertase to produce C5b which is followed by the initiation of the common terminal complex (Shishido et al., 2012) .", [["C3b", "GENE_OR_GENE_PRODUCT", 6, 9], ["C5", "GENE_OR_GENE_PRODUCT", 31, 33], ["C5 convertase", "GENE_OR_GENE_PRODUCT", 37, 50], ["C5b", "GENE_OR_GENE_PRODUCT", 62, 65], ["C3b", "PROTEIN", 6, 9], ["C5", "PROTEIN", 31, 33], ["C5 convertase", "PROTEIN", 37, 50], ["C5b", "PROTEIN", 62, 65], ["common terminal complex", "PROTEIN", 109, 132], ["C5", "ANATOMY_MODIFIER", 31, 33]]], ["These processes result in the formation of the membrane attack complex (MAC) which lyses host or pathogenic cells by formation of pores in the cellular membrane.", [["membrane", "ANATOMY", 47, 55], ["cells", "ANATOMY", 108, 113], ["pores", "ANATOMY", 130, 135], ["cellular membrane", "ANATOMY", 143, 160], ["membrane", "CELLULAR_COMPONENT", 47, 55], ["cells", "CELL", 108, 113], ["cellular membrane", "CELLULAR_COMPONENT", 143, 160], ["membrane attack complex", "PROTEIN", 47, 70], ["MAC", "PROTEIN", 72, 75], ["pathogenic cells", "CELL_TYPE", 97, 113], ["the membrane attack complex", "PROBLEM", 43, 70], ["pathogenic cells", "PROBLEM", 97, 113], ["pores in the cellular membrane", "PROBLEM", 130, 160], ["membrane attack", "OBSERVATION", 47, 62], ["pathogenic cells", "OBSERVATION", 97, 113], ["pores", "OBSERVATION_MODIFIER", 130, 135], ["cellular membrane", "OBSERVATION", 143, 160]]], ["C3b opsonised pathogens are recognized by complement receptor 3 (CR3) expressed on neutrophils and macrophages.", [["neutrophils", "ANATOMY", 83, 94], ["macrophages", "ANATOMY", 99, 110], ["C3b", "GENE_OR_GENE_PRODUCT", 0, 3], ["complement receptor 3", "GENE_OR_GENE_PRODUCT", 42, 63], ["CR3", "GENE_OR_GENE_PRODUCT", 65, 68], ["neutrophils", "CELL", 83, 94], ["macrophages", "CELL", 99, 110], ["C3b", "PROTEIN", 0, 3], ["complement receptor 3", "PROTEIN", 42, 63], ["CR3", "PROTEIN", 65, 68], ["neutrophils", "CELL_TYPE", 83, 94], ["macrophages", "CELL_TYPE", 99, 110], ["C3b opsonised pathogens", "PROBLEM", 0, 23], ["neutrophils", "TEST", 83, 94], ["macrophages", "ANATOMY", 99, 110]]], ["Complement receptor 2 (CR2) on the B cell recognizes cleavage products which triggers induction of antibody production (Molina et al., 1996) .", [["B cell", "ANATOMY", 35, 41], ["Complement receptor 2", "GENE_OR_GENE_PRODUCT", 0, 21], ["CR2", "GENE_OR_GENE_PRODUCT", 23, 26], ["B cell", "CELL", 35, 41], ["Complement receptor 2", "PROTEIN", 0, 21], ["CR2", "PROTEIN", 23, 26], ["B cell", "CELL_TYPE", 35, 41], ["cleavage products", "PROTEIN", 53, 70], ["Complement receptor", "TEST", 0, 19], ["the B cell", "TREATMENT", 31, 41], ["cleavage products", "TREATMENT", 53, 70], ["antibody production", "PROBLEM", 99, 118]]], ["As well, C3a and C5a released from their respective convertases are potent anaphylatoxins.", [["C3a", "GENE_OR_GENE_PRODUCT", 9, 12], ["C5a", "GENE_OR_GENE_PRODUCT", 17, 20], ["anaphylatoxins", "GENE_OR_GENE_PRODUCT", 75, 89], ["C3a", "PROTEIN", 9, 12], ["C5a", "PROTEIN", 17, 20], ["C3a and C5a", "TREATMENT", 9, 20], ["potent anaphylatoxins", "PROBLEM", 68, 89]]], ["Many components of the complement system also participate in organ development, trimming of unused neuronal connections, cell migration/morphogenesis, and regeneration/cell-signalling (Leslie and Mayor, 2013) .The complement systemThe pig has been used as an animal model to study the response of the complement cascade in human diseases (Abu-El-Haija et al., 2012; Dalle Lucca et al., 2012; Fernandes et al., 2012) .", [["organ", "ANATOMY", 61, 66], ["neuronal", "ANATOMY", 99, 107], ["cell", "ANATOMY", 121, 125], ["cell", "ANATOMY", 168, 172], ["organ", "ORGAN", 61, 66], ["neuronal", "CELL", 99, 107], ["cell", "CELL", 121, 125], ["cell", "CELL", 168, 172], ["pig", "ORGANISM", 235, 238], ["human", "ORGANISM", 323, 328], ["pig", "SPECIES", 235, 238], ["human", "SPECIES", 323, 328], ["pig", "SPECIES", 235, 238], ["human", "SPECIES", 323, 328], ["unused neuronal connections", "PROBLEM", 92, 119], ["cell migration/morphogenesis", "PROBLEM", 121, 149], ["The pig", "TREATMENT", 231, 238], ["human diseases", "PROBLEM", 323, 337], ["unused neuronal connections", "OBSERVATION", 92, 119], ["cell migration", "OBSERVATION", 121, 135], ["cell", "OBSERVATION", 168, 172]]], ["Using pig as a model to study cystic fibrosis (CF) (Rogers et al., 2008) , largescale transcript profiling revealed that the pancreas in foetal and newborn CF pigs exhibited significantly increased expression of genes whose products play a role in inflammation, fibrosis and the complement cascade compared to age matched, non-CF pigs (Abu-El-Haija et al., 2012) .", [["cystic", "ANATOMY", 30, 36], ["pancreas", "ANATOMY", 125, 133], ["foetal", "ANATOMY", 137, 143], ["cystic fibrosis", "DISEASE", 30, 45], ["CF", "DISEASE", 47, 49], ["inflammation", "DISEASE", 248, 260], ["fibrosis", "DISEASE", 262, 270], ["pig", "ORGANISM", 6, 9], ["pancreas", "ORGAN", 125, 133], ["foetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 137, 143], ["CF pigs", "ORGANISM", 156, 163], ["pigs", "ORGANISM", 330, 334], ["pig", "SPECIES", 6, 9], ["pigs", "SPECIES", 159, 163], ["pigs", "SPECIES", 330, 334], ["pig", "SPECIES", 6, 9], ["pig", "TREATMENT", 6, 9], ["cystic fibrosis", "PROBLEM", 30, 45], ["largescale transcript profiling", "TEST", 75, 106], ["inflammation", "PROBLEM", 248, 260], ["fibrosis", "PROBLEM", 262, 270], ["the complement cascade", "PROBLEM", 275, 297], ["cystic", "OBSERVATION_MODIFIER", 30, 36], ["fibrosis", "OBSERVATION", 37, 45], ["pancreas", "ANATOMY", 125, 133], ["significantly", "OBSERVATION_MODIFIER", 174, 187], ["increased", "OBSERVATION_MODIFIER", 188, 197], ["inflammation", "OBSERVATION", 248, 260], ["fibrosis", "OBSERVATION", 262, 270]]], ["Other studies showed that activation of the complement system has been associated with tissue injury after hemorrhage and resuscitation (Dalle Lucca et al., 2012) .", [["tissue", "ANATOMY", 87, 93], ["tissue injury", "DISEASE", 87, 100], ["hemorrhage", "DISEASE", 107, 117], ["tissue", "TISSUE", 87, 93], ["Other studies", "TEST", 0, 13], ["activation of the complement system", "PROBLEM", 26, 61], ["tissue injury", "PROBLEM", 87, 100], ["hemorrhage", "PROBLEM", 107, 117], ["resuscitation", "TREATMENT", 122, 135], ["associated with", "UNCERTAINTY", 71, 86], ["tissue", "OBSERVATION_MODIFIER", 87, 93], ["injury", "OBSERVATION", 94, 100], ["hemorrhage", "OBSERVATION", 107, 117]]], ["In a porcine model of hemorrhagic shock, administration of recombinant human C1-esterase inhibitor reduced tissue damage and cytokine release and improved metabolic acidosis (Dalle Lucca et al., 2012) .", [["tissue", "ANATOMY", 107, 113], ["hemorrhagic shock", "DISEASE", 22, 39], ["metabolic acidosis", "DISEASE", 155, 173], ["human", "ORGANISM", 71, 76], ["C1-esterase", "GENE_OR_GENE_PRODUCT", 77, 88], ["tissue", "TISSUE", 107, 113], ["recombinant human C1", "PROTEIN", 59, 79], ["cytokine", "PROTEIN", 125, 133], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 71, 76], ["hemorrhagic shock", "PROBLEM", 22, 39], ["recombinant human C1-esterase inhibitor", "TREATMENT", 59, 98], ["reduced tissue damage", "PROBLEM", 99, 120], ["cytokine release", "TEST", 125, 141], ["improved metabolic acidosis", "PROBLEM", 146, 173], ["hemorrhagic", "OBSERVATION_MODIFIER", 22, 33], ["shock", "OBSERVATION", 34, 39], ["improved", "OBSERVATION_MODIFIER", 146, 154], ["metabolic acidosis", "OBSERVATION", 155, 173]]], ["In pigs, complement mediated damage and immunosuppression are key features of post-weaning multi-systemic wasting syndrome (PMWS) (Fernandes et al., 2012) .", [["multi-systemic wasting syndrome", "DISEASE", 91, 122], ["PMWS", "DISEASE", 124, 128], ["pigs", "ORGANISM", 3, 7], ["pigs", "SPECIES", 3, 7], ["pigs", "SPECIES", 3, 7], ["complement mediated damage", "PROBLEM", 9, 35], ["immunosuppression", "TREATMENT", 40, 57], ["post-weaning multi-systemic wasting syndrome", "PROBLEM", 78, 122]]], ["When large scale transcriptional analysis was compared between mediastinal lymph nodes from healthy pigs and pigs naturally affected by PMWS, affected animals had increased relative abundance of mRNAs coded by a large set of genes involved in the inflammatory responses (e.g. cytokines, acute phase proteins, and respiratory burst proteins) (Fernandes et al., 2012) .", [["mediastinal lymph nodes", "ANATOMY", 63, 86], ["PMWS", "DISEASE", 136, 140], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 75, 86], ["pigs", "ORGANISM", 100, 104], ["pigs", "ORGANISM", 109, 113], ["acute phase proteins", "GENE_OR_GENE_PRODUCT", 287, 307], ["mRNAs", "RNA", 195, 200], ["cytokines", "PROTEIN", 276, 285], ["acute phase proteins", "PROTEIN", 287, 307], ["respiratory burst proteins", "PROTEIN", 313, 339], ["pigs", "SPECIES", 100, 104], ["pigs", "SPECIES", 109, 113], ["pigs", "SPECIES", 100, 104], ["pigs", "SPECIES", 109, 113], ["large scale transcriptional analysis", "TEST", 5, 41], ["mediastinal lymph nodes", "PROBLEM", 63, 86], ["PMWS", "PROBLEM", 136, 140], ["the inflammatory responses", "TEST", 243, 269], ["cytokines", "TEST", 276, 285], ["acute phase proteins", "PROBLEM", 287, 307], ["respiratory burst proteins", "PROBLEM", 313, 339], ["mediastinal", "ANATOMY", 63, 74], ["lymph nodes", "OBSERVATION", 75, 86], ["increased", "OBSERVATION_MODIFIER", 163, 172], ["inflammatory", "OBSERVATION", 247, 259], ["respiratory", "ANATOMY", 313, 324]]], ["However, the level of CR1 mRNA was decreased suggesting an altered complement system (Fernandes et al., 2012) .", [["CR1", "GENE_OR_GENE_PRODUCT", 22, 25], ["CR1 mRNA", "RNA", 22, 30], ["CR1 mRNA", "TEST", 22, 30], ["an altered complement system", "PROBLEM", 56, 84], ["altered", "OBSERVATION_MODIFIER", 59, 66]]], ["This decreased CR1 gene expression may contribute to increased complement deposition and secondary infections by impairing phagocytosis (Fernandes et al., 2012) .", [["infections", "DISEASE", 99, 109], ["CR1", "GENE_OR_GENE_PRODUCT", 15, 18], ["CR1 gene", "DNA", 15, 23], ["This decreased CR1 gene expression", "PROBLEM", 0, 34], ["increased complement deposition", "PROBLEM", 53, 84], ["secondary infections", "PROBLEM", 89, 109], ["impairing phagocytosis", "PROBLEM", 113, 135], ["may contribute to", "UNCERTAINTY", 35, 52], ["increased", "OBSERVATION_MODIFIER", 53, 62], ["complement deposition", "OBSERVATION", 63, 84], ["secondary", "OBSERVATION_MODIFIER", 89, 98], ["infections", "OBSERVATION", 99, 109], ["phagocytosis", "OBSERVATION_MODIFIER", 123, 135]]], ["Research groups sequenced porcine C3 (Wimmers et al., 2003) , C5 (Kumar et al., 2004) , and mannosebinding lectin genes (Phatsara et al., 2007) , and screened them for polymorphisms in a population of crossed Duroc and Berlin miniature pigs (DUMI).", [["porcine", "ORGANISM", 26, 33], ["mannosebinding lectin", "GENE_OR_GENE_PRODUCT", 92, 113], ["Berlin miniature pigs", "ORGANISM", 219, 240], ["mannosebinding lectin genes", "DNA", 92, 119], ["pigs", "SPECIES", 236, 240], ["Duroc", "SPECIES", 209, 214], ["Berlin miniature pigs", "SPECIES", 219, 240], ["polymorphisms", "PROBLEM", 168, 181], ["crossed Duroc", "TREATMENT", 201, 214], ["Berlin miniature pigs (DUMI)", "TREATMENT", 219, 247], ["C5", "ANATOMY", 62, 64]]], ["C3c and haptoglobin (HP) serum levels were measured before and after vaccination against Mycoplasma hyopneumoniae (Mh), Aujeszky disease virus (ADV), and PRRSV.", [["serum", "ANATOMY", 25, 30], ["Aujeszky disease", "DISEASE", 120, 136], ["C3c", "GENE_OR_GENE_PRODUCT", 0, 3], ["haptoglobin", "GENE_OR_GENE_PRODUCT", 8, 19], ["HP", "GENE_OR_GENE_PRODUCT", 21, 23], ["serum", "ORGANISM_SUBSTANCE", 25, 30], ["Mycoplasma hyopneumoniae", "ORGANISM", 89, 113], ["Mh", "ORGANISM", 115, 117], ["Aujeszky disease virus", "ORGANISM", 120, 142], ["ADV", "ORGANISM", 144, 147], ["PRRSV", "ORGANISM", 154, 159], ["C3c", "PROTEIN", 0, 3], ["haptoglobin", "PROTEIN", 8, 19], ["HP", "PROTEIN", 21, 23], ["Mycoplasma hyopneumoniae", "SPECIES", 89, 113], ["Aujeszky disease virus", "SPECIES", 120, 142], ["PRRSV", "SPECIES", 154, 159], ["Mycoplasma hyopneumoniae", "SPECIES", 89, 113], ["Aujeszky disease virus", "SPECIES", 120, 142], ["ADV", "SPECIES", 144, 147], ["PRRSV", "SPECIES", 154, 159], ["C3c", "TEST", 0, 3], ["haptoglobin (HP) serum levels", "TEST", 8, 37], ["vaccination", "TREATMENT", 69, 80], ["Mycoplasma hyopneumoniae", "PROBLEM", 89, 113], ["Aujeszky disease virus", "PROBLEM", 120, 142], ["PRRSV", "PROBLEM", 154, 159], ["haptoglobin", "OBSERVATION_MODIFIER", 8, 19]]], ["Wimmers et al. determined that the individual variation in the acute-phase response to vaccinations observed within the DUMI resource population depended on the C3 genotype for C3c levels but that serum HP levels was not associated with C3 genomic variation (Wimmers et al., 2003) .", [["serum", "ANATOMY", 197, 202], ["C3", "GENE_OR_GENE_PRODUCT", 161, 163], ["C3c", "GENE_OR_GENE_PRODUCT", 177, 180], ["serum", "ORGANISM_SUBSTANCE", 197, 202], ["C3c", "PROTEIN", 177, 180], ["C3", "PROTEIN", 237, 239], ["the individual variation", "PROBLEM", 31, 55], ["vaccinations", "TREATMENT", 87, 99], ["the C3 genotype", "TEST", 157, 172], ["C3c levels", "TEST", 177, 187], ["serum HP levels", "TEST", 197, 212], ["C3 genomic variation", "PROBLEM", 237, 257], ["individual", "OBSERVATION_MODIFIER", 35, 45], ["variation", "OBSERVATION_MODIFIER", 46, 55], ["acute", "OBSERVATION_MODIFIER", 63, 68]]], ["Four polymorphic sites were detected on the C5 gene, one of which was segregating in the DUMI population in three genotypic patterns: AA, AC, and CC (Kumar et al., 2004) .", [["CC", "CHEMICAL", 146, 148], ["C5", "GENE_OR_GENE_PRODUCT", 44, 46], ["C5 gene", "DNA", 44, 51], ["Four polymorphic sites", "PROBLEM", 0, 22], ["AA, AC", "TEST", 134, 140], ["C5", "ANATOMY_MODIFIER", 44, 46]]], ["Classical and alternative complement activities, C3c and HP levels, and antibody titres against Mh and ADV were measured in the resource population (Kumar et al., 2004) .", [["C3c", "GENE_OR_GENE_PRODUCT", 49, 52], ["Mh", "GENE_OR_GENE_PRODUCT", 96, 98], ["C3c", "PROTEIN", 49, 52], ["HP", "PROTEIN", 57, 59], ["ADV", "SPECIES", 103, 106], ["alternative complement activities", "TEST", 14, 47], ["C3c and HP levels", "TEST", 49, 66], ["antibody titres", "TEST", 72, 87]]], ["The homozygote AA animals were found to be significantly different from the other two genotypes with respect to alternative and classical complement activation and genotype CC was found to be significantly different from the other genotypes for C3c and HP levels (Kumar et al., 2004) .", [["CC", "CHEMICAL", 173, 175], ["C3c", "GENE_OR_GENE_PRODUCT", 245, 248], ["C3c", "PROTEIN", 245, 248], ["The homozygote AA animals", "TEST", 0, 25], ["genotype CC", "TEST", 164, 175], ["C3c", "TEST", 245, 248], ["HP levels", "TEST", 253, 262]]], ["No significant difference could be seen between genotypes for antibody titres against vaccinations (Kumar et al., 2004) .", [["antibody titres", "TEST", 62, 77], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION", 15, 25]]], ["SNPs of porcine MBL1 and MBL2 (Phatsara et al., 2007) genes were found and genotyped.", [["porcine", "ORGANISM", 8, 15], ["MBL1", "GENE_OR_GENE_PRODUCT", 16, 20], ["MBL2", "GENE_OR_GENE_PRODUCT", 25, 29], ["MBL1", "DNA", 16, 20], ["MBL2", "DNA", 25, 29], ["porcine", "SPECIES", 8, 15], ["porcine MBL1", "TREATMENT", 8, 20], ["MBL2", "TEST", 25, 29]]], ["MBL1 genotypes differed in C3c serum concentration suggesting potential impact on complement activity.", [["serum", "ANATOMY", 31, 36], ["MBL1", "GENE_OR_GENE_PRODUCT", 0, 4], ["C3c", "GENE_OR_GENE_PRODUCT", 27, 30], ["serum", "ORGANISM_SUBSTANCE", 31, 36], ["MBL1", "PROTEIN", 0, 4], ["C3c", "PROTEIN", 27, 30], ["MBL1 genotypes", "TEST", 0, 14], ["C3c serum concentration", "TEST", 27, 50]]], ["Further, linkage analysis identified a quantitative trait locus for C3c serum level close to the position of the MBL genes which may indicate that porcine MBL2 and MBL1 could be possible functional and positional candidate genes for complement activity (Phatsara et al., 2007) .", [["serum", "ANATOMY", 72, 77], ["C3c", "GENE_OR_GENE_PRODUCT", 68, 71], ["serum", "ORGANISM_SUBSTANCE", 72, 77], ["MBL", "GENE_OR_GENE_PRODUCT", 113, 116], ["porcine", "ORGANISM", 147, 154], ["MBL2", "GENE_OR_GENE_PRODUCT", 155, 159], ["MBL1", "GENE_OR_GENE_PRODUCT", 164, 168], ["C3c", "PROTEIN", 68, 71], ["MBL genes", "DNA", 113, 122], ["MBL2", "DNA", 155, 159], ["MBL1", "DNA", 164, 168], ["linkage analysis", "TEST", 9, 25], ["a quantitative trait locus", "PROBLEM", 37, 63], ["C3c serum level", "TEST", 68, 83], ["porcine MBL2", "PROBLEM", 147, 159]]], ["These data suggest that genes for components of the complement cascade may be highly polymorphic and therefore, it may be possible to breed animals with advantageous complement activation to promote natural resistance to microorganisms (Wimmers et al., 2003) .", [["These data", "TEST", 0, 10], ["the complement cascade", "PROBLEM", 48, 70], ["advantageous complement activation", "TREATMENT", 153, 187]]], ["In a follow-up study, this research group wished to determine whether they could identify any links between polymorphisms, differential basal expression of porcine terminal complement components (TCC) genes (C6, C7, C8a, C8b, and C9), and disease resistance (Wimmers et al., 2011) .", [["porcine terminal complement components", "GENE_OR_GENE_PRODUCT", 156, 194], ["TCC", "GENE_OR_GENE_PRODUCT", 196, 199], ["C8b", "GENE_OR_GENE_PRODUCT", 221, 224], ["C9", "GENE_OR_GENE_PRODUCT", 230, 232], ["porcine terminal complement components", "PROTEIN", 156, 194], ["TCC", "PROTEIN", 196, 199], ["C6", "DNA", 208, 210], ["C7", "DNA", 212, 214], ["C8a", "DNA", 216, 219], ["C9", "DNA", 230, 232], ["a follow-up study", "TEST", 3, 20], ["porcine terminal complement components (TCC) genes (C6, C7, C8a, C8b, and C9)", "PROBLEM", 156, 233], ["disease resistance", "PROBLEM", 239, 257], ["basal", "ANATOMY_MODIFIER", 136, 141], ["porcine", "OBSERVATION_MODIFIER", 156, 163], ["terminal", "OBSERVATION_MODIFIER", 164, 172], ["C6", "ANATOMY_MODIFIER", 208, 210], ["C7", "ANATOMY_MODIFIER", 212, 214], ["C8", "ANATOMY_MODIFIER", 221, 223], ["C9", "ANATOMY", 230, 232], ["disease", "OBSERVATION_MODIFIER", 239, 246], ["resistance", "OBSERVATION_MODIFIER", 247, 257]]], ["Lung lesions were recorded as a parameter of health and the transcript levels of TCC genes from lung tissue were obtained from German Landrace, Pi\u00e9train, Hampshire, Duroc, Vietnamese Potbelly, and Berlin miniature pig (BMP) breeds (Wimmers et al., 2011) .", [["Lung lesions", "ANATOMY", 0, 12], ["lung tissue", "ANATOMY", 96, 107], ["Lung lesions", "CANCER", 0, 12], ["TCC", "GENE_OR_GENE_PRODUCT", 81, 84], ["lung tissue", "TISSUE", 96, 107], ["pig", "ORGANISM", 214, 217], ["TCC genes", "DNA", 81, 90], ["pig", "SPECIES", 214, 217], ["pig", "SPECIES", 214, 217], ["Lung lesions", "PROBLEM", 0, 12], ["TCC genes from lung tissue", "PROBLEM", 81, 107], ["Berlin miniature pig (BMP) breeds", "TREATMENT", 197, 230], ["lesions", "OBSERVATION", 5, 12], ["lung tissue", "ANATOMY", 96, 107]]], ["The analysis revealed thirty SNPs indicating considerable polymorphism as well as differences in the levels of expression among various complement genes (Wimmers et al., 2011) .", [["complement genes", "DNA", 136, 152], ["The analysis", "TEST", 0, 12], ["thirty SNPs", "PROBLEM", 22, 33], ["considerable polymorphism", "PROBLEM", 45, 70], ["thirty SNPs", "OBSERVATION", 22, 33], ["considerable", "OBSERVATION_MODIFIER", 45, 57], ["polymorphism", "OBSERVATION", 58, 70]]], ["The majority of SNPs were located in conserved regions on the gene promoters which may indicate that they affect transcription factor binding.", [["conserved regions", "DNA", 37, 54], ["gene promoters", "DNA", 62, 76], ["transcription factor", "PROTEIN", 113, 133], ["SNPs", "PROBLEM", 16, 20]]], ["In summary, the pig is an attractive model to study complement cascade and further studies must be performed to determine whether animals with particular complement gene expression variations may be more resistant to disease.The contact systemThere is considerable cross-talk between the complement and contact cascades.", [["pig", "ORGANISM", 16, 19], ["pig", "SPECIES", 16, 19], ["pig", "SPECIES", 16, 19], ["study complement cascade", "TEST", 46, 70], ["further studies", "TEST", 75, 90], ["particular complement gene expression variations", "PROBLEM", 143, 191], ["disease", "PROBLEM", 217, 224]]], ["Coagulation factors XI and XII, and plasma kallikrein are the three serine proteases that comprise the contact system, along with the non-enzymatic co-factor high molecular weight kininogen (HK) (Amara et al., 2008; Colman and Schmaier, 1997; Hamad et al., 2012) .", [["plasma", "ANATOMY", 36, 42], ["serine", "CHEMICAL", 68, 74], ["Coagulation factors XI", "GENE_OR_GENE_PRODUCT", 0, 22], ["XII", "GENE_OR_GENE_PRODUCT", 27, 30], ["plasma", "ORGANISM_SUBSTANCE", 36, 42], ["kallikrein", "GENE_OR_GENE_PRODUCT", 43, 53], ["high molecular weight kininogen", "GENE_OR_GENE_PRODUCT", 158, 189], ["HK", "GENE_OR_GENE_PRODUCT", 191, 193], ["Coagulation factors", "PROTEIN", 0, 19], ["XI", "PROTEIN", 20, 22], ["XII", "PROTEIN", 27, 30], ["plasma kallikrein", "PROTEIN", 36, 53], ["serine proteases", "PROTEIN", 68, 84], ["non-enzymatic co-factor", "PROTEIN", 134, 157], ["high molecular weight kininogen", "PROTEIN", 158, 189], ["HK", "PROTEIN", 191, 193], ["Coagulation factors XI", "TEST", 0, 22], ["XII", "TEST", 27, 30], ["plasma kallikrein", "TEST", 36, 53], ["the three serine proteases", "PROBLEM", 58, 84], ["the non-enzymatic co-factor", "PROBLEM", 130, 157]]], ["Both factor XIIa and kallikrein activate the complement cascade independently of known complement initiators, and activated members of the contact cascade such as factors Xa, Xia, and plasmin can cleave C5 and C3 to produce C5a and C3a (Amara et al., 2008; Hamad et al., 2012) .", [["factor XIIa", "GENE_OR_GENE_PRODUCT", 5, 16], ["kallikrein", "GENE_OR_GENE_PRODUCT", 21, 31], ["Xa", "GENE_OR_GENE_PRODUCT", 171, 173], ["Xia", "GENE_OR_GENE_PRODUCT", 175, 178], ["plasmin", "GENE_OR_GENE_PRODUCT", 184, 191], ["C5", "GENE_OR_GENE_PRODUCT", 203, 205], ["C3", "GENE_OR_GENE_PRODUCT", 210, 212], ["C5a", "GENE_OR_GENE_PRODUCT", 224, 227], ["C3a", "GENE_OR_GENE_PRODUCT", 232, 235], ["factor XIIa", "PROTEIN", 5, 16], ["kallikrein", "PROTEIN", 21, 31], ["complement initiators", "PROTEIN", 87, 108], ["Xa", "PROTEIN", 171, 173], ["Xia", "PROTEIN", 175, 178], ["plasmin", "PROTEIN", 184, 191], ["C5", "PROTEIN", 203, 205], ["C3", "PROTEIN", 210, 212], ["C5a", "PROTEIN", 224, 227], ["C3a", "PROTEIN", 232, 235], ["kallikrein activate", "TREATMENT", 21, 40], ["plasmin", "TREATMENT", 184, 191], ["C5a", "TEST", 224, 227]]], ["Further, complement inhibitor C1INH also inhibits coagulation factor XIIa indicating considerable overlap between the two pathways (Amara et al., 2008; Colman and Schmaier, 1997; Hamad et al., 2012) .", [["C1INH", "CHEMICAL", 30, 35], ["C1INH", "CHEMICAL", 30, 35], ["C1INH", "SIMPLE_CHEMICAL", 30, 35], ["coagulation factor XIIa", "GENE_OR_GENE_PRODUCT", 50, 73], ["coagulation factor XIIa", "PROTEIN", 50, 73], ["complement inhibitor C1INH", "TREATMENT", 9, 35], ["coagulation factor XIIa", "PROBLEM", 50, 73]]], ["When in contact with negatively charged surface, the contact system is activated and coagulation factor XII is then cleaved to form factor XIIa which in turn initiates the coagulation cascade.", [["surface", "ANATOMY", 40, 47], ["surface", "CELLULAR_COMPONENT", 40, 47], ["XII", "GENE_OR_GENE_PRODUCT", 104, 107], ["factor XIIa", "GENE_OR_GENE_PRODUCT", 132, 143], ["coagulation factor XII", "PROTEIN", 85, 107], ["factor XIIa", "PROTEIN", 132, 143], ["coagulation factor XII", "PROBLEM", 85, 107], ["factor XIIa", "PROBLEM", 132, 143], ["the coagulation cascade", "TREATMENT", 168, 191]]], ["Upon cleavage of prekallikrein to kallikrein, bradykinin (BK) is released (Shishido et al., 2012) .", [["bradykinin", "CHEMICAL", 46, 56], ["BK", "CHEMICAL", 58, 60], ["bradykinin", "CHEMICAL", 46, 56], ["prekallikrein", "GENE_OR_GENE_PRODUCT", 17, 30], ["kallikrein", "GENE_OR_GENE_PRODUCT", 34, 44], ["bradykinin", "SIMPLE_CHEMICAL", 46, 56], ["BK", "SIMPLE_CHEMICAL", 58, 60], ["prekallikrein", "PROTEIN", 17, 30], ["kallikrein", "PROTEIN", 34, 44], ["prekallikrein", "TREATMENT", 17, 30]]], ["BK binds its receptor and induces vasodilation, neutrophil chemotaxis, and vascular permeability, as well as triggers the release of pro-inflammatory mediators such as histamine, prostaglandins, leukotrienes, and cytokines, the latter mostly derived from polymorphonuclear cells (Renne, 2012) .", [["neutrophil", "ANATOMY", 48, 58], ["vascular", "ANATOMY", 75, 83], ["polymorphonuclear cells", "ANATOMY", 255, 278], ["histamine", "CHEMICAL", 168, 177], ["prostaglandins", "CHEMICAL", 179, 193], ["leukotrienes", "CHEMICAL", 195, 207], ["histamine", "CHEMICAL", 168, 177], ["prostaglandins", "CHEMICAL", 179, 193], ["leukotrienes", "CHEMICAL", 195, 207], ["BK", "GENE_OR_GENE_PRODUCT", 0, 2], ["neutrophil", "CELL", 48, 58], ["vascular", "MULTI-TISSUE_STRUCTURE", 75, 83], ["histamine", "SIMPLE_CHEMICAL", 168, 177], ["prostaglandins", "SIMPLE_CHEMICAL", 179, 193], ["leukotrienes", "SIMPLE_CHEMICAL", 195, 207], ["polymorphonuclear cells", "CELL", 255, 278], ["Renne", "CELL", 280, 285], ["pro-inflammatory mediators", "PROTEIN", 133, 159], ["cytokines", "PROTEIN", 213, 222], ["polymorphonuclear cells", "CELL_TYPE", 255, 278], ["vasodilation", "PROBLEM", 34, 46], ["neutrophil chemotaxis", "TEST", 48, 69], ["pro-inflammatory mediators", "TREATMENT", 133, 159], ["histamine", "TREATMENT", 168, 177], ["prostaglandins", "TREATMENT", 179, 193], ["leukotrienes", "TREATMENT", 195, 207], ["cytokines", "TREATMENT", 213, 222], ["neutrophil chemotaxis", "OBSERVATION", 48, 69], ["vascular", "ANATOMY", 75, 83], ["permeability", "OBSERVATION", 84, 96], ["polymorphonuclear cells", "OBSERVATION", 255, 278]]], ["In circulation, kallikrein, factor XII as well as tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA) bind plasminogen which recognizes and binds to fibrin blood clots.", [["fibrin blood clots", "ANATOMY", 174, 192], ["kallikrein", "GENE_OR_GENE_PRODUCT", 16, 26], ["factor XII", "GENE_OR_GENE_PRODUCT", 28, 38], ["tissue plasminogen activator", "GENE_OR_GENE_PRODUCT", 50, 78], ["tPA", "GENE_OR_GENE_PRODUCT", 80, 83], ["urokinase plasminogen activator", "GENE_OR_GENE_PRODUCT", 89, 120], ["uPA", "GENE_OR_GENE_PRODUCT", 122, 125], ["plasminogen", "GENE_OR_GENE_PRODUCT", 132, 143], ["fibrin", "GENE_OR_GENE_PRODUCT", 174, 180], ["blood", "ORGANISM_SUBSTANCE", 181, 186], ["clots", "ORGANISM_SUBSTANCE", 187, 192], ["kallikrein", "PROTEIN", 16, 26], ["factor XII", "PROTEIN", 28, 38], ["tissue plasminogen activator", "PROTEIN", 50, 78], ["urokinase plasminogen activator", "PROTEIN", 89, 120], ["uPA", "PROTEIN", 122, 125], ["plasminogen", "PROTEIN", 132, 143], ["kallikrein", "TREATMENT", 16, 26], ["factor XII", "TREATMENT", 28, 38], ["tissue plasminogen activator", "TREATMENT", 50, 78], ["tPA)", "TREATMENT", 80, 84], ["urokinase plasminogen activator (uPA) bind plasminogen", "TREATMENT", 89, 143], ["fibrin blood clots", "PROBLEM", 174, 192]]], ["These kinases cleave plasminogen and release plasmin, a potent extracellular protease which mediates, among other things, degradation of protein matrices involved in resolution of blood clots, embryogenesis, tumor invasion, wound healing, and angiogenesis (Castellino and Ploplis, 2005) .", [["extracellular", "ANATOMY", 63, 76], ["blood clots", "ANATOMY", 180, 191], ["tumor", "ANATOMY", 208, 213], ["wound", "ANATOMY", 224, 229], ["blood clots", "DISEASE", 180, 191], ["tumor", "DISEASE", 208, 213], ["plasminogen", "GENE_OR_GENE_PRODUCT", 21, 32], ["plasmin", "GENE_OR_GENE_PRODUCT", 45, 52], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 63, 76], ["blood", "ORGANISM_SUBSTANCE", 180, 185], ["clots", "ORGANISM_SUBSTANCE", 186, 191], ["tumor", "CANCER", 208, 213], ["wound", "PATHOLOGICAL_FORMATION", 224, 229], ["kinases", "PROTEIN", 6, 13], ["plasminogen", "PROTEIN", 21, 32], ["plasmin", "PROTEIN", 45, 52], ["extracellular protease", "PROTEIN", 63, 85], ["These kinases cleave plasminogen", "TREATMENT", 0, 32], ["release plasmin", "TREATMENT", 37, 52], ["a potent extracellular protease", "TREATMENT", 54, 85], ["protein matrices", "TREATMENT", 137, 153], ["blood clots", "PROBLEM", 180, 191], ["embryogenesis", "PROBLEM", 193, 206], ["tumor invasion", "PROBLEM", 208, 222], ["wound healing", "PROBLEM", 224, 237], ["angiogenesis", "PROBLEM", 243, 255], ["protein matrices", "OBSERVATION", 137, 153], ["blood clots", "OBSERVATION", 180, 191], ["tumor", "OBSERVATION_MODIFIER", 208, 213], ["invasion", "OBSERVATION_MODIFIER", 214, 222], ["wound", "OBSERVATION_MODIFIER", 224, 229], ["healing", "OBSERVATION_MODIFIER", 230, 237]]], ["Studies in pig showed that plasmin activates matrix metalloproteinases (MMPs) at sights of trauma enabling the degra-dation of all components of extracellular matrix and suggesting its involvement in remodelling (Salo et al., 2008) .Naturally occurring antibodiesNaturally occurring antibodies (NAbs) are germline-encoded antibodies with restricted epitope specificities and they are produced by B1 lymphocytes in primary lymphoid organs (Shishido et al., 2012) .", [["extracellular matrix", "ANATOMY", 145, 165], ["B1 lymphocytes", "ANATOMY", 396, 410], ["primary lymphoid organs", "ANATOMY", 414, 437], ["trauma", "DISEASE", 91, 97], ["pig", "ORGANISM", 11, 14], ["plasmin", "GENE_OR_GENE_PRODUCT", 27, 34], ["matrix metalloproteinases", "GENE_OR_GENE_PRODUCT", 45, 70], ["MMPs", "GENE_OR_GENE_PRODUCT", 72, 76], ["extracellular matrix", "CELLULAR_COMPONENT", 145, 165], ["B1 lymphocytes", "CELL", 396, 410], ["lymphoid organs", "TISSUE", 422, 437], ["plasmin", "PROTEIN", 27, 34], ["matrix metalloproteinases", "PROTEIN", 45, 70], ["MMPs", "PROTEIN", 72, 76], ["antibodies", "PROTEIN", 253, 263], ["antibodies", "PROTEIN", 283, 293], ["NAbs", "PROTEIN", 295, 299], ["germline", "DNA", 305, 313], ["B1 lymphocytes", "CELL_TYPE", 396, 410], ["pig", "SPECIES", 11, 14], ["pig", "SPECIES", 11, 14], ["Studies in pig", "TEST", 0, 14], ["plasmin activates matrix metalloproteinases", "PROBLEM", 27, 70], ["MMPs", "TEST", 72, 76], ["trauma", "PROBLEM", 91, 97], ["Naturally occurring antibodies", "PROBLEM", 233, 263], ["germline-encoded antibodies", "PROBLEM", 305, 332], ["restricted epitope specificities", "PROBLEM", 338, 370], ["plasmin", "OBSERVATION", 27, 34], ["extracellular matrix", "OBSERVATION", 145, 165], ["B1 lymphocytes", "OBSERVATION", 396, 410], ["lymphoid organs", "OBSERVATION", 422, 437]]], ["Furthermore, NAbs mainly target cellular debris and they bind pathogens with low affinity.", [["cellular debris", "ANATOMY", 32, 47], ["cellular", "CELL", 32, 40], ["NAbs", "PROTEIN", 13, 17], ["NAbs mainly target cellular debris", "PROBLEM", 13, 47], ["low affinity", "PROBLEM", 77, 89], ["NAbs", "OBSERVATION_MODIFIER", 13, 17], ["mainly target", "OBSERVATION_MODIFIER", 18, 31], ["cellular debris", "OBSERVATION", 32, 47], ["low affinity", "OBSERVATION_MODIFIER", 77, 89]]], ["The broad reactivity of individual NAbs allows rapid recognition and protection from pathogens never encountered before.", [["NAbs", "PROTEIN", 35, 39], ["individual NAbs", "PROBLEM", 24, 39], ["pathogens", "PROBLEM", 85, 94], ["broad", "OBSERVATION_MODIFIER", 4, 9], ["reactivity", "OBSERVATION_MODIFIER", 10, 20], ["NAbs", "OBSERVATION_MODIFIER", 35, 39]]], ["Additionally, they can also modulate the adaptive immune response by interacting with B cells, T cells, and DCs (Ochsenbein et al., 1999) .", [["B cells", "ANATOMY", 86, 93], ["T cells", "ANATOMY", 95, 102], ["DCs", "ANATOMY", 108, 111], ["B cells", "CELL", 86, 93], ["T cells", "CELL", 95, 102], ["DCs", "CELL", 108, 111], ["B cells", "CELL_TYPE", 86, 93], ["T cells", "CELL_TYPE", 95, 102], ["DCs", "CELL_TYPE", 108, 111]]], ["The VH genes of NAbs show little somatic hypermutation in human infants, rodents or swine (Butler et al., , 2006 .", [["VH", "GENE_OR_GENE_PRODUCT", 4, 6], ["NAbs", "GENE_OR_GENE_PRODUCT", 16, 20], ["human", "ORGANISM", 58, 63], ["VH genes", "DNA", 4, 12], ["NAbs", "PROTEIN", 16, 20], ["human", "SPECIES", 58, 63], ["infants", "SPECIES", 64, 71], ["swine", "SPECIES", 84, 89], ["human", "SPECIES", 58, 63], ["swine", "SPECIES", 84, 89], ["little somatic hypermutation in human infants", "PROBLEM", 26, 71], ["NAbs", "OBSERVATION", 16, 20], ["little", "OBSERVATION_MODIFIER", 26, 32], ["somatic hypermutation", "OBSERVATION", 33, 54]]], ["In most species, the majority of NAbs are IgM isotype but NAbs can also include IgG and IgA isotypes (Engelhardt et al., 2002a) .", [["NAbs", "ORGANISM", 33, 37], ["IgM", "GENE_OR_GENE_PRODUCT", 42, 45], ["IgG", "GENE_OR_GENE_PRODUCT", 80, 83], ["IgA", "GENE_OR_GENE_PRODUCT", 88, 91], ["NAbs", "PROTEIN", 33, 37], ["IgM isotype", "PROTEIN", 42, 53], ["NAbs", "PROTEIN", 58, 62], ["IgG", "PROTEIN", 80, 83], ["IgA isotypes", "PROTEIN", 88, 100], ["IgM isotype", "PROBLEM", 42, 53], ["IgG", "TEST", 80, 83], ["IgA isotypes", "PROBLEM", 88, 100], ["most species", "OBSERVATION_MODIFIER", 3, 15], ["NAbs", "OBSERVATION", 33, 37], ["IgM isotype", "OBSERVATION", 42, 53]]], ["NAbs are potent initiators of the complement cascade and they improve immunogenicity through enhanced antigen-trapping in secondary lymphoid organ and promotion of opsonisation (Michael et al., 1962; Ochsenbein et al., 1999; Shishido et al., 2012) .Acute phase proteinsAcute phase proteins (APPs) are blood proteins which are rapidly induced in response to inflammation caused by tissue injury, infections or stress (Gonzalez-Ramon et al., 1995; Lampreave et al., 1994) .", [["lymphoid organ", "ANATOMY", 132, 146], ["blood", "ANATOMY", 301, 306], ["tissue", "ANATOMY", 380, 386], ["inflammation", "DISEASE", 357, 369], ["tissue injury", "DISEASE", 380, 393], ["infections", "DISEASE", 395, 405], ["lymphoid organ", "MULTI-TISSUE_STRUCTURE", 132, 146], ["Acute phase proteins", "GENE_OR_GENE_PRODUCT", 269, 289], ["APPs", "GENE_OR_GENE_PRODUCT", 291, 295], ["blood", "ORGANISM_SUBSTANCE", 301, 306], ["tissue", "TISSUE", 380, 386], ["Acute phase proteins", "PROTEIN", 249, 269], ["Acute phase proteins", "PROTEIN", 269, 289], ["APPs", "PROTEIN", 291, 295], ["blood proteins", "PROTEIN", 301, 315], ["the complement cascade", "PROBLEM", 30, 52], ["enhanced antigen", "TEST", 93, 109], ["secondary lymphoid organ", "PROBLEM", 122, 146], ["Acute phase proteinsAcute phase proteins", "PROBLEM", 249, 289], ["APPs", "TEST", 291, 295], ["blood proteins", "PROBLEM", 301, 315], ["inflammation", "PROBLEM", 357, 369], ["tissue injury", "PROBLEM", 380, 393], ["infections", "PROBLEM", 395, 405], ["stress", "PROBLEM", 409, 415], ["secondary lymphoid organ", "OBSERVATION", 122, 146], ["Acute", "OBSERVATION_MODIFIER", 269, 274], ["inflammation", "OBSERVATION", 357, 369], ["tissue", "ANATOMY", 380, 386], ["injury", "OBSERVATION", 387, 393]]], ["The two major APPs in pigs acute phase protein (pig-MAP) and HP (Gonzalez-Ramon et al., 1995; Lampreave et al., 1994) show 10-fold increased concentration in response to inflammation induced by oil injection, surgical trauma, stress, and acute bacterial or viral infections (Asai et al., 1999; Carpintero et al., 2007; Gonzalez-Ramon et al., 1995; Heegaard et al., 1998; Lampreave et al., 1994) .", [["oil", "ANATOMY", 194, 197], ["inflammation", "DISEASE", 170, 182], ["trauma", "DISEASE", 218, 224], ["acute bacterial or viral infections", "DISEASE", 238, 273], ["APPs", "GENE_OR_GENE_PRODUCT", 14, 18], ["pigs", "ORGANISM", 22, 26], ["pig", "ORGANISM", 48, 51], ["-MAP", "GENE_OR_GENE_PRODUCT", 51, 55], ["oil", "ORGANISM_SUBSTANCE", 194, 197], ["APPs", "PROTEIN", 14, 18], ["MAP", "PROTEIN", 52, 55], ["pigs", "SPECIES", 22, 26], ["pig", "SPECIES", 48, 51], ["pigs acute phase protein", "TEST", 22, 46], ["HP", "TEST", 61, 63], ["10-fold increased concentration", "PROBLEM", 123, 154], ["inflammation", "PROBLEM", 170, 182], ["oil injection", "TREATMENT", 194, 207], ["surgical trauma", "PROBLEM", 209, 224], ["stress", "PROBLEM", 226, 232], ["acute bacterial or viral infections", "PROBLEM", 238, 273], ["inflammation", "OBSERVATION", 170, 182], ["acute", "OBSERVATION_MODIFIER", 238, 243], ["bacterial", "OBSERVATION_MODIFIER", 244, 253], ["viral", "OBSERVATION_MODIFIER", 257, 262], ["infections", "OBSERVATION", 263, 273]]], ["For instance, pigs infected with Actinobacillus pleuropneumoniae showed rapid induction of HP, C-reactive protein, pig-MAP, and serum amyloid A (Heegaard et al., 1998) .", [["serum", "ANATOMY", 128, 133], ["pigs", "ORGANISM", 14, 18], ["Actinobacillus pleuropneumoniae", "ORGANISM", 33, 64], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 95, 113], ["pig", "ORGANISM", 115, 118], ["-MAP", "GENE_OR_GENE_PRODUCT", 118, 122], ["serum", "ORGANISM_SUBSTANCE", 128, 133], ["amyloid A", "SIMPLE_CHEMICAL", 134, 143], ["C-reactive protein", "PROTEIN", 95, 113], ["MAP", "PROTEIN", 119, 122], ["pigs", "SPECIES", 14, 18], ["Actinobacillus pleuropneumoniae", "SPECIES", 33, 64], ["pig", "SPECIES", 115, 118], ["pigs", "SPECIES", 14, 18], ["Actinobacillus pleuropneumoniae", "SPECIES", 33, 64], ["pig", "SPECIES", 115, 118], ["Actinobacillus pleuropneumoniae", "PROBLEM", 33, 64], ["HP", "TEST", 91, 93], ["C", "TEST", 95, 96], ["reactive protein", "TEST", 97, 113], ["pig-MAP", "TEST", 115, 122], ["serum amyloid A", "PROBLEM", 128, 143], ["reactive protein", "OBSERVATION", 97, 113]]], ["Interestingly, apolipoprotein A-I (ApoA-I) concentration decreased two to five folds in pig serum after sterile inflammation induced by turpentine injection or after infection with A. pleuropneumoniae or S. suis (Carpintero et al., 2005) .", [["serum", "ANATOMY", 92, 97], ["inflammation", "DISEASE", 112, 124], ["turpentine", "CHEMICAL", 136, 146], ["infection", "DISEASE", 166, 175], ["apolipoprotein A-I", "GENE_OR_GENE_PRODUCT", 15, 33], ["ApoA-I", "GENE_OR_GENE_PRODUCT", 35, 41], ["pig", "ORGANISM", 88, 91], ["serum", "ORGANISM_SUBSTANCE", 92, 97], ["turpentine", "SIMPLE_CHEMICAL", 136, 146], ["A. pleuropneumoniae", "ORGANISM", 181, 200], ["S. suis", "ORGANISM", 204, 211], ["pig", "SPECIES", 88, 91], ["A. pleuropneumoniae", "SPECIES", 181, 200], ["S. suis", "SPECIES", 204, 211], ["pig", "SPECIES", 88, 91], ["A. pleuropneumoniae", "SPECIES", 181, 200], ["S. suis", "SPECIES", 204, 211], ["apolipoprotein A-I (ApoA-I) concentration", "TREATMENT", 15, 56], ["pig serum", "TREATMENT", 88, 97], ["sterile inflammation", "PROBLEM", 104, 124], ["turpentine injection", "TREATMENT", 136, 156], ["infection", "PROBLEM", 166, 175], ["A. pleuropneumoniae", "PROBLEM", 181, 200], ["inflammation", "OBSERVATION", 112, 124]]], ["Pigs infected with ASFV or ADV showed elevated pig-MAP and decreased ApoA-I levels suggesting that the latter is a negative acute-phase protein .", [["ADV", "CHEMICAL", 27, 30], ["Pigs", "ORGANISM", 0, 4], ["ASFV", "ORGANISM", 19, 23], ["ADV", "ORGANISM", 27, 30], ["pig", "ORGANISM", 47, 50], ["MAP", "GENE_OR_GENE_PRODUCT", 51, 54], ["ApoA-I", "GENE_OR_GENE_PRODUCT", 69, 75], ["ApoA", "PROTEIN", 69, 73], ["negative acute-phase protein", "PROTEIN", 115, 143], ["Pigs", "SPECIES", 0, 4], ["pig", "SPECIES", 47, 50], ["Pigs", "SPECIES", 0, 4], ["ASFV", "SPECIES", 19, 23], ["ADV", "SPECIES", 27, 30], ["pig", "SPECIES", 47, 50], ["ASFV", "PROBLEM", 19, 23], ["ADV", "PROBLEM", 27, 30], ["elevated pig-MAP", "PROBLEM", 38, 54], ["decreased ApoA-I levels", "PROBLEM", 59, 82], ["a negative acute-phase protein", "PROBLEM", 113, 143], ["decreased", "OBSERVATION_MODIFIER", 59, 68]]], ["Stress due to transport or change in diet have also been shown to induce the concentration of pig-MAP and HP (Eurell et al., 1992; Pi\u00f1eiro et al., 2007; Pineiro et al., 2007) .", [["pig", "ORGANISM", 94, 97], ["-MAP", "GENE_OR_GENE_PRODUCT", 97, 101], ["pig", "SPECIES", 94, 97]]], ["Peripheral blood mononucleated cells (PBMCs) from pigs injected with a TLR9 agonist showed consistently increased production of IP-10 suggesting that IP-10 may be a potential biomarker for CpG ODNs activation in pigs (Dar et al., 2010) .", [["Peripheral blood mononucleated cells", "ANATOMY", 0, 36], ["PBMCs", "ANATOMY", 38, 43], ["CpG", "CHEMICAL", 189, 192], ["Peripheral blood mononucleated cells", "CELL", 0, 36], ["PBMCs", "CELL", 38, 43], ["pigs", "ORGANISM", 50, 54], ["TLR9", "GENE_OR_GENE_PRODUCT", 71, 75], ["IP-10", "GENE_OR_GENE_PRODUCT", 128, 133], ["IP-10", "GENE_OR_GENE_PRODUCT", 150, 155], ["pigs", "ORGANISM", 212, 216], ["Peripheral blood mononucleated cells", "CELL_TYPE", 0, 36], ["PBMCs", "CELL_TYPE", 38, 43], ["TLR9", "PROTEIN", 71, 75], ["pigs", "SPECIES", 50, 54], ["pigs", "SPECIES", 212, 216], ["pigs", "SPECIES", 50, 54], ["pigs", "SPECIES", 212, 216], ["Peripheral blood mononucleated cells", "TREATMENT", 0, 36], ["PBMCs", "TEST", 38, 43], ["a TLR9 agonist", "TEST", 69, 83], ["increased production of IP", "PROBLEM", 104, 130], ["CpG ODNs activation", "TREATMENT", 189, 208], ["blood", "ANATOMY", 11, 16], ["mononucleated cells", "OBSERVATION", 17, 36], ["increased", "OBSERVATION_MODIFIER", 104, 113], ["production", "OBSERVATION_MODIFIER", 114, 124]]], ["Pig-MAP shows homology with human serum protein PK-120 which is a putative substrate for kallikrein indicating again how the humoral innate immune system pathways show significant overlap (Gonzalez-Ramon et al., 1995; Nishimura et al., 1995) .Host defence peptides/antimicrobial peptidesHost defence peptides (HDPs), also known as antimicrobial peptides, are expressed in epithelial cells and phagocytes, stored in secretory granules, and released via regulated exocytic pathways at mucosal surfaces and at sites of infection (Dybvig et al., 2011; Sang and Blecha, 2009 ).", [["serum", "ANATOMY", 34, 39], ["epithelial cells", "ANATOMY", 372, 388], ["phagocytes", "ANATOMY", 393, 403], ["secretory granules", "ANATOMY", 415, 433], ["exocytic", "ANATOMY", 462, 470], ["mucosal surfaces", "ANATOMY", 483, 499], ["sites", "ANATOMY", 507, 512], ["infection", "DISEASE", 516, 525], ["Pig-MAP", "GENE_OR_GENE_PRODUCT", 0, 7], ["human", "ORGANISM", 28, 33], ["serum", "ORGANISM_SUBSTANCE", 34, 39], ["PK-120", "GENE_OR_GENE_PRODUCT", 48, 54], ["kallikrein", "GENE_OR_GENE_PRODUCT", 89, 99], ["Host defence peptides", "GENE_OR_GENE_PRODUCT", 287, 308], ["HDPs", "GENE_OR_GENE_PRODUCT", 310, 314], ["epithelial cells", "CELL", 372, 388], ["phagocytes", "CELL", 393, 403], ["secretory granules", "CELLULAR_COMPONENT", 415, 433], ["mucosal surfaces", "TISSUE", 483, 499], ["MAP", "PROTEIN", 4, 7], ["human serum protein PK-120", "PROTEIN", 28, 54], ["kallikrein", "PROTEIN", 89, 99], ["epithelial cells", "CELL_TYPE", 372, 388], ["phagocytes", "CELL_TYPE", 393, 403], ["Pig", "SPECIES", 0, 3], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 28, 33], ["human serum protein PK", "TEST", 28, 50], ["kallikrein", "PROBLEM", 89, 99], ["Host defence peptides", "TREATMENT", 243, 264], ["antimicrobial peptides", "TREATMENT", 265, 287], ["antimicrobial peptides", "PROBLEM", 331, 353], ["phagocytes", "PROBLEM", 393, 403], ["secretory granules", "PROBLEM", 415, 433], ["infection", "PROBLEM", 516, 525], ["significant", "OBSERVATION_MODIFIER", 168, 179], ["antimicrobial peptides", "OBSERVATION", 265, 287], ["antimicrobial peptides", "OBSERVATION", 331, 353], ["epithelial cells", "OBSERVATION", 372, 388], ["secretory granules", "OBSERVATION", 415, 433], ["exocytic pathways", "OBSERVATION", 462, 479], ["mucosal surfaces", "OBSERVATION_MODIFIER", 483, 499], ["infection", "OBSERVATION", 516, 525]]], ["Many HDPs are naturally antibacterial, antiviral, and antiparasitic and mediate their antimicrobial effects by peptide-mediated membrane disruption (Bowdish et al., 2006; Shai, 1999) .", [["membrane", "ANATOMY", 128, 136], ["HDPs", "CHEMICAL", 5, 9], ["HDPs", "SIMPLE_CHEMICAL", 5, 9], ["membrane", "CELLULAR_COMPONENT", 128, 136], ["naturally antibacterial", "TREATMENT", 14, 37], ["antiviral", "TREATMENT", 39, 48], ["antiparasitic", "TREATMENT", 54, 67], ["their antimicrobial effects", "TREATMENT", 80, 107]]], ["HDPs promote recruitment of neutrophils, monocytes, and mast cells causing release of nitric oxide, macrophage phagocytosis, and mast cell degranulation.", [["neutrophils", "ANATOMY", 28, 39], ["monocytes", "ANATOMY", 41, 50], ["mast cells", "ANATOMY", 56, 66], ["macrophage", "ANATOMY", 100, 110], ["mast cell", "ANATOMY", 129, 138], ["nitric oxide", "CHEMICAL", 86, 98], ["nitric oxide", "CHEMICAL", 86, 98], ["HDPs", "SIMPLE_CHEMICAL", 0, 4], ["neutrophils", "CELL", 28, 39], ["monocytes", "CELL", 41, 50], ["mast cells", "CELL", 56, 66], ["nitric oxide", "SIMPLE_CHEMICAL", 86, 98], ["macrophage", "CELL", 100, 110], ["mast cell", "CELL", 129, 138], ["neutrophils", "CELL_TYPE", 28, 39], ["monocytes", "CELL_TYPE", 41, 50], ["mast cells", "CELL_TYPE", 56, 66], ["neutrophils", "TEST", 28, 39], ["monocytes", "TEST", 41, 50], ["mast cells", "PROBLEM", 56, 66], ["nitric oxide", "TREATMENT", 86, 98], ["macrophage phagocytosis", "PROBLEM", 100, 123], ["mast cell degranulation", "PROBLEM", 129, 152], ["recruitment", "OBSERVATION_MODIFIER", 13, 24], ["neutrophils", "OBSERVATION", 28, 39], ["mast cells", "OBSERVATION", 56, 66], ["nitric oxide", "OBSERVATION", 86, 98], ["macrophage phagocytosis", "OBSERVATION", 100, 123], ["mast cell degranulation", "OBSERVATION", 129, 152]]], ["Furthermore, HDPs stimulate tissue and wound repair, promote angiogenesis, and can also suppress the stimulated release of pro-inflammatory cytokines (Bowdish et al., 2004; Garlapati et al., 2009; Hancock and Scott, 2000; Iimura et al., 2005; Mookherjee et al., 2006; Nijnik et al., 2009; Yu et al., 2007) .", [["tissue", "ANATOMY", 28, 34], ["wound", "ANATOMY", 39, 44], ["HDPs", "SIMPLE_CHEMICAL", 13, 17], ["tissue", "TISSUE", 28, 34], ["wound", "PATHOLOGICAL_FORMATION", 39, 44], ["HDPs", "PROTEIN", 13, 17], ["pro-inflammatory cytokines", "PROTEIN", 123, 149], ["HDPs stimulate tissue", "PROBLEM", 13, 34], ["wound repair", "TREATMENT", 39, 51], ["wound repair", "OBSERVATION", 39, 51], ["angiogenesis", "OBSERVATION", 61, 73]]], ["Thus, HDPs provide a functional linkage between the innate and adaptive immune systems (Dybvig et al., 2011) .Host defence peptides/antimicrobial peptidesMammalian HDPs consist of two peptide families: cathelicidins and defensins.", [["HDPs", "GENE_OR_GENE_PRODUCT", 6, 10], ["HDPs", "GENE_OR_GENE_PRODUCT", 164, 168], ["cathelicidins", "GENE_OR_GENE_PRODUCT", 202, 215], ["defensins", "GENE_OR_GENE_PRODUCT", 220, 229], ["HDPs", "PROTEIN", 6, 10], ["cathelicidins", "PROTEIN", 202, 215], ["defensins", "PROTEIN", 220, 229], ["Host defence peptides", "TREATMENT", 110, 131], ["antimicrobial peptides", "TREATMENT", 132, 154], ["cathelicidins and defensins", "TREATMENT", 202, 229]]], ["Cathelicidins are small, cationic, mostly a-helical, amphipathic molecules synthesized with a highly conserved cathelin propeptide sequence (Gallo et al., 1997; Sang and Blecha, 2009; Zanetti, 2004) .", [["Cathelicidins", "SIMPLE_CHEMICAL", 0, 13], ["cathelin propeptide", "GENE_OR_GENE_PRODUCT", 111, 130], ["amphipathic molecules", "PROTEIN", 53, 74], ["cathelin propeptide sequence", "PROTEIN", 111, 139], ["Cathelicidins", "TREATMENT", 0, 13], ["small, cationic", "PROBLEM", 18, 33], ["Zanetti", "TREATMENT", 184, 191], ["small", "OBSERVATION_MODIFIER", 18, 23], ["amphipathic molecules", "OBSERVATION", 53, 74]]], ["Cathelicidins are expressed in the skin and mucosal surfaces and are found in their proteolytically processed mature form at mucosal surfaces and in most body secretions including sweat, breast milk, and saliva (Murakami et al., 2002; Phadke et al., 2005) .", [["skin", "ANATOMY", 35, 39], ["mucosal surfaces", "ANATOMY", 44, 60], ["mucosal surfaces", "ANATOMY", 125, 141], ["body secretions", "ANATOMY", 154, 169], ["sweat", "ANATOMY", 180, 185], ["breast milk", "ANATOMY", 187, 198], ["Cathelicidins", "GENE_OR_GENE_PRODUCT", 0, 13], ["skin", "ORGAN", 35, 39], ["mucosal surfaces", "TISSUE", 44, 60], ["mucosal surfaces", "TISSUE", 125, 141], ["body secretions", "ORGANISM_SUBSTANCE", 154, 169], ["sweat", "ORGANISM_SUBDIVISION", 180, 185], ["breast milk", "ORGANISM_SUBSTANCE", 187, 198], ["saliva", "ORGANISM_SUBSTANCE", 204, 210], ["Cathelicidins", "PROTEIN", 0, 13], ["milk", "SPECIES", 194, 198], ["Cathelicidins", "TREATMENT", 0, 13], ["skin", "ANATOMY", 35, 39], ["mucosal surfaces", "ANATOMY", 44, 60], ["mature", "OBSERVATION_MODIFIER", 110, 116], ["mucosal surfaces", "OBSERVATION", 125, 141], ["most body", "ANATOMY_MODIFIER", 149, 158], ["breast", "ANATOMY", 187, 193]]], ["Defensins are cationic cystine-rich peptides comprised of three families: a-, b-, and h-defensins.", [["Defensins", "CHEMICAL", 0, 9], ["cystine", "CHEMICAL", 23, 30], ["cystine", "CHEMICAL", 23, 30], ["Defensins", "SIMPLE_CHEMICAL", 0, 9], ["cystine", "SIMPLE_CHEMICAL", 23, 30], ["a-, b-", "SIMPLE_CHEMICAL", 74, 80], ["h-defensins", "SIMPLE_CHEMICAL", 86, 97], ["a-, b-, and h-defensins", "PROTEIN", 74, 97], ["cationic cystine", "TREATMENT", 14, 30], ["h-defensins", "TREATMENT", 86, 97], ["cationic cystine", "OBSERVATION", 14, 30]]], ["They are extremely diverse in sequence and structure, the majority are 65 kDa in size, cationic at neutral pH, and amphipathic (Fahlgren et al., 2004) .", [["65 kDa", "OBSERVATION_MODIFIER", 71, 77], ["size", "OBSERVATION_MODIFIER", 81, 85]]], ["They are either constitutively expressed or induced by bacterial products or pro-inflammatory cytokines (Starner et al., 2005; Sumikawa et al., 2006; Vora et al., 2004) .", [["bacterial products", "PROTEIN", 55, 73], ["pro-inflammatory cytokines", "PROTEIN", 77, 103], ["pro-inflammatory cytokines", "PROBLEM", 77, 103]]], ["Current annotation of the porcine immunome has demonstrated expansion of the cathelicidin and type 1 IFN gene families (Dawson et al., 2013) and, like that of cattle, the pig genome does not contain any identifiable adefensins .", [["porcine", "ORGANISM", 26, 33], ["immunome", "CANCER", 34, 42], ["cathelicidin", "GENE_OR_GENE_PRODUCT", 77, 89], ["type 1 IFN", "GENE_OR_GENE_PRODUCT", 94, 104], ["cattle", "ORGANISM", 159, 165], ["pig", "ORGANISM", 171, 174], ["adefensins", "GENE_OR_GENE_PRODUCT", 216, 226], ["cathelicidin and type 1 IFN gene families", "DNA", 77, 118], ["pig genome", "DNA", 171, 181], ["adefensins", "PROTEIN", 216, 226], ["porcine", "SPECIES", 26, 33], ["cattle", "SPECIES", 159, 165], ["pig", "SPECIES", 171, 174], ["cattle", "SPECIES", 159, 165], ["pig", "SPECIES", 171, 174], ["the porcine immunome", "TREATMENT", 22, 42], ["the cathelicidin", "TREATMENT", 73, 89], ["the pig genome", "TREATMENT", 167, 181], ["expansion", "OBSERVATION_MODIFIER", 60, 69]]], ["Studies in our laboratory have revealed that porcine b-defensin 1 (pBD-1), a porcine defensin homolog of human BD-2 (hBD-2), is absent in the upper respiratory tract in neonatal pigs (Elahi et al., 2006) .", [["upper respiratory tract", "ANATOMY", 142, 165], ["porcine b-defensin 1", "GENE_OR_GENE_PRODUCT", 45, 65], ["pBD-1", "GENE_OR_GENE_PRODUCT", 67, 72], ["porcine defensin homolog", "GENE_OR_GENE_PRODUCT", 77, 101], ["human", "ORGANISM", 105, 110], ["BD-2", "GENE_OR_GENE_PRODUCT", 111, 115], ["hBD-2", "GENE_OR_GENE_PRODUCT", 117, 122], ["upper respiratory", "ORGANISM_SUBDIVISION", 142, 159], ["tract", "ORGANISM_SUBDIVISION", 160, 165], ["pigs", "ORGANISM", 178, 182], ["porcine b-defensin 1", "PROTEIN", 45, 65], ["pBD", "PROTEIN", 67, 70], ["porcine defensin homolog", "PROTEIN", 77, 101], ["human BD-2 (hBD-2", "DNA", 105, 122], ["porcine", "SPECIES", 45, 52], ["human", "SPECIES", 105, 110], ["pigs", "SPECIES", 178, 182], ["human", "SPECIES", 105, 110], ["pigs", "SPECIES", 178, 182], ["porcine b-defensin", "TEST", 45, 63], ["pBD", "TEST", 67, 70], ["a porcine defensin homolog of human BD", "TEST", 75, 113], ["hBD", "TEST", 117, 120], ["absent in the upper respiratory tract", "PROBLEM", 128, 165], ["absent", "OBSERVATION", 128, 134], ["upper", "ANATOMY_MODIFIER", 142, 147], ["respiratory tract", "ANATOMY", 148, 165], ["neonatal pigs", "ANATOMY", 169, 182]]], ["The expression of pBD-1 was detected in all analysed tissues in 4-to 5-week-old piglets.", [["tissues", "ANATOMY", 53, 60], ["pBD-1", "GENE_OR_GENE_PRODUCT", 18, 23], ["tissues", "TISSUE", 53, 60], ["piglets", "ORGANISM", 80, 87], ["pBD", "PROTEIN", 18, 21], ["piglets", "SPECIES", 80, 87], ["pBD", "TEST", 18, 21], ["pBD", "ANATOMY", 18, 21]]], ["Broncho-alveolar lavage (BAL) specimens collected from piglets older than 4 weeks of age and chemically synthesized pBD-1 displayed strong antimicrobial activity against Bordetella pertussis, in vitro.", [["Broncho-alveolar lavage (BAL) specimens", "ANATOMY", 0, 39], ["pBD-1", "CHEMICAL", 116, 121], ["Bordetella pertussis", "DISEASE", 170, 190], ["Broncho-alveolar lavage", "CELL", 0, 23], ["piglets", "ORGANISM", 55, 62], ["pBD-1", "GENE_OR_GENE_PRODUCT", 116, 121], ["Bordetella pertussis", "ORGANISM", 170, 190], ["piglets", "SPECIES", 55, 62], ["Bordetella pertussis", "SPECIES", 170, 190], ["Bordetella pertussis", "SPECIES", 170, 190], ["Broncho-alveolar lavage (BAL) specimens", "TEST", 0, 39], ["chemically synthesized pBD", "PROBLEM", 93, 119], ["strong antimicrobial activity", "TREATMENT", 132, 161], ["Bordetella pertussis", "PROBLEM", 170, 190], ["lavage", "OBSERVATION", 17, 23]]], ["Furthermore, in vivo treatment of newborn piglets with only 500 lg of pBD-1 at the time of challenge conferred protection against infection with B. pertussis (Elahi et al., 2006) .", [["pBD-1", "CHEMICAL", 70, 75], ["infection", "DISEASE", 130, 139], ["piglets", "ORGANISM", 42, 49], ["pBD-1", "GENE_OR_GENE_PRODUCT", 70, 75], ["B. pertussis", "ORGANISM", 145, 157], ["pBD", "PROTEIN", 70, 73], ["piglets", "SPECIES", 42, 49], ["B. pertussis", "SPECIES", 145, 157], ["B. pertussis", "SPECIES", 145, 157], ["newborn piglets", "PROBLEM", 34, 49], ["pBD", "TEST", 70, 73], ["infection", "PROBLEM", 130, 139], ["B. pertussis", "PROBLEM", 145, 157]]], ["Thus, there is evidence that pBD-1 expression is developmentally regulated in piglets, and that its absence in newborns may contribute to their increased susceptibility to B. pertussis.", [["B. pertussis", "DISEASE", 172, 184], ["pBD-1", "GENE_OR_GENE_PRODUCT", 29, 34], ["piglets", "ORGANISM", 78, 85], ["newborns", "ORGANISM", 111, 119], ["B. pertussis", "ORGANISM", 172, 184], ["pBD", "PROTEIN", 29, 32], ["piglets", "SPECIES", 78, 85], ["B. pertussis", "SPECIES", 172, 184], ["B. pertussis", "SPECIES", 172, 184], ["their increased susceptibility to B. pertussis", "PROBLEM", 138, 184], ["pBD", "OBSERVATION", 29, 32]]], ["HDPs may play a role in wound healing and the resolution of infection.", [["wound", "ANATOMY", 24, 29], ["HDPs", "CHEMICAL", 0, 4], ["infection", "DISEASE", 60, 69], ["HDPs", "SIMPLE_CHEMICAL", 0, 4], ["wound", "PATHOLOGICAL_FORMATION", 24, 29], ["wound healing", "PROBLEM", 24, 37], ["infection", "PROBLEM", 60, 69], ["infection", "OBSERVATION", 60, 69]]], ["Staphylococcus aureus-infected wounds present a major complication experienced by diabetic patients (Hirsch et al., 2009 ).", [["wounds", "ANATOMY", 31, 37], ["Staphylococcus aureus-infected wounds", "DISEASE", 0, 37], ["diabetic", "DISEASE", 82, 90], ["Staphylococcus aureus", "ORGANISM", 0, 21], ["wounds", "PATHOLOGICAL_FORMATION", 31, 37], ["patients", "ORGANISM", 91, 99], ["Staphylococcus aureus", "SPECIES", 0, 21], ["patients", "SPECIES", 91, 99], ["Staphylococcus aureus", "SPECIES", 0, 21], ["Staphylococcus aureus", "PROBLEM", 0, 21], ["infected wounds", "PROBLEM", 22, 37], ["a major complication", "PROBLEM", 46, 66], ["aureus", "OBSERVATION", 15, 21], ["infected", "OBSERVATION_MODIFIER", 22, 30], ["wounds", "OBSERVATION", 31, 37], ["major", "OBSERVATION_MODIFIER", 48, 53], ["complication", "OBSERVATION", 54, 66]]], ["In the diabetic Yorkshire pig animal model, excisional wounds transduced with an adenoviral vector coding for hBD-3 and seeded with S. aureus showed that overexpression of hBD-3 significantly impeded bacterial growth of seeded S. aureus and induced wound closure (Hirsch et al., 2009) .Host defence peptides/antimicrobial peptidesIn summary, the humoral innate immune system consisting of the complement system, the contact system, natural antibodies, acute phase proteins, and HDPs produce soluble proteins or factors which attempt to contain and/or kill microbes that invade the body.", [["wounds", "ANATOMY", 55, 61], ["wound", "ANATOMY", 249, 254], ["body", "ANATOMY", 581, 585], ["diabetic", "DISEASE", 7, 15], ["pig", "ORGANISM", 26, 29], ["wounds", "PATHOLOGICAL_FORMATION", 55, 61], ["adenoviral", "ORGANISM", 81, 91], ["hBD-3", "GENE_OR_GENE_PRODUCT", 110, 115], ["S. aureus", "ORGANISM", 132, 141], ["hBD-3", "GENE_OR_GENE_PRODUCT", 172, 177], ["S. aureus", "ORGANISM", 227, 236], ["wound", "PATHOLOGICAL_FORMATION", 249, 254], ["HDPs", "SIMPLE_CHEMICAL", 478, 482], ["body", "ORGANISM_SUBDIVISION", 581, 585], ["hBD-3", "PROTEIN", 110, 115], ["hBD-3", "PROTEIN", 172, 177], ["natural antibodies", "PROTEIN", 432, 450], ["acute phase proteins", "PROTEIN", 452, 472], ["HDPs", "PROTEIN", 478, 482], ["soluble proteins", "PROTEIN", 491, 507], ["pig", "SPECIES", 26, 29], ["S. aureus", "SPECIES", 132, 141], ["S. aureus", "SPECIES", 227, 236], ["pig", "SPECIES", 26, 29], ["S. aureus", "SPECIES", 132, 141], ["S. aureus", "SPECIES", 227, 236], ["excisional wounds", "TREATMENT", 44, 61], ["an adenoviral vector", "TREATMENT", 78, 98], ["hBD", "TEST", 110, 113], ["S. aureus", "PROBLEM", 132, 141], ["overexpression of hBD", "PROBLEM", 154, 175], ["bacterial growth", "PROBLEM", 200, 216], ["S. aureus", "PROBLEM", 227, 236], ["induced wound closure", "PROBLEM", 241, 262], ["Host defence peptides", "TREATMENT", 286, 307], ["antimicrobial peptides", "TREATMENT", 308, 330], ["acute phase proteins", "PROBLEM", 452, 472], ["HDPs", "PROBLEM", 478, 482], ["soluble proteins", "PROBLEM", 491, 507], ["excisional", "OBSERVATION_MODIFIER", 44, 54], ["wounds", "OBSERVATION", 55, 61], ["aureus", "OBSERVATION", 135, 141], ["hBD", "ANATOMY", 172, 175], ["bacterial", "OBSERVATION_MODIFIER", 200, 209], ["growth", "OBSERVATION_MODIFIER", 210, 216], ["aureus", "OBSERVATION", 230, 236], ["wound closure", "OBSERVATION", 249, 262], ["antimicrobial peptides", "OBSERVATION", 308, 330], ["body", "ANATOMY", 581, 585]]], ["The components which make up this system are pre-formed and immediately released when a microbe is sensed offering a swift response to infection.Cells of the innate immune responseMany cell types are involved in the innate immune response.", [["Cells", "ANATOMY", 145, 150], ["cell", "ANATOMY", 185, 189], ["infection", "DISEASE", 135, 144], ["Cells", "CELL", 145, 150], ["cell", "CELL", 185, 189], ["infection", "PROBLEM", 135, 144], ["infection", "OBSERVATION", 135, 144], ["cell types", "OBSERVATION", 185, 195]]], ["In this section we present the best known cellular types and we highlight their main characteristics in the pig model.Epithelial cellsEpithelial cells constitute epithelia, the first barriers to pathogen entry.", [["cellular", "ANATOMY", 42, 50], ["Epithelial cellsEpithelial cells", "ANATOMY", 118, 150], ["epithelia", "ANATOMY", 162, 171], ["cellular", "CELL", 42, 50], ["pig", "ORGANISM", 108, 111], ["Epithelial cellsEpithelial cells", "CELL", 118, 150], ["epithelia", "TISSUE", 162, 171], ["Epithelial cellsEpithelial cells", "CELL_TYPE", 118, 150], ["pig", "SPECIES", 108, 111], ["Epithelial cellsEpithelial cells", "PROBLEM", 118, 150], ["epithelia", "PROBLEM", 162, 171], ["cellular types", "OBSERVATION", 42, 56], ["main", "OBSERVATION_MODIFIER", 80, 84], ["pig model", "OBSERVATION", 108, 117], ["cellsEpithelial cells", "OBSERVATION", 129, 150]]], ["They play a crucial role in the initiation of the innate immune response to protect the different mucosae (genital, intestinal, and respiratory) and the skin.", [["mucosae", "ANATOMY", 98, 105], ["genital", "ANATOMY", 107, 114], ["intestinal", "ANATOMY", 116, 126], ["respiratory", "ANATOMY", 132, 143], ["skin", "ANATOMY", 153, 157], ["mucosae", "MULTI-TISSUE_STRUCTURE", 98, 105], ["genital", "ORGAN", 107, 114], ["intestinal", "ORGAN", 116, 126], ["skin", "ORGAN", 153, 157], ["the innate immune response", "TREATMENT", 46, 72], ["the different mucosae (genital, intestinal, and respiratory) and the skin", "PROBLEM", 84, 157], ["intestinal", "ANATOMY", 116, 126], ["skin", "ANATOMY", 153, 157]]], ["Porcine epithelial cells respond to various pathogens with production of TNF-a and IFN type I (a and b) and III (k) which block pathogen replication.", [["epithelial cells", "ANATOMY", 8, 24], ["Porcine", "ORGANISM", 0, 7], ["epithelial cells", "CELL", 8, 24], ["TNF-a", "GENE_OR_GENE_PRODUCT", 73, 78], ["IFN type I", "GENE_OR_GENE_PRODUCT", 83, 93], ["b", "GENE_OR_GENE_PRODUCT", 101, 102], ["III", "GENE_OR_GENE_PRODUCT", 108, 111], ["Porcine epithelial cells", "CELL_TYPE", 0, 24], ["TNF", "PROTEIN", 73, 76], ["IFN type I", "PROTEIN", 83, 93], ["Porcine", "SPECIES", 0, 7], ["Porcine epithelial cells", "PROBLEM", 0, 24], ["various pathogens", "PROBLEM", 36, 53], ["TNF", "TEST", 73, 76], ["block pathogen replication", "PROBLEM", 122, 148], ["epithelial cells", "OBSERVATION", 8, 24], ["various", "OBSERVATION_MODIFIER", 36, 43], ["pathogens", "OBSERVATION_MODIFIER", 44, 53]]], ["They also produce chemoattractant/pro-inflammatory cytokines, including interleukin 1 (IL-1), IL-6, IL-8, chemokine (C-X-C motif) ligand 1 (CXCL1), and granulocyte-macrophage colony-stimulating factor (GM-CSF) involved in the recruitment and the activation of immune cells.", [["immune cells", "ANATOMY", 260, 272], ["interleukin 1", "GENE_OR_GENE_PRODUCT", 72, 85], ["IL-1", "GENE_OR_GENE_PRODUCT", 87, 91], ["IL-6", "GENE_OR_GENE_PRODUCT", 94, 98], ["IL-8", "GENE_OR_GENE_PRODUCT", 100, 104], ["C-X-C motif) ligand 1", "GENE_OR_GENE_PRODUCT", 117, 138], ["CXCL1", "GENE_OR_GENE_PRODUCT", 140, 145], ["granulocyte-macrophage colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 152, 200], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 202, 208], ["immune cells", "CELL", 260, 272], ["chemoattractant/pro-inflammatory cytokines", "PROTEIN", 18, 60], ["interleukin 1 (IL-1", "PROTEIN", 72, 91], ["IL-8", "PROTEIN", 100, 104], ["chemokine", "PROTEIN", 106, 115], ["CXCL1", "PROTEIN", 140, 145], ["granulocyte-macrophage colony-stimulating factor", "PROTEIN", 152, 200], ["GM", "PROTEIN", 202, 204], ["CSF", "PROTEIN", 205, 208], ["immune cells", "CELL_TYPE", 260, 272], ["chemoattractant/pro-inflammatory cytokines", "TEST", 18, 60], ["interleukin", "TEST", 72, 83], ["IL", "TEST", 87, 89], ["IL", "TEST", 94, 96], ["IL", "TEST", 100, 102], ["chemokine (C-X-C motif) ligand", "TEST", 106, 136], ["CXCL1", "TEST", 140, 145], ["granulocyte", "TEST", 152, 163], ["macrophage colony", "TEST", 164, 181], ["stimulating factor", "PROBLEM", 182, 200], ["immune cells", "PROBLEM", 260, 272], ["granulocyte", "ANATOMY", 152, 163], ["macrophage colony", "OBSERVATION", 164, 181], ["immune cells", "OBSERVATION", 260, 272]]], ["As well, the epithelial cells of humans, mice, rats, and dogs express major histocompatibility complex II (MHC class II) and are thought to be capable of presenting antigen directly to T cells (Bland, 1988; German et al., 1998) .", [["epithelial cells", "ANATOMY", 13, 29], ["T cells", "ANATOMY", 185, 192], ["epithelial cells", "CELL", 13, 29], ["humans", "ORGANISM", 33, 39], ["mice", "ORGANISM", 41, 45], ["rats", "ORGANISM", 47, 51], ["dogs", "ORGANISM", 57, 61], ["major histocompatibility complex II", "GENE_OR_GENE_PRODUCT", 70, 105], ["MHC class II", "GENE_OR_GENE_PRODUCT", 107, 119], ["T cells", "CELL", 185, 192], ["epithelial cells", "CELL_TYPE", 13, 29], ["major histocompatibility complex II", "PROTEIN", 70, 105], ["MHC class II", "PROTEIN", 107, 119], ["T cells", "CELL_TYPE", 185, 192], ["humans", "SPECIES", 33, 39], ["mice", "SPECIES", 41, 45], ["rats", "SPECIES", 47, 51], ["dogs", "SPECIES", 57, 61], ["humans", "SPECIES", 33, 39], ["mice", "SPECIES", 41, 45], ["epithelial cells", "OBSERVATION", 13, 29], ["thought to be", "UNCERTAINTY", 129, 142]]], ["In contrast, MHC class II expression is reported to be absent in the intestinal epithelium of swine (Wilson et al., 1996) and in the porcine intestinal columnar epithelial cell line IPEC-J2 (Schierack et al., 2006) .", [["intestinal epithelium", "ANATOMY", 69, 90], ["intestinal columnar epithelial cell line IPEC-J2", "ANATOMY", 141, 189], ["MHC class II", "GENE_OR_GENE_PRODUCT", 13, 25], ["intestinal epithelium", "TISSUE", 69, 90], ["swine", "ORGANISM", 94, 99], ["porcine", "ORGANISM", 133, 140], ["intestinal columnar epithelial cell line IPEC-J2", "CELL", 141, 189], ["MHC class II", "PROTEIN", 13, 25], ["porcine intestinal columnar epithelial cell line", "CELL_LINE", 133, 181], ["IPEC-J2", "CELL_LINE", 182, 189], ["swine", "SPECIES", 94, 99], ["porcine", "SPECIES", 133, 140], ["swine", "SPECIES", 94, 99], ["intestinal epithelium", "ANATOMY", 69, 90], ["porcine", "ANATOMY_MODIFIER", 133, 140], ["intestinal", "ANATOMY", 141, 151], ["columnar", "ANATOMY_MODIFIER", 152, 160], ["epithelial cell line", "OBSERVATION", 161, 181], ["J2", "ANATOMY", 187, 189]]], ["However, endothelial cells which lie below the basement membrane of the intestinal vessels show strong expression of MHC class II antigens (Wilson et al., 1996) .", [["endothelial cells", "ANATOMY", 9, 26], ["basement membrane", "ANATOMY", 47, 64], ["intestinal vessels", "ANATOMY", 72, 90], ["endothelial cells", "CELL", 9, 26], ["basement membrane", "CELLULAR_COMPONENT", 47, 64], ["intestinal vessels", "MULTI-TISSUE_STRUCTURE", 72, 90], ["endothelial cells", "CELL_TYPE", 9, 26], ["MHC class II antigens", "PROTEIN", 117, 138], ["endothelial cells", "PROBLEM", 9, 26], ["endothelial cells", "OBSERVATION", 9, 26], ["basement", "ANATOMY_MODIFIER", 47, 55], ["membrane", "ANATOMY_MODIFIER", 56, 64], ["intestinal vessels", "ANATOMY", 72, 90], ["strong", "OBSERVATION_MODIFIER", 96, 102]]], ["The specialized epithelial cells covering the dome area of porcine PP (M cells) are mantled by densely packed, long, thick, and irregularly-shaped microvilli (Torres-Medina, 1981) which can be identified in swine with anti-cytokeratin 18 antibody (Gebert et al., 1994; Pabst and Rothkotter, 1999) .", [["epithelial cells", "ANATOMY", 16, 32], ["dome area", "ANATOMY", 46, 55], ["PP (M cells", "ANATOMY", 67, 78], ["microvilli", "ANATOMY", 147, 157], ["epithelial cells", "CELL", 16, 32], ["porcine", "ORGANISM", 59, 66], ["PP", "GENE_OR_GENE_PRODUCT", 67, 69], ["M cells", "CELL", 71, 78], ["microvilli", "CELLULAR_COMPONENT", 147, 157], ["swine", "ORGANISM", 207, 212], ["epithelial cells", "CELL_TYPE", 16, 32], ["porcine PP (M cells", "CELL_TYPE", 59, 78], ["anti-cytokeratin 18 antibody", "PROTEIN", 218, 246], ["porcine", "SPECIES", 59, 66], ["swine", "SPECIES", 207, 212], ["swine", "SPECIES", 207, 212], ["The specialized epithelial cells", "PROBLEM", 0, 32], ["porcine PP (M cells", "TREATMENT", 59, 78], ["densely packed, long, thick, and irregularly-shaped microvilli", "PROBLEM", 95, 157], ["epithelial cells", "OBSERVATION", 16, 32], ["dome", "OBSERVATION_MODIFIER", 46, 50], ["porcine PP", "OBSERVATION", 59, 69], ["densely", "OBSERVATION_MODIFIER", 95, 102], ["packed", "OBSERVATION_MODIFIER", 103, 109], ["long", "OBSERVATION_MODIFIER", 111, 115], ["irregularly", "OBSERVATION_MODIFIER", 128, 139], ["-shaped", "OBSERVATION_MODIFIER", 139, 146], ["microvilli", "OBSERVATION_MODIFIER", 147, 157]]], ["Even though not strictly related to the innate immune system, epithelial cells are involved in the active transport of polymeric Igs such as IgA and IgM across the epithelial barrier which is mediated by polymeric immunoglobulin receptor (PIGR).Epithelial cellsVarious epithelial cell lines such as porcine jejunal and ileal cell line IPEC-1 (Gonzalez-Vallina et al., 1996) , porcine jejunal cell line IPEC-J2 (Berschneider, 1989) , porcine intestinal epithelial cell IPI-2I (Kaeffer et al., 1993) , porcine kidney 13 (PK13, ATCC CRL-6489), PK15 (ATCC CCL-33), and newborn porcine trachea (NPTr) cells (Ferrari et al., 2003) are available.", [["immune system", "ANATOMY", 47, 60], ["epithelial cells", "ANATOMY", 62, 78], ["epithelial barrier", "ANATOMY", 164, 182], ["Epithelial cellsVarious epithelial cell lines", "ANATOMY", 245, 290], ["jejunal", "ANATOMY", 307, 314], ["ileal cell line IPEC-1", "ANATOMY", 319, 341], ["jejunal cell line IPEC-J2", "ANATOMY", 384, 409], ["intestinal epithelial cell", "ANATOMY", 441, 467], ["kidney", "ANATOMY", 508, 514], ["ATCC CRL-6489", "ANATOMY", 525, 538], ["ATCC CCL-33", "ANATOMY", 547, 558], ["newborn porcine trachea (NPTr) cells", "ANATOMY", 565, 601], ["epithelial cells", "CELL", 62, 78], ["Igs", "GENE_OR_GENE_PRODUCT", 129, 132], ["IgA", "GENE_OR_GENE_PRODUCT", 141, 144], ["IgM", "GENE_OR_GENE_PRODUCT", 149, 152], ["epithelial barrier", "TISSUE", 164, 182], ["polymeric immunoglobulin receptor", "GENE_OR_GENE_PRODUCT", 204, 237], ["PIGR", "GENE_OR_GENE_PRODUCT", 239, 243], ["Epithelial cellsVarious epithelial cell lines", "CELL", 245, 290], ["porcine", "ORGANISM", 299, 306], ["jejunal", "MULTI-TISSUE_STRUCTURE", 307, 314], ["ileal cell line IPEC-1", "CELL", 319, 341], ["porcine", "ORGANISM", 376, 383], ["jejunal cell line IPEC-J2", "CELL", 384, 409], ["porcine", "ORGANISM", 433, 440], ["intestinal epithelial cell IPI-2I", "CELL", 441, 474], ["porcine", "ORGANISM", 500, 507], ["kidney 13", "CELL", 508, 517], ["PK13", "CELL", 519, 523], ["ATCC CRL-6489", "CELL", 525, 538], ["PK15", "CELL", 541, 545], ["ATCC CCL-33", "CELL", 547, 558], ["porcine trachea (NPTr) cells", "CELL", 573, 601], ["epithelial cells", "CELL_TYPE", 62, 78], ["polymeric Igs", "PROTEIN", 119, 132], ["IgA", "PROTEIN", 141, 144], ["IgM", "PROTEIN", 149, 152], ["polymeric immunoglobulin receptor", "PROTEIN", 204, 237], ["PIGR", "PROTEIN", 239, 243], ["Epithelial cellsVarious epithelial cell lines", "CELL_LINE", 245, 290], ["ileal cell line IPEC", "CELL_LINE", 319, 339], ["porcine jejunal cell line IPEC", "CELL_LINE", 376, 406], ["J2", "CELL_LINE", 407, 409], ["Berschneider, 1989", "CELL_LINE", 411, 429], ["porcine intestinal epithelial cell IPI-2I", "CELL_LINE", 433, 474], ["porcine kidney 13", "CELL_LINE", 500, 517], ["PK15", "CELL_LINE", 541, 545], ["ATCC CCL-33", "CELL_LINE", 547, 558], ["newborn porcine trachea (NPTr) cells", "CELL_LINE", 565, 601], ["porcine", "SPECIES", 299, 306], ["porcine", "SPECIES", 376, 383], ["porcine", "SPECIES", 433, 440], ["porcine", "SPECIES", 500, 507], ["porcine", "SPECIES", 573, 580], ["porcine", "SPECIES", 299, 306], ["ATCC CRL-6489", "SPECIES", 525, 538], ["ATCC CCL-33", "SPECIES", 547, 558], ["epithelial cells", "PROBLEM", 62, 78], ["polymeric Igs", "TREATMENT", 119, 132], ["IgA", "TEST", 141, 144], ["IgM", "TEST", 149, 152], ["the epithelial barrier", "TREATMENT", 160, 182], ["polymeric immunoglobulin receptor", "TREATMENT", 204, 237], ["Epithelial cellsVarious epithelial cell lines", "PROBLEM", 245, 290], ["porcine jejunal", "TREATMENT", 299, 314], ["ileal cell line IPEC", "TREATMENT", 319, 339], ["porcine jejunal cell line IPEC", "TREATMENT", 376, 406], ["porcine intestinal epithelial cell IPI", "TEST", 433, 471], ["porcine kidney", "TEST", 500, 514], ["PK13", "TEST", 519, 523], ["ATCC CRL", "TEST", 525, 533], ["PK15", "TEST", 541, 545], ["ATCC CCL", "TEST", 547, 555], ["newborn porcine trachea", "TREATMENT", 565, 588], ["epithelial cells", "OBSERVATION", 62, 78], ["active", "OBSERVATION_MODIFIER", 99, 105], ["polymeric Igs", "OBSERVATION", 119, 132], ["epithelial barrier", "OBSERVATION", 164, 182], ["cellsVarious epithelial cell lines", "OBSERVATION", 256, 290], ["porcine", "ANATOMY_MODIFIER", 299, 306], ["jejunal", "ANATOMY", 307, 314], ["ileal", "ANATOMY", 319, 324], ["cell line", "OBSERVATION", 325, 334], ["jejunal", "ANATOMY", 384, 391], ["cell line", "OBSERVATION", 392, 401], ["intestinal epithelial", "ANATOMY", 441, 462], ["cell IPI", "OBSERVATION", 463, 471], ["kidney", "ANATOMY", 508, 514], ["trachea", "ANATOMY", 581, 588]]], ["When cultivated on an appropriate support IPEC-1 and IPEC-J2 cell lines can develop a phenotype similar to the one observed in primary epithelial cells (Bruel et al., 2010; Zakrzewski et al., 2013) .", [["IPEC-1", "ANATOMY", 42, 48], ["IPEC-J2 cell lines", "ANATOMY", 53, 71], ["primary epithelial cells", "ANATOMY", 127, 151], ["IPEC-1", "CELL", 42, 48], ["IPEC-J2 cell lines", "CELL", 53, 71], ["epithelial cells", "CELL", 135, 151], ["IPEC-1 and IPEC-J2 cell lines", "CELL_LINE", 42, 71], ["primary epithelial cells", "CELL_TYPE", 127, 151], ["an appropriate support IPEC", "TEST", 19, 46], ["IPEC-J2 cell lines", "TREATMENT", 53, 71], ["a phenotype", "PROBLEM", 84, 95], ["J2 cell lines", "OBSERVATION", 58, 71], ["epithelial cells", "OBSERVATION", 135, 151]]], ["Recently it has been demonstrated that the supplementation of culture media with porcine serum instead of bovine serum could drastically improve the phenotype developed by IPEC-J2 cells making them more similar to primary intestinal cells (Zakrzewski et al., 2013) .Mast cellsMast cells are tissue resident immune cells that are best known for their involvement in IgE-mediated immune reactions.", [["serum", "ANATOMY", 89, 94], ["serum", "ANATOMY", 113, 118], ["IPEC-J2 cells", "ANATOMY", 172, 185], ["primary intestinal cells", "ANATOMY", 214, 238], ["Mast cells", "ANATOMY", 266, 276], ["Mast cells", "ANATOMY", 276, 286], ["tissue", "ANATOMY", 291, 297], ["immune cells", "ANATOMY", 307, 319], ["porcine", "ORGANISM", 81, 88], ["serum", "ORGANISM_SUBSTANCE", 89, 94], ["bovine", "ORGANISM", 106, 112], ["serum", "ORGANISM_SUBSTANCE", 113, 118], ["IPEC-J2 cells", "CELL", 172, 185], ["intestinal cells", "CELL", 222, 238], ["Mast cells", "CELL", 266, 276], ["Mast cells", "CELL", 276, 286], ["tissue resident immune cells", "CELL", 291, 319], ["IgE", "GENE_OR_GENE_PRODUCT", 365, 368], ["IPEC-J2 cells", "CELL_LINE", 172, 185], ["primary intestinal cells", "CELL_TYPE", 214, 238], ["Mast cells", "CELL_TYPE", 266, 276], ["Mast cells", "CELL_TYPE", 276, 286], ["tissue resident immune cells", "CELL_TYPE", 291, 319], ["IgE", "PROTEIN", 365, 368], ["porcine", "SPECIES", 81, 88], ["bovine", "SPECIES", 106, 112], ["porcine", "SPECIES", 81, 88], ["bovine", "SPECIES", 106, 112], ["culture media", "TREATMENT", 62, 75], ["porcine serum", "TEST", 81, 94], ["bovine serum", "TEST", 106, 118], ["the phenotype", "PROBLEM", 145, 158], ["IPEC-J2 cells", "TREATMENT", 172, 185], ["Mast cells", "PROBLEM", 266, 276], ["Mast cells", "PROBLEM", 276, 286], ["IgE-mediated immune reactions", "PROBLEM", 365, 394], ["J2 cells", "OBSERVATION_MODIFIER", 177, 185], ["intestinal cells", "ANATOMY", 222, 238], ["cells", "OBSERVATION", 271, 276], ["immune cells", "OBSERVATION", 307, 319]]], ["They can be divided into tissue mast cells and mucosal mast cells depending on their location and function.", [["tissue mast cells", "ANATOMY", 25, 42], ["mucosal mast cells", "ANATOMY", 47, 65], ["tissue mast cells", "CELL", 25, 42], ["mucosal mast cells", "CELL", 47, 65], ["tissue mast cells", "CELL_TYPE", 25, 42], ["mucosal mast cells", "CELL_TYPE", 47, 65], ["mucosal mast cells", "PROBLEM", 47, 65], ["mast cells", "OBSERVATION", 32, 42], ["mucosal mast cells", "OBSERVATION", 47, 65]]], ["Mucosal mast cells are key players in maintaining homeostasis at the mucosal surfaces, and are involved in the mucosal response to intestinal pathogens, foodborne allergies and probiotics.", [["Mucosal mast cells", "ANATOMY", 0, 18], ["mucosal surfaces", "ANATOMY", 69, 85], ["mucosal", "ANATOMY", 111, 118], ["intestinal", "ANATOMY", 131, 141], ["foodborne allergies", "DISEASE", 153, 172], ["Mucosal mast cells", "CELL", 0, 18], ["mucosal surfaces", "TISSUE", 69, 85], ["mucosal", "TISSUE", 111, 118], ["intestinal", "ORGAN", 131, 141], ["Mucosal mast cells", "CELL_TYPE", 0, 18], ["Mucosal mast cells", "PROBLEM", 0, 18], ["intestinal pathogens", "PROBLEM", 131, 151], ["foodborne allergies", "PROBLEM", 153, 172], ["probiotics", "TREATMENT", 177, 187], ["mast cells", "OBSERVATION", 8, 18], ["mucosal surfaces", "ANATOMY", 69, 85], ["mucosal", "ANATOMY", 111, 118], ["intestinal", "ANATOMY", 131, 141], ["pathogens", "OBSERVATION", 142, 151]]], ["Upon binding of immunoglobulines via surface Fc-Receptors, mast cells release a variety of immune mediators, including histamines, leukotrienes, prostaglandins and heparin, all of them needed for recruitment and activation of pro-inflammatory immune cells.", [["surface", "ANATOMY", 37, 44], ["mast cells", "ANATOMY", 59, 69], ["immune cells", "ANATOMY", 243, 255], ["leukotrienes", "CHEMICAL", 131, 143], ["prostaglandins", "CHEMICAL", 145, 159], ["heparin", "CHEMICAL", 164, 171], ["prostaglandins", "CHEMICAL", 145, 159], ["immunoglobulines", "SIMPLE_CHEMICAL", 16, 32], ["mast cells", "CELL", 59, 69], ["histamines", "GENE_OR_GENE_PRODUCT", 119, 129], ["leukotrienes", "SIMPLE_CHEMICAL", 131, 143], ["prostaglandins", "SIMPLE_CHEMICAL", 145, 159], ["heparin", "SIMPLE_CHEMICAL", 164, 171], ["immune cells", "CELL", 243, 255], ["immunoglobulines", "PROTEIN", 16, 32], ["surface Fc", "PROTEIN", 37, 47], ["mast cells", "CELL_TYPE", 59, 69], ["immune mediators", "PROTEIN", 91, 107], ["pro-inflammatory immune cells", "CELL_TYPE", 226, 255], ["immunoglobulines via surface Fc", "TREATMENT", 16, 47], ["Receptors", "TREATMENT", 48, 57], ["mast cells", "TREATMENT", 59, 69], ["immune mediators", "TREATMENT", 91, 107], ["histamines", "TREATMENT", 119, 129], ["leukotrienes", "TREATMENT", 131, 143], ["prostaglandins", "TREATMENT", 145, 159], ["heparin", "TREATMENT", 164, 171], ["recruitment", "PROBLEM", 196, 207], ["pro-inflammatory immune cells", "TREATMENT", 226, 255], ["mast cells", "OBSERVATION", 59, 69], ["leukotrienes", "ANATOMY", 131, 143], ["pro-inflammatory immune cells", "OBSERVATION", 226, 255]]], ["To this end, mast cells are equipped with a panel of high affinity Fc-Receptors, in particular FcE-and FcG-Receptors, that ensure rapidly binding and release of these molecules.", [["mast cells", "ANATOMY", 13, 23], ["mast cells", "CELL", 13, 23], ["FcE", "GENE_OR_GENE_PRODUCT", 95, 98], ["mast cells", "CELL_TYPE", 13, 23], ["high affinity Fc-Receptors", "PROTEIN", 53, 79], ["FcE", "PROTEIN", 95, 98], ["FcG", "PROTEIN", 103, 106], ["mast cells", "PROBLEM", 13, 23], ["a panel", "TEST", 42, 49], ["Receptors", "TREATMENT", 70, 79], ["FcG", "TREATMENT", 103, 106], ["Receptors", "TREATMENT", 107, 116], ["rapidly binding", "PROBLEM", 130, 145], ["mast cells", "OBSERVATION", 13, 23]]], ["Secretion of these mediators can also be directly induced via complement, peptides, toxins, bacteria, and parasites (Marone et al., 1997) .", [["toxins", "PROBLEM", 84, 90], ["bacteria", "PROBLEM", 92, 100], ["parasites", "PROBLEM", 106, 115]]], ["In pigs, very little is known about the phenotype and the distribution of mast cells throughout the body.", [["mast cells", "ANATOMY", 74, 84], ["body", "ANATOMY", 100, 104], ["pigs", "ORGANISM", 3, 7], ["mast cells", "CELL", 74, 84], ["body", "ORGANISM_SUBDIVISION", 100, 104], ["mast cells", "CELL_TYPE", 74, 84], ["pigs", "SPECIES", 3, 7], ["pigs", "SPECIES", 3, 7], ["the phenotype", "PROBLEM", 36, 49], ["mast cells", "PROBLEM", 74, 84], ["mast cells", "OBSERVATION", 74, 84], ["body", "ANATOMY", 100, 104]]], ["More than twenty years ago, Xu et al. described the morphology of porcine mast cells from various organs in one to six monthold pigs using histochemical staining techniques (Xu et al., 1993) .", [["mast cells", "ANATOMY", 74, 84], ["organs", "ANATOMY", 98, 104], ["porcine", "ORGANISM", 66, 73], ["mast cells", "CELL", 74, 84], ["organs", "ORGAN", 98, 104], ["pigs", "ORGANISM", 128, 132], ["porcine mast cells", "CELL_TYPE", 66, 84], ["porcine", "SPECIES", 66, 73], ["pigs", "SPECIES", 128, 132], ["porcine", "SPECIES", 66, 73], ["porcine mast cells", "PROBLEM", 66, 84], ["histochemical staining techniques", "TEST", 139, 172], ["porcine mast cells", "OBSERVATION", 66, 84]]], ["Ten years later, Rieger et al. established methods to reliably stain mast cells for mast cell counting and nitric oxide production by porcine mast cells of the autonomic ganglia, nerves and renal vessels was described by Vodenicharov (2008) and Vodenicharov et al. (2005) .", [["mast cells", "ANATOMY", 69, 79], ["mast cell", "ANATOMY", 84, 93], ["mast cells", "ANATOMY", 142, 152], ["autonomic ganglia", "ANATOMY", 160, 177], ["nerves", "ANATOMY", 179, 185], ["renal vessels", "ANATOMY", 190, 203], ["nitric oxide", "CHEMICAL", 107, 119], ["nitric oxide", "CHEMICAL", 107, 119], ["mast cells", "CELL", 69, 79], ["mast cell", "CELL", 84, 93], ["nitric oxide", "SIMPLE_CHEMICAL", 107, 119], ["porcine", "ORGANISM", 134, 141], ["mast cells", "CELL", 142, 152], ["autonomic ganglia", "MULTI-TISSUE_STRUCTURE", 160, 177], ["nerves", "MULTI-TISSUE_STRUCTURE", 179, 185], ["renal vessels", "MULTI-TISSUE_STRUCTURE", 190, 203], ["mast cells", "CELL_TYPE", 69, 79], ["porcine mast cells", "CELL_TYPE", 134, 152], ["porcine", "SPECIES", 134, 141], ["reliably stain mast cells", "PROBLEM", 54, 79], ["mast cell counting", "TEST", 84, 102], ["nitric oxide production", "TREATMENT", 107, 130], ["mast cells", "OBSERVATION", 69, 79], ["mast cell counting", "OBSERVATION", 84, 102], ["mast cells", "OBSERVATION", 142, 152], ["autonomic ganglia", "ANATOMY", 160, 177], ["nerves", "ANATOMY", 179, 185], ["renal vessels", "ANATOMY", 190, 203]]], ["Martinez et al. published a case report of a pig with multiple cutaneous mast cell tumors (Martinez et al., 2011) .", [["cutaneous mast cell tumors", "ANATOMY", 63, 89], ["mast cell tumors", "DISEASE", 73, 89], ["pig", "ORGANISM", 45, 48], ["cutaneous mast cell tumors", "CANCER", 63, 89], ["pig", "SPECIES", 45, 48], ["pig", "SPECIES", 45, 48], ["a pig", "TREATMENT", 43, 48], ["multiple cutaneous mast cell tumors", "PROBLEM", 54, 89], ["multiple", "OBSERVATION_MODIFIER", 54, 62], ["cutaneous", "ANATOMY", 63, 72], ["mast cell tumors", "OBSERVATION", 73, 89]]], ["This type of cancer is rarely seen in pigs, and usually more frequent in dogs and cats.", [["cancer", "ANATOMY", 13, 19], ["cancer", "DISEASE", 13, 19], ["cancer", "CANCER", 13, 19], ["pigs", "ORGANISM", 38, 42], ["dogs", "ORGANISM", 73, 77], ["cats", "ORGANISM", 82, 86], ["pigs", "SPECIES", 38, 42], ["dogs", "SPECIES", 73, 77], ["cats", "SPECIES", 82, 86], ["pigs", "SPECIES", 38, 42], ["cancer", "PROBLEM", 13, 19], ["cancer", "OBSERVATION", 13, 19]]], ["Femenia et al. reported a novel mast cell line derived from hematopoetic progenitors to further investigate the response to nematodes such as Ascaris suum and others (Femenia et al., 2005) .", [["mast cell line", "ANATOMY", 32, 46], ["hematopoetic progenitors", "ANATOMY", 60, 84], ["Ascaris suum", "DISEASE", 142, 154], ["mast cell line", "CELL", 32, 46], ["hematopoetic progenitors", "CELL", 60, 84], ["Ascaris suum", "ORGANISM", 142, 154], ["mast cell line", "CELL_LINE", 32, 46], ["hematopoetic progenitors", "CELL_TYPE", 60, 84], ["Ascaris suum", "SPECIES", 142, 154], ["Ascaris suum", "SPECIES", 142, 154], ["a novel mast cell line", "TREATMENT", 24, 46], ["hematopoetic progenitors", "TREATMENT", 60, 84], ["Ascaris suum", "PROBLEM", 142, 154], ["mast cell line", "OBSERVATION", 32, 46], ["hematopoetic progenitors", "OBSERVATION", 60, 84]]], ["Interestingly, a trypsin-serin proteinase from porcine mast cells was shown to mediate post-translational proteolytic cleavage of influenza hemagglutinins and other RNA viruses, indicating that mast cell tryptase in pigs might be a trigger of pneumotopic infections in pigs (Chen et al., 2000) .Mast cellsEnrichment of the sow diet with linseed oil induced changes in the postnatal development of the piglet ileum, including altered mast cell regulation (Boudry et al., 2009) .", [["mast cells", "ANATOMY", 55, 65], ["mast cell", "ANATOMY", 194, 203], ["Mast cells", "ANATOMY", 295, 305], ["oil", "ANATOMY", 345, 348], ["piglet ileum", "ANATOMY", 401, 413], ["mast cell", "ANATOMY", 433, 442], ["pneumotopic infections", "DISEASE", 243, 265], ["linseed oil", "CHEMICAL", 337, 348], ["trypsin-serin proteinase", "GENE_OR_GENE_PRODUCT", 17, 41], ["porcine", "ORGANISM", 47, 54], ["mast cells", "CELL", 55, 65], ["influenza hemagglutinins", "ORGANISM", 130, 154], ["mast cell", "CELL", 194, 203], ["tryptase", "GENE_OR_GENE_PRODUCT", 204, 212], ["pigs", "ORGANISM", 216, 220], ["pigs", "ORGANISM", 269, 273], ["Mast cells", "CELL", 295, 305], ["oil", "ORGANISM_SUBSTANCE", 345, 348], ["piglet ileum", "ORGAN", 401, 413], ["mast cell", "CELL", 433, 442], ["trypsin", "PROTEIN", 17, 24], ["serin proteinase", "PROTEIN", 25, 41], ["porcine mast cells", "CELL_TYPE", 47, 65], ["mast cell tryptase", "PROTEIN", 194, 212], ["Mast cells", "CELL_TYPE", 295, 305], ["porcine", "SPECIES", 47, 54], ["pigs", "SPECIES", 216, 220], ["pigs", "SPECIES", 269, 273], ["sow", "SPECIES", 323, 326], ["piglet", "SPECIES", 401, 407], ["pigs", "SPECIES", 216, 220], ["pigs", "SPECIES", 269, 273], ["a trypsin", "TEST", 15, 24], ["serin proteinase", "PROBLEM", 25, 41], ["porcine mast cells", "PROBLEM", 47, 65], ["translational proteolytic cleavage", "PROBLEM", 92, 126], ["influenza hemagglutinins", "PROBLEM", 130, 154], ["other RNA viruses", "PROBLEM", 159, 176], ["mast cell tryptase", "PROBLEM", 194, 212], ["pneumotopic infections", "PROBLEM", 243, 265], ["Mast cells", "PROBLEM", 295, 305], ["linseed oil", "TREATMENT", 337, 348], ["altered mast cell regulation", "PROBLEM", 425, 453], ["mast cells", "OBSERVATION", 55, 65], ["RNA viruses", "OBSERVATION", 165, 176], ["mast cell tryptase", "OBSERVATION", 194, 212], ["infections", "OBSERVATION", 255, 265], ["postnatal development", "OBSERVATION", 372, 393], ["piglet ileum", "ANATOMY", 401, 413], ["altered", "OBSERVATION_MODIFIER", 425, 432], ["mast cell regulation", "OBSERVATION", 433, 453]]], ["The role of mast cells in the context of soybean allergies was described by Sun et al. who found that the levels of mast cells and the intensity of histamine release was greatly triggered by glycinin, the main storage protein of soybeans (Sun et al., 2008) .", [["mast cells", "ANATOMY", 12, 22], ["mast cells", "ANATOMY", 116, 126], ["soybean allergies", "DISEASE", 41, 58], ["histamine", "CHEMICAL", 148, 157], ["glycinin", "CHEMICAL", 191, 199], ["histamine", "CHEMICAL", 148, 157], ["glycinin", "CHEMICAL", 191, 199], ["mast cells", "CELL", 12, 22], ["soybean", "ORGANISM", 41, 48], ["mast cells", "CELL", 116, 126], ["histamine", "SIMPLE_CHEMICAL", 148, 157], ["glycinin", "SIMPLE_CHEMICAL", 191, 199], ["mast cells", "CELL_TYPE", 12, 22], ["mast cells", "CELL_TYPE", 116, 126], ["soybean", "SPECIES", 41, 48], ["soybeans", "SPECIES", 229, 237], ["soybean", "SPECIES", 41, 48], ["soybeans", "SPECIES", 229, 237], ["mast cells", "PROBLEM", 12, 22], ["soybean allergies", "PROBLEM", 41, 58], ["mast cells", "PROBLEM", 116, 126], ["histamine release", "PROBLEM", 148, 165], ["glycinin", "TREATMENT", 191, 199], ["mast cells", "OBSERVATION", 12, 22], ["soybean allergies", "OBSERVATION", 41, 58], ["mast cells", "OBSERVATION", 116, 126]]], ["Mast cells are also becoming frequently recognized as mediators of stress-related intestinal disorders.", [["Mast cells", "ANATOMY", 0, 10], ["intestinal", "ANATOMY", 82, 92], ["intestinal disorders", "DISEASE", 82, 102], ["Mast cells", "CELL", 0, 10], ["intestinal", "ORGAN", 82, 92], ["Mast cells", "CELL_TYPE", 0, 10], ["Mast cells", "PROBLEM", 0, 10], ["stress-related intestinal disorders", "PROBLEM", 67, 102], ["intestinal", "ANATOMY", 82, 92]]], ["For example, early weaning of piglets, as often proposed by the industry, can cause stress gastrointestinal dysfunction in pigs.", [["gastrointestinal", "ANATOMY", 91, 107], ["gastrointestinal dysfunction", "DISEASE", 91, 119], ["piglets", "ORGANISM", 30, 37], ["gastrointestinal", "ORGANISM_SUBDIVISION", 91, 107], ["pigs", "ORGANISM", 123, 127], ["piglets", "SPECIES", 30, 37], ["pigs", "SPECIES", 123, 127], ["pigs", "SPECIES", 123, 127], ["piglets", "TREATMENT", 30, 37], ["stress gastrointestinal dysfunction", "PROBLEM", 84, 119], ["early", "OBSERVATION_MODIFIER", 13, 18], ["gastrointestinal", "ANATOMY", 91, 107], ["dysfunction", "OBSERVATION", 108, 119]]], ["Moeser et al. and Smith et al. found that much of this dysfunction is mediated by mast cells and their products, and that the mast cell stabilizer drug sodium cromoglycerate can ameliorate some of these effects (Moeser et al., 2007; Smith et al., 2010) .", [["mast cells", "ANATOMY", 82, 92], ["mast cell", "ANATOMY", 126, 135], ["sodium cromoglycerate", "CHEMICAL", 152, 173], ["sodium cromoglycerate", "CHEMICAL", 152, 173], ["mast cells", "CELL", 82, 92], ["mast cell", "CELL", 126, 135], ["sodium cromoglycerate", "SIMPLE_CHEMICAL", 152, 173], ["mast cells", "CELL_TYPE", 82, 92], ["this dysfunction", "PROBLEM", 50, 66], ["mast cells", "PROBLEM", 82, 92], ["the mast cell stabilizer drug sodium cromoglycerate", "TREATMENT", 122, 173], ["dysfunction", "OBSERVATION", 55, 66], ["mast cells", "OBSERVATION", 82, 92], ["mast cell", "OBSERVATION", 126, 135]]], ["Also, supplementation with L-arginine can greatly enhance intestinal barrier function and maintain intestinal integrity after LPS challenge .MacrophagesMacrophages differentiate from hemopoietic progenitors either directly or via circulating monocytes (Geissmann et al., 2010) after cell migration to the different compartments of the body.", [["intestinal barrier", "ANATOMY", 58, 76], ["intestinal", "ANATOMY", 99, 109], ["MacrophagesMacrophages", "ANATOMY", 141, 163], ["hemopoietic progenitors", "ANATOMY", 183, 206], ["monocytes", "ANATOMY", 242, 251], ["cell", "ANATOMY", 283, 287], ["compartments", "ANATOMY", 315, 327], ["body", "ANATOMY", 335, 339], ["L-arginine", "CHEMICAL", 27, 37], ["LPS", "CHEMICAL", 126, 129], ["L-arginine", "CHEMICAL", 27, 37], ["L-arginine", "SIMPLE_CHEMICAL", 27, 37], ["intestinal barrier", "MULTI-TISSUE_STRUCTURE", 58, 76], ["intestinal", "ORGAN", 99, 109], ["LPS", "SIMPLE_CHEMICAL", 126, 129], ["MacrophagesMacrophages", "CELL", 141, 163], ["hemopoietic progenitors", "CELL", 183, 206], ["monocytes", "CELL", 242, 251], ["cell", "CELL", 283, 287], ["body", "ORGANISM_SUBDIVISION", 335, 339], ["MacrophagesMacrophages", "CELL_TYPE", 141, 163], ["hemopoietic progenitors", "CELL_TYPE", 183, 206], ["circulating monocytes", "CELL_TYPE", 230, 251], ["L-arginine", "TREATMENT", 27, 37], ["intestinal barrier function", "TREATMENT", 58, 85], ["LPS challenge", "TREATMENT", 126, 139], ["MacrophagesMacrophages", "PROBLEM", 141, 163], ["hemopoietic progenitors", "PROBLEM", 183, 206], ["cell migration", "TREATMENT", 283, 297], ["intestinal", "ANATOMY", 58, 68], ["intestinal", "ANATOMY", 99, 109], ["hemopoietic progenitors", "OBSERVATION", 183, 206], ["different", "ANATOMY_MODIFIER", 305, 314], ["compartments", "ANATOMY_MODIFIER", 315, 327], ["body", "ANATOMY", 335, 339]]], ["This migration is controlled by various adhesion molecules like integrins, immunoglobulin-superfamily members, selectins, and others.", [["integrins", "GENE_OR_GENE_PRODUCT", 64, 73], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 75, 89], ["selectins", "GENE_OR_GENE_PRODUCT", 111, 120], ["adhesion molecules", "PROTEIN", 40, 58], ["integrins", "PROTEIN", 64, 73], ["immunoglobulin-superfamily members", "PROTEIN", 75, 109], ["selectins", "PROTEIN", 111, 120], ["This migration", "PROBLEM", 0, 14], ["adhesion molecules", "OBSERVATION", 40, 58]]], ["In the tissues, macrophages are able to adapt to their local microenvironment, develop different phenotypes, and reside as Kupffer cells (liver), Langerhans cells (skin) or alveolar macrophages (lung) (Gordon, 2002) .", [["tissues", "ANATOMY", 7, 14], ["macrophages", "ANATOMY", 16, 27], ["Kupffer cells", "ANATOMY", 123, 136], ["liver", "ANATOMY", 138, 143], ["Langerhans cells", "ANATOMY", 146, 162], ["skin", "ANATOMY", 164, 168], ["alveolar macrophages", "ANATOMY", 173, 193], ["lung", "ANATOMY", 195, 199], ["tissues", "TISSUE", 7, 14], ["macrophages", "CELL", 16, 27], ["Kupffer cells", "CELL", 123, 136], ["liver", "ORGAN", 138, 143], ["Langerhans cells", "CELL", 146, 162], ["skin", "ORGAN", 164, 168], ["alveolar macrophages", "CELL", 173, 193], ["lung", "ORGAN", 195, 199], ["macrophages", "CELL_TYPE", 16, 27], ["Kupffer cells", "CELL_TYPE", 123, 136], ["Langerhans cells", "CELL_TYPE", 146, 162], ["alveolar macrophages", "CELL_TYPE", 173, 193], ["different phenotypes", "PROBLEM", 87, 107], ["Langerhans cells (skin) or alveolar macrophages", "PROBLEM", 146, 193], ["tissues", "ANATOMY", 7, 14], ["macrophages", "OBSERVATION", 16, 27], ["liver", "ANATOMY", 138, 143], ["Langerhans cells", "OBSERVATION", 146, 162], ["skin", "ANATOMY", 164, 168], ["alveolar macrophages", "ANATOMY", 173, 193], ["lung", "ANATOMY", 195, 199]]], ["Recently, it has been demonstrated in mice that some tissue macrophages derived from non-hematopoietic stem cells (Geissmann et al., 2010; Guilliams et al., 2013; Hashimoto et al., 2013; Schulz et al., 2012) .", [["tissue macrophages", "ANATOMY", 53, 71], ["non-hematopoietic stem cells", "ANATOMY", 85, 113], ["mice", "ORGANISM", 38, 42], ["tissue macrophages", "CELL", 53, 71], ["non-hematopoietic stem cells", "CELL", 85, 113], ["tissue macrophages", "CELL_TYPE", 53, 71], ["non-hematopoietic stem cells", "CELL_TYPE", 85, 113], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 38, 42], ["some tissue macrophages", "PROBLEM", 48, 71], ["some tissue", "OBSERVATION_MODIFIER", 48, 59], ["macrophages", "OBSERVATION", 60, 71], ["non-hematopoietic stem cells", "OBSERVATION", 85, 113]]], ["Differentiated residential macrophages can comprise 10-15% of the total cells in tissue.", [["macrophages", "ANATOMY", 27, 38], ["cells", "ANATOMY", 72, 77], ["tissue", "ANATOMY", 81, 87], ["macrophages", "CELL", 27, 38], ["cells", "CELL", 72, 77], ["tissue", "TISSUE", 81, 87], ["residential macrophages", "CELL_TYPE", 15, 38], ["Differentiated residential macrophages", "PROBLEM", 0, 38], ["macrophages", "OBSERVATION", 27, 38], ["10-15", "OBSERVATION_MODIFIER", 52, 57], ["tissue", "ANATOMY", 81, 87]]], ["They provide a first line of defence against pathogens mainly via antigen uptake and presentation as well as by the production of inflammatory cytokines (Fairbairn et al., 2011; Murtaugh and Foss, 2002) .", [["antigen", "GENE_OR_GENE_PRODUCT", 66, 73], ["inflammatory cytokines", "PROTEIN", 130, 152], ["pathogens", "PROBLEM", 45, 54], ["inflammatory cytokines", "PROBLEM", 130, 152], ["inflammatory", "OBSERVATION_MODIFIER", 130, 142]]], ["Macrophages facilitate humoral immunity, allergic and anti-parasite responses.", [["Macrophages", "ANATOMY", 0, 11], ["allergic", "DISEASE", 41, 49], ["Macrophages", "CELL", 0, 11], ["Macrophages", "CELL_TYPE", 0, 11], ["Macrophages", "TREATMENT", 0, 11], ["allergic", "PROBLEM", 41, 49], ["humoral immunity", "OBSERVATION", 23, 39]]], ["They can also like alveolar macrophages (Hussell and Bell, 2014) dampen the immune response through anti-inflammatory cytokines such as IL-10 and TGF-b and participate to tissue repair.MacrophagesGordon and Martinez divide the macrophage life cycle in four different stages: differentiation, priming, activation, and resolution (Gordon and Martinez, 2010 ).", [["alveolar macrophages", "ANATOMY", 19, 39], ["tissue", "ANATOMY", 171, 177], ["macrophage", "ANATOMY", 227, 237], ["alveolar macrophages", "CELL", 19, 39], ["Hussell", "CELL", 41, 48], ["IL-10", "GENE_OR_GENE_PRODUCT", 136, 141], ["TGF-b", "GENE_OR_GENE_PRODUCT", 146, 151], ["tissue", "TISSUE", 171, 177], ["macrophage", "CELL", 227, 237], ["alveolar macrophages", "CELL_TYPE", 19, 39], ["anti-inflammatory cytokines", "PROTEIN", 100, 127], ["IL-10", "PROTEIN", 136, 141], ["TGF", "PROTEIN", 146, 149], ["alveolar macrophages", "PROBLEM", 19, 39], ["anti-inflammatory cytokines", "TREATMENT", 100, 127], ["IL", "TREATMENT", 136, 138], ["TGF-b", "TREATMENT", 146, 151], ["tissue repair", "TREATMENT", 171, 184], ["MacrophagesGordon", "TREATMENT", 185, 202], ["Martinez", "TREATMENT", 207, 215], ["the macrophage life cycle", "TREATMENT", 223, 248], ["alveolar macrophages", "OBSERVATION", 19, 39], ["tissue", "ANATOMY", 171, 177], ["repair", "OBSERVATION", 178, 184], ["macrophage", "OBSERVATION_MODIFIER", 227, 237], ["four different", "OBSERVATION_MODIFIER", 252, 266]]], ["In the differential stage, the balance of macrophage colony-stimulating factor (MCSF) and granulocytemacrophage colony-stimulating factor (GM-CSF), retinoic acid, and lipoproteins can impact the future phenotype and function of the mature macrophage (Gordon and Martinez, 2010) .", [["macrophage", "ANATOMY", 239, 249], ["retinoic acid", "CHEMICAL", 148, 161], ["retinoic acid", "CHEMICAL", 148, 161], ["macrophage colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 42, 78], ["MCSF", "GENE_OR_GENE_PRODUCT", 80, 84], ["granulocytemacrophage colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 90, 137], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 139, 145], ["retinoic acid", "SIMPLE_CHEMICAL", 148, 161], ["macrophage", "CELL", 239, 249], ["macrophage colony-stimulating factor", "PROTEIN", 42, 78], ["MCSF", "PROTEIN", 80, 84], ["granulocytemacrophage colony-stimulating factor", "PROTEIN", 90, 137], ["GM", "PROTEIN", 139, 141], ["CSF", "PROTEIN", 142, 145], ["lipoproteins", "PROTEIN", 167, 179], ["mature macrophage", "CELL_TYPE", 232, 249], ["macrophage colony", "TEST", 42, 59], ["stimulating factor", "TEST", 60, 78], ["MCSF", "TEST", 80, 84], ["granulocytemacrophage colony", "TEST", 90, 118], ["stimulating factor", "TEST", 119, 137], ["GM-CSF", "TEST", 139, 145], ["retinoic acid", "TEST", 148, 161], ["macrophage colony", "OBSERVATION", 42, 59]]], ["In the next phase, macrophage priming is accomplished by the different cytokine milieus during their continuous recruitment into tissue.", [["macrophage", "ANATOMY", 19, 29], ["tissue", "ANATOMY", 129, 135], ["macrophage", "CELL", 19, 29], ["tissue", "TISSUE", 129, 135], ["cytokine", "PROTEIN", 71, 79], ["the different cytokine milieus", "PROBLEM", 57, 87], ["macrophage", "OBSERVATION", 19, 29], ["cytokine milieus", "OBSERVATION", 71, 87]]], ["This priming has a substantial impact on their response following stimulations and to their role in the innate immune response (Gordon and Martinez, 2010) .", [["substantial", "OBSERVATION_MODIFIER", 19, 30], ["impact", "OBSERVATION_MODIFIER", 31, 37]]], ["The presence of IFN-c leads to macrophage activation in the ''classical way'' (''M1''), whereas the presence of IL-4 and/or IL-13 leads to macrophage activation in the ''alternative way'' (''M2'') (Dalton et al., 1993; Stein and Keshav, 1992) .", [["macrophage", "ANATOMY", 31, 41], ["macrophage", "ANATOMY", 139, 149], ["IFN-c", "GENE_OR_GENE_PRODUCT", 16, 21], ["macrophage", "CELL", 31, 41], ["IL-4", "GENE_OR_GENE_PRODUCT", 112, 116], ["IL-13", "GENE_OR_GENE_PRODUCT", 124, 129], ["macrophage", "CELL", 139, 149], ["IFN-c", "PROTEIN", 16, 21], ["IL", "PROTEIN", 112, 114], ["IL-13", "PROTEIN", 124, 129], ["IFN-c leads to macrophage activation", "TREATMENT", 16, 52], ["IL", "TEST", 112, 114], ["IL", "TREATMENT", 124, 126], ["macrophage activation", "TREATMENT", 139, 160]]], ["After recognition of microbes by macrophage PRRs or via opsonic stimulation via antibody complexes, a mature macrophage becomes fully competent to fulfil its role in the innate immune response.Macrophages''Classical activation'' via IFN-c, produced mainly by activated Th1 cells or natural killer (NK) cells, leads to a pro-inflammatory, antimicrobial activity by the macrophage and the promotion of a Th1 response (Fairbairn et al., 2011) .", [["macrophage", "ANATOMY", 33, 43], ["macrophage", "ANATOMY", 109, 119], ["Macrophages", "ANATOMY", 193, 204], ["Th1 cells", "ANATOMY", 269, 278], ["natural killer (NK) cells", "ANATOMY", 282, 307], ["macrophage", "ANATOMY", 368, 378], ["macrophage", "CELL", 33, 43], ["opsonic", "GENE_OR_GENE_PRODUCT", 56, 63], ["macrophage", "CELL", 109, 119], ["Macrophages", "CELL", 193, 204], ["IFN-c", "GENE_OR_GENE_PRODUCT", 233, 238], ["Th1 cells", "CELL", 269, 278], ["natural killer (NK) cells", "CELL", 282, 307], ["macrophage", "CELL", 368, 378], ["macrophage PRRs", "PROTEIN", 33, 48], ["antibody complexes", "PROTEIN", 80, 98], ["Macrophages", "CELL_TYPE", 193, 204], ["IFN-c", "PROTEIN", 233, 238], ["Th1 cells", "CELL_TYPE", 269, 278], ["natural killer (NK) cells", "CELL_TYPE", 282, 307], ["macrophage", "CELL_TYPE", 368, 378], ["macrophage PRRs", "TREATMENT", 33, 48], ["opsonic stimulation via antibody complexes", "TREATMENT", 56, 98], ["a mature macrophage", "PROBLEM", 100, 119], ["Macrophages", "PROBLEM", 193, 204], ["IFN", "PROBLEM", 233, 236], ["activated Th1 cells", "PROBLEM", 259, 278], ["macrophage", "OBSERVATION", 109, 119]]], ["IFN-c priming was shown to promote classical activation of macrophages (Charley et al., 1990 ) and viral pathogen resistance in pigs (Lunney et al., 2010) .", [["macrophages", "ANATOMY", 59, 70], ["IFN-c", "GENE_OR_GENE_PRODUCT", 0, 5], ["macrophages", "CELL", 59, 70], ["pigs", "ORGANISM", 128, 132], ["IFN", "PROTEIN", 0, 3], ["macrophages", "CELL_TYPE", 59, 70], ["pigs", "SPECIES", 128, 132], ["pigs", "SPECIES", 128, 132], ["viral pathogen resistance", "PROBLEM", 99, 124], ["viral", "OBSERVATION", 99, 104], ["pathogen resistance", "OBSERVATION", 105, 124]]], ["Activation of macrophages through the ''alternative pathway'' via IL-4 and/or IL-13 leads to promotion of a Th2 and antibody-mediated immune response.", [["macrophages", "ANATOMY", 14, 25], ["macrophages", "CELL", 14, 25], ["IL-4", "GENE_OR_GENE_PRODUCT", 66, 70], ["IL-13", "GENE_OR_GENE_PRODUCT", 78, 83], ["Th2", "GENE_OR_GENE_PRODUCT", 108, 111], ["macrophages", "CELL_TYPE", 14, 25], ["IL", "PROTEIN", 66, 68], ["IL-13", "PROTEIN", 78, 83], ["Activation of macrophages", "TREATMENT", 0, 25], ["IL", "TREATMENT", 78, 80], ["a Th2", "TEST", 106, 111], ["antibody", "TEST", 116, 124]]], ["The role of IL-4 in porcine macrophages was mainly analysed in combination with GM-CSF in the induction of monocyte-derived DC (moDCs) and it triggered decreased expression of inflammatory markers CD14 and CD18, and increased expression of T-cell co-stimulation molecules such as MHC class II and CD80/86 (Swiggard et al., 1995) .", [["macrophages", "ANATOMY", 28, 39], ["monocyte", "ANATOMY", 107, 115], ["DC", "ANATOMY", 124, 126], ["moDCs", "ANATOMY", 128, 133], ["T-cell", "ANATOMY", 240, 246], ["GM", "CHEMICAL", 80, 82], ["IL-4", "GENE_OR_GENE_PRODUCT", 12, 16], ["porcine", "ORGANISM", 20, 27], ["macrophages", "CELL", 28, 39], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 80, 86], ["monocyte-derived DC", "CELL", 107, 126], ["moDCs", "CELL", 128, 133], ["CD14", "GENE_OR_GENE_PRODUCT", 197, 201], ["CD18", "GENE_OR_GENE_PRODUCT", 206, 210], ["T-cell co-stimulation molecules", "GENE_OR_GENE_PRODUCT", 240, 271], ["MHC class II", "GENE_OR_GENE_PRODUCT", 280, 292], ["CD80/86", "GENE_OR_GENE_PRODUCT", 297, 304], ["IL-4", "PROTEIN", 12, 16], ["porcine macrophages", "CELL_TYPE", 20, 39], ["CSF", "PROTEIN", 83, 86], ["DC", "CELL_TYPE", 124, 126], ["moDCs", "CELL_TYPE", 128, 133], ["inflammatory markers", "PROTEIN", 176, 196], ["CD14", "PROTEIN", 197, 201], ["CD18", "PROTEIN", 206, 210], ["T-cell co-stimulation molecules", "PROTEIN", 240, 271], ["MHC class II", "PROTEIN", 280, 292], ["IL-4 in porcine macrophages", "TREATMENT", 12, 39], ["inflammatory markers CD14", "PROBLEM", 176, 201], ["CD18", "TEST", 206, 210], ["T-cell co-stimulation molecules", "PROBLEM", 240, 271], ["inflammatory", "OBSERVATION_MODIFIER", 176, 188], ["increased", "OBSERVATION_MODIFIER", 216, 225], ["cell co-stimulation", "OBSERVATION", 242, 261]]], ["Several other cytokines may be involved in the fine-tuning of macrophage activation.", [["macrophage", "ANATOMY", 62, 72], ["macrophage", "CELL", 62, 72], ["cytokines", "PROTEIN", 14, 23], ["cytokines", "OBSERVATION", 14, 23], ["macrophage activation", "OBSERVATION", 62, 83]]], ["At the end of infectious process, anti-inflammatory cytokines increase and the macrophage can undergo its final maturation step that Gordon and Martinez termed ''resolution''.", [["macrophage", "ANATOMY", 79, 89], ["macrophage", "CELL", 79, 89], ["anti-inflammatory cytokines", "PROTEIN", 34, 61], ["macrophage", "CELL_TYPE", 79, 89], ["infectious process", "PROBLEM", 14, 32], ["anti-inflammatory cytokines", "PROBLEM", 34, 61], ["Martinez termed ''resolution", "TREATMENT", 144, 172], ["infectious", "OBSERVATION", 14, 24], ["anti-inflammatory cytokines", "OBSERVATION", 34, 61]]], ["In this stage, the pro-inflammatory potential is suppressed and the macrophage is involved in debris clearance and general repair functions (Gordon and Martinez, 2010) .MacrophagesActivation of porcine macrophage by PRRs stimulation (Fairbairn et al., 2011; Jungi et al., 1996; Zelnickova et al., 2008) revealed a major similarity between porcine and human macrophages which contrast with studies carried out in mice.", [["macrophage", "ANATOMY", 68, 78], ["debris", "ANATOMY", 94, 100], ["macrophage", "ANATOMY", 202, 212], ["macrophages", "ANATOMY", 357, 368], ["macrophage", "CELL", 68, 78], ["porcine", "ORGANISM", 194, 201], ["macrophage", "CELL", 202, 212], ["PRRs", "GENE_OR_GENE_PRODUCT", 216, 220], ["porcine", "ORGANISM", 339, 346], ["human", "ORGANISM", 351, 356], ["macrophages", "CELL", 357, 368], ["mice", "ORGANISM", 412, 416], ["porcine macrophage", "CELL_TYPE", 194, 212], ["PRRs", "PROTEIN", 216, 220], ["porcine and human macrophages", "CELL_TYPE", 339, 368], ["porcine", "SPECIES", 194, 201], ["porcine", "SPECIES", 339, 346], ["human", "SPECIES", 351, 356], ["mice", "SPECIES", 412, 416], ["human", "SPECIES", 351, 356], ["mice", "SPECIES", 412, 416], ["debris clearance", "PROBLEM", 94, 110], ["porcine macrophage", "TREATMENT", 194, 212], ["porcine and human macrophages", "TREATMENT", 339, 368], ["studies", "TEST", 389, 396], ["pro-inflammatory", "OBSERVATION_MODIFIER", 19, 35], ["suppressed", "OBSERVATION_MODIFIER", 49, 59], ["macrophage", "OBSERVATION_MODIFIER", 68, 78], ["debris", "OBSERVATION", 94, 100], ["porcine macrophage", "OBSERVATION", 194, 212], ["human macrophages", "OBSERVATION", 351, 368]]], ["Specifically, LPS stimulation of murine macrophages in combination with IFN-c leads to the induction of NO synthase (NOS2, iNOS) triggering the antimicrobial response.", [["macrophages", "ANATOMY", 40, 51], ["LPS", "CHEMICAL", 14, 17], ["NO", "CHEMICAL", 104, 106], ["NO", "CHEMICAL", 104, 106], ["LPS", "SIMPLE_CHEMICAL", 14, 17], ["murine", "ORGANISM", 33, 39], ["macrophages", "CELL", 40, 51], ["IFN-c", "GENE_OR_GENE_PRODUCT", 72, 77], ["NO synthase", "GENE_OR_GENE_PRODUCT", 104, 115], ["NOS2", "GENE_OR_GENE_PRODUCT", 117, 121], ["iNOS", "GENE_OR_GENE_PRODUCT", 123, 127], ["murine macrophages", "CELL_TYPE", 33, 51], ["IFN-c", "PROTEIN", 72, 77], ["NO synthase", "PROTEIN", 104, 115], ["NOS2", "PROTEIN", 117, 121], ["iNOS", "PROTEIN", 123, 127], ["murine", "SPECIES", 33, 39], ["LPS stimulation of murine macrophages", "TREATMENT", 14, 51], ["IFN", "TREATMENT", 72, 75], ["antimicrobial response", "OBSERVATION", 144, 166]]], ["In contrast, human and porcine (Fairbairn et al., 2011; Jungi et al., 1996; Zelnickova et al., 2008) macrophages produce indoleamine 2,3-dioxygenase (IDO) instead of NOS2 upon LPS activation leading to production of pro-inflammatory cytokines such as TNF-a, IL-1b, IL-6, IL-8, and IL-12 (Fairbairn et al., 2011) .", [["macrophages", "ANATOMY", 101, 112], ["indoleamine 2,3-dioxygenase", "CHEMICAL", 121, 148], ["LPS", "CHEMICAL", 176, 179], ["indoleamine", "CHEMICAL", 121, 132], ["human", "ORGANISM", 13, 18], ["porcine", "ORGANISM", 23, 30], ["macrophages", "CELL", 101, 112], ["indoleamine 2,3-dioxygenase", "GENE_OR_GENE_PRODUCT", 121, 148], ["IDO", "GENE_OR_GENE_PRODUCT", 150, 153], ["NOS2", "GENE_OR_GENE_PRODUCT", 166, 170], ["LPS", "SIMPLE_CHEMICAL", 176, 179], ["TNF-a", "GENE_OR_GENE_PRODUCT", 251, 256], ["IL-1b", "GENE_OR_GENE_PRODUCT", 258, 263], ["IL-6", "GENE_OR_GENE_PRODUCT", 265, 269], ["IL-8", "GENE_OR_GENE_PRODUCT", 271, 275], ["IL-12", "GENE_OR_GENE_PRODUCT", 281, 286], ["macrophages", "CELL_TYPE", 101, 112], ["indoleamine 2,3-dioxygenase", "PROTEIN", 121, 148], ["IDO", "PROTEIN", 150, 153], ["NOS2", "PROTEIN", 166, 170], ["pro-inflammatory cytokines", "PROTEIN", 216, 242], ["TNF", "PROTEIN", 251, 254], ["human", "SPECIES", 13, 18], ["porcine", "SPECIES", 23, 30], ["human", "SPECIES", 13, 18], ["indoleamine", "TEST", 121, 132], ["dioxygenase (IDO)", "TREATMENT", 137, 154], ["NOS2 upon LPS activation", "TREATMENT", 166, 190], ["pro-inflammatory cytokines", "PROBLEM", 216, 242], ["TNF", "TEST", 251, 254], ["IL", "TEST", 258, 260], ["IL", "TEST", 265, 267], ["IL", "TEST", 271, 273]]], ["IL-1b and IL-12 promote expansion, differentiation, and survival of T cells (Fairbairn et al., 2011) .", [["T cells", "ANATOMY", 68, 75], ["IL-1b", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL-12", "GENE_OR_GENE_PRODUCT", 10, 15], ["T cells", "CELL", 68, 75], ["IL-1b and IL-12", "PROTEIN", 0, 15], ["T cells", "CELL_TYPE", 68, 75], ["IL", "TEST", 0, 2], ["IL", "TREATMENT", 10, 12], ["expansion", "OBSERVATION_MODIFIER", 24, 33]]], ["In addition, they are able to induce IFN-c production by T and NK cells which starts a pro-inflammatory feedback loop and even stronger IL-1b, IL-12, and CD80/86 levels to prevent the development of tolerance.", [["T", "ANATOMY", 57, 58], ["NK cells", "ANATOMY", 63, 71], ["IFN-c", "GENE_OR_GENE_PRODUCT", 37, 42], ["T", "CELL", 57, 58], ["NK cells", "CELL", 63, 71], ["IL-1b", "GENE_OR_GENE_PRODUCT", 136, 141], ["IL-12", "GENE_OR_GENE_PRODUCT", 143, 148], ["CD80", "GENE_OR_GENE_PRODUCT", 154, 158], ["86", "GENE_OR_GENE_PRODUCT", 159, 161], ["IFN", "PROTEIN", 37, 40], ["T and NK cells", "CELL_TYPE", 57, 71], ["CD80", "PROTEIN", 154, 158], ["IFN", "TEST", 37, 40], ["a pro-inflammatory feedback loop", "PROBLEM", 85, 117], ["IL", "TEST", 136, 138], ["IL", "TEST", 143, 145], ["CD80", "TEST", 154, 158]]], ["As well as LPS, cholera toxin (CT) is able to increase IL-1 and CD80/86 expression by macrophages and might be a promising adjuvant to boost the innate immunity (Foss et al., 1999; Murtaugh and Foss, 2002) .MacrophagesThe various phases of macrophage differentiation and activation lead to a complex and diverse phenotype of macrophages.", [["macrophages", "ANATOMY", 86, 97], ["Macrophages", "ANATOMY", 207, 218], ["macrophage", "ANATOMY", 240, 250], ["macrophages", "ANATOMY", 325, 336], ["LPS", "CHEMICAL", 11, 14], ["cholera toxin", "CHEMICAL", 16, 29], ["LPS", "SIMPLE_CHEMICAL", 11, 14], ["cholera toxin", "SIMPLE_CHEMICAL", 16, 29], ["CT", "SIMPLE_CHEMICAL", 31, 33], ["IL-1", "GENE_OR_GENE_PRODUCT", 55, 59], ["CD80", "GENE_OR_GENE_PRODUCT", 64, 68], ["86", "GENE_OR_GENE_PRODUCT", 69, 71], ["macrophages", "CELL", 86, 97], ["Macrophages", "CELL", 207, 218], ["macrophage", "CELL", 240, 250], ["macrophages", "CELL", 325, 336], ["cholera toxin", "PROTEIN", 16, 29], ["CD80", "PROTEIN", 64, 68], ["macrophages", "CELL_TYPE", 86, 97], ["Macrophages", "CELL_TYPE", 207, 218], ["macrophages", "CELL_TYPE", 325, 336], ["LPS", "TEST", 11, 14], ["cholera toxin (CT)", "TEST", 16, 34], ["IL", "TEST", 55, 57], ["a complex and diverse phenotype of macrophages", "PROBLEM", 290, 336], ["various phases", "OBSERVATION_MODIFIER", 222, 236], ["macrophage differentiation", "OBSERVATION", 240, 266], ["macrophages", "OBSERVATION", 325, 336]]], ["Additionally, they can differentiate from shared myeloid progenitors which make them difficult to identify and segregate phenotypically from other mononuclear phagocytes such as myeloid DCs.", [["myeloid progenitors", "ANATOMY", 49, 68], ["mononuclear phagocytes", "ANATOMY", 147, 169], ["myeloid DCs", "ANATOMY", 178, 189], ["myeloid progenitors", "CELL", 49, 68], ["mononuclear phagocytes", "CELL", 147, 169], ["myeloid DCs", "CELL", 178, 189], ["myeloid progenitors", "CELL_TYPE", 49, 68], ["mononuclear phagocytes", "CELL_TYPE", 147, 169], ["myeloid DCs", "CELL_TYPE", 178, 189], ["shared myeloid progenitors", "PROBLEM", 42, 68], ["segregate phenotypically", "PROBLEM", 111, 135], ["mononuclear phagocytes", "PROBLEM", 147, 169], ["myeloid DCs", "PROBLEM", 178, 189], ["myeloid progenitors", "OBSERVATION", 49, 68], ["mononuclear phagocytes", "OBSERVATION", 147, 169], ["myeloid DCs", "OBSERVATION", 178, 189]]], ["In mice, CD11b, CD18, CD68, F4/80 and Fc receptors are common markers for the phenotypic definition of macrophages (Murray and Wynn, 2011) but this cannot be directly transferred in other species (Fairbairn et al., 2011) .", [["macrophages", "ANATOMY", 103, 114], ["mice", "ORGANISM", 3, 7], ["CD11b", "GENE_OR_GENE_PRODUCT", 9, 14], ["CD18", "GENE_OR_GENE_PRODUCT", 16, 20], ["CD68", "GENE_OR_GENE_PRODUCT", 22, 26], ["F4/80", "GENE_OR_GENE_PRODUCT", 28, 33], ["Fc receptors", "GENE_OR_GENE_PRODUCT", 38, 50], ["macrophages", "CELL", 103, 114], ["CD11b", "PROTEIN", 9, 14], ["CD18", "PROTEIN", 16, 20], ["CD68", "PROTEIN", 22, 26], ["F4", "PROTEIN", 28, 30], ["Fc receptors", "PROTEIN", 38, 50], ["macrophages", "CELL_TYPE", 103, 114], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 3, 7], ["CD11b", "TEST", 9, 14], ["CD18", "TEST", 16, 20], ["CD68", "TEST", 22, 26], ["F4", "TEST", 28, 30], ["Fc receptors", "TEST", 38, 50], ["macrophages", "PROBLEM", 103, 114], ["macrophages", "OBSERVATION", 103, 114]]], ["In swine, macrophages are defined as CD172a + CD1 +/\u00c0 CD4 \u00c0 CD11R1 \u00c0 CD14 +/\u00c0 CD16 + MHC class II low CD80/86 low (Summerfield and McCullough, 2009a) .", [["macrophages", "ANATOMY", 10, 21], ["CD172a + CD1 +/\u00c0 CD4 \u00c0 CD11R1 \u00c0 CD14 +/\u00c0", "ANATOMY", 37, 77], ["swine", "ORGANISM", 3, 8], ["macrophages", "CELL", 10, 21], ["CD172a", "GENE_OR_GENE_PRODUCT", 37, 43], ["CD1", "GENE_OR_GENE_PRODUCT", 46, 49], ["CD4", "GENE_OR_GENE_PRODUCT", 54, 57], ["CD14", "GENE_OR_GENE_PRODUCT", 69, 73], ["CD16", "GENE_OR_GENE_PRODUCT", 78, 82], ["CD80", "GENE_OR_GENE_PRODUCT", 102, 106], ["macrophages", "CELL_TYPE", 10, 21], ["CD172a", "PROTEIN", 37, 43], ["CD1", "PROTEIN", 46, 49], ["CD4", "PROTEIN", 54, 57], ["11R1", "PROTEIN", 62, 66], ["CD14", "PROTEIN", 69, 73], ["CD16", "PROTEIN", 78, 82], ["MHC class II", "PROTEIN", 85, 97], ["CD80", "PROTEIN", 102, 106], ["swine", "SPECIES", 3, 8], ["swine", "SPECIES", 3, 8], ["CD", "TEST", 37, 39], ["CD1", "TEST", 46, 49], ["CD4", "TEST", 54, 57], ["CD", "TEST", 60, 62], ["CD14", "TEST", 69, 73], ["\u00c0", "TEST", 76, 77], ["CD16", "TEST", 78, 82], ["MHC class", "TEST", 85, 94], ["II", "TEST", 95, 97], ["CD80", "TEST", 102, 106], ["Summerfield", "TEST", 115, 126], ["McCullough", "TEST", 131, 141], ["macrophages", "OBSERVATION", 10, 21]]], ["Furthermore, CD163 is selectively expressed on monocytes and macrophages and therefore a useful marker to define this subset (Fairbairn et al., 2011) .", [["monocytes", "ANATOMY", 47, 56], ["macrophages", "ANATOMY", 61, 72], ["CD163", "GENE_OR_GENE_PRODUCT", 13, 18], ["monocytes", "CELL", 47, 56], ["macrophages", "CELL", 61, 72], ["CD163", "PROTEIN", 13, 18], ["monocytes", "CELL_TYPE", 47, 56], ["macrophages", "CELL_TYPE", 61, 72], ["monocytes", "TEST", 47, 56], ["CD163", "OBSERVATION", 13, 18]]], ["This molecule is also a receptor used by the PRRSV to infect this important immune cell subset (Calvert et al., 2007) .MacrophagesPRRSV is the most economically significant viral pathogens for the pig industry world-wide and causes reproductive problems and pneumonia (Chand et al., 2012) .", [["immune cell", "ANATOMY", 76, 87], ["MacrophagesPRRSV", "CHEMICAL", 119, 135], ["pneumonia", "DISEASE", 258, 267], ["PRRSV", "ORGANISM", 45, 50], ["immune cell", "CELL", 76, 87], ["MacrophagesPRRSV", "GENE_OR_GENE_PRODUCT", 119, 135], ["pig", "ORGANISM", 197, 200], ["immune cell subset", "CELL_TYPE", 76, 94], ["pig", "SPECIES", 197, 200], ["PRRSV", "SPECIES", 45, 50], ["pig", "SPECIES", 197, 200], ["a receptor", "TREATMENT", 22, 32], ["reproductive problems", "PROBLEM", 232, 253], ["pneumonia", "PROBLEM", 258, 267], ["most economically", "OBSERVATION_MODIFIER", 143, 160], ["significant", "OBSERVATION_MODIFIER", 161, 172], ["viral pathogens", "OBSERVATION", 173, 188], ["pneumonia", "OBSERVATION", 258, 267]]], ["Infection leads to a significant shift in the gene expression of PAMs.", [["Infection", "PROBLEM", 0, 9], ["a significant shift", "PROBLEM", 19, 38], ["PAMs", "PROBLEM", 65, 69], ["significant", "OBSERVATION_MODIFIER", 21, 32], ["shift", "OBSERVATION", 33, 38], ["PAMs", "OBSERVATION", 65, 69]]], ["PRRSV strongly induces IFN-b, but not IFN-a, expression (Sang et al., 2011) .", [["PRRSV", "ORGANISM", 0, 5], ["IFN-b", "GENE_OR_GENE_PRODUCT", 23, 28], ["IFN", "GENE_OR_GENE_PRODUCT", 38, 41], ["IFN", "PROTEIN", 23, 26], ["IFN", "PROTEIN", 38, 41], ["PRRSV", "SPECIES", 0, 5]]], ["Additionally, the antiinflammatory cytokine IL-10 is up-regulated within twelve hours indicating that PRRSV is able to induce the ''resolution'' stage very early after infection of macrophages (Genini et al., 2008) .MacrophagesUnfortunately, many other viral pathogens like porcine circovirus 2 (PCV2) and ASFV and bacterial pathogens like A. pleuropneumoniae and Chlamydia suis also replicate in macrophages altering their function and negatively impacting swine welfare and economic returns to swine producers (Fairbairn et al., 2011; Opriessnig et al., 2008; Schautteet and Vanrompay, 2011) .MacrophagesPCV2 is the primary causative agent of the multi-factorial disease PMWS, which is detrimental to pig production (Kekarainen et al., 2010) .", [["macrophages", "ANATOMY", 181, 192], ["Macrophages", "ANATOMY", 216, 227], ["macrophages", "ANATOMY", 397, 408], ["infection", "DISEASE", 168, 177], ["MacrophagesPCV2", "CHEMICAL", 595, 610], ["PMWS", "DISEASE", 673, 677], ["IL-10", "GENE_OR_GENE_PRODUCT", 44, 49], ["PRRSV", "ORGANISM", 102, 107], ["macrophages", "CELL", 181, 192], ["Macrophages", "CELL", 216, 227], ["porcine circovirus 2", "ORGANISM", 274, 294], ["PCV2", "ORGANISM", 296, 300], ["ASFV", "ORGANISM", 306, 310], ["bacterial pathogens", "ORGANISM", 315, 334], ["A. pleuropneumoniae", "ORGANISM", 340, 359], ["Chlamydia suis", "ORGANISM", 364, 378], ["macrophages", "CELL", 397, 408], ["swine", "ORGANISM", 496, 501], ["MacrophagesPCV2", "GENE_OR_GENE_PRODUCT", 595, 610], ["pig", "ORGANISM", 703, 706], ["antiinflammatory cytokine IL-10", "PROTEIN", 18, 49], ["macrophages", "CELL_TYPE", 181, 192], ["Macrophages", "CELL_TYPE", 216, 227], ["macrophages", "CELL_TYPE", 397, 408], ["porcine circovirus", "SPECIES", 274, 292], ["A. pleuropneumoniae", "SPECIES", 340, 359], ["Chlamydia suis", "SPECIES", 364, 378], ["swine", "SPECIES", 496, 501], ["pig", "SPECIES", 703, 706], ["PRRSV", "SPECIES", 102, 107], ["porcine circovirus 2", "SPECIES", 274, 294], ["PCV2", "SPECIES", 296, 300], ["ASFV", "SPECIES", 306, 310], ["A. pleuropneumoniae", "SPECIES", 340, 359], ["Chlamydia suis", "SPECIES", 364, 378], ["swine", "SPECIES", 458, 463], ["swine", "SPECIES", 496, 501], ["pig", "SPECIES", 703, 706], ["the antiinflammatory cytokine IL", "TREATMENT", 14, 46], ["PRRSV", "PROBLEM", 102, 107], ["infection of macrophages", "PROBLEM", 168, 192], ["Macrophages", "PROBLEM", 216, 227], ["many other viral pathogens", "PROBLEM", 242, 268], ["porcine circovirus", "PROBLEM", 274, 292], ["PCV2", "PROBLEM", 296, 300], ["ASFV", "PROBLEM", 306, 310], ["bacterial pathogens", "PROBLEM", 315, 334], ["A. pleuropneumoniae", "PROBLEM", 340, 359], ["Chlamydia suis", "PROBLEM", 364, 378], ["MacrophagesPCV2", "TREATMENT", 595, 610], ["the multi-factorial disease PMWS", "PROBLEM", 645, 677], ["antiinflammatory", "OBSERVATION_MODIFIER", 18, 34], ["PRRSV", "OBSERVATION", 102, 107], ["viral", "OBSERVATION_MODIFIER", 253, 258], ["pathogens", "OBSERVATION", 259, 268], ["porcine circovirus", "OBSERVATION", 274, 292], ["bacterial pathogens", "OBSERVATION", 315, 334], ["multi-factorial", "OBSERVATION_MODIFIER", 649, 664], ["disease", "OBSERVATION", 665, 672]]], ["Symptoms include wasting, dyspnoea and growth retardation and affect mainly pigs between 6 and 18 weeks of age (Segales et al., 2005) .", [["wasting", "DISEASE", 17, 24], ["dyspnoea", "DISEASE", 26, 34], ["growth retardation", "DISEASE", 39, 57], ["pigs", "ORGANISM", 76, 80], ["pigs", "SPECIES", 76, 80], ["Symptoms", "PROBLEM", 0, 8], ["wasting", "PROBLEM", 17, 24], ["dyspnoea", "PROBLEM", 26, 34], ["growth retardation", "PROBLEM", 39, 57], ["wasting", "OBSERVATION", 17, 24], ["dyspnoea", "OBSERVATION", 26, 34], ["growth", "OBSERVATION_MODIFIER", 39, 45], ["retardation", "OBSERVATION", 46, 57]]], ["Transcriptional analysis of the response of PAMs on PCV2 infection via microarray and quantitative PCR revealed that PCV2 is able to prevent apoptosis in PAMs and to induce the expression of pro-inflammatory cytokines mainly through TLR1 and TLR9 pathways.", [["PCV2 infection", "DISEASE", 52, 66], ["PCV2", "ORGANISM", 52, 56], ["PCV2", "ORGANISM", 117, 121], ["PAMs", "CELL", 154, 158], ["TLR1", "GENE_OR_GENE_PRODUCT", 233, 237], ["TLR9", "GENE_OR_GENE_PRODUCT", 242, 246], ["pro-inflammatory cytokines", "PROTEIN", 191, 217], ["TLR1", "PROTEIN", 233, 237], ["TLR9", "PROTEIN", 242, 246], ["PCV2", "SPECIES", 52, 56], ["PCV2", "SPECIES", 117, 121], ["Transcriptional analysis", "TEST", 0, 24], ["PAMs", "PROBLEM", 44, 48], ["PCV2 infection", "PROBLEM", 52, 66], ["microarray", "TEST", 71, 81], ["quantitative PCR", "TEST", 86, 102], ["PCV2", "PROBLEM", 117, 121], ["apoptosis in PAMs", "PROBLEM", 141, 158], ["pro-inflammatory cytokines", "PROBLEM", 191, 217], ["PCV2 infection", "OBSERVATION", 52, 66], ["PCV2", "OBSERVATION", 117, 121], ["pro-inflammatory cytokines", "OBSERVATION", 191, 217]]], ["Elevated secretion of proinflammatory cytokines TNF-a, IL-6, and IL-8 could be further validated by ELISA (Li et al., 2013b) .", [["TNF-a", "GENE_OR_GENE_PRODUCT", 48, 53], ["IL-6", "GENE_OR_GENE_PRODUCT", 55, 59], ["IL-8", "GENE_OR_GENE_PRODUCT", 65, 69], ["proinflammatory cytokines", "PROTEIN", 22, 47], ["TNF", "PROTEIN", 48, 51], ["IL", "PROTEIN", 65, 67], ["Elevated secretion", "PROBLEM", 0, 18], ["proinflammatory cytokines", "TEST", 22, 47], ["TNF", "TEST", 48, 51], ["IL", "TEST", 55, 57], ["secretion", "OBSERVATION_MODIFIER", 9, 18], ["proinflammatory cytokines", "OBSERVATION", 22, 47]]], ["ASF is a haemorrhagic disease and ASFV replicates in macrophages causes their swelling and rounding, increased phagocytic and secretory activity as well as stronger proliferation (Gomez-Villamandos et al., 2013) .", [["macrophages", "ANATOMY", 53, 64], ["haemorrhagic disease", "DISEASE", 9, 29], ["swelling", "DISEASE", 78, 86], ["ASFV", "ORGANISM", 34, 38], ["macrophages", "CELL", 53, 64], ["macrophages", "CELL_TYPE", 53, 64], ["ASFV", "SPECIES", 34, 38], ["ASF", "PROBLEM", 0, 3], ["a haemorrhagic disease", "PROBLEM", 7, 29], ["ASFV", "PROBLEM", 34, 38], ["their swelling", "PROBLEM", 72, 86], ["increased phagocytic and secretory activity", "PROBLEM", 101, 144], ["haemorrhagic", "OBSERVATION_MODIFIER", 9, 21], ["disease", "OBSERVATION", 22, 29], ["ASFV", "OBSERVATION_MODIFIER", 34, 38], ["macrophages", "OBSERVATION_MODIFIER", 53, 64], ["swelling", "OBSERVATION", 78, 86], ["increased", "OBSERVATION_MODIFIER", 101, 110], ["phagocytic", "OBSERVATION_MODIFIER", 111, 121], ["secretory activity", "OBSERVATION", 126, 144]]], ["These pro-inflammatory changes in the macrophage phenotype and function play a key role in ASF pathogenesis which is characterized by pulmonary oedema, haemorrhage, and lymphoid depletion.", [["macrophage", "ANATOMY", 38, 48], ["pulmonary", "ANATOMY", 134, 143], ["lymphoid", "ANATOMY", 169, 177], ["pulmonary oedema", "DISEASE", 134, 150], ["haemorrhage", "DISEASE", 152, 163], ["macrophage", "CELL", 38, 48], ["ASF", "CANCER", 91, 94], ["pulmonary", "ORGAN", 134, 143], ["lymphoid", "CELL", 169, 177], ["These pro-inflammatory changes", "PROBLEM", 0, 30], ["ASF pathogenesis", "PROBLEM", 91, 107], ["pulmonary oedema", "PROBLEM", 134, 150], ["haemorrhage", "PROBLEM", 152, 163], ["lymphoid depletion", "PROBLEM", 169, 187], ["pro-inflammatory", "OBSERVATION", 6, 22], ["macrophage phenotype", "OBSERVATION", 38, 58], ["pulmonary", "ANATOMY", 134, 143], ["oedema", "OBSERVATION", 144, 150], ["haemorrhage", "OBSERVATION", 152, 163], ["lymphoid depletion", "OBSERVATION", 169, 187]]], ["Furthermore, macrophages are involved in ASFV replication by hemadsorption and cell necrosis at the end of the replication cycle (Gomez-Villamandos et al., 2013) .", [["macrophages", "ANATOMY", 13, 24], ["cell", "ANATOMY", 79, 83], ["necrosis", "DISEASE", 84, 92], ["macrophages", "CELL", 13, 24], ["ASFV", "ORGANISM", 41, 45], ["cell", "CELL", 79, 83], ["macrophages", "CELL_TYPE", 13, 24], ["ASFV", "SPECIES", 41, 45], ["macrophages", "PROBLEM", 13, 24], ["ASFV replication", "TREATMENT", 41, 57], ["hemadsorption", "PROBLEM", 61, 74], ["cell necrosis", "PROBLEM", 79, 92], ["the replication cycle", "TREATMENT", 107, 128], ["macrophages", "OBSERVATION", 13, 24], ["ASFV replication", "OBSERVATION", 41, 57], ["hemadsorption", "OBSERVATION_MODIFIER", 61, 74], ["cell necrosis", "OBSERVATION", 79, 92]]], ["A. pleuropneumoniae belongs to the most economically significant bacterial pathogens in pig production world-wide and causes lung lesions, pneumonia and a strongly impaired animal welfare.", [["lung lesions", "ANATOMY", 125, 137], ["lung lesions", "DISEASE", 125, 137], ["pneumonia", "DISEASE", 139, 148], ["impaired animal welfare", "DISEASE", 164, 187], ["A. pleuropneumoniae", "ORGANISM", 0, 19], ["pig", "ORGANISM", 88, 91], ["lung lesions", "PATHOLOGICAL_FORMATION", 125, 137], ["A. pleuropneumoniae", "SPECIES", 0, 19], ["pig", "SPECIES", 88, 91], ["A. pleuropneumoniae", "SPECIES", 0, 19], ["pig", "SPECIES", 88, 91], ["A. pleuropneumoniae", "PROBLEM", 0, 19], ["significant bacterial pathogens", "PROBLEM", 53, 84], ["lung lesions", "PROBLEM", 125, 137], ["pneumonia", "PROBLEM", 139, 148], ["pleuropneumoniae", "OBSERVATION", 3, 19], ["most economically", "OBSERVATION_MODIFIER", 35, 52], ["significant", "OBSERVATION_MODIFIER", 53, 64], ["bacterial", "OBSERVATION_MODIFIER", 65, 74], ["pathogens", "OBSERVATION", 75, 84], ["pig production", "OBSERVATION", 88, 102], ["wide", "OBSERVATION_MODIFIER", 109, 113], ["lung", "ANATOMY", 125, 129], ["lesions", "OBSERVATION", 130, 137], ["pneumonia", "OBSERVATION", 139, 148]]], ["Infection of macrophages induces their rapid influx into the lung and the local induction of pro-inflammatory cytokines (Baarsch et al., 2000) .", [["macrophages", "ANATOMY", 13, 24], ["lung", "ANATOMY", 61, 65], ["macrophages", "CELL", 13, 24], ["lung", "ORGAN", 61, 65], ["macrophages", "CELL_TYPE", 13, 24], ["pro-inflammatory cytokines", "PROTEIN", 93, 119], ["Infection of macrophages", "PROBLEM", 0, 24], ["their rapid influx into the lung", "PROBLEM", 33, 65], ["pro-inflammatory cytokines", "PROBLEM", 93, 119], ["macrophages", "OBSERVATION", 13, 24], ["rapid", "OBSERVATION_MODIFIER", 39, 44], ["influx", "OBSERVATION", 45, 51], ["lung", "ANATOMY", 61, 65], ["local", "OBSERVATION_MODIFIER", 74, 79]]], ["Transcriptional profiling indicates that A. pleuropneumoniae can circumvent the host immune factors and survive within macrophages by active evasion of the host defences e.g. by urease activity or cell surface sialylation (Klitgaard et al., 2012) .MacrophagesC. suis infections have a minor impact on swine health and economics of swine production but its role in various reproductive problems are not precisely determined and might be underestimated (Schautteet and Vanrompay, 2011) .", [["macrophages", "ANATOMY", 119, 130], ["cell surface", "ANATOMY", 197, 209], ["suis infections", "DISEASE", 262, 277], ["A. pleuropneumoniae", "ORGANISM", 41, 60], ["macrophages", "CELL", 119, 130], ["urease", "GENE_OR_GENE_PRODUCT", 178, 184], ["cell", "CELL", 197, 201], ["suis", "ORGANISM", 262, 266], ["macrophages", "CELL_TYPE", 119, 130], ["urease", "PROTEIN", 178, 184], ["A. pleuropneumoniae", "SPECIES", 41, 60], ["suis", "SPECIES", 262, 266], ["swine", "SPECIES", 301, 306], ["swine", "SPECIES", 331, 336], ["A. pleuropneumoniae", "SPECIES", 41, 60], ["suis", "SPECIES", 262, 266], ["swine", "SPECIES", 301, 306], ["swine", "SPECIES", 331, 336], ["Transcriptional profiling", "TEST", 0, 25], ["A. pleuropneumoniae", "PROBLEM", 41, 60], ["urease activity", "TEST", 178, 193], ["cell surface sialylation", "TREATMENT", 197, 221], ["MacrophagesC", "PROBLEM", 248, 260], ["suis infections", "PROBLEM", 262, 277], ["swine production", "PROBLEM", 331, 347], ["various reproductive problems", "PROBLEM", 364, 393], ["minor", "OBSERVATION_MODIFIER", 285, 290], ["impact", "OBSERVATION_MODIFIER", 291, 297]]], ["Moreover, due to the earlier mentioned high homology with humans including similar immune response pathways in macrophages and the susceptibility also for the human pathogen Chlamydia trachomatis, the pig is a suitable large animal model for human chlamydial infections.", [["macrophages", "ANATOMY", 111, 122], ["Chlamydia trachomatis", "DISEASE", 174, 195], ["chlamydial infections", "DISEASE", 248, 269], ["humans", "ORGANISM", 58, 64], ["macrophages", "CELL", 111, 122], ["human", "ORGANISM", 159, 164], ["pathogen", "ORGANISM", 165, 173], ["Chlamydia trachomatis", "ORGANISM", 174, 195], ["pig", "ORGANISM", 201, 204], ["human", "ORGANISM", 242, 247], ["macrophages", "CELL_TYPE", 111, 122], ["humans", "SPECIES", 58, 64], ["human", "SPECIES", 159, 164], ["Chlamydia trachomatis", "SPECIES", 174, 195], ["pig", "SPECIES", 201, 204], ["human", "SPECIES", 242, 247], ["humans", "SPECIES", 58, 64], ["human", "SPECIES", 159, 164], ["Chlamydia trachomatis", "SPECIES", 174, 195], ["pig", "SPECIES", 201, 204], ["human", "SPECIES", 242, 247], ["macrophages", "PROBLEM", 111, 122], ["the susceptibility", "PROBLEM", 127, 145], ["the human pathogen Chlamydia trachomatis", "PROBLEM", 155, 195], ["a suitable large animal model", "TREATMENT", 208, 237], ["human chlamydial infections", "PROBLEM", 242, 269], ["chlamydial", "OBSERVATION_MODIFIER", 248, 258], ["infections", "OBSERVATION", 259, 269]]], ["Chlamydial infection of epithelial cells and macrophages promotes IL-1 production and plays a central role by the induction of a strong Th1 response leading to the production of IFN-c which is essential for pathogen clearance (Darville and Hiltke, 2010) .MacrophagesIn addition to its role in various infections, porcine macrophages may be involved in xenograft rejection and their blocking ''could be effective approach to downregulate human anti-pig cellular immune responses'' (Plege and Schwinzer, 2010) .MacrophagesIn conclusion, porcine macrophages are an important innate immune cells since they provide one of the first lines of defence against infections, are targets of and significant players against various viral, bacterial, and parasitic pathogens.", [["Chlamydial", "ANATOMY", 0, 10], ["epithelial cells", "ANATOMY", 24, 40], ["macrophages", "ANATOMY", 45, 56], ["Macrophages", "ANATOMY", 255, 266], ["macrophages", "ANATOMY", 321, 332], ["xenograft", "ANATOMY", 352, 361], ["cellular", "ANATOMY", 452, 460], ["Macrophages", "ANATOMY", 509, 520], ["macrophages", "ANATOMY", 543, 554], ["immune cells", "ANATOMY", 579, 591], ["Chlamydial infection", "DISEASE", 0, 20], ["infections", "DISEASE", 301, 311], ["infections", "DISEASE", 653, 663], ["viral, bacterial, and parasitic pathogens", "DISEASE", 720, 761], ["Chlamydial", "ORGANISM", 0, 10], ["epithelial cells", "CELL", 24, 40], ["macrophages", "CELL", 45, 56], ["IL-1", "GENE_OR_GENE_PRODUCT", 66, 70], ["IFN-c", "GENE_OR_GENE_PRODUCT", 178, 183], ["Macrophages", "CELL", 255, 266], ["porcine", "ORGANISM", 313, 320], ["macrophages", "CELL", 321, 332], ["xenograft", "CANCER", 352, 361], ["human", "ORGANISM", 437, 442], ["anti-pig cellular", "CELL", 443, 460], ["Macrophages", "CELL", 509, 520], ["porcine", "ORGANISM", 535, 542], ["macrophages", "CELL", 543, 554], ["innate immune cells", "CELL", 572, 591], ["epithelial cells", "CELL_TYPE", 24, 40], ["macrophages", "CELL_TYPE", 45, 56], ["IL", "PROTEIN", 66, 68], ["IFN", "PROTEIN", 178, 181], ["Macrophages", "CELL_TYPE", 255, 266], ["porcine macrophages", "CELL_TYPE", 313, 332], ["Macrophages", "CELL_TYPE", 509, 520], ["porcine macrophages", "CELL_TYPE", 535, 554], ["innate immune cells", "CELL_TYPE", 572, 591], ["human", "SPECIES", 437, 442], ["porcine", "SPECIES", 535, 542], ["human", "SPECIES", 437, 442], ["porcine", "SPECIES", 535, 542], ["Chlamydial infection of epithelial cells", "PROBLEM", 0, 40], ["macrophages", "PROBLEM", 45, 56], ["Macrophages", "PROBLEM", 255, 266], ["various infections", "PROBLEM", 293, 311], ["porcine macrophages", "TREATMENT", 313, 332], ["xenograft rejection", "PROBLEM", 352, 371], ["porcine macrophages", "PROBLEM", 535, 554], ["infections", "PROBLEM", 653, 663], ["various viral, bacterial, and parasitic pathogens", "PROBLEM", 712, 761], ["infection", "OBSERVATION", 11, 20], ["epithelial cells", "OBSERVATION", 24, 40], ["macrophages", "OBSERVATION_MODIFIER", 45, 56], ["various", "OBSERVATION_MODIFIER", 293, 300], ["infections", "OBSERVATION", 301, 311], ["xenograft rejection", "OBSERVATION", 352, 371], ["porcine macrophages", "OBSERVATION", 535, 554], ["immune cells", "OBSERVATION", 579, 591], ["infections", "OBSERVATION", 653, 663], ["significant", "OBSERVATION_MODIFIER", 684, 695], ["bacterial", "OBSERVATION_MODIFIER", 727, 736], ["parasitic pathogens", "OBSERVATION", 742, 761]]], ["As well, they may have an important impact on human health as a model cell subset as well as in xenograft transplantation.Dendritic cellsDendritic cells play a major role in sensing infections and danger through PAMPs and damage-associated molecular pattern molecules (DAMPs), in antigen transport from the site of entry at the skin and the mucosa to the lymphoid tissue, as well as in the regulation of tolerance versus immunity.", [["cell", "ANATOMY", 70, 74], ["xenograft", "ANATOMY", 96, 105], ["Dendritic cellsDendritic cells", "ANATOMY", 122, 152], ["skin", "ANATOMY", 328, 332], ["mucosa", "ANATOMY", 341, 347], ["lymphoid tissue", "ANATOMY", 355, 370], ["infections", "DISEASE", 182, 192], ["human", "ORGANISM", 46, 51], ["cell", "CELL", 70, 74], ["xenograft", "CANCER", 96, 105], ["Dendritic cellsDendritic cells", "CELL", 122, 152], ["damage-associated molecular pattern molecules", "GENE_OR_GENE_PRODUCT", 222, 267], ["DAMPs", "GENE_OR_GENE_PRODUCT", 269, 274], ["antigen", "GENE_OR_GENE_PRODUCT", 280, 287], ["skin", "ORGAN", 328, 332], ["mucosa", "MULTI-TISSUE_STRUCTURE", 341, 347], ["lymphoid tissue", "TISSUE", 355, 370], ["model cell subset", "CELL_LINE", 64, 81], ["Dendritic cellsDendritic cells", "CELL_TYPE", 122, 152], ["PAMPs", "PROTEIN", 212, 217], ["damage-associated molecular pattern molecules", "PROTEIN", 222, 267], ["DAMPs", "PROTEIN", 269, 274], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 46, 51], ["a model cell subset", "TREATMENT", 62, 81], ["xenograft transplantation", "TREATMENT", 96, 121], ["Dendritic cellsDendritic cells", "PROBLEM", 122, 152], ["sensing infections", "PROBLEM", 174, 192], ["damage", "PROBLEM", 222, 228], ["xenograft transplantation", "OBSERVATION", 96, 121], ["cellsDendritic cells", "OBSERVATION", 132, 152], ["infections", "OBSERVATION", 182, 192], ["skin", "ANATOMY", 328, 332], ["mucosa", "ANATOMY", 341, 347], ["lymphoid tissue", "OBSERVATION", 355, 370]]], ["Consequently, DCs plays a major role in orchestrating the immune response.", [["DCs", "ANATOMY", 14, 17], ["DCs", "CELL", 14, 17], ["DCs", "CELL_TYPE", 14, 17]]], ["In mouse and man, DCs are recognized to represent a heterogeneous family of cells with specialized functions.", [["DCs", "ANATOMY", 18, 21], ["cells", "ANATOMY", 76, 81], ["mouse", "ORGANISM", 3, 8], ["man", "ORGANISM", 13, 16], ["DCs", "CELL", 18, 21], ["cells", "CELL", 76, 81], ["DCs", "CELL_TYPE", 18, 21], ["mouse", "SPECIES", 3, 8], ["man", "SPECIES", 13, 16], ["mouse", "SPECIES", 3, 8]]], ["DCs can be subdivided into plasmacytoid DCs (pDCs) which have a main function in sensing nucleic acid, and classical DCs (cDCs) which are specialized in antigen presentation. cDCs consist of two distinct subsets, one more specialized in cross-presentation and stimulation of cytotoxic T lymphocyte responses through MHC class I, the other more specialized in stimulating Th responses through MHC class II.", [["DCs", "ANATOMY", 0, 3], ["plasmacytoid DCs", "ANATOMY", 27, 43], ["pDCs", "ANATOMY", 45, 49], ["DCs", "ANATOMY", 117, 120], ["cDCs", "ANATOMY", 122, 126], ["cDCs", "ANATOMY", 175, 179], ["T lymphocyte", "ANATOMY", 285, 297], ["DCs", "CELL", 0, 3], ["plasmacytoid DCs", "CELL", 27, 43], ["pDCs", "CELL", 45, 49], ["DCs", "CELL", 117, 120], ["cDCs", "CELL", 122, 126], ["cDCs", "CELL", 175, 179], ["T lymphocyte", "CELL", 285, 297], ["MHC class I", "GENE_OR_GENE_PRODUCT", 316, 327], ["MHC class II", "GENE_OR_GENE_PRODUCT", 392, 404], ["DCs", "CELL_TYPE", 0, 3], ["plasmacytoid DCs", "CELL_TYPE", 27, 43], ["pDCs", "CELL_TYPE", 45, 49], ["classical DCs", "CELL_TYPE", 107, 120], ["cDCs", "CELL_TYPE", 122, 126], ["cDCs", "CELL_TYPE", 175, 179], ["cytotoxic T lymphocyte", "CELL_TYPE", 275, 297], ["MHC class I", "PROTEIN", 316, 327], ["MHC class II", "PROTEIN", 392, 404], ["sensing nucleic acid", "TEST", 81, 101], ["cDCs", "PROBLEM", 175, 179], ["two", "OBSERVATION_MODIFIER", 191, 194], ["distinct", "OBSERVATION_MODIFIER", 195, 203], ["subsets", "OBSERVATION", 204, 211]]], ["All DC subsets have a different phenotype in mouse and man as well as in other species studied but they have not yet been completely characterized phenotypically and functionally for each species.", [["DC", "ANATOMY", 4, 6], ["mouse", "ORGANISM", 45, 50], ["man", "ORGANISM", 55, 58], ["DC subsets", "CELL_TYPE", 4, 14], ["mouse", "SPECIES", 45, 50], ["man", "SPECIES", 55, 58], ["mouse", "SPECIES", 45, 50], ["a different phenotype in mouse", "PROBLEM", 20, 50]]], ["In addition, the phenotype of DC subsets is known to be organ-specific further complicating the issue of DC identification.", [["DC", "ANATOMY", 30, 32], ["organ", "ANATOMY", 56, 61], ["DC", "ANATOMY", 105, 107], ["DC", "CELL", 30, 32], ["organ", "ORGAN", 56, 61], ["DC", "CELL", 105, 107], ["DC subsets", "CELL_TYPE", 30, 40], ["DC", "CELL_TYPE", 105, 107]]], ["For instance, monocyte-derived DCs are ontogenetically and functionally distinct from the above bona-fida DCs, as their name indicates.", [["monocyte", "ANATOMY", 14, 22], ["DCs", "ANATOMY", 31, 34], ["DCs", "ANATOMY", 106, 109], ["monocyte", "CELL", 14, 22], ["DCs", "CELL", 31, 34], ["fida DCs", "CELL", 101, 109], ["DCs", "CELL_TYPE", 31, 34], ["bona-fida DCs", "CELL_TYPE", 96, 109], ["monocyte", "TEST", 14, 22]]], ["Only with the help of studies on the ontogeny of the DC family and transcriptomics, which has made significant progress through studies in the murine system, it is now possible to characterize the DC subtypes Miller et al., 2012) .", [["DC", "ANATOMY", 53, 55], ["DC", "ANATOMY", 197, 199], ["murine", "ORGANISM", 143, 149], ["DC family", "PROTEIN", 53, 62], ["DC", "CELL_TYPE", 197, 199], ["murine", "SPECIES", 143, 149]]], ["Sets of genes and transcription factors specifically expressed in DCs, subsets of DCs, and other haemotopoietic lineages such as monocytes and macrophages have been identified.", [["DCs", "ANATOMY", 66, 69], ["DCs", "ANATOMY", 82, 85], ["haemotopoietic lineages", "ANATOMY", 97, 120], ["monocytes", "ANATOMY", 129, 138], ["macrophages", "ANATOMY", 143, 154], ["DCs", "CELL", 66, 69], ["DCs", "CELL", 82, 85], ["haemotopoietic lineages", "CELL", 97, 120], ["monocytes", "CELL", 129, 138], ["macrophages", "CELL", 143, 154], ["transcription factors", "PROTEIN", 18, 39], ["DCs", "CELL_TYPE", 66, 69], ["DCs", "CELL_TYPE", 82, 85], ["haemotopoietic lineages", "CELL_TYPE", 97, 120], ["monocytes", "CELL_TYPE", 129, 138], ["macrophages", "CELL_TYPE", 143, 154], ["DCs", "TREATMENT", 82, 85], ["other haemotopoietic lineages", "PROBLEM", 91, 120], ["macrophages", "PROBLEM", 143, 154]]], ["Selected transcription factors tightly regulate the development of particular DC subsets in a specific manner Reizis, 2012; Shortman et al., 2013) .Dendritic cellsConsidering that porcine DCs have been recently reviewed in detail (Summerfield and McCullough, 2009b) we will only give an overview of the topic and focus on important pitfalls in the identification and classification of DCs in the pig for the present review.", [["DC", "ANATOMY", 78, 80], ["Dendritic cells", "ANATOMY", 148, 163], ["DCs", "ANATOMY", 188, 191], ["DCs", "ANATOMY", 385, 388], ["Dendritic cells", "CELL", 148, 163], ["porcine", "ORGANISM", 180, 187], ["DCs", "CELL", 188, 191], ["DCs", "CELL", 385, 388], ["pig", "ORGANISM", 396, 399], ["transcription factors", "PROTEIN", 9, 30], ["DC subsets", "CELL_TYPE", 78, 88], ["Dendritic cells", "CELL_TYPE", 148, 163], ["porcine DCs", "CELL_TYPE", 180, 191], ["DCs", "CELL_TYPE", 385, 388], ["porcine", "SPECIES", 180, 187], ["pig", "SPECIES", 396, 399], ["porcine", "SPECIES", 180, 187], ["pig", "SPECIES", 396, 399], ["Selected transcription factors", "TREATMENT", 0, 30], ["Dendritic cells", "PROBLEM", 148, 163], ["cells", "OBSERVATION", 158, 163]]], ["Porcine blood-derived pDCs have been described as CD4 + CD172a low CD123 + CD135 + cells, which express low levels of CD8, CD16, CD45RA, and MHC class II but are negative for CD14.", [["blood", "ANATOMY", 8, 13], ["pDCs", "ANATOMY", 22, 26], ["CD4 + CD172a low CD123 + CD135 + cells", "ANATOMY", 50, 88], ["Porcine", "ORGANISM", 0, 7], ["blood", "ORGANISM_SUBSTANCE", 8, 13], ["pDCs", "CELL", 22, 26], ["CD4", "GENE_OR_GENE_PRODUCT", 50, 53], ["CD123", "GENE_OR_GENE_PRODUCT", 67, 72], ["CD8", "GENE_OR_GENE_PRODUCT", 118, 121], ["CD16", "GENE_OR_GENE_PRODUCT", 123, 127], ["CD45RA", "GENE_OR_GENE_PRODUCT", 129, 135], ["MHC class II", "GENE_OR_GENE_PRODUCT", 141, 153], ["CD14", "GENE_OR_GENE_PRODUCT", 175, 179], ["pDCs", "CELL_TYPE", 22, 26], ["CD4", "PROTEIN", 50, 53], ["CD123", "PROTEIN", 67, 72], ["CD135 + cells", "CELL_TYPE", 75, 88], ["CD8", "PROTEIN", 118, 121], ["CD16", "PROTEIN", 123, 127], ["CD45RA", "PROTEIN", 129, 135], ["MHC class II", "PROTEIN", 141, 153], ["CD14", "PROTEIN", 175, 179], ["Porcine", "SPECIES", 0, 7], ["Porcine blood", "TEST", 0, 13], ["CD4", "TEST", 50, 53], ["CD135 + cells", "PROBLEM", 75, 88], ["CD8", "TEST", 118, 121], ["CD16", "TEST", 123, 127], ["CD45RA", "TEST", 129, 135], ["CD14", "PROBLEM", 175, 179]]], ["Porcine cDCs have a similar phenotype but lack CD4, CD123 and have high levels of MHC class II.", [["cDCs", "ANATOMY", 8, 12], ["Porcine", "ORGANISM", 0, 7], ["cDCs", "CELL", 8, 12], ["CD4", "GENE_OR_GENE_PRODUCT", 47, 50], ["CD123", "GENE_OR_GENE_PRODUCT", 52, 57], ["MHC class II", "GENE_OR_GENE_PRODUCT", 82, 94], ["Porcine cDCs", "CELL_TYPE", 0, 12], ["CD4", "PROTEIN", 47, 50], ["CD123", "PROTEIN", 52, 57], ["MHC class II", "PROTEIN", 82, 94], ["Porcine", "SPECIES", 0, 7], ["Porcine cDCs", "PROBLEM", 0, 12], ["CD123", "TEST", 52, 57]]], ["Thus, in the blood DC can be differentiated from monocytes by expression of CD135 (Flt3) and their lack of CD14.", [["blood DC", "ANATOMY", 13, 21], ["monocytes", "ANATOMY", 49, 58], ["blood", "ORGANISM_SUBSTANCE", 13, 18], ["DC", "CELL", 19, 21], ["monocytes", "CELL", 49, 58], ["CD135", "GENE_OR_GENE_PRODUCT", 76, 81], ["Flt3", "GENE_OR_GENE_PRODUCT", 83, 87], ["CD14", "GENE_OR_GENE_PRODUCT", 107, 111], ["blood DC", "CELL_TYPE", 13, 21], ["monocytes", "CELL_TYPE", 49, 58], ["CD135", "PROTEIN", 76, 81], ["Flt3", "PROTEIN", 83, 87], ["CD14", "PROTEIN", 107, 111], ["CD135", "TEST", 76, 81], ["CD14", "PROBLEM", 107, 111]]], ["The phenotypic and functional differentiation of the two subsets of cDCs is not yet available in the pig, although based on several markers such as CD1, CD16 and CD172a at least two subsets of cDCs can be defined (Guzylack-Piriou et al., 2010; Summerfield et al., 2003; Summerfield and McCullough, 2009b) .", [["cDCs", "ANATOMY", 68, 72], ["cDCs", "ANATOMY", 193, 197], ["cDCs", "CELL", 68, 72], ["pig", "ORGANISM", 101, 104], ["CD1", "GENE_OR_GENE_PRODUCT", 148, 151], ["CD16", "GENE_OR_GENE_PRODUCT", 153, 157], ["CD172a", "GENE_OR_GENE_PRODUCT", 162, 168], ["cDCs", "CELL", 193, 197], ["cDCs", "CELL_TYPE", 68, 72], ["CD1", "PROTEIN", 148, 151], ["CD16", "PROTEIN", 153, 157], ["CD172a", "PROTEIN", 162, 168], ["cDCs", "CELL_TYPE", 193, 197], ["pig", "SPECIES", 101, 104], ["pig", "SPECIES", 101, 104], ["cDCs", "TEST", 68, 72], ["CD16", "TEST", 153, 157]]], ["It is evident from several other studies that a CD172a \u00c0 subset of DCs probably exists in the blood, the skin, lymph nodes and the pseudo-afferent lymph of skin, and intestinal duct Bimczok et al., 2005; Guzylack-Piriou et al., 2010; Marquet et al., 2011) .Dendritic cellsDespite this knowledge, a major problem in the porcine immune system remains the clear discernment of DCs from other cells such as macrophages and even B cells.", [["DCs", "ANATOMY", 67, 70], ["blood", "ANATOMY", 94, 99], ["skin", "ANATOMY", 105, 109], ["lymph nodes", "ANATOMY", 111, 122], ["afferent lymph", "ANATOMY", 138, 152], ["skin", "ANATOMY", 156, 160], ["intestinal duct", "ANATOMY", 166, 181], ["Dendritic cells", "ANATOMY", 257, 272], ["immune system", "ANATOMY", 327, 340], ["DCs", "ANATOMY", 374, 377], ["cells", "ANATOMY", 389, 394], ["macrophages", "ANATOMY", 403, 414], ["B cells", "ANATOMY", 424, 431], ["CD172a", "GENE_OR_GENE_PRODUCT", 48, 54], ["DCs", "CELL", 67, 70], ["blood", "ORGANISM_SUBSTANCE", 94, 99], ["skin", "ORGAN", 105, 109], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 111, 122], ["afferent lymph", "MULTI-TISSUE_STRUCTURE", 138, 152], ["skin", "ORGAN", 156, 160], ["intestinal duct", "MULTI-TISSUE_STRUCTURE", 166, 181], ["Dendritic cells", "CELL", 257, 272], ["porcine", "ORGANISM", 319, 326], ["DCs", "CELL", 374, 377], ["cells", "CELL", 389, 394], ["macrophages", "CELL", 403, 414], ["B cells", "CELL", 424, 431], ["CD172a", "PROTEIN", 48, 54], ["DCs", "CELL_TYPE", 67, 70], ["Dendritic cells", "CELL_TYPE", 257, 272], ["DCs", "CELL_TYPE", 374, 377], ["macrophages", "CELL_TYPE", 403, 414], ["B cells", "CELL_TYPE", 424, 431], ["several other studies", "TEST", 19, 40], ["Dendritic cells", "PROBLEM", 257, 272], ["a major problem in the porcine immune system", "PROBLEM", 296, 340], ["DCs", "PROBLEM", 374, 377], ["other cells", "PROBLEM", 383, 394], ["macrophages", "PROBLEM", 403, 414], ["blood", "ANATOMY", 94, 99], ["skin", "ANATOMY", 105, 109], ["lymph nodes", "OBSERVATION", 111, 122], ["afferent", "ANATOMY_MODIFIER", 138, 146], ["lymph", "ANATOMY", 147, 152], ["skin", "ANATOMY", 156, 160], ["intestinal duct", "ANATOMY", 166, 181], ["cells", "OBSERVATION", 267, 272]]], ["While DC identification is clear in the blood, we have found that in lymphoid tissues the phenotypic definitions are only partially valid and that the function and phenotype of DCs, macrophages and B cells do overlap.", [["DC", "ANATOMY", 6, 8], ["blood", "ANATOMY", 40, 45], ["lymphoid tissues", "ANATOMY", 69, 85], ["DCs", "ANATOMY", 177, 180], ["macrophages", "ANATOMY", 182, 193], ["B cells", "ANATOMY", 198, 205], ["DC", "CELL", 6, 8], ["blood", "ORGANISM_SUBSTANCE", 40, 45], ["lymphoid tissues", "TISSUE", 69, 85], ["DCs", "CELL", 177, 180], ["macrophages", "CELL", 182, 193], ["B cells", "CELL", 198, 205], ["DC", "CELL_TYPE", 6, 8], ["DCs", "CELL_TYPE", 177, 180], ["macrophages", "CELL_TYPE", 182, 193], ["B cells", "CELL_TYPE", 198, 205], ["DCs", "PROBLEM", 177, 180], ["B cells", "PROBLEM", 198, 205], ["clear", "OBSERVATION", 27, 32], ["lymphoid tissues", "OBSERVATION", 69, 85], ["phenotypic definitions", "OBSERVATION", 90, 112]]], ["In fact, most porcine 'DC' markers are also expressed on many other leukocyte populations.", [["DC", "ANATOMY", 23, 25], ["leukocyte", "ANATOMY", 68, 77], ["porcine", "ORGANISM", 14, 21], ["DC", "CELL", 23, 25], ["leukocyte populations", "CELL", 68, 89], ["DC", "CELL_TYPE", 23, 25], ["leukocyte populations", "CELL_TYPE", 68, 89], ["most porcine", "OBSERVATION_MODIFIER", 9, 21]]], ["For instance, CD1 is expressed at high levels on thymocytes, B cells (Pescovitz et al., 1990) , and can also be found on monocyte-derived macrophages (unpublished data).", [["thymocytes", "ANATOMY", 49, 59], ["B cells", "ANATOMY", 61, 68], ["monocyte", "ANATOMY", 121, 129], ["macrophages", "ANATOMY", 138, 149], ["CD1", "GENE_OR_GENE_PRODUCT", 14, 17], ["thymocytes", "CELL", 49, 59], ["B cells", "CELL", 61, 68], ["monocyte", "CELL", 121, 129], ["macrophages", "CELL", 138, 149], ["CD1", "PROTEIN", 14, 17], ["thymocytes", "CELL_TYPE", 49, 59], ["B cells", "CELL_TYPE", 61, 68], ["monocyte-derived macrophages", "CELL_TYPE", 121, 149], ["monocyte", "TEST", 121, 129], ["thymocytes", "ANATOMY", 49, 59]]], ["CD11R1 (corresponding to human CD11b) which has been used to identify subsets of DCs in combination with CD172a in mucosal tissue (Bimczok et al., 2005) , is also found on subsets of monocytes, macrophages, and neutrophils (Dominguez et al., 2001) .", [["DCs", "ANATOMY", 81, 84], ["mucosal tissue", "ANATOMY", 115, 129], ["monocytes", "ANATOMY", 183, 192], ["macrophages", "ANATOMY", 194, 205], ["neutrophils", "ANATOMY", 211, 222], ["CD11R1", "GENE_OR_GENE_PRODUCT", 0, 6], ["human", "ORGANISM", 25, 30], ["CD11b", "GENE_OR_GENE_PRODUCT", 31, 36], ["DCs", "CELL", 81, 84], ["CD172a", "GENE_OR_GENE_PRODUCT", 105, 111], ["mucosal tissue", "TISSUE", 115, 129], ["monocytes", "CELL", 183, 192], ["macrophages", "CELL", 194, 205], ["neutrophils", "CELL", 211, 222], ["CD11R1", "PROTEIN", 0, 6], ["human CD11b", "PROTEIN", 25, 36], ["DCs", "CELL_TYPE", 81, 84], ["CD172a", "PROTEIN", 105, 111], ["monocytes", "CELL_TYPE", 183, 192], ["macrophages", "CELL_TYPE", 194, 205], ["neutrophils", "CELL_TYPE", 211, 222], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 25, 30], ["DCs", "PROBLEM", 81, 84], ["monocytes", "TEST", 183, 192], ["macrophages", "TEST", 194, 205], ["neutrophils", "TEST", 211, 222], ["mucosal tissue", "ANATOMY", 115, 129], ["monocytes", "ANATOMY", 183, 192], ["macrophages", "ANATOMY", 194, 205], ["neutrophils", "ANATOMY", 211, 222]]], ["High levels of CD4 are a hallmark of pDCs in the pig.", [["pDCs", "ANATOMY", 37, 41], ["CD4", "GENE_OR_GENE_PRODUCT", 15, 18], ["pDCs", "CELL", 37, 41], ["pig", "ORGANISM", 49, 52], ["CD4", "PROTEIN", 15, 18], ["pDCs", "CELL_TYPE", 37, 41], ["pig", "SPECIES", 49, 52], ["pig", "SPECIES", 49, 52]]], ["However, in addition to its expression on Th cells, this marker is also expressed on a subset of cells co-expressing CD14 and CD172a representing an unknown lineage, presumably of myeloid origin (Guzylack-Piriou et al., 2010; Summerfield et al., 2003) .", [["Th cells", "ANATOMY", 42, 50], ["cells", "ANATOMY", 97, 102], ["myeloid", "ANATOMY", 180, 187], ["Th cells", "CELL", 42, 50], ["cells", "CELL", 97, 102], ["CD14", "GENE_OR_GENE_PRODUCT", 117, 121], ["CD172a", "GENE_OR_GENE_PRODUCT", 126, 132], ["myeloid", "CELL", 180, 187], ["Th cells", "CELL_TYPE", 42, 50], ["CD14", "PROTEIN", 117, 121], ["CD172a", "PROTEIN", 126, 132], ["its expression on Th cells", "PROBLEM", 24, 50], ["CD14", "TEST", 117, 121], ["unknown lineage", "OBSERVATION", 149, 164], ["presumably of", "UNCERTAINTY", 166, 179], ["myeloid origin", "OBSERVATION", 180, 194]]], ["This phenotype is much more frequent in the lymphoid tissue as compared to the peripheral blood, making the identification of pDCs simply based on CD4 and CD172a expression difficult or impossible in tissue other than blood (Summerfield et al., unpublished data) .", [["lymphoid tissue", "ANATOMY", 44, 59], ["peripheral blood", "ANATOMY", 79, 95], ["pDCs", "ANATOMY", 126, 130], ["tissue", "ANATOMY", 200, 206], ["blood", "ANATOMY", 218, 223], ["lymphoid tissue", "TISSUE", 44, 59], ["peripheral blood", "ORGANISM_SUBSTANCE", 79, 95], ["pDCs", "CELL", 126, 130], ["CD4", "GENE_OR_GENE_PRODUCT", 147, 150], ["CD172a", "GENE_OR_GENE_PRODUCT", 155, 161], ["tissue", "TISSUE", 200, 206], ["blood", "ORGANISM_SUBSTANCE", 218, 223], ["pDCs", "CELL_TYPE", 126, 130], ["CD4", "PROTEIN", 147, 150], ["CD172a", "PROTEIN", 155, 161], ["CD4", "TEST", 147, 150], ["much", "OBSERVATION_MODIFIER", 18, 22], ["more frequent", "OBSERVATION_MODIFIER", 23, 36], ["lymphoid tissue", "OBSERVATION", 44, 59], ["peripheral", "ANATOMY_MODIFIER", 79, 89], ["blood", "ANATOMY", 90, 95]]], ["Furthermore, considering the expression of CD11R1 on myeloid cells, the employment of this marker to identify DCs is currently not appropriate, even if combined with CD172a, which is also widely expressed on myeloid cells.", [["myeloid cells", "ANATOMY", 53, 66], ["DCs", "ANATOMY", 110, 113], ["myeloid cells", "ANATOMY", 208, 221], ["CD11R1", "GENE_OR_GENE_PRODUCT", 43, 49], ["myeloid cells", "CELL", 53, 66], ["DCs", "CELL", 110, 113], ["CD172a", "GENE_OR_GENE_PRODUCT", 166, 172], ["myeloid cells", "CELL", 208, 221], ["CD11R1", "PROTEIN", 43, 49], ["myeloid cells", "CELL_TYPE", 53, 66], ["DCs", "CELL_TYPE", 110, 113], ["CD172a", "PROTEIN", 166, 172], ["myeloid cells", "CELL_TYPE", 208, 221], ["myeloid cells", "TREATMENT", 53, 66], ["myeloid cells", "OBSERVATION", 53, 66], ["myeloid cells", "OBSERVATION", 208, 221]]], ["Also, expression of MHC class II, CD80 and CD86 can be misleading.", [["MHC class II", "GENE_OR_GENE_PRODUCT", 20, 32], ["CD80", "GENE_OR_GENE_PRODUCT", 34, 38], ["CD86", "GENE_OR_GENE_PRODUCT", 43, 47], ["MHC class II", "PROTEIN", 20, 32], ["CD80", "PROTEIN", 34, 38], ["CD86", "PROTEIN", 43, 47]]], ["In the pig, activated macrophages, memory Th cells and cytotoxic T cells (although the levels on T cells are lower) express high levels of MHC class II, CD80, and CD86.", [["macrophages", "ANATOMY", 22, 33], ["memory Th cells", "ANATOMY", 35, 50], ["cytotoxic T cells", "ANATOMY", 55, 72], ["T cells", "ANATOMY", 97, 104], ["pig", "ORGANISM", 7, 10], ["macrophages", "CELL", 22, 33], ["memory Th cells", "CELL", 35, 50], ["cytotoxic T cells", "CELL", 55, 72], ["T cells", "CELL", 97, 104], ["MHC class II", "GENE_OR_GENE_PRODUCT", 139, 151], ["CD80", "GENE_OR_GENE_PRODUCT", 153, 157], ["CD86", "GENE_OR_GENE_PRODUCT", 163, 167], ["activated macrophages", "CELL_TYPE", 12, 33], ["memory Th cells", "CELL_TYPE", 35, 50], ["cytotoxic T cells", "CELL_TYPE", 55, 72], ["T cells", "CELL_TYPE", 97, 104], ["MHC class II", "PROTEIN", 139, 151], ["CD80", "PROTEIN", 153, 157], ["CD86", "PROTEIN", 163, 167], ["pig", "SPECIES", 7, 10], ["pig", "SPECIES", 7, 10], ["memory Th cells", "PROBLEM", 35, 50], ["cytotoxic T cells", "PROBLEM", 55, 72], ["the levels on T cells", "TEST", 83, 104], ["CD80", "TEST", 153, 157], ["CD86", "TEST", 163, 167], ["macrophages", "ANATOMY", 22, 33]]], ["CD14 is typically expressed on cells of the myeloid lineage including monocytederived DCs (albeit the expression can be low).", [["cells", "ANATOMY", 31, 36], ["myeloid lineage", "ANATOMY", 44, 59], ["DCs", "ANATOMY", 86, 89], ["CD14", "GENE_OR_GENE_PRODUCT", 0, 4], ["cells", "CELL", 31, 36], ["myeloid lineage", "CELL", 44, 59], ["monocytederived DCs", "CELL", 70, 89], ["CD14", "PROTEIN", 0, 4], ["myeloid lineage", "CELL_TYPE", 44, 59], ["monocytederived DCs", "CELL_TYPE", 70, 89], ["CD14", "PROBLEM", 0, 4], ["monocytederived DCs", "TREATMENT", 70, 89], ["myeloid lineage", "OBSERVATION", 44, 59]]], ["Although, it is not expressed on blood DCs, its expression on lymphoid tissue and non-lymphoid tissue in the pig needs to be determined.Dendritic cellsIn the skin, at least four subsets of putative DC have been described.", [["blood DCs", "ANATOMY", 33, 42], ["lymphoid tissue", "ANATOMY", 62, 77], ["non-lymphoid tissue", "ANATOMY", 82, 101], ["Dendritic cells", "ANATOMY", 136, 151], ["skin", "ANATOMY", 158, 162], ["DC", "ANATOMY", 198, 200], ["blood DCs", "CELL", 33, 42], ["lymphoid tissue", "TISSUE", 62, 77], ["non-lymphoid tissue", "TISSUE", 82, 101], ["pig", "ORGANISM", 109, 112], ["Dendritic cells", "CELL", 136, 151], ["skin", "ORGAN", 158, 162], ["DC", "CELL", 198, 200], ["blood DCs", "CELL_TYPE", 33, 42], ["Dendritic cells", "CELL_TYPE", 136, 151], ["DC", "CELL_TYPE", 198, 200], ["pig", "SPECIES", 109, 112], ["pig", "SPECIES", 109, 112], ["blood DCs", "TEST", 33, 42], ["lymphoid tissue", "PROBLEM", 62, 77], ["non-lymphoid tissue", "PROBLEM", 82, 101], ["Dendritic cells", "PROBLEM", 136, 151], ["putative DC", "TREATMENT", 189, 200], ["lymphoid tissue", "OBSERVATION", 62, 77], ["non-lymphoid tissue", "OBSERVATION", 82, 101], ["cells", "OBSERVATION", 146, 151], ["skin", "ANATOMY", 158, 162], ["putative DC", "OBSERVATION", 189, 200]]], ["In the epidermis, Langerhans cells have been identified as CD172 + CD1 + CD207 + (Nfon et al., 2008) .", [["epidermis", "ANATOMY", 7, 16], ["Langerhans cells", "ANATOMY", 18, 34], ["CD172 + CD1 + CD207 +", "ANATOMY", 59, 80], ["epidermis", "TISSUE", 7, 16], ["Langerhans cells", "CELL", 18, 34], ["CD172", "GENE_OR_GENE_PRODUCT", 59, 64], ["CD1", "GENE_OR_GENE_PRODUCT", 67, 70], ["Langerhans cells", "CELL_TYPE", 18, 34], ["CD172", "PROTEIN", 59, 64], ["CD1", "PROTEIN", 67, 70], ["CD207", "PROTEIN", 73, 78], ["Langerhans cells", "TEST", 18, 34], ["CD172", "TEST", 59, 64], ["CD1", "TEST", 67, 70], ["CD207", "TEST", 73, 78], ["epidermis", "ANATOMY", 7, 16], ["Langerhans cells", "OBSERVATION", 18, 34]]], ["In the dermis a population of CD172a \u00c0 CD163 \u00c0 CD207 \u00c0 CADM1 + and a CD172a + CD163 \u00c0/low CD207 + CADM1 \u00c0 population was found.", [["dermis", "ANATOMY", 7, 13], ["CD172a \u00c0 CD163 \u00c0 CD207 \u00c0 CADM1 +", "ANATOMY", 30, 62], ["dermis", "TISSUE", 7, 13], ["CD172a", "GENE_OR_GENE_PRODUCT", 30, 36], ["CD163", "GENE_OR_GENE_PRODUCT", 39, 44], ["CD207", "GENE_OR_GENE_PRODUCT", 47, 52], ["CADM1", "GENE_OR_GENE_PRODUCT", 55, 60], ["CD207", "GENE_OR_GENE_PRODUCT", 90, 95], ["CD172a", "PROTEIN", 30, 36], ["CD163", "PROTEIN", 39, 44], ["CD207", "PROTEIN", 47, 52], ["CADM1", "PROTEIN", 55, 60], ["CD207", "PROTEIN", 90, 95], ["CADM1 \u00c0 population", "CELL_LINE", 98, 116], ["CD163", "TEST", 39, 44], ["CADM1", "TEST", 55, 60], ["a CD", "TEST", 67, 71], ["CD", "TEST", 78, 80], ["CADM1 \u00c0 population", "PROBLEM", 98, 116], ["dermis", "ANATOMY", 7, 13]]], ["The observation that these two subsets efficiently migrate in the lymph supports their DC origin.", [["lymph", "ANATOMY", 66, 71], ["DC", "ANATOMY", 87, 89], ["lymph", "ORGAN", 66, 71], ["DC", "CELL_TYPE", 87, 89], ["lymph supports", "OBSERVATION", 66, 80], ["origin", "ANATOMY_MODIFIER", 90, 96]]], ["In addition, a CD172a + CD163 + CD207 \u00c0 CADM1 \u00c0 population which also expressed CD206 and CD209 as well as high levels of CD16 was described .", [["CD172a + CD163 + CD207", "ANATOMY", 15, 37], ["CD206", "GENE_OR_GENE_PRODUCT", 80, 85], ["CD209", "GENE_OR_GENE_PRODUCT", 90, 95], ["CD16", "GENE_OR_GENE_PRODUCT", 122, 126], ["CD207", "PROTEIN", 32, 37], ["CADM1 \u00c0 population", "CELL_LINE", 40, 58], ["CD206", "PROTEIN", 80, 85], ["CD209", "PROTEIN", 90, 95], ["CD16", "PROTEIN", 122, 126], ["a CD", "TEST", 13, 17], ["CD", "TEST", 24, 26], ["CADM1 \u00c0 population", "PROBLEM", 40, 58], ["CD206", "TEST", 80, 85], ["CD209", "TEST", 90, 95], ["high levels of CD16", "PROBLEM", 107, 126], ["CD16", "OBSERVATION", 122, 126]]], ["The latter is denominated as a DC population by the authors, probably of monocytic origin.", [["DC", "ANATOMY", 31, 33], ["monocytic", "ANATOMY", 73, 82], ["monocytic", "CELL", 73, 82], ["DC population", "CELL_TYPE", 31, 44], ["a DC population", "TREATMENT", 29, 44], ["latter", "OBSERVATION_MODIFIER", 4, 10], ["probably of", "UNCERTAINTY", 61, 72], ["monocytic origin", "OBSERVATION", 73, 89]]], ["Whether these cells are DCs or macrophage needs clarification.", [["cells", "ANATOMY", 14, 19], ["DCs", "ANATOMY", 24, 27], ["macrophage", "ANATOMY", 31, 41], ["cells", "CELL", 14, 19], ["DCs", "CELL", 24, 27], ["macrophage", "CELL", 31, 41], ["DCs", "CELL_TYPE", 24, 27], ["macrophage", "CELL_TYPE", 31, 41], ["macrophage", "OBSERVATION_MODIFIER", 31, 41]]], ["Taken together, the characterization of the porcine DC cell system in various lymphoid and non-lymphoid tissues is only partially sufficient to identify these cells phenotypically.", [["DC cell system", "ANATOMY", 52, 66], ["lymphoid", "ANATOMY", 78, 86], ["non-lymphoid tissues", "ANATOMY", 91, 111], ["cells", "ANATOMY", 159, 164], ["porcine", "ORGANISM", 44, 51], ["DC cell", "CELL", 52, 59], ["lymphoid", "CELL", 78, 86], ["non-lymphoid tissues", "TISSUE", 91, 111], ["cells", "CELL", 159, 164], ["cell system", "OBSERVATION", 55, 66], ["various lymphoid", "OBSERVATION", 70, 86], ["non-lymphoid tissues", "OBSERVATION", 91, 111]]], ["Of course with microscopic studies, morphological and spatial aspects are helpful but rarely provide a proof of cell identity such as with Langerhans cells in the epidermis.", [["cell", "ANATOMY", 112, 116], ["Langerhans cells", "ANATOMY", 139, 155], ["epidermis", "ANATOMY", 163, 172], ["cell", "CELL", 112, 116], ["Langerhans cells", "CELL", 139, 155], ["epidermis", "TISSUE", 163, 172], ["Langerhans cells", "CELL_TYPE", 139, 155], ["microscopic studies", "TEST", 15, 34], ["Langerhans cells in the epidermis", "PROBLEM", 139, 172], ["Langerhans cells", "OBSERVATION", 139, 155], ["epidermis", "ANATOMY", 163, 172]]], ["It is therefore necessary to define precisely which combinations of markers permit the clear differentiation from other cell types such as macrophages and how the different DC populations can be discriminated.", [["cell", "ANATOMY", 120, 124], ["macrophages", "ANATOMY", 139, 150], ["DC", "ANATOMY", 173, 175], ["cell", "CELL", 120, 124], ["macrophages", "CELL", 139, 150], ["DC populations", "CELL", 173, 187], ["macrophages", "CELL_TYPE", 139, 150], ["DC populations", "CELL_TYPE", 173, 187], ["macrophages", "PROBLEM", 139, 150], ["the different DC populations", "TREATMENT", 159, 187], ["cell types", "OBSERVATION", 120, 130]]], ["Transcriptomic analysis such as those performed with murine cell by the Immunological Genome Consortium (Miller et al., 2012) should be undertaken and an effort in generating new reagents for the pig is required.NeutrophilsPolymorphonuclear neutrophils (PMNs or neutrophils), the major acute innate specialized phagocyte, act in the first line of defence against various pathogens including bacteria and fungi (for a review see Kumar and Sharma (2010) ).", [["cell", "ANATOMY", 60, 64], ["Neutrophils", "ANATOMY", 212, 223], ["neutrophils", "ANATOMY", 241, 252], ["PMNs", "ANATOMY", 254, 258], ["neutrophils", "ANATOMY", 262, 273], ["phagocyte", "ANATOMY", 311, 320], ["murine", "ORGANISM", 53, 59], ["cell", "CELL", 60, 64], ["pig", "ORGANISM", 196, 199], ["NeutrophilsPolymorphonuclear neutrophils", "CELL", 212, 252], ["PMNs", "CELL", 254, 258], ["neutrophils", "CELL", 262, 273], ["phagocyte", "CELL", 311, 320], ["Neutrophils", "CELL_TYPE", 212, 223], ["Polymorphonuclear neutrophils", "CELL_TYPE", 223, 252], ["PMNs", "CELL_TYPE", 254, 258], ["neutrophils", "CELL_TYPE", 262, 273], ["murine", "SPECIES", 53, 59], ["pig", "SPECIES", 196, 199], ["Transcriptomic analysis", "TEST", 0, 23], ["new reagents", "TREATMENT", 175, 187], ["the pig", "TREATMENT", 192, 199], ["Neutrophils", "TEST", 212, 223], ["Polymorphonuclear neutrophils", "TEST", 223, 252], ["PMNs", "TEST", 254, 258], ["neutrophils", "TEST", 262, 273], ["the major acute innate specialized phagocyte", "PROBLEM", 276, 320], ["various pathogens", "PROBLEM", 363, 380], ["bacteria", "PROBLEM", 391, 399], ["fungi", "PROBLEM", 404, 409], ["Polymorphonuclear neutrophils", "OBSERVATION", 223, 252]]], ["Since their discovery by Elie Metchnikoff in the 1880s (see Kaufmann (2008) ), neutrophils are also considered as potent inflammatory cells potentially causing massive collateral damage of host tissues.", [["neutrophils", "ANATOMY", 79, 90], ["inflammatory cells", "ANATOMY", 121, 139], ["collateral", "ANATOMY", 168, 178], ["tissues", "ANATOMY", 194, 201], ["neutrophils", "CELL", 79, 90], ["inflammatory cells", "CELL", 121, 139], ["tissues", "TISSUE", 194, 201], ["neutrophils", "CELL_TYPE", 79, 90], ["inflammatory cells", "CELL_TYPE", 121, 139], ["neutrophils", "TEST", 79, 90], ["potent inflammatory cells", "PROBLEM", 114, 139], ["massive collateral damage of host tissues", "PROBLEM", 160, 201], ["potent", "OBSERVATION_MODIFIER", 114, 120], ["inflammatory cells", "OBSERVATION", 121, 139], ["massive", "OBSERVATION_MODIFIER", 160, 167], ["collateral damage", "OBSERVATION", 168, 185], ["host tissues", "OBSERVATION", 189, 201]]], ["Neutrophils can kill pathogens intracellularly by phagocytosis and extracellularly through degranulation and neutrophil extracellular traps (NETs) formation (Brinkmann et al., 2004; Kumar and Sharma, 2010) .", [["Neutrophils", "ANATOMY", 0, 11], ["neutrophil extracellular", "ANATOMY", 109, 133], ["NETs", "ANATOMY", 141, 145], ["Neutrophils", "CELL", 0, 11], ["neutrophil", "CELL", 109, 119], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 120, 133], ["Neutrophils", "CELL_TYPE", 0, 11], ["Neutrophils", "TEST", 0, 11], ["phagocytosis", "TEST", 50, 62], ["extracellularly through degranulation", "TEST", 67, 104], ["neutrophil extracellular traps", "TEST", 109, 139]]], ["These structures are able to trap various pathogens and to kill them extracellularly by release of their antimicrobial peptides such as neutrophil serine proteases (NSPs), i.e. neutrophil elastase (NE) cathepsin G (CatG) and proteinase 3 (Pr3) (Kumar and Sharma, 2010) .", [["serine", "CHEMICAL", 147, 153], ["neutrophil serine proteases", "GENE_OR_GENE_PRODUCT", 136, 163], ["NSPs", "GENE_OR_GENE_PRODUCT", 165, 169], ["neutrophil elastase", "GENE_OR_GENE_PRODUCT", 177, 196], ["NE) cathepsin G", "GENE_OR_GENE_PRODUCT", 198, 213], ["CatG", "GENE_OR_GENE_PRODUCT", 215, 219], ["proteinase 3", "GENE_OR_GENE_PRODUCT", 225, 237], ["Pr3", "GENE_OR_GENE_PRODUCT", 239, 242], ["neutrophil serine proteases", "PROTEIN", 136, 163], ["NSPs", "PROTEIN", 165, 169], ["neutrophil elastase", "PROTEIN", 177, 196], ["NE", "PROTEIN", 198, 200], ["cathepsin G", "PROTEIN", 202, 213], ["CatG", "PROTEIN", 215, 219], ["proteinase 3", "PROTEIN", 225, 237], ["Pr3", "PROTEIN", 239, 242], ["trap various pathogens", "PROBLEM", 29, 51], ["their antimicrobial peptides", "TEST", 99, 127], ["neutrophil serine proteases", "TEST", 136, 163], ["NSPs", "TEST", 165, 169], ["neutrophil elastase", "TEST", 177, 196], ["cathepsin G (CatG)", "TREATMENT", 202, 220], ["proteinase", "TEST", 225, 235], ["neutrophil elastase", "OBSERVATION", 177, 196]]], ["Only a few reports describe the role of porcine PMNs in the host response to microorganisms.", [["PMNs", "ANATOMY", 48, 52], ["porcine", "ORGANISM", 40, 47], ["PMNs", "CELL", 48, 52], ["porcine PMNs", "CELL_TYPE", 40, 52], ["porcine PMNs", "PROBLEM", 40, 52]]], ["Panyutich et al. demonstrated the bactericidal activity of pig PMNs against L. monocytogenes (Panyutich et al., 1997) .", [["PMNs", "ANATOMY", 63, 67], ["pig", "ORGANISM", 59, 62], ["PMNs", "CELL", 63, 67], ["L. monocytogenes", "ORGANISM", 76, 92], ["pig PMNs", "CELL_TYPE", 59, 67], ["pig", "SPECIES", 59, 62], ["L. monocytogenes", "SPECIES", 76, 92], ["pig", "SPECIES", 59, 62], ["L. monocytogenes", "SPECIES", 76, 92], ["bactericidal activity", "OBSERVATION", 34, 55]]], ["These authors showed that secretion and elastase-mediated activation of proprotegrins accounted for much of the stable microbicidal activity of PMN secretions against L. monocytogenes.", [["PMN", "ANATOMY", 144, 147], ["elastase", "GENE_OR_GENE_PRODUCT", 40, 48], ["proprotegrins", "SIMPLE_CHEMICAL", 72, 85], ["PMN", "CELL", 144, 147], ["L. monocytogenes", "ORGANISM", 167, 183], ["elastase", "PROTEIN", 40, 48], ["proprotegrins", "PROTEIN", 72, 85], ["L. monocytogenes", "SPECIES", 167, 183], ["L. monocytogenes", "SPECIES", 167, 183], ["secretion and elastase", "PROBLEM", 26, 48], ["proprotegrins", "TREATMENT", 72, 85], ["PMN secretions", "PROBLEM", 144, 158], ["L. monocytogenes", "PROBLEM", 167, 183], ["stable", "OBSERVATION_MODIFIER", 112, 118], ["microbicidal activity", "OBSERVATION", 119, 140], ["monocytogenes", "OBSERVATION", 170, 183]]], ["Since then, the bactericidal activity of porcine PMN secretions has been reported (Scapinello et al., 2011) and it has been revealed that the bacteria S. aureus and Pseudomonas aeruginosa induce porcine NETs secretion (Brea et al., 2012) .", [["PMN secretions", "ANATOMY", 49, 63], ["NETs", "ANATOMY", 203, 207], ["porcine", "ORGANISM", 41, 48], ["PMN", "CELL", 49, 52], ["bacteria", "ORGANISM", 142, 150], ["S. aureus", "ORGANISM", 151, 160], ["Pseudomonas aeruginosa", "ORGANISM", 165, 187], ["porcine", "ORGANISM", 195, 202], ["NETs", "GENE_OR_GENE_PRODUCT", 203, 207], ["porcine", "SPECIES", 41, 48], ["S. aureus", "SPECIES", 151, 160], ["Pseudomonas aeruginosa", "SPECIES", 165, 187], ["porcine", "SPECIES", 195, 202], ["porcine", "SPECIES", 41, 48], ["S. aureus", "SPECIES", 151, 160], ["Pseudomonas aeruginosa", "SPECIES", 165, 187], ["the bactericidal activity", "TEST", 12, 37], ["porcine PMN secretions", "PROBLEM", 41, 63], ["the bacteria S. aureus", "PROBLEM", 138, 160], ["Pseudomonas aeruginosa", "PROBLEM", 165, 187], ["porcine NETs secretion", "PROBLEM", 195, 217], ["bactericidal", "OBSERVATION_MODIFIER", 16, 28], ["activity", "OBSERVATION_MODIFIER", 29, 37], ["porcine PMN secretions", "OBSERVATION", 41, 63], ["aureus", "OBSERVATION", 154, 160]]], ["Porcine PMNs (swine cluster 1, SWC1 + or CD52, and SWC8 + cells (Piriou-Guzylack and Salmon, 2008) ) display the same morphology as those of humans with a round shape and rough surface (Clapperton et al., 2005) but are smaller in size, have lower granularity and a higher activation threshold (Brea et al., 2012) .", [["PMNs", "ANATOMY", 8, 12], ["CD52", "ANATOMY", 41, 45], ["SWC8 + cells", "ANATOMY", 51, 63], ["surface", "ANATOMY", 177, 184], ["Porcine", "ORGANISM", 0, 7], ["PMNs", "CELL", 8, 12], ["SWC1 +", "CELL", 31, 37], ["CD52", "GENE_OR_GENE_PRODUCT", 41, 45], ["humans", "ORGANISM", 141, 147], ["Porcine PMNs", "CELL_TYPE", 0, 12], ["Porcine", "SPECIES", 0, 7], ["swine", "SPECIES", 14, 19], ["humans", "SPECIES", 141, 147], ["humans", "SPECIES", 141, 147], ["Porcine PMNs", "TEST", 0, 12], ["SWC1", "TEST", 31, 35], ["CD52", "TEST", 41, 45], ["SWC8", "TEST", 51, 55], ["Piriou", "TEST", 65, 71], ["lower granularity", "PROBLEM", 241, 258], ["CD52", "ANATOMY", 41, 45], ["round", "OBSERVATION_MODIFIER", 155, 160], ["shape", "OBSERVATION_MODIFIER", 161, 166], ["rough", "OBSERVATION_MODIFIER", 171, 176], ["surface", "OBSERVATION_MODIFIER", 177, 184], ["smaller", "OBSERVATION_MODIFIER", 219, 226], ["size", "OBSERVATION_MODIFIER", 230, 234], ["lower", "OBSERVATION_MODIFIER", 241, 246], ["granularity", "OBSERVATION", 247, 258]]], ["Additionally, differences in PMN morphology and function have been reported between pig breeds.", [["PMN", "ANATOMY", 29, 32], ["PMN", "CELL", 29, 32], ["pig", "ORGANISM", 84, 87], ["PMN", "CELL_TYPE", 29, 32], ["pig", "SPECIES", 84, 87], ["pig", "SPECIES", 84, 87], ["PMN morphology", "TEST", 29, 43], ["PMN morphology", "OBSERVATION", 29, 43]]], ["PMNs from Meishan pigs, are smaller and less efficient in phagocytising Escherichia coli than PMNs of Large White pigs (Clapperton et al., 2005) .", [["PMNs", "ANATOMY", 0, 4], ["PMNs", "ANATOMY", 94, 98], ["PMNs", "CELL", 0, 4], ["Meishan pigs", "ORGANISM", 10, 22], ["Escherichia coli", "ORGANISM", 72, 88], ["PMNs", "CELL", 94, 98], ["Large White pigs", "ORGANISM", 102, 118], ["PMNs", "CELL_TYPE", 0, 4], ["PMNs", "CELL_TYPE", 94, 98], ["Meishan pigs", "SPECIES", 10, 22], ["Escherichia coli", "SPECIES", 72, 88], ["pigs", "SPECIES", 114, 118], ["Meishan pigs", "SPECIES", 10, 22], ["Escherichia coli", "SPECIES", 72, 88], ["Large White pigs", "SPECIES", 102, 118], ["PMNs", "PROBLEM", 0, 4], ["phagocytising Escherichia coli", "PROBLEM", 58, 88], ["Large White pigs", "PROBLEM", 102, 118], ["Meishan pigs", "OBSERVATION", 10, 22], ["smaller", "OBSERVATION_MODIFIER", 28, 35], ["less", "OBSERVATION_MODIFIER", 40, 44], ["efficient", "OBSERVATION_MODIFIER", 45, 54], ["Escherichia coli", "OBSERVATION", 72, 88], ["Large", "OBSERVATION_MODIFIER", 102, 107], ["White pigs", "OBSERVATION_MODIFIER", 108, 118]]], ["Moreover, porcine PMNs behaved similarly to human blood PMNs in response to A23187 with the same morphological changes, no DNA secretion and exposure of the three proteases at the cell surface (Brea et al., 2012) .", [["PMNs", "ANATOMY", 18, 22], ["blood PMNs", "ANATOMY", 50, 60], ["cell surface", "ANATOMY", 180, 192], ["A23187", "CHEMICAL", 76, 82], ["A23187", "CHEMICAL", 76, 82], ["porcine", "ORGANISM", 10, 17], ["PMNs", "CELL", 18, 22], ["human", "ORGANISM", 44, 49], ["blood PMNs", "CELL", 50, 60], ["A23187", "SIMPLE_CHEMICAL", 76, 82], ["DNA", "CELLULAR_COMPONENT", 123, 126], ["cell surface", "CELLULAR_COMPONENT", 180, 192], ["porcine PMNs", "CELL_TYPE", 10, 22], ["human blood PMNs", "CELL_TYPE", 44, 60], ["proteases", "PROTEIN", 163, 172], ["porcine", "SPECIES", 10, 17], ["human", "SPECIES", 44, 49], ["porcine", "SPECIES", 10, 17], ["human", "SPECIES", 44, 49], ["porcine PMNs", "PROBLEM", 10, 22], ["human blood PMNs", "TEST", 44, 60], ["A23187", "TEST", 76, 82], ["DNA secretion", "PROBLEM", 123, 136], ["no", "UNCERTAINTY", 120, 122], ["DNA secretion", "OBSERVATION", 123, 136]]], ["The close structural homology between porcine and human NSPs explains their immunological cross-reactivity and indicates closer substrate specificity between pig and human NSPs than observed with mouse NSPs (Kalupov et al., 2009) .Basophils and eosinophilsBasophils and eosinophils are white blood cells of the immune system expressing CD172a as others myeloid cells (Piriou-Guzylack and Salmon, 2008) and they can be differentiated from neutrophils by the lack of expression of surface antigen 2B2, which is selectively expressed on mature neutrophils (Perez et al., 2007) .", [["NSPs", "ANATOMY", 56, 60], ["NSPs", "ANATOMY", 172, 176], ["Basophils", "ANATOMY", 231, 240], ["eosinophils", "ANATOMY", 245, 256], ["eosinophils", "ANATOMY", 270, 281], ["white blood cells", "ANATOMY", 286, 303], ["immune system", "ANATOMY", 311, 324], ["myeloid cells", "ANATOMY", 353, 366], ["neutrophils", "ANATOMY", 438, 449], ["surface", "ANATOMY", 479, 486], ["neutrophils", "ANATOMY", 541, 552], ["porcine", "ORGANISM", 38, 45], ["human", "ORGANISM", 50, 55], ["NSPs", "GENE_OR_GENE_PRODUCT", 56, 60], ["pig", "ORGANISM", 158, 161], ["human", "ORGANISM", 166, 171], ["NSPs", "GENE_OR_GENE_PRODUCT", 172, 176], ["mouse", "ORGANISM", 196, 201], ["NSPs", "CELL", 202, 206], ["Basophils", "CELL", 231, 240], ["eosinophilsBasophils", "CELL", 245, 265], ["eosinophils", "CELL", 270, 281], ["white blood cells", "CELL", 286, 303], ["immune system", "ANATOMICAL_SYSTEM", 311, 324], ["CD172a", "GENE_OR_GENE_PRODUCT", 336, 342], ["myeloid cells", "CELL", 353, 366], ["Piriou-Guzylack", "CELL", 368, 383], ["neutrophils", "CELL", 438, 449], ["surface antigen 2B2", "GENE_OR_GENE_PRODUCT", 479, 498], ["neutrophils", "CELL", 541, 552], ["porcine and human NSPs", "PROTEIN", 38, 60], ["Basophils", "CELL_TYPE", 231, 240], ["eosinophils", "CELL_TYPE", 245, 256], ["Basophils", "CELL_TYPE", 256, 265], ["eosinophils", "CELL_TYPE", 270, 281], ["white blood cells", "CELL_TYPE", 286, 303], ["CD172a", "PROTEIN", 336, 342], ["myeloid cells", "CELL_TYPE", 353, 366], ["neutrophils", "CELL_TYPE", 438, 449], ["surface antigen 2B2", "PROTEIN", 479, 498], ["mature neutrophils", "CELL_TYPE", 534, 552], ["porcine", "SPECIES", 38, 45], ["human", "SPECIES", 50, 55], ["pig", "SPECIES", 158, 161], ["human", "SPECIES", 166, 171], ["mouse", "SPECIES", 196, 201], ["human", "SPECIES", 50, 55], ["pig", "SPECIES", 158, 161], ["human", "SPECIES", 166, 171], ["mouse", "SPECIES", 196, 201], ["pig and human NSPs", "TREATMENT", 158, 176], ["Basophils", "TEST", 231, 240], ["eosinophilsBasophils", "TEST", 245, 265], ["eosinophils", "TEST", 270, 281], ["white blood cells", "TEST", 286, 303], ["myeloid cells", "TEST", 353, 366], ["Piriou", "TEST", 368, 374], ["surface antigen", "TEST", 479, 494], ["eosinophilsBasophils", "OBSERVATION", 245, 265], ["myeloid cells", "OBSERVATION", 353, 366]]], ["Basophils are the least common of the granulocytes and they are associated with many inflammatory reactions, particularly in the context of allergic symptoms and the host defence against parasites.", [["Basophils", "ANATOMY", 0, 9], ["granulocytes", "ANATOMY", 38, 50], ["allergic symptoms", "DISEASE", 140, 157], ["Basophils", "GENE_OR_GENE_PRODUCT", 0, 9], ["granulocytes", "CELL", 38, 50], ["Basophils", "CELL_TYPE", 0, 9], ["granulocytes", "CELL_TYPE", 38, 50], ["Basophils", "TREATMENT", 0, 9], ["many inflammatory reactions", "PROBLEM", 80, 107], ["allergic symptoms", "PROBLEM", 140, 157], ["parasites", "PROBLEM", 187, 196], ["least", "OBSERVATION_MODIFIER", 18, 23], ["common", "OBSERVATION_MODIFIER", 24, 30], ["granulocytes", "OBSERVATION", 38, 50], ["associated with", "UNCERTAINTY", 64, 79], ["many", "OBSERVATION_MODIFIER", 80, 84], ["inflammatory", "OBSERVATION", 85, 97], ["allergic", "OBSERVATION", 140, 148]]], ["Their large basophilic cytoplasmic granules contain heparin and histamine.", [["basophilic cytoplasmic granules", "ANATOMY", 12, 43], ["heparin", "CHEMICAL", 52, 59], ["histamine", "CHEMICAL", 64, 73], ["histamine", "CHEMICAL", 64, 73], ["cytoplasmic", "ORGANISM_SUBSTANCE", 23, 34], ["granules", "ORGANISM_SUBSTANCE", 35, 43], ["heparin", "SIMPLE_CHEMICAL", 52, 59], ["histamine", "SIMPLE_CHEMICAL", 64, 73], ["Their large basophilic cytoplasmic granules", "PROBLEM", 0, 43], ["heparin", "TREATMENT", 52, 59], ["histamine", "TREATMENT", 64, 73], ["large", "OBSERVATION_MODIFIER", 6, 11], ["basophilic cytoplasmic granules", "OBSERVATION", 12, 43], ["heparin", "OBSERVATION_MODIFIER", 52, 59]]], ["Moreover, they express on their cytoplasmic membrane receptor for IgE immunoglobulins and prostaglandin D2 receptor.", [["cytoplasmic membrane", "ANATOMY", 32, 52], ["prostaglandin", "CHEMICAL", 90, 103], ["prostaglandin D2", "CHEMICAL", 90, 106], ["cytoplasmic", "ORGANISM_SUBSTANCE", 32, 43], ["membrane", "CELLULAR_COMPONENT", 44, 52], ["IgE immunoglobulins", "GENE_OR_GENE_PRODUCT", 66, 85], ["prostaglandin D2 receptor", "GENE_OR_GENE_PRODUCT", 90, 115], ["cytoplasmic membrane receptor", "PROTEIN", 32, 61], ["IgE immunoglobulins", "PROTEIN", 66, 85], ["prostaglandin D2 receptor", "PROTEIN", 90, 115], ["their cytoplasmic membrane receptor", "TREATMENT", 26, 61], ["IgE immunoglobulins", "TREATMENT", 66, 85], ["prostaglandin D2 receptor", "TREATMENT", 90, 115]]], ["Antagonism of this prostaglandin receptor is known to inhibit their activation as well as eosinophil chemotaxis and Th2 cytokine production (Stebbins et al., 2012) .", [["eosinophil", "ANATOMY", 90, 100], ["prostaglandin", "CHEMICAL", 19, 32], ["prostaglandin", "CHEMICAL", 19, 32], ["prostaglandin receptor", "GENE_OR_GENE_PRODUCT", 19, 41], ["eosinophil", "CELL", 90, 100], ["prostaglandin receptor", "PROTEIN", 19, 41], ["Th2 cytokine", "PROTEIN", 116, 128], ["this prostaglandin receptor", "TREATMENT", 14, 41], ["eosinophil chemotaxis", "TEST", 90, 111]]], ["Pigs sensitized to Ascaris suum eggs showed significantly greater histamine release from basophils compared to non-sensitized pigs (Uston et al., 2007) .", [["basophils", "ANATOMY", 89, 98], ["histamine", "CHEMICAL", 66, 75], ["histamine", "CHEMICAL", 66, 75], ["Pigs", "ORGANISM", 0, 4], ["Ascaris suum", "ORGANISM", 19, 31], ["eggs", "ORGANISM", 32, 36], ["histamine", "SIMPLE_CHEMICAL", 66, 75], ["basophils", "CELL", 89, 98], ["pigs", "ORGANISM", 126, 130], ["basophils", "CELL_TYPE", 89, 98], ["Pigs", "SPECIES", 0, 4], ["Ascaris suum", "SPECIES", 19, 31], ["pigs", "SPECIES", 126, 130], ["Pigs", "SPECIES", 0, 4], ["Ascaris suum", "SPECIES", 19, 31], ["pigs", "SPECIES", 126, 130], ["Pigs", "TREATMENT", 0, 4], ["Ascaris suum eggs", "TEST", 19, 36], ["significantly greater histamine release from basophils", "PROBLEM", 44, 98]]], ["Thus, basophils play a role in the control of the mechanisms associated with allergy and asthma.Basophils and eosinophilsEosinophils are involved in the response against multicellular parasites and certain infections in vertebrates (Magyar et al., 1995) .", [["basophils", "ANATOMY", 6, 15], ["Basophils", "ANATOMY", 96, 105], ["eosinophilsEosinophils", "ANATOMY", 110, 132], ["allergy", "DISEASE", 77, 84], ["asthma", "DISEASE", 89, 95], ["infections", "DISEASE", 206, 216], ["basophils", "CELL", 6, 15], ["Basophils", "CELL", 96, 105], ["eosinophilsEosinophils", "CELL", 110, 132], ["multicellular parasites", "CELL", 170, 193], ["basophils", "CELL_TYPE", 6, 15], ["Basophils", "CELL_TYPE", 96, 105], ["eosinophils", "CELL_TYPE", 110, 121], ["Eosinophils", "CELL_TYPE", 121, 132], ["basophils", "TREATMENT", 6, 15], ["allergy", "PROBLEM", 77, 84], ["asthma", "PROBLEM", 89, 95], ["Basophils", "TEST", 96, 105], ["eosinophilsEosinophils", "TEST", 110, 132], ["multicellular parasites", "PROBLEM", 170, 193], ["certain infections in vertebrates", "PROBLEM", 198, 231], ["asthma", "OBSERVATION", 89, 95], ["eosinophilsEosinophils", "OBSERVATION", 110, 132], ["multicellular parasites", "OBSERVATION", 170, 193], ["certain", "OBSERVATION_MODIFIER", 198, 205], ["infections", "OBSERVATION", 206, 216]]], ["Their cytoplasmic granules, appearing brick-red after coloration with eosin, are rich in histamines, eosinophil peroxidase, ribonuclease, deoxyribonucleases, lipase, plasminogen, and others proteins.", [["cytoplasmic granules", "ANATOMY", 6, 26], ["eosin", "CHEMICAL", 70, 75], ["cytoplasmic", "ORGANISM_SUBSTANCE", 6, 17], ["granules", "ORGANISM_SUBSTANCE", 18, 26], ["eosin", "SIMPLE_CHEMICAL", 70, 75], ["histamines", "GENE_OR_GENE_PRODUCT", 89, 99], ["eosinophil peroxidase", "GENE_OR_GENE_PRODUCT", 101, 122], ["ribonuclease", "GENE_OR_GENE_PRODUCT", 124, 136], ["deoxyribonucleases", "GENE_OR_GENE_PRODUCT", 138, 156], ["lipase", "GENE_OR_GENE_PRODUCT", 158, 164], ["plasminogen", "GENE_OR_GENE_PRODUCT", 166, 177], ["histamines", "PROTEIN", 89, 99], ["eosinophil peroxidase", "PROTEIN", 101, 122], ["ribonuclease", "PROTEIN", 124, 136], ["deoxyribonucleases", "PROTEIN", 138, 156], ["lipase", "PROTEIN", 158, 164], ["plasminogen", "PROTEIN", 166, 177], ["Their cytoplasmic granules", "PROBLEM", 0, 26], ["eosin", "TREATMENT", 70, 75], ["histamines", "TEST", 89, 99], ["eosinophil peroxidase", "TEST", 101, 122], ["ribonuclease", "TEST", 124, 136], ["deoxyribonucleases", "TEST", 138, 156], ["lipase", "TEST", 158, 164], ["plasminogen", "TEST", 166, 177], ["cytoplasmic granules", "OBSERVATION", 6, 26], ["brick-red", "OBSERVATION_MODIFIER", 38, 47], ["eosinophil peroxidase", "OBSERVATION", 101, 122], ["lipase", "ANATOMY", 158, 164]]], ["All these molecules are released in the environment after degranulation.", [["molecules", "OBSERVATION", 10, 19], ["degranulation", "OBSERVATION", 58, 71]]], ["They are toxic for parasites but also host tissue.", [["tissue", "ANATOMY", 43, 49], ["tissue", "TISSUE", 43, 49], ["parasites", "PROBLEM", 19, 28], ["toxic", "OBSERVATION_MODIFIER", 9, 14], ["host tissue", "OBSERVATION", 38, 49]]], ["Transcriptional profiling of swine lung tissue and hilar lymph nodes after experimental infection with Actinobacillus pleuropneumoniae showed induction of many genes such as GM-CSF whose increased protein expression can stimulate stem cells to differentiate into granulocytes such as basophils, eosinophils and neutrophils (Yu et al., 2013; Zuo et al., 2013) . miRNAs are evolutionarily conserved short single stranded RNAs that can inhibit gene expression at the post-transcriptional level playing an important role in the control of inflammation and immune response.", [["lung tissue", "ANATOMY", 35, 46], ["hilar lymph nodes", "ANATOMY", 51, 68], ["stem cells", "ANATOMY", 230, 240], ["granulocytes", "ANATOMY", 263, 275], ["basophils", "ANATOMY", 284, 293], ["eosinophils", "ANATOMY", 295, 306], ["neutrophils", "ANATOMY", 311, 322], ["infection", "DISEASE", 88, 97], ["GM", "CHEMICAL", 174, 176], ["inflammation", "DISEASE", 535, 547], ["swine", "ORGANISM", 29, 34], ["lung tissue", "TISSUE", 35, 46], ["hilar lymph nodes", "MULTI-TISSUE_STRUCTURE", 51, 68], ["Actinobacillus pleuropneumoniae", "ORGANISM", 103, 134], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 174, 180], ["stem cells", "CELL", 230, 240], ["granulocytes", "CELL", 263, 275], ["basophils", "CELL", 284, 293], ["eosinophils", "CELL", 295, 306], ["neutrophils", "CELL", 311, 322], ["GM", "PROTEIN", 174, 176], ["CSF", "PROTEIN", 177, 180], ["stem cells", "CELL_TYPE", 230, 240], ["granulocytes", "CELL_TYPE", 263, 275], ["basophils", "CELL_TYPE", 284, 293], ["eosinophils", "CELL_TYPE", 295, 306], ["neutrophils", "CELL_TYPE", 311, 322], ["miRNAs", "RNA", 361, 367], ["short single stranded RNAs", "RNA", 397, 423], ["swine", "SPECIES", 29, 34], ["Actinobacillus pleuropneumoniae", "SPECIES", 103, 134], ["swine", "SPECIES", 29, 34], ["Actinobacillus pleuropneumoniae", "SPECIES", 103, 134], ["Transcriptional profiling of swine lung tissue", "PROBLEM", 0, 46], ["hilar lymph nodes", "PROBLEM", 51, 68], ["experimental infection", "PROBLEM", 75, 97], ["Actinobacillus pleuropneumoniae", "PROBLEM", 103, 134], ["GM-CSF", "TEST", 174, 180], ["increased protein expression", "PROBLEM", 187, 215], ["stem cells", "TEST", 230, 240], ["granulocytes", "TEST", 263, 275], ["basophils", "TEST", 284, 293], ["eosinophils", "TEST", 295, 306], ["neutrophils", "TEST", 311, 322], ["short single stranded RNAs", "PROBLEM", 397, 423], ["gene expression", "PROBLEM", 441, 456], ["inflammation", "PROBLEM", 535, 547], ["swine", "OBSERVATION_MODIFIER", 29, 34], ["lung", "ANATOMY", 35, 39], ["tissue", "ANATOMY_MODIFIER", 40, 46], ["hilar", "ANATOMY", 51, 56], ["lymph nodes", "OBSERVATION", 57, 68], ["infection", "OBSERVATION", 88, 97], ["basophils", "ANATOMY", 284, 293], ["short", "OBSERVATION_MODIFIER", 397, 402], ["stranded RNAs", "OBSERVATION", 410, 423], ["inflammation", "OBSERVATION", 535, 547]]], ["One study showed that a specific miR-155 SNP was significantly associated with basophil percentage and absolute eosinophil value in pigs suggesting that miR-155 may have, a previously unknown, role in immune function .Basophils and eosinophilsPig eosinophils can be isolated using discontinuous Percoll gradient to separate the granulocyte fraction and by a negative magnetic activated cell separation with mouse anti-pig CD16 antibody (Masure et al., 2013) .", [["basophil", "ANATOMY", 79, 87], ["eosinophil", "ANATOMY", 112, 122], ["Basophils", "ANATOMY", 218, 227], ["eosinophils", "ANATOMY", 232, 243], ["eosinophils", "ANATOMY", 247, 258], ["granulocyte", "ANATOMY", 328, 339], ["cell", "ANATOMY", 386, 390], ["SNP", "CHEMICAL", 41, 44], ["miR-155", "CHEMICAL", 153, 160], ["miR-155", "GENE_OR_GENE_PRODUCT", 33, 40], ["basophil", "CELL", 79, 87], ["eosinophil", "CELL", 112, 122], ["pigs", "ORGANISM", 132, 136], ["miR-155", "GENE_OR_GENE_PRODUCT", 153, 160], ["Basophils", "CELL", 218, 227], ["eosinophils", "CELL", 232, 243], ["Pig", "ORGANISM", 243, 246], ["eosinophils", "CELL", 247, 258], ["granulocyte", "CELL", 328, 339], ["cell", "CELL", 386, 390], ["mouse", "ORGANISM", 407, 412], ["CD16", "GENE_OR_GENE_PRODUCT", 422, 426], ["miR-155 SNP", "DNA", 33, 44], ["Basophils", "CELL_TYPE", 218, 227], ["eosinophils", "CELL_TYPE", 232, 243], ["Pig eosinophils", "CELL_TYPE", 243, 258], ["granulocyte fraction", "CELL_TYPE", 328, 348], ["mouse anti-pig CD16 antibody", "PROTEIN", 407, 435], ["pigs", "SPECIES", 132, 136], ["Pig", "SPECIES", 243, 246], ["mouse", "SPECIES", 407, 412], ["pigs", "SPECIES", 132, 136], ["Pig", "SPECIES", 243, 246], ["mouse", "SPECIES", 407, 412], ["One study", "TEST", 0, 9], ["a specific miR", "TEST", 22, 36], ["SNP", "TEST", 41, 44], ["basophil percentage", "TEST", 79, 98], ["absolute eosinophil value", "TEST", 103, 128], ["Basophils", "TEST", 218, 227], ["eosinophils", "TEST", 232, 243], ["Pig eosinophils", "PROBLEM", 243, 258], ["discontinuous Percoll gradient", "TREATMENT", 281, 311], ["the granulocyte fraction", "TEST", 324, 348], ["a negative magnetic activated cell separation", "TREATMENT", 356, 401], ["mouse anti-pig CD16 antibody", "TREATMENT", 407, 435], ["basophil percentage", "OBSERVATION", 79, 98], ["absolute eosinophil value", "OBSERVATION", 103, 128], ["immune function", "OBSERVATION", 201, 216], ["eosinophils", "OBSERVATION", 232, 243], ["granulocyte fraction", "OBSERVATION", 328, 348]]], ["Several publications presented data related to eosinophils, especially in the context of parasitic infections with A. suum (Masure et al., 2013) , Trichuris suis (Steenhard et al., 2007) , and Toxocara canis (Sommerfelt et al., 2006) .Natural killer cellsNatural killer (NK) cells in mice were initially identified as cells that spontaneously kill tumor or virus-infected cells but do not belong to the B-or T-cell lineage (Herberman et al., 1975; Kiessling et al., 1975) .", [["eosinophils", "ANATOMY", 47, 58], ["Natural killer cells", "ANATOMY", 235, 255], ["Natural killer (NK) cells", "ANATOMY", 255, 280], ["cells", "ANATOMY", 318, 323], ["tumor", "ANATOMY", 348, 353], ["cells", "ANATOMY", 372, 377], ["B-or T-cell lineage", "ANATOMY", 403, 422], ["parasitic infections", "DISEASE", 89, 109], ["Trichuris suis", "DISEASE", 147, 161], ["Toxocara canis", "DISEASE", 193, 207], ["tumor", "DISEASE", 348, 353], ["eosinophils", "CELL", 47, 58], ["A. suum", "ORGANISM", 115, 122], ["Trichuris suis", "ORGANISM", 147, 161], ["Toxocara canis", "ORGANISM", 193, 207], ["Natural killer cells", "CELL", 235, 255], ["Natural killer (NK) cells", "CELL", 255, 280], ["mice", "ORGANISM", 284, 288], ["cells", "CELL", 318, 323], ["tumor", "CANCER", 348, 353], ["cells", "CELL", 372, 377], ["B-or T-cell lineage", "CELL", 403, 422], ["eosinophils", "CELL_TYPE", 47, 58], ["Natural killer cells", "CELL_TYPE", 235, 255], ["Natural killer (NK) cells", "CELL_TYPE", 255, 280], ["tumor or virus-infected cells", "CELL_TYPE", 348, 377], ["B-or T-cell lineage", "CELL_TYPE", 403, 422], ["A. suum", "SPECIES", 115, 122], ["Trichuris suis", "SPECIES", 147, 161], ["Toxocara canis", "SPECIES", 193, 207], ["mice", "SPECIES", 284, 288], ["A. suum", "SPECIES", 115, 122], ["Trichuris suis", "SPECIES", 147, 161], ["Toxocara canis", "SPECIES", 193, 207], ["mice", "SPECIES", 284, 288], ["eosinophils", "PROBLEM", 47, 58], ["parasitic infections", "PROBLEM", 89, 109], ["Trichuris suis", "PROBLEM", 147, 161], ["Toxocara canis", "PROBLEM", 193, 207], ["Natural killer cells", "TREATMENT", 235, 255], ["Natural killer (NK) cells", "TREATMENT", 255, 280], ["spontaneously kill tumor", "PROBLEM", 329, 353], ["virus", "PROBLEM", 357, 362], ["infected cells", "PROBLEM", 363, 377], ["eosinophils", "OBSERVATION", 47, 58], ["parasitic", "OBSERVATION_MODIFIER", 89, 98], ["infections", "OBSERVATION", 99, 109], ["killer cells", "OBSERVATION", 243, 255]]], ["Similar, early studies in swine showed that non-B non-T cells have a spontaneous lytic activity against NK-susceptible targets like the MHC class I lacking cell line K562 as well as transmissible gastroenteritis virus or ADV infected target cells (Cepica and Derbyshire, 1986; Martin and Wardley, 1984; Yang et al., 1987) .", [["B non-T cells", "ANATOMY", 48, 61], ["NK", "ANATOMY", 104, 106], ["cell line K562", "ANATOMY", 156, 170], ["cells", "ANATOMY", 241, 246], ["transmissible gastroenteritis", "DISEASE", 182, 211], ["ADV", "CHEMICAL", 221, 224], ["swine", "ORGANISM", 26, 31], ["B non-T cells", "CELL", 48, 61], ["NK", "CELL", 104, 106], ["cell line K562", "CELL", 156, 170], ["transmissible gastroenteritis virus", "ORGANISM", 182, 217], ["ADV", "ORGANISM", 221, 224], ["cells", "CELL", 241, 246], ["B non-T cells", "CELL_TYPE", 48, 61], ["MHC class I lacking cell line K562", "CELL_LINE", 136, 170], ["ADV infected target cells", "CELL_TYPE", 221, 246], ["swine", "SPECIES", 26, 31], ["swine", "SPECIES", 26, 31], ["transmissible gastroenteritis virus", "SPECIES", 182, 217], ["ADV", "SPECIES", 221, 224], ["early studies", "TEST", 9, 22], ["non-B non-T cells", "PROBLEM", 44, 61], ["a spontaneous lytic activity", "PROBLEM", 67, 95], ["lacking cell line K562", "TREATMENT", 148, 170], ["transmissible gastroenteritis virus", "PROBLEM", 182, 217], ["lytic", "OBSERVATION_MODIFIER", 81, 86], ["cell line K562", "OBSERVATION", 156, 170]]], ["Due to the lack of specific markers recognizing only NK cells in swine, the identification and phenotypic description of this porcine lymphocyte population was rather difficult.", [["NK cells", "ANATOMY", 53, 61], ["lymphocyte", "ANATOMY", 134, 144], ["NK cells", "CELL", 53, 61], ["swine", "ORGANISM", 65, 70], ["porcine", "ORGANISM", 126, 133], ["lymphocyte", "CELL", 134, 144], ["NK cells", "CELL_TYPE", 53, 61], ["porcine lymphocyte population", "CELL_TYPE", 126, 155], ["swine", "SPECIES", 65, 70], ["swine", "SPECIES", 65, 70], ["NK cells", "PROBLEM", 53, 61], ["the identification", "TEST", 72, 90], ["this porcine lymphocyte population", "PROBLEM", 121, 155], ["NK cells", "OBSERVATION", 53, 61]]], ["In contrast to other species where NK cells are described as large granular lymphocytes, porcine NK cells morphologically resemble small to medium sized cells that lack granules Yang et al., 1987) .", [["NK cells", "ANATOMY", 35, 43], ["granular lymphocytes", "ANATOMY", 67, 87], ["NK cells", "ANATOMY", 97, 105], ["cells", "ANATOMY", 153, 158], ["granules", "ANATOMY", 169, 177], ["NK cells", "CELL", 35, 43], ["granular lymphocytes", "CELL", 67, 87], ["porcine NK cells", "CELL", 89, 105], ["cells", "CELL", 153, 158], ["NK cells", "CELL_TYPE", 35, 43], ["large granular lymphocytes", "CELL_TYPE", 61, 87], ["porcine NK cells", "CELL_TYPE", 89, 105], ["small to medium sized cells", "CELL_TYPE", 131, 158], ["NK cells", "PROBLEM", 35, 43], ["large granular lymphocytes", "PROBLEM", 61, 87], ["porcine NK cells", "TEST", 89, 105], ["small to medium sized cells", "PROBLEM", 131, 158], ["NK cells", "OBSERVATION", 35, 43], ["large", "OBSERVATION_MODIFIER", 61, 66], ["granular lymphocytes", "OBSERVATION", 67, 87], ["porcine NK cells", "OBSERVATION", 89, 105], ["small to medium sized", "OBSERVATION_MODIFIER", 131, 152], ["cells", "OBSERVATION", 153, 158]]], ["Nevertheless, porcine NK cells lack the T-cell receptor CD3 as well as T-cell co-receptors like CD4, CD5 and CD6 and were characterized by a uniform expression of CD2, CD8a, CD16, CD45RC as well as the effector molecule perforin Gerner et al., 2009; Pauly et al., 1996; Pintaric et al., 2008; Saalmuller et al., 1994) .", [["NK cells", "ANATOMY", 22, 30], ["T-cell", "ANATOMY", 40, 46], ["T-cell", "ANATOMY", 71, 77], ["porcine", "ORGANISM", 14, 21], ["NK cells", "CELL", 22, 30], ["T-cell receptor CD3", "GENE_OR_GENE_PRODUCT", 40, 59], ["T-cell co-receptors", "GENE_OR_GENE_PRODUCT", 71, 90], ["CD4", "GENE_OR_GENE_PRODUCT", 96, 99], ["CD5", "GENE_OR_GENE_PRODUCT", 101, 104], ["CD6", "GENE_OR_GENE_PRODUCT", 109, 112], ["CD2", "GENE_OR_GENE_PRODUCT", 163, 166], ["CD8a", "GENE_OR_GENE_PRODUCT", 168, 172], ["CD16", "GENE_OR_GENE_PRODUCT", 174, 178], ["CD45RC", "GENE_OR_GENE_PRODUCT", 180, 186], ["porcine NK cells", "CELL_TYPE", 14, 30], ["T-cell receptor CD3", "PROTEIN", 40, 59], ["T-cell co-receptors", "PROTEIN", 71, 90], ["CD4", "PROTEIN", 96, 99], ["CD5", "PROTEIN", 101, 104], ["CD6", "PROTEIN", 109, 112], ["CD2", "PROTEIN", 163, 166], ["CD8a", "PROTEIN", 168, 172], ["CD16", "PROTEIN", 174, 178], ["CD45RC", "PROTEIN", 180, 186], ["perforin", "PROTEIN", 220, 228], ["porcine NK cells", "TEST", 14, 30], ["T-cell co-receptors", "TEST", 71, 90], ["CD4", "TEST", 96, 99], ["CD5", "TEST", 101, 104], ["CD6", "TEST", 109, 112], ["CD8a", "TEST", 168, 172], ["CD16", "TEST", 174, 178], ["NK cells", "OBSERVATION", 22, 30], ["uniform", "OBSERVATION_MODIFIER", 141, 148]]], ["A minor fraction of NK cells express swine leukocyte antigen-DR (SLA-DR) and this molecule can be further up-regulated after in vitro stimulation (Pintaric et al., 2008) .", [["NK cells", "ANATOMY", 20, 28], ["NK cells", "CELL", 20, 28], ["swine leukocyte antigen-DR", "GENE_OR_GENE_PRODUCT", 37, 63], ["SLA-DR", "GENE_OR_GENE_PRODUCT", 65, 71], ["NK cells", "CELL_TYPE", 20, 28], ["swine leukocyte antigen", "PROTEIN", 37, 60], ["DR", "PROTEIN", 61, 63], ["SLA", "PROTEIN", 65, 68], ["DR", "PROTEIN", 69, 71], ["swine", "SPECIES", 37, 42], ["swine", "SPECIES", 37, 42], ["A minor fraction of NK cells", "PROBLEM", 0, 28], ["swine leukocyte antigen", "TEST", 37, 60], ["this molecule", "PROBLEM", 77, 90], ["minor", "OBSERVATION_MODIFIER", 2, 7], ["fraction of NK cells", "OBSERVATION", 8, 28]]], ["More recently the characterization of the activating receptor NKp46 in swine by novel monoclonal antibodies led to additional insight into the phenotype of porcine NK cells.", [["NK", "ANATOMY", 62, 64], ["NK cells", "ANATOMY", 164, 172], ["NKp46", "GENE_OR_GENE_PRODUCT", 62, 67], ["swine", "ORGANISM", 71, 76], ["porcine", "ORGANISM", 156, 163], ["NK cells", "CELL", 164, 172], ["activating receptor NKp46", "PROTEIN", 42, 67], ["monoclonal antibodies", "PROTEIN", 86, 107], ["porcine NK cells", "CELL_TYPE", 156, 172], ["swine", "SPECIES", 71, 76], ["swine", "SPECIES", 71, 76], ["novel monoclonal antibodies", "PROBLEM", 80, 107], ["porcine NK cells", "OBSERVATION", 156, 172]]], ["In contrast to other species wherein NKp46 is considered as a pan-NK marker , NKp46 is not expressed on all porcine NK cells (Mair et al., 2012) .", [["NK", "ANATOMY", 37, 39], ["NK cells", "ANATOMY", 116, 124], ["NKp46", "GENE_OR_GENE_PRODUCT", 37, 42], ["pan-NK", "GENE_OR_GENE_PRODUCT", 62, 68], ["NKp46", "GENE_OR_GENE_PRODUCT", 78, 83], ["porcine", "ORGANISM", 108, 115], ["NK cells", "CELL", 116, 124], ["NKp46", "PROTEIN", 37, 42], ["NKp46", "PROTEIN", 78, 83], ["porcine NK cells", "CELL_TYPE", 108, 124], ["a pan-NK marker", "TEST", 60, 75], ["porcine NK cells", "OBSERVATION", 108, 124]]], ["Three distinct porcine NK-cell subsets could be defined on the basis of their NKp46 expression: NKp46 \u00c0 , NKp46 + and NKp46 high cells (Mair et al., 2012 .", [["NK-cell", "ANATOMY", 23, 30], ["NK", "ANATOMY", 78, 80], ["NKp46 \u00c0", "ANATOMY", 96, 103], ["NKp46 +", "ANATOMY", 106, 113], ["NKp46 high cells", "ANATOMY", 118, 134], ["porcine", "ORGANISM", 15, 22], ["NK-cell subsets", "CELL", 23, 38], ["NKp46", "GENE_OR_GENE_PRODUCT", 78, 83], ["porcine NK-cell subsets", "CELL_TYPE", 15, 38], ["NKp46", "CELL_LINE", 106, 111], ["NKp46 high cells", "CELL_LINE", 118, 134], ["NKp", "TEST", 96, 99], ["NK", "TEST", 106, 108], ["p", "TEST", 108, 109], ["NK", "TEST", 118, 120], ["high cells", "PROBLEM", 124, 134], ["porcine NK", "OBSERVATION", 15, 25], ["cell subsets", "OBSERVATION", 26, 38], ["high cells", "OBSERVATION", 124, 134]]], ["Whereas NKp46 \u00c0 and NKp46 + NK cells are very similar in their phenotype, NKp46 high cells differ in their expression pattern of various NK-associated markers.", [["NKp46 \u00c0", "ANATOMY", 8, 15], ["NKp46 + NK cells", "ANATOMY", 20, 36], ["NKp46 high cells", "ANATOMY", 74, 90], ["NK", "ANATOMY", 137, 139], ["NKp46", "GENE_OR_GENE_PRODUCT", 8, 13], ["NKp46", "GENE_OR_GENE_PRODUCT", 20, 25], ["NKp46 high cells", "CELL", 74, 90], ["NK", "CELL", 137, 139], ["NKp46", "CELL_LINE", 8, 13], ["NKp46", "CELL_LINE", 20, 25], ["NK cells", "CELL_TYPE", 28, 36], ["NKp46 high cells", "CELL_TYPE", 74, 90], ["NK-associated markers", "PROTEIN", 137, 158], ["NKp", "TEST", 8, 11], ["NKp", "TEST", 20, 23], ["NK cells", "TEST", 28, 36], ["NK", "TEST", 74, 76], ["high cells", "PROBLEM", 80, 90], ["NK cells", "OBSERVATION", 28, 36], ["high cells", "OBSERVATION", 80, 90], ["various NK", "OBSERVATION", 129, 139]]], ["Although it was postulated earlier that all porcine NK cells express CD8a Pescovitz et al., 1988; Saalmuller et al., 1994) , more recent data show that the NKp46 high NK-cell subset is rather associated with a CD8a dim/\u00c0 phenotype .", [["NK cells", "ANATOMY", 52, 60], ["NKp46 high NK-cell", "ANATOMY", 156, 174], ["porcine", "ORGANISM", 44, 51], ["NK cells", "CELL", 52, 60], ["NKp46", "GENE_OR_GENE_PRODUCT", 156, 161], ["NK-cell", "CELL", 167, 174], ["CD8a", "GENE_OR_GENE_PRODUCT", 210, 214], ["porcine NK cells", "CELL_TYPE", 44, 60], ["NKp46 high NK-cell subset", "CELL_LINE", 156, 181], ["the NKp", "TEST", 152, 159], ["a CD8a dim/\u00c0 phenotype", "PROBLEM", 208, 230]]], ["The recent identification and characterization of SWC2 molecule as porcine CD27 revealed that all porcine NK cells express this marker (Reutner et al., 2012) .", [["NK cells", "ANATOMY", 106, 114], ["SWC2 molecule", "GENE_OR_GENE_PRODUCT", 50, 63], ["porcine", "ORGANISM", 67, 74], ["CD27", "GENE_OR_GENE_PRODUCT", 75, 79], ["porcine", "ORGANISM", 98, 105], ["NK cells", "CELL", 106, 114], ["SWC2 molecule", "PROTEIN", 50, 63], ["porcine CD27", "PROTEIN", 67, 79], ["porcine NK cells", "CELL_TYPE", 98, 114], ["The recent identification", "TEST", 0, 25], ["porcine CD27", "TEST", 67, 79], ["all porcine NK cells", "TREATMENT", 94, 114], ["porcine NK cells", "OBSERVATION", 98, 114]]], ["Although NKp46 \u00c0 and NKp46 + NK cells express CD27 at relative low density, NKp46 high NK cells show an increased expression of this TNFreceptor family member .", [["NKp46 \u00c0", "ANATOMY", 9, 16], ["NKp46 + NK cells", "ANATOMY", 21, 37], ["NKp46 high NK cells", "ANATOMY", 76, 95], ["NKp46", "CELL", 9, 14], ["NKp46", "GENE_OR_GENE_PRODUCT", 21, 26], ["CD27", "GENE_OR_GENE_PRODUCT", 46, 50], ["NK cells", "CELL", 87, 95], ["TNFreceptor", "GENE_OR_GENE_PRODUCT", 133, 144], ["NKp46", "CELL_LINE", 21, 26], ["NK cells", "CELL_TYPE", 29, 37], ["CD27", "PROTEIN", 46, 50], ["NK cells", "CELL_TYPE", 87, 95], ["TNFreceptor family member", "PROTEIN", 133, 158], ["NKp", "TEST", 9, 12], ["NKp", "TEST", 21, 24], ["NK cells", "TEST", 29, 37], ["CD27", "TEST", 46, 50], ["relative low density", "PROBLEM", 54, 74], ["NKp", "TEST", 76, 79], ["high NK cells", "PROBLEM", 82, 95], ["low density", "OBSERVATION_MODIFIER", 63, 74], ["high NK cells", "OBSERVATION", 82, 95], ["increased", "OBSERVATION_MODIFIER", 104, 113]]], ["So far, information on other NK-associated receptors on porcine NK cells is limited due to the lack of monoclonal antibodies.", [["NK", "ANATOMY", 29, 31], ["NK cells", "ANATOMY", 64, 72], ["NK", "CELL", 29, 31], ["porcine", "ORGANISM", 56, 63], ["NK cells", "CELL", 64, 72], ["NK-associated receptors", "PROTEIN", 29, 52], ["porcine NK cells", "CELL_TYPE", 56, 72], ["monoclonal antibodies", "PROTEIN", 103, 124], ["porcine", "SPECIES", 56, 63], ["porcine NK cells", "TREATMENT", 56, 72], ["monoclonal antibodies", "PROBLEM", 103, 124]]], ["The activating receptors NKp30 and NKG2D together with its adaptor proteins DAP10 and DAP12 were investigated on mRNA level on enriched or sorted NK cells Toka et al., 2009a,b) .", [["NK", "ANATOMY", 25, 27], ["NK cells", "ANATOMY", 146, 154], ["NKp30", "GENE_OR_GENE_PRODUCT", 25, 30], ["NKG2D", "GENE_OR_GENE_PRODUCT", 35, 40], ["DAP10", "GENE_OR_GENE_PRODUCT", 76, 81], ["DAP12", "GENE_OR_GENE_PRODUCT", 86, 91], ["NK cells", "CELL", 146, 154], ["activating receptors", "PROTEIN", 4, 24], ["NKp30", "PROTEIN", 25, 30], ["NKG2D", "PROTEIN", 35, 40], ["adaptor proteins", "PROTEIN", 59, 75], ["DAP10", "PROTEIN", 76, 81], ["DAP12", "PROTEIN", 86, 91], ["NK cells", "CELL_TYPE", 146, 154], ["NKG2D", "TREATMENT", 35, 40], ["its adaptor proteins DAP10", "TREATMENT", 55, 81], ["DAP12", "TREATMENT", 86, 91], ["mRNA level", "TEST", 113, 123]]], ["More recently it could be shown that NKG2D was very uniformly expressed on the three NKp46-defined NK-cell subsets, whereas NK cells with higher NKp46 expression seem to express lower levels of NKp30 .", [["NK-cell", "ANATOMY", 99, 106], ["NK cells", "ANATOMY", 124, 132], ["NK", "ANATOMY", 145, 147], ["NK", "ANATOMY", 194, 196], ["NKG2D", "GENE_OR_GENE_PRODUCT", 37, 42], ["NKp46", "GENE_OR_GENE_PRODUCT", 85, 90], ["NK-cell", "CELL", 99, 106], ["NK cells", "CELL", 124, 132], ["NKp46", "GENE_OR_GENE_PRODUCT", 145, 150], ["NKp30", "GENE_OR_GENE_PRODUCT", 194, 199], ["NKG2D", "PROTEIN", 37, 42], ["NKp46", "PROTEIN", 85, 90], ["NK-cell subsets", "CELL_TYPE", 99, 114], ["NK cells", "CELL_TYPE", 124, 132], ["p46", "PROTEIN", 147, 150], ["NKp30", "PROTEIN", 194, 199], ["NK cells", "TEST", 124, 132], ["cell subsets", "OBSERVATION", 102, 114], ["NK cells", "OBSERVATION", 124, 132]]], ["During the evolution of mammals, two families of inhibitory NK-cell receptors that recognize classical MHC class I molecules developed: killer cell immunoglobulin-like receptors (KIR) and the Ly49 lectin-like receptors.", [["NK-cell", "ANATOMY", 60, 67], ["NK-cell", "CELL", 60, 67], ["killer cell immunoglobulin-like receptors", "GENE_OR_GENE_PRODUCT", 136, 177], ["KIR", "GENE_OR_GENE_PRODUCT", 179, 182], ["Ly49 lectin-like receptors", "GENE_OR_GENE_PRODUCT", 192, 218], ["inhibitory NK-cell receptors", "PROTEIN", 49, 77], ["MHC class I molecules", "PROTEIN", 103, 124], ["killer cell immunoglobulin-like receptors", "PROTEIN", 136, 177], ["KIR", "PROTEIN", 179, 182], ["Ly49 lectin-like receptors", "PROTEIN", 192, 218], ["killer cell immunoglobulin", "TEST", 136, 162], ["the Ly49 lectin", "TEST", 188, 203]]], ["In swine, one gene of each family was detected so far.", [["swine", "ORGANISM", 3, 8], ["swine", "SPECIES", 3, 8], ["swine", "SPECIES", 3, 8]]], ["A single KIR gene encoding for a predicted inhibitory receptor was identified in the porcine leukocyte receptor complex (Sambrook et al., 2006) .", [["leukocyte", "ANATOMY", 93, 102], ["KIR", "GENE_OR_GENE_PRODUCT", 9, 12], ["porcine leukocyte receptor", "GENE_OR_GENE_PRODUCT", 85, 111], ["KIR gene", "DNA", 9, 17], ["inhibitory receptor", "PROTEIN", 43, 62], ["porcine leukocyte receptor complex", "PROTEIN", 85, 119], ["A single KIR gene encoding", "TREATMENT", 0, 26], ["a predicted inhibitory receptor", "TREATMENT", 31, 62], ["porcine leukocyte", "OBSERVATION", 85, 102]]], ["Additionally, also a single Ly49 gene was identified, but due to a mutation in a highly conserved cysteine, which is involved in disulphide-bridge formation, the expressed protein may not be functional (Gagnier et al., 2003) .Natural killer cellsA vast heterogeneity in NK-cell numbers could be observed in swine, ranging from 1% to 24% of blood lymphocytes Mair et al., 2012) .", [["NK-cell", "ANATOMY", 270, 277], ["blood lymphocytes", "ANATOMY", 340, 357], ["cysteine", "CHEMICAL", 98, 106], ["cysteine", "CHEMICAL", 98, 106], ["disulphide", "CHEMICAL", 129, 139], ["Ly49", "GENE_OR_GENE_PRODUCT", 28, 32], ["cysteine", "AMINO_ACID", 98, 106], ["NK-cell", "CELL", 270, 277], ["swine", "ORGANISM", 307, 312], ["blood", "ORGANISM_SUBSTANCE", 340, 345], ["Ly49 gene", "DNA", 28, 37], ["blood lymphocytes", "CELL_TYPE", 340, 357], ["swine", "SPECIES", 307, 312], ["swine", "SPECIES", 307, 312], ["a mutation in a highly conserved cysteine", "PROBLEM", 65, 106], ["cell numbers", "TEST", 273, 285], ["blood lymphocytes", "TEST", 340, 357], ["bridge formation", "OBSERVATION", 140, 156], ["may not be", "UNCERTAINTY", 180, 190]]], ["Comparable to other species, porcine NK cells can be found in many anatomical locations.", [["NK cells", "ANATOMY", 37, 45], ["porcine", "ORGANISM", 29, 36], ["NK cells", "CELL", 37, 45], ["porcine NK cells", "CELL_TYPE", 29, 45], ["porcine NK cells", "TREATMENT", 29, 45], ["species", "OBSERVATION", 20, 27], ["porcine NK cells", "OBSERVATION", 29, 45], ["anatomical locations", "OBSERVATION", 67, 87]]], ["In lymphatic organs the highest frequency can be found in spleen (2-15%), whereas lower frequencies were observed in lymph nodes, tonsils, and thymus (<3%).", [["lymphatic organs", "ANATOMY", 3, 19], ["spleen", "ANATOMY", 58, 64], ["lymph nodes", "ANATOMY", 117, 128], ["tonsils", "ANATOMY", 130, 137], ["thymus", "ANATOMY", 143, 149], ["lymphatic organs", "MULTI-TISSUE_STRUCTURE", 3, 19], ["spleen", "ORGAN", 58, 64], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 117, 128], ["tonsils", "ORGAN", 130, 137], ["thymus", "ORGAN", 143, 149], ["lymphatic organs", "ANATOMY", 3, 19], ["highest", "OBSERVATION_MODIFIER", 24, 31], ["spleen", "ANATOMY", 58, 64], ["lower frequencies", "OBSERVATION_MODIFIER", 82, 99], ["lymph nodes", "OBSERVATION", 117, 128], ["tonsils", "ANATOMY", 130, 137], ["thymus", "ANATOMY", 143, 149]]], ["In the bone marrow NK cells were barely detectable Mair et al., 2012) .", [["bone marrow NK cells", "ANATOMY", 7, 27], ["bone marrow NK cells", "CELL", 7, 27], ["bone marrow NK cells", "CELL_TYPE", 7, 27], ["bone", "ANATOMY", 7, 11], ["marrow NK cells", "OBSERVATION", 12, 27]]], ["In contrast, non-lymphatic organs like the liver and lung harbor high frequencies of NK cells that can make up to 15-40% of lymphocytes in these organs (Mair et al., 2012) .", [["non-lymphatic organs", "ANATOMY", 13, 33], ["liver", "ANATOMY", 43, 48], ["lung", "ANATOMY", 53, 57], ["NK cells", "ANATOMY", 85, 93], ["lymphocytes", "ANATOMY", 124, 135], ["organs", "ANATOMY", 145, 151], ["organs", "ORGAN", 27, 33], ["liver", "ORGAN", 43, 48], ["lung", "ORGAN", 53, 57], ["NK cells", "CELL", 85, 93], ["lymphocytes", "CELL", 124, 135], ["organs", "ORGAN", 145, 151], ["NK cells", "CELL_TYPE", 85, 93], ["lymphocytes", "CELL_TYPE", 124, 135], ["NK cells", "PROBLEM", 85, 93], ["liver", "ANATOMY", 43, 48], ["lung", "ANATOMY", 53, 57], ["high frequencies", "OBSERVATION_MODIFIER", 65, 81], ["NK cells", "OBSERVATION", 85, 93], ["organs", "ANATOMY", 145, 151]]], ["Likewise, the high abundance of NK cells in nonlymphatic organs was observed in mouse and human (Gregoire et al., 2007) .", [["NK cells", "ANATOMY", 32, 40], ["nonlymphatic organs", "ANATOMY", 44, 63], ["NK cells", "CELL", 32, 40], ["organs", "ORGAN", 57, 63], ["mouse", "ORGANISM", 80, 85], ["human", "ORGANISM", 90, 95], ["NK cells", "CELL_TYPE", 32, 40], ["mouse", "SPECIES", 80, 85], ["human", "SPECIES", 90, 95], ["mouse", "SPECIES", 80, 85], ["human", "SPECIES", 90, 95], ["NK cells in nonlymphatic organs", "PROBLEM", 32, 63], ["high", "OBSERVATION_MODIFIER", 14, 18], ["abundance", "OBSERVATION_MODIFIER", 19, 28], ["NK cells", "OBSERVATION", 32, 40]]], ["Furthermore it was reported that porcine NK cells were recruited to the uterus during early pregnancy, thus indicating a special role of NK cells at the maternal-foetal interface also in swine (Engelhardt et al., 2002b) .", [["NK cells", "ANATOMY", 41, 49], ["uterus", "ANATOMY", 72, 78], ["NK cells", "ANATOMY", 137, 145], ["foetal", "ANATOMY", 162, 168], ["porcine", "ORGANISM", 33, 40], ["NK cells", "CELL", 41, 49], ["uterus", "ORGAN", 72, 78], ["NK cells", "CELL", 137, 145], ["foetal interface", "MULTI-TISSUE_STRUCTURE", 162, 178], ["porcine NK cells", "CELL_TYPE", 33, 49], ["NK cells", "CELL_TYPE", 137, 145], ["swine", "SPECIES", 187, 192], ["swine", "SPECIES", 187, 192], ["porcine NK cells", "PROBLEM", 33, 49], ["early pregnancy", "PROBLEM", 86, 101], ["NK cells", "PROBLEM", 137, 145], ["porcine NK cells", "OBSERVATION", 33, 49], ["uterus", "ANATOMY", 72, 78], ["NK cells", "OBSERVATION", 137, 145]]], ["In regard to the NKp46-defined NK-cell subsets also a vast heterogeneity between individual animals could be observed.", [["NK-cell", "ANATOMY", 31, 38], ["NKp46", "GENE_OR_GENE_PRODUCT", 17, 22], ["NK-cell", "CELL", 31, 38], ["NKp46", "PROTEIN", 17, 22], ["NK-cell subsets", "CELL_TYPE", 31, 46], ["the NKp46", "TEST", 13, 22], ["cell subsets", "OBSERVATION", 34, 46], ["vast", "OBSERVATION_MODIFIER", 54, 58], ["heterogeneity", "OBSERVATION", 59, 72]]], ["While some animals show higher frequencies of NKp46 + NK cells, others only have minor numbers within the CD3 \u00c0-CD8a + NK population (Mair et al., 2012) .", [["NKp46 + NK cells", "ANATOMY", 46, 62], ["CD3 \u00c0-CD8a + NK", "ANATOMY", 106, 121], ["NKp46", "GENE_OR_GENE_PRODUCT", 46, 51], ["CD3", "GENE_OR_GENE_PRODUCT", 106, 109], ["NK cells", "CELL_TYPE", 54, 62], ["CD3", "PROTEIN", 106, 109], ["CD8a", "PROTEIN", 112, 116], ["the CD3", "TEST", 102, 109], ["NK cells", "OBSERVATION", 54, 62], ["NK", "ANATOMY", 119, 121]]], ["In regard to anatomical distribution NKp46 \u00c0 and NKp46 + NK cells can be found in all organs analysed, but NKp46 high NK cells are more abundant in lymphatic as well as non-lymphatic organs and are only found in very low numbers in the blood (Mair et al., 2012) .", [["NKp46 \u00c0", "ANATOMY", 37, 44], ["NKp46 + NK cells", "ANATOMY", 49, 65], ["organs", "ANATOMY", 86, 92], ["NKp46 high NK cells", "ANATOMY", 107, 126], ["lymphatic", "ANATOMY", 148, 157], ["non-lymphatic organs", "ANATOMY", 169, 189], ["blood", "ANATOMY", 236, 241], ["NKp46", "GENE_OR_GENE_PRODUCT", 49, 54], ["organs", "ORGAN", 86, 92], ["NKp46", "CELL", 107, 112], ["NK cells", "CELL", 118, 126], ["lymphatic", "ORGAN", 148, 157], ["organs", "ORGAN", 183, 189], ["blood", "ORGANISM_SUBSTANCE", 236, 241], ["NKp46", "CELL_LINE", 49, 54], ["NK cells", "CELL_TYPE", 57, 65], ["NK cells", "CELL_TYPE", 118, 126], ["NK", "TEST", 49, 51], ["NK cells", "TEST", 57, 65], ["NKp", "TEST", 107, 110], ["high NK cells", "PROBLEM", 113, 126], ["NK cells", "OBSERVATION", 57, 65], ["high NK cells", "OBSERVATION", 113, 126], ["lymphatic", "ANATOMY", 148, 157], ["very", "OBSERVATION_MODIFIER", 212, 216], ["low", "OBSERVATION", 217, 220], ["blood", "ANATOMY", 236, 241]]], ["A possible explanation for this may be a differing expression pattern of chemokine receptors for migration and/or recruitment of NK cells.", [["NK cells", "ANATOMY", 129, 137], ["NK cells", "CELL", 129, 137], ["chemokine receptors", "PROTEIN", 73, 92], ["NK cells", "CELL_TYPE", 129, 137], ["chemokine receptors", "TREATMENT", 73, 92], ["migration", "PROBLEM", 97, 106], ["recruitment of NK cells", "PROBLEM", 114, 137], ["possible explanation for", "UNCERTAINTY", 2, 26], ["NK cells", "OBSERVATION", 129, 137]]], ["First evidence thereof may be the observed elevated expression of the chemokine receptor CXCR3 on cells belonging to the NKp46 high subset in spleen .", [["cells", "ANATOMY", 98, 103], ["NK", "ANATOMY", 121, 123], ["spleen", "ANATOMY", 142, 148], ["CXCR3", "GENE_OR_GENE_PRODUCT", 89, 94], ["cells", "CELL", 98, 103], ["NK", "CELL", 121, 123], ["p46", "GENE_OR_GENE_PRODUCT", 123, 126], ["spleen", "ORGAN", 142, 148], ["chemokine receptor", "PROTEIN", 70, 88], ["CXCR3", "PROTEIN", 89, 94], ["NKp46 high subset", "CELL_TYPE", 121, 138], ["the NK", "TEST", 117, 123], ["high subset in spleen", "PROBLEM", 127, 148], ["may be", "UNCERTAINTY", 23, 29], ["spleen", "ANATOMY", 142, 148]]], ["Up to date, no lineage markers and therefore no information about NK-cell ontogeny are available for porcine NK cells.", [["NK-cell", "ANATOMY", 66, 73], ["NK cells", "ANATOMY", 109, 117], ["NK-cell", "CELL", 66, 73], ["porcine", "ORGANISM", 101, 108], ["NK cells", "CELL", 109, 117], ["porcine NK cells", "CELL_TYPE", 101, 117]]], ["Nevertheless, some information about the phenotype and distribution of porcine NK cells in blood in the first six month of life was recently described in more detail (Talker et al., 2013) .", [["NK cells", "ANATOMY", 79, 87], ["blood", "ANATOMY", 91, 96], ["porcine", "ORGANISM", 71, 78], ["NK cells", "CELL", 79, 87], ["blood", "ORGANISM_SUBSTANCE", 91, 96], ["porcine NK cells", "CELL_TYPE", 71, 87], ["the phenotype", "PROBLEM", 37, 50], ["porcine NK cells", "PROBLEM", 71, 87], ["porcine NK cells", "OBSERVATION", 71, 87]]], ["Like in adult pigs, heterogeneity in NK-cell number between individual animals could also be observed in young piglets.", [["NK-cell", "ANATOMY", 37, 44], ["pigs", "ORGANISM", 14, 18], ["NK-cell", "CELL", 37, 44], ["piglets", "ORGANISM", 111, 118], ["pigs", "SPECIES", 14, 18], ["piglets", "SPECIES", 111, 118], ["pigs", "SPECIES", 14, 18], ["heterogeneity", "OBSERVATION_MODIFIER", 20, 33], ["NK", "ANATOMY", 37, 39], ["could also be observed", "UNCERTAINTY", 79, 101]]], ["Total NK-cell numbers increased after birth and declined after a peak at weeks 5-7, resulting in a relatively low, but stable plateau phase.", [["NK-cell", "ANATOMY", 6, 13], ["NK-cell", "CELL", 6, 13], ["Total NK-cell numbers", "TEST", 0, 21], ["cell", "OBSERVATION", 9, 13], ["numbers", "OBSERVATION_MODIFIER", 14, 21], ["increased", "OBSERVATION_MODIFIER", 22, 31], ["stable", "OBSERVATION_MODIFIER", 119, 125], ["plateau phase", "OBSERVATION", 126, 139]]], ["Therefore, levels of NK cells seem to vary with age and higher levels can be observed in younger pigs Talker et al., 2013) .", [["NK cells", "ANATOMY", 21, 29], ["NK cells", "CELL", 21, 29], ["NK cells", "CELL_TYPE", 21, 29], ["pigs", "SPECIES", 97, 101], ["NK cells", "PROBLEM", 21, 29]]], ["Phenotypically, extracellular markers like CD2 and CD8a were already detectable on NK cells of newborns, whereas SLA-DR expression started only after three months of age (Talker et al., 2013) .", [["extracellular", "ANATOMY", 16, 29], ["NK cells", "ANATOMY", 83, 91], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 16, 29], ["CD2", "GENE_OR_GENE_PRODUCT", 43, 46], ["CD8a", "GENE_OR_GENE_PRODUCT", 51, 55], ["NK cells", "CELL", 83, 91], ["newborns", "ORGANISM", 95, 103], ["SLA-DR", "GENE_OR_GENE_PRODUCT", 113, 119], ["extracellular markers", "PROTEIN", 16, 37], ["CD2", "PROTEIN", 43, 46], ["CD8a", "PROTEIN", 51, 55], ["NK cells", "CELL_TYPE", 83, 91], ["SLA", "PROTEIN", 113, 116], ["DR", "PROTEIN", 117, 119], ["extracellular markers", "TEST", 16, 37], ["NK cells", "OBSERVATION", 83, 91]]], ["Additionally, porcine NK cells were already distributed into NKp46-defined subsets from birth on and no age-related changes in the pattern of the NKp46-defined subsets could be observed.", [["NK cells", "ANATOMY", 22, 30], ["porcine", "ORGANISM", 14, 21], ["NK cells", "CELL", 22, 30], ["NKp46", "GENE_OR_GENE_PRODUCT", 61, 66], ["NKp46", "GENE_OR_GENE_PRODUCT", 146, 151], ["porcine NK cells", "CELL_TYPE", 14, 30], ["NKp46", "PROTEIN", 61, 66], ["NKp46", "PROTEIN", 146, 151], ["porcine NK cells", "PROBLEM", 14, 30], ["NKp46", "TEST", 61, 66], ["porcine NK cells", "OBSERVATION", 14, 30], ["subsets", "OBSERVATION_MODIFIER", 75, 82]]], ["Interestingly, all NK cells of newborns already expressed the effector molecule perforin indicating that porcine NK cells seem to be functional and competent for cytolytic activity at very early time-point in life (Talker et al., 2013) .", [["NK cells", "ANATOMY", 19, 27], ["NK cells", "ANATOMY", 113, 121], ["NK cells", "CELL", 19, 27], ["newborns", "ORGANISM", 31, 39], ["perforin", "GENE_OR_GENE_PRODUCT", 80, 88], ["porcine", "ORGANISM", 105, 112], ["NK cells", "CELL", 113, 121], ["NK cells", "CELL_TYPE", 19, 27], ["effector molecule", "PROTEIN", 62, 79], ["perforin", "PROTEIN", 80, 88], ["porcine NK cells", "CELL_TYPE", 105, 121], ["porcine NK cells", "PROBLEM", 105, 121], ["cytolytic activity", "PROBLEM", 162, 180], ["NK cells", "OBSERVATION", 19, 27]]], ["This parallels findings in NK cells of human and mice, where perforin + NK cells can be found in cord blood of newborns and in the neonatal liver (Rukavina et al., 1998; Wu et al., 2012) .", [["NK cells", "ANATOMY", 27, 35], ["perforin + NK cells", "ANATOMY", 61, 80], ["cord blood", "ANATOMY", 97, 107], ["liver", "ANATOMY", 140, 145], ["NK cells", "CELL", 27, 35], ["human", "ORGANISM", 39, 44], ["mice", "ORGANISM", 49, 53], ["perforin", "GENE_OR_GENE_PRODUCT", 61, 69], ["NK cells", "CELL", 72, 80], ["cord blood", "ORGANISM_SUBSTANCE", 97, 107], ["newborns", "ORGANISM", 111, 119], ["liver", "ORGAN", 140, 145], ["NK cells", "CELL_TYPE", 27, 35], ["perforin", "PROTEIN", 61, 69], ["NK cells", "CELL_TYPE", 72, 80], ["human", "SPECIES", 39, 44], ["mice", "SPECIES", 49, 53], ["human", "SPECIES", 39, 44], ["mice", "SPECIES", 49, 53], ["NK cells", "PROBLEM", 72, 80], ["cord blood of newborns", "PROBLEM", 97, 119], ["NK cells", "OBSERVATION", 27, 35], ["NK cells", "OBSERVATION", 72, 80], ["cord", "ANATOMY", 97, 101], ["newborns", "OBSERVATION", 111, 119], ["neonatal liver", "ANATOMY", 131, 145]]], ["However, it was reported that NK cells of newborn pigs are not competent to kill susceptible target-cell lines like K562 (Yang and Schultz, 1986) .Natural killer cellsThe two main functions of NK cells are their lytic activity and production of cytokines such as IFN-c.", [["NK cells", "ANATOMY", 30, 38], ["target-cell lines", "ANATOMY", 93, 110], ["K562", "ANATOMY", 116, 120], ["Natural killer cells", "ANATOMY", 147, 167], ["NK cells", "ANATOMY", 193, 201], ["NK cells", "CELL", 30, 38], ["newborn pigs", "ORGANISM", 42, 54], ["target-cell lines", "CELL", 93, 110], ["K562", "CELL", 116, 120], ["Natural killer cells", "CELL", 147, 167], ["NK cells", "CELL", 193, 201], ["NK cells", "CELL_TYPE", 30, 38], ["target-cell lines", "CELL_LINE", 93, 110], ["K562", "CELL_LINE", 116, 120], ["Natural killer cells", "CELL_TYPE", 147, 167], ["NK cells", "CELL_TYPE", 193, 201], ["cytokines", "PROTEIN", 245, 254], ["IFN", "PROTEIN", 263, 266], ["pigs", "SPECIES", 50, 54], ["pigs", "SPECIES", 50, 54], ["NK cells of newborn pigs", "TREATMENT", 30, 54], ["Natural killer cells", "TREATMENT", 147, 167], ["NK cells", "TREATMENT", 193, 201], ["cytokines", "PROBLEM", 245, 254], ["NK cells", "OBSERVATION", 30, 38], ["cell lines", "OBSERVATION", 100, 110], ["killer cells", "OBSERVATION", 155, 167], ["two", "OBSERVATION_MODIFIER", 171, 174], ["main", "OBSERVATION_MODIFIER", 175, 179], ["NK cells", "OBSERVATION", 193, 201], ["lytic", "OBSERVATION_MODIFIER", 212, 217], ["activity", "OBSERVATION_MODIFIER", 218, 226]]], ["Porcine NK cells stimulated with different cytokines including IL-2, IL-12, IL-15, IL-18, and IFNa increased the expression of CD25 and perforin and induced the production of IFN-c in porcine NK cells (Pintaric et al., 2008; Toka et al., 2009b) .", [["NK cells", "ANATOMY", 8, 16], ["NK cells", "ANATOMY", 192, 200], ["Porcine", "ORGANISM", 0, 7], ["NK cells", "CELL", 8, 16], ["IL-2", "GENE_OR_GENE_PRODUCT", 63, 67], ["IL-12", "GENE_OR_GENE_PRODUCT", 69, 74], ["IL-15", "GENE_OR_GENE_PRODUCT", 76, 81], ["IL-18", "GENE_OR_GENE_PRODUCT", 83, 88], ["IFNa", "GENE_OR_GENE_PRODUCT", 94, 98], ["CD25", "GENE_OR_GENE_PRODUCT", 127, 131], ["perforin", "GENE_OR_GENE_PRODUCT", 136, 144], ["IFN-c", "GENE_OR_GENE_PRODUCT", 175, 180], ["porcine", "ORGANISM", 184, 191], ["NK cells", "CELL", 192, 200], ["Porcine NK cells", "CELL_TYPE", 0, 16], ["cytokines", "PROTEIN", 43, 52], ["IL-18", "PROTEIN", 83, 88], ["IFNa", "PROTEIN", 94, 98], ["CD25", "PROTEIN", 127, 131], ["perforin", "PROTEIN", 136, 144], ["IFN-c", "PROTEIN", 175, 180], ["porcine NK cells", "CELL_TYPE", 184, 200], ["Porcine", "SPECIES", 0, 7], ["Porcine NK cells", "TREATMENT", 0, 16], ["different cytokines", "TEST", 33, 52], ["IL", "TEST", 63, 65], ["IL", "TEST", 69, 71], ["IL", "TEST", 76, 78], ["IL", "TEST", 83, 85], ["perforin", "TREATMENT", 136, 144], ["IFN-c in porcine NK cells", "TREATMENT", 175, 200], ["NK cells", "OBSERVATION", 8, 16]]], ["Resting porcine NK cells showed only low cytolytic activity against susceptible target-cell lines or infected cells, but this lytic activity could be enhanced by stimulation with different combinations of the above mentioned cytokines (Pintaric et al., 2008; Toka et al., 2009b) .", [["NK cells", "ANATOMY", 16, 24], ["target-cell lines", "ANATOMY", 80, 97], ["cells", "ANATOMY", 110, 115], ["porcine", "ORGANISM", 8, 15], ["NK cells", "CELL", 16, 24], ["target-cell lines", "CELL", 80, 97], ["cells", "CELL", 110, 115], ["Resting porcine NK cells", "CELL_TYPE", 0, 24], ["susceptible target-cell lines", "CELL_LINE", 68, 97], ["infected cells", "CELL_TYPE", 101, 115], ["cytokines", "PROTEIN", 225, 234], ["Resting porcine NK cells", "TEST", 0, 24], ["low cytolytic activity", "PROBLEM", 37, 59], ["cell lines", "PROBLEM", 87, 97], ["infected cells", "PROBLEM", 101, 115], ["this lytic activity", "PROBLEM", 121, 140], ["NK cells", "OBSERVATION", 16, 24], ["low cytolytic", "OBSERVATION_MODIFIER", 37, 50], ["cell lines", "OBSERVATION", 87, 97], ["infected cells", "OBSERVATION", 101, 115], ["lytic", "OBSERVATION_MODIFIER", 126, 131]]], ["Similar effects on NK-cell function and effector molecule production could be observed after stimulation of NK cells with TLR agonists.", [["NK-cell", "ANATOMY", 19, 26], ["NK cells", "ANATOMY", 108, 116], ["NK-cell", "CELL", 19, 26], ["NK cells", "CELL", 108, 116], ["TLR agonists", "GENE_OR_GENE_PRODUCT", 122, 134], ["NK cells", "CELL_TYPE", 108, 116], ["TLR", "PROTEIN", 122, 125], ["effector molecule production", "PROBLEM", 40, 68], ["stimulation of NK cells", "TREATMENT", 93, 116], ["TLR agonists", "TREATMENT", 122, 134], ["cell function", "OBSERVATION", 22, 35]]], ["TLR7, TLR8 as well as TLR9 agonists showed either direct effect on NK cells that were shown to express TLR7 and TLR8 on mRNA level (Toka et al., 2009c) , or via indirect effect by cytokines produced by activated accessory bystander cells (Dar et al., 2008; Toka et al., 2009c) .Natural killer cellsIn human as well as in mouse, distinct subsets of NK cells exist that possess different functional properties (Cooper et al., 2001; Hayakawa et al., 2006) .", [["NK cells", "ANATOMY", 67, 75], ["accessory bystander cells", "ANATOMY", 212, 237], ["Natural killer cells", "ANATOMY", 278, 298], ["NK cells", "ANATOMY", 348, 356], ["TLR7", "GENE_OR_GENE_PRODUCT", 0, 4], ["TLR8", "GENE_OR_GENE_PRODUCT", 6, 10], ["TLR9", "GENE_OR_GENE_PRODUCT", 22, 26], ["NK cells", "CELL", 67, 75], ["TLR7", "GENE_OR_GENE_PRODUCT", 103, 107], ["TLR8", "GENE_OR_GENE_PRODUCT", 112, 116], ["accessory bystander cells", "CELL", 212, 237], ["Natural killer cells", "CELL", 278, 298], ["human", "ORGANISM", 301, 306], ["mouse", "ORGANISM", 321, 326], ["NK cells", "CELL", 348, 356], ["TLR7", "PROTEIN", 0, 4], ["TLR8", "PROTEIN", 6, 10], ["TLR9", "PROTEIN", 22, 26], ["NK cells", "CELL_TYPE", 67, 75], ["TLR7", "PROTEIN", 103, 107], ["TLR8", "PROTEIN", 112, 116], ["cytokines", "PROTEIN", 180, 189], ["activated accessory bystander cells", "CELL_TYPE", 202, 237], ["Natural killer cells", "CELL_TYPE", 278, 298], ["NK cells", "CELL_TYPE", 348, 356], ["human", "SPECIES", 301, 306], ["mouse", "SPECIES", 321, 326], ["human", "SPECIES", 301, 306], ["mouse", "SPECIES", 321, 326], ["TLR7", "TREATMENT", 0, 4], ["TLR8", "TREATMENT", 6, 10], ["TLR9 agonists", "TREATMENT", 22, 35], ["direct effect on NK cells", "PROBLEM", 50, 75], ["TLR7", "TEST", 103, 107], ["mRNA level", "TEST", 120, 130], ["Natural killer cells", "TREATMENT", 278, 298], ["NK cells", "TREATMENT", 348, 356], ["killer cells", "OBSERVATION", 286, 298], ["NK cells", "OBSERVATION", 348, 356]]], ["Likewise, the three NKp46-defined NK-cell subsets in swine show different capacities to produce cytokines and have distinct degranulation properties.", [["NK-cell", "ANATOMY", 34, 41], ["NKp46", "GENE_OR_GENE_PRODUCT", 20, 25], ["NK-cell", "CELL", 34, 41], ["swine", "ORGANISM", 53, 58], ["NKp46", "PROTEIN", 20, 25], ["NK-cell subsets", "CELL_TYPE", 34, 49], ["cytokines", "PROTEIN", 96, 105], ["swine", "SPECIES", 53, 58], ["swine", "SPECIES", 53, 58], ["different capacities", "PROBLEM", 64, 84], ["cytokines", "PROBLEM", 96, 105], ["distinct degranulation properties", "PROBLEM", 115, 148], ["cell subsets", "OBSERVATION", 37, 49], ["different capacities", "OBSERVATION", 64, 84], ["distinct", "OBSERVATION_MODIFIER", 115, 123], ["degranulation properties", "OBSERVATION", 124, 148]]], ["NKp46 expression levels seem to be correlated with IFN-c and TNF-a production.", [["NKp46", "GENE_OR_GENE_PRODUCT", 0, 5], ["IFN-c", "GENE_OR_GENE_PRODUCT", 51, 56], ["TNF-a", "GENE_OR_GENE_PRODUCT", 61, 66], ["NKp46", "PROTEIN", 0, 5], ["IFN", "PROTEIN", 51, 54], ["TNF", "PROTEIN", 61, 64], ["NKp46 expression levels", "TEST", 0, 23], ["IFN", "TEST", 51, 54], ["TNF", "PROBLEM", 61, 64]]], ["Therefore, NKp46 high NK cells produced the highest levels of these cytokines after activation, whereas NKp46 \u00c0 cells produced the lowest levels (Mair et al., 2012 .", [["NK cells", "ANATOMY", 22, 30], ["NKp46 \u00c0 cells", "ANATOMY", 104, 117], ["NKp46", "GENE_OR_GENE_PRODUCT", 11, 16], ["NK cells", "CELL", 22, 30], ["NKp46 \u00c0 cells", "CELL", 104, 117], ["NKp46", "PROTEIN", 11, 16], ["NK cells", "CELL_TYPE", 22, 30], ["cytokines", "PROTEIN", 68, 77], ["NKp46 \u00c0 cells", "CELL_LINE", 104, 117], ["NKp46 high NK cells", "PROBLEM", 11, 30], ["cells", "TEST", 112, 117], ["high NK cells", "OBSERVATION", 17, 30]]], ["Although both, NKp46 \u00c0 as well as NKp46 + NK cells had similar cytolytic properties towards susceptible target-cell lines (Mair et al., 2012) , NKp46 \u00c0 NK cells only showed a reduced degranulation capacity after triggering of activating receptors CD16 and NKp46 compared to the NKp46 + and NKp46 high NK cells .Natural killer cellsSince NK cells play important roles in the defence against viral, parasitic, and bacterial pathogens (Lodoen and Lanier, 2006) , porcine NK cells were investigated as to the immune response against various infectious agents.", [["NK", "ANATOMY", 15, 17], ["NKp46 + NK cells", "ANATOMY", 34, 50], ["target-cell lines", "ANATOMY", 104, 121], ["NKp46 \u00c0 NK cells", "ANATOMY", 144, 160], ["NK", "ANATOMY", 256, 258], ["NKp46 +", "ANATOMY", 278, 285], ["NKp46 high NK cells", "ANATOMY", 290, 309], ["Natural killer cells", "ANATOMY", 311, 331], ["NK cells", "ANATOMY", 337, 345], ["NK cells", "ANATOMY", 468, 476], ["viral, parasitic, and bacterial pathogens", "DISEASE", 390, 431], ["NKp46", "GENE_OR_GENE_PRODUCT", 34, 39], ["target-cell lines", "CELL", 104, 121], ["NKp46", "CELL", 144, 149], ["NK cells", "CELL", 152, 160], ["CD16", "GENE_OR_GENE_PRODUCT", 247, 251], ["NKp46", "GENE_OR_GENE_PRODUCT", 256, 261], ["NKp46", "CELL", 278, 283], ["NK cells", "CELL", 301, 309], ["Natural killer cells", "CELL", 311, 331], ["NK cells", "CELL", 337, 345], ["porcine", "ORGANISM", 460, 467], ["NK cells", "CELL", 468, 476], ["NKp46", "CELL_LINE", 34, 39], ["NK cells", "CELL_TYPE", 42, 50], ["susceptible target-cell lines", "CELL_LINE", 92, 121], ["NKp46", "CELL_LINE", 144, 149], ["NK cells", "CELL_TYPE", 152, 160], ["activating receptors", "PROTEIN", 226, 246], ["CD16", "PROTEIN", 247, 251], ["NKp46", "PROTEIN", 256, 261], ["NKp46", "CELL_LINE", 278, 283], ["NKp46 high NK cells", "CELL_LINE", 290, 309], ["Natural killer cells", "CELL_TYPE", 311, 331], ["NK cells", "CELL_TYPE", 337, 345], ["porcine NK cells", "CELL_TYPE", 460, 476], ["porcine", "SPECIES", 460, 467], ["porcine", "SPECIES", 460, 467], ["NKp", "TEST", 34, 37], ["NK cells", "TEST", 42, 50], ["cell lines", "TEST", 111, 121], ["Mair et al.", "TEST", 123, 134], ["NKp", "TEST", 144, 147], ["NK cells", "TEST", 152, 160], ["a reduced degranulation capacity", "PROBLEM", 173, 205], ["CD16", "TEST", 247, 251], ["NKp", "TEST", 256, 259], ["the NKp", "TEST", 274, 281], ["NKp", "TEST", 290, 293], ["high NK cells", "PROBLEM", 296, 309], ["Natural killer cells", "TREATMENT", 311, 331], ["NK cells", "TREATMENT", 337, 345], ["viral, parasitic, and bacterial pathogens", "PROBLEM", 390, 431], ["porcine NK cells", "TREATMENT", 460, 476], ["various infectious agents", "TREATMENT", 529, 554], ["cell lines", "OBSERVATION", 111, 121], ["reduced", "OBSERVATION_MODIFIER", 175, 182], ["degranulation capacity", "OBSERVATION", 183, 205], ["high NK cells", "OBSERVATION", 296, 309], ["killer cells", "OBSERVATION", 319, 331], ["bacterial pathogens", "OBSERVATION", 412, 431]]], ["Increased NK-cell numbers were observed during Isospora suis infection (Worliczek et al., 2010) , whereas reduced numbers were found after PRRSV and PCV2 infections (Nielsen et al., 2003; Shi et al., 2008) .", [["NK-cell", "ANATOMY", 10, 17], ["Isospora suis infection", "DISEASE", 47, 70], ["PCV2 infections", "DISEASE", 149, 164], ["NK-cell", "CELL", 10, 17], ["Isospora suis", "ORGANISM", 47, 60], ["PRRSV", "ORGANISM", 139, 144], ["PCV2", "ORGANISM", 149, 153], ["Isospora suis", "SPECIES", 47, 60], ["Isospora suis", "SPECIES", 47, 60], ["PRRSV", "SPECIES", 139, 144], ["PCV2", "SPECIES", 149, 153], ["Increased NK-cell numbers", "PROBLEM", 0, 25], ["Isospora suis infection", "PROBLEM", 47, 70], ["reduced numbers", "PROBLEM", 106, 121], ["PRRSV", "PROBLEM", 139, 144], ["PCV2 infections", "PROBLEM", 149, 164], ["cell numbers", "OBSERVATION", 13, 25], ["PCV2 infections", "OBSERVATION", 149, 164]]], ["Additionally, NK cell function may be influenced by infections.", [["NK cell", "ANATOMY", 14, 21], ["infections", "DISEASE", 52, 62], ["NK cell", "CELL", 14, 21], ["NK cell function", "TEST", 14, 30], ["infections", "PROBLEM", 52, 62], ["NK cell function", "OBSERVATION", 14, 30], ["infections", "OBSERVATION", 52, 62]]], ["Thus, a decrease in cytolytic activity of porcine NK cells could be observed after ASFV infection (Norley and Wardley, 1983) as well as in PRRSV (Cao et al., 2013; Dwivedi et al., 2012; Jung et al., 2009; Renukaradhya et al., 2010) and porcine respiratory corona virus infections (Jung et al., 2009; Renukaradhya et al., 2010) .", [["NK cells", "ANATOMY", 50, 58], ["infection", "DISEASE", 88, 97], ["respiratory corona virus infections", "DISEASE", 244, 279], ["porcine", "ORGANISM", 42, 49], ["NK cells", "CELL", 50, 58], ["ASFV", "ORGANISM", 83, 87], ["PRRSV", "ORGANISM", 139, 144], ["porcine", "ORGANISM", 236, 243], ["respiratory corona virus", "ORGANISM", 244, 268], ["porcine NK cells", "CELL_TYPE", 42, 58], ["porcine", "SPECIES", 236, 243], ["ASFV", "SPECIES", 83, 87], ["PRRSV", "SPECIES", 139, 144], ["porcine respiratory corona virus", "SPECIES", 236, 268], ["a decrease in cytolytic activity of porcine NK cells", "PROBLEM", 6, 58], ["ASFV infection", "PROBLEM", 83, 97], ["porcine respiratory corona virus infections", "PROBLEM", 236, 279], ["decrease", "OBSERVATION_MODIFIER", 8, 16], ["cytolytic activity", "OBSERVATION", 20, 38], ["porcine NK cells", "OBSERVATION", 42, 58], ["ASFV", "OBSERVATION_MODIFIER", 83, 87], ["infection", "OBSERVATION", 88, 97], ["respiratory", "ANATOMY", 244, 255], ["corona virus", "OBSERVATION", 256, 268]]], ["Moreover decreased lytic function and reduced numbers of IFN-c producing NK cells were found following FMDV infection (Toka et al., 2009a) .Natural killer cellsIn summary, a more detailed picture on phenotypical and functional characteristics of porcine NK cells has evolved during the last years, indicating similarities but also peculiarities compared to the knowledge on human and murine NK cells.", [["NK cells", "ANATOMY", 73, 81], ["Natural killer cells", "ANATOMY", 140, 160], ["NK cells", "ANATOMY", 254, 262], ["NK cells", "ANATOMY", 391, 399], ["FMDV infection", "DISEASE", 103, 117], ["IFN-c", "GENE_OR_GENE_PRODUCT", 57, 62], ["NK cells", "CELL", 73, 81], ["FMDV", "ORGANISM", 103, 107], ["Natural killer cells", "CELL", 140, 160], ["porcine", "ORGANISM", 246, 253], ["NK cells", "CELL", 254, 262], ["human", "ORGANISM", 374, 379], ["murine", "ORGANISM", 384, 390], ["NK cells", "CELL", 391, 399], ["IFN-c producing NK cells", "CELL_TYPE", 57, 81], ["Natural killer cells", "CELL_TYPE", 140, 160], ["porcine NK cells", "CELL_TYPE", 246, 262], ["human and murine NK cells", "CELL_TYPE", 374, 399], ["FMDV", "SPECIES", 103, 107], ["human", "SPECIES", 374, 379], ["murine", "SPECIES", 384, 390], ["FMDV", "SPECIES", 103, 107], ["human", "SPECIES", 374, 379], ["decreased lytic function", "PROBLEM", 9, 33], ["IFN", "TEST", 57, 60], ["NK cells", "PROBLEM", 73, 81], ["FMDV infection", "PROBLEM", 103, 117], ["Natural killer cells", "TREATMENT", 140, 160], ["porcine NK cells", "PROBLEM", 246, 262], ["decreased", "OBSERVATION_MODIFIER", 9, 18], ["lytic", "OBSERVATION_MODIFIER", 19, 24], ["reduced", "OBSERVATION_MODIFIER", 38, 45], ["numbers", "OBSERVATION_MODIFIER", 46, 53], ["NK cells", "OBSERVATION", 73, 81], ["killer cells", "OBSERVATION", 148, 160], ["porcine NK cells", "OBSERVATION", 246, 262], ["murine NK cells", "OBSERVATION", 384, 399]]], ["Undoubtedly, due to its unique position as a large animal model, the pig still holds much promise for further discoveries in NK-cell biology.Gamma delta T cellsIn all vertebrates, T cells can be separated into two populations on the basis of the expression of different forms of the T-cell receptor (TCR): ab T cells and cd T cells. cd T cells are evolutionary highly conserved immune cells (Hayday, 2000) .", [["NK-cell", "ANATOMY", 125, 132], ["Gamma delta T cells", "ANATOMY", 141, 160], ["T cells", "ANATOMY", 180, 187], ["T-cell", "ANATOMY", 283, 289], ["T cells", "ANATOMY", 309, 316], ["cd T cells", "ANATOMY", 321, 331], ["cd T cells", "ANATOMY", 333, 343], ["immune cells", "ANATOMY", 378, 390], ["pig", "ORGANISM", 69, 72], ["NK-cell", "CELL", 125, 132], ["Gamma delta", "GENE_OR_GENE_PRODUCT", 141, 152], ["T cells", "CELL", 180, 187], ["T-cell receptor", "GENE_OR_GENE_PRODUCT", 283, 298], ["TCR", "GENE_OR_GENE_PRODUCT", 300, 303], ["cd T cells", "CELL", 321, 331], ["cd T cells", "CELL", 333, 343], ["immune cells", "CELL", 378, 390], ["Gamma delta T cells", "CELL_LINE", 141, 160], ["T cells", "CELL_TYPE", 180, 187], ["T-cell receptor (TCR): ab T cells", "CELL_TYPE", 283, 316], ["cd T cells", "CELL_TYPE", 321, 331], ["cd T cells", "CELL_TYPE", 333, 343], ["immune cells", "CELL_TYPE", 378, 390], ["pig", "SPECIES", 69, 72], ["a large animal model", "TREATMENT", 43, 63], ["the pig", "TREATMENT", 65, 72], ["Gamma delta T cells", "PROBLEM", 141, 160], ["ab T cells", "PROBLEM", 306, 316], ["cd T cells", "PROBLEM", 321, 331], ["cd T cells", "TEST", 333, 343], ["large", "OBSERVATION_MODIFIER", 45, 50], ["delta T cells", "OBSERVATION", 147, 160], ["all vertebrates", "ANATOMY", 163, 178], ["immune cells", "OBSERVATION", 378, 390]]], ["Depending on their tissue distribution and respective TCR recombination, cd T cells can perform different functions including (i) protective immunity against extracellular and intracellular pathogens, (ii) tumor surveillance, (iii) modulation of innate and adaptive immune responses, (iv) tissue healing and epithelial cell maintenance and (v) regulation of physiological organ function (Bonneville et al., 2010) .", [["tissue", "ANATOMY", 19, 25], ["cd T cells", "ANATOMY", 73, 83], ["extracellular", "ANATOMY", 158, 171], ["intracellular", "ANATOMY", 176, 189], ["tumor", "ANATOMY", 206, 211], ["tissue", "ANATOMY", 289, 295], ["epithelial cell", "ANATOMY", 308, 323], ["organ", "ANATOMY", 372, 377], ["tumor", "DISEASE", 206, 211], ["tissue", "TISSUE", 19, 25], ["TCR", "GENE_OR_GENE_PRODUCT", 54, 57], ["cd T cells", "CELL", 73, 83], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 158, 171], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 176, 189], ["tumor", "CANCER", 206, 211], ["tissue", "TISSUE", 289, 295], ["epithelial cell", "CELL", 308, 323], ["organ", "ORGAN", 372, 377], ["TCR", "PROTEIN", 54, 57], ["cd T cells", "CELL_TYPE", 73, 83], ["respective TCR recombination", "TREATMENT", 43, 71], ["cd T cells", "PROBLEM", 73, 83], ["extracellular and intracellular pathogens", "PROBLEM", 158, 199], ["tumor surveillance", "TEST", 206, 224], ["iv) tissue healing", "TREATMENT", 285, 303], ["epithelial cell maintenance", "TREATMENT", 308, 335], ["intracellular pathogens", "OBSERVATION", 176, 199], ["healing", "OBSERVATION_MODIFIER", 296, 303], ["epithelial cell", "OBSERVATION", 308, 323]]], ["Moreover, activation of cd T cells is not only transmitted via the TCR but also by receptors associated with NK cells or myeloid cells, like NKG2D, NKp46 or TLRs (Bonneville et al., 2010; Correia et al., 2011) .", [["cd T cells", "ANATOMY", 24, 34], ["NK cells", "ANATOMY", 109, 117], ["myeloid cells", "ANATOMY", 121, 134], ["NK", "ANATOMY", 148, 150], ["cd T", "GENE_OR_GENE_PRODUCT", 24, 28], ["TCR", "GENE_OR_GENE_PRODUCT", 67, 70], ["NK cells", "CELL", 109, 117], ["myeloid cells", "CELL", 121, 134], ["NKG2D", "GENE_OR_GENE_PRODUCT", 141, 146], ["NKp46", "GENE_OR_GENE_PRODUCT", 148, 153], ["TLRs", "GENE_OR_GENE_PRODUCT", 157, 161], ["cd T cells", "CELL_TYPE", 24, 34], ["TCR", "PROTEIN", 67, 70], ["NK cells", "CELL_TYPE", 109, 117], ["myeloid cells", "CELL_TYPE", 121, 134], ["NKG2D", "PROTEIN", 141, 146], ["NKp46", "PROTEIN", 148, 153], ["TLRs", "PROTEIN", 157, 161], ["cd T cells", "PROBLEM", 24, 34], ["NK cells", "PROBLEM", 109, 117], ["myeloid cells", "PROBLEM", 121, 134], ["TLRs", "TEST", 157, 161], ["NK cells", "OBSERVATION", 109, 117], ["myeloid cells", "OBSERVATION", 121, 134]]], ["Hence, cd T cells display features of both, the innate and adaptive immune system and are therefore covered in this review.Gamma delta T cellsTheir frequency and distribution varies greatly among different species.", [["cd T cells", "ANATOMY", 7, 17], ["immune system", "ANATOMY", 68, 81], ["Gamma delta T cells", "ANATOMY", 123, 142], ["cd T cells", "CELL", 7, 17], ["Gamma delta", "GENE_OR_GENE_PRODUCT", 123, 134], ["cd T cells", "CELL_TYPE", 7, 17], ["Gamma delta T cells", "CELL_LINE", 123, 142], ["Gamma delta T cells", "PROBLEM", 123, 142], ["delta T cells", "OBSERVATION", 129, 142], ["distribution", "OBSERVATION_MODIFIER", 162, 174], ["varies", "OBSERVATION_MODIFIER", 175, 181], ["greatly", "OBSERVATION_MODIFIER", 182, 189], ["different species", "OBSERVATION", 196, 213]]], ["In most adult animals and humans, cd T cells represent only a small proportion (1-5%) in the blood and peripheral organs but are enriched in epithelial surfaces (Carding and Egan, 2002) .Gamma delta T cellsTogether with ruminants and chicken, pigs are cd -''high'' species in which cd T cells are strongly enriched in the blood (approximately 18-47%) and can constitute up to 85% of total lymphocytes .", [["cd T cells", "ANATOMY", 34, 44], ["blood", "ANATOMY", 93, 98], ["peripheral organs", "ANATOMY", 103, 120], ["epithelial surfaces", "ANATOMY", 141, 160], ["cd T cells", "ANATOMY", 282, 292], ["blood", "ANATOMY", 322, 327], ["lymphocytes", "ANATOMY", 389, 400], ["humans", "ORGANISM", 26, 32], ["cd T cells", "CELL", 34, 44], ["blood", "ORGANISM_SUBSTANCE", 93, 98], ["peripheral organs", "MULTI-TISSUE_STRUCTURE", 103, 120], ["epithelial surfaces", "TISSUE", 141, 160], ["Gamma delta T", "GENE_OR_GENE_PRODUCT", 187, 200], ["chicken", "ORGANISM", 234, 241], ["pigs", "ORGANISM", 243, 247], ["cd T cells", "CELL", 282, 292], ["blood", "ORGANISM_SUBSTANCE", 322, 327], ["lymphocytes", "CELL", 389, 400], ["cd T cells", "CELL_TYPE", 34, 44], ["cd T cells", "CELL_TYPE", 282, 292], ["lymphocytes", "CELL_TYPE", 389, 400], ["humans", "SPECIES", 26, 32], ["ruminants", "SPECIES", 220, 229], ["chicken", "SPECIES", 234, 241], ["pigs", "SPECIES", 243, 247], ["humans", "SPECIES", 26, 32], ["chicken", "SPECIES", 234, 241], ["pigs", "SPECIES", 243, 247], ["Gamma delta T cellsTogether", "PROBLEM", 187, 214], ["high'' species", "PROBLEM", 258, 272], ["the blood", "TEST", 318, 327], ["most adult", "OBSERVATION_MODIFIER", 3, 13], ["animals", "OBSERVATION", 14, 21], ["small", "OBSERVATION_MODIFIER", 62, 67], ["blood", "ANATOMY", 93, 98], ["peripheral", "ANATOMY_MODIFIER", 103, 113], ["organs", "ANATOMY", 114, 120], ["enriched", "OBSERVATION_MODIFIER", 129, 137], ["epithelial", "ANATOMY_MODIFIER", 141, 151], ["surfaces", "OBSERVATION_MODIFIER", 152, 160], ["blood", "ANATOMY", 322, 327]]], ["In conventional pigs, substantial cd T cell proportions can also be found in spleen (18-57%), within liverresiding lymphocytes (22-37%) and to a lower extent in thymus (5-31%) (Sedlak et al., 2014) .", [["cd T cell", "ANATOMY", 34, 43], ["spleen", "ANATOMY", 77, 83], ["liverresiding lymphocytes", "ANATOMY", 101, 126], ["thymus", "ANATOMY", 161, 167], ["pigs", "ORGANISM", 16, 20], ["cd T cell", "CELL", 34, 43], ["spleen", "ORGAN", 77, 83], ["liverresiding lymphocytes", "CELL", 101, 126], ["thymus", "ORGAN", 161, 167], ["liverresiding lymphocytes", "CELL_TYPE", 101, 126], ["pigs", "SPECIES", 16, 20], ["pigs", "SPECIES", 16, 20], ["substantial cd T cell proportions", "PROBLEM", 22, 55], ["spleen", "TEST", 77, 83], ["liverresiding lymphocytes", "TEST", 101, 126], ["substantial", "OBSERVATION_MODIFIER", 22, 33], ["cd T cell proportions", "OBSERVATION", 34, 55], ["spleen", "ANATOMY", 77, 83], ["liverresiding lymphocytes", "OBSERVATION", 101, 126], ["lower extent", "OBSERVATION_MODIFIER", 145, 157], ["thymus", "ANATOMY", 161, 167]]], ["Intermediate proportions are present within lymphocytes residing in lungs ($15%) and the intestine ($10%).", [["lymphocytes", "ANATOMY", 44, 55], ["lungs", "ANATOMY", 68, 73], ["intestine", "ANATOMY", 89, 98], ["lymphocytes", "CELL", 44, 55], ["lungs", "ORGAN", 68, 73], ["intestine", "ORGAN", 89, 98], ["lymphocytes", "CELL_TYPE", 44, 55], ["lungs", "ANATOMY", 68, 73], ["intestine", "ANATOMY", 89, 98]]], ["Lower frequencies have been reported for the bone marrow ($7%), tonsils ($5%), and lymph nodes (average 5-6%) (Sedlak et al., 2014; Stepanova and Sinkora, 2012) .", [["bone marrow", "ANATOMY", 45, 56], ["tonsils", "ANATOMY", 64, 71], ["lymph nodes", "ANATOMY", 83, 94], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 45, 56], ["tonsils", "ORGAN", 64, 71], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 83, 94], ["Lower frequencies", "PROBLEM", 0, 17], ["tonsils", "TEST", 64, 71], ["lymph nodes", "TEST", 83, 94], ["bone marrow", "ANATOMY", 45, 56], ["tonsils", "ANATOMY", 64, 71], ["lymph nodes", "OBSERVATION", 83, 94]]], ["In regard to TCR-diversity in pigs, the existence of 28 Vd, 6 Dd, 4 Jd and 1Cd gene segment has been reported , while to date no information is available about the germline encoded gene segments of the c-chain.", [["TCR", "CHEMICAL", 13, 16], ["TCR", "GENE_OR_GENE_PRODUCT", 13, 16], ["pigs", "ORGANISM", 30, 34], ["Dd", "GENE_OR_GENE_PRODUCT", 62, 64], ["Jd", "GENE_OR_GENE_PRODUCT", 68, 70], ["1Cd", "GENE_OR_GENE_PRODUCT", 75, 78], ["TCR", "PROTEIN", 13, 16], ["1Cd gene segment", "DNA", 75, 91], ["germline encoded gene segments", "DNA", 164, 194], ["c-chain", "DNA", 202, 209], ["pigs", "SPECIES", 30, 34], ["pigs", "SPECIES", 30, 34], ["segment", "ANATOMY_MODIFIER", 84, 91], ["c-chain", "ANATOMY", 202, 209]]], ["It was also shown that the porcine d-chain repertoire has the potential of an enormous recombinatorial diversity -greater than that described for humans and mice.", [["humans", "ORGANISM", 146, 152], ["mice", "ORGANISM", 157, 161], ["porcine d-chain repertoire", "PROTEIN", 27, 53], ["humans", "SPECIES", 146, 152], ["mice", "SPECIES", 157, 161], ["humans", "SPECIES", 146, 152], ["mice", "SPECIES", 157, 161], ["the porcine d-chain repertoire", "TREATMENT", 23, 53], ["an enormous recombinatorial diversity", "PROBLEM", 75, 112], ["enormous", "OBSERVATION_MODIFIER", 78, 86], ["recombinatorial diversity", "OBSERVATION", 87, 112], ["greater", "OBSERVATION_MODIFIER", 114, 121]]], ["Similar to human and mice, the porcine TCR d repertoire is diverse in young piglets and becomes oligoclonal and compartmentalized in 2-to 5-year old pigs at mucosal and extraintestinal sites, suggesting that intestinal cd T cells are shaped by selection over time (Holtmeier et al., 2002) .", [["mucosal", "ANATOMY", 157, 164], ["extraintestinal sites", "ANATOMY", 169, 190], ["intestinal cd T cells", "ANATOMY", 208, 229], ["TCR", "CHEMICAL", 39, 42], ["human", "ORGANISM", 11, 16], ["mice", "ORGANISM", 21, 25], ["porcine", "ORGANISM", 31, 38], ["TCR", "GENE_OR_GENE_PRODUCT", 39, 42], ["piglets", "ORGANISM", 76, 83], ["pigs", "ORGANISM", 149, 153], ["mucosal", "MULTI-TISSUE_STRUCTURE", 157, 164], ["extraintestinal sites", "MULTI-TISSUE_STRUCTURE", 169, 190], ["intestinal cd T cells", "CELL", 208, 229], ["porcine TCR d repertoire", "PROTEIN", 31, 55], ["intestinal cd T cells", "CELL_TYPE", 208, 229], ["human", "SPECIES", 11, 16], ["mice", "SPECIES", 21, 25], ["piglets", "SPECIES", 76, 83], ["pigs", "SPECIES", 149, 153], ["human", "SPECIES", 11, 16], ["mice", "SPECIES", 21, 25], ["pigs", "SPECIES", 149, 153], ["the porcine TCR d repertoire", "TREATMENT", 27, 55], ["oligoclonal", "PROBLEM", 96, 107], ["old pigs at mucosal and extraintestinal sites", "PROBLEM", 145, 190], ["intestinal cd T cells", "PROBLEM", 208, 229], ["diverse", "OBSERVATION_MODIFIER", 59, 66], ["oligoclonal", "OBSERVATION", 96, 107], ["mucosal", "ANATOMY", 157, 164], ["extraintestinal sites", "ANATOMY", 169, 190], ["intestinal", "ANATOMY", 208, 218]]], ["Knowledge on the expression of other receptors involved in the activation of innate immune cells is only fragmentary in the pig.", [["immune cells", "ANATOMY", 84, 96], ["innate immune cells", "CELL", 77, 96], ["pig", "ORGANISM", 124, 127], ["innate immune cells", "CELL_TYPE", 77, 96], ["pig", "SPECIES", 124, 127], ["pig", "SPECIES", 124, 127], ["innate immune cells", "TREATMENT", 77, 96]]], ["However, a subset of porcine cd T cells may express the activating natural killer receptor NKG2D, commonly present in NK cells, CD8 + ab T cells and cd T cells similar to humans, mice, and ruminants .Gamma delta T cellsA phenotypical discrimination of cd T cells in swine was achieved by differences in CD2/CD8a expression, demonstrating the existence of CD2 \u00c0 CD8a \u00c0 , CD2 + CD8a + and CD2 + CD8a \u00c0 cd T cells.", [["cd T cells", "ANATOMY", 29, 39], ["NK cells", "ANATOMY", 118, 126], ["CD8 + ab T cells", "ANATOMY", 128, 144], ["cd T cells", "ANATOMY", 149, 159], ["Gamma delta T cells", "ANATOMY", 200, 219], ["cd T cells", "ANATOMY", 252, 262], ["CD2 \u00c0 CD8a \u00c0", "ANATOMY", 355, 367], ["CD2 + CD8a + and CD2 + CD8a \u00c0 cd T cells", "ANATOMY", 370, 410], ["porcine", "ORGANISM", 21, 28], ["cd T cells", "CELL", 29, 39], ["NKG2D", "GENE_OR_GENE_PRODUCT", 91, 96], ["NK cells", "CELL", 118, 126], ["CD8", "GENE_OR_GENE_PRODUCT", 128, 131], ["cd T cells", "CELL", 149, 159], ["humans", "ORGANISM", 171, 177], ["mice", "ORGANISM", 179, 183], ["cd T cells", "CELL", 252, 262], ["swine", "ORGANISM", 266, 271], ["CD2", "GENE_OR_GENE_PRODUCT", 303, 306], ["CD8a", "GENE_OR_GENE_PRODUCT", 307, 311], ["CD2", "GENE_OR_GENE_PRODUCT", 355, 358], ["CD8a", "GENE_OR_GENE_PRODUCT", 361, 365], ["CD2", "GENE_OR_GENE_PRODUCT", 370, 373], ["CD8a", "GENE_OR_GENE_PRODUCT", 376, 380], ["CD2", "GENE_OR_GENE_PRODUCT", 387, 390], ["porcine cd T cells", "CELL_LINE", 21, 39], ["activating natural killer receptor NKG2D", "PROTEIN", 56, 96], ["NK cells", "CELL_TYPE", 118, 126], ["CD8 + ab T cells", "CELL_TYPE", 128, 144], ["cd T cells", "CELL_TYPE", 149, 159], ["Gamma delta T cells", "CELL_LINE", 200, 219], ["cd T cells", "CELL_TYPE", 252, 262], ["CD2", "PROTEIN", 303, 306], ["CD8a", "PROTEIN", 307, 311], ["CD2", "PROTEIN", 355, 358], ["CD8a", "PROTEIN", 361, 365], ["CD2", "PROTEIN", 370, 373], ["CD8a", "PROTEIN", 376, 380], ["CD2", "PROTEIN", 387, 390], ["CD8a \u00c0 cd T cells", "CELL_TYPE", 393, 410], ["humans", "SPECIES", 171, 177], ["mice", "SPECIES", 179, 183], ["swine", "SPECIES", 266, 271], ["humans", "SPECIES", 171, 177], ["mice", "SPECIES", 179, 183], ["swine", "SPECIES", 266, 271], ["porcine cd T cells", "TREATMENT", 21, 39], ["CD8", "TEST", 128, 131], ["cd T cells", "PROBLEM", 149, 159], ["Gamma delta T cells", "PROBLEM", 200, 219], ["cd T cells", "PROBLEM", 252, 262], ["CD2", "TEST", 355, 358], ["CD8a", "TEST", 361, 365], ["CD2", "TEST", 370, 373], ["CD8a", "TEST", 376, 380], ["CD2", "TEST", 387, 390], ["CD8a", "TEST", 393, 397], ["NK cells", "OBSERVATION", 118, 126], ["CD2", "ANATOMY", 387, 390]]], ["In terms of their distribution, CD2 \u00c0 and CD2 + cd T cells are enriched at distinct anatomical sites.", [["CD2 \u00c0", "ANATOMY", 32, 37], ["CD2 + cd T cells", "ANATOMY", 42, 58], ["sites", "ANATOMY", 95, 100], ["CD2", "GENE_OR_GENE_PRODUCT", 32, 35], ["CD2", "GENE_OR_GENE_PRODUCT", 42, 45], ["anatomical sites", "MULTI-TISSUE_STRUCTURE", 84, 100], ["CD2 \u00c0 and CD2 + cd T cells", "CELL_TYPE", 32, 58], ["CD2", "TEST", 32, 35], ["CD2", "TEST", 42, 45], ["cd T cells", "PROBLEM", 48, 58], ["distinct", "OBSERVATION_MODIFIER", 75, 83], ["anatomical sites", "OBSERVATION", 84, 100]]], ["CD2 \u00c0 cd T cells clearly dominate in blood and liver, while CD2 + cd T cells preferentially reside in spleen, thymus, and lymph nodes (Hirt et al., 1990; Yang and Parkhouse, 1996; Sedlak et al., 2014) .", [["CD2 \u00c0 cd T cells", "ANATOMY", 0, 16], ["blood", "ANATOMY", 37, 42], ["liver", "ANATOMY", 47, 52], ["CD2 + cd T cells", "ANATOMY", 60, 76], ["spleen", "ANATOMY", 102, 108], ["thymus", "ANATOMY", 110, 116], ["lymph nodes", "ANATOMY", 122, 133], ["CD2", "GENE_OR_GENE_PRODUCT", 0, 3], ["blood", "ORGANISM_SUBSTANCE", 37, 42], ["liver", "ORGAN", 47, 52], ["CD2", "GENE_OR_GENE_PRODUCT", 60, 63], ["spleen", "ORGAN", 102, 108], ["thymus", "ORGAN", 110, 116], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 122, 133], ["CD2", "PROTEIN", 0, 3], ["cd T cells", "CELL_TYPE", 6, 16], ["CD2", "PROTEIN", 60, 63], ["cd T cells", "CELL_TYPE", 66, 76], ["CD2", "TEST", 0, 3], ["cd T cells", "TEST", 6, 16], ["blood", "TEST", 37, 42], ["CD2", "TEST", 60, 63], ["cd T cells", "PROBLEM", 66, 76], ["cd T cells", "OBSERVATION", 6, 16], ["blood", "ANATOMY", 37, 42], ["liver", "ANATOMY", 47, 52], ["spleen", "ANATOMY", 102, 108], ["thymus", "ANATOMY", 110, 116], ["lymph nodes", "OBSERVATION", 122, 133]]], ["In regard to their function, it was suggested, that the CD2 \u00c0 CD8 \u00c0 subset is mostly composed of naive cells, whereas CD2 + CD8 \u00c0 cells may represent an effector/ memory subset and CD2 + CD8 + probably present terminally differentiated cells (Stepanova and Sinkora, 2012) .", [["CD2 \u00c0 CD8 \u00c0", "ANATOMY", 56, 67], ["cells", "ANATOMY", 103, 108], ["CD2 + CD8 \u00c0 cells", "ANATOMY", 118, 135], ["CD2 + CD8 +", "ANATOMY", 181, 192], ["cells", "ANATOMY", 236, 241], ["CD2", "GENE_OR_GENE_PRODUCT", 56, 59], ["CD8", "GENE_OR_GENE_PRODUCT", 62, 65], ["cells", "CELL", 103, 108], ["CD2", "GENE_OR_GENE_PRODUCT", 118, 121], ["CD8", "GENE_OR_GENE_PRODUCT", 124, 127], ["CD2", "GENE_OR_GENE_PRODUCT", 181, 184], ["CD8", "GENE_OR_GENE_PRODUCT", 187, 190], ["cells", "CELL", 236, 241], ["CD2", "PROTEIN", 56, 59], ["CD8", "PROTEIN", 62, 65], ["naive cells", "CELL_TYPE", 97, 108], ["CD2", "PROTEIN", 118, 121], ["CD8 \u00c0 cells", "CELL_TYPE", 124, 135], ["memory subset", "CELL_TYPE", 163, 176], ["CD2", "PROTEIN", 181, 184], ["CD8", "PROTEIN", 187, 190], ["terminally differentiated cells", "CELL_TYPE", 210, 241], ["the CD2", "TEST", 52, 59], ["naive cells", "PROBLEM", 97, 108], ["CD2", "TEST", 118, 121], ["CD8 \u00c0 cells", "PROBLEM", 124, 135], ["CD2", "TEST", 181, 184], ["CD8", "TEST", 187, 190], ["naive cells", "OBSERVATION", 97, 108], ["CD8 \u00c0 cells", "OBSERVATION", 124, 135], ["may represent", "UNCERTAINTY", 136, 149], ["memory subset", "OBSERVATION", 163, 176]]], ["More recently, Stepanova et al. showed that CD2 expression determines two independent cd T-cell lineages (Stepanova and Sinkora, 2013) .Gamma delta T cellsSimilar to other species, porcine cd T cells are the earliest detectable T-cell subset in the thymus.", [["cd T-cell", "ANATOMY", 86, 95], ["cd T cells", "ANATOMY", 189, 199], ["T-cell", "ANATOMY", 228, 234], ["thymus", "ANATOMY", 249, 255], ["CD2", "GENE_OR_GENE_PRODUCT", 44, 47], ["Gamma delta T", "GENE_OR_GENE_PRODUCT", 136, 149], ["porcine", "ORGANISM", 181, 188], ["cd T cells", "CELL", 189, 199], ["T-cell", "CELL", 228, 234], ["thymus", "ORGAN", 249, 255], ["CD2", "PROTEIN", 44, 47], ["cd T-cell lineages", "CELL_TYPE", 86, 104], ["porcine cd T cells", "CELL_TYPE", 181, 199], ["T-cell subset", "CELL_TYPE", 228, 241], ["CD2 expression", "PROBLEM", 44, 58], ["Gamma delta T cellsSimilar to other species", "PROBLEM", 136, 179], ["porcine cd T cells", "PROBLEM", 181, 199], ["CD2 expression", "OBSERVATION", 44, 58], ["cell lineages", "OBSERVATION", 91, 104], ["detectable", "OBSERVATION_MODIFIER", 217, 227], ["T-cell subset", "OBSERVATION", 228, 241], ["thymus", "ANATOMY", 249, 255]]], ["As early as day 40 of gestation, the first mature CD3e hi cd thymocytes appear and subsequently migrate into the periphery (mature CD3e hi ab thymocytes were observed 15 days later).", [["CD3e hi cd thymocytes", "ANATOMY", 50, 71], ["periphery", "ANATOMY", 113, 122], ["thymocytes", "ANATOMY", 142, 152], ["CD3e hi cd thymocytes", "CELL_LINE", 50, 71], ["thymocytes", "CELL_TYPE", 142, 152], ["cd thymocytes", "OBSERVATION", 58, 71], ["periphery", "ANATOMY_MODIFIER", 113, 122]]], ["Compared to ab T cells, cd T cells mature faster and can develop without any CD3e lo or TCR-cd lo transitional stage (Sinkora et al., 2000a (Sinkora et al., , 2005 .", [["T cells", "ANATOMY", 15, 22], ["cd T cells", "ANATOMY", 24, 34], ["ab T cells", "CELL", 12, 22], ["cd T cells", "CELL", 24, 34], ["TCR", "GENE_OR_GENE_PRODUCT", 88, 91], ["ab T cells", "CELL_TYPE", 12, 22], ["cd T cells", "CELL_TYPE", 24, 34], ["TCR", "PROTEIN", 88, 91], ["ab T cells", "TEST", 12, 22], ["transitional stage", "OBSERVATION_MODIFIER", 98, 116]]], ["The CD2/CD8a-defined cd T-cell subsets have been identified already in the thymus and probably originate from a common cd T-cell precursor (CD4 \u00c0 CD2 + CD8 \u00c0 CD1 + CD45RC \u00c0 ; ).", [["cd T-cell", "ANATOMY", 21, 30], ["thymus", "ANATOMY", 75, 81], ["cd T-cell precursor", "ANATOMY", 119, 138], ["CD4 \u00c0 CD2 + CD8 \u00c0 CD1 + CD45RC \u00c0", "ANATOMY", 140, 172], ["CD2", "GENE_OR_GENE_PRODUCT", 4, 7], ["CD8a", "GENE_OR_GENE_PRODUCT", 8, 12], ["thymus", "ORGAN", 75, 81], ["cd T-cell", "CELL", 119, 128], ["CD4", "GENE_OR_GENE_PRODUCT", 140, 143], ["CD2", "GENE_OR_GENE_PRODUCT", 146, 149], ["CD8", "GENE_OR_GENE_PRODUCT", 152, 155], ["CD2", "PROTEIN", 4, 7], ["CD8a", "PROTEIN", 8, 12], ["cd T-cell subsets", "CELL_TYPE", 21, 38], ["CD4", "PROTEIN", 140, 143], ["CD2", "PROTEIN", 146, 149], ["CD8", "PROTEIN", 152, 155], ["CD1", "PROTEIN", 158, 161], ["CD45RC", "PROTEIN", 164, 170], ["The CD2", "TEST", 0, 7], ["CD8a", "TEST", 8, 12], ["CD4", "TEST", 140, 143], ["CD2", "TEST", 146, 149], ["CD8", "TEST", 152, 155], ["CD1", "TEST", 158, 161], ["cd T-cell subsets", "OBSERVATION", 21, 38], ["thymus", "ANATOMY", 75, 81]]], ["After birth, circulating cd T cells strongly increase until 19-25 weeks of age, indicating an important role during adolescence.", [["cd T cells", "ANATOMY", 25, 35], ["cd T cells", "CELL", 25, 35], ["circulating cd T cells", "CELL_TYPE", 13, 35], ["circulating cd T cells", "TREATMENT", 13, 35], ["increase", "OBSERVATION_MODIFIER", 45, 53]]], ["However, the ratio of the CD2 + and CD2 \u00c0 subset in blood remains relatively stable during this time period (Talker et al., 2013) .Gamma delta T cellsAs mentioned above, cd T cells show a high variability in their functional capacities.", [["blood", "ANATOMY", 52, 57], ["Gamma delta T cells", "ANATOMY", 131, 150], ["cd T cells", "ANATOMY", 170, 180], ["CD2", "GENE_OR_GENE_PRODUCT", 26, 29], ["CD2", "GENE_OR_GENE_PRODUCT", 36, 39], ["blood", "ORGANISM_SUBSTANCE", 52, 57], ["Gamma delta", "GENE_OR_GENE_PRODUCT", 131, 142], ["cd T cells", "CELL", 170, 180], ["CD2", "PROTEIN", 26, 29], ["CD2", "PROTEIN", 36, 39], ["Gamma delta T cells", "CELL_LINE", 131, 150], ["cd T cells", "CELL_TYPE", 170, 180], ["the ratio", "TEST", 9, 18], ["the CD2", "TEST", 22, 29], ["CD2", "TEST", 36, 39], ["Gamma delta T cells", "PROBLEM", 131, 150], ["cd T cells", "TEST", 170, 180], ["a high variability in their functional capacities", "PROBLEM", 186, 235], ["relatively", "OBSERVATION_MODIFIER", 66, 76], ["stable", "OBSERVATION_MODIFIER", 77, 83], ["delta T cells", "OBSERVATION", 137, 150], ["high variability", "OBSERVATION_MODIFIER", 188, 204], ["functional capacities", "OBSERVATION", 214, 235]]], ["In humans and ruminants, cd T cells have been shown to play a vital role early in mycobacterial infections (Meraviglia et al., 2011; Plattner and Hostetter, 2011) .", [["cd T cells", "ANATOMY", 25, 35], ["mycobacterial infections", "DISEASE", 82, 106], ["humans", "ORGANISM", 3, 9], ["cd T cells", "CELL", 25, 35], ["cd T cells", "CELL_TYPE", 25, 35], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["cd T cells", "PROBLEM", 25, 35], ["mycobacterial infections", "PROBLEM", 82, 106]]], ["Mycobacterial phosphoantigens were identified as potent stimulators of human Vc9d2 cells (Chen, 2013) .", [["Vc9d2 cells", "ANATOMY", 77, 88], ["human", "ORGANISM", 71, 76], ["Vc9d2 cells", "CELL", 77, 88], ["Mycobacterial phosphoantigens", "PROTEIN", 0, 29], ["human Vc9d2 cells", "CELL_LINE", 71, 88], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 71, 76], ["Mycobacterial phosphoantigens", "TEST", 0, 29]]], ["In swine, enhanced in vitro proliferation and IFN-c production to mycobacterial antigens following Mycobacterium bovis Bacillus Calmette-Gu\u00e9rin (BCG) vaccination has been detected as well as memory-like functions of porcine cd T cells at an early age were suggested (Lee et al., 2004) .", [["cd T cells", "ANATOMY", 224, 234], ["Mycobacterium bovis Bacillus Calmette-Gu\u00e9rin", "CHEMICAL", 99, 143], ["BCG", "CHEMICAL", 145, 148], ["swine", "ORGANISM", 3, 8], ["IFN-c", "GENE_OR_GENE_PRODUCT", 46, 51], ["Mycobacterium bovis", "ORGANISM", 99, 118], ["Bacillus Calmette-Gu\u00e9rin", "ORGANISM", 119, 143], ["BCG", "ORGANISM", 145, 148], ["porcine", "ORGANISM", 216, 223], ["cd T cells", "CELL", 224, 234], ["IFN", "PROTEIN", 46, 49], ["mycobacterial antigens", "PROTEIN", 66, 88], ["porcine cd T cells", "CELL_TYPE", 216, 234], ["swine", "SPECIES", 3, 8], ["Mycobacterium bovis", "SPECIES", 99, 118], ["Bacillus Calmette", "SPECIES", 119, 136], ["swine", "SPECIES", 3, 8], ["Mycobacterium bovis", "SPECIES", 99, 118], ["enhanced in vitro proliferation", "PROBLEM", 10, 41], ["IFN", "TEST", 46, 49], ["c production", "PROBLEM", 50, 62], ["mycobacterial antigens", "TEST", 66, 88], ["Mycobacterium bovis Bacillus Calmette", "PROBLEM", 99, 136], ["Gu\u00e9rin (BCG) vaccination", "TREATMENT", 137, 161], ["porcine cd T cells", "PROBLEM", 216, 234], ["vitro proliferation", "OBSERVATION", 22, 41]]], ["This is in accordance with humans, where Vc9d2 cd T cells in Mycobacterium tuberculosis infections initially produce IFN-c and TNF-a and show memory characteristics indicated by a marked expansion in blood, lungs and intestinal tissue after a secondary BCG inoculation (Meraviglia et al., 2011) .Gamma delta T cellsFor human Vc9d2 T cells it could be shown that phosphoantigens like isopentenyl pyrophosphate derived from the mevalonate pathway serving in isoprenoid biosynthesis in eukaryotic and prokaryotic cells) and (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP, derived from alternative isoprenoid biosynthesis pathway used in most eubacteria) are potent stimulators for proliferation and cytokine production (Morita et al., 2007) .", [["Vc9d2 cd T cells", "ANATOMY", 41, 57], ["blood", "ANATOMY", 200, 205], ["lungs", "ANATOMY", 207, 212], ["intestinal tissue", "ANATOMY", 217, 234], ["Gamma delta T cells", "ANATOMY", 296, 315], ["Vc9d2 T cells", "ANATOMY", 325, 338], ["cells", "ANATOMY", 510, 515], ["Mycobacterium tuberculosis infections", "DISEASE", 61, 98], ["isopentenyl pyrophosphate", "CHEMICAL", 383, 408], ["mevalonate", "CHEMICAL", 426, 436], ["isoprenoid", "CHEMICAL", 456, 466], ["4-hydroxy-3-methyl-but-2-enyl pyrophosphate", "CHEMICAL", 525, 568], ["HMBPP", "CHEMICAL", 570, 575], ["isopentenyl pyrophosphate", "CHEMICAL", 383, 408], ["mevalonate", "CHEMICAL", 426, 436], ["isoprenoid", "CHEMICAL", 456, 466], ["(E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate", "CHEMICAL", 521, 568], ["HMBPP", "CHEMICAL", 570, 575], ["isoprenoid", "CHEMICAL", 602, 612], ["humans", "ORGANISM", 27, 33], ["Vc9d2 cd T cells", "CELL", 41, 57], ["Mycobacterium tuberculosis", "ORGANISM", 61, 87], ["IFN-c", "GENE_OR_GENE_PRODUCT", 117, 122], ["TNF", "GENE_OR_GENE_PRODUCT", 127, 130], ["blood", "ORGANISM_SUBSTANCE", 200, 205], ["lungs", "ORGAN", 207, 212], ["intestinal tissue", "TISSUE", 217, 234], ["human", "ORGANISM", 319, 324], ["Vc9d2 T cells", "CELL", 325, 338], ["phosphoantigens", "SIMPLE_CHEMICAL", 362, 377], ["isopentenyl pyrophosphate", "SIMPLE_CHEMICAL", 383, 408], ["mevalonate", "SIMPLE_CHEMICAL", 426, 436], ["isoprenoid", "SIMPLE_CHEMICAL", 456, 466], ["cells", "CELL", 510, 515], ["(E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate", "SIMPLE_CHEMICAL", 521, 568], ["HMBPP", "SIMPLE_CHEMICAL", 570, 575], ["isoprenoid", "SIMPLE_CHEMICAL", 602, 612], ["Vc9d2 cd T cells", "CELL_LINE", 41, 57], ["IFN", "PROTEIN", 117, 120], ["TNF", "PROTEIN", 127, 130], ["Gamma delta T cells", "CELL_LINE", 296, 315], ["human Vc9d2 T cells", "CELL_LINE", 319, 338], ["eukaryotic and prokaryotic cells", "CELL_TYPE", 483, 515], ["cytokine", "PROTEIN", 704, 712], ["humans", "SPECIES", 27, 33], ["Mycobacterium tuberculosis", "SPECIES", 61, 87], ["human", "SPECIES", 319, 324], ["humans", "SPECIES", 27, 33], ["Mycobacterium tuberculosis", "SPECIES", 61, 87], ["human", "SPECIES", 319, 324], ["Mycobacterium tuberculosis infections", "PROBLEM", 61, 98], ["IFN", "TEST", 117, 120], ["TNF", "TEST", 127, 130], ["a marked expansion in blood, lungs and intestinal tissue", "PROBLEM", 178, 234], ["a secondary BCG inoculation", "TREATMENT", 241, 268], ["Gamma delta T cells", "PROBLEM", 296, 315], ["human Vc9d2 T cells", "PROBLEM", 319, 338], ["phosphoantigens", "PROBLEM", 362, 377], ["isopentenyl pyrophosphate", "PROBLEM", 383, 408], ["the mevalonate pathway", "TEST", 422, 444], ["isoprenoid biosynthesis", "TEST", 456, 479], ["hydroxy", "TEST", 527, 534], ["methyl", "TEST", 537, 543], ["enyl pyrophosphate (HMBPP", "TREATMENT", 550, 575], ["alternative isoprenoid biosynthesis pathway", "TREATMENT", 590, 633], ["potent stimulators", "TREATMENT", 663, 681], ["proliferation", "PROBLEM", 686, 699], ["cytokine production", "PROBLEM", 704, 723], ["Mycobacterium tuberculosis", "OBSERVATION", 61, 87], ["marked", "OBSERVATION_MODIFIER", 180, 186], ["expansion", "OBSERVATION", 187, 196], ["blood", "ANATOMY", 200, 205], ["lungs", "ANATOMY", 207, 212], ["intestinal tissue", "ANATOMY", 217, 234]]], ["However, porcine cd T cells did not respond on isopentenyl pyrophosphate or HMBPP stimulation in proliferation assays, regardless of the presence of antigen presenting cells or IL-2 [Sedlak, unpublished results] .", [["cd T cells", "ANATOMY", 17, 27], ["cells", "ANATOMY", 168, 173], ["isopentenyl pyrophosphate", "CHEMICAL", 47, 72], ["HMBPP", "CHEMICAL", 76, 81], ["isopentenyl pyrophosphate", "CHEMICAL", 47, 72], ["HMBPP", "CHEMICAL", 76, 81], ["porcine", "ORGANISM", 9, 16], ["cd T cells", "CELL", 17, 27], ["isopentenyl pyrophosphate", "SIMPLE_CHEMICAL", 47, 72], ["HMBPP", "SIMPLE_CHEMICAL", 76, 81], ["cells", "CELL", 168, 173], ["IL-2", "GENE_OR_GENE_PRODUCT", 177, 181], ["porcine cd T cells", "CELL_LINE", 9, 27], ["antigen presenting cells", "CELL_TYPE", 149, 173], ["IL", "PROTEIN", 177, 179], ["porcine cd T cells", "PROBLEM", 9, 27], ["isopentenyl pyrophosphate", "TREATMENT", 47, 72], ["HMBPP stimulation", "TREATMENT", 76, 93], ["proliferation assays", "TEST", 97, 117], ["antigen presenting cells", "PROBLEM", 149, 173]]], ["These results indicate that, similar to cattle and mice, porcine cd T cells most probably use alternative ways to sense bacterial pathogens.Gamma delta T cellsFurther, cd T cells were identified as the main source of IL-17 after pulmonary BCG infection in mice.", [["cd T cells", "ANATOMY", 65, 75], ["cd T cells", "ANATOMY", 168, 178], ["pulmonary", "ANATOMY", 229, 238], ["BCG infection", "DISEASE", 239, 252], ["cattle", "ORGANISM", 40, 46], ["mice", "ORGANISM", 51, 55], ["porcine", "ORGANISM", 57, 64], ["cd T cells", "CELL", 65, 75], ["Gamma delta", "GENE_OR_GENE_PRODUCT", 140, 151], ["cd T cells", "CELL", 168, 178], ["IL-17", "GENE_OR_GENE_PRODUCT", 217, 222], ["pulmonary", "ORGAN", 229, 238], ["mice", "ORGANISM", 256, 260], ["porcine cd T cells", "CELL_TYPE", 57, 75], ["Gamma delta T cellsFurther, cd T cells", "CELL_LINE", 140, 178], ["IL-17", "PROTEIN", 217, 222], ["cattle", "SPECIES", 40, 46], ["mice", "SPECIES", 51, 55], ["porcine", "SPECIES", 57, 64], ["mice", "SPECIES", 256, 260], ["cattle", "SPECIES", 40, 46], ["mice", "SPECIES", 51, 55], ["mice", "SPECIES", 256, 260], ["cattle and mice, porcine cd T cells", "TREATMENT", 40, 75], ["sense bacterial pathogens", "PROBLEM", 114, 139], ["Gamma delta T cellsFurther", "PROBLEM", 140, 166], ["cd T cells", "PROBLEM", 168, 178], ["IL", "TEST", 217, 219], ["pulmonary BCG infection", "PROBLEM", 229, 252], ["bacterial", "OBSERVATION_MODIFIER", 120, 129], ["pathogens", "OBSERVATION", 130, 139], ["main", "OBSERVATION_MODIFIER", 202, 206], ["pulmonary", "ANATOMY", 229, 238], ["BCG", "OBSERVATION", 239, 242], ["infection", "OBSERVATION", 243, 252]]], ["IL-17 production by cd T cells has also been confirmed in na\u00efve mice and humans but has to be elucidated in cattle (Plattner and Hostetter, 2011) .", [["cd T cells", "ANATOMY", 20, 30], ["IL-17", "GENE_OR_GENE_PRODUCT", 0, 5], ["cd T cells", "CELL", 20, 30], ["mice", "ORGANISM", 64, 68], ["humans", "ORGANISM", 73, 79], ["cattle", "ORGANISM", 108, 114], ["IL-17", "PROTEIN", 0, 5], ["cd T cells", "CELL_TYPE", 20, 30], ["mice", "SPECIES", 64, 68], ["humans", "SPECIES", 73, 79], ["cattle", "SPECIES", 108, 114], ["mice", "SPECIES", 64, 68], ["humans", "SPECIES", 73, 79], ["cattle", "SPECIES", 108, 114], ["IL", "TEST", 0, 2]]], ["Recently, we identified the porcine CD2 \u00c0 cd T cell subset as the main IL-17 producers within total cd T cells, which mainly co-produced TNFa, following polyclonal stimulation.", [["CD2 \u00c0 cd T cell", "ANATOMY", 36, 51], ["cd T cells", "ANATOMY", 100, 110], ["porcine", "ORGANISM", 28, 35], ["CD2", "GENE_OR_GENE_PRODUCT", 36, 39], ["IL-17", "GENE_OR_GENE_PRODUCT", 71, 76], ["cd T cells", "CELL", 100, 110], ["TNFa", "GENE_OR_GENE_PRODUCT", 137, 141], ["porcine CD2 \u00c0 cd T cell subset", "CELL_LINE", 28, 58], ["cd T cells", "CELL_TYPE", 100, 110], ["TNFa", "PROTEIN", 137, 141], ["the porcine CD2", "TEST", 24, 39], ["total cd T cells", "PROBLEM", 94, 110], ["TNFa", "TEST", 137, 141], ["polyclonal stimulation", "TREATMENT", 153, 175], ["main", "OBSERVATION_MODIFIER", 66, 70], ["TNFa", "OBSERVATION", 137, 141], ["polyclonal stimulation", "OBSERVATION", 153, 175]]], ["Within CD2 + cd T cells an enrichment of IFN-c and IFN-c/TNF-a co-producing cells was identified (Sedlak et al., 2014) .", [["CD2 + cd T cells", "ANATOMY", 7, 23], ["cells", "ANATOMY", 76, 81], ["CD2", "GENE_OR_GENE_PRODUCT", 7, 10], ["IFN-c", "GENE_OR_GENE_PRODUCT", 41, 46], ["IFN-c", "GENE_OR_GENE_PRODUCT", 51, 56], ["TNF", "GENE_OR_GENE_PRODUCT", 57, 60], ["cells", "CELL", 76, 81], ["CD2 + cd T cells", "CELL_LINE", 7, 23], ["IFN", "PROTEIN", 41, 44], ["IFN", "PROTEIN", 51, 54], ["TNF", "PROTEIN", 57, 60], ["co-producing cells", "CELL_TYPE", 63, 81], ["cd T cells", "PROBLEM", 13, 23], ["an enrichment", "TEST", 24, 37], ["IFN", "TEST", 41, 44], ["c", "TEST", 45, 46], ["IFN", "TEST", 51, 54], ["TNF", "PROBLEM", 57, 60], ["a co-producing cells", "PROBLEM", 61, 81], ["TNF", "ANATOMY", 57, 60]]], ["Moreover, in vitro stimulation of FACS-sorted CD2 + cd T cells with IL-2 and the macrophage-derived cytokines IL-12 and IL-18 induced strong IFN-c production.", [["CD2 + cd T cells", "ANATOMY", 46, 62], ["macrophage", "ANATOMY", 81, 91], ["FACS", "CELL", 34, 38], ["CD2", "GENE_OR_GENE_PRODUCT", 46, 49], ["IL-2", "GENE_OR_GENE_PRODUCT", 68, 72], ["macrophage", "CELL", 81, 91], ["IL-12", "GENE_OR_GENE_PRODUCT", 110, 115], ["IL-18", "GENE_OR_GENE_PRODUCT", 120, 125], ["IFN-c", "GENE_OR_GENE_PRODUCT", 141, 146], ["FACS-sorted CD2 + cd T cells", "CELL_LINE", 34, 62], ["IL-2", "PROTEIN", 68, 72], ["cytokines", "PROTEIN", 100, 109], ["IL-12", "PROTEIN", 110, 115], ["IL-18", "PROTEIN", 120, 125], ["IFN", "PROTEIN", 141, 144], ["FACS", "TEST", 34, 38], ["CD2", "TEST", 46, 49], ["IL", "TEST", 68, 70], ["the macrophage", "TEST", 77, 91], ["cytokines IL", "TEST", 100, 112], ["IL", "TEST", 120, 122], ["macrophage", "ANATOMY", 81, 91]]], ["Lower amounts of IFN-c were also produced by sorted CD2 \u00c0 cd T cells after both stimulation strategies.", [["CD2 \u00c0 cd T cells", "ANATOMY", 52, 68], ["IFN-c", "GENE_OR_GENE_PRODUCT", 17, 22], ["CD2", "GENE_OR_GENE_PRODUCT", 52, 55], ["IFN-c", "PROTEIN", 17, 22], ["sorted CD2 \u00c0 cd T cells", "CELL_LINE", 45, 68], ["Lower amounts of IFN", "PROBLEM", 0, 20], ["both stimulation strategies", "TREATMENT", 75, 102]]], ["Moreover, CD2 was up-regulated within the CD2 \u00c0 cd T cell subset after combined ConA, IL-2, IL-12 and IL-18 stimulation (Sedlak et al., submitted for publication).Gamma delta T cellsThese results indicate that porcine cd T cells have a high degree of plasticity in regard to phenotype and cytokine production profile, slightly reminiscent of that what is observed for human cd T cell lineages, that are considered to acquire distinct Th1-, Th2-, Th17-, T FH and T regulatory-like effector functions (Caccamo et al., 2013) .Gamma delta T cellsCytolytic activity by porcine cd T cells has been described in some studies.", [["CD2 \u00c0 cd T cell", "ANATOMY", 42, 57], ["Gamma delta T cells", "ANATOMY", 163, 182], ["cd T cells", "ANATOMY", 218, 228], ["cd T cell", "ANATOMY", 374, 383], ["Gamma delta T cells", "ANATOMY", 523, 542], ["cd T cells", "ANATOMY", 572, 582], ["CD2", "GENE_OR_GENE_PRODUCT", 10, 13], ["CD2", "GENE_OR_GENE_PRODUCT", 42, 45], ["ConA", "SIMPLE_CHEMICAL", 80, 84], ["IL-2", "GENE_OR_GENE_PRODUCT", 86, 90], ["IL-12", "GENE_OR_GENE_PRODUCT", 92, 97], ["IL-18", "GENE_OR_GENE_PRODUCT", 102, 107], ["Gamma delta", "GENE_OR_GENE_PRODUCT", 163, 174], ["porcine", "ORGANISM", 210, 217], ["cd T cells", "CELL", 218, 228], ["human", "ORGANISM", 368, 373], ["cd T cell lineages", "CELL", 374, 392], ["Th1", "GENE_OR_GENE_PRODUCT", 434, 437], ["Th2", "GENE_OR_GENE_PRODUCT", 440, 443], ["Th17", "GENE_OR_GENE_PRODUCT", 446, 450], ["T FH", "GENE_OR_GENE_PRODUCT", 453, 457], ["Gamma delta", "GENE_OR_GENE_PRODUCT", 523, 534], ["porcine", "ORGANISM", 564, 571], ["cd T cells", "CELL", 572, 582], ["CD2", "PROTEIN", 10, 13], ["CD2", "PROTEIN", 42, 45], ["Gamma delta T cells", "CELL_LINE", 163, 182], ["porcine cd T cells", "CELL_LINE", 210, 228], ["cytokine", "PROTEIN", 289, 297], ["human cd T cell lineages", "CELL_TYPE", 368, 392], ["Gamma delta T cells", "CELL_LINE", 523, 542], ["porcine cd T cells", "CELL_LINE", 564, 582], ["human", "SPECIES", 368, 373], ["human", "SPECIES", 368, 373], ["CD2", "TEST", 10, 13], ["combined ConA, IL", "TREATMENT", 71, 88], ["IL", "TREATMENT", 92, 94], ["IL", "TREATMENT", 102, 104], ["Gamma delta T cells", "PROBLEM", 163, 182], ["porcine cd T cells", "PROBLEM", 210, 228], ["phenotype and cytokine production profile", "PROBLEM", 275, 316], ["human cd T cell lineages", "PROBLEM", 368, 392], ["Th1", "TEST", 434, 437], ["Th2", "TEST", 440, 443], ["Th17", "TEST", 446, 450], ["Gamma delta T cells", "TEST", 523, 542], ["Cytolytic activity", "TEST", 542, 560], ["porcine cd T cells", "PROBLEM", 564, 582], ["some studies", "TEST", 605, 617], ["delta T cells", "OBSERVATION", 169, 182], ["high degree", "OBSERVATION_MODIFIER", 236, 247], ["cells", "OBSERVATION", 537, 542], ["Cytolytic activity", "OBSERVATION", 542, 560]]], ["Olin et al. observed enhanced natural killer (NK) cytotoxic activity of porcine cd T cells against K562 target cells prior to mycobacterium vaccination, whereas, following M. bovis BCG vaccination this cytolytic activity was enhanced.", [["natural killer", "ANATOMY", 30, 44], ["NK", "ANATOMY", 46, 48], ["cd T cells", "ANATOMY", 80, 90], ["K562", "ANATOMY", 99, 103], ["cells", "ANATOMY", 111, 116], ["natural killer", "CELL", 30, 44], ["NK", "CELL", 46, 48], ["porcine", "ORGANISM", 72, 79], ["cd T cells", "CELL", 80, 90], ["K562 target cells", "CELL", 99, 116], ["M. bovis", "ORGANISM", 172, 180], ["BCG", "ORGANISM", 181, 184], ["porcine cd T cells", "CELL_LINE", 72, 90], ["K562 target cells", "CELL_LINE", 99, 116], ["porcine", "SPECIES", 72, 79], ["M. bovis", "SPECIES", 172, 180], ["M. bovis", "SPECIES", 172, 180], ["porcine cd T cells", "TREATMENT", 72, 90], ["K562 target cells", "PROBLEM", 99, 116], ["mycobacterium vaccination", "TREATMENT", 126, 151], ["M. bovis BCG vaccination", "TREATMENT", 172, 196], ["natural killer", "OBSERVATION", 30, 44]]], ["Moreover, memory-like cytolytic responses against mycobacterium-infected autologous monocytes as target cells were demonstrated for 3-week-old, BCG-vaccinated pigs (Olin et al., 2005b) .", [["monocytes", "ANATOMY", 84, 93], ["cells", "ANATOMY", 104, 109], ["monocytes", "CELL", 84, 93], ["cells", "CELL", 104, 109], ["BCG", "ORGANISM", 144, 147], ["pigs", "ORGANISM", 159, 163], ["mycobacterium-infected autologous monocytes", "CELL_TYPE", 50, 93], ["target cells", "CELL_TYPE", 97, 109], ["pigs", "SPECIES", 159, 163], ["pigs", "SPECIES", 159, 163], ["cytolytic responses", "TEST", 22, 41], ["mycobacterium", "PROBLEM", 50, 63], ["infected autologous monocytes", "PROBLEM", 64, 93], ["target cells", "PROBLEM", 97, 109], ["BCG", "TEST", 144, 147], ["infected", "OBSERVATION_MODIFIER", 64, 72], ["autologous monocytes", "OBSERVATION", 73, 93]]], ["CD2 + CD8 + cd T cell clones were observed to be capable to kill MHCcompatible as well as MHC-incompatible target cells and further, CD8 lo cd T cells were demonstrated to show cytotoxicity in a CD3-redirected lysis assay (de Bruin et al., 1997; Yang and Parkhouse, 1997) .", [["CD2 + CD8 + cd T cell clones", "ANATOMY", 0, 28], ["cells", "ANATOMY", 114, 119], ["CD8 lo cd T cells", "ANATOMY", 133, 150], ["CD2", "GENE_OR_GENE_PRODUCT", 0, 3], ["CD8", "GENE_OR_GENE_PRODUCT", 6, 9], ["cells", "CELL", 114, 119], ["CD8", "GENE_OR_GENE_PRODUCT", 133, 136], ["CD3", "GENE_OR_GENE_PRODUCT", 195, 198], ["CD2", "PROTEIN", 0, 3], ["CD8 + cd T cell clones", "CELL_LINE", 6, 28], ["MHC-incompatible target cells", "CELL_TYPE", 90, 119], ["CD8 lo cd T cells", "CELL_LINE", 133, 150], ["CD3", "PROTEIN", 195, 198], ["CD2", "TEST", 0, 3], ["CD8", "PROBLEM", 6, 9], ["cd T cell clones", "PROBLEM", 12, 28], ["MHC", "TEST", 90, 93], ["incompatible target cells", "PROBLEM", 94, 119], ["CD8 lo cd T cells", "TEST", 133, 150], ["cytotoxicity", "TEST", 177, 189], ["a CD3", "TEST", 193, 198], ["cell clones", "OBSERVATION", 17, 28]]], ["These findings are somewhat in contrast to the observation that circulating cd T cells in swine do not express perforin, even after IL-2 stimulation .", [["cd T cells", "ANATOMY", 76, 86], ["cd T cells", "CELL", 76, 86], ["swine", "ORGANISM", 90, 95], ["perforin", "GENE_OR_GENE_PRODUCT", 111, 119], ["IL-2", "GENE_OR_GENE_PRODUCT", 132, 136], ["circulating cd T cells", "CELL_TYPE", 64, 86], ["perforin", "PROTEIN", 111, 119], ["swine", "SPECIES", 90, 95], ["swine", "SPECIES", 90, 95], ["circulating cd T cells", "TREATMENT", 64, 86], ["IL-2 stimulation", "TREATMENT", 132, 148], ["perforin", "OBSERVATION", 111, 119]]], ["Further, the functional aspects of porcine cd T cells in the context of viral infections or viral antigen stimulation was investigated.", [["cd T cells", "ANATOMY", 43, 53], ["viral infections", "DISEASE", 72, 88], ["porcine", "ORGANISM", 35, 42], ["cd T cells", "CELL", 43, 53], ["porcine cd T cells", "CELL_TYPE", 35, 53], ["porcine cd T cells", "TREATMENT", 35, 53], ["viral infections", "PROBLEM", 72, 88], ["viral antigen stimulation", "TREATMENT", 92, 117], ["viral", "OBSERVATION_MODIFIER", 72, 77], ["infections", "OBSERVATION", 78, 88]]], ["In vitro stimulation with FMDV vaccine antigen stimulated purified cd T cells from FMDV-na\u00efve pigs to produce mRNA of IL-1, IFN-a and GM-CSF in vitro .", [["cd T cells", "ANATOMY", 67, 77], ["GM", "CHEMICAL", 134, 136], ["FMDV", "ORGANISM", 26, 30], ["cd T cells", "CELL", 67, 77], ["FMDV", "ORGANISM", 83, 87], ["pigs", "ORGANISM", 94, 98], ["IL-1", "GENE_OR_GENE_PRODUCT", 118, 122], ["IFN-a", "GENE_OR_GENE_PRODUCT", 124, 129], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 134, 140], ["FMDV vaccine antigen", "PROTEIN", 26, 46], ["purified cd T cells", "CELL_LINE", 58, 77], ["mRNA", "RNA", 110, 114], ["IL", "PROTEIN", 118, 120], ["IFN", "PROTEIN", 124, 127], ["GM", "PROTEIN", 134, 136], ["CSF", "PROTEIN", 137, 140], ["FMDV", "SPECIES", 26, 30], ["FMDV", "SPECIES", 83, 87], ["pigs", "SPECIES", 94, 98], ["FMDV", "SPECIES", 26, 30], ["FMDV", "SPECIES", 83, 87], ["pigs", "SPECIES", 94, 98], ["vitro stimulation", "TREATMENT", 3, 20], ["FMDV vaccine antigen", "TREATMENT", 26, 46], ["FMDV", "TEST", 83, 87], ["na\u00efve pigs", "TREATMENT", 88, 98], ["mRNA of IL", "TEST", 110, 120], ["IFN", "TEST", 124, 127]]], ["Somewhat different to this, cd T cells isolated from the blood of PRRSVinfected gilts showed a higher proliferation and IFN-c production compared to cd T cells from non-infected animals (Olin et al., 2005a) .", [["cd T cells", "ANATOMY", 28, 38], ["blood", "ANATOMY", 57, 62], ["cd T cells", "ANATOMY", 149, 159], ["cd T cells", "CELL", 28, 38], ["blood", "ORGANISM_SUBSTANCE", 57, 62], ["IFN-c", "GENE_OR_GENE_PRODUCT", 120, 125], ["cd T cells", "CELL", 149, 159], ["cd T cells", "CELL_TYPE", 28, 38], ["IFN", "PROTEIN", 120, 123], ["cd T cells", "CELL_TYPE", 149, 159], ["cd T cells", "PROBLEM", 28, 38], ["the blood of PRRSVinfected gilts", "TEST", 53, 85], ["a higher proliferation", "PROBLEM", 93, 115], ["IFN-c production", "PROBLEM", 120, 136], ["higher", "OBSERVATION_MODIFIER", 95, 101], ["proliferation", "OBSERVATION_MODIFIER", 102, 115]]], ["The infection of gnotobiotic pigs with human rotaviruses (HRV) indicated low frequencies of TLR2, TLR3, and TLR9 expressing cd T cell isolated from the ileum during the first 5 days following infection.", [["cd T cell", "ANATOMY", 124, 133], ["ileum", "ANATOMY", 152, 157], ["infection", "DISEASE", 4, 13], ["infection", "DISEASE", 192, 201], ["gnotobiotic pigs", "ORGANISM", 17, 33], ["human", "ORGANISM", 39, 44], ["rotaviruses", "ORGANISM", 45, 56], ["TLR2", "GENE_OR_GENE_PRODUCT", 92, 96], ["TLR3", "GENE_OR_GENE_PRODUCT", 98, 102], ["TLR9", "GENE_OR_GENE_PRODUCT", 108, 112], ["cd T cell", "CELL", 124, 133], ["ileum", "ORGAN", 152, 157], ["TLR2", "PROTEIN", 92, 96], ["TLR3", "PROTEIN", 98, 102], ["TLR9", "PROTEIN", 108, 112], ["cd T cell", "CELL_TYPE", 124, 133], ["gnotobiotic pigs", "SPECIES", 17, 33], ["human", "SPECIES", 39, 44], ["pigs", "SPECIES", 29, 33], ["human", "SPECIES", 39, 44], ["HRV", "SPECIES", 58, 61], ["The infection", "PROBLEM", 0, 13], ["gnotobiotic pigs", "TREATMENT", 17, 33], ["human rotaviruses", "PROBLEM", 39, 56], ["low frequencies of TLR2", "PROBLEM", 73, 96], ["TLR3", "TREATMENT", 98, 102], ["TLR9", "TREATMENT", 108, 112], ["infection", "PROBLEM", 192, 201], ["infection", "OBSERVATION", 4, 13], ["low frequencies", "OBSERVATION_MODIFIER", 73, 88], ["ileum", "ANATOMY", 152, 157], ["infection", "OBSERVATION", 192, 201]]], ["Further, an increase in IFN-c producing CD2 + cd T cells derived from spleen and ileum was observed 2 days after infection .Gamma delta T cellsHuman cd T cells are not only considered to play important roles in protective immunity through cytokine secretion and cytotoxic activity but also can act as professional antigen presenting cells (APCs) (Brandes et al., 2005) .", [["CD2 + cd T cells", "ANATOMY", 40, 56], ["spleen", "ANATOMY", 70, 76], ["ileum", "ANATOMY", 81, 86], ["Gamma delta T cells", "ANATOMY", 124, 143], ["cd T cells", "ANATOMY", 149, 159], ["antigen presenting cells", "ANATOMY", 314, 338], ["APCs", "ANATOMY", 340, 344], ["infection", "DISEASE", 113, 122], ["IFN-c", "GENE_OR_GENE_PRODUCT", 24, 29], ["CD2", "GENE_OR_GENE_PRODUCT", 40, 43], ["spleen", "ORGAN", 70, 76], ["ileum", "ORGAN", 81, 86], ["cells", "CELL", 333, 338], ["APCs", "CELL", 340, 344], ["IFN", "PROTEIN", 24, 27], ["CD2", "PROTEIN", 40, 43], ["cd T cells", "CELL_TYPE", 46, 56], ["Gamma delta T cells", "CELL_LINE", 124, 143], ["Human cd T cells", "CELL_LINE", 143, 159], ["cytokine", "PROTEIN", 239, 247], ["professional antigen presenting cells", "CELL_TYPE", 301, 338], ["APCs", "CELL_TYPE", 340, 344], ["Human", "SPECIES", 143, 148], ["IFN", "TEST", 24, 27], ["cd T cells", "PROBLEM", 46, 56], ["infection", "PROBLEM", 113, 122], ["Gamma delta T cellsHuman cd T cells", "PROBLEM", 124, 159], ["cytokine secretion", "PROBLEM", 239, 257], ["cytotoxic activity", "PROBLEM", 262, 280], ["increase", "OBSERVATION_MODIFIER", 12, 20], ["spleen", "ANATOMY", 70, 76], ["ileum", "ANATOMY", 81, 86], ["infection", "OBSERVATION", 113, 122]]], ["In cattle, cultured cd T cells were able to present soluble antigens after changing their phenotype, but this was not true for freshly isolated bovine cd T cells (Collins et al., 1998) .", [["cd T cells", "ANATOMY", 20, 30], ["cd T cells", "ANATOMY", 151, 161], ["cattle", "ORGANISM", 3, 9], ["cd T cells", "CELL", 20, 30], ["bovine", "ORGANISM", 144, 150], ["cd T cells", "CELL", 151, 161], ["cultured cd T cells", "CELL_LINE", 11, 30], ["soluble antigens", "PROTEIN", 52, 68], ["bovine cd T cells", "CELL_TYPE", 144, 161], ["cattle", "SPECIES", 3, 9], ["bovine", "SPECIES", 144, 150], ["cattle", "SPECIES", 3, 9], ["freshly isolated bovine cd T cells", "PROBLEM", 127, 161]]], ["In swine, CD2 and/or CD8 positive cd T cells co-expressed surface molecules associated with APCs (MHC class II, CD80/ CD86, CD40 and CD31) and showed OVA uptake within 20 min (Takamatsu et al., 2002) , indicating phagocytic activity of porcine cd T cells.Gamma delta T cellsIn summary, the data available so far, indicate that porcine cd T cells show a similar degree of functional plasticity as reported for human and murine cd T cells.", [["CD8 positive cd T cells", "ANATOMY", 21, 44], ["surface molecules", "ANATOMY", 58, 75], ["APCs", "ANATOMY", 92, 96], ["cd T cells", "ANATOMY", 244, 254], ["Gamma delta T cells", "ANATOMY", 255, 274], ["cd T cells", "ANATOMY", 335, 345], ["cd T cells", "ANATOMY", 426, 436], ["swine", "ORGANISM", 3, 8], ["CD2", "GENE_OR_GENE_PRODUCT", 10, 13], ["CD8", "GENE_OR_GENE_PRODUCT", 21, 24], ["APCs", "CELL", 92, 96], ["MHC class II", "GENE_OR_GENE_PRODUCT", 98, 110], ["CD80", "GENE_OR_GENE_PRODUCT", 112, 116], ["CD86", "GENE_OR_GENE_PRODUCT", 118, 122], ["CD40", "GENE_OR_GENE_PRODUCT", 124, 128], ["CD31", "GENE_OR_GENE_PRODUCT", 133, 137], ["OVA", "SIMPLE_CHEMICAL", 150, 153], ["porcine", "ORGANISM", 236, 243], ["cd T cells", "CELL", 244, 254], ["Gamma delta", "GENE_OR_GENE_PRODUCT", 255, 266], ["porcine", "ORGANISM", 327, 334], ["cd T cells", "CELL", 335, 345], ["human", "ORGANISM", 409, 414], ["murine", "ORGANISM", 419, 425], ["cd T cells", "CELL", 426, 436], ["CD2 and/or CD8 positive cd T cells", "CELL_TYPE", 10, 44], ["surface molecules", "PROTEIN", 58, 75], ["APCs", "CELL_TYPE", 92, 96], ["MHC class II", "PROTEIN", 98, 110], ["CD80", "PROTEIN", 112, 116], ["CD86", "PROTEIN", 118, 122], ["CD40", "PROTEIN", 124, 128], ["CD31", "PROTEIN", 133, 137], ["porcine cd T cells", "CELL_LINE", 236, 254], ["Gamma delta T cells", "CELL_LINE", 255, 274], ["porcine cd T cells", "CELL_LINE", 327, 345], ["human and murine cd T cells", "CELL_TYPE", 409, 436], ["swine", "SPECIES", 3, 8], ["human", "SPECIES", 409, 414], ["murine", "SPECIES", 419, 425], ["swine", "SPECIES", 3, 8], ["human", "SPECIES", 409, 414], ["CD2", "TEST", 10, 13], ["CD8 positive cd T cells co-expressed surface molecules", "PROBLEM", 21, 75], ["APCs", "TEST", 92, 96], ["CD80", "TEST", 112, 116], ["CD86", "TEST", 118, 122], ["CD40", "TEST", 124, 128], ["CD31", "TEST", 133, 137], ["OVA uptake", "PROBLEM", 150, 160], ["porcine cd T cells", "PROBLEM", 236, 254], ["Gamma delta T cells", "PROBLEM", 255, 274], ["the data", "TEST", 286, 294], ["porcine cd T cells", "PROBLEM", 327, 345], ["functional plasticity", "PROBLEM", 371, 392], ["phagocytic activity", "OBSERVATION", 213, 232], ["delta T cells", "OBSERVATION", 261, 274], ["functional plasticity", "OBSERVATION", 371, 392]]], ["However, due to their high frequency in blood, especially during adolescence, the pig is an attractive model to study the role of these cells further, especially in regard to their unique combination of features of the innate and the adaptive immune system.The porcine toolboxThe pig toolbox has considerably increased in the last few years.", [["blood", "ANATOMY", 40, 45], ["cells", "ANATOMY", 136, 141], ["immune system", "ANATOMY", 243, 256], ["blood", "ORGANISM_SUBSTANCE", 40, 45], ["pig", "ORGANISM", 82, 85], ["cells", "CELL", 136, 141], ["immune system", "ANATOMICAL_SYSTEM", 243, 256], ["porcine", "ORGANISM", 261, 268], ["pig", "ORGANISM", 280, 283], ["pig", "SPECIES", 82, 85], ["pig", "SPECIES", 82, 85], ["pig", "SPECIES", 280, 283], ["their high frequency in blood", "PROBLEM", 16, 45], ["The porcine toolbox", "TREATMENT", 257, 276], ["The pig toolbox", "TREATMENT", 276, 291], ["considerably", "OBSERVATION_MODIFIER", 296, 308], ["increased", "OBSERVATION_MODIFIER", 309, 318]]], ["Recent advances in the availability of genomic (Dawson et al., 2013; Groenen et al., 2012) , transcriptomic (Tsoi et al., 2012) and proteomic (Trigal et al., 2013; Verma et al., 2011) data have made the analysis of porcine physiology at the molecular level cost effective and comprehensive.", [["porcine", "ORGANISM", 215, 222], ["porcine physiology", "PROBLEM", 215, 233]]], ["The porcine genome sequence has been published with the most recent build (Sscrofa10.2) including all 17 autosomes as well as both X and Y chromosomes and encompassing over 26,000 genes (Groenen et al., 2012) .", [["chromosomes", "ANATOMY", 139, 150], ["porcine", "ORGANISM", 4, 11], ["X", "CELLULAR_COMPONENT", 131, 132], ["Y chromosomes", "CELLULAR_COMPONENT", 137, 150], ["porcine genome sequence", "DNA", 4, 27], ["17 autosomes", "DNA", 102, 114], ["X and Y chromosomes", "DNA", 131, 150], ["26,000 genes", "DNA", 173, 185], ["The porcine genome sequence", "PROBLEM", 0, 27], ["Sscrofa", "TEST", 75, 82], ["all 17 autosomes", "PROBLEM", 98, 114], ["porcine genome", "OBSERVATION", 4, 18]]], ["Rapid advances in the understanding of the porcine immune system at a genetic level have been made following the long awaited publication of the full genome.", [["porcine", "ORGANISM", 43, 50], ["immune system", "ANATOMICAL_SYSTEM", 51, 64], ["the porcine immune system", "TREATMENT", 39, 64], ["full genome", "OBSERVATION", 145, 156]]], ["Curated annotation has associated more than 1300 genes to the porcine immunome (Dawson et al., 2013) .", [["porcine", "ORGANISM", 62, 69], ["1300 genes", "DNA", 44, 54]]], ["In 2009, a high quality bacterial artificial chromosome map of the genome was done and more than 375,000 single nucleotide polymorphism were identified (Ramos et al., 2009 ).Porcine stem cells and transformed cellsWhile the development of transgenic porcine models is still in its infancy, the tools to generate induced stem cells Wu et al., 2009) and to perform nuclear transfer (Park et al., 2001) exist and have been successfully applied (Aigner et al., 2010) .", [["chromosome", "ANATOMY", 45, 55], ["stem cells", "ANATOMY", 182, 192], ["cells", "ANATOMY", 209, 214], ["stem cells", "ANATOMY", 320, 330], ["nuclear", "ANATOMY", 363, 370], ["genome", "CELLULAR_COMPONENT", 67, 73], ["Porcine", "ORGANISM", 174, 181], ["stem cells", "CELL", 182, 192], ["transformed cells", "CELL", 197, 214], ["porcine", "ORGANISM", 250, 257], ["stem cells", "CELL", 320, 330], ["nuclear", "CELLULAR_COMPONENT", 363, 370], ["Porcine stem cells", "CELL_TYPE", 174, 192], ["transformed cells", "CELL_LINE", 197, 214], ["Porcine", "SPECIES", 174, 181], ["a high quality bacterial artificial chromosome map", "PROBLEM", 9, 59], ["single nucleotide polymorphism", "PROBLEM", 105, 135], ["Porcine stem cells", "TREATMENT", 174, 192], ["transformed cells", "PROBLEM", 197, 214], ["transgenic porcine models", "TREATMENT", 239, 264], ["stem cells", "OBSERVATION", 182, 192], ["transformed cells", "OBSERVATION", 197, 214], ["transgenic porcine models", "OBSERVATION", 239, 264]]], ["Induced pluripotent stem cells (iPSC) derived from fibroblasts have been generated (Esteban et al., 2009; Ezashi et al., 2009) .", [["pluripotent stem cells", "ANATOMY", 8, 30], ["iPSC", "ANATOMY", 32, 36], ["fibroblasts", "ANATOMY", 51, 62], ["Induced pluripotent stem cells", "CELL", 0, 30], ["iPSC", "CELL", 32, 36], ["fibroblasts", "CELL", 51, 62], ["Induced pluripotent stem cells", "CELL_LINE", 0, 30], ["iPSC", "CELL_LINE", 32, 36], ["fibroblasts", "CELL_TYPE", 51, 62], ["Induced pluripotent stem cells", "PROBLEM", 0, 30], ["pluripotent stem cells", "OBSERVATION", 8, 30]]], ["Existing relevant models include for instance antibody and B cell deficient swine (Mendicino et al., 2011) , CFTR disrupted cystic fibrosis pigs (Rogers et al., 2008) , and additional models are likely forthcoming following since the recent publication of the full genome (Groenen et al., 2012) .", [["B cell", "ANATOMY", 59, 65], ["cystic fibrosis", "DISEASE", 124, 139], ["B cell", "CELL", 59, 65], ["CFTR", "GENE_OR_GENE_PRODUCT", 109, 113], ["swine", "SPECIES", 76, 81], ["pigs", "SPECIES", 140, 144], ["instance antibody", "TEST", 37, 54], ["CFTR disrupted cystic fibrosis", "PROBLEM", 109, 139], ["cystic", "OBSERVATION_MODIFIER", 124, 130], ["fibrosis", "OBSERVATION", 131, 139]]], ["Several transgenesis techniques were used successfully such as pronuclear DNA microinjection, sperm-mediated gene transfer, lentiviral gene transfer, and somatic nuclear transfer (Aigner et al., 2010) .", [["pronuclear", "ANATOMY", 63, 73], ["sperm", "ANATOMY", 94, 99], ["nuclear", "ANATOMY", 162, 169], ["DNA", "CELLULAR_COMPONENT", 74, 77], ["sperm", "CELLULAR_COMPONENT", 94, 99], ["lentiviral", "ORGANISM", 124, 134], ["sperm", "CELL_TYPE", 94, 99], ["Several transgenesis techniques", "TREATMENT", 0, 31], ["pronuclear DNA microinjection", "TREATMENT", 63, 92], ["lentiviral gene transfer", "TREATMENT", 124, 148]]], ["Transformed porcine cells have been developed which, when returned to the isogenic host, produced large tumours similar to their human counterparts (Adam et al., 2006) .", [["cells", "ANATOMY", 20, 25], ["tumours", "ANATOMY", 104, 111], ["porcine", "ORGANISM", 12, 19], ["cells", "CELL", 20, 25], ["tumours", "CANCER", 104, 111], ["human", "ORGANISM", 129, 134], ["porcine", "SPECIES", 12, 19], ["human", "SPECIES", 129, 134], ["human", "SPECIES", 129, 134], ["Transformed porcine cells", "PROBLEM", 0, 25], ["large tumours", "PROBLEM", 98, 111], ["porcine cells", "OBSERVATION", 12, 25], ["large", "OBSERVATION_MODIFIER", 98, 103], ["tumours", "OBSERVATION", 104, 111]]], ["The cells provide a robust cancer model for preclinical studies interested in large tumour treatment.", [["cells", "ANATOMY", 4, 9], ["cancer", "ANATOMY", 27, 33], ["tumour", "ANATOMY", 84, 90], ["cancer", "DISEASE", 27, 33], ["tumour", "DISEASE", 84, 90], ["cells", "CELL", 4, 9], ["cancer", "CANCER", 27, 33], ["tumour", "CANCER", 84, 90], ["a robust cancer model", "TREATMENT", 18, 39], ["preclinical studies", "TEST", 44, 63], ["large tumour treatment", "TREATMENT", 78, 100], ["cancer", "OBSERVATION", 27, 33], ["large", "OBSERVATION_MODIFIER", 78, 83], ["tumour", "OBSERVATION", 84, 90]]], ["So far, using somatic cell nuclear transfer more than eight knocked out and two knock ins pigs have been produced (Aigner et al., 2010; Walters et al., 2012) .Gnotobiotic pigs and databasesGnotobiotic piglets are delivered via caesarean section and then isolated in a pathogen-free environment .", [["somatic cell nuclear", "ANATOMY", 14, 34], ["somatic cell", "CELL", 14, 26], ["pigs", "ORGANISM", 90, 94], ["piglets", "ORGANISM", 201, 208], ["pigs", "SPECIES", 90, 94], ["pigs", "SPECIES", 171, 175], ["piglets", "SPECIES", 201, 208], ["somatic cell nuclear transfer", "TREATMENT", 14, 43], ["Gnotobiotic pigs", "TREATMENT", 159, 175], ["Gnotobiotic piglets", "TREATMENT", 189, 208], ["caesarean section", "TREATMENT", 227, 244]]], ["Because isolators allow most environmental influences to be controlled by the experimenter, gnotobiotic pigs offer a unique model to study mucosal immune systems under controlled settings.", [["mucosal", "ANATOMY", 139, 146], ["gnotobiotic pigs", "ORGANISM", 92, 108], ["mucosal", "ANATOMICAL_SYSTEM", 139, 146], ["pigs", "SPECIES", 104, 108], ["pigs", "SPECIES", 104, 108], ["isolators", "TREATMENT", 8, 17], ["gnotobiotic pigs", "TREATMENT", 92, 108]]], ["As of the writing of this review, over 500 papers have been published using gnotobiotic piglets.", [["gnotobiotic piglets", "ORGANISM", 76, 95], ["piglets", "SPECIES", 88, 95], ["gnotobiotic piglets", "TREATMENT", 76, 95]]], ["Gnotobiotic pigs allow researchers to study many enteric diseases which affect humans and pigs such as rotavirus (Yuan et al., 1996) , Cryptosporidium parvum (Widmer et al., 2000) , disseminated candidiasis (Andrutis et al., 2000) , entero-hemorragic E. coli (Brady et al., 2011) , S. Typhimurium (Martins et al., 2013a,b; Meurens et al., 2009) and acute gastritis from Shigella dysenteriae Type I (Jeong et al., 2010) .", [["enteric diseases", "DISEASE", 49, 65], ["Cryptosporidium parvum", "DISEASE", 135, 157], ["disseminated candidiasis", "DISEASE", 182, 206], ["acute gastritis", "DISEASE", 349, 364], ["pigs", "ORGANISM", 12, 16], ["humans", "ORGANISM", 79, 85], ["pigs", "ORGANISM", 90, 94], ["rotavirus", "ORGANISM", 103, 112], ["Cryptosporidium parvum", "ORGANISM", 135, 157], ["E. coli", "ORGANISM", 251, 258], ["S. Typhimurium", "ORGANISM", 282, 296], ["Shigella dysenteriae", "ORGANISM", 370, 390], ["pigs", "SPECIES", 12, 16], ["humans", "SPECIES", 79, 85], ["pigs", "SPECIES", 90, 94], ["Cryptosporidium parvum", "SPECIES", 135, 157], ["E. coli", "SPECIES", 251, 258], ["S. Typhimurium", "SPECIES", 282, 296], ["Shigella dysenteriae", "SPECIES", 370, 390], ["humans", "SPECIES", 79, 85], ["pigs", "SPECIES", 90, 94], ["Cryptosporidium parvum", "SPECIES", 135, 157], ["E. coli", "SPECIES", 251, 258], ["S. Typhimurium", "SPECIES", 282, 296], ["Shigella dysenteriae Type I", "SPECIES", 370, 397], ["Gnotobiotic pigs", "TREATMENT", 0, 16], ["many enteric diseases", "PROBLEM", 44, 65], ["Cryptosporidium parvum", "PROBLEM", 135, 157], ["disseminated candidiasis", "PROBLEM", 182, 206], ["entero", "TEST", 233, 239], ["hemorragic E. coli", "PROBLEM", 240, 258], ["S. Typhimurium", "TEST", 282, 296], ["acute gastritis", "PROBLEM", 349, 364], ["Shigella dysenteriae", "PROBLEM", 370, 390], ["enteric", "ANATOMY", 49, 56], ["diseases", "OBSERVATION", 57, 65], ["disseminated", "OBSERVATION_MODIFIER", 182, 194], ["candidiasis", "OBSERVATION", 195, 206], ["E. coli", "OBSERVATION", 251, 258], ["acute", "OBSERVATION_MODIFIER", 349, 354], ["gastritis", "OBSERVATION", 355, 364]]], ["The gastro-intestinal tract of germ-free piglets colonized with human fecal microbiome better approximate the human gastro-intestinal tract than the mouse gastro-intestinal tract (Che et al., 2009; Zhang et al., 2013b) .", [["gastro-intestinal tract", "ANATOMY", 4, 27], ["germ", "ANATOMY", 31, 35], ["fecal microbiome", "ANATOMY", 70, 86], ["gastro-intestinal tract", "ANATOMY", 116, 139], ["gastro-intestinal tract", "ANATOMY", 155, 178], ["gastro-intestinal tract", "PATHOLOGICAL_FORMATION", 4, 27], ["piglets", "ORGANISM", 41, 48], ["human", "ORGANISM", 64, 69], ["fecal", "ORGANISM_SUBDIVISION", 70, 75], ["human", "ORGANISM", 110, 115], ["gastro-", "MULTI-TISSUE_STRUCTURE", 116, 123], ["intestinal tract", "ORGAN", 123, 139], ["mouse", "ORGANISM", 149, 154], ["gastro-intestinal", "ORGAN", 155, 172], ["tract", "ORGAN", 173, 178], ["piglets", "SPECIES", 41, 48], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 110, 115], ["mouse", "SPECIES", 149, 154], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 110, 115], ["mouse", "SPECIES", 149, 154], ["human fecal microbiome", "TREATMENT", 64, 86], ["gastro", "ANATOMY", 4, 10], ["intestinal tract", "ANATOMY", 11, 27], ["free piglets", "OBSERVATION", 36, 48], ["gastro", "ANATOMY", 116, 122], ["intestinal tract", "ANATOMY", 123, 139], ["intestinal tract", "ANATOMY", 162, 178]]], ["With these pigs, important discoveries can be made studying how microbial dysbiosis may contribute to diseases such as asthma, diabetes, and irritable bowel syndrome and we can acquire a deeper knowledge of the interactions between commensal flora and the innate and adaptive immune systems in the gut.", [["bowel", "ANATOMY", 151, 156], ["commensal flora", "ANATOMY", 232, 247], ["gut", "ANATOMY", 298, 301], ["microbial dysbiosis", "DISEASE", 64, 83], ["asthma", "DISEASE", 119, 125], ["diabetes", "DISEASE", 127, 135], ["irritable bowel syndrome", "DISEASE", 141, 165], ["pigs", "ORGANISM", 11, 15], ["bowel", "ORGAN", 151, 156], ["gut", "ORGANISM_SUBDIVISION", 298, 301], ["pigs", "SPECIES", 11, 15], ["microbial dysbiosis", "PROBLEM", 64, 83], ["diseases", "PROBLEM", 102, 110], ["asthma", "PROBLEM", 119, 125], ["diabetes", "PROBLEM", 127, 135], ["irritable bowel syndrome", "PROBLEM", 141, 165], ["commensal flora", "PROBLEM", 232, 247], ["asthma", "OBSERVATION", 119, 125], ["diabetes", "OBSERVATION", 127, 135], ["irritable bowel syndrome", "OBSERVATION", 141, 165], ["gut", "ANATOMY", 298, 301]]], ["The number of antibodies available to detect pig proteins is increasing.", [["pig", "ORGANISM", 45, 48], ["antibodies", "PROTEIN", 14, 24], ["pig proteins", "PROTEIN", 45, 57], ["pig", "SPECIES", 45, 48], ["pig", "SPECIES", 45, 48], ["antibodies", "TREATMENT", 14, 24], ["pig proteins", "PROBLEM", 45, 57], ["increasing", "OBSERVATION_MODIFIER", 61, 71]]], ["Considering all the suppliers and the different conjugations available >17,000 pig-specific antibodies are available (www.biocompare.com) for ELISA applications and >8000 antibodies for flow cytometry.", [["pig", "ORGANISM", 79, 82], ["17,000 pig-specific antibodies", "PROTEIN", 72, 102], ["pig", "SPECIES", 79, 82], ["pig", "SPECIES", 79, 82], ["the different conjugations", "TEST", 34, 60], ["pig-specific antibodies", "TEST", 79, 102], ["ELISA applications", "TEST", 142, 160], ["flow cytometry", "TEST", 186, 200]]], ["In the pig model, there is also the advantage that many antibodies directed against human markers cross-react with their counterparts.", [["pig", "ORGANISM", 7, 10], ["human", "ORGANISM", 84, 89], ["antibodies", "PROTEIN", 56, 66], ["human markers", "PROTEIN", 84, 97], ["pig", "SPECIES", 7, 10], ["human", "SPECIES", 84, 89], ["pig", "SPECIES", 7, 10], ["human", "SPECIES", 84, 89], ["many antibodies", "TREATMENT", 51, 66], ["human markers", "TEST", 84, 97]]], ["Several databases exist and present porcine immunological tools including antibodies and real-time PCR primers.", [["porcine", "ORGANISM", 36, 43], ["antibodies", "PROTEIN", 74, 84], ["Several databases", "TEST", 0, 17], ["antibodies", "TEST", 74, 84], ["PCR primers", "TEST", 99, 110]]], ["The database established by Dr. Dawson (USDA, Beltsville, USA) named ''Porcine Immunology and Nutrition Database'' is found at http:// 199.133.11.115/fmi/iwp/cgi?-db=PINdb&-loadframes.", [["Porcine", "SPECIES", 71, 78]]], ["Information on swine leukocyte antigen is deposited in the immune polymorphism database (http://www.ebi.ac.uk/ipd/).", [["swine leukocyte antigen", "GENE_OR_GENE_PRODUCT", 15, 38], ["swine leukocyte antigen", "PROTEIN", 15, 38], ["swine", "SPECIES", 15, 20], ["swine", "SPECIES", 15, 20], ["swine leukocyte antigen", "TEST", 15, 38]]], ["Additionally, in the NetMHCpan (http://www.cbs.dtu.dk/services/NetMHCpan/) it is possible to predict cytotoxic T cell epitopes.Microarrays and kinome arrayMicroarray tools are also available for the pig model and Agilent Technologies sells a porcine gene expression microarray with 43,803 60-mer oligoprobes (www.genomics.agilent.com/article.jsp?pageId=1508&_requestid=430140) and Affymetrix sells a system with 23,937 probes assessing the expression of 23,256 transcripts, which represents 20,201 genes (Freeman et al., 2012) . http://www.affymetrix.com/estore/browse/products.jsp?produc-tId=131488#1_1).", [["T cell", "ANATOMY", 111, 117], ["T cell", "CELL", 111, 117], ["pig", "ORGANISM", 199, 202], ["porcine", "ORGANISM", 242, 249], ["NetMHCpan", "DNA", 21, 30], ["cytotoxic T cell epitopes", "PROTEIN", 101, 126], ["43,803 60-mer oligoprobes", "DNA", 282, 307], ["www.genomics.agilent.com/article.jsp?pageId=1508&_requestid=430140", "DNA", 309, 375], ["23,256 transcripts", "RNA", 454, 472], ["20,201 genes", "DNA", 491, 503], ["pig", "SPECIES", 199, 202], ["cytotoxic T cell epitopes", "PROBLEM", 101, 126], ["Microarrays", "TEST", 127, 138], ["kinome arrayMicroarray tools", "TEST", 143, 171], ["the pig model", "TREATMENT", 195, 208], ["a porcine gene expression microarray", "TREATMENT", 240, 276], ["cell epitopes", "OBSERVATION", 113, 126]]], ["Proteomics approaches are also available and the pig proteome database (http://www.peptideatlas.org/) covers roughly 20 tissues for more than 15,000 peptides.", [["tissues", "ANATOMY", 120, 127], ["pig", "ORGANISM", 49, 52], ["tissues", "TISSUE", 120, 127], ["pig", "SPECIES", 49, 52], ["Proteomics approaches", "TREATMENT", 0, 21], ["the pig proteome database", "TEST", 45, 70]]], ["Nevertheless, mapping of the pig proteome is still limited although it progressed rapidly in the last few years.", [["pig", "ORGANISM", 29, 32], ["pig", "SPECIES", 29, 32], ["pig", "SPECIES", 29, 32], ["mapping of the pig proteome", "TEST", 14, 41], ["progressed", "OBSERVATION_MODIFIER", 71, 81], ["rapidly", "OBSERVATION_MODIFIER", 82, 89]]], ["New peptide arrays to analyze pig kinome, i.e. the set of protein kinases in porcine genome, are also under development (unpublished data) opening the door to new exciting studies.GrantsComputerized retrieval of information on scientific projects (CRISP) search (1999) (2000) (2001) (2002) (2003) reveals that NIH-sponsored research from over 20 institutes and centers supported over 2500 separate grants using the pig.ConclusionThere is an increasing interest in the pig model which we predict will continue to expand, especially with the development of new porcine models enabled by the improvement of cell-based transgenic techniques and the increasing interest for the model in the scientific community.", [["cell", "ANATOMY", 604, 608], ["pig", "ORGANISM", 30, 33], ["porcine", "ORGANISM", 77, 84], ["pig", "ORGANISM", 415, 418], ["pig", "ORGANISM", 468, 471], ["porcine", "ORGANISM", 559, 566], ["cell", "CELL", 604, 608], ["protein kinases", "PROTEIN", 58, 73], ["pig", "SPECIES", 30, 33], ["porcine", "SPECIES", 77, 84], ["pig", "SPECIES", 415, 418], ["pig", "SPECIES", 30, 33], ["pig", "SPECIES", 415, 418], ["pig", "SPECIES", 468, 471], ["New peptide arrays", "TREATMENT", 0, 18], ["pig kinome", "TREATMENT", 30, 40], ["protein kinases in porcine genome", "TREATMENT", 58, 91], ["new exciting studies", "TEST", 159, 179], ["the pig", "TREATMENT", 411, 418], ["the pig model", "TREATMENT", 464, 477], ["new porcine models", "PROBLEM", 555, 573], ["cell-based transgenic techniques", "TREATMENT", 604, 636], ["porcine genome", "OBSERVATION", 77, 91], ["increasing", "OBSERVATION_MODIFIER", 441, 451], ["interest", "OBSERVATION", 452, 460], ["new", "OBSERVATION_MODIFIER", 555, 558], ["porcine models", "OBSERVATION", 559, 573], ["improvement", "OBSERVATION_MODIFIER", 589, 600], ["increasing", "OBSERVATION_MODIFIER", 645, 655]]], ["Moreover, the ongoing annotation of the porcine genome allows us to have a clear idea of which gene have to be targeted and/or modified to model human diseases.", [["porcine", "ORGANISM", 40, 47], ["human", "ORGANISM", 145, 150], ["porcine genome", "DNA", 40, 54], ["human", "SPECIES", 145, 150], ["human", "SPECIES", 145, 150], ["model human diseases", "PROBLEM", 139, 159]]], ["The identification and the determination of the specificities of porcine immune system are progressing (Table 3 ).", [["immune system", "ANATOMY", 73, 86], ["porcine", "ORGANISM", 65, 72], ["immune system", "ANATOMICAL_SYSTEM", 73, 86], ["The identification", "TEST", 0, 18], ["porcine immune system", "TREATMENT", 65, 86]]], ["The involvement of epigenetics in the porcine innate immune response is still at its infancy but there are first results indicating a significant role of epigenetics in the variation in porcine host-pathogen interactions observed between animals (Gomez-Diaz et al., 2012; Tarakhovsky, 2010) .", [["porcine", "ORGANISM", 38, 45], ["porcine", "ORGANISM", 186, 193], ["significant", "OBSERVATION_MODIFIER", 134, 145]]], ["There is no doubt that the next few years are going to be very exciting in the field of pig research.", [["pig", "ORGANISM", 88, 91], ["pig", "SPECIES", 88, 91], ["no doubt", "UNCERTAINTY", 9, 17]]], ["Table 3 Particularities of the pig innate immune system: a few examples.Conclusion-Ten different TLRs (TLR1-10) like in humans -TLR7 and TLR9 restricted to pDCs and not expressed on cDCs as it is the case in mice -Great diversity for interferon type I (39 genes versus 19 in humans).", [["pDCs", "ANATOMY", 156, 160], ["cDCs", "ANATOMY", 182, 186], ["pig", "ORGANISM", 31, 34], ["TLRs", "GENE_OR_GENE_PRODUCT", 97, 101], ["TLR1-10", "GENE_OR_GENE_PRODUCT", 103, 110], ["humans", "ORGANISM", 120, 126], ["TLR7", "GENE_OR_GENE_PRODUCT", 128, 132], ["TLR9", "GENE_OR_GENE_PRODUCT", 137, 141], ["pDCs", "CELL", 156, 160], ["cDCs", "CELL", 182, 186], ["mice", "ORGANISM", 208, 212], ["interferon type I", "GENE_OR_GENE_PRODUCT", 234, 251], ["humans", "ORGANISM", 275, 281], ["TLRs", "PROTEIN", 97, 101], ["TLR1", "PROTEIN", 103, 107], ["TLR7", "PROTEIN", 128, 132], ["TLR9", "PROTEIN", 137, 141], ["pDCs", "CELL_TYPE", 156, 160], ["cDCs", "CELL_TYPE", 182, 186], ["interferon type I", "PROTEIN", 234, 251], ["pig", "SPECIES", 31, 34], ["humans", "SPECIES", 120, 126], ["mice", "SPECIES", 208, 212], ["humans", "SPECIES", 275, 281], ["pig", "SPECIES", 31, 34], ["humans", "SPECIES", 120, 126], ["mice", "SPECIES", 208, 212], ["humans", "SPECIES", 275, 281], ["Conclusion", "TEST", 72, 82], ["TLR1", "TEST", 103, 107], ["interferon type I", "TREATMENT", 234, 251], ["TLR7", "ANATOMY", 128, 132]]], ["Particularly a, d, and X -No induction of NOS2 in response to LPS like in humans -More cathelicidin genes than in humans (10 versus 1) -No alpha-defensins in pigs -Duplication of IL-1b gene (IL-1b and IL1-bL) -Duplication of 2 0 ,5 0 -oligoadenylate synthetase 1 (OAS1) gene (OAS1 and OAS1L) -Duplication of CD163 gene (CD163 and CD163L) -Substantial proportion of NKp46 \u00c0 NK cells -Very high frequency of cd T cells in the blood of adolescent animals", [["NKp46 \u00c0 NK cells", "ANATOMY", 365, 381], ["cd T cells", "ANATOMY", 406, 416], ["blood", "ANATOMY", 424, 429], ["LPS", "CHEMICAL", 62, 65], ["NOS2", "GENE_OR_GENE_PRODUCT", 42, 46], ["LPS", "SIMPLE_CHEMICAL", 62, 65], ["humans", "ORGANISM", 74, 80], ["cathelicidin", "GENE_OR_GENE_PRODUCT", 87, 99], ["humans", "ORGANISM", 114, 120], ["alpha-defensins", "GENE_OR_GENE_PRODUCT", 139, 154], ["pigs", "ORGANISM", 158, 162], ["IL-1b", "GENE_OR_GENE_PRODUCT", 179, 184], ["IL-1b", "GENE_OR_GENE_PRODUCT", 191, 196], ["IL1-bL", "GENE_OR_GENE_PRODUCT", 201, 207], [",5 0 -oligoadenylate synthetase 1", "GENE_OR_GENE_PRODUCT", 229, 262], ["OAS1", "GENE_OR_GENE_PRODUCT", 264, 268], ["OAS1", "GENE_OR_GENE_PRODUCT", 276, 280], ["OAS1L", "GENE_OR_GENE_PRODUCT", 285, 290], ["CD163", "GENE_OR_GENE_PRODUCT", 308, 313], ["CD163", "GENE_OR_GENE_PRODUCT", 320, 325], ["CD163L", "GENE_OR_GENE_PRODUCT", 330, 336], ["NK cells", "CELL", 373, 381], ["cd T cells", "CELL", 406, 416], ["blood", "ORGANISM_SUBSTANCE", 424, 429], ["NOS2", "PROTEIN", 42, 46], ["cathelicidin genes", "DNA", 87, 105], ["IL-1b gene", "DNA", 179, 189], ["IL1", "DNA", 201, 204], ["bL", "DNA", 205, 207], ["2 0 ,5 0 -oligoadenylate synthetase 1 (OAS1) gene", "DNA", 225, 274], ["OAS1", "DNA", 276, 280], ["OAS1L", "DNA", 285, 290], ["CD163 gene", "DNA", 308, 318], ["CD163", "DNA", 320, 325], ["CD163L", "DNA", 330, 336], ["NK cells", "CELL_TYPE", 373, 381], ["cd T cells", "CELL_TYPE", 406, 416], ["humans", "SPECIES", 74, 80], ["humans", "SPECIES", 114, 120], ["pigs", "SPECIES", 158, 162], ["humans", "SPECIES", 74, 80], ["humans", "SPECIES", 114, 120], ["NOS2", "PROBLEM", 42, 46], ["LPS", "TEST", 62, 65], ["alpha-defensins", "PROBLEM", 139, 154], ["IL", "TEST", 179, 181], ["IL", "TEST", 191, 193], ["IL1", "TEST", 201, 204], ["Duplication", "TEST", 210, 221], ["oligoadenylate synthetase", "TEST", 235, 260], ["CD163", "TEST", 320, 325], ["CD", "TEST", 330, 332], ["NKp", "TEST", 365, 368], ["NK cells", "TEST", 373, 381], ["cd T cells", "PROBLEM", 406, 416], ["NK cells", "OBSERVATION", 373, 381]]]]}